Recently O -
, O +
it O +
was O +
shown O +
that O +
diclofenac O +
was O +
metabolized O +
in O +
rats O +
to O +
reactive O +
benzoquinone O +
imines O +
via O +
cytochrome B-Gene +
P450-catalyzed I-Gene +
oxidation O -
. O +

These O +
metabolites O +
also O +
were O +
detected O +
in O +
human O +
hepatocyte O +
cultures O +
in O +
the O +
form O +
of O +
glutathione O +
( O -
GSH O -
) O +
adducts O -
. O +

This O +
report O +
describes O +
the O +
results O +
of O +
further O +
studies O +
aimed O +
at O +
characterizing O +
the O +
human O +
hepatic O +
P450-mediated B-Gene +
bioactivation O +
of O +
diclofenac O -
. O +

The O +
reactive O +
metabolites O +
formed O +
in O +
vitro O +
were O +
trapped O +
by O +
GSH O +
and O +
analyzed O +
by O +
LC O -
/ O -
MS O -
/ O -
MS O -
. O +

Thus O -
, O +
three O +
GSH O +
adducts O -
, O +
namely O -
, O +
5-hydroxy-4- O -
( O -
glutathion O -
- O -
S O -
- O -
yl O -
) O -
diclofenac O +
( O -
M1 O -
) O -
, O +
4'-hydroxy-3'- O -
( O -
glutathion O -
- O -
S O -
- O -
yl O -
) O -
diclofenac O +
( O -
M2 O -
) O -
, O +
and O +
5-hydroxy-6- O -
( O -
glutathion O -
- O -
S O -
- O -
yl O -
) O -
diclofenac O +
( O -
M3 O -
) O -
, O +
were O +
identified O +
in O +
incubations O +
of O +
diclofenac O +
with O +
human O +
liver O +
microsomes O +
in O +
the O +
presence O +
of O +
NADPH O +
and O +
GSH O -
. O +

The O +
formation O +
of O +
the O +
adducts O +
was O +
taken O +
to O +
reflect O +
the O +
intermediacy O +
of O +
the O +
corresponding O +
putative O +
benzoquinone O +
imines O -
. O +

While O +
M2 O +
was O +
the O +
dominant O +
metabolite O +
over O +
a O +
substrate O +
concentration O +
range O +
of O +
10 O -
- O -
50 O +
microM O -
, O +
M1 O +
and O +
M3 O +
became O +
equally O +
important O +
products O +
at O +
> O -
/=100 O +
microM O +
diclofenac O -
. O +

The O +
formation O +
of O +
M2 O +
was O +
inhibited O +
by O +
sulfaphenazole O +
or O +
an O +
anti B-Gene -
- I-Gene -
P450 I-Gene +
2C9 I-Gene +
antibody I-Gene +
( O -
5 O -
- O -
10 O -
% O +
of O +
control O +
values O -
) O -
. O +

The O +
formation O +
of O +
M1 O +
and O +
M3 O +
was O +
inhibited O +
by O +
troleandomycin O -
, O +
ketoconazole O -
, O +
or O +
an O +
anti B-Gene -
- I-Gene -
P450 I-Gene +
3A4 I-Gene +
antibody I-Gene +
( O -
30 O -
- O -
50 O -
% O +
of O +
control O +
values O -
) O -
. O +

In O +
studies O +
in O +
which O +
recombinant O +
P450 B-Gene +
isoforms O +
were O +
used O -
, O +
M2 O +
was O +
generated O +
only O +
by O +
P450 B-Gene +
2C9-catalyzed I-Gene +
reaction O -
, O +
while O +
M1 O +
and O +
M3 O +
were O +
produced O +
by O +
P450 B-Gene +
3A4-catalyzed I-Gene +
reaction O -
. O +

Good O +
correlations O +
were O +
established O +
between O +
the O +
extent O +
of O +
formation O +
of O +
M2 O +
and O +
P450 B-Gene +
2C9 I-Gene +
activities O +
( O -
r O +
= O +
0.93 O -
, O +
n O +
= O +
10 O -
) O +
and O +
between O +
the O +
extent O +
of O +
formation O +
of O +
M1 O +
and O +
M3 O +
and O +
P450 B-Gene +
3A4 I-Gene +
activities O +
( O -
r O +
= O +
0.98 O -
, O +
n O +
= O +
10 O -
) O +
in O +
human O +
liver O +
microsomal O +
incubations O -
. O +

Taken O +
together O -
, O +
the O +
data O +
suggest O +
that O +
the O +
biotransformation O +
of O +
diclofenac O +
to O +
M2 O +
is O +
P450 B-Gene +
2C9-dependent I-Gene -
, O +
whereas O +
metabolism O +
of O +
the O +
drug O +
to O +
M1 O +
and O +
M3 O +
involves O +
mainly O +
P450 B-Gene +
3A4 I-Gene -
. O +

Although O +
P450s B-Gene +
2C9 B-Gene +
and O +
3A4 B-Gene +
both O +
catalyze O +
the O +
bioactivation O +
of O +
diclofenac O -
, O +
P450 B-Gene +
2C9 I-Gene +
is O +
capable O +
of O +
producing O +
the O +
benzoquinone O +
imine O +
intermediate O +
at O +
lower O +
drug O +
concentrations O +
which O +
may O +
be O +
more O +
clinically O +
relevant O -
. O +

Cytochrome B-Gene +
P450 I-Gene +
2C11 I-Gene +
in O +
rats O +
was O +
recently O +
found O +
to O +
metabolize O +
diclofenac O +
into O +
a O +
highly O +
reactive O +
product O +
that O +
covalently O +
bound O +
to O +
this O +
enzyme B-Gene +
before O +
it O +
could O +
diffuse O +
away O +
and O +
react O +
with O +
other O +
proteins B-Gene -
. O +

To O +
determine O +
whether O +
cytochromes B-Gene +
P450 I-Gene +
in O +
human O +
liver O +
could O +
catalyze O +
a O +
similar O +
reaction O -
, O +
we O +
have O +
studied O +
the O +
covalent O +
binding O +
of O +
diclofenac O +
in O +
vitro O +
to O +
liver O +
microsomes O +
of O +
16 O +
individuals O -
. O +

Only O +
three O +
of O +
16 O +
samples O +
were O +
found O +
by O +
immunoblot O +
analysis O +
to O +
activate O +
diclofenac O +
appreciably O +
to O +
form O +
protein B-Gene +
adducts I-Gene +
in O +
a O +
NADPH O -
- O -
dependent O +
pathway O -
. O +

Cytochrome B-Gene +
P450 I-Gene +
2C9 I-Gene -
, O +
which O +
catalyzes O +
the O +
major O +
route O +
of O +
oxidative O +
metabolism O +
of O +
diclofenac O +
to O +
produce O +
4'-hydroxydiclofenac O -
, O +
did O +
not O +
appear O +
to O +
be O +
responsible O +
for O +
the O +
formation O +
of O +
the O +
protein B-Gene +
adducts I-Gene -
, O +
because O +
sulfaphenazole O -
, O +
an O +
inhibitor O +
of O +
this O +
enzyme O -
, O +
did O +
not O +
affect O +
protein B-Gene +
adduct I-Gene +
formation O -
. O +

In O +
contrast O -
, O +
troleandomycin O -
, O +
an O +
inhibitor O +
of O +
P450 B-Gene +
3A4 I-Gene -
, O +
inhibited O +
both O +
protein B-Gene +
adduct I-Gene +
formation O +
and O +
5-hydroxylation O +
of O +
diclofenac O -
. O +

These O +
findings O +
were O +
confirmed O +
with O +
the O +
use O +
of O +
baculovirus O -
- O -
expressed O +
human O +
P450 B-Gene +
2C9 I-Gene +
and O +
P450 B-Gene +
3A4 I-Gene -
. O +

One O +
possible O +
reactive O +
intermediate O +
that O +
would O +
be O +
expected O +
to O +
bind O +
covalently O +
to O +
liver O +
proteins B-Gene +
was O +
the O +
p O -
- O -
benzoquinone O +
imine O +
derivative O +
of O +
5-hydroxydiclofenac O -
. O +

This O +
product O +
was O +
formed O +
by O +
an O +
apparent O +
metal O -
- O -
catalyzed O +
oxidation O +
of O +
5-hydroxydiclofenac O +
that O +
was O +
inhibited O +
by O +
EDTA O -
, O +
glutathione O -
, O +
and O +
NADPH O -
. O +

The O +
p O -
- O -
benzoquinone O +
imine O +
decomposition O +
product O +
bound O +
covalently O +
to O +
human O +
liver O +
microsomes O +
in O +
vitro O +
in O +
a O +
reaction O +
that O +
was O +
inhibited O +
by O +
GSH O -
. O +

In O +
contrast O -
, O +
GSH O +
did O +
not O +
prevent O +
the O +
covalent O +
binding O +
of O +
diclofenac O +
to O +
human O +
liver O +
microsomes O -
. O +

These O +
results O +
suggest O +
that O +
for O +
appreciable O +
P450-mediated B-Gene +
bioactivation O +
of O +
diclofenac O +
to O +
occur O +
in O +
vivo O -
, O +
an O +
individual O +
may O +
have O +
to O +
have O +
both O +
high O +
activities O +
of O +
P450 B-Gene +
3A4 B-Gene +
and O +
perhaps O +
low O +
activities O +
of O +
other O +
enzymes B-Gene +
that O +
catalyze O +
competing O +
pathways O +
of O +
metabolism O +
of O +
diclofenac O -
. O +

Moreover O -
, O +
the O +
p O -
- O -
benzoquinone O +
imine O +
derivative O +
of O +
5-hydroxydiclofenac O +
probably O +
has O +
a O +
role O +
in O +
covalent O +
binding O +
in O +
the O +
liver O +
only O +
under O +
the O +
conditions O +
where O +
levels O +
of O +
NADPH O -
, O +
GSH O -
, O +
and O +
other O +
reducing O +
agents O +
would O +
be O +
expected O +
to O +
be O +
low O -
. O +

The O +
marked O +
analgesic O +
efficacy O +
of O +
ketorolac O +
in O +
humans O -
, O +
relative O +
to O +
other O +
nonsteroidal O +
anti O -
- O -
inflammatory O +
drugs O +
( O -
NSAIDs O -
) O -
, O +
has O +
lead O +
to O +
speculation O +
as O +
to O +
whether O +
additional O +
non O -
- O -
NSAID O +
mechanism O -
( O -
s O -
) O +
contribute O +
to O +
its O +
analgesic O +
actions O -
. O +

To O +
evaluate O +
this O +
possibility O -
, O +
we O +
characterized O +
( O -
R O -
, O -
S O -
) O -
-ketorolac O -
's O +
pharmacological O +
properties O +
in O +
vivo O +
and O +
in O +
vitro O +
using O +
the O +
nonselective O +
cyclooxygenase B-Gene +
( O -
COX B-Gene -
) O +
inhibitors O +
[ O -
indomethacin O +
( O -
INDO O -
) O +
and O +
diclofenac O +
sodium O +
( O -
DS O -
) O -
] O +
as O +
well O +
as O +
the O +
selective O +
COX-2 B-Gene +
inhibitor O -
, O +
celecoxib O -
, O +
as O +
references O -
. O +

The O +
potency O +
of O +
racemic O +
( O -
R O -
, O -
S O -
) O -
-ketorolac O +
was O +
similar O +
in O +
tests O +
of O +
acetic O +
acid O -
- O -
induced O +
writhing O -
, O +
carrageenan O -
- O -
induced O +
paw O +
hyperalgesia O -
, O +
and O +
carrageenan O -
- O -
induced O +
edema O +
formation O +
in O +
rats O -
; O +
ID50 O +
values O +
= O +
0.24 O -
, O +
0 O -
. O +
29 O -
, O +
and O +
0.08 O +
mg O -
/ O -
kg O -
, O +
respectively O -
. O +

( O -
R O -
, O -
S O -
) O -
-ketorolac O -
's O +
actions O +
were O +
stereospecific O -
, O +
with O +
( O -
S O -
) O -
-ketorolac O +
possessing O +
the O +
biological O +
activity O +
of O +
the O +
racemate O +
in O +
the O +
above O +
tests O -
. O +

The O +
analgesic O +
potencies O +
for O +
( O -
R O -
, O -
S O -
) O -
- O -
, O +
( O -
S O -
) O -
- O -
, O +
and O +
( O -
R O -
) O -
-ketorolac O -
, O +
INDO O -
, O +
and O +
DS O +
were O +
highly O +
correlated O +
with O +
their O +
anti O -
- O -
inflammatory O +
potencies O -
, O +
suggesting O +
a O +
common O +
mechanism O -
. O +

( O -
R O -
, O -
S O -
) O -
-ketorolac O +
was O +
significantly O +
more O +
potent O +
than O +
INDO O +
or O +
DS O +
in O +
vivo O -
. O +

Neither O +
difference O +
in O +
relative O +
potency O +
of O +
COX B-Gene +
inhibition O +
for O +
( O -
R O -
, O -
S O -
) O -
-ketorolac O +
over O +
INDO O +
and O +
DS O +
nor O +
activity O +
of O +
( O -
S O -
) O -
-ketorolac O +
at O +
a O +
number O +
of O +
other O +
enzymes B-Gene -
, O +
channels B-Gene -
, O +
or O +
receptors B-Gene +
could O +
account O +
for O +
the O +
differences O +
in O +
observed O +
potency O -
. O +

The O +
distribution O +
coefficient O +
for O +
( O -
R O -
, O -
S O -
) O -
-ketorolac O +
was O +
approximately O +
30-fold O +
less O +
than O +
for O +
DS O +
or O +
INDO O -
, O +
indicating O +
that O +
( O -
R O -
, O -
S O -
) O -
-ketorolac O +
is O +
much O +
less O +
lipophilic O +
than O +
these O +
NSAIDs O -
. O +

Therefore O -
, O +
the O +
physicochemical O +
and O +
pharmacokinetics O +
properties O +
of O +
( O -
R O -
, O -
S O -
) O -
-ketorolac O +
may O +
optimize O +
the O +
concentrations O +
of O +
( O -
S O -
) O -
-ketorolac O +
at O +
its O +
biological O +
target O -
( O -
s O -
) O -
, O +
resulting O +
in O +
greater O +
efficacy O +
and O +
potency O +
in O +
vivo O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
investigate O +
the O +
distribution O -
, O +
excretion O +
and O +
metabolism O +
of O +
1,2-dimethylnaphthalene- O -
[ O -
ring O -
- O -
U-3H O -
] O +
in O +
rats O -
. O +

The O +
experiments O +
were O +
performed O +
on O +
54 O +
male O +
outbred O +
IMP O -
: O +

Wist O +
rats O +
with O +
body O +
weight O +
of O +
200 O +
g O +
+ O -
/- O +

20 O -
% O -
. O +

The O +
compound O +
was O +
given O +
i.p O -
. O +

in O +
olive O +
oil O +
in O +
a O +
single O +
dose O +
of O +
28 O +
mg O -
/ O -
kg O +
( O -
about O +
6.2 O +
MBq O +
per O +
animal O -
) O -
. O +

3H O +
radioactivity O +
was O +
traced O +
in O +
selected O +
organs O +
and O +
tissues O -
, O +
blood O -
, O +
urine O +
and O +
faeces O -
, O +
1 O -
- O -
72 O +
h O +
following O +
the O +
administration O -
. O +

The O +
main O +
metabolites O +
were O +
isolated O +
from O +
urine O +
and O +
identified O +
by O +
the O +
GC O -
- O -
MS O +
method O -
. O +

Faeces O +
and O +
urine O +
proved O +
to O +
be O +
the O +
main O +
route O +
of O +
tritium O +
elimination O -
. O +

Over O +
93 O -
% O +
of O +
the O +
given O +
compound O +
was O +
excreted O +
during O +
the O +
first O +
72 O +
h. O +
Maximum O +
level O +
of O +
tritium O +
in O +
plasma O +
was O +
observed O +
during O +
the O +
4th O +
h O +
after O +
the O +
compound O +
administration O -
. O +

The O +
accretion O +
of O +
3H O +
proceeded O +
with O +
kinetic O +
constant O +
of O +
0.7 O +
h O -
, O +
followed O +
by O +
monophasic O +
decline O +
with O +
the O +
half O -
- O -
life O +
of O +
about O +
19h O -
. O +

In O +
organs O +
and O +
tissue O -
, O +
the O +
highest O +
concentration O +
during O +
the O +
first O +
hours O +
after O +
administration O +
were O +
detected O +
in O +
the O +
fat O -
, O +
adrenals O -
, O +
liver O -
, O +
spleen O +
and O +
kidneys O -
. O +

Then O +
gradual O +
decline O +
of O +
tritium O +
was O +
noticed O +
in O +
all O +
examined O +
tissues O -
. O +

The O +
following O +
urinary O +
metabolites O +
were O +
identified O -
: O +
1 O -
. O +

1,2-dimethylthionaphthalene O -
, O +
2 O -
. O +

1,2-dimethylnaphthol O -
, O +
3 O -
. O +
1-methylnaphthalene-2-methanol O -
, O +
4 O -
. O +
1-methyl-2-naphthoic O +
acid O +
and O +
5 O -
. O +

1,2-dimethylmethylthionaphthalene O -
. O +

In O +
conclusion O -
, O +
1,2-dimethylnaphthalene O +
has O +
a O +
relatively O +
rapid O +
turnover O +
rate O +
in O +
the O +
rat O +
organism O +
and O +
does O +
not O +
form O +
deposits O +
in O +
the O +
tissue O -
. O +

The O +
metabolism O +
encompasses O +
ring O +
hydroxylation O +
and O +
glutathione O +
conjugation O +
leading O +
to O +
thionaphthol O +
and O +
oxygenation O -
, O +
and O +
then O +
to O +
naphthoic O +
acid O -
. O +

Trimethylbenzene O +
isomers O +
( O -
TMBs O -
) O -
: O +
1,2,4-TMB O +
( O -
pseudocumene O -
-- O -
PS O -
) O -
, O +
1,2,3-TMB O +
( O -
hemimellitene O -
-- O -
HM O -
) O +
and O +
1,3,5-TMB O +
( O -
mesitylene O -
-- O -
MES O -
) O +
are O +
important O +
constituents O +
of O +
solvent O +
mixtures O -
. O +

In O +
the O +
US O -
, O +
the O +
adopted O +
TLV O -
- O -
TWA O +
value O +
for O +
TMBs O +
is O +
125 O +
mg O -
/ O -
m3 O +
or O +
25 O +
ppm O +
( O -
ACGIH O +
1996 O -
) O -
. O +

Recent O +
experiments O +
at O +
our O +
laboratory O +
have O +
revealed O +
an O +
impaired O +
learning O +
of O +
passive O +
and O +
active O +
avoidance O +
responses O +
and O +
a O +
longer O +
persistence O +
of O +
an O +
effect O +
of O +
footshock O +
( O -
increase O +
in O +
latency O +
of O +
the O +
paw O -
- O -
lick O +
response O +
to O +
heat O -
) O +
in O +
rats O +
tested O +
several O +
weeks O +
after O +
a O +
four O -
- O -
week O +
inhalation O +
exposure O +
( O -
6h O -
/ O -
day O -
, O +
five O +
days O -
/ O -
week O -
) O +
to O +
PS O +
at O +
a O +
concentration O +
of O +
100 O +
or O +
250 O +
ppm O +
( O -
15 O -
) O -
. O +

The O +
concentration O -
- O -
effect O +
relationship O +
appeared O +
to O +
be O +
nonlinear O -
; O +
the O +
effect O +
of O +
100 O +
ppm O +
HM O +
was O +
more O +
pronounced O +
than O +
that O +
of O +
250 O +
ppm O -
. O +

In O +
the O +
present O +
experiment O +
we O +
investigated O +
the O +
effects O +
of O +
a O +
repeated O +
four O -
- O -
week O +
( O -
6h O -
/ O -
day O -
, O +
5 O +
days O -
/ O -
week O -
) O +
inhalation O +
exposure O +
to O +
HM O +
at O +
concentrations O +
of O +
0 O -
, O +
25 O -
, O +
100 O +
or O +
250 O +
ppm O +
on O +
radial O -
- O -
maze O +
performance O -
, O +
open O -
- O -
field O +
activity O -
, O +
passive O +
and O +
active O +
avoidance O +
learning O -
, O +
and O +
on O +
the O +
shock O -
- O -
induced O +
changes O +
in O +
latency O +
of O +
the O +
paw O -
- O -
lick O +
response O +
to O +
heat O +
( O -
hot O -
- O -
plate O +
test O -
) O -
. O +

The O +
tests O +
were O +
performed O +
between O +
days O +
14 O +
and O +
61 O +
after O +
the O +
last O +
exposure O -
. O +

No O +
significant O +
effects O +
on O +
radial O -
- O -
maze O +
performance O +
and O +
open O -
- O -
field O +
activity O +
were O +
noted O +
in O +
any O +
of O +
the O +
dose O +
groups O -
. O +

In O +
the O +
remaining O +
tests O +
effects O +
of O +
exposure O +
were O +
noted O +
but O -
, O +
similarly O +
as O +
in O +
the O +
case O +
of O +
PS O +
exposure O -
, O +
the O +
concentration O -
- O -
effect O +
relationship O +
was O +
not O +
linear O -
. O +

In O +
rats O +
exposed O +
to O +
HM O +
at O +
25 O +
or O +
100 O +
ppm O -
, O +
but O +
not O +
250 O +
ppm O -
, O +
learning O +
of O +
the O +
passive O +
avoidance O -
, O +
i.e. O +
refraining O +
from O +
performance O +
of O +
a O +
punished O +
response O +
( O -
stepping O +
off O +
an O +
elevated O +
platform O -
) O +
was O +
significantly O +
impaired O -
. O +

Moreover O -
, O +
in O +
rats O +
exposed O +
to O +
100 O -
, O +
but O +
not O +
250 O +
ppm O +
of O +
HM O -
, O +
acquisition O +
of O +
the O +
two O -
- O -
way O +
active O +
avoidance O +
in O +
the O +
shuttle O -
- O -
box O +
was O +
slower O +
and O +
the O +
footshock O -
- O -
induced O +
increase O +
in O +
latency O +
of O +
the O +
paw O -
- O -
lick O +
response O +
to O +
heat O +
persisted O +
longer O +
than O +
in O +
the O +
unexposed O +
animals O -
. O +

The O +
results O +
suggest O +
that O +
a O +
low O -
- O -
level O +
inhalation O +
exposure O +
to O +
HM O -
, O +
just O +
like O +
low O -
- O -
level O +
exposure O +
to O +
PS O -
, O +
may O +
lead O +
to O +
long O -
- O -
lasting O +
disturbances O +
in O +
the O +
CNS O +
functions O -
. O +

The O +
nonlinear O +
concentration O -
- O -
effect O +
relationship O +
observed O +
in O +
the O +
case O +
of O +
both O +
TMB O -
- O -
s O +
requires O +
clarification O +
in O +
further O +
studies O -
. O +

All O +
the O +
benzodiazepines O +
( O -
BZDs O -
) O +
in O +
clinical O +
use O +
have O +
the O +
capacity O +
to O +
promote O +
the O +
binding O +
of O +
the O +
major O +
inhibitory O +
neurotransmitter O -
, O +
gamma O -
- O -
amino O -
- O -
butyric O +
acid O +
( O -
GABA O -
) O -
, O +
to O +
sub O -
- O -
types O +
of O +
GABA B-Gene +
receptors I-Gene +
which O +
exist O +
as O +
multi O -
- O -
subunit O +
ligand B-Gene -
- I-Gene -
gated I-Gene +
chloride I-Gene +
channels I-Gene -
. I-Gene +

Thus O -
, O +
the O +
BZDs O +
facilitate O +
the O +
actions O +
of O +
GABA O +
in O +
the O +
brain O -
. O +

The O +
BZDs O +
in O +
use O +
as O +
antiepileptic O +
drugs O +
are O +
diazepam O -
, O +
clonazepam O -
, O +
clobazam O -
, O +
nitrazepam O -
, O +
and O +
lately O -
, O +
also O +
lorazepam O +
and O +
midazolam O +
as O +
emergency O +
therapy O -
. O +

The O +
BZDs O +
have O +
a O +
wide O -
- O -
spectrum O +
of O +
proven O +
clinical O +
efficacy O +
in O +
the O +
prevention O +
of O +
different O +
kind O +
of O +
seizures O -
. O +

Clonazepam O +
and O +
clobazam O -
, O +
as O +
well O +
as O +
nitrazepam O +
in O +
some O +
cases O -
, O +
can O +
be O +
useful O +
as O +
an O +
adjunct O +
treatment O +
in O +
refractory O +
epilepsies O -
. O +

However O -
, O +
the O +
clinical O +
use O +
of O +
BZDs O +
for O +
the O +
prophylactic O +
treatment O +
of O +
epilepsy O +
is O +
associated O +
with O +
two O +
major O +
problems O +
which O +
have O +
limited O +
the O +
long O -
- O -
term O +
use O +
of O +
these O +
drugs O -
: O +
the O +
potential O +
for O +
side O -
- O -
effects O -
, O +
especially O +
sedative O +
effects O -
, O +
and O +
the O +
high O +
risk O +
of O +
development O +
of O +
tolerance O -
. O +

Despite O +
the O +
limitations O +
of O +
BZDs O +
in O +
the O +
prophylactic O +
treatment O +
of O +
epilepsies O -
, O +
these O +
drugs O +
play O +
a O +
prominent O +
role O +
in O +
clinical O +
practice O +
in O +
the O +
emergency O +
management O +
of O +
acute O +
seizures O +
and O +
status O +
epilepticus O -
. O +

Diazepam O -
, O +
clonazepam O +
and O +
lorazepam O +
are O +
all O +
considered O +
first O -
- O -
line O +
agents O +
in O +
the O +
emergency O +
management O +
of O +
acute O +
seizures O +
and O +
status O +
epilepticus O -
. O +

Furthermore O -
, O +
the O +
value O +
of O +
midazolam O +
as O +
an O +
emergency O +
therapy O +
in O +
epilepsy O +
has O +
been O +
increasingly O +
recognized O +
in O +
recent O +
years O -
. O +

Anti O -
- O -
ulcer O +
effects O +
of O +
cetraxate O -
, O +
a O +
new O +
compound O +
possessing O +
anti O -
- O -
plasmin B-Gene -
, O +
anti O -
- O -
casein B-Gene +
and O +
anti O -
- O -
trypsin B-Gene +
actions O +
were O +
investigated O +
by O +
using O +
experimental O +
gastric O +
ulcer O +
models O +
in O +
rats O -
. O +

Cetraxate O -
, O +
300 O +
mg O -
/ O -
kg O +
p.o O -
. O +
showed O +
significant O +
inhibitory O +
effects O +
of O +
65.3 O -
% O -
, O +
70.0 O -
% O -
, O +
30.2 O -
% O -
, O +
and O +
67.1 O -
% O +
against O +
aucte O +
types O +
of O +
ulcers O +
producing O +
by O +
aspirin O -
, O +
phenylbutazone O -
, O +
indomethacin O -
, O +
and O +
pyloric O +
ligature O +
( O -
Shay O -
's O +
ulcer O -
) O -
, O +
respectively O -
. O +

These O +
effects O +
were O +
greater O +
than O +
those O +
obtained O +
by O +
gefarnate O +
and O +
aluminum O +
sucrose O +
sulfate O +
may O +
be O +
mainly O +
attributed O +
to O +
the O +
protecting O +
action O +
of O +
this O +
drug O +
on O +
gastric O +
mucosa O -
. O +

Ctraxate O +
further O +
revealed O +
remarkable O +
inhibitory O +
effects O +
on O +
chronic O +
types O +
of O +
ulcers O +
produced O +
by O +
acetic O +
acid O -
, O +
clamping O -
, O +
and O +
clamping O -
- O -
cortisone O -
. O +

In O +
acetic O +
acid O +
ulcer O +
in O +
particular O -
, O +
cetraxate O +
was O +
found O +
to O +
have O +
a O +
dose O -
- O -
dependent O +
inhibitory O +
effect O +
at O +
doses O +
over O +
50 O +
mg O -
/ O -
kg O -
. O +

Of O +
test O +
drugs O +
including O +
L O -
- O -
glutamine O +
and O +
methylmethionine O +
sulfonium O +
chloride O -
, O +
cetraxate O +
showed O +
the O +
most O +
remarkable O +
inhibitory O +
effect O +
on O +
beta B-Gene -
- I-Gene -
glucuronidase I-Gene +
activity O +
in O +
ulcer O +
tissue O +
of O +
these O +
three O +
types O +
of O +
ulcers O -
. O +

These O +
findings O +
suggest O +
that O +
cetraxate O +
may O +
prevent O +
the O +
connective O +
tissue O +
in O +
the O +
ulcer O +
location O +
from O +
decomposition O +
due O +
to O +
lysosomal B-Gene +
enzymes I-Gene +
such O +
as O +
beta B-Gene -
- I-Gene -
glucuronidase I-Gene -
, O +
thereby O +
accelerating O +
the O +
recovery O +
from O +
ulcer O -
. O +

Sequence O +
analysis O +
reveals O +
that O +
the O +
Bacillus O +
subtilis O +
168 O +
tuaABCDEFGH O +
operon O +
encodes O +
enzymes B-Gene +
required O +
for O +
the O +
polymerization O +
of O +
teichuronic O +
acid O +
as O +
well O +
as O +
for O +
the O +
synthesis O +
of O +
one O +
of O +
its O +
precursors O -
, O +
the O +
UDP O -
- O -
glucuronate O -
. O +

Mutants O +
deficient O +
in O +
any O +
of O +
the O +
tua O +
genes O -
, O +
grown O +
in O +
batch O +
cultures O +
under O +
conditions O +
of O +
phosphate O +
limitation O -
, O +
were O +
characterized O +
by O +
reduced O +
amounts O +
of O +
uronate O +
in O +
their O +
cell O +
walls O -
. O +

The O +
teichuronic O +
acid O +
operon O +
belongs O +
to O +
the O +
Pho O +
regulon O -
, O +
as O +
phosphate O +
limitation O +
induces O +
its O +
transcription O -
. O +

Placing O +
the O +
tuaABCDEFGH O +
operon O +
under O +
the O +
control O +
of O +
the O +
inducible O +
Pspac O +
promoter O +
allowed O +
its O +
constitutive O +
expression O +
independently O +
of O +
the O +
phosphate O +
concentration O +
in O +
the O +
medium O -
; O +
the O +
level O +
of O +
uronic O +
acid O +
in O +
cell O +
walls O +
was O +
dependent O +
on O +
the O +
concentration O +
of O +
the O +
inducer O -
. O +

Apparently O -
, O +
owing O +
to O +
an O +
interdependence O +
between O +
teichoic O +
and O +
teichuronic O +
acid O +
incorporation O +
into O +
the O +
cell O +
wall O -
, O +
in O +
examined O +
growth O +
conditions O -
, O +
the O +
balance O +
between O +
the O +
two O +
polymers O +
is O +
maintained O +
in O +
order O +
to O +
insure O +
a O +
constant O +
level O +
of O +
the O +
wall O +
negative O +
charge O -
. O +

Evidence O +
has O +
accumulated O +
supporting O +
the O +
concept O +
that O +
reactive O +
oxygen O +
metabolites O -
, O +
including O +
free O +
radical O +
spe­cies O +
( O -
such O +
as O +
superoxide O +
and O +
hydroxyl O -
) O -
, O +
and O +
other O +
oxygen O +
metabolites O +
( O -
such O +
as O +
hydrogen O +
peroxide O +
and O +
hypochlo­rous O +
acid O -
) O +
play O +
an O +
important O +
role O +
in O +
tissue O +
injury O +
( O -
BAUD O +
and O +
ARDALILLOU O +
1986 O -
) O -
. O +

Recent O +
in O +
vitro O +
and O +
in O +
vivo O +
studies O +
have O +
implicated O +
reactive O +
oxygen O +
metabolites O +
in O +
various O +
forms O +
of O +
toxic O +
nephropathy O +
( O -
PALLER O +
et O +
al. O +
1984 O -
; O +
WALKER O +
and O +
SHAH O +
1987 O -
, O +
1988 O -
; O +
PALLER O +
1988 O -
; O +
SHAH O +
1989 O -
) O -
. O +

The O +
putative O +
site O +
of O +
injury O +
in O +
most O +
forms O +
of O +
toxic O +
nephropathy O +
is O +
the O +
epithelial O +
cells O +
lining O +
the O +
tubules O +
( O -
BREZIS O +
et O +
al. O +
1991 O -
) O -
. O +

From O +
this O +
viewpoint O -
, O +
therefore O -
, O +
protecting O +
these O +
cells O +
from O +
toxic O +
oxygen O +
metabolites O +
may O +
reduce O +
the O +
risk O +
of O +
renal O +
disorders O -
. O +

Although O +
a O +
native O +
scavenger O +
system O +
is O +
capable O +
ofdoing O +
this O -
, O +
it O +
may O +
lose O +
its O +
activity O +
under O +
pathogenic O +
conditions O +
due O +
to O +
organ O +
dysfunction O +
and O +
an O +
excess O +
of O +
free O +
radicals O -
. O +

Therefore O -
, O +
supplementation O +
with O +
chemical O +
scavengers O +
would O +
be O +
necessary O +
in O +
order O +
to O +
decompose O +
these O +
excess O +
pathogenic O +
metabolites O -
. O +

In O +
this O +
study O -
, O +
we O +
evaluated O +
the O +
membrane O +
protective O +
effects O +
of O +
some O +
flavonoids O +
on O +
the O +
LLC O -
- O -
PKj O +
cell O +
line O -
, O +
which O +
maintains O +
the O +
differentiated O +
characteristics O +
of O +
renal O +
proximal O +
tubular O +
cells O +
( O -
CANTIELLO O +
et O +
al. O +
1987 O -
) O -
. O +

This O +
cell O +
line O +
has O +
been O +
used O +
extensively O +
in O +
in O +
vitro O +
studies O +
to O +
examine O +
both O +
physiologic O +
and O +
pathophysiologic O +
mecha­nisms O +
in O +
renal O +
tubules O +
( O -
CANTIELLO O +
et O +
al. O +
1987 O -
; O +
MULLIN O +
and O +
McGINN O +
1988 O -
; O +
ANDREOLI O +
and O +
McATEER O +
1990 O -
; O +
ER­COLANI O +
et O +
al. O +
1990 O -
; O +
YOKOZAWA O +
et O +
al. O +
1997a O -
, O +
1997b O -
) O -
. O +

The O +
purposes O +
of O +
this O +
study O +
were O +
to O +
screen O +
out O +
a O +
potentially O +
useful O +
agent O +
for O +
cell O +
membrane O +
protection O -
, O +
and O +
to O +
shed O +
light O +
on O +
the O +
possible O +
mechanism O +
of O +
this O +
process O -
. O +

Material O +
and O +
methods O +
Compounds O -
: O +
Flavones O +
( O -
acacetin O -
, O +
apigenin O -
, O +
apiin O -
, O +
bai­calein O -
, O +
baicalin O -
, O +
chrysoeriol O -
, O +
cirsilineol O -
, O +
cirsiliol O -
, O +
cirsimarin O -
, O +
cirsimaritin O -
, O +
cosmosiin O -
, O +
genkwanin O -
, O +
6-hydroxyluteolin O -
, O +
linarin O -
, O +
luteolin O -
, O +
luteolin O +
7 O +
-glucoside O -
, O +
pectolinarigenin O -
, O +
pec­tolinarin O -
, O +
plantaginin O -
, O +
rhoifolin O -
, O +
scutellarein O -
, O +
sorbarin O -
, O +
tecto­chrysin O +
and O +
toringin O -
) O +
and O +
flavonols O +
( O -
afzelin O -
, O +
chrysosplenol O +
B O -
, O +
chrysosplenol O +
C O -
, O +
chrysosplenol O +
D O -
, O +
hyperin O -
, O +
isoquercitrin O -
, O +
isorhamnetin O -
, O +
kaempferitrin O -
, O +
kaempferol O -
, O +
kaempferol-7­glucoside O -
, O +
oxyayanin O +
A O -
, O +
quercetin O -
, O +
quercimeritrin O -
, O +
quer­citrin O -
, O +
rhamnetin O -
, O +
rutin O +
and O +
tetramethylquercitin O -
) O +
used O +
in O +
this O +
experiment O +
were O +
isolated O +
from O +
natural O +
sources O -
. O +

Medium O +
and O +
reagents O -
: O +
Dulbecco O -
's O +
modified O +
Eagle O +
medium O -
/ O -
nutrient O +
mixture O +
F-12 O +
( O -
D O -
- O -
MEMIF-12 O -
) O +
and O +
fetal O +
calf O +
serum O +
( O -
FCS O -
) O +
were O +
purchased O +
from O +
Life O +
Technologies O -
, O +
Exp O +
Toxic O +
Patho151 O +
( O -
1999 O -
) O +
1 O +
ries O +
( O -
Cleveland O -
, O +
OH O -
, O +
USA O -
) O -
, O +
respectively O -
. O +

A O +
commercial O +
kit O +
( O -
lactate B-Gene +
dehydrogenase I-Gene +
ClI O -
- O -
Test O +
Wako O -
) O +
for O +
assaying O +
lactate B-Gene +
dehydrogenase I-Gene +
( O -
LDH B-Gene -
) O +
was O +
obtained O +
from O +
Wako O +
Pure O +
Chemical O +
Industries O -
, O +
Ltd. O -
, O +
Osaka O -
, O +
Japan O -
. O +

Cultured O +
cell O +
experiments O -
: O +
Commercially O +
available O +
LLC O -
- O -
PK1 O +
cells O +
were O +
maintained O +
at O +
37 O -
° O -
C O +
in O +
a O +
humidified O +
at­mosphere O +
of O +
5 O +
% O +
CO2 O +
in O +
air O +
( O -
routine O +
conditions O -
) O +
on O +
culture O +
plates O +
with O +
5 O +
% O -
FCS O -
- O -
supplemented O +
D O -
- O -
MEM O -
/ O -
F-12 O +
medium O -
. O +

After O +
confluence O +
had O +
been O +
reached O -
, O +
the O +
cells O +
were O +
seeded O +
on O +
fresh O +
96-well O +
culture O +
plates O +
at O +
104 O +
per O +
well O -
. O +

Each O +
flavonoid O +
compound O +
was O +
added O +
to O +
the O +
culture O +
2 O +
h O +
later O -
, O +
and O +
the O +
plates O +
were O +
incubated O +
under O +
routine O +
conditions O +
for O +
48 O +
h. O +
Leakage O +
of O +
LDH B-Gene +
into O +
the O +
culture O +
medium O +
was O +
assayed O +
using O +
a O +
com­mercial O +
kit O -
. O +

The O +
level O +
of O +
lipid O +
peroxidant O +
released O +
from O +
the O +
cultured O +
cells O +
was O +
estimated O +
by O +
measuring O +
the O +
amount O +
of O +
malondialdehyde O +
( O -
MDA O -
) O +
as O +
described O +
by O +
YAGI O +
( O -
1976 O -
) O -
. O +

All O +
assays O +
were O +
performed O +
5 O +
times O -
. O +

Statistics O -
: O +
Data O +
are O +
presented O +
as O +
mean O +
± O +
S.E. O +
Differences O +
among O +
groups O +
were O +
analyzed O +
by O +
Dunnett O -
's O +
test O -
. O +

Signifi­cance O +
was O +
accepted O +
at O +
p O +
< O +
0.05 O -
. O +

Results O +
Flavone O -
- O -
type O +
compounds O -
: O +
Eighteen O +
of O +
24 O +
flavones O +
( O -
75 O +
% O -
) O +
demonstrated O +
different O +
degrees O +
of O +
membrane O +
pro­tective O +
activity O -
. O +

Baicalin O -
, O +
cirsimaritin O -
, O +
6-hydroxyluteolin O -
, O +
luteolin O -
, O +
plantaginin O -
, O +
rhoifolin O +
and O +
sorbarin O +
appeared O +
to O +
be O +
the O +
most O +
effective O +
compounds O +
for O +
preventing O +
LDH B-Gene +
leakage O -
, O +
since O +
only O +
a O +
very O +
low O +
concentration O +
of O +
0.25 O +
Ilg O -
/ O -
ml O +
was O +
needed O +
for O +
coculture O +
with O +
the O +
cells O -
, O +
as O +
shown O +
in O +
table O +
1 O -
. O +

Cirsimarin O -
, O +
luteolin O +
7 O +
-glucoside O -
, O +
pectolinarigenin O -
, O +
tec­tochrysin O +
and O +
toringin O +
showed O +
significant O +
inhibition O +
at O +
a O +
concentration O +
of O +
0.5 O +
Ilg O -
/ O -
ml O -
. O +

Five O +
compounds O -
, O +
baicalein O -
, O +
chrysoeriol O -
, O +
cirsiliol O -
, O +
linarin O +
and O +
scutellarein O -
, O +
suppressed O +
the O +
leakage O +
significantly O +
at O +
a O +
minimum O +
concentration O +
of O +
2.5 O +
Ilg O -
/ O -
ml O -
. O +

However O -
, O +
the O +
other O +
flavone O +
compounds O +
acted O +
only O +
weakly O +
in O +
comparison O +
with O +
those O +
described O +
above O -
. O +

In O +
addition O -
, O +
LDH B-Gene +
efflux O +
was O +
apparently O +
associated O +
with O +
the O +
MDA O +
level O -
. O +

The O +
amount O +
ofthis O +
lipid O +
peroxidant O +
form­ed O +
declined O +
markedly O +
when O +
the O +
cells O +
were O +
cultured O +
in O +
the O +
presence O +
of O +
baicalin O -
, O +
cirsimarin O -
, O +
cirsimaritin O -
, O +
6-hydroxy­luteolin O -
, O +
luteolin O -
, O +
luteolin O +
7-glucoside O -
, O +
pectolinarigenin O -
, O +
plantaginin O -
, O +
rhoifolin O -
, O +
sorbarin O +
and O +
tectochrysin O -
. O +

The O +
in­hibition O +
ofMDA O +
formation O +
by O +
these O +
compounds O +
was O +
con­centration O -
- O -
dependent O -
. O +

Flavonol O -
- O -
type O +
compounds O -
: O +
As O +
shown O +
in O +
table O +
2 O -
, O +
most O +
flavonol O +
compounds O +
tested O +
( O -
14 O +
out O +
of O +
17 O -
) O +
revealed O +
much O +
higher O +
activity O +
in O +
preventing O +
enzyme O +
efflux O -
. O +

Afzelin O -
, O +
hy­perin O -
, O +
isoquercitrin O -
, O +
isorhamnetin O -
, O +
kaempferitrin O -
, O +
kaemp­ferol-7 O +
-glucoside O -
, O +
oxyayanin O +
A O -
, O +
quercetin O -
, O +
quercitrin O -
, O +
rhamnetin O +
and O +
rutin O +
were O +
markedly O +
effective O +
because O +
the O +
released O +
LDH B-Gene +
was O +
significantly O +
decreased O +
when O +
they O +
were O +
cocultured O +
with O +
the O +
cells O +
even O +
at O +
a O +
concentration O +
of O +
0.25 O +
Ilg O -
/ O -
ml O -
, O +
isoquercitrin O +
and O +
isorhamnetin O +
exerting O +
the O +
strongest O +
effect O -
. O +

Higher O +
concentrations O +
of O +
chrysosplenol O +
B O +
and O +
chrysosplenol O +
C O +
( O -
20 O +
times O +
those O +
of O +
the O +
above O +
com­pounds O -
) O +
were O +
required O +
to O +
inhibit O +
LDH B-Gene +
release O +
to O +
the O +
same O +
extent O -
, O +
but O +
tetramethylquercitin O +
did O +
not O +
affect O +
LDH B-Gene +
re- O +
Exp O +
Toxic O +
Pathol O +
51 O +
( O -
1999 O -
) O +
1 O +
MDA O +
leakage O +
from O +
LLC O -
- O -
PK1 O +
Compound O +
Con­ O +
centration O +
( O -
Ilg O -
/ O -
ml O -
) O +
Acacetin O +
0.25 O +
0.5 O +
2.5 O +
5 O +
Apigenin O +
0.25 O +
0.5 O +
2.5 O +
5 O +
Apiin O +
0.25 O +
0.5 O +
2.5 O +
5 O +
Baicalein O +
0.25 O +
0.5 O +
2.5 O +
5 O +
Baicalin O +
0.25 O +
0.5 O +
2.5 O +
5 O +
Chrysoeriol O +
0.25 O +
0.5 O +
2.5 O +
5 O +
Cirsilineol O +
0.25 O +
0.5 O +
2.5 O +
5 O +
Cirsiliol O +
0.25 O +
0.5 O +
2.5 O +
5 O +
Cirsimarin O +
0.25 O +
0.5 O +
2.5 O +
5 O +
Cirsimaritin O +
0.25 O +
0.5 O +
2.5 O +
5 O +
Cosmosiin O +
0.25 O +
0.5 O +
2.5 O +
5 O +
cells O -
. O +

LDH B-Gene +
leakage O +
rate O +
( O -
% O -
) O +
92.8 O +
± O +
6.2 O +
90.2 O +
± O +
6.3 O +
89.8 O +
± O +
5.9 O +
89.2 O +
± O +
9.5 O +
96.7 O +
±6.7 O +
94.9 O +
± O +
5.6 O +
95.5 O +
± O +
7.5 O +
91.8 O +
± O +
5.2 O +
98.3 O +
± O +
6.3 O +
89.2 O +
± O +
7.0 O +
88.9 O +
± O +
6.2 O +
87.9±7.1 O +
96.5 O +
± O +
2.8 O +
91.3 O +
± O +
4.2 O +
82.9 O +
± O +
9.4b O +
81.4 O +
± O +
6.lb O +
80.0 O +
± O +
6.5 O -
" O +
80.3 O +
± O +
5.ge O +
80.7 O +
± O +
5.8e O +
76.2 O +
± O +
3.4 O -
< O +
101.1 O +
± O +
5.7 O +
89.3 O +
± O +
4.3 O +
84.6 O +
± O +
8.9b O +
85.2 O +
± O +
8.0 O -
" O +
99.9 O +
± O +
5.9 O +
96.5 O +
± O +
8.9 O +
93.9 O +
± O +
9.5 O +
88.1 O +
± O +
7.6 O +
94.0 O +
±7.9 O +
88.4 O +
± O +
7.0 O +
82.9 O +
± O +
6.4 O -
" O +
71.6 O +
± O +
6.3c O +
89.3 O +
± O +
6.4 O +
82.9 O +
± O +
6.1b O +
77.3 O +
± O +
5.7e O +
67.6 O +
± O +
6.7e O +
80.5 O +
± O +
5.1e O +
71.1 O +
±5.9c O +
59.9 O +
± O +
6.7c O +
52.8 O +
± O +
7.4c O +
97.5 O +
± O +
6.1 O +
88.6 O +
± O +
6.5 O +
85.5 O +
± O +
6.7 O +
79.1 O +
±7.5 O -
" O +
MDA O +
leakage O +
rate O +
( O -
% O -
) O +
89.5 O +
± O +
8.4 O +
85.7 O +
± O +
8.5 O +
86.4 O +
± O +
8.2 O +
79.9 O +
± O +
6.8b O +
97.3 O +
± O +
9.7 O +
95.6 O +
± O +
8.3 O +
88.5 O +
± O +
5.4 O +
85.7 O +
± O +
6.6 O +
93.2 O +
± O +
5.1 O +
94.2 O +
± O +
5.7 O +
94.2 O +
± O +
5.7 O +
92.4 O +
± O +
4.4 O +
95.5 O +
± O +
4.7 O +
93.2 O +
± O +
6.1 O +
91.7 O +
± O +
4.2 O +
89.1 O +
±4.4 O -
" O +
81.9 O +
± O +
7.8b O +
79.0 O +
± O +
5.2b O +
75.4 O +
± O +
6.3e O +
72.1 O +
± O +
6.1c O +
97.9 O +
± O +
8.7 O +
95.8 O +
± O +
8.7 O +
93.7 O +
± O +
7.6 O +
89.4 O +
± O +
7.8 O +
95.6 O +
± O +
5.7 O +
94.2 O +
± O +
8.7 O +
90.5 O +
± O +
7.8 O +
92.6 O +
± O +
6.4 O +
97.8±7.1 O +
91.6 O +
± O +
5.8 O +
80.0 O +
± O +
7.8b O +
76.1 O +
± O +
5.9c O +
85.7 O +
± O +
6.7 O -
" O +
83.2 O +
± O +
7.2b O +
76.6 O +
± O +
5.7e O +
69.5 O +
± O +
5.8c O +
85.2 O +
± O +
6.7 O -
" O +
75.7 O +
± O +
5.7c O +
63.7 O +
± O +
6.1e O +
57.3 O +
± O +
6.0e O +
93.1 O +
± O +
7.1 O +
89.6 O +
± O +
7.1 O +
82.6 O +
± O +
6.8 O -
" O +
77.2 O +
± O +
6.3b O +
Compound O +
Con- O +
LDH B-Gene +
leakage O +
MDA O +
leakage O +

Compound O +
Con- O +
LDH B-Gene +
leakage O +
MDAleakage O +
centration O +
rate O +
rate O +
centration O +
rate O +
rate O +
( O -
Ilg O -
/ O -
ml O -
) O +
( O -
% O -
) O +
( O -
% O -
) O +
( O -
Ilg O -
/ O -
ml O -
) O +
( O -
% O -
) O +
( O -
% O -
) O +
Genkwanin O +
0.25 O +
0.5 O +
116.4 O +
± O +
18.1 O +
108.1 O +
± O +
11.9 O +
110.5 O +
± O +
13.6 O +
106.8 O +
± O +
7.1 O +
Tectochrysin O +
0.25 O +
0.5 O +
93.6 O +
± O +

6.0 O +
84.5 O +
± O +
6.7a O +
95.0 O +
± O +
7.5 O +
85.2 O +
± O +
7.7b O +
2.5 O +
101.9 O +
± O +
10.9 O +
103.7 O +
± O +
6.5 O +
2.5 O +
82.2 O +
± O +
7.5b O +
85.8 O +
± O +
6.9a O +
5 O +
100.2 O +
± O +
9.2 O +
103.4 O +
± O +
6.2 O +
5 O +
71.2 O +
± O +
5.ge O +
68.4 O +
± O +
7.6e O +
6-Hydro­ O +
xyluteolin O +
0.25 O +
n.3 O +
± O +
7.2e O +
78.6 O +
± O +
5.2e O +
Toringin O +
0.25 O +
88.9 O +
± O +
6.5 O +
91.0 O +
± O +
6.9 O +
0.5 O +
69.1 O +
±5.7e O +
n.6 O +
± O +
6.8c O +
0.5 O +
86.9 O +
± O +
7.8a O +
89.3 O +
± O +
6.3 O +
2.5 O +
53.8 O +
± O +
5.8c O +
59.4±6.1c O +
2.5 O +
83.4 O +
± O +
6.1b O +
78.4 O +
± O +
5.7e O +
5 O +
50.9 O +
± O +
5.6e O +
54.7 O +
± O +
7.2e O +
5 O +
76.5 O +
± O +
5.4e O +
73.9 O +
± O +
4.ge O +
Linarin O +
0.25 O +
97.4 O +
± O +
5.6 O +
95.3 O +
± O +
7.6 O +
Control O +
100.0 O +
± O +
6.1 O +
100.0 O +
± O +
6.9 O +
0.5 O +
94.5 O +
± O +
5.1 O +
' O -
91.4 O +
± O +
7.1 O +
2.5 O +
79.3 O +
± O +
7.3e O +
82.1 O +
± O +
6.2b O +
Significantly O +
different O +
from O +
the O +
control O +
value O -
: O +
ap O +
< O +
0.05 O -
, O +
5 O +
68.2 O +
± O +
8.2e O +
69.5 O +
± O +
7.6e O +
bp O +
< O +
0.01 O -
, O +
ep O +
< O +
0.001 O -
. O +

Luteolin O +
0.25 O +
78.9±4.1e O +
83.5 O +
± O +
6.2b O +
Table O +
2 O -
. O +

Effect O +
of O +
flavonol O -
- O -
type O +
compounds O +
on O +
LDH B-Gene +
and O +
0.5 O +
76.6 O +
± O +
5.7e O +
81.7±6.1b O +
MDA O +
leakage O +
from O +
LLC O -
- O -
PK1 O +
cells O -
. O +

2.5 O +
74.6 O +
± O +
5.8e O +
78.0 O +
± O +
5.4e O +
5 O +
67.8 O +
± O +
5.2e O +
66.8 O +
± O +
6.ge O +
Compound O +
Con- O +
LDH B-Gene +
leakage O +
MDA O +
leakage O +
Luteolin O +
centration O +
rate O +
rate O +
7 O +
-glucoside O +
0.25 O +
97.5 O +
± O +
5.6 O +
96.3 O +
± O +
4.9 O +
( O -
Ilg O -
/ O -
ml O -
) O +
( O -
% O -
) O +
( O -
% O -
) O +
0.5 O +
83.2±7.1b O +
86.3 O +
± O +
6.2a O +
2.5 O +
5 O +
70.3 O +
± O +
7.ge O +
63.2 O +
± O +
7.4e O +
75.2 O +
± O +
6.2e O +
65.7 O +
± O +
5.8e O +
Afzelin O +
0.25 O +
0.5 O +
67.8 O +
± O +
3.5b O +
63.2±3.1b O +
73.9 O +
± O +
5.9b O +
70.8 O +
± O +
6.4b O +
Pecto­ O +
2.5 O +
59.7 O +
± O +
6.9b O +
65.3 O +
± O +
6.7b O +
linarigenin O +
0.25 O +
93.2 O +
± O +
7.7 O +
96.8 O +
±4.7 O +
5 O +
56.1 O +
± O +
4.5b O +
53.7 O +
± O +
4.6b O +
0.5 O +
69.2 O +
± O +
5.2e O +
n.6±7.1e O +
Chryso­ O +
2.5 O +
57.4 O +
± O +
6.1c O +
62.6 O +
± O +
6.4e O +
splenol O +
B O +
0.25 O +
107.7 O +
± O +
7.0 O +
100.2 O +
± O +
9.1 O +
5 O +
48.0 O +
± O +
6.5 O -
< O +
54.1 O +
± O +
5.3e O +
0.5 O +
100.3 O +
± O +
6.7 O +
95.8 O +
± O +
7.6 O +
2.5 O +
89.8 O +
± O +
6.4 O +
92.7 O +
± O +
6.7 O +
Pectolinarin O +
0.25 O +
103.8 O +
± O +
5.7 O +
103.1 O +
± O +
5.1 O +
5 O +
70.4 O +
± O +
5.3b O +
76.2 O +
± O +
6.8b O +
0.5 O +
100.5 O +
± O +
7.1 O +
100.3 O +
± O +
6.2 O +
Chryso­ O +
2.5 O +
99.2 O +
± O +
5.1 O +
96.3 O +
± O +
4.8 O +
splenol O +
C O +
0.25 O +
100.7 O +
± O +
6.9 O +
94.8 O +
± O +
5.8 O +
5 O +
89.3 O +
± O +
6.2 O +
92.0 O +
± O +
5.7 O +
0.5 O +
98.2 O +
± O +
6.6 O +
94.2 O +
±4.5 O +

2.5 O +
94.6 O +
± O +
6.5 O +
90.5 O +
± O +
7.7 O +
Plantaginin O +
0.25 O +
80.0 O +
± O +
4.2c O +
83.2 O +
± O +
4.4b O +
5 O +
84.2 O +
± O +
4.7a O +
81.1 O +
±6.4b O +
0.5 O +
71.3 O +
± O +
5.2e O +
76.8 O +
± O +
4.7e O +
Chryso­ O +
2.5 O +
67.5 O +
± O +
5.7e O +
67.8 O +
± O +
6.2e O +
splenol O +
D O +
0.25 O +
91.6 O +
± O +
6.8 O +
95.2 O +
± O +
4.2 O +
5 O +
63.0 O +
± O +
6.3e O +
59.5 O +
± O +
5.0e O +
0.5 O +
84.7 O +
± O +
5.3a O +
90.5 O +
± O +
7.4 O +
2.5 O +
80.8 O +
± O +
4.4b O +
81.1 O +
± O +
5.8b O +
Rhoifolin O +
0.25 O +
82.4 O +
± O +
5.7e O +
85.3±6.1b O +
5 O +
75.6 O +
± O +
5.4b O +
73.7±5.1b O +
0.5 O +
2.5 O +
5 O +
79.5 O +
± O +
5.1e O +
71.9±6.1e O +
71.3 O +
± O +
4.4e O +
81.5 O +
± O +
5.ge O +
73.9 O +
± O +
6.3e O +
n.l O +
± O +
6.ge O +
Hyperin O +
0.25 O +
0.5 O +
2.5 O +
86.9 O +
± O +
6.8a O +
63.7 O +
± O +
5.6b O +
50.2 O +
± O +
3.9b O +
94.6 O +
± O +
6.1 O +
71.7 O +
± O +
6.9b O +
59.5 O +
± O +
4.4b O +
Scutellarein O +
0.25 O +
95.9 O +
± O +
7.4 O +
93.7 O +
± O +
4.2 O +
5 O +
41.9 O +
± O +
4.0b O +
48.2 O +
± O +
4.3b O +
0.5 O +
2.5 O +
5 O +
90.6 O +
± O +
6.9 O +
80.6 O +
± O +
7.7b O +
63.5 O +
± O +
6.4e O +
91.4 O +
± O +
5.9 O +
84.3 O +
± O +
7.4b O +
60.0 O +
± O +
5.3e O +
Isoquercitrin O +
0.25 O +
0.5 O +
2.5 O +
47.6 O +
± O +
4.9b O +
46.5 O +
± O +
3.5b O +
42.2 O +
± O +
4.7b O +
57.1 O +
±4.9b O +
52.0 O +
± O +
4.9b O +
50.5 O +
± O +
5.8b O +
Sorbarin O +
0.25 O +
60.0 O +
± O +
4.4e O +
63.3 O +
± O +
6.7e O +
5 O +
39.1 O +
± O +
3.5b O +
45.6 O +
± O +
4.0b O +
0.5 O +
2.5 O +
5 O +
54.9 O +
± O +
5.5 O -
< O +
50.1 O +
± O +
7.8e O +
47.0 O +
± O +
5.2e O +
59.2 O +
± O +
5.5 O -
< O +
53.3 O +
± O +
5.8e O +
42.6 O +
± O +
4.8e O +
Isorhamnetin O +
0.25 O +
0.5 O +
2.5 O +
63.0 O +
± O +
5.4b O +
51.4 O +
± O +
4.8b O +
32.2 O +
± O +
3.7b O +
74.2 O +
± O +
6.8b O +
62.8 O +
± O +
6.2b O +
40.1 O +
± O +
3.6b O +
5 O +
21.6 O +
± O +
3.7b O +
32.3 O +
± O +
3.0b O +
Exp O +
Toxic O +
Pathol51 O +
( O -
1999 O -
) O +

I O +
Discussion O +
Compound O +
Con O -
- O -
LDH B-Gene +
leakage O +
MDAleakage O +
centration O +
rate O +
rate O +
( O -
Ilg O -
/ O -
ml O -
) O +
( O -
% O -
) O +
( O -
% O -
) O +
Kaempferitrin O +
0.25 O +
78.5 O +
± O +
5.4b O +
82.2 O +
± O +
6.1b O +
0.5 O +
75.9 O +
± O +
3.2b O +
78.9 O +
± O +
6.8b O +
2.5 O +
74.3 O +
± O +
5.6b O +
71.6 O +
± O +
4.3b O +
5 O +
72.3 O +
± O +
6.1b O +
68.4 O +
± O +
4.9b O +
Kaempferol O +
0.25 O +
99.3 O +
± O +
5.4 O +
92.6 O +
± O +
7.1 O +
0.5 O +
79.4 O +
± O +
6.5b O +
84.1 O +
± O +
4.7a O +
2.5 O +
73.3 O +
± O +
5.7b O +
78.9 O +
± O +
4.9b O +
5 O +
66.9 O +
±4.4b O +
62.1 O +
±4.6b O +
Kaempferol- O +
0.25 O +
77.2 O +
± O +
5.7b O +
81.5 O +
± O +
6.9b O +
7-glucoside O +
0.5 O +
72.2 O +
±4.1b O +
77.9±5.1b O +
2.5 O +
61.4 O +
± O +
5.7b O +
66.3 O +
± O +
6.2b O +
5 O +
53.7 O +
± O +
4.8b O +
60.2 O +
± O +
4.2b O +
Oxyayanin O +
A O +
0.25 O +
86.0 O +
± O +
5.78 O +
83.7 O +
± O +
4.3a O +
0.5 O +
83.3 O +
± O +
4.8b O +
77.3±7.1b O +
2.5 O +
73.5 O +
± O +
4.7b O +
68.9 O +
± O +
6.9b O +
5 O +
67.6 O +
± O +
4.8b O +
60.2 O +
± O +
5.2b O +
Quercetin O +
0.25 O +
77.2 O +
± O +
5.8b O +
81.5 O +
± O +
5.6b O +
0.5 O +
76.5 O +
±4.8b O +
79.7 O +
± O +
6.2b O +
2.5 O +
75.6 O +
± O +
3.3b O +
72.1 O +
± O +
5.0b O +
5 O +
73.5 O +
± O +
4.3b O +
69.5 O +
±4.6b O +
Quercimeritrin O +
0.25 O +
107.0 O +
± O +
7.1 O +
99.9 O +
±4.0 O +
0.5 O +
98.7 O +
±4.7 O +
94.7 O +
± O +
6.9 O +
2.5 O +
86.3 O +
± O +
5.7a O +
89.4 O +
± O +
6.1 O +
5 O +
74.6 O +
± O +
4.4b O +
77.4 O +
±4.9b O +
Quercitrin O +
0.25 O +
79.1 O +
± O +
3.1b O +
81.4 O +
± O +
5.5b O +
0.5 O +
75.5 O +
± O +
4.2b O +
82.1 O +
± O +
4.8b O +
2.5 O +
70.5 O +
±4.9b O +
74.2 O +
± O +
4.2b O +
5 O +
63.5 O +
± O +
4.5b O +
58.1 O +
± O +
5.3b O +
Rhamnetin O +
0.25 O +
70.4 O +
± O +
4.1 O +
b O +
80.2 O +
± O +
5.2b O +
0.5 O +
66.3 O +
± O +
4.2b O +
71.0 O +
± O +
5.6b O +
2.5 O +
51.3±3.1b O +
56.5 O +
± O +
4.8b O +
5 O +
32.3 O +
± O +
3.2b O +
38.4 O +
± O +
2.5b O +
Rutin O +
0.25 O +
73.2 O +
± O +
5.1b O +
79.5 O +
± O +
5.5b O +
0.5 O +
68.4 O +
± O +
4.4b O +
73.4 O +
± O +
6.2b O +
2.5 O +
62.5 O +
± O +
4.2b O +
69.7 O +
± O +
5.5b O +
5 O +
57.2 O +
± O +
4.6b O +
62.6 O +
± O +
6.8b O +
Tetramethyl-0.25 O +
99.6 O +
± O +
7.4 O +
97.1 O +
± O +
4.9 O +
quercitin O +
0.5 O +
94.1 O +
± O +
7.7 O +
96.3 O +
± O +
5.3 O +
2.5 O +
94.3±7.1 O +
91.5 O +
± O +
7.7 O +
5 O +
93.4 O +
± O +
6.8 O +
90.5 O +
± O +
8.0 O +
Control O +
100.0± O +
5.8 O +
100.0 O +
± O +
7.1 O +
Significantly O +
different O +
from O +
the O +
control O +
value O -
: O +
ap O +
< O -
0.01 O -
, O +
bp O +
< O -
0.001 O -
. O +

lease O -
. O +

The O +
generation O +
of O +
MDA O +
was O +
found O +
to O +
be O +
markedly O +
decreased O +
in O +
the O +
groups O +
with O +
decreased O +
LDH B-Gene +
efflux O -
, O +
which O +
indicated O +
a O +
possible O +
cause O +
and O +
effect O +
relationship O +
between O +
them O -
. O +

Exp O +
Toxic O +
Patho151 O +
( O -
1999 O -
) O +
1 O +
One O +
ofremarkable O +
features O +
ofcellular O +
injury O +
is O +
leakage O +
ofLDH O -
, O +
a O +
soluble O +
cytosolic O +
enzyme B-Gene -
, O +
from O +
inside O +
the O +
cells O -
. O +

This O +
leakage O +
is O +
due O +
largely O +
to O +
increased O +
membrane O +
per­meability O -
, O +
which O +
is O +
probably O +
modified O +
by O +
certain O +
factors O +
such O +
as O +
antineoplastic O +
drugs O -
, O +
radiation O -
, O +
and O +
attack O +
by O +
oxy­gen O +
free O +
radical O +
species O -
. O +

It O +
is O +
therefore O +
a O +
useful O +
indicator O +
of O +
membrane O +
integrity O +
and O +
provides O +
a O +
convenient O +
ap­proach O +
for O +
cytotoxicity O +
evaluation O -
. O +

On O +
the O +
other O +
hand O -
, O +
ANDREOLI O +
and O +
McATEER O +
( O -
1990 O -
) O -
, O +
RaVIN O +
et O +
al. O +
( O -
1990 O -
) O +
and O +
WALKER O +
and O +
SHAH O +
( O -
1991 O -
) O +
have O +
reported O +
that O +
renal O +
tubule O +
cells O +
have O +
the O +
potential O +
to O +
produce O +
reactive O +
oxygen O +
meta­bolites O +
in O +
response O +
to O +
various O +
stimuli O -
, O +
and O +
are O +
the O +
major O +
site O +
affected O +
in O +
renal O +
failure O -
. O +

In O +
this O +
study O -
, O +
therefore O -
, O +
we O +
used O +
LDH B-Gene +
leakage O +
from O +
LLC O -
- O -
PK1 O +
cells O +
as O +
an O +
indicator O +
to O +
evaluate O +
cellular O +
membrane O +
permeability O +
upon O +
incubation O +
with O +
41 O +
flavonoids O +
under O +
normal O +
culture O +
conditions O -
. O +

Flavonoids O +
are O +
phenolic O +
compounds O +
widely O +
distributed O +
in O +
plants O -
, O +
with O +
thousands O +
of O +
individual O +
substances O +
known O -
, O +
and O +
the O +
list O +
is O +
constantly O +
expanding O -
. O +

These O +
important O +
bio­active O +
compounds O +
have O +
been O +
shown O +
to O +
have O +
many O +
medi­cal O +
uses O -
, O +
such O +
as O +
diuresis O -
, O +
laxation O -
, O +
and O +
antispasmodic O -
, O +
antihypertensive O +
and O +
anti O -
- O -
inflammatory O +
actions O +
( O -
MITsv­HASHI O +
et O +
al. O +
1989 O -
) O -
. O +

Most O +
of O +
the O +
compounds O +
we O +
tested O +
in O +
this O +
study O +
also O +
showed O +
significant O +
effectiveness O +
in O +
in­hibiting O +
the O +
efflux O +
of O +
LDH B-Gene +
from O +
LLC O -
- O -
PK1 O +
cells O -
, O +
and O +
thus O +
appeared O +
to O +
change O +
the O +
permeability O +
of O +
the O +
cellular O +
mem­brane O -
. O +

To O +
determine O +
the O +
nature O +
of O +
their O +
effect O -
, O +
we O +
measur­ed O +
the O +
MDA O +
content O +
in O +
the O +
culture O +
medium O -
, O +
and O +
found O +
that O +
under O +
routine O +
culture O +
conditions O +
such O +
as O +
5 O +
% O +
CO2 O -
, O +
95 O +
% O +
air O +
and O +
37 O +
DC O +
for O +
48 O +
h O -
, O +
a O +
certain O +
amount O +
of O +
MDA O +
was O +
generated O -
. O +

This O +
suggests O +
that O +
LDH B-Gene +
efflux O +
from O +
the O +
cells O +
may O +
be O +
due O +
largely O +
to O +
lipid O +
peroxidation O +
of O +
the O +
mem­brane O -
, O +
although O +
this O +
may O +
occur O +
slowly O +
under O +
normal O +
con­ditions O -
. O +

Interestingly O -
, O +
when O +
the O +
cells O +
were O +
cocultured O +
with O +
different O +
types O +
of O +
flavones O +
and O +
flavonols O -
, O +
the O +
levels O +
of O +
both O +
LDH B-Gene +
and O +
MDA O +
in O +
the O +
medium O +
showed O +
an O +
obvious O +
de­crease O -
, O +
indicating O +
a O +
possible O +
link O +
between O +
them O -
. O +

Itis O +
there­fore O +
reasonable O +
to O +
infer O +
that O +
an O +
antiperoxidation O +
or O +
free O +
ra­dical O +
scavenging O +
mechanism O +
is O +
involved O +
in O +
this O +
process O +
because O +
of O +
the O +
reducing O +
property O +
of O +
these O +
compounds O -
. O +

Much O +
attention O +
has O +
been O +
drawn O +
to O +
the O +
antioxidative O +
ac­tivity O +
of O +
flavonoids O +
due O +
to O +
their O +
structure O -
, O +
especially O +
since O +
a O +
superoxidation O +
injury O +
hypothesis O +
has O +
been O +
put O +
forward O +
to O +
explain O +
the O +
etiology O +
and O +
pathology O +
of O +
some O +
diseases O -
, O +
and O +
this O +
has O +
prompted O +
extensive O +
studies O +
on O +
their O +
antioxi­dative O +
and O +
lipid O +
peroxidation O -
- O -
inhibiting O +
potential O -
. O +

Our O +
data O +
revealed O +
that O +
the O +
action O +
of O +
flavonoids O +
was O +
closely O +
re­lated O +
to O +
their O +
chemical O +
structures O -
. O +

First O -
, O +
as O +
shown O +
in O +
table O +
3 O -
, O +
those O +
that O +
demonstrated O +
marked O +
inhibition O +
of O +
LDH B-Gene +
efflux O +
activity O +
possess O +
more O +
phenolic O +
hydroxyl O +
groups O +
linked O +
to O +
the O +
backbone O -
. O +

For O +
example O -
, O +
having O +
an O +
extra O +
OH O +
at O +
the O +
3-position O +
made O +
10 O +
of O +
the O +
17 O +
flavonols O +
tested O +
here O +
exhibit O +
a O +
significant O +
effect O +
at O +
a O +
concentration O +
as O +
low O +
as O +
0.25 O +
Ilg O +
in O +
the O +
medium O -
; O +
in O +
contrast O -
, O +
among O +
flavone O +
types O -
, O +
only O +
7 O +
out O +
of O +
24 O +
( O -
about O +
29 O +
% O -
) O +
showed O +
such O +
activity O +
at O +
the O +
same O +
concentration O -
, O +
suggesting O +
that O +
hydroxyl O +
groups O +
are O +
of O +
prime O +
importance O +
for O +
their O +
effects O -
. O +

Compound O +
5 O +
6 O +
7 O +
8 O +
3 O +
2 O -
' O +
3 O -
' O +
4 O -
' O +
5 O -
' O +
6 O -
' O +
* O +
Aeaeetin O +
OH O +

OH O +
OMe O +
Apigenin O +
OH O +
OH O +
OH O +
Apiin O +
OH O +

OH O -
* O +
OH O +
apioglue O +
Baicalein O +
OH O +
OH O +
OH O +
Baiealin O +
OH O +
OH O +

OH O +

* O +
glueur O +
Chrysoeriol O +
OH O +
OH O +
OMe O +
OH O +
Cirsilineol O +
OH O +
OMe O +
OMe O +
OMe O +
OH O +
Cirsiliol O +
OH O +
OMe O +
OMe O +
OH O +

OH O +
Cirsimarin O +
OH O +
OMe O +
OMe O +
OH O +

* O +
glue O +
Cirsimaritin O +
OH O +
OMe O +
OMe O +
OH O +
Cosmosiin O +
OH O +

OH O +

* O +
OH O +
glue O +
Genkwanin O +
OH O +
OMe O +
OH O +
6-Hydroxyluteolin O +
OH O +
OH O +
OH O +
OH O +
OH O +
Linarin O +
OH O +

OH O -
* O +
OMe O +
rham O -
, O +
glue O +
Luteolin O +
OH O +
OH O +
OH O +
OH O +
Luteolin O +
7-glueoside O +
OH O +

OH O +

* O +
OH O +
OH O +
glue O +
Peetolinarigenin O +
OH O +
OMe O +
OMe O +
OMe O +
rham O -
, O +
glue O +
Peetolinarin O +
OH O +
OMe O +
OH O -
* O +
OMe O +
rham O -
, O +
glue O +
Plantaginin O +

OH O +
OH O +

OH O +

* O +
OH O +
glue O +
Rhoifolin O +
OH O +

OH O -
* O +
OH O +
rham O -
, O +
glue O +
Scutellarein O +
OR O +
OH O +
OH O +
OH O +
Sorbarin O +

OH O +
OH O +

OH O -
* O +
OH O +
rham O +
Tectochrysin O +
OH O +
OMe O +

Toringin O +
OH O +

* O +
OH O +
gluc O +
Afzelin O +
OH O +
OH O +

OH O -
* O +
OH O +
rham O +
Chrysosplenol O +
B O +
OH O +
OMe O +
OMe O +
OMe O +
OH O +
OH O +
Chrysosplenol O +
C O +
OH O +
OH O +
OMe O +
OMe O +
OMe O +
OH O +
Chrysosplenol O +
D O +
OH O +
OMe O +
OMe O +
OMe O +
OH O +
OH O +
Hyperin O +

OH O +
OH O +

OH O +

* O +
OH O +
OH O +
galac O +
Isoquercitrin O +
OH O +
OR O +
OH O +

* O +
OH O +
OH O +
gluc O +
Isorhamnetin O +
OR O +
OH O +
OH O +
OMe O +
OH O +
Kaempferitrin O +
OH O +

OH O +

* O +
OH O -
* O +
OH O +
rham O +
Kaempferol O +
OH O +
OH O +
OH O +
OH O +
Kaempferol-7 O +
-glucoside O +
OH O +

OR O -
* O +
OH O +
OH O +
gluc O +
Oxyayanin O +
A O +
OH O +
OMe O +
OMe O +
OH O +
OMe O +
OH O +
Quercetin O +
OH O +
OH O +
OH O +
OH O +
OH O +
Quercimeritrin O +
OH O +
OR O -
* O +
OH O +
OH O +
OH O +
gluc O +
Quercitrin O +
OH O +
OH O +

OH O -
* O +
OH O +
OH O +
rham O +
Rhamnetin O +
OH O +
OMe O +
OH O +
OH O +
OH O +
Rutin O +

OH O +
OH O +

OH O -
* O +
OH O +
OH O +
rham O -
, O +
gluc O +
Tetramethylquercitin O +
OMe O +
OMe O +
OH O +
OMe O +
OMe O +
Exp O +
Toxic O +
Pathol51 O +
( O -
1999 O -
) O +
1 O +
On O +
the O +
other O +
hand O -
, O +
different O +
capabilities O +
of O +
cell O +
mem­brane O +
protection O +
were O +
observed O +
in O +
compounds O +
ofthe O +
same O +
type O -
, O +
due O +
mainly O +
to O +
the O +
hydroxyl O +
group O +
position O +
on O +
the O +
fla­vonoid O +
backbone O -
. O +

Most O +
flavone O -
- O -
type O +
compounds O +
gener­ally O +
possessing O +
6-or O +
3'-OH O +
in O +
their O +
structure O +
demonstrat­ed O +
marked O +
LDH B-Gene +
leakage O +
inhibition O +
and O +
antioxidation O +
activity O -
. O +

For O +
example O -
, O +
baicalin O -
, O +
plantaginin O +
and O +
sorbarin O +
belonged O +
to O +
the O +
former O -
, O +
while O +
luteolin O +
and O +
luteolin O +
7-glu­coside O +
were O +
ofthe O +
latter O +
type O -
; O +
6-hydroxyluteolin O +
had O +
both O -
. O +

However O -
, O +
there O +
were O +
some O +
exceptions O -
. O +

Although O +
lacking O +
6-and O +
3'-OH O -
, O +
cirsimaritin O +
and O +
rhoifolin O +
still O +
showed O +
membrane O +
protection O +
and O +
banding O +
MDA O +
production O -
; O +
in O +
contrast O -
, O +
baicalein O -
, O +
cirsiliol O +
and O +
scutellarein O +
showed O +
a O +
weak O +
effect O -
, O +
even O +
though O +
they O +
possess O +
either O +
6 O -
- O -
0H O +
or O +
3'­OH O -
. O +

The O +
reason O +
for O +
this O +
remains O +
unclear O -
. O +

In O +
addition O -
, O +
it O +
has O +
been O +
observed O +
that O +
linked O +
sugar O +
might O +
contribute O +
to O +
membrane O +
protection O -
. O +

Among O +
the O +
most O +
effective O +
com­pounds O +
in O +
this O +
study O +
-baicalin O -
, O +
cirsimaritin O -
, O +
6-hydroxy­luteolin O -
, O +
luteolin O -
, O +
plantaginin O -
, O +
rhoifolin O +
and O +
sorbarin O +
­four O +
possess O +
glucuronic O +
acid O -
, O +
glucose O +
or O +
rhamnose O -
. O +

This O +
implies O +
that O +
sugar O +
may O +
account O +
for O +
the O +
varying O +
radical O +
scavenger O +
activity O +
through O +
changing O +
the O +
electron O +
distri­bution O +
and O +
participating O +
in O +
electron O +
delocalization O +
on O +
the O +
structural O +
backbone O -
, O +
or O +
through O +
some O +
other O +
unknown O +
mechanisms O -
. O +

Similarly O -
, O +
flavonol O -
- O -
type O +
compounds O -
, O +
having O +
an O +
addi­tional O +
-OH O +
at O +
C-3 O -
, O +
performed O +
more O +
effectively O +
than O +
the O +
previous O +
type O -
. O +

Chemically O -
, O +
their O +
actions O +
were O +
probably O +
dependent O +
on O +
C-7 O -
, O +
3 O -
' O +
or O +
4 O -
' O -
, O +
as O +
well O +
as O +
3 O -
- O -
0H O -
, O +
such O +
as O +
af­zelin O -
, O +
hyperin O -
, O +
isoquercitrin O -
, O +
isorhamnetin O -
, O +
kaempferitrin O -
, O +
kaempferol-7-glucoside O -
, O +
quercetin O -
, O +
quercitrin O -
, O +
rhamnetin O +
and O +
rutin O -
. O +

Sugar O +
linked O +
at O +
C-3 O +
would O +
also O +
affect O +
antioxi­dation O +
capability O -
. O +

For O +
example O -
, O +
a O +
lack O +
of O +
3'-OH O -
, O +
but O +
pos­session O +
of O +
rhamnoses O +
at O +
C-3 O +
and O +
7 O -
, O +
made O +
kaempferitrin O +
act O +
powerfully O +
in O +
both O +
membrane O +
protection O +
and O +
anti­peroxidation O -
, O +
similarly O +
to O +
afzelin O -
, O +
hyperin O -
, O +
isoquercitrin O -
, O +
kaempferol-7 O +
-glucoside O -
, O +
quercitrin O +
and O +
rutin O -
. O +

In O +
terms O +
of O +
results O -
, O +
we O +
attempted O +
to O +
draw O +
a O +
general O +
con­cept O +
about O +
the O +
structural O +
principles O +
necessary O +
for O +
optimal O +
cellular O +
membrane O +
protection O +
and O +
antioxidative O +
capacity O -
. O +

It O +
is O +
assumed O +
that O +
the O +
bioactivity O +
of O +
both O +
types O +
of O +
com­pounds O +
is O +
decided O +
mainly O +
by O +
the O +
following O +
three O +
impor­tant O +
structural O +
groups O -
: O +
( O -
a O -
) O +
the O +
o O -
- O -
dihydroxy O +
( O -
catechol O -
) O +
structure O +
in O +
the O +
B O +
ring O -
, O +
which O +
is O +
the O +
obvious O +
radical O +
target O +
site O +
for O +
all O +
flavonoids O +
with O +
a O +
saturated O +
2,3-bond O +
( O -
flavan­3-ols O -
, O +
flavanones O -
) O -
; O +
( O -
b O -
) O +
the O +
2,3-double O +
bond O +
in O +
conjugation O +
with O +
a O +
4-oxo O +
function O -
, O +
which O +
are O +
responsible O +
for O +
electron O +
delocalization O +
from O +
the O +
B O +
ring O -
; O +
and O +
( O -
c O -
) O +
the O +
additional O +
pre­sence O +
of O +
both O +
3-and O +
5-hydroxyl O +
groups O +
for O +
maximal O +
radical O -
- O -
scavenging O +
potential O +
and O +
strongest O +
radical O +
absorp­tion O -
; O +
in O +
fact O -
, O +
the O +
3-and O +
5-hydroxyl O +
groups O +
are O +
equivalent O +
owing O +
to O +
their O +
hydrogen O +
bonds O +
with O +
the O +
keto O +
group O -
, O +
from O +
a O +
kinetic O +
standpoint O +
( O -
SLABBERT O +
1977 O -
) O -
. O +

These O +
sites O +
can O +
be O +
considered O +
as O +
the O +
active O +
centers O +
on O +
the O +
compounds O -
, O +
or O +
as O +
a O +
prerequisite O +
factor O +
for O +
the O +
scavenging O +
of O +
oxygen O +
free O +
radicals O -
. O +

Here O -
, O +
we O +
should O +
note O +
that O +
from O +
tables O +
1 O +
and O +
2 O -
, O +
the O +
po­tentials O +
of O +
the O +
two O +
types O +
of O +
compounds O +
are O +
not O +
absolutely O +
Exp O +
Toxic O +
Pathol51 O +
( O -
1999 O -
) O +
1 O +
affected O +
by O +
whether O +
they O +
are O +
flavonoids O +
or O +
aglycones O -
. O +

It O +
is O +
thought O +
that O +
the O +
configuration O +
of O +
functional O +
groups O +
may O +
also O +
playa O +
crucial O +
role O +
in O +
determining O +
their O +
bioactivity O -
. O +

The O +
FM4 O -
- O -
64 O -
, O +
a O +
member O +
of O +
the O +
family O +
of O +
fluorescent O +
dyes O -
, O +
has O +
been O +
applied O +
to O +
the O +
cerebellar O +
cortex O +
to O +
evaluate O +
its O +
properties O +
as O +
an O +
intracellular O +
stain O +
and O +
intracortical O +
tracer O -
. O +

Slabs O +
of O +
hamster O +
cerebellum O -
, O +
1 O -
- O -
2 O +
mm O +
thick O -
, O +
were O +
incubated O +
in O +
10 O -
, O +
30 O -
, O +
and O +
100 O +
microns O +
solutions O +
of O +
FM4 O -
- O -
64 O +
in O +
sodium O +
phosphate O +
buffer O +
and O +
observed O +
in O +
a O +
slow O +
scan O +
confocal O +
laser O +
scanning O +
microscope O -
. O +

Mossy O +
and O +
climbing O +
fibers O +
were O +
traced O +
in O +
the O +
cerebellar O +
white O +
and O +
gray O +
substances O -
. O +

They O +
exhibited O +
a O +
high O +
fluorescence O +
signal O +
at O +
the O +
level O +
of O +
the O +
myelin O +
sheath O -
. O +

Mossy O +
fibers O +
were O +
identified O +
in O +
the O +
granular O +
layer O +
by O +
their O +
typical O +
rosette O +
formation O +
and O +
dichotomous O +
bifurcation O +
pattern O -
. O +

Climbing O +
fiber O +
bundles O +
were O +
observed O +
crossing O +
the O +
granular O +
layer O +
and O +
giving O +
collateral O +
branches O +
around O +
Golgi O +
cell O +
bodies O -
. O +

They O +
ascend O +
to O +
the O +
Purkinje O +
cell O +
layer O +
on O +
their O +
way O +
to O +
the O +
molecular O +
layer O -
. O +

Cerebellar O +
macroneurons O +
( O -
Golgi O +
and O +
Purkinje O +
cells O -
) O +
and O +
microneurons O +
( O -
granule O -
, O +
basket O -
, O +
and O +
stellate O +
cells O -
) O +
showed O +
optimal O +
intracellular O +
staining O +
of O +
cell O +
soma O -
, O +
axonal O -
, O +
and O +
dendritic O +
processes O -
. O +

The O +
z O -
- O -
series O +
of O +
stacks O +
of O +
optodigital O +
sections O +
allowed O +
us O +
to O +
explore O +
in O +
depth O +
the O +
cytoarchitectonic O +
arrangement O -
, O +
nerve O +
and O +
glial O +
cell O +
morphology O -
, O +
and O +
the O +
topographic O +
relationship O +
with O +
the O +
afferent O +
fibers O -
. O +

AIMS O -
: O +
Cysteamine O -
, O +
the O +
only O +
drug O +
available O +
for O +
the O +
treatment O +
of O +
cystinosis O +
in O +
paediatric O +
patients O -
, O +
is O +
available O +
as O +
the O +
hydrochloride O -
, O +
the O +
bitartrate O +
and O +
as O +
sodium O +
phosphocysteamine O +
salts O -
. O +

It O +
has O +
been O +
suggested O +
that O +
cysteamine O +
bitartrate O +
and O +
phosphocysteamine O +
are O +
better O +
tolerated O +
and O +
may O +
have O +
a O +
better O +
bioavailability O +
than O +
cysteamine O +
hydrochloride O -
. O +

This O +
has O -
, O +
however O -
, O +
never O +
been O +
demonstrated O -
. O +

METHODS O -
: O +
We O +
compared O +
the O +
pharmacokinetics O +
and O +
tolerance O +
of O +
these O +
three O +
formulations O +
of O +
cysteamine O +
in O +
18 O +
healthy O +
adult O +
male O +
volunteers O +
in O +
a O +
double O -
- O -
blind O -
, O +
latin O -
- O -
square O -
, O +
three O -
- O -
period O -
, O +
single O +
oral O +
dose O +
cross O -
- O -
over O +
relative O +
bioavailability O +
study O -
. O +

RESULTS O -
: O +
No O +
statistical O +
difference O +
was O +
found O +
between O +
relative O +
bioavailabilities O -
, O +
AUC O +
( O -
0 O -
, O +
infinity O -
) O +
( O -
geometric O +
mean O +
and O +
s.d O -
. O +

in O +
micromol O +
l O -
( O -
-1 O -
) O +
h O -
: O +
169+ O -
/ O -
-51 O -
, O +
158+ O -
/ O -
-46 O -
, O +
173+ O -
/ O -
-49 O +
with O +
cysteamine O +
hydrochloride O -
, O +
phosphocysteamine O +
and O +
cysteamine O +
bitartrate O +
respectively O -
) O -
, O +
Cmax O +
( O -
geometric O +
mean O +
and O +
s.d O -
. O +

in O +
micromol O +
l O -
( O -
-1 O -
) O -
; O +
66+ O -
/ O -
-25.5 O -
, O +
59+ O -
/ O -
-12 O -
, O +
63+ O -
/ O -
-20 O -
) O +
and O +
tmax O +
( O -
median O +
and O +
range O +
in O +
h O -
: O +
0.88 O +
( O -
0.25 O -
- O -
2 O -
) O -
, O +
1.25 O +
( O -
0.25 O -
- O -
2 O -
) O -
, O +
0.88 O +
( O -
0.25 O -
- O -
2 O -
) O -
) O +
with O +
each O +
of O +
the O +
three O +
forms O +
of O +
cysteamine O +
tested O -
. O +

Bioequivalence O +
statistics O +
( O -
90 O -
% O +
confidence O +
intervals O -
) O +
showed O +
non O +
equivalence O +
of O +
Cmax O +
of O +
cysteamine O +
base O +
as O +
the O +
only O +
non O +
equivalence O +
of O +
pharmacokinetics O +
between O +
the O +
three O +
formulations O -
: O +
90 O -
% O +
CI O +
for O +
Cmax O +
relative O +
ratios O +
to O +
cysteamine O +
hydrochloride O +
were O +
[ O -
75.6 O -
- O -
105.81 O +
for O +
phosphocysteamine O +
and O +
[ O -
74.2 O -
- O -
124.2 O -
] O +
for O +
cysteamine O +
bitartrate O -
. O +

The O +
only O +
significant O +
adverse O +
event O +
was O +
vomiting O +
whose O +
frequency O +
was O +
inversely O +
correlated O +
with O +
body O +
weight O +
( O -
Spearman O -
's O +
r=-0.76 O -
, O +
P<0.001 O -
) O -
. O +

The O +
nature O +
of O +
the O +
salt O +
tested O +
did O +
not O +
influence O +
vomiting O -
. O +

CONCLUSIONS O -
: O +
While O +
none O +
of O +
the O +
three O +
forms O +
of O +
cysteamine O +
tested O +
has O +
a O +
clear O +
advantage O +
over O +
the O +
others O +
in O +
terms O +
of O +
pharmacokinetics O +
and O +
tolerance O +
profile O -
, O +
this O +
should O +
now O +
however O +
be O +
addressed O +
in O +
patients O +
treated O +
for O +
cystinosis O +
during O +
repeat O +
administrations O -
. O +

Both O +
alpha- O +
and O +
beta O -
- O -
D O -
- O -
glucose O +
pentaacetate O +
( O -
1.7 O +
mM O +
each O -
) O +
augmented O -
, O +
to O +
almost O +
the O +
same O +
extent O -
, O +
insulin B-Gene +
release O +
caused O +
by O +
succinic O +
acid O +
dimethyl O +
ester O +
( O -
10.0 O +
mM O -
) O +
in O +
rat O +
pancreatic O +
islets O -
. O +

The O +
secretory O +
response O +
to O +
these O +
hexose O +
esters O +
largely O +
exceeded O +
that O +
evoked O +
by O +
unesterified O +
D O -
- O -
glucose O +
tested O +
at O +
the O +
same O +
concentration O +
( O -
1.7 O +
mM O -
) O -
. O +

The O +
release O +
of O +
insulin B-Gene +
provoked O +
by O +
succinic O +
acid O +
dimethyl O +
ester O +
was O +
inhibited O -
, O +
however O -
, O +
by O +
alpha O -
- O -
D O -
- O -
galactose O +
pentaacetate O -
, O +
whilst O +
being O +
unaffected O +
by O +
beta O -
- O -
D O -
- O -
galactose O +
pentaacetate O +
( O -
each O +
also O +
1.7 O +
mM O -
) O -
. O +

It O +
appears O -
, O +
therefore O -
, O +
that O +
the O +
insulinotropic O +
action O +
of O +
hexose O +
esters O +
is O +
not O +
attributable O +
solely O +
to O +
the O +
catabolism O +
of O +
their O +
carbohydrate O +
moiety O -
, O +
but O +
may O +
also O +
involve O +
a O +
receptor O +
system O +
that O +
displays O +
anomeric O +
specificity O +
and O +
can O +
be O +
directly O +
activated O +
or O +
inhibited O +
by O +
the O +
esters O +
themselves O -
. O +

Hence O -
, O +
it O +
is O +
proposed O +
that O +
selected O +
esters O +
of O +
non O -
- O -
nutrient O +
monosaccharides O +
may O +
represent O +
new O +
tools O +
to O +
either O +
stimulate O +
insulin B-Gene +
release O +
in O +
diabetes O +
or O +
prevent O +
excessive O +
hormonal O +
secretion O +
in O +
situations O +
of O +
hyperinsulinemia O -
. O +

Bioassay O -
- O -
directed O +
fractionation O +
of O +
the O +
methanolic O +
extract O +
of O +
seeds O +
of O +
Casimiroa O +
edulis O +
led O +
to O +
the O +
isolation O +
of O +
seven O +
constituents O +
with O +
cardiovascular O +
activity O -
, O +
namely O +
the O +
new O +
compound O +
synephrine O +
acetonide O +
and O +
the O +
known O +
compounds O +
N O -
- O -
monomethylhistamine O -
, O +
N O -
, O -
N O -
- O -
dimethylhistamine O -
, O +
proline O -
, O +
N O -
- O -
methylproline O -
, O +
gamma O -
- O -
aminobutyric O +
acid O +
and O +
casimiroedine O -
. O +

In O +
anesthetized O +
rats O -
, O +
both O +
histamine O +
derivatives O +
produced O +
transient O +
hypotension O +
mediated O +
via O +
H1-histaminergic B-Gene +
receptors I-Gene +
and O +
in O +
the O +
case O +
of O +
N O -
, O -
N O -
- O -
dimethylhistamine O -
, O +
via O +
nitric O +
oxide O +
release O -
. O +

Synephrine O +
acetonide O +
produced O +
transient O +
hypertension O +
and O +
tachycardia O -
, O +
mediated O +
via O +
alpha- B-Gene +
and O +
alpha- B-Gene +
and O +
beta B-Gene -
- I-Gene -
adrenergic I-Gene +
receptores I-Gene -
, O +
respectively O -
. O +

The O +
chromatographic O +
zone O +
containing O +
N O -
- O -
methyproline O -
, O +
proline O +
and O +
gamma O -
- O -
aminobutyric O +
acid O +
elicited O +
marked O +
and O +
prolonged O +
hypotension O -
. O +

Finally O -
, O +
casimiroedine O +
did O +
not O +
modify O +
the O +
blood O +
pressure O +
of O +
anesthetized O +
rats O -
, O +
but O +
lowered O +
it O +
persistently O +
in O +
anesthetized O +
guinea O +
pigs O -
. O +

It O +
was O +
concluded O +
that O +
hypotension O +
produced O +
by O +
C. O +
edulis O +
is O +
due O +
to O +
several O +
active O +
components O -
. O +

The O +
immediate O +
effect O +
can O +
be O +
attributed O +
to O +
the O +
histamine O +
derivatives O +
acting O +
on O +
H1-receptors B-Gene -
. O +

More O +
prolonged O +
hypotension O +
would O +
be O +
produced O +
by O +
the O +
mixture O +
of O +
amino O +
acids O +
through O +
an O +
unknown O +
mechanism O -
, O +
as O +
well O +
as O +
by O +
casimiroedine O -
, O +
possibly O +
by O +
activation O +
of O +
H3-receptors B-Gene -
. O +

Hypotension O +
is O +
partially O +
offset O +
by O +
synephrine O +
acetonide O +
through O +
adrenergic O +
mechanisms O -
. O +

Fractionation O +
of O +
cube O +
resin O +
from O +
Lonchocarpus O +
utilus O +
and O +
L. O +
urucu O +
roots O +
led O +
to O +
the O +
isolation O +
and O +
identification O +
of O +
11 O +
minor O +
flavonoids O +
and O +
stilbenes O +
containing O +
the O +
gem O -
- O -
dimethylpyran O +
moiety O +
or O +
a O +
dihydrodiol O +
derivative O +
thereof O -
. O +

The O +
eight O +
new O +
compounds O +
were O +
as O +
follows O -
: O +
the O +
isoflavonoid O +
cis-4'',5''-dihydro-4'',5 O -
' O +
' O -
-dihydroxylonchocarpusone O +
( O -
2 O -
) O -
; O +
four O +
( O -
2S O -
) O -
-6- O -
( O -
gamma O -
, O +
gamma O -
- O -
dimethylallyl O -
) O -
-6'',6''-dimethylpyran O -
[ O -
2'',3'':7 O -
, O +
8 O -
] O -
flavanones O +
with O +
substituents O +
of O +
5-hydroxy-3',4'-dimethoxy O +
( O -
3 O -
) O -
, O +
5 O -
, O +
3'-dihydroxy-4'-methoxy O +
( O -
4 O -
) O -
, O +
5,4'-dihydroxy-3'-methoxy O +
( O -
5 O -
) O -
, O +
and O +
3 O -
' O -
, O +
4'-dimethoxy O +
( O -
6 O -
) O -
; O +
and O +
three O +
6'',6''-dimethylpyran O -
[ O -
2'',3'':3 O -
' O -
, O +
4' O -
] O -
stilbenes O +
with O +
4-hydroxy-5'-methoxy O +
( O -
9 O -
) O -
, O +
3,5'-dimethoxy-4-hydroxy O +
( O -
10 O -
) O +
and O +
3,4,5-trimethoxy O +
( O -
11 O -
) O +
substitution O +
patterns O -
. O +

Structure O -
- O -
activity O +
relationships O +
for O +
inhibition O +
of O +
NADH B-Gene -
: I-Gene -
ubiquinone I-Gene +
oxidoreductase I-Gene +
activity O +
( O -
bovine O +
heart O +
electron O +
transport O +
particles O -
) O +
and O +
phorbol O +
ester O -
- O -
induced O +
ornithine B-Gene +
decarboxylase I-Gene +
activity O +
( O -
cultured O +
MCF-7 O +
cells O -
) O +
generally O +
parallel O +
those O +
for O +
cytotoxicity O +
( O -
MCF-7 O +
and O +
Hepa O +
1clc7 O +
cells O -
) O -
. O +

Reinvestigation O +
of O +
fractions O +
derived O +
from O +
large O -
- O -
scale O +
fractionation O +
of O +
Maytenus O +
buchananii O +
led O +
to O +
the O +
isolation O +
of O +
two O +
new O +
maytansinoids O -
. O +

The O +
structures O +
of O +
these O +
principles O +
were O +
determined O +
using O +
electrospray O +
MS O -
, O +
1H O +
NMR O -
, O +
13C O +
NMR O -
, O +
and O +
2D O +
NMR O +
techniques O -
. O +

One O +
principle O +
was O +
found O +
to O +
be O +
2'-N O -
- O -
demethylmaytanbutine O +
( O -
2 O -
) O -
, O +
while O +
the O +
other O +
was O +
found O +
to O +
be O +
maytanbicyclinol O +
( O -
3 O -
) O -
, O +
the O +
first O +
maytansinoid O +
with O +
two O +
macrocyclic O +
rings O +
to O +
be O +
isolated O +
from O +
a O +
Maytenus O +
species O -
. O +

Previous O +
studies O +
have O +
indicated O +
that O +
part O +
of O +
the O +
binding O +
of O +
[ O -
3H O -
] O +
[ O -
1- O -
[ O -
2- O -
( O -
diphenylmethoxy O -
) O -
ethyl O -
] O -
-4- O -
( O -
3-phenylpropyl O -
) O +
piperazine O +
dihydrochloride O -
] O +
( O -
[ O -
3H O -
] O -
GBR O +
12935 O -
) O +
to O +
human O +
platelets O +
is O +
to O +
a O +
piperazine B-Gene +
acceptor I-Gene +
site I-Gene -
, O +
which O +
might O +
be O +
associated O +
with O +
cytochrome B-Gene +
P-450IID6 I-Gene +
( O -
CYP4502D6 B-Gene -
, O +
debrisoquine-4-hydroxylase B-Gene -
) O -
. O +

Due O +
to O +
mutant O +
CYP4502D6 B-Gene +
alleles O -
, O +
5 O -
- O -
10 O -
% O +
of O +
Caucasians O +
are O +
poor O +
metabolizers O +
of O +
CYP4502D6 B-Gene +
substrates O +
such O +
as O +
debrisoquine O +
and O +
dextromethorphan O -
. O +

In O +
the O +
present O +
study O -
, O +
possible O +
differences O +
in O +
binding O +
characteristics O +
of O +
[ O -
3H O -
] O -
GBR O +
12935 O +
in O +
platelets O +
from O +
CYP4502D6 B-Gene +
poor O +
and O +
extensive O +
metabolizers O +
were O +
investigated O -
. O +

The O +
most O +
prominent O +
finding O +
was O +
a O +
gender O +
difference O -
, O +
with O +
males O +
having O +
significantly O +
higher O +
Kd O +
values O +
than O +
females O -
. O +

There O +
were O +
no O +
differences O +
in O +
Bmax O -
. O +

After O +
correction O +
for O +
gender O -
, O +
there O +
was O +
a O +
tendency O +
towards O +
higher O +
Kd O +
values O +
in O +
poor O +
metabolizers O +
than O +
in O +
extensive O +
metabolizers O -
, O +
although O +
the O +
difference O +
was O +
not O +
statistically O +
significant O -
. O +

Whether O +
this O +
finding O +
corresponds O +
to O +
reduced O +
CYP4502D6 B-Gene +
activity O +
is O +
a O +
matter O +
of O +
further O +
investigation O -
. O +

Rhus O +
javanica O -
, O +
a O +
medicinal O +
herb O -
, O +
has O +
been O +
shown O +
to O +
exhibit O +
oral O +
therapeutic O +
anti O -
- O -
herpes O +
simplex O +
virus O +
( O -
HSV O -
) O +
activity O +
in O +
mice O -
. O +

We O +
purified O +
two O +
major O +
anti O -
- O -
HSV O +
compounds O -
, O +
moronic O +
acid O +
and O +
betulonic O +
acid O -
, O +
from O +
the O +
herbal O +
extract O +
by O +
extraction O +
with O +
ethyl O +
acetate O +
at O +
pH O +
10 O +
followed O +
by O +
chromatographic O +
separations O +
and O +
examined O +
their O +
anti O -
- O -
HSV O +
activity O +
in O +
vitro O +
and O +
in O +
vivo O -
. O +

Moronic O +
acid O +
was O +
quantitatively O +
a O +
major O +
anti O -
- O -
HSV O +
compound O +
in O +
the O +
ethyl O +
acetate O -
- O -
soluble O +
fraction O -
. O +

The O +
effective O +
concentrations O +
for O +
50 O -
% O +
plaque O +
reduction O +
of O +
moronic O +
acid O +
and O +
betulonic O +
acid O +
for O +
wild O -
- O -
type O +
HSV O +
type O +
1 O +
( O -
HSV-1 O -
) O +
were O +
3.9 O +
and O +
2.6 O +
microgram O -
/ O -
ml O -
, O +
respectively O -
. O +

The O +
therapeutic O +
index O +
of O +
moronic O +
acid O +
( O -
10.3 O -
- O -
16.3 O -
) O +
was O +
larger O +
than O +
that O +
of O +
betulonic O +
acid O +
( O -
6.2 O -
) O -
. O +

Susceptibility O +
of O +
acyclovir O -
- O -
phosphonoacetic O +
acid O -
- O -
resistant O +
HSV-1 O -
, O +
thymidine B-Gene +
kinase I-Gene -
- O -
deficient O +
HSV-1 O -
, O +
and O +
wild O -
- O -
type O +
HSV O +
type O +
2 O +
to O +
moronic O +
acid O +
was O +
similar O +
to O +
that O +
of O +
the O +
wild O -
- O -
type O +
HSV-1 O -
. O +

When O +
this O +
compound O +
was O +
administered O +
orally O +
to O +
mice O +
infected O +
cutaneously O +
with O +
HSV-1 O +
three O +
times O +
daily O -
, O +
it O +
significantly O +
retarded O +
the O +
development O +
of O +
skin O +
lesions O +
and/or O +
prolonged O +
the O +
mean O +
survival O +
times O +
of O +
infected O +
mice O +
without O +
toxicity O +
compared O +
with O +
the O +
control O -
. O +

Moronic O +
acid O +
suppressed O +
virus O +
yields O +
in O +
the O +
brain O +
more O +
efficiently O +
than O +
those O +
in O +
the O +
skin O -
. O +

This O +
was O +
consistent O +
with O +
the O +
prolongation O +
of O +
mean O +
survival O +
times O -
. O +

Thus O -
, O +
moronic O +
acid O +
was O +
purified O +
as O +
a O +
major O +
anti O -
- O -
HSV O +
compound O +
from O +
the O +
herbal O +
extract O +
of O +
Rhus O +
javanica O -
. O +

Mode O +
of O +
the O +
anti O -
- O -
HSV O +
activity O +
was O +
different O +
from O +
that O +
of O +
ACV O -
. O +

Moronic O +
acid O +
showed O +
oral O +
therapeutic O +
efficacy O +
in O +
HSV O -
- O -
infected O +
mice O +
and O +
possessed O +
novel O +
anti O -
- O -
HSV O +
activity O +
that O +
was O +
consistent O +
with O +
that O +
of O +
the O +
extract O -
. O +

IC202A O +
( O -
1 O -
) O +
was O +
isolated O +
from O +
the O +
culture O +
filtrate O +
of O +
Streptoalloteichus O +
sp. O +
1454 O -
- O -
19 O -
. O +

The O +
structure O +
of O +
1 O +
was O +
determined O +
by O +
spectral O +
analysis O +
including O +
a O +
variety O +
of O +
two O -
- O -
dimentional O +
NMR O +
and O +
FAB O -
- O -
MS O +
experiments O -
. O +

IC202A O +
is O +
a O +
ferrioxamine O -
- O -
related O +
compound O +
containing O +
a O +
butylidene O +
N O -
- O -
oxide O +
function O -
. O +

It O +
is O +
suspected O +
that O +
not O +
only O +
fibrinogen B-Gene +
concentration O +
but O +
also O +
the O +
quality O +
of O +
fibrin B-Gene +
networks O +
may O +
contribute O +
to O +
cardiovascular O +
risk O -
. O +

Evidence O +
is O +
accumulating O +
that O +
a O +
" O -
prudent O -
" O +
diet O +
may O +
protect O +
against O +
diseases O +
associated O +
with O +
raised O +
clotting O +
factors O -
. O +

The O +
effect O +
of O +
diet O +
on O +
fibrinogen B-Gene +
is O -
, O +
however O -
, O +
still O +
controversial O -
. O +

In O +
a O +
previous O +
study O +
performed O +
in O +
our O +
laboratory O -
, O +
it O +
was O +
shown O +
that O +
dietary O +
pectin O +
influences O +
fibrin B-Gene +
network O +
architecture O +
in O +
hypercholesterolaemic O +
men O +
without O +
causing O +
any O +
changes O +
in O +
fibrinogen B-Gene +
concentration O -
. O +

To O +
elucidate O +
the O +
possible O +
mechanisms O -
, O +
it O +
was O +
necessary O +
to O +
study O +
the O +
possibility O +
that O +
pectin O +
may O +
itself O +
have O +
indirect O +
effects O +
on O +
fibrin O +
network O +
architecture O -
. O +

Pectin O +
is O +
fermented O +
in O +
the O +
gastrointestinal O +
tract O +
to O +
acetate O -
, O +
propionate O -
, O +
and O +
butyrate O -
. O +

In O +
humans O -
, O +
only O +
acetate O +
reaches O +
the O +
circulation O +
beyond O +
the O +
liver O -
. O +

This O +
investigation O +
primarily O +
examined O +
the O +
possibility O +
that O +
pectin O +
may O -
, O +
through O +
acetate O -
, O +
influence O +
fibrin B-Gene +
network O +
architecture O +
in O +
vivo O -
. O +

The O +
effects O +
of O +
pectin O +
and O +
acetate O +
supplementation O +
in O +
hypercholesterolaemic O +
subjects O +
were O +
compared O -
. O +

Furthermore O -
, O +
this O +
study O +
also O +
aimed O +
at O +
describing O +
the O +
possible O +
in O +
vitro O +
effects O +
of O +
acetate O +
on O +
fibrin B-Gene +
network O +
architecture O -
. O +

Two O +
groups O +
of O +
10 O +
male O +
hyperlipidaemic O +
volunteers O +
each O +
received O +
a O +
pectin O +
( O -
15 O +
g O -
/ O -
day O -
) O +
or O +
acetate O +
( O -
6.8 O +
g O -
/ O -
day O -
) O +
supplement O +
for O +
4 O +
weeks O -
. O +

Acetate O +
supplementation O +
did O +
not O +
cause O +
a O +
significant O +
change O +
in O +
plasma O +
fibrinogen B-Gene +
levels O -
. O +

As O +
in O +
the O +
pectin O +
group O -
, O +
significant O +
differences O +
were O +
found O +
in O +
the O +
characteristics O +
of O +
fibrin B-Gene +
networks O +
developed O +
in O +
plasma O +
after O +
4 O +
weeks O +
of O +
acetate O +
supplementation O -
. O +

Fibrin B-Gene +
networks O +
were O +
more O +
permeable O +
( O -
from O +
213+ O -
/ O -
-76 O +
to O +
307+ O -
/ O -
-81 O +
x O +
10 O -
( O -
11 O -
) O +
cm2 O -
) O -
, O +
had O +
lower O +
tensile O +
strength O +
( O -
from O +
23+ O -
/ O -
-3 O +
to O +
32+ O -
/ O -
-9 O -
% O +
compaction O -
) O -
, O +
and O +
were O +
more O +
lyseable O +
( O -
from O +
252+ O -
/ O -
-11 O +
to O +
130+ O -
/ O -
-15 O +
minutes O -
) O -
. O +

These O +
results O +
strongly O +
suggest O +
that O +
the O +
effect O +
of O +
pectin O +
on O +
network O +
architecture O +
could O +
partially O +
be O +
mediated O +
by O +
acetate O -
. O +

Progressive O +
amounts O +
of O +
acetate O +
were O +
used O +
in O +
vitro O +
to O +
investigate O +
the O +
possibility O +
that O +
acetate O +
may O +
be O +
directly O +
responsible O +
for O +
changes O +
that O +
occurred O +
in O +
fibrin B-Gene +
network O +
architecture O +
in O +
the O +
plasma O +
medium O -
. O +

Results O +
indicated O +
that O +
acetate O +
influenced O +
fibrin B-Gene +
network O +
architecture O +
directly O -
. O +

From O +
the O +
results O -
, O +
it O +
seems O +
highly O +
possible O +
that O +
acetate O +
may O +
be O +
responsible O +
in O +
part O +
for O +
the O +
beneficial O +
effects O +
of O +
pectin O +
supplementation O +
in O +
vivo O -
. O +

It O +
is O +
evident O +
that O +
pectin O +
or O +
acetate O +
supplementation O +
can O +
be O +
useful O +
during O +
the O +
treatment O +
or O +
prevention O +
of O +
some O +
clinical O +
manifestations O -
, O +
especially O +
those O +
associated O +
with O +
raised O +
total O +
cholesterol O +
and O +
possibly O +
also O +
plasma O +
fibrinogen B-Gene -
. O +

INTRODUCTION O +
Chemical O +
substitution O +
of O +
ribosomal B-Gene +
proteins I-Gene +
by O +
dansyl O +
chloride O +
[ O -
I O -
] O +
and O +
iodoacetamide O +
[ O -
2 O -
] O +
has O +
yielded O +
first O +
results O +
concerning O +
the O +
localisation O +
of O +
proteins B-Gene +
in O +
rat O +
liver O +
ribosomes O -
. O +

The O +
accessibility O +
of O +
proteins B-Gene +
can O +
be O +
further O +
Abbreviations O -
: O +
MAI O -
, O +
methyl O +
acetimidate O -
; O +
NPA O -
, O +
p O -
- O -
nitrophenyl O +
acetate O -
; O +
TEA O -
, O +
triethanol- O +
amine O -
. O +

310 O +
studied O +
by O +
substitution O +
of O +
their O +
amino O +
groups O +
by O +
NPA O +
or O +
by O +
MAI O +
as O +
will O +
be O +
demonstrated O +
in O +
this O +
paper O -
. O +

These O +
new O +
results O +
agree O +
in O +
general O +
with O +
those O +
ob- O +
tained O +
earlier O -
, O +
but O +
give O +
more O +
precise O +
data O +
as O +
to O +
the O +
localisation O +
of O +
proteins B-Gene +
in O +
the O +
ribosomal O +
subunit O -
. O +

MATERIAL O +
AND O +
METHODS O +
[ O -
~4C O -
] O -
MAI O +
was O +
prepared O +
immediately O +
before O +
use O +
according O +
to O +
Hunter O +
and O +
Ludwig O +
[ O -
3 O -
] O +
using O +
[ O -
~4C O -
] O +
acetonitrile O +
( O -
1.85 O +
mCi O -
/ O -
mmole O -
; O +
Institute O +
for O +
Isotopes O -
, O +
Budapest O -
) O -
. O +

[ O -
3H O -
] O -
NPA O -
, O +
synthesized O +
as O +
described O +
elsewhere O +
[ O -
4 O -
] O +
was O +
a O +
gift O +
from O +
Dr. O +
B. O +
Mehlis O -
. O +

Preparation O +
of O +
ribosomal O +
subunits O +
Polysomes O +
isolated O +
from O +
rat O +
livers O +
according O +
to O +
Noll O +
et O +
al. O +
[ O -
5 O -
] O +
were O +
in- O +
cubated O +
in O +
500 O +
mM O +
KCI O -
, O +
50 O +
mM O +
TEA O +
HC1 O -
, O +
pH O +
7.8 O -
, O +
1.5 O +
mM O +
MgC12 O -
, O +
5 O +
mM O +
fi O -
- O -
mercaptoethanol O +
and O +
0.1 O +
mM O +
puromycin O +
for O +
30 O +
min O +
at O +
0 O +
and O +
then O +
for O +
10 O +
min O +
at O +
37 O +
[ O -
6 O -
] O -
. O +

The O +
ribosomal O +
subunits O +
were O +
separated O +
according O +
to O +
Eikenberry O +
et O +
al. O +
[ O -
7 O -
] O +
and O +
pelleted O +
after O +
dilution O +
of O +
the O +
gradient O +
fractions O +
with O +
2 O +
vol O -
. O +
of O +
50 O +
mM O +
TEA O +
HC1 O -
, O +
pH O +
7.8 O -
, O +
30 O +
mM O +
MgC12 O -
. O +

Thereafter O +
the O +
sub- O +
units O +
were O +
dialysed O +
against O +
a O +
buffer O +
of O +
50 O +
mM O +
TEA O +
HC1 O -
, O +
pH O +
7.8 O -
, O +
50 O +
mM O +
KC1 O +
and O +
5 O +
mM O +
MgC12 O +
( O -
buffer O +
A O -
) O +
and O +
clarified O +
by O +
centrifugation O +
for O +
10 O +
min O +
at O +
10 O +
000 O +
g. O +
Isolation O +
of O +
proteins B-Gene +
of O +
ribosomal O +
subunits O +
To O +
the O +
solution O +
of O +
ribosomal O +
subunits O +
( O -
5 O +
mg O -
/ O -
ml O -
) O +
1 O -
/ O -
3 O +
vol O -
. O +
of O +
1 O +
N O +
HC1 O +
was O +
added O +
[ O -
8 O -
] O -
, O +
the O +
RNA O +
was O +
pelleted O +
by O +
centrifugation O +
for O +
10 O +
min O +
at O +
10 O +
000 O +
g O +
and O +
the O +
supernatant O +
dialysed O +
against O +
50 O +
mM O +
KC1 O -
, O +
50 O +
mM O +
TEA O +
HC1 O -
, O +
pH O +
7.8 O -
, O +
1 O +
mM O +
MgC12 O -
, O +
4 O +
M O +
urea O +
( O -
buffer O +
B O -
) O -
. O +

Substitution O +
of O +
proteins B-Gene +
or O +
ribosomal O +
subunits O +
by O +
[ O -
~4C O -
] O -
methyl O +
acetimidate O +
To O +
3 O +
mg O +
of O +
total O +
ribosomal O +
protein O +
mixture O +
in O +
1 O +
ml O +
buffer O +
B O +
or O +
to O +
5 O +
mg O +
ribosomal O +
subunits O +
in O +
1 O +
ml O +
buffer O +
A O -
, O +
3 O +
pmoles O +
MAI O +
were O +
added O +
and O +
incu- O +
bated O +
for O +
30 O +
min O +
at O +
37 O -
. O +

Thereafter O +
4 O +
M O +
NH4C1 O +
was O +
added O +
to O +
give O +
a O +
final O +
concentration O +
of O +
50 O +
mM. O +
The O +
proteins B-Gene +
were O +
isolated O +
as O +
described O +
and O +
dial- O +
ysed O +
against O +
6 O +
M O +
urea O -
, O +
5 O +
mM O +
methylamine O +
acetate O -
, O +
pH O +
5.0 O -
, O +
5 O +
mM O +
fi O -
- O -
mercap- O +
toethanol O -
. O +

A O +
label O +
of O +
4.9 O +
10s O +
dpm O +
with O +
an O +
average O +
error O +
of O +
+ O +
10 O -
% O +
was O +
counted O +
per O +
mg O +
protein B-Gene +
of O +
the O +
small O +
ribosomal O +
subunit O +
after O +
dialysis O +
against O +
0.1 O +
M O +
sodium O +
acetate O +
( O -
pH O +
5.5 O -
) O +
and O +
solubilization O +
in O +
a O +
hyamine O +
hydroxide O +
containing O +
scin- O +
tillation O +
mixture O +
as O +
described O +
below O -
. O +

Protein B-Gene +
was O +
estimated O +
by O +
the O +
Lowry O +
method O +
using O +
ribosomal B-Gene +
protein I-Gene +
as O +
a O +
standard O -
. O +

The O +
labelling O +
value O +
corre- O +
sponds O +
to O +
2.4 O +
acetimidoyl O +
groups O +
per O +
20 O +
000 O +
daltons O +
which O +
is O +
the O +
mean O +
molecular O +
weight O +
of O +
the O +
proteins B-Gene +
of O +
the O +
small O +
ribosomal O +
subunit O +
( O -
see O +
also O +
ref O -
. O +

5 O -
) O -
. O +

For O +
the O +
proteins B-Gene +
of O +
the O +
large O +
ribosomal O +
subunit O +
3.9 O +
acetimidoyl O +
groups O +
per O +
20 O +
000 O +
daltons O +
were O +
calculated O -
. O +

Substitution O +
of O +
proteins B-Gene +
or O +
ribosomal O +
subunits O +
by O +
[ O -
3 O +
H O -
] O -
p O -
- O -
nitrophenyl O +
acetate O +
The O +
substitution O +
was O +
performed O +
using O +
1.5 O +
pmoles O +
NPA O +
( O -
10 O +
mCi O -
/ O -
mmole O -
) O +
311 O +
per O +
1.0 O +
ml O +
by O +
incubation O +
for O +
60 O +
min O +
at O +
37 O +
in O +
analogy O +
to O +
the O +
reaction O +
de- O +
scribed O +
before O -
. O +

The O +
excess O +
of O +
reagent O +
was O +
destroyed O +
by O +
incubation O +
with O +
0.25 O +
N O +
HC1 O +
for O +
1 O +
h O +
at O +
0 O -
. O +

TABLE O +
I O +
SUBSTITUTION O +
OF O +
PROTEINS B-Gene +
ISOLATED O +
FROM O +
SMALL O +
RIBOSOME O +
SUBUNITS O +
OF O +
RAT O +
LIVER O +
AND O +
OF O +
SMALL O +
RIBOSOMAL O +
SUBUNITS O +
BY O +
[ O -
14C O -
] O -
METHYL O +
ACETIMIDATE O +
OR O +
BY O +
[ O +
3H O +
] O -
ao O -
- O -
NITROPHENYL O +
ACETATE O +
Average O +
values O +
of O +
5 O -
- O -
-10 O +
independent O +
experiments O +
are O +
given O -
; O +
the O +
average O +
errors O +
of O +
the O +
mean O +
values O +
not O +
specified O +
for O +
the O +
individual O +
proteins B-Gene +
did O +
not O +
exceed O +
10 O -
% O -
. O +

Small O +
subunit O +
protein B-Gene +
Label O +
of O +
proteins B-Gene +
obtained O +
by O +
[ O +
14C O -
] O -
methyl O +
acetimidate O +
Label O +
of O +
proteins B-Gene +
obtained O +

by O +
[ O -
3H O +
] O -
p O -
- O -
nitrophenyl O +
acetate O +
1 O +
2 O +
3 O +
4 O +
1 O +
2 O +
3 O +
Protein B-Gene +
Par- O +
Ratio O +
Classifi- O +
Protein B-Gene +
Par- O +

Ratio O +
mixture O +
ticle O +
of O +
2 O +
: O +
1 O +
cation O +
mixture O +
ticle O +
of O +
6 O +
: O +
5 O +
dpm O -
/ O -
AsT8"10 O -
- O -
3 O +
% O +
dpm O -
/ O -
AsTs O -
" O +
10 O -
- O -
3 O +
% O +
4 O +
Classifi- O +
cation O +
$ O -
1 O +
3.4 O +
4.3 O +
126 O +
23.2 O +
5.4 O +
23 O +
2 O +
4.4 O +

5.4 O +
123 O +
32.5 O +
15.4 O +
47 O +
+ O +
3 O +
n.d O -
. O +

3.8 O +
n.d O -
. O +

n.d O -
. O +

n.d O -
. O +

n.d O -
. O +

4 O +
7.5 O +
4.2 O +
56 O +
-- O +
19.8 O +
8.3 O +
42 O +
+ O +
5 O +
2.2 O +
6.1 O +
277 O +
+ O +
29.8 O +
7.4 O +
25 O +
6 O +
n.d O -
. O +

5.2 O +
n.d O -
. O +

36.1 O +
23.7 O +
66 O +
+ O +
7 O +
3.2 O +
5.8 O +
181 O +
+ O +
n.d O -
. O +

n.d O -
. O +

n.d O -
. O +

8 O +
4.1 O +
4.2 O +
102 O +
37.1 O +
13.9 O +
37 O +
+ O +
9 O +
6.1 O +
4.8 O +
79 O +
26.2 O +
4.1 O +
16 O +
-- O +
10 O +
5.0 O +
7.1 O +
142 O +
+ O +
33.6 O +
10.7 O +
32 O +
+ O +
11 O +
5.6 O +
3.8 O +
68 O +
-- O +
21.3 O +
6.9 O +
32 O +
+ O +
12 O +
5.4 O +
3.2 O +
59 O +
-- O +
27.4 O +
16.2 O +
59 O +
+ O +
13 O +
3.7 O +
2.9 O +
78 O +
15.6 O +
4.4 O +
28 O +
14 O +
6.1 O +
4.3 O +
70 O +
-- O +
34.1 O +
7.5 O +
22 O +
-- O +
15 O +
6.8 O +
6.8 O +
100 O +

26.7 O +
11.4 O +
43 O +
+ O +
16 O +
3.3 O +
4.4 O +
133 O +
+ O +
30.2 O +
7.1 O +
24 O +
17 O +
n.d O -
. O +

n.d O -
. O +

n.d O -
. O +

31.0 O +
7.2 O +
23 O +
18 O +
3.4 O +
4.3 O +
126 O +
22.5 O +
6.8 O +
30 O +
-+ O +
19 O +
3.8 O +
3.4 O +
89 O +
27.3 O +
5.5 O +
20 O +
-- O +
20 O +
5.2 O +
4.2 O +
81 O +
-+ O +
21.1 O +
3.9 O +
18 O +
-- O +
21 O +
3.9 O +
2.7 O +
69 O +
-- O +
17.3 O +
4.2 O +
24 O +
22 O +
4.4 O +
4.2 O +
95 O +
27.3 O +
9.1 O +
33 O +
+ O +
23 O +
n.d O -
. O +

n.d O -
. O +

n.d O -
. O +

25.4 O +
5.1 O +
20 O +
-- O +
24 O +
7.9 O +
5.2 O +
66 O +
-- O +
35.3 O +
7.3 O +
21 O +
-- O +
25 O +
7.9 O +
5.2 O +
66 O +
-- O +
33.3 O +
7.3 O +
22 O +
-- O +
26 O +
8.3 O +
9.0 O +
108 O +
24.7 O +
6.9 O +
28 O +
27 O +
4.4 O +
2.0 O +
45 O +
-- O +
15.1 O +
5.9 O +
39 O +
+ O +
28 O +
n.d O -
. O +

n.d O -
. O +

n.d O -
. O +

26.3 O +
3.0 O +
11 O +
-- O +
29 O +
4.3 O +
2.0 O +
46 O +
-- O +
10.6 O +
2.9 O +
27 O +
30 O +
n.d O -
. O +

4.7 O +
n.d O -
. O +

12.5 O +
2.7 O +
22 O +
-- O +
31 O +
n.d O -
. O +

n.d O -
. O +

n.d O -
. O +

n.d O -
. O +

n.d O -
. O +

n.d O -
. O +

TABLE O +
II O +
SUBSTITUTION O +
OF O +
PROTEINS B-Gene +
ISOLATED O +
FROM O +
LARGE O +
RIBOSOMAL O +
SUBUNITS O +
OF O +
RAT O +
LIVER O +
AND O +
OF O +
LARGE O +
RIBO- O +
SOMAL O +
SUBUNITS O +
BY O +
[ O +
14C O -
] O -
METHYL O +
ACETIMIDATE O +
Average O +
values O +
of O +
5 O -
- O -
-10 O +
independent O +
experiments O +
are O +
given O -
; O +
the O +
average O +
errors O +
of O +
the O +
mean O +
values O +
not O +
specified O +
for O +
the O +
individual O +
proteins O +
did O +
not O +
exceed O +
10 O -
% O -
. O +

b.a O +
b~ O +
Large O +
Labelling O +
coefficients O +
Large O +
subunit O +
subunit O +
protein B-Gene +
1 O +
2 O +
3 O +
4 O +
protein B-Gene +
Protein B-Gene +
Particle O +
Ratio O +
Classifi- O +
mixture O +
of O +
2 O +
: O +
1 O +
cation O +
dpm O -
/ O -
AsT8 O +
10 O -
- O -
3 O +
% O +
Labelling O +
coefficients O +
1 O +
2 O +
3 O +
4 O +
Protein B-Gene +
Particle O +
Ratio O +
Classifi- O +
mixture O +
of O +
2 O +
: O +
1 O +
cation O +
dpm O -
/ O -
AsTs O +
10 O -
- O -
3 O +
% O +
L O +
1 O +
n.d O -
. O +

5.8 O +
n.d O -
. O +

L O +
21 O +
2 O +
9.3 O -
. O +

1.1 O +
12 O +
-- O +
22 O +
3 O +
n.d O -
. O +

n.d O -
. O +

n.d O -
. O +

23 O +
4 O +
11.0 O +
3.0 O +
27 O +
+ O +
24 O +
5 O +
13.0 O +
4.6 O +
35 O +
+ O +
25 O +
6 O +
14.2 O +
5.1 O +
36 O +
+ O +
26 O +
7 O +
13.9 O +
3.0 O +
22 O +
+ O +
27 O +
8 O +
12.4 O +
2.2 O +
18 O +
-- O +
28 O +
9 O +
9.6 O +
1.9 O +
20 O +
-- O +
29 O +
10 O +
9.0 O +
1.8 O +
20 O +
-- O +
30 O +
11 O +
9.0 O +
1.8 O +
20 O +
-- O +
31 O +
12 O +
9.7 O +
n.d O -
. O +

n.d O -
. O +

32 O +
13 O +
6.9 O +
2.5 O +
36 O +
+ O +
33 O +
14 O +
n.d O -
. O +

n.d O -
. O +

n.d O -
. O +

34 O +
15 O +
8.1 O +
2.4 O +
30 O +
+ O +
35 O +
16 O +
n.d O -
. O +

3.5 O +
n.d O -
. O +

36 O +
17 O +
6.6 O +
3.0 O +
45 O +
+ O +
37 O +
18 O +
n.d O -
. O +

n.d O -
. O +

n.d O -
. O +

38 O +
19 O +
6.1 O +
1.0 O +
16 O +
-- O +
39 O +
20 O +
5.9 O +
1.4 O +
24 O +
-+ O +
10.1 O +
2.3 O +
23 O +
+ O +
12.3 O +
1.9 O +
15 O +
-- O +
5.9 O +
3.6 O +
61 O +
+ O +
4.8 O +
2.1 O +
44 O +
+ O +
8.3 O +
2.4 O +
29 O +
+ O +
6.2 O +
1.8 O +
29 O +
+ O +
8.2 O +
2.3 O +
28 O +
+ O +
6.6 O +
1.6 O +
24 O +
-+ O +
7.5 O +
2.3 O +
31 O +
+ O +
6.1 O +
1.9 O +
31 O +
+ O +
9.3 O +
1.3 O +
14 O +
-- O +
7.9 O +
1.3 O +
16 O +
-- O +
4.8 O +
1.5 O +
31 O +
+ O +
6.0 O +
2.4 O +
40 O +
+ O +
7.0 O +
2.0 O +
28 O +
+ O -
- O +
7.3 O +
1.7 O +
23 O +
+ O +
n.d O -
. O +

n.d O -
. O +

n.d O -
. O +

5.5 O +
3.1 O +
56 O +
+ O +
n.d O -
. O +

n.d O -
. O +

n.d O -
. O +

313 O +
For O +
the O +
proteins B-Gene +
of O +
the O +
small O +
ribosomal O +
subunit O +
1.9 O +
106 O +
dpm O +
per O +
mg O +
protein O +
were O +
measured O +
by O +
the O +
method O +
described O +
above O -
, O +
corresponding O +
to O +
1.7 O +
acetyl O +
groups O +
per O +
20 O +
000 O +
daltons O +
protein B-Gene -
. O +

TABLE O +
III O +
TENTATIVE O +
LOCALIZATION O +
OF O +
PROTEINS B-Gene +
IN O +
RIBOSOMAL O +
SUBUNITS O +
OF O +
RAT O +
LIVER O +
ESTIMATED O +
BY O +
USING O +
CHEMICAL O +
SUBSTITUTIONS O +
Small O +
Substitution O +
" O -
by O +
Preponderant O +
subunit O +
localization O +
protein B-Gene +
Methyl O +
p O -
- O -
Nitrophenyl O +
Iodo- O +
acetimidate O +
acetate O +
acetamide O +
S O +
2 O +
+ O +
+ O +
+ O +
exposed O +
5 O +
+ O +
-+ O +
+ O +
exposed O +
7 O +
+ O +
n.d O -
. O +

+ O +
exposed O +
8 O +
-+ O +
+ O +
+ O +
exposed O +
9 O +
+ O +
-- O +
-- O +
buried O +
10 O +
+ O +
+ O +

-+ O +
exposed O +
13 O +
+ O +
+ O +
+ O +
exposed O +
14 O +
-- O +
-- O +
-- O +
buried O +
19 O +
+ O +
-- O +
-- O +
buried O +
20 O +
+ O +
-- O +
-- O +

buried O +
24 O +
-- O +
-- O +
+ O +
buried O +
25 O +
-- O +
-- O +
-- O +
buried O +
27 O +
-- O +
+ O +
-- O +

buried O +
29 O +
-- O +
+ O +
-- O +
buried O +
30 O +
n.d O -
. O +

-- O +
-- O +
buried O +
Large O +
subunit O +
protein B-Gene +
L O +
1 O +
n.d O -
. O +

-- O +
buried O +
7 O +
+ O +
-- O +
buried O +
-- O +
buried O +
8 O +
-- O +
buried O +
10 O -
+ O -
11 O +
15 O +
+ O +
+ O +
exposed O +
17 O +
+ O +
+ O +
exposed O +
-- O +
buried O +
19 O +
20 O +
+ O -
- O +
+ O +
exposed O +
24 O +
+ O +
+ O +
exposed O +
25 O +
+ O +
+ O +
exposed O +
27 O +
+ O +
+ O +
exposed O +
28 O +
+ O +
-- O +
buried O +
29 O +
+ O +
+ O +
exposed O +
-- O +

buried O +
31 O +
-- O +
buried O +
32 O +
33 O +
+ O +
+ O +
exposed O +
34 O +
+ O +
+ O +
exposed O +
35 O +
-+ O +
+ O +
exposed O +
38 O +
+ O +
+ O +
exposed O +
314 O +
Two O -
- O -
dimensional O +
polyacrylamide O +
gel O +
electrophoresis O +
and O +
estimation O +
of O +
the O +
labelling O +
of O +
the O +
proteins B-Gene +
Electrophoresis O +
and O +
numbering O +
of O +
the O +
protein B-Gene +
spots O +
were O +
performed O +
as O +
de- O +
scribed O +
by O +
Welfle O +
et O +
al. O +
[ O -
9 O -
] O -
. O +

The O +
gel O +
slabs O +
were O +
stained O +
with O +
0.0005 O -
% O +
Coo- O +
massie O +
Brillant O +
Blue O +
G O +
250 O +
in O +
3 O -
% O +
trichloroacetic O +
acid O +
for O +
24 O +
h. O +
Thereafter O +
the O +
gel O +
pieces O +
containing O +
the O +
stained O +
proteins B-Gene +
were O +
cut O +
and O +
their O +
staining O +
intensi- O +
ties O +
measured O +
in O +
10 O +
mm O +
glass O +
cuvettes O +
at O +
578 O +
nm O -
. O +

For O +
the O +
estimation O +
of O +
the O +
labelling O +
the O +
gel O +
pieces O +
were O +
squashed O +
using O +
a O +
1 O +
ml O +
syringe O +
with O +
a O +
I O +
mm O +
aperture O +
and O +
incubated O +
for O +
16 O +
h O +
with O +
1 O +
ml O +
of O +
0.5 O +
N O +
hyamine O +
hydroxide O +
( O -
Packard O +
Instruments O -
, O +
Ill. O -
) O +
in O +
toluene O -
. O +

The O +
counting O +
efficiency O +
against O +
an O +
ex- O +
ternal O +
standard O +
was O +
about O +
80 O -
% O +
using O +
a O +
scintillation O +
mixture O +
with O +
0.4 O -
% O +
2,5- O +
diphenyloxazole O -
, O +
0.01 O -
% O +
1,4-bis- O -
( O -
5-phenyloxazol-2-yl O -
) O -
benzene O -
, O +
10 O -
% O +
Triton O +
X- O +
100 O -
, O +
0.3 O -
% O +
acetic O +
acid O +
in O +
toluene O -
. O +

After O +
measuring O +
the O +
label O +
for O +
10 O +
min O +
the O +
disin- O +
tegrations O +
per O +
min O +
( O -
dpm O -
) O +
were O +
correlated O +
for O +
each O +
spot O +
to O +
1.0 O +
A O +
s78 O -
. O +

The O +
average O +
values O +
of O +
5 O -
- O -
-10 O +
independent O +
experiments O +
are O +
given O +
in O +
Tables O +
I O +
and O +
II O -
. O +

The O +
average O +
errors O +
of O +
the O +
mean O +
values O +
not O +
specified O +
for O +
the O +
individual O +
proteins B-Gene +
did O +
not O +
exceed O +
10 O -
% O -
. O +

RESULTS O +
MAI O +
reacts O +
exclusively O +
with O +
the O +
amino O +
groups O +
of O +
proteins B-Gene +
[ O -
3 O -
] O -
, O +
whereas O +
NPA O +
also O +
substitutes O +
tyrosine O +
and O +
cysteine O +
residues O +
[ O -
10 O -
] O -
. O +

Because O +
of O +
the O +
relatively O +
high O +
lysine O +
content O -
, O +
the O +
low O +
portion O +
of O +
tyrosine O +
and O +
cysteine O +
in O +
ribosomal B-Gene +
proteins I-Gene +
of O +
rat O +
liver O +
[ O -
11 O -
] O +
and O +
the O +
lower O +
reactivity O +
of O +
tyrosine O +
OH- O +
groups O +
[ O -
12 O -
] O -
, O +
it O +
can O +
be O +
expected O +
that O +
both O +
reagents O +
predominantly O +
react O +
with O +
amino O +
groups O -
. O +

The O +
substitution O +
of O +
ribosomal B-Gene +
protein I-Gene +
mixtures O +
by O +
both O +
reagents O +
is O +
com- O +
pleted O +
after O +
30 O +
min O +
at O +
37 O +
to O +
more O +
than O +
90 O -
% O -
. O +

The O +
proteins B-Gene +
isolated O +
from O +
the O +
small O +
ribosomal O +
subunit O +
incorporate O +
on O +
the O +
average O +
1,7-acetyl O +
and O +
2,4- O +
acetimidoyl O +
groups O -
, O +
respectively O -
, O +
per O +
20 O +
000 O +
dalton O -
, O +
and O +
the O +
proteins B-Gene +
of O +
the O +
large O +
subunit O +
bind O +
3,9-acetimidoyl O +
groups O +
per O +
20 O +
000 O +
dalton O -
. O +

The O +
labelling O +
values O +
for O +
the O +
proteins B-Gene +
of O +
the O +
small O +
subunit O +
are O +
presented O +
in O +
Table O +
I. O +
The O +
values O +
for O +
labelling O +
of O +
the O +
protein B-Gene +
mixture O +
with O +
NPA O +
vary O +
from O +
10 O +
600 O +
to O +
37 O +
100 O +
dpm O +
per O +
1.0 O +
As78 O -
. O +

When O +
using O +
the O +
subunits O -
, O +
values O +
between O +
2700 O +
and O +
23 O +
700 O +
dpm O +
per O +
1.0 O +
AsTa O +
are O +
measured O -
. O +

It O +
is O +
obvious O +
from O +
these O +
results O +
that O +
the O +
reactive O +
groups O +
of O +
the O +
proteins B-Gene +
in O +
the O +
subunit O +
structure O +
are O +
only O +
available O +
to O +
about O +
10 O +
to O +
65 O -
% O -
. O +

28 O +
proteins B-Gene +
can O +
be O +
classified O +
into O +
3 O +
groups O +
with O +
10 O -
- O -
-22 O -
% O -
, O +
23 O -
- O -
-30 O -
% O +
and O +
31 O -
- O -
-66 O -
% O +
remaining O +
reactivity O -
: O +
Proteins B-Gene +
$ B-Gene -
9 I-Gene -
, O +
14 B-Gene -
, O +
19 B-Gene -
, O +
20 B-Gene -
, O +
23 B-Gene -
, O +
24 B-Gene -
, O +
25 B-Gene -
, O +
28 B-Gene +
and O +
30 B-Gene +
{ O -
marked O +
by-- O -
) O +
are O +
strongly O +
protected O -
, O +
the O +
reactivity O +
of O +
9 O +
other O +
proteins B-Gene +
is O +
diminished O +
moderately O +
( O -
$ B-Gene -
1 I-Gene -
, O +
5 B-Gene -
, O +
13 B-Gene -
, O +
16 B-Gene -
, O +
17 B-Gene -
, O +
18 B-Gene -
, O +
21 B-Gene -
, O +
26 B-Gene +
and O +
29 B-Gene +
( O -
marked O +
by O +
+ O -
) O -
, O +
and O +
the O +
proteins B-Gene +
$ B-Gene -
2 I-Gene -
, O +
4 B-Gene -
, O +
6 B-Gene -
, O +
8 B-Gene -
, O +
10 B-Gene -
, O +
11 B-Gene -
, O +
12 B-Gene -
, O +
15 B-Gene -
, O +
22 B-Gene +
and O +
27 B-Gene +
( O -
marked O +
by O +
+ O -
) O +
are O +
exposed O +
to O +
a O +
relatively O +
high O +
extent O -
. O +

The O +
reaction O +
of O +
proteins B-Gene +
with O +
MAI O +
in O +
the O +
small O +
ribosomal O +
subunit O +
is O +
on O +
the O +
average O +
only O +
little O +
decreased O +
in O +
comparison O +
to O +
the O +
free O +
proteins B-Gene -
. O +

As O +
demon- O +
strated O +
in O +
Table O +
I O -
, O +
the O +
reactivity O +
of O +
proteins B-Gene +
$ B-Gene -
4 I-Gene -
, O +
11 B-Gene -
, O +
12 B-Gene -
, O +
14 B-Gene -
, O +
21 B-Gene -
, O +
24 B-Gene -
, O +
25 B-Gene -
, O +
27 B-Gene +
and O +
29 B-Gene +
( O -
marked O +
by O +
-- O -
} O +
is O +
inhibited O +
by O +
30 O -
% O +
or O +
more O +
if O +
the O +
subunit O +
is O +
com- O +
315 O +
pared O +
with O +
the O +
protein B-Gene +
mixture O -
. O +

The O +
proteins B-Gene +
$ B-Gene -
5 I-Gene -
, O +
7 B-Gene -
, O +
10 B-Gene +
and O +
16 B-Gene +
( O -
marked O +
by O +
+ O +
} O +
are O +
labelled O +
more O +
strongly O +
in O +
the O +
subunit O +
than O +
in O +
the O +
isolated O +
protein B-Gene +
mixture O -
, O +
showing O +
values O +
of O +
more O +
than O +
130 O -
% O -
. O +

For O +
11 O +
proteins B-Gene +
( O -
S1 B-Gene -
, O +
2 B-Gene -
, O +
8 B-Gene -
, O +
9 B-Gene -
, O +
13 B-Gene -
, O +
15 B-Gene -
, O +
18 B-Gene -
, O +
19 B-Gene -
, O +
20 B-Gene -
, O +
22 B-Gene +
and O +
26 B-Gene -
; O +
marked O +
by O +
-+ O -
) O -
, O +
the O +
labelling O +
is O +
about O +
the O +
same O +
both O +
in O +
the O +
subunit O +
and O +
in O +
the O +
protein O +
mixture O +
{ O -
70 O -
- O -
-130% O -
} O -
. O +
A O +
stronger O +
inhibition O +
of O +
the O +
reaction O +
of O +
MAI O +
with O +
proteins B-Gene +
is O +
observed O +
in O +
the O +
large O +
ribosomal O +
subunit O +
( O -
Table O +
II O -
) O -
. O +

On O +
the O +
average O +
a O +
value O +
of O +
30 O -
% O +
is O +
es- O +
timated O +
in O +
comparison O +
ta O +
the O +
protein B-Gene +
mixture O -
. O +

Proteins B-Gene +
L2 B-Gene -
, O +
8 B-Gene -
, O +
9 B-Gene -
, O +
10 B-Gene -
, O +
11 B-Gene -
, O +
19 B-Gene -
, O +
22 B-Gene -
, O +
31 B-Gene +
and O +
32 B-Gene +
( O -
marked O +
by O +
-- O -
) O +
in O +
the O +
subunit O +
structure O +
take O +
up O +
only O +
20 O -
% O +
or O +
even O +
less O +
of O +
the O +
label O +
taken O +
up O +
by O +
the O +
isolated O +
protein B-Gene +
mixture O -
. O +

When O +
la- O +
belled O +
in O +
the O +
subunit O +
a O +
second O +
group O +
of O +
proteins B-Gene +
( O -
L4 B-Gene -
, O +
7 B-Gene -
, O +
20 B-Gene -
, O +
21 B-Gene -
, O +
27 B-Gene -
, O +
28 B-Gene -
, O +
35 B-Gene +
and O +
36 B-Gene -
; O +
marked O +
by O +
+ O -
) O +
show O +
21 O -
- O -
-28 O -
% O +
and O +
a O +
third O +
group O +
{ O -
L5 B-Gene -
, O +
6 B-Gene -
, O +
13 B-Gene -
, O +
15 B-Gene -
, O +
17 B-Gene -
; O +
23 B-Gene -
, O +
24 B-Gene -
, O +
25 B-Gene -
, O +
26 B-Gene -
, O +
29 B-Gene -
, O +
30 B-Gene -
, O +
33 B-Gene -
, O +
34 B-Gene +
and O +
38 B-Gene -
; O +
marked O +
by O +
+ O -
) O -
more O +
than O +
29 O -
% O +
of O +
the O +
label O +
of O +
the O +
protein O +
mixture O -
. O +

DISCUSSION O +
Chemical O +
substitutions O +
of O +
ribosomal B-Gene +
proteins I-Gene +
by O +
iodoacetate O +
and O +
2- O +
methoxy-5-nitrotropone O +
[ O -
13 O -
] O -
, O +
fluorescein O +
isothiocyanate O +
[ O -
14 O -
] O -
, O +
acetanhy- O +
dride O +
[ O -
15 O -
] O -
, O +
iodine O +
[ O -
16,17 O -
] O -
, O +
5,5-dithiobis- O -
( O -
2-nitro O -
- O -
benzoic O +
acid O -
) O +
[ O -
18 O -
] O -
, O +
N- O +
ethyl O -
- O -
maleimide O +
and O +
iodoacetamide O +
[ O -
19 O -
] O -
, O +
aldehydes O +
[ O -
20 O -
] O +
and O +
kethoxal O +
[ O -
21 O -
] O +
have O +
been O +
successfully O +
used O +
to O +
elucidate O +
the O +
topography O +
of O +
proteins B-Gene +
in O +
ribo- O +
somal O +
subunits O +
of O +
E. O +
coli O -
. O +

As O +
was O +
demonstrated O +
before O -
, O +
all O +
proteins B-Gene +
organized O +
in O +
the O +
ribosomal O +
sub- O +
units O +
of O +
rat O +
liver O +
are O +
accessible O +
to O +
the O +
reaction O +
with O +
MAI O +
and O +
with O +
NPA O -
. O +

The O +
extent O +
of O +
reaction O -
, O +
however O -
, O +
is O +
less O +
than O +
with O +
the O +
isolated O +
protein B-Gene +
mixture O -
. O +

Both O +
findings O +
are O +
in O +
good O +
agreement O +
with O +
results O +
obtained O +
with O +
iodoacet- O +
amide O +
[ O -
2 O -
] O -
, O +
2-methoxy-5-nitrotropone O +
[ O -
22 O -
] O +
and O +
also O +
with O +
conclusions O +
drawn O +
from O +
iodination O +
experiments O +
[ O -
23 O -
] O -
. O +

When O +
comparing O +
experiments O +
with O +
MAI O +
and O +
NPA O +
it O +
is O +
remarkable O +
that O +
the O +
reactivity O +
to O +
NPA O +
of O +
the O +
proteins B-Gene +
organized O +
in O +
the O +
small O +
ribosomal O +
subunit O +
is O +
inhibited O +
more O +
strongly O +
than O +
the O +
reactivity O +
to O +
MAI O +
in O +
comparison O +
to O +
the O +
free O +
protein B-Gene +
mixture O -
. O +

This O +
may O +
be O +
due O +
to O +
the O +
less O +
hydrophilic O +
properties O +
of O +
NPA O +
which O +
prevent O +
this O +
reagent O +
from O +
penetrating O +
the O +
ribosomal O +
subunit O +
structure O +
as O +
readily O +
as O +
the O +
more O +
hydrophilic O +
MAI O +
obviously O +
can O -
. O +

The O +
reaction O +
of O +
the O +
proteins B-Gene +
in O +
the O +
small O +
ribosomal O +
subunit O +
to O +
MAI O -
, O +
on O +
the O +
whole O -
, O +
occurs O +
more O +
readily O +
than O +
those O +
in O +
the O +
large O +
ribosomal O +
subunit O +
in O +
com- O +
parison O +
to O +
the O +
corresponding O +
free O +
protein B-Gene +
mixtures O -
. O +

This O +
finding O +
favours O +
a O +
more O +
dense O +
structure O +
of O +
the O +
large O +
ribosomal O +
subunit O -
. O +

The O +
explanation O +
that O +
more O +
reactive O +
protein B-Gene +
groups O +
are O +
localized O +
on O +
the O +
surface O +
of O +
the O +
small O +
ribo- O +
somal O +
subunit O +
in O +
comparison O +
to O +
their O +
total O +
number O +
than O +
in O +
the O +
large O +
ribo- O +
somal O +
subunit O +
is O +
unlikely O -
, O +
because O +
the O +
reaction O +
of O +
small O +
and O +
large O +
subunit O +
proteins O +
with O +
NPA O +
is O +
inhibited O +
to O +
the O +
same O +
extent O +
in O +
the O +
subunit O +
structures O -
. O +

Different O +
proportions O +
of O +
reactive O +
amino O +
groups O +
in O +
small O +
and O +
large O +
ribosomal O +
subunits O +
from O +
E. O +
coli O +
have O +
also O +
been O +
reported O +
by O +
Slobin O +
[ O -
24 O -
] O +
using O +
methyl O +
picolinimidate O -
. O +

316 O +
If O +
the O +
proteins B-Gene +
are O +
classified O +
as O +
weakly O +
exposed O +
( O -
-- O -
) O -
, O +
moderately O +
exposed O +
( O -
-+ O -
) O +
and O +
strongly O +
exposed O +
( O -
+ O -
) O +
proteins O -
, O +
it O +
can O +
be O +
demonstrated O +
that O +
the O +
re- O +
sults O +
obtained O +
with O +
different O +
reagents O +
agree O +
for O +
the O +
preponderantly O +
buried O +
proteins B-Gene +
$ B-Gene -
14 I-Gene -
, O +
25 B-Gene -
, O +
L8 B-Gene -
, O +
10 B-Gene -
, O +
11 B-Gene -
, O +
19 B-Gene -
, O +
31 B-Gene +
and O +
32 B-Gene +
and O +
for O +
the O +
mainly O +
exposed O +
pro- B-Gene +
teins I-Gene +
L15 B-Gene -
, O +
17 B-Gene -
, O +
25 B-Gene -
, O +
29 B-Gene -
, O +
33 B-Gene -
, O +
34 B-Gene +
and O +
38 B-Gene +
( O -
see O +
Table O +
III O -
) O -
. O +

For O +
the O +
other O +
proteins B-Gene +
also O +
listed O +
in O +
Table O +
III O -
, O +
the O +
results O +
obtained O +
with O +
different O +
reagents O +
are O +
not O +
in O +
full O +
agreement O -
. O +

However O -
, O +
the O +
accessibility O +
of O +
proteins B-Gene +
in O +
the O +
subunit O +
struc- O +
ture O +
to O +
trypsin B-Gene +
[ O -
25 O -
] O +
and O +
their O +
tendency O +
to O +
be O +
split O +
from O +
the O +
subunits O +
by O +
dif- O +
ferent O +
LiC1 O +
concentrations O +
[ O -
26 O -
] O +
argue O +
in O +
favour O +
of O +
a O +
relatively O +
buried O +
locali- O +
zation O +
of O +
the O +
proteins B-Gene +
$ B-Gene -
9 I-Gene -
, O +
19 B-Gene -
, O +
20 B-Gene -
, O +
24 B-Gene -
, O +
27 B-Gene -
, O +
29 B-Gene -
, O +
30 B-Gene -
, O +
L1 B-Gene -
, O +
7 B-Gene +
and O +
28 B-Gene +
and O +
an O +
ex- O +
posed O +
arrangement O +
of O +
the O +
proteins B-Gene +
$ B-Gene -
2,5 I-Gene -
, O +
7 B-Gene -
, O +
8 B-Gene -
, O +
10 B-Gene -
, O +
13 B-Gene -
, O +
L20 B-Gene -
, O +
24 B-Gene -
, O +
27 B-Gene +
and O +
35 B-Gene -
. O +

Exposed O +
positions O +
were O +
also O +
reported O +
for O +
proteins B-Gene +
moving O +
electrophoreti- O +
cally O +
like O +
L17 B-Gene -
, O +
24 B-Gene +
and O +
29 B-Gene +
by O +
Reboud O -
, O +
studying O +
the O +
reaction O +
of O +
large O +
subunits O +
of O +
rat O +
liver O +
ribosomes O +
with O +
2-methoxy-5-nitrotropone O +
and O +
glutaraldehyde O +
[ O +
22 O +
] O -
, O +
respectively O -
. O +

Glutamate O +
contributes O +
to O +
secondary O +
brain O +
damage O -
, O +
resulting O +
in O +
cell O +
swelling O +
and O +
brain O +
edema O -
. O +

Under O +
in O +
vitro O +
conditions O -
, O +
increased O +
extracellular O +
levels O +
of O +
the O +
amino O +
acid O +
taurine O +
reflect O +
glutamate O -
- O -
induced O +
osmotic O +
cell O +
swelling O -
. O +

In O +
vivo O -
, O +
increases O +
in O +
cerebrospinal O +
fluid O +
( O -
CSF O -
) O +
taurine O +
could O -
, O +
therefore O -
, O +
unmask O +
glutamate O -
- O -
mediated O +
cytotoxic O +
edema O +
formation O +
and O +
possibly O +
differentiate O +
it O +
from O +
vasogenic O +
edema O -
. O +

To O +
test O +
this O +
hypothesis O -
, O +
ventricular O +
CSF O +
glutamate O +
and O +
taurine O +
levels O +
were O +
measured O +
in O +
28 O +
severely O +
brain O -
- O -
injured O +
patients O +
on O +
days O +
1 O -
, O +
5 O -
, O +
and O +
14 O +
after O +
trauma O -
. O +

Posttraumatic O +
changes O +
in O +
CSF O +
amino O +
acids O +
were O +
investigated O +
in O +
regard O +
to O +
extent O +
of O +
tissue O +
damage O +
and O +
alterations O +
in O +
brain O +
edema O +
as O +
estimated O +
by O +
computerized O +
tomography O -
. O +

On O +
day O +
1 O -
, O +
CSF O +
glutamate O +
and O +
taurine O +
levels O +
were O +
significantly O +
increased O +
in O +
patients O +
with O +
subdural O +
or O +
epidural O +
hematomas O +
( O -
8+ O -
/ O -
-0.8 O -
/ O -
71+ O -
/ O -
-12 O +
microM O -
) O -
, O +
contusions O +
( O -
21+ O -
/ O -
-4.1 O -
/ O -
122+ O -
/ O -
-18 O +
microM O -
) O -
, O +
and O +
generalized O +
brain O +
edema O +
( O -
13+ O -
/ O -
-3.2 O -
/ O -
80+ O -
/ O -
-15 O +
microM O -
) O +
compared O +
to O +
lumbar O +
control O +
CSF O +
( O -
1.3+ O -
/ O -
-0.1 O -
/ O -
12+ O -
/ O -
-1 O +
microM O -
; O +
p O +
< O +
0.001 O -
) O -
. O +

CSF O +
amino O +
acids O -
, O +
however O -
, O +
did O +
not O +
reflect O +
edema O +
formation O +
and O +
resolution O +
as O +
estimated O +
by O +
computerized O +
tomography O -
. O +

CSF O +
taurine O +
correlated O +
positively O +
with O +
glutamate O -
, O +
eventually O +
depicting O +
glutamate O -
- O -
induced O +
cell O +
swelling O -
. O +

However O -
, O +
parallel O +
neuronal O +
release O +
of O +
taurine O +
with O +
its O +
inhibitory O +
function O +
can O -
not O +
be O +
excluded O -
. O +

Thus O -
, O +
the O +
sensitivity O +
of O +
taurine O +
in O +
unmasking O +
cytotoxic O +
edema O +
formation O +
is O +
weakened O +
by O +
the O +
inability O +
in O +
defining O +
its O +
origin O +
and O +
function O +
under O +
the O +
conditions O +
chosen O +
in O +
the O +
present O +
study O -
. O +

Overall O -
, O +
persisting O +
pathologic O +
ventricular O +
CSF O +
glutamate O +
and O +
taurine O +
levels O +
are O +
highly O +
suggestive O +
of O +
ongoing O +
glial O +
and O +
neuronal O +
impairment O +
in O +
humans O +
following O +
severe O +
traumatic O +
brain O +
injury O -
. O +

Dopamine O +
is O +
a O +
biogenic O +
amine O +
synthesized O +
in O +
the O +
hypothalamus O -
, O +
in O +
the O +
arcuate O +
nucleus O -
, O +
the O +
caudad O -
, O +
and O +
various O +
areas O +
of O +
the O +
central O +
and O +
peripheral O +
nervous O +
system O -
. O +

It O +
has O +
been O +
widely O +
established O +
that O +
dopamine O +
and O +
its O +
agonists O +
play O +
an O +
important O +
role O +
in O +
cardiovascular O -
, O +
renal O -
, O +
hormonal O -
, O +
and O +
central O +
nervous O +
system O +
regulation O +
through O +
stimulation O +
of O +
alpha B-Gene +
and I-Gene +
beta I-Gene +
adrenergic I-Gene +
and O +
dopaminergic B-Gene +
receptors I-Gene -
. O +

There O +
are O +
several O +
agonists O +
of O +
dopamine-2 B-Gene +
( I-Gene -
DA I-Gene +
2 I-Gene +
) I-Gene +
dopaminergic I-Gene +
receptors I-Gene -
, O +
such O +
as O +
bromocriptine O -
, O +
pergolide O -
, O +
lisuride O -
, O +
quinpirole O -
, O +
and O +
carmoxirole O -
, O +
which O +
inhibit O +
norepinephrine O +
release O +
and O +
produce O +
a O +
decrease O +
in O +
arterial O +
blood O +
pressure O -
; O +
in O +
some O +
cases O -
, O +
bromocriptine O +
and O +
pergolide O +
also O +
reduce O +
heart O +
rate O -
. O +

From O +
a O +
therapeutic O +
point O +
of O +
view O -
, O +
the O +
above O -
- O -
mentioned O +
agonists O +
are O +
used O +
for O +
treating O +
Parkinson O -
's O +
disease O -
, O +
acting O +
over O +
DA B-Gene +
2 I-Gene +
dopaminergic I-Gene +
receptors I-Gene +
of O +
the O +
nigrostriatal O +
system O -
. O +

Bromocriptine O +
and O +
the O +
other O +
dopaminergic O +
agonists O +
mentioned O +
act O +
over O +
DA B-Gene +
2 I-Gene +
receptors I-Gene +
of O +
the O +
tuberoinfundibular O +
system O -
, O +
inhibiting O +
prolactin O +
release O +
and O +
decreasing O +
hyperprolactinemia O +
and O +
tumor O +
size O -
. O +

Among O +
DA B-Gene +
1 I-Gene +
receptor I-Gene +
agonists O -
, O +
we O +
can O +
mention O +
fenoldopam O -
, O +
piribedil O -
, O +
ibopamine O -
, O +
SKF O +
3893 O -
, O +
and O +
apomorphine O +
( O -
nonspecific O -
) O -
. O +

Activation O +
of O +
these O +
receptors O +
decreases O +
peripheral O +
resistance O -
, O +
inducing O +
lowering O +
of O +
arterial O +
blood O +
pressure O +
and O +
increases O +
in O +
heart O +
rate O -
, O +
sympathetic O +
tone O -
, O +
and O +
activity O +
of O +
the O +
renin O +
aldosterone O +
system O -
. O +

Among O +
DA B-Gene +
2 I-Gene +
receptor I-Gene +
antagonists O -
, O +
we O +
can O +
mention O +
metoclopramide O -
, O +
domperidone O -
, O +
sulpiride O -
, O +
and O +
haloperidol O -
. O +

From O +
a O +
therapeutic O +
point O +
of O +
view O -
, O +
metoclopramide O +
and O +
domperidone O +
are O +
used O +
in O +
gastric O +
motility O +
disorders O -
, O +
and O +
haloperidol O +
is O +
used O +
in O +
psychotic O +
alterations O -
. O +

Antagonists O +
of O +
DA B-Gene +
1 I-Gene +
receptors I-Gene +
are O +
SCH23390 O +
and O +
clozapine O -
. O +

Clozapine O +
is O +
used O +
for O +
treating O +
schizophrenia O -
. O +

Administered O +
to O +
rats O +
by O +
stomach O +
tubing O +
oxythioquinox O +
( O -
Morestan O -
) O +
toxicity O +
is O +
very O +
strongly O +
increased O +
after O +
solubilisation O +
in O +
olive O +
oil O -
. O +

The O +
oxythioquinox O +
DL50 O -
, O +
in O +
this O +
case O -
, O +
is O +
500 O +
mg O -
/ O -
kg O +
although O +
we O +
can O +
reach O +
2.8 O +
g O -
/ O -
kg O +
in O +
aqueous O +
suspensions O -
. O +

When O +
it O +
is O +
administered O +
( O -
1 O +
g O -
/ O -
kg O -
) O +
in O +
aqueous O +
suspension O -
, O +
the O +
decrease O +
in O +
body O +
weight O +
is O +
the O +
same O +
as O +
these O +
observed O +
with O +
a O +
5 O +
fold O +
lower O +
dose O +
in O +
oil O -
. O +

Conversion O +
rate O +
feed O +
and O +
weight O +
of O +
differents O +
organs O +
decrease O +
when O +
animals O +
are O +
daily O +
submitted O +
to O +
oxythioquinox O +
in O +
oil O -
, O +
during O +
16 O +
days O -
, O +
compared O +
with O +
animals O +
treated O +
with O +
an O +
equivalent O +
dose O +
in O +
aqueous O +
suspension O -
. O +

Potentiation O -
, O +
in O +
oil O +
solutions O -
, O +
of O +
the O +
decrease O +
of O +
oxythioquinox O +
intestinal O +
transit O -
, O +
promoting O +
its O +
absorption O -
, O +
could O +
explain O +
the O +
increase O +
of O +
oxythioquinox O +
toxicity O +
in O +
oil O +
solution O -
. O +

We O +
have O +
previously O +
shown O +
that O +
the O +
methyl O +
ester O +
of O +
hepoxilin O +
A3 O +
causes O +
a O +
receptor B-Gene -
- O -
induced O +
rise O +
in O +
intracellular O +
calcium O +
through O +
the O +
release O +
from O +
intracellular O +
stores O +
in O +
suspended O +
human O +
neutrophils O -
. O +

The O +
corresponding O +
free O +
acid O +
was O +
devoid O +
of O +
activity O -
. O +

We O +
now O +
report O +
that O +
the O +
action O +
of O +
the O +
free O +
acid O +
form O +
of O +
hepoxilin O +
A3 O +
is O +
dependent O +
on O +
the O +
type O +
of O +
vehicle O +
used O -
, O +
i.e. O +
it O +
is O +
active O +
in O +
releasing O +
calcium O +
when O +
used O +
in O +
an O +
ethanol O +
vehicle O +
but O +
not O +
in O +
DMSO O -
. O +

The O +
methyl O +
ester O +
is O +
equally O +
active O +
in O +
either O +
vehicle O -
. O +

The O +
pattern O +
of O +
calcium O +
release O +
between O +
the O +
free O +
acid O +
and O +
the O +
methyl O +
ester O +
is O +
qualitatively O +
different O -
. O +

Both O +
compounds O +
show O +
a O +
biphasic O +
pattern O -
, O +
i.e. O +
an O +
initial O +
rapid O +
phase O +
followed O +
by O +
a O +
slow O +
decline O +
in O +
calcium O +
levels O +
but O +
never O +
reaching O +
pre O -
- O -
hepoxilin O +
A3 O +
baseline O +
levels O -
. O +

The O +
methyl O +
ester O +
appears O +
slightly O +
more O +
potent O +
in O +
the O +
initial O +
phase O +
of O +
calcium O +
release O +
than O +
the O +
free O +
acid O +
( O -
methyl O +
= O +
188+ O -
/ O -
-14 O +
S.D. O -
, O +
free O +
acid O +
= O +
135+ O -
/ O -
-11 O +
S.D. O +
nM O -
, O +
P O +
< O +
0.0005 O -
) O -
. O +

Both O +
compounds O +
appear O +
to O +
reach O +
the O +
same O +
calcium O +
levels O +
at O +
the O +
plateau O +
of O +
the O +
second O +
prolonged O +
phase O +
( O -
methyl O +
= O +
88+ O -
/ O -
-8 O +
S.D. O -
, O +
free O +
acid O +
= O +
107+ O -
/ O -
-15 O +
S.D. O +
nM O -
, O +
not O +
significant O -
) O -
. O +

Lanthanum O +
chloride O +
( O -
an O +
inhibitor O +
of O +
calcium O +
influx O -
) O +
interfered O +
with O +
the O +
second O +
phase O +
of O +
the O +
curve O +
causing O +
calcium O +
levels O +
to O +
return O +
to O +
normal O +
pre O -
- O -
hepoxilin O +
levels O +
for O +
both O +
compounds O -
. O +

Addition O +
of O +
lanthanum O +
chloride O +
prior O +
to O +
the O +
hepoxilin O +
addition O +
or O +
carrying O +
out O +
the O +
experiments O +
in O +
calcium O -
- O -
free O +
medium O -
, O +
eliminated O +
the O +
second O +
phase O +
completely O -
, O +
with O +
the O +
calcium O +
peak O +
returning O +
rapidly O +
to O +
normal O +
baseline O +
levels O -
, O +
suggesting O +
that O +
the O +
second O +
phase O +
is O +
due O +
to O +
calcium O +
influx O -
. O +

Again O +
the O +
methyl O +
ester O +
is O +
more O +
active O +
than O +
the O +
free O +
acid O +
( O -
methyl O -
, O +
189+ O -
/ O -
-12 O -
; O +
free O +
acid O -
, O +
145+ O -
/ O -
-6 O +
S.D. O +
nM O -
, O +
P<0.005 O -
) O -
. O +

Additional O +
experiments O +
with O +
tritium O -
- O -
labelled O +
methyl O +
ester O +
of O +
hepoxilin O +
A3 O +
demonstrated O +
that O +
the O +
compound O +
is O +
hydrolyzed O +
into O +
the O +
free O +
acid O +
intracellularly O -
. O +

These O +
experiments O +
demonstrate O +
that O +
DMSO O +
interacts O +
with O +
hepoxilin O +
free O +
acid O -
, O +
interfering O +
with O +
its O +
entry O +
into O +
the O +
cell O +
while O +
ethanol O +
does O +
not O -
. O +

Once O +
inside O +
the O +
cell O -
, O +
hepoxilin O +
interacts O +
with O +
its O +
own O +
receptor O +
to O +
release O +
calcium O +
rapidly O +
from O +
stores O -
, O +
but O +
it O +
also O +
causes O +
a O +
more O +
prolonged O +
influx O +
of O +
calcium O +
from O +
the O +
extracellular O +
milieu O -
. O +

We O +
have O +
recently O +
shown O +
that O +
hepoxilin O +
( O -
Hx O -
) O +
A3 O +
interacts O +
with O +
a O +
specific O +
binding B-Gene +
protein I-Gene +
in O +
the O +
intact O +
human O +
neutrophil O +
resulting O +
in O +
the O +
release O +
of O +
intracellular O +
calcium O +
[ O -
1 O -
] O +
. O +

In O +
those O +
studies O +
we O +
used O +
the O +
methyl O +
( O -
Me O -
) O +
ester O +
form O +
in O +
DMSO O +
because O +
we O +
found O +
that O +
the O +
free O +
acid O +
( O -
FA O -
) O +
was O +
without O +
effect O +
in O +
intact O +
cells O +
both O +
in O +
terms O +
of O +
binding O +
and O +
calcium O +
release O +
[ O -
2 O -
] O +
. O +

We O +
also O +
found O +
that O +
both O +
the O +
FA O +
and O +
Me O +
ester O +
( O -
in O +
DMSO O -
) O +
were O +
active O +
in O +
specific O +
binding O +
to O +
disrupted O +
neutrophil O +
membranes O +
[ O -
3 O -
] O +
. O +

This O +
suggested O +
that O +
the O +
FA O +
did O +
not O +
penetrate O +
into O +
the O +
intact O +
cell O +
and O +
that O +
the O +
binding B-Gene +
protein I-Gene +
was O +
intracellular O +
and O +
not O +
at O +
the O +
outside O +
surface O +
of O +
the O +
plasma O +
membrane O -
. O +

We O +
now O +
describe O +
new O +
findings O +
which O +
support O +
a O +
binding O -
/ O -
calcium O +
release O +
coupling O +
where O +
both O +
the O +
FA O +
and O +
the O +
Me O +
ester O +
are O +
found O +
active O +
( O -
in O +
ethanol O +
vehicle O -
) O +
in O +
the O +
intact O +
neutrophil O +
and O +
demonstrate O +
a O +
biphasic O +
action O +
of O +
HxA3 O +
, O +
one O +
in O +
releasing O +
calcium O +
from O +
intracellular O +
stores O -
, O +
a O +
second O +
in O +
increasing O +
calcium O +
influx O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Materials O +
Pure O +
8 O -
( O -
R O -
) O -
-HxA3 O +
Me O +
ester O +
was O +
prepared O +
in O +
our O +
laboratory O +
as O +
previously O +
reported O +
[ O -
4 O -
] O +
. O +

The O +
FA O +
was O +
prepared O +
by O +
hydrolysis O +
of O +
the O +
Me O +
ester O +
with O +
1 O +
N O +
KOH O -
/ O -
ethanol O +
followed O +
by O +
mild O +
acidification O -
, O +
extraction O +
and O +
further O +
purification O +
by O +
chromatography O +
[ O -
5 O -
] O +
. O +

[ O -
3 O +
H6 O +
] O -
( O -
8R O -
) O -
-HxA3 O +
Me O +
ester O +
was O +
prepared O +
as O +
previously O +
reported O +
[ O -
5 O -
] O +
. O +

Lanthanum O +
chloride O +
was O +
purchased O +
from O +
Sigma O +
( O -
St. O +
Louis O -
, O +
MO O -
, O +
USA O -
) O -
. O +

2.2 O +
Preparation O +
of O +
human O +
neutrophils O +
Human O +
neutrophils O +
were O +
prepared O +
essentially O +
as O +
described O +
previously O +
[ O -
3 O -
] O +
. O +

Typically O -
, O +
neutrophils O +
were O +
obtained O +
from O +
40 O +
ml O +
venous O +
blood O +
from O +
volunteers O +
that O +
had O +
not O +
taken O +
any O +
medication O -
. O +

The O +
blood O +
was O +
anti O -
- O -
coagulated O +
with O +
heparin O +
sodium O +
( O -
Organon O +
Tecknica O -
, O +
Durham O -
, O +
NC O -
, O +
USA O -
) O -
. O +

Erythrocytes O +
were O +
removed O +
by O +
4.5 O -
% O +
dextran O +
sedimentation O -
. O +

Neutrophils O +
were O +
collected O +
and O +
pelleted O +
after O +
Ficoll O -
- O -
Paque O +
gradient O +
centrifugation O -
. O +

Further O +
removal O +
of O +
contaminating O +
erythrocytes O +
was O +
carried O +
out O +
by O +
ammonium O +
chloride O +
lysis O -
. O +

After O +
washing O +
twice O +
with O +
centrifugation O -
, O +
neutrophils O +
were O +
resuspended O +
in O +
RPMI O +
1640 O +
medium O +
and O +
were O +
counted O +
in O +
a O +
Coulter O +
counter O +
( O -
Model O +
901 O -
) O -
. O +

The O +
cells O +
were O +
adjusted O +
to O +
a O +
concentration O +
of O +
107 O +
cells O -
/ O -
ml O +
in O +
RPMI O +
1640 O +
medium O -
. O +

2.3 O +
Intracellular O +
calcium O +
release O +
Freshly O +
prepared O +
neutrophil O +
suspensions O +
( O -
1 O +
ml O -
: O +
1 O -
× O -
107 O +
cells O -
) O +
were O +
loaded O +
with O +
3 O +
mM O +
( O -
final O +
concentration O +
3 O +
μM O -
) O +
of O +
the O +
acetoxymethyl O +
ester O +
precursor O +
of O +
the O +
calcium O +
indicator O +
( O -
Indo-1-AM O -
, O +
Calbiochem O -
, O +
La O +
Jolla O -
, O +
CA O -
, O +
USA O -
) O +
during O +
30 O +
min O +
at O +
37 O -
° O -
C O -
. O +

Excess O +
dye O +
was O +
removed O +
by O +
centrifugation O +
and O +
the O +
cells O +
were O +
suspended O +
in O +
fresh O +
RPMI O +
1640 O +
medium O -
. O +

Dye O -
- O -
loaded O +
cells O +
were O +
kept O +
at O +
room O +
temperature O +
on O +
a O +
rotator O -
. O +

Each O +
measurement O +
consisted O +
of O +
the O +
following O -
: O +
2 O -
× O -
106 O +
cells O +
were O +
suspended O +
in O +
1 O +
ml O +
of O +
assay O +
medium O +
of O +
the O +
following O +
composition O +
in O +
mM O -
: O +
NaCl O +
140 O -
, O +
KCl O +
5 O -
, O +
MgCl2 O +
1 O -
, O +
CaCl2 O +
1 O -
, O +
HEPES O +
sodium O -
- O -
free O +
10 O +
and O +
glucose O +
10 O -
, O +
pH O +
7.3 O +
and O +
placed O +
in O +
a O +
plastic O +
cuvette O +
( O -
Diamed O +
Lab O -
. O -
, O +
Toronto O -
, O +
Canada O -
) O +
whose O +
temperature O +
was O +
controlled O +
at O +
37 O -
° O -
C O -
. O +

Calcium O -
- O -
free O +
media O +
contained O +
no O +
calcium O +
and O +
1 O +
mM O +
EGTA O +
was O +
added O -
. O +

The O +
cell O +
suspension O +
was O +
continuously O +
stirred O +
magnetically O -
. O +

Fluorescence O +
was O +
continuously O +
monitored O +
with O +
a O +
Perkin O -
- O -
Elmer O +
fluorescence O +
spectrophotometer O +
( O -
model O +
650 O -
- O -
40 O -
) O +
and O +
recorded O +
on O +
a O +
chart O +
recorder O +
( O -
LKB O +
model O +
2210 O -
) O +
set O +
at O +
1 O +
cm O -
/ O -
min O -
. O +

The O +
excitation O +
wavelength O +
was O +
set O +
at O +
331 O +
nm O -
, O +
the O +
emission O +
wavelength O +
at O +
410 O +
nm O -
, O +
with O +
slits O +
of O +
excitation O +
and O +
emission O +
set O +
at O +
3 O +
and O +
15 O +
nm O +
respectively O -
. O +

At O +
the O +
end O +
of O +
each O +
test O -
, O +
a O +
calibration O +
was O +
carried O +
out O +
to O +
determine O +
the O +
maximal O +
fluorescence O +
by O +
adding O +
ionomycin O +
( O -
Sigma O -
) O +
at O +
1 O +
mM O +
( O -
final O +
concentration O +
1 O +
μM O -
) O +
and O +
minimal O +
fluorescence O +
by O +
adding O +
MnCl2 O +
( O -
final O +
concentration O +
3 O +
mM O -
) O +
as O +
previously O +
described O +
[ O -
6 O -
] O +
. O +

Test O +
compounds O +
were O +
prepared O +
in O +
DMSO O +
( O -
Caledon O -
, O +
Georgetown O -
, O +
OR O -
, O +
USA O -
) O +
or O +
glass O -
- O -
distilled O +
ethanol O +
( O -
100 O -
% O -
) O +
at O +
a O +
stock O +
solution O +
of O +
1 O +
μg O -
/ O -
μl O +
or O +
5 O +
μg O -
/ O -
μl O +
and O +
1 O +
μl O +
of O +
this O +
solution O +
was O +
added O +
to O +
2 O -
× O -
106 O +
cells O +
in O +
1 O +
ml O -
. O +

2.4 O +
Metabolism O +
of O +
[ O -
3 O +
H6 O +
] O -
HxA3 O +
Me O +
ester O +
Freshly O +
prepared O +
human O +
neutrophils O +
were O +
incubated O +
in O +
the O +
above O +
assay O +
medium O +
in O +
a O +
siliconized O +
glass O +
tube O +
to O +
which O +
had O +
been O +
added O +
[ O -
3 O +
H O -
] O -
( O -
8R O -
) O -
-HxA3 O +
Me O +
ester O +
( O -
5 O -
× O -
106 O +
cpm O -
) O +
diluted O +
with O +
3 O +
μg O +
of O +
the O +
unlabelled O +
compound O -
. O +

The O +
mixture O +
was O +
incubated O +
for O +
1 O +
or O +
5 O +
minutes O +
and O +
the O +
incubation O +
mixture O +
was O +
extracted O +
with O +
ethyl O +
acetate O +
without O +
prior O +
acidification O +
to O +
extract O +
the O +
intact O +
Hx O +
structure O +
and O +
its O +
products O +
( O -
which O +
are O +
acid O +
sensitive O -
) O -
. O +

The O +
solvent O +
was O +
evaporated O +
to O +
dryness O +
with O +
N2 O +
gas O +
and O +
the O +
residue O +
was O +
dissolved O +
in O +
a O +
small O +
amount O +
of O +
ethyl O +
acetate O +
and O +
spotted O +
on O +
TLC O +
( O -
silica O +
gel O +
G O -
, O +
ethyl O +
acetate O -
/ O -
acetic O +
acid O +
99.5 O -
/ O -
0.5 O +
( O -
v O -
/ O -
v O -
) O -
) O -
. O +

The O +
plate O +
was O +
developed O +
for O +
60 O +
min O -
, O +
then O +
the O +
solvent O +
was O +
dried O +
with O +
cold O +
air O +
and O +
scanned O +
for O +
radioactivity O +
on O +
a O +
TLC O +
radiochromatogram O +
scanner O +
( O -
Berthold O -
) O -
. O +

Authentic O +
standards O +
of O +
HxA3 O +
Me O +
ester O +
and O +
FA O +
as O +
well O +
as O +
the O +
ω O -
- O -
hydroxy O +
( O -
ωH O -
) O +
metabolite O +
FA O +
( O -
product O +
of O +
ω O -
- O -
oxidation O +
[ O -
7 O -
] O +
) O +
and O +
the O +
trihydroxy O +
metabolite O +
FA O +
( O -
product O +
of O +
epoxide B-Gene +
hydrolase I-Gene -
) O +
were O +
spotted O +
as O +
reference O +
compounds O -
. O +

3 O +
Results O +
and O +
discussion O +
We O +
show O +
herein O +
that O +
HxA3 O +
FA O +
but O +
not O +
the O +
Me O +
ester O +
is O +
vehicle O +
sensitive O +
in O +
evoking O +
a O +
rise O +
in O +
intracellular O +
calcium O +
in O +
suspensions O +
of O +
human O +
neutrophils O -
. O +

Fig. O +
1 O +
A O +
shows O +
a O +
typical O +
pattern O +
of O +
intracellular O +
calcium O +
resulting O +
from O +
the O +
addition O +
of O +
HxA3 O +
Me O +
ester O +
( O -
upper O +
trace O -
) O +
and O +
FA O +
( O -
lower O +
trace O -
) O +
in O +
DMSO O +
as O +
vehicle O -
. O +

This O +
is O +
compared O +
with O +
the O +
same O +
two O +
compounds O +
added O +
in O +
ethanol O +
as O +
vehicle O +
( O -
Fig. O +
1 O +
B O -
) O -
. O +

The O +
following O +
three O +
points O +
are O +
apparent O -
. O +

First O -
, O +
the O +
pattern O +
for O +
the O +
Me O +
ester O +
is O +
similar O +
and O +
independent O +
of O +
the O +
vehicle O +
used O +
( O -
compare O +
upper O +
traces O +
in O +
Fig. O +
1 O +
A O +
and O +
B O -
) O -
. O +

Second O -
, O +
the O +
FA O +
is O +
inactive O +
when O +
made O +
up O +
in O +
DMSO O +
but O +
is O +
active O +
when O +
added O +
in O +
ethanol O +
vehicle O +
( O -
compare O +
lower O +
traces O +
in O +
Fig. O +
1 O +
A O +
and O +
B O -
) O -
. O +

Third O -
, O +
both O +
compounds O +
added O +
in O +
ethanol O +
show O +
a O +
rapid O +
action O +
( O -
rise O +
in O +
intracellular O +
calcium O -
) O +
and O +
a O +
slower O +
more O +
prolonged O +
decrease O +
in O +
calcium O +
levels O +
but O +
never O +
decreasing O +
to O +
pre O -
- O -
HxA3 O +
levels O +
( O -
see O +
Fig. O +
1 O +
B O -
) O -
. O +

The O +
Me O +
ester O +
appears O +
more O +
potent O +
in O +
the O +
rapid O +
initial O +
phase O +
of O +
calcium O +
release O +
than O +
the O +
FA O +
( O -
Me O -
, O +
188±14 O +
S.D. O -
; O +
FA O -
, O +
135±11 O +
S.D. O +
nM O -
, O +
P O +
< O -
0.0005 O -
, O +
n O +
=3 O -
) O +
and O +
decreases O +
to O +
a O +
similar O +
plateau O +
level O +
as O +
with O +
the O +
FA O +
( O -
Me O -
, O +
88±8 O +
S.D. O -
; O +
FA O -
, O +
107±15 O +
S.D. O +
nM O -
, O +
not O +
significant O -
, O +
n O +
= O -
3 O -
) O -
. O +

Hence O -
, O +
the O +
decrease O +
to O +
the O +
second O +
phase O +
( O -
prolonged O +
calcium O +
rise O -
) O +
is O +
greater O +
with O +
the O +
Me O +
ester O +
( O -
from O +
188 O +
to O +
88 O +
nM=53 O -
% O -
) O +
than O +
with O +
the O +
FA O +
( O -
from O +
135 O +
to O +
107 O +
nM=20 O -
% O -
) O -
. O +

In O +
order O +
to O +
address O +
this O +
second O +
phase O +
of O +
calcium O +
` O -
retention O -
' O -
, O +
we O +
administered O +
lanthanum O +
chloride O +
( O -
1 O +
μM O +
final O +
concentration O -
) O +
at O +
the O +
plateau O +
of O +
the O +
profile O +
( O -
about O +
5 O +
min O +
after O +
the O +
addition O +
of O +
HxA3 O +
) O -
. O +

Lanthanum O +
chloride O +
blocks O +
the O +
entry O +
of O +
calcium O +
by O +
inhibiting O +
calcium O +
channels O +
[ O -
8 O -
, O +
9 O -
] O +
. O +

Lanthanum O +
caused O +
an O +
immediate O +
decrease O +
in O +
intracellular O +
calcium O +
levels O +
towards O +
the O +
baseline O +
for O +
both O +
the O +
Me O +
ester O +
as O +
well O +
as O +
the O +
FA O +
( O -
Fig. O +
1 O +
B O -
, O +
upper O +
and O +
lower O +
traces O -
) O -
. O +

In O +
separate O +
experiments O +
( O -
Fig. O +
1 O +
C O -
) O +
carried O +
out O +
in O +
medium O +
devoid O +
of O +
extracellular O +
calcium O +
( O -
containing O +
EGTA O -
) O -
, O +
the O +
Me O +
ester O +
( O -
tested O +
in O +
DMSO O +
or O +
ethanol O -
) O +
effected O +
the O +
same O +
rapid O +
initial O +
phase O +
of O +
intracellular O +
calcium O +
rise O +
but O +
the O +
peak O +
response O +
quickly O +
returned O +
to O +
baseline O +
( O -
Fig. O +
1 O +
C O -
, O +
upper O +
trace O -
) O -
, O +
suggesting O +
that O +
the O +
second O +
( O -
longer O -
) O +
phase O +
of O +
the O +
normal O +
HxA3 O +
response O +
was O +
due O +
to O +
the O +
entry O +
of O +
extracellular O +
calcium O -
. O +

Similar O +
results O +
were O +
observed O +
with O +
the O +
FA O +
of O +
HxA3 O +
( O -
Fig. O +
1 O +
C O -
, O +
lower O +
trace O -
) O -
. O +

Again O +
the O +
Me O +
ester O +
is O +
slightly O +
more O +
potent O +
than O +
the O +
FA O +
( O -
Me O -
, O +
189±12 O +
S.D. O -
; O +
FA O -
, O +
145±6 O +
S.D. O +
nM O -
, O +
P O +
< O -
0.005 O -
, O +
n O +
= O -
3 O -
) O -
. O +

Similar O +
results O +
to O +
the O +
extracellular O +
calcium O -
- O -
free O +
experiments O +
were O +
observed O +
when O +
lanthanum O +
chloride O +
was O +
added O +
to O +
the O +
cells O +
prior O +
to O +
HxA3 O +
( O -
data O +
not O +
shown O -
) O -
. O +

In O +
order O +
to O +
investigate O +
further O +
whether O +
the O +
calcium O +
releasing O +
action O +
of O +
HxA3 O +
on O +
neutrophils O +
was O +
mediated O +
via O +
its O +
conversion O +
into O +
other O +
compounds O -
, O +
we O +
incubated O +
tritiated O +
HxA3 O +
Me O +
ester O +
with O +
human O +
neutrophils O +
and O +
analyzed O +
the O +
products O +
after O +
1 O +
and O +
5 O +
min O +
incubation O -
, O +
the O +
periods O +
of O +
maximal O +
change O +
in O +
intracellular O +
calcium O -
. O +

The O +
ethyl O +
acetate O +
extract O +
of O +
the O +
incubation O +
was O +
analyzed O +
by O +
TLC O -
. O +

Fig. O +
2 O +
shows O +
that O +
within O +
a O +
1 O +
min O +
incubation O +
( O -
the O +
period O +
of O +
sharp O +
initial O +
calcium O +
rise O -
) O +
the O +
Me O +
ester O +
is O +
only O +
partially O +
hydrolyzed O +
( O -
about O +
10 O -
% O -
) O +
into O +
the O +
FA O +
by O +
intracellular O +
esterases B-Gene -
, O +
demonstrating O +
that O +
the O +
Me O +
ester O +
penetrates O +
into O +
the O +
cell O +
where O +
it O +
acts O +
to O +
release O +
calcium O +
from O +
calcium O +
stores O +
( O -
rapid O +
initial O +
phase O -
) O -
. O +

About O +
50 O -
% O +
of O +
the O +
Me O +
ester O +
is O +
converted O +
into O +
the O +
FA O +
as O +
the O +
sole O +
metabolite O +
within O +
5 O +
min O +
of O +
incubation O -
. O +

Hence O -
, O +
the O +
rapid O +
initial O +
phase O +
of O +
the O +
calcium O +
profile O +
of O +
the O +
Me O +
ester O +
of O +
HxA3 O +
is O +
due O +
to O +
a O +
large O +
part O +
to O +
the O +
Me O +
ester O +
form O +
itself O +
while O +
the O +
prolonged O +
phase O +
occurs O +
during O +
and O +
subsequent O +
to O +
the O +
formation O +
of O +
the O +
FA O -
. O +

The O +
important O +
experiment O +
in O +
Fig. O +
1 O +
C O +
( O -
bottom O +
trace O -
) O +
demonstrates O +
that O +
the O +
FA O +
is O +
also O +
active O +
on O +
intracellular O +
stores O +
to O +
cause O +
the O +
release O +
of O +
intracellular O +
calcium O -
, O +
i.e. O +
it O +
has O +
dual O +
actions O -
. O +

These O +
experiments O +
demonstrate O +
that O +
HxA3 O +
, O +
both O +
as O +
the O +
FA O +
as O +
well O +
as O +
the O +
Me O +
ester O -
, O +
are O +
taken O +
up O +
into O +
the O +
cell O +
and O +
act O +
to O +
release O +
calcium O +
from O +
intracellular O +
stores O -
. O +

Within O +
the O +
time O +
frame O +
of O +
initial O +
action O +
( O -
rapid O +
phase O -
, O +
1 O +
min O -
) O -
, O +
studies O +
with O +
tritiated O +
HxA3 O +
show O +
that O +
the O +
Me O +
ester O +
is O +
not O +
substantially O +
hydrolyzed O +
into O +
the O +
FA O -
, O +
although O +
this O +
takes O +
place O +
subsequently O +
and O +
is O +
likely O +
involved O +
in O +
calcium O +
influx O -
. O +

Supporting O +
this O +
is O +
the O +
finding O +
that O +
the O +
second O +
phase O +
of O +
calcium O +
response O +
is O +
equally O +
pronounced O +
when O +
the O +
FA O +
is O +
used O +
( O -
Fig. O +
1 O +
B O -
) O +
and O +
is O +
absent O +
in O +
calcium O -
- O -
free O +
medium O +
( O -
Fig. O +
1 O +
C O -
) O -
. O +

Finally O -
, O +
caution O +
should O +
be O +
exerted O +
in O +
the O +
choice O +
of O +
vehicle O +
as O +
we O +
show O +
that O +
DMSO O +
interacts O +
with O +
the O +
FA O +
form O +
of O +
HxA3 O +
( O -
likely O +
through O +
formation O +
of O +
a O +
polar O +
hydrogen O -
- O -
bonded O +
DMSO O -
- O -
HxA3 O +
adduct O +
[ O -
10 O -
] O +
) O +
making O +
the O +
adduct O +
incapable O +
of O +
entering O +
the O +
cell O +
and O +
rendering O +
HxA3 O +
inactive O -
. O +

In O +
ethanol O +
as O +
vehicle O -
, O +
the O +
FA O +
enters O +
the O +
cell O +
where O +
it O +
is O +
capable O +
both O +
of O +
releasing O +
calcium O +
from O +
intracellular O +
stores O +
( O -
see O +
Fig. O +
1 O +
C O -
) O +
and O +
causing O +
influx O +
of O +
extracellular O +
calcium O +
( O -
compare O +
Fig. O +
1 O +
B O +
and O +
C O -
) O -
. O +

Similar O +
findings O +
were O +
observed O +
with O +
Hx O +
binding O +
studies O -
. O +

The O +
FA O +
dissolved O +
in O +
DMSO O +
did O +
not O +
bind O +
to O +
intact O +
neutrophils O +
but O +
did O +
bind O +
to O +
membranes O +
from O +
disrupted O +
cells O -
, O +
while O +
the O +
Me O +
ester O +
was O +
equally O +
well O +
bound O +
to O +
the O +
intact O +
cell O +
as O +
well O +
as O +
disrupted O +
cells O +
[ O -
3 O -
] O +
. O +

Acknowledgements O +
This O +
study O +
was O +
supported O +
by O +
a O +
Grant O +
( O -
MT-4181 O -
) O +
to O +
CRP O -
- O -
A O +
from O +
the O +
Medical O +
Research O +
Council O +
of O +
Canada O +
and O +
from O +
FO O -
/ O -
FUB O +
to O +
SN O -
. O +

Manoalide O +
is O +
a O +
potent O +
analgesic O +
and O +
antiinflammatory O +
sesterterpene O +
isolated O +
in O +
1980 O +
from O +
a O +
marine O +
sponge O -
. O +

The O +
antiinflammatory O +
activity O +
of O +
manoalide O +
is O +
due O +
to O +
inhibition O +
of O +
PLA2 B-Gene -
, O +
through O +
irreversible O +
binding O +
to O +
several O +
lysine O +
residues O -
. O +

The O +
binding O +
is O +
realized O +
by O +
means O +
of O +
the O +
two O +
masked O +
aldehyde O +
functions O +
present O +
in O +
the O +
polar O +
part O +
of O +
manoalide O -
. O +

Of O +
the O +
two O +
aldehyde O +
groups O -
, O +
only O +
that O +
present O +
in O +
the O +
g O -
- O -
hydroxybutenolide O +
ring O +
seems O +
to O +
be O +
essential O -
, O +
since O +
cacospongionolides O -
, O +
naturally O +
occurring O +
analogues O +
lacking O +
the O +
second O +
masked O +
aldehyde O +
group O -
, O +
were O +
also O +
shown O +
to O +
be O +
irreversible O +
PLA2 B-Gene +
inhibitors O -
. O +

It O +
appears O +
that O +
the O +
minimum O +
structural O +
requirement O +
for O +
exhibiting O +
manoalide O -
- O -
like O +
PLA2 B-Gene +
inhibition O +
would O +
be O +
the O +
presence O +
in O +
the O +
inhibitor O +
of O +
functional O +
groups O +
able O +
to O +
seize O +
the O +
amino O +
groups O +
of O +
PLA2 B-Gene +
lysine O +
residues O +
with O +
formation O +
of O +
stable O +
covalent O +
bonds O -
. O +

Many O +
manoalide O +
analogues O +
have O +
been O +
isolated O +
from O +
marine O +
sponges O -
, O +
most O +
of O +
them O +
sharing O +
PLA2 B-Gene +
inhibitory O +
properties O -
. O +

Other O +
interesting O +
bioactivities O +
have O +
also O +
been O +
reported O +
for O +
some O +
of O +
these O +
compounds O -
. O +

Bis O -
( O -
monoacylglycerol O -
) O -
phosphate O +
( O -
BMP O -
) O +
was O +
first O +
described O +
in O +
1967 O +
by O +
Body O +
and O +
Gray O +
[ O -
1 O -
] O +
, O +
and O +
was O +
shown O +
by O +
Waite O +
et O +
al. O +
[ O -
2 O -
] O +
to O +
be O +
synthesized O +
in O +
alveolar O +
macrophages O +
from O +
exogenous O +
phosphatidylglycerol O +
( O -
PG O -
) O -
. O +

BMP O +
is O +
a O +
unique O +
phospholipid O +
having O +
a O +
sn O +
-1 O +
rather O +
than O +
sn O +
-3 O +
glycerol O +
phosphate O +
ester O +
[ O -
3 O -
] O +
and O +
one O +
acyl O +
group O +
attached O +
to O +
each O +
of O +
the O +
glycerol O +
moieties O -
. O +

While O +
it O +
is O +
unclear O +
whether O +
the O +
acyl O +
esters O +
are O +
at O +
the O +
primary O +
or O +
secondary O +
hydroxyl O +
[ O -
4,5 O -
] O +
, O +
the O +
acyl O +
groups O +
of O +
BMP O +
are O +
unusually O +
rich O +
in O +
polyunsaturated O +
species O +
[ O -
5–7 O -
] O +
which O +
implies O +
acyl O +
linkage O +
at O +
the O +
sn O +
-2 O +
and O +
sn O +
-2′ O +
positions O -
. O +

We O +
proposed O +
a O +
biochemical O +
pathway O +
by O +
which O +
BMP O +
is O +
synthesized O +
but O +
this O +
remains O +
to O +
be O +
proven O +
( O -
Scheme O +
1 O +
) O +
[ O -
8 O -
] O +
. O +

Recent O +
work O +
within O +
our O +
laboratory O +
has O +
focused O +
on O +
characterizing O +
the O +
enzymes B-Gene +
that O +
are O +
involved O +
in O +
the O +
biosynthesis O +
of O +
BMP O +
from O +
PG O -
. O +

In O +
this O +
proposed O +
pathway O -
, O +
PG O -
, O +
presumably O +
from O +
lung O +
surfactant O -
, O +
is O +
taken O +
into O +
the O +
cell O +
and O +
metabolized O +
to O +
BMP O -
. O +

There O +
is O +
reason O +
to O +
suggest O +
that O +
BMP O +
synthesis O +
occurs O +
in O +
the O +
endosomal O +
system O +
since O +
a O +
role O +
for O +
BMP O +
in O +
the O +
endosomal O +
function O +
has O +
recently O +
been O +
proposed O +
[ O -
9 O -
] O +
. O +

The O +
first O +
proposed O +
step O +
in O +
conversion O +
to O +
BMP O +
is O +
the O +
hydrolysis O +
of O +
PG O +
catalyzed O +
by O +
a O +
lysosomal O +
PLA2 B-Gene +
to O +
form O +
1-acyl O -
- O -
sn O +
-glycero-3-phospho O -
- O -
rac O +
-glycerol O +
( O -
LPG O -
) O -
. O +

In O +
the O +
second O +
step O -
, O +
sn O +
-3 O -
: O -
sn O +
-1′ O +
LPG O +
is O +
acylated O +
on O +
the O +
head O +
group O +
( O -
prime O +
designation O -
) O +
glycerol O +
with O +
an O +
acyl O +
group O +
from O +
a O +
donor O +
phospholipid O -
. O +

The O +
next O +
step O +
proposed O +
is O +
the O +
reorientation O +
of O +
the O +
phosphoryl O +
ester O +
from O +
the O +
sn O +
-3 O +
to O +
the O +
sn O +
-1 O +
position O -
, O +
with O +
liberation O +
of O +
the O +
sn O +
-1 O +
linked O +
acyl O +
chain O +
concomitant O +
to O +
the O +
phosphoryl O +
migration O +
[ O -
10 O -
] O +
. O +

While O +
this O +
proposal O +
provides O +
the O +
energy O +
and O +
specificity O +
for O +
the O +
transfer O +
of O +
the O +
phosphate O +
to O +
the O +
sn O +
-1 O +
position O -
, O +
it O +
has O +
yet O +
to O +
be O +
demonstrated O +
in O +
a O +
cell O +
homogenate O -
. O +

The O +
final O +
proposed O +
step O +
is O +
a O +
second O +
transacylation O +
to O +
incorporate O +
an O +
acyl O +
chain O +
into O +
the O +
original O +
backbone O +
glycerol O +
( O -
non O -
- O -
prime O +
designation O -
) O +
of O +
sn O +
-1 O -
: O -
sn O +
-1′ O +
LPG O -
. O +

If O +
the O +
sn O +
-2 O +
chain O +
of O +
a O +
phospholipid O +
were O +
the O +
substrate O +
for O +
the O +
transacylation O +
steps O -
, O +
the O +
final O +
BMP O +
structure O +
would O +
contain O +
the O +
expected O +
polyunsaturated O +
fatty O +
acid O -
. O +

Various O +
groups O +
have O +
shown O +
that O +
diacyl O +
phospholipid O +
stimulates O +
the O +
conversion O +
of O +
sn O +
-3 O -
: O -
sn O +
-1′ O +
LPG O +
to O +
sn O +
-3 O -
: O -
sn O +
-1′ O +
BMP O +
( O -
Scheme O +
1 O +
step O +
2 O -
) O -
. O +

Our O +
studies O +
[ O -
8 O -
] O +
showed O +
that O +
the O +
lipid O +
product O +
of O +
the O +
reaction O +
catalyzed O +
by O +
the O +
partially O +
purified O +
transacylase B-Gene +
was O +
BMP O -
, O +
as O +
predicted O +
in O +
Scheme O +
1 O +
. O +

Matsuzawa O +
et O +
al. O +
[ O -
11 O -
] O +
earlier O +
reported O +
that O +
PI O +
was O +
preferentially O +
used O +
by O +
a O +
rat O +
liver O +
lysosomal O +
transacylase B-Gene +
to O +
form O +
BMP O -
, O +
whereas O +
the O +
work O +
of O +
Huterer O +
and O +
Wherett O +
[ O -
12 O -
] O +
indicated O +
that O +
the O +
acyl O +
moiety O +
from O +
either O +
the O +
sn O +
-1 O +
or O +
sn O +
-2 O +
position O +
of O +
PC O +
was O +
incorporated O +
into O +
BMP O -
. O +

Huterer O +
et O +
al. O +
[ O -
13 O -
] O +
proposed O +
that O +
the O +
lysosomal O +
PLA1 B-Gene +
is O +
also O +
a O +
transacylase B-Gene +
and O +
could O +
be O +
responsible O +
for O +
the O +
formation O +
of O +
BMP O +
and O +
acylphosphatidylglycerol O +
( O -
APG O -
) O -
. O +

The O +
stereoconfiguration O +
of O +
the O +
BMP O +
formed O +
was O +
not O +
determined O +
in O +
the O +
later O +
reports O -
. O +

Considering O +
the O +
differences O +
in O +
these O +
reports O -
, O +
we O +
felt O +
it O +
necessary O +
to O +
more O +
clearly O +
define O +
the O +
transacylation O +
step O +
( O -
Scheme O +
1 O +
step O +
2 O -
) O -
. O +

In O +
particular O -
, O +
we O +
set O +
out O +
to O +
establish O +
what O +
the O +
substrate O -
( O -
s O -
) O +
for O +
the O +
reaction O +
are O +
and O +
if O +
indeed O +
the O +
presence O +
of O +
polyunsaturated O +
fatty O +
acids O +
in O +
BMP O +
was O +
accounted O +
for O +
by O +
this O +
transacylation O -
. O +

To O +
our O +
surprise O +
LPG O +
served O +
as O +
both O +
the O +
acyl O +
donor O +
and O +
acyl O +
acceptor O -
, O +
even O +
though O +
diradyl O +
phospholipid O +
enhanced O +
activity O +
several O -
- O -
fold O -
. O +

The O +
data O +
supporting O +
this O +
conclusion O +
are O +
reported O +
herein O -
. O +

2 O +
Methods O +
and O +
materials O +
2.1 O +

Materials O +
RAW O +
264.7 O +
( O -
murine O +
monocytic O -
, O +
macrophage O +
like O -
, O +
Abelson O +
leukemia O +
virus O +
transformed O +
BALB O -
/ O -
c O -
) O +
cells O +
were O +
purchased O +
from O +
American O +
Type O +
Tissue O +
Culture O -
. O +

Tissue O +
culture O +
medium O +
was O +
from O +
Gibco O -
. O +

Phospholipids O +
( O -
except O +
for O +
RAW O +
264.7 O +
lipid O -
) O +
were O +
from O +
Avanti O +
Polar O +
Lipids O -
. O +

Salts O -
, O +
buffers O -
, O +
and O +
organic O +
solvents O +
were O +
from O +
Fisher O -
. O +

Protein O +
assay O +
reagents O +
were O +
from O +
Pierce O +
and O +
microconcentrators O +
were O +
from O +
Amicon O -
. O +

S-300 O +
column O +
matrix O +
was O +
from O +
Pharmacia O -
. O +

Silica O +
gel O +
G O +
plates O +
were O +
from O +
Analtech O -
. O +

Preparative O +
enzymes B-Gene +
were O +
from O +
Sigma O -
. O +

The O +
1-acyl O -
[ O -
1,2,3 O -
- O -
3 O +
H O -
] O -
-sn O +
-glycero-3-phospho O -
- O -
rac O +
-glycerol O +
( O -
[ O -
3 O +
H O -
] O -
LPG O -
) O +
was O +
synthesized O +
as O +
described O +
earlier O +
[ O -
14 O -
] O +
. O +

2.2 O +
Cell O +
culture O +
RAW O +
264.7 O +
cells O +
were O +
grown O +
in O +
Dulbecco O -
's O +
minimum O +
essential O +
medium O +
with O +
10 O +
mM O +
HEPES O -
, O +
pH O +
7.4 O -
, O +
4.5 O +
g O -
/ O -
l O +
of O +
d O +
-glucose O -
, O +
584 O +
mg O -
/ O -
l O +
of O +
l O +
-glutamine O -
, O +
110 O +
mg O -
/ O -
l O +
of O +
sodium O +
pyruvate O -
, O +
4 O +
mg O -
/ O -
l O +
of O +
pyridoxal O +
HCl O -
, O +
10 O -
% O +
heat O +
inactivated O +
FBS O +
( O -
by O +
volume O -
) O +
in O +
an O +
atmosphere O +
supplemented O +
with O +
5 O -
% O +
CO2 O +
. O +

These O +
cells O +
were O +
grown O +
to O +
confluence O +
in O +
15 O +
ml O +
of O +
medium O +
in O +
a O +
75 O +
cm2 O +
flask O -
, O +
then O +
passaged O +
into O +
150 O +
ml O +
of O +
medium O +
in O +
225 O +
cm2 O +
plates O -
. O +

Once O +
the O +
population O +
reached O +
1 O -
× O -
108 O +
total O +
cells O -
, O +
the O +
cells O +
were O +
passed O +
into O +
200 O +
ml O +
of O +
medium O +
and O +
transferred O +
to O +
a O +
500 O +
ml O +
cell O +
culture O +
stir O +
bottle O +
and O +
placed O +
in O +
a O +
second O +
incubator O -
. O +

Since O +
this O +
incubator O +
did O +
not O +
have O +
a O +
CO2 O +
atmosphere O +
supplementation O +
system O -
, O +
the O +
medium O +
buffering O +
capacity O +
was O +
increased O +
with O +
additional O +
HEPES O +
( O -
pH O +
7.4 O -
, O +
20 O +
mM O -
) O -
. O +

Suspension O +
cultures O +
were O +
initiated O +
with O +
5 O -
× O -
105 O +
cells O -
/ O -
ml O +
and O +
allowed O +
to O +
proliferate O +
until O +
reaching O +
approx O -
. O +

2 O -
× O -
106 O +
/ml O -
. O +

They O +
were O +
then O +
passed O +
into O +
600 O +
ml O +
of O +
medium O +
in O +
a O +
1 O +
l O +
culture O +
bottle O +
and O +
allowed O +
to O +
grow O +
until O +
the O +
population O +
reached O +
6 O -
× O -
108 O +
cells O +
at O +
which O +
time O +
the O +
cells O +
were O +
taken O +
for O +
LPG B-Gene +
transacylase I-Gene +
( O -
TA B-Gene -
) O +
isolation O -
. O +

2.3 O +
Transacylase B-Gene +
isolation O +
RAW O +
264.7 O +
( O -
6 O -
× O -
108 O +
) O +
cells O +
were O +
pelleted O +
from O +
medium O +
by O +
centrifugation O +
at O +
1000 O -
× O -
g O +
, O +
resuspended O -
, O +
then O +
washed O +
twice O +
by O +
centrifugation O +
in O +
ice O +
cold O +
0.9 O -
% O +
saline O -
. O +

Cells O +
were O +
resuspended O +
in O +
5 O +
ml O +
of O +
1 O +
mM O +
NaHCO3 O +
and O +
lipids O +
were O +
removed O +
by O +
adding O +
an O +
equal O +
volume O +
of O +
water O -
- O -
saturated O +
1-butanol O -
. O +

The O +
mixture O +
was O +
vortexed O +
for O +
15 O +
s O -
, O +
placed O +
on O +
ice O +
for O +
2 O +
min O -
, O +
then O +
the O +
phases O +
were O +
separated O +
by O +
centrifugation O +
at O +
20 O +
000 O -
× O -
g O +
for O +
15 O +
min O +
at O +
4 O -
° O -
C O -
. O +

The O +
aqueous O +
( O -
lower O -
) O +
layer O +
was O +
applied O +
to O +
an O +
S-300 O +
column O +
( O -
1.5 O +
cm O -
× O -
84 O +
cm O -
) O +
which O +
had O +
been O +
previously O +
equilibrated O +
in O +
10 O +
mM O +
Tris O -
, O +
pH O +
7.4 O -
, O +
and O +
eluted O +
with O +
the O +
same O +
buffer O +
at O +
a O +
flow O +
rate O +
of O +
0.55 O +
ml O -
/ O -
min O -
. O +

Fifty O +
fractions O +
of O +
2.2 O +
ml O +
were O +
collected O +
from O +
the O +
S-300 O +
column O -
, O +
assayed O +
for O +
TA B-Gene +
activity O -
, O +
and O +
those O +
fractions O +
exhibiting O +
TA B-Gene +
activity O +
were O +
pooled O -
. O +

Pooled O +
TA B-Gene +
intended O +
for O +
experiments O +
utilizing O +
gas O +
chromatography O +
( O -
GC O -
) O +
or O +
mass O +
spectrometry O +
( O -
MS O -
) O +
analysis O +
were O +
concentrated O +
using O +
an O +
Amicon O +
filtration O +
system O -
. O +

Pooled O +
fractions O +
were O +
then O +
assayed O +
for O +
total O +
protein B-Gene +
concentration O -
. O +

2.4 O +
Transacylase B-Gene +
assay O +
For O +
each O +
assay O -
, O +
10 O +
nmol O +
of O +
diradyl O +
lipid O -
, O +
[ O -
3 O +
H O -
] O -
LPG O +
( O -
5 O -
× O -
104 O +
DPM O -
, O +
200 O +
pmol O -
) O +
and O +
10 O +
nmol O +
of O +
1-myristoyl O +
LPG O +
were O +
dried O +
under O +
a O +
stream O +
of O +
N2 O +
and O +
0.1 O +
ml O +
of O +
1 O +
M O +
Na O +
acetate O -
, O +
pH O +
4.5 O +
was O +
added O -
. O +

The O +
lipids O +
were O +
sonically O +
dispersed O +
and O +
0.1 O +
ml O +
of O +
the O +
solution O +
was O +
aliquoted O +
to O +
the O +
various O +
tubes O -
. O +

Seventy O -
- O -
five O +
μg O +
of O +
the O +
TA B-Gene +
were O +
added O +
to O +
each O +
tube O -
, O +
the O +
reaction O +
volume O +
was O +
adjusted O +
to O +
1 O +
ml O +
with O +
water O -
, O +
and O +
samples O +
were O +
incubated O +
for O +
1 O +
h O +
at O +
37 O -
° O -
C O -
. O +

The O +
reactions O +
were O +
stopped O +
and O +
the O +
lipids O +
extracted O +
by O +
the O +
method O +
of O +
Bligh O +
and O +
Dyer O +
[ O -
15 O -
] O +
. O +

The O +
organic O +
phase O +
was O +
evaporated O +
under O +
N2 O +
, O +
and O +
lipids O +
were O +
spotted O +
on O +
a O +
silica O +
G O +
plate O +
in O +
methanol O +
and O +
separated O +
by O +
a O +
thin O +
layer O +
chromatography O +
( O -
TLC O -
) O +
system O +
containing O +
chloroform O -
/ O -
methanol O -
/ O -
ammonium O +
hydroxide O +
( O -
130:70:10 O +
v O -
/ O -
v O -
/ O -
v O -
) O +
( O -
R O +
f O +
values O -
: O +
LPG O +
0.27 O -
, O +
PG O +
0.40 O -
, O +
BMP O +
0.53 O -
) O -
. O +

Radioactive O +
lipids O +
were O +
visualized O +
by O +
scanning O +
the O +
TLC O +
plate O +
using O +
a O +
Bioscanner O +
detector O +
and O +
compared O +
to O +
authentic O +
standards O -
. O +

Silica O -
, O +
containing O +
the O +
radioactive O +
products O -
, O +
was O +
scraped O +
from O +
the O +
plate O +
into O +
a O +
scintillation O +
vial O +
and O +
then O +
counted O +
in O +
a O +
liquid O +
scintillation O +
counter O +
and O +
TA B-Gene +
activity O +
was O +
determined O +
as O +
the O +
percentage O +
of O +
the O +
radiolabeled O +
BMP O +
formed O +
compared O +
to O +
the O +
sum O +
of O +
radioactivity O +
from O +
the O +
silica O +
plate O +
plus O +
the O +
methanol O -
/ O -
water O +
phase O +
of O +
the O +
extract O -
. O +

This O +
percentage O +
was O +
converted O +
to O +
mass O +
based O +
on O +
the O +
specific O +
radioactivity O +
of O +
the O +
substrate O -
. O +

Due O +
to O +
enzyme B-Gene +
instability O -
, O +
experiments O +
were O +
completed O +
within O +
1–2 O +
days O +
of O +
preparation O -
. O +

Even O +
so O -
, O +
considerable O +
variability O +
in O +
specific O +
enzymatic O +
activity O +
existed O +
between O +
preparations O -
. O +

2.5 O +
Gas O +
chromatographic O +
analysis O +
Fatty O +
acid O +
methyl O +
esters O +
were O +
prepared O +
and O +
examined O +
by O +
the O +
method O +
of O +
Wang O +
and O +
Peter O +
[ O -
16 O -
] O +
. O +

The O +
lipids O +
were O +
separated O +
by O +
TLC O +
and O +
5 O +
μg O +
of O +
pentadecanoic O +
acid O +
( O -
C15:0 O -
) O +
in O +
hexane O +
was O +
pipetted O +
onto O +
each O +
zone O +
of O +
the O +
silica O +
plate O +
to O +
be O +
scraped O -
. O +

In O +
these O +
and O +
experiments O +
employing O +
MS O -
, O +
a O +
trace O +
amount O +
of O +
[ O -
3 O +
H O -
] O -
LPG O +
was O +
included O +
to O +
localize O +
BMP O +
on O +
the O +
TLC O +
plate O -
. O +

One O +
ml O +
of O +
7 O -
% O +
HCl O +
in O +
MeOH O +
was O +
added O +
to O +
the O +
scraped O +
silica O -
, O +
vortexed O -
, O +
and O +
heated O +
to O +
100 O -
° O -
C O +
for O +
15 O +
min O -
. O +

After O +
cooling O +
to O +
0 O -
° O -
C O -
, O +
2 O +
ml O +
of O +
hexane O +
were O +
added O +
followed O +
by O +
the O +
addition O +
of O +
1 O +
ml O +
of O +
2.5 O +
N O +
NaOH O -
. O +

The O +
hexane O +
was O +
collected O -
, O +
the O +
samples O +
were O +
extracted O +
again O +
with O +
2 O +
ml O +
of O +
hexane O +
and O +
the O +
hexane O +
was O +
dried O +
under O +
N2 O +
. O +

The O +
fatty O +
acid O +
methyl O +
esters O +
were O +
dissolved O +
in O +
100 O +
μl O +
of O +
undecane O +
and O +
analyzed O +
by O +
gas O +
chromatography O -
/ O -
flame O +
ionization O +
detection O +
( O -
GC O -
/ O -
FID O -
) O -
. O +

2.6 O +
MS O +
analysis O +
MS O +
analysis O +
was O +
conducted O +
by O +
the O +
method O +
of O +
Lehmann O +
[ O -
17 O -
] O +
. O +

BMP O +
was O +
isolated O +
by O +
TLC O -
, O +
dissolved O +
in O +
250 O +
μl O +
of O +
MeOH O -
: O -
MeCl2 O +
1:1 O -
, O +
injected O +
into O +
a O +
VG O +
Quattro O +
II O +
triple O +
quadrupole O +
mass O +
spectrometer O -
, O +
and O +
resultant O +
data O +
analyzed O +
using O +
Masslynx O +
software O -
. O +

Both O +
parent O +
and O +
daughter O +
ions O +
were O +
detected O +
over O +
a O +
range O +
from O +
200 O +
to O +
900 O +
m O -
/ O -
z O -
. O +

Ion O +
spectra O +
were O +
assigned O +
acyl O +
compositions O +
based O +
on O +
detected O +
ion O +
molecular O +
weight O +
and O +
previously O +
determined O +
standards O -
. O +

Parent O +
ions O +
were O +
detected O +
in O +
the O +
first O +
quadrupole O -
, O +
ionized O +
in O +
the O +
second O +
quadrupole O +
and O +
daughter O +
ions O +
corresponding O +
to O +
acyl O +
chains O +
esterified O +
on O +
BMP O +
detected O +
in O +
the O +
third O +
quadrupole O -
. O +

3 O +
Results O +
Studies O +
reported O +
thus O +
far O +
have O +
not O +
established O +
systematically O +
the O +
optimal O +
conditions O +
for O +
the O +
TA B-Gene -
. O +

For O +
these O +
studies O -
, O +
it O +
is O +
important O +
to O +
remove O +
contaminating O +
phospholipases O +
that O +
may O +
hydrolyze O +
substrates O +
and/or O +
products O -
. O +

Previous O +
work O +
from O +
our O +
lab O +
demonstrates O +
that O +
lysosomal O +
PLA B-Gene +
activity O +
was O +
minimal O +
in O +
our O +
transacylase B-Gene +
preparation O +
and O +
that O +
no O +
ATP O +
and O +
CoA O +
dependent O +
transacylases B-Gene +
were O +
present O +
[ O -
8 O -
] O +
. O +

We O +
first O +
demonstrated O +
that O +
the O +
reaction O +
was O +
linear O +
for O +
30 O +
min O +
using O +
our O +
standard O +
assay O +
conditions O -
, O +
and O +
although O +
at O +
a O +
somewhat O +
decreased O +
rate O -
, O +
the O +
enzyme B-Gene +
was O +
active O +
up O +
to O +
90 O +
min O +
( O -
data O +
not O +
shown O -
) O -
. O +

Optimal O +
activity O +
was O +
observed O +
between O +
pH O +
4.0 O +
and O +
5.5 O -
, O +
as O +
previously O +
reported O +
with O +
lower O +
concentrations O +
of O +
substrate O +
[ O -
8 O -
] O +
. O +

We O +
also O +
showed O +
using O +
10 O +
or O +
30 O +
μM O +
LPG O +
that O +
lipids O +
extracted O +
from O +
the O +
RAW O +
264.7 O +
cells O +
stimulated O +
the O +
TA B-Gene +
in O +
concentrations O +
up O +
to O +
50 O +
μM. O +
Since O +
it O +
would O +
be O +
difficult O +
to O +
define O +
the O +
substrates O +
involved O +
in O +
transacylation O +
using O +
total O +
lipid O +
extracts O -
, O +
we O +
used O +
synthetic O +
substrates O +
with O +
defined O +
acyl O +
groups O -
, O +
with O +
the O +
exception O +
of O +
the O +
[ O -
3 O +
H O -
] O -
LPG O +
which O +
contained O +
mainly O +
palmitate O -
. O +

The O +
[ O -
3 O +
H O -
] O -
LPG O +
used O +
was O +
present O +
in O +
trace O +
amounts O -
, O +
being O +
diluted O +
approx O -
. O +

100-fold O +
with O +
synthetic O +
1-myristoyl O +
LPG O -
. O +

Using O +
LPG O +
and O +
either O +
1-palmitoyl-2-oleoyl O -
- O -
sn O +
-glycero-3-phosphocholine O +
( O -
POPC O -
) O +
or O +
1-palmitoyl-2-oleoyl O -
- O -
sn O +
-glycero-3-phosphoethanolamine O +
( O -
POPE O -
) O -
, O +
we O +
find O +
a O +
concentration O +
dependence O +
of O +
both O +
the O +
LPG O +
and O +
the O +
POPC O +
( O -
Fig. O +
1A O -
, O -
B O +
) O -
. O +

On O +
the O +
other O +
hand O -
, O +
POPE O +
did O +
not O +
stimulate O +
the O +
transacylase B-Gene +
( O -
Fig. O +
1B O +
) O -
. O +

The O +
concentration O +
dependence O +
of O +
LPG O +
and O +
POPC O +
showed O +
that O +
both O +
were O +
required O +
in O +
concentrations O +
above O +
1–3 O +
μM O +
before O +
stimulation O +
was O +
seen O -
. O +

The O +
complexity O +
of O +
substrate O +
dependence O +
suggests O +
that O +
the O +
physical O +
state O +
of O +
the O +
substrate O +
may O +
regulate O +
the O +
TA B-Gene -
. O +

In O +
order O +
to O +
better O +
define O +
the O +
properties O +
of O +
the O +
reaction O +
we O +
investigated O +
the O +
effects O +
of O +
detergents O +
on O +
transacylation O +
( O -
Fig. O +
2A O +
) O -
. O +

Only O +
the O +
bile O +
acids O +
deoxycholic O +
acid O +
( O -
DOC O -
) O +
or O +
cholic O +
acid O +
( O -
CHO O -
) O +
were O +
seen O +
to O +
stimulate O +
activity O +
and O +
both O +
Tween O +
20 O +
and O +
cetyltrimethylammonium O +
bromide O +
markedly O +
inhibited O +
at O +
20 O +
μM. O +
The O +
stimulation O +
by O +
DOC O +
was O +
optimal O +
between O +
10 O +
and O +
500 O +
μM O +
while O +
it O +
became O +
inhibitory O +
above O +
that O +
concentration O +
( O -
Fig. O +
2B O +
) O -
. O +

At O +
pH O +
4.5 O +
DOC O +
and O +
CHO O +
are O +
protonated O -
. O +

This O +
reduces O +
their O +
critical O +
micellar O +
concentration O +
and O +
may O +
account O +
for O +
their O +
stimulatory O +
properties O -
. O +

We O +
next O +
sought O +
to O +
determine O +
the O +
effects O +
on O +
transacylation O +
of O +
various O +
phospholipids O +
in O +
the O +
presence O +
of O +
20 O +
μM O +
DOC O +
( O -
Fig. O +
3 O +
) O -
. O +

The O +
purpose O +
of O +
these O +
experiments O +
was O +
to O +
determine O +
whether O +
phospholipid O +
had O +
an O +
additional O +
stimulatory O +
effect O +
beyond O +
that O +
of O +
DOC O +
and O +
to O +
determine O +
whether O +
phospholipid O +
that O +
lacked O +
an O +
acyl O +
group O +
in O +
sn O +
-1 O +
and O +
sn O +
-2 O +
positions O +
would O +
stimulate O +
the O +
TA B-Gene -
. O +

In O +
this O +
case O +
a O +
plasmalogen O +
rich O +
PE O +
from O +
brain O +
was O +
stimulatory O -
. O +

Perhaps O +
the O +
most O +
striking O +
feature O +
of O +
Fig. O +
3 O +
is O +
the O +
stimulation O +
by O +
1,2-dihexadecyl O -
- O -
sn O +
-glycero-3-phosphocholine O +
( O -
dialkyl O +
PC O -
) O -
, O +
a O +
phospholipid O +
with O +
ether O +
rather O +
than O +
ester O +
bonds O +
that O +
can O -
not O +
undergo O +
transacylation O -
. O +

This O +
indicates O +
that O +
the O +
stimulatory O +
effect O +
of O +
diradyl O +
phospholipids O +
on O +
transacylation O +
may O +
not O +
be O +
as O +
a O +
substrate O +
but O +
provides O +
a O +
favorable O +
lipid O +
milieu O -
. O +

Since O +
the O +
lipids O +
used O +
in O +
these O +
studies O +
have O +
defined O +
acyl O +
groups O -
, O +
we O +
determined O +
whether O +
an O +
acyl O +
group O +
is O +
transferred O +
from O +
PC O +
by O +
fatty O +
acid O +
analysis O +
of O +
the O +
product O +
BMP O -
. O +

Fig. O +
4 O +
shows O +
the O +
acyl O +
composition O +
of O +
the O +
BMP O +
in O +
which O +
1-myristoyl O +
LPG O +
and O +
POPC O +
were O +
used O +
as O +
substrates O +
( O -
from O +
Fig. O +
1 O +
) O -
. O +

As O +
determined O +
by O +
the O +
GC O -
, O +
myristate O +
was O +
the O +
predominant O +
fatty O +
acid O +
present O +
in O +
BMP O +
with O +
only O +
a O +
trace O +
of O +
the O +
acyl O +
groups O -
, O +
palmitate O +
and O +
oleate O -
, O +
from O +
the O +
POPC O +
being O +
used O +
in O +
the O +
biosynthesis O +
of O +
BMP O -
. O +

These O +
data O +
show O +
that O +
PC O +
does O +
not O +
participate O +
significantly O +
as O +
substrate O +
in O +
transacylation O -
. O +

This O +
observation O +
is O +
consistent O +
with O +
the O +
finding O +
that O +
dialkyl O +
PC O +
can O +
stimulate O +
transacylation O +
( O -
Fig. O +
3 O +
) O -
. O +

The O +
results O +
of O +
Fig. O +
4 O +
were O +
verified O +
using O +
lipids O +
with O +
different O +
acyl O +
chains O +
to O +
rule O +
out O +
the O +
possibility O +
that O +
the O +
TA B-Gene +
was O +
selecting O +
only O +
myristate O -
. O +

When O +
1-palmitoyl O +
LPG O +
and O +
1-myristoyl-2-stearoyl O -
- O -
sn O +
-glycero-3-phosphocholine O +
( O -
MSPC O -
) O +
were O +
used O +
in O +
combination O +
and O +
the O +
product O +
BMP O +
analyzed O +
by O +
electrospray O +
tandem O +
MS O -
, O +
the O +
mass O +
was O +
721 O -
, O +
showing O +
that O +
BMP O +
contained O +
two O +
palmitate O +
chains O +
( O -
Fig. O +
5 O +
) O -
. O +

In O +
this O +
experiment O +
MSPC O +
increased O +
transacylation O +
3-fold O +
which O +
indicates O +
that O +
MSPC O +
was O +
capable O +
of O +
stimulation O -
, O +
but O +
not O +
acyl O +
donation O -
. O +

Using O +
MS O +
we O +
could O +
also O +
determine O +
whether O +
the O +
TA B-Gene +
has O +
substrate O +
specificity O +
for O +
the O +
acyl O +
chains O -
. O +

We O +
analyzed O +
BMP O +
synthesized O +
from O +
reactions O +
that O +
contained O +
dialkyl O +
PC O +
and O +
mixed O +
LPGs O -
, O +
in O +
which O +
the O +
LPG O +
contained O +
either O +
myristate O -
, O +
palmitate O -
, O +
stearate O -
, O +
or O +
oleate O +
on O +
the O +
sn O +
-1 O +
position O -
. O +

Fig. O +
6A O +
shows O +
that O +
all O +
of O +
the O +
saturated O +
fatty O +
acyl O +
moieties O +
on O +
LPG O +
were O +
present O +
in O +
BMP O +
synthesized O +
whereas O +
monounsaturated O +
oleate O +
was O +
not O -
. O +

( O -
In O +
other O +
experiments O -
, O +
not O +
shown O -
, O +
where O +
a O +
single O +
species O +
of O +
LPG O +
was O +
used O -
, O +
1-oleoyl O +
LPG O +
was O +
transacylated O +
to O +
a O +
low O +
extent O +
only O -
. O -
) O +

The O +
major O +
BMP O +
ion O +
at O +
721 O +
m O -
/ O -
z O +
could O +
be O +
a O +
mixture O +
of O +
myristoyl O -
/ O -
stearoyl O +
BMP O +
and O +
dipalmitoyl O +
BMP O +
so O +
the O +
daughter O +
ions O +
were O +
determined O +
( O -
Fig. O +
6B O +
) O -
. O +

Although O +
the O +
daughter O +
ion O +
analysis O +
is O +
not O +
strictly O +
qualitative O -
, O +
it O +
appears O +
that O +
the O +
721 O +
m O -
/ O -
z O +
peak O +
contains O +
approximately O +
equimolar O +
amounts O +
of O +
myristate O -
, O +
palmitate O -
, O +
and O +
stearate O -
. O +

Table O +
1 O +
has O +
the O +
quantitative O +
analysis O +
of O +
the O +
data O +
in O +
Fig. O +
6A O +
and O +
indicates O +
that O -
, O +
assuming O +
equal O +
amounts O +
of O +
dipalmitoyl O +
and O +
myristoyl O -
/ O -
stearoyl O +
BMP O +
are O +
present O +
in O +
the O +
721 O +
m O -
/ O -
z O +
peak O -
, O +
the O +
TA O +
has O +
a O +
slight O +
preference O +
for O +
the O +
longer O +
chain O +
species O +
of O +
LPG O -
. O +

We O +
then O +
examined O +
the O +
relative O +
activity O +
of O +
1-palmitoyl O +
LPG O +
vs. O +
2-oleoyl O +
LPG O +
( O -
Fig. O +
7 O +
) O -
. O +

We O +
had O +
studied O +
their O +
metabolism O +
earlier O +
with O +
low O +
concentrations O +
of O +
LPGs O +
but O +
without O +
stimulatory O +
diradyl O +
phospholipid O -
. O +

In O +
that O +
case O +
we O +
found O +
that O +
the O +
TA B-Gene +
had O +
approximately O +
equal O +
activity O +
on O +
the O +
two O +
LPG O +
species O +
[ O -
8 O -
] O +
. O +

For O +
the O +
study O +
reported O +
here O -
, O +
1-palmitoyl-2-oleoyl O -
- O -
sn O +
-glycero-3-phospho O -
- O -
rac O +
-glycerol O +
( O -
POPG O -
) O +
was O +
hydrolyzed O +
by O +
either O +
a O +
lipase B-Gene +
from O +
Rhizopus O +
arrhizus O +
var O -
. O +

delemer O -
, O +
which O +
yields O +
2-oleoyl O +
LPG O +
[ O -
18 O -
] O +
or O +
porcine B-Gene +
pancreatic I-Gene +
PLA2 I-Gene +
, O +
which O +
yields O +
1-palmitoyl O +
LPG O +
[ O -
19 O -
] O +
. O +

When O +
used O +
as O +
substrates O +
singly O +
or O +
in O +
combination O -
, O +
the O +
1-palmitoyl O +
LPG O +
was O +
the O +
better O +
substrate O +
( O -
Fig. O +
6 O +
) O -
. O +

Ideally O -
, O +
the O +
experiment O +
should O +
be O +
conducted O +
with O +
the O +
same O +
acyl O +
chain O +
present O +
in O +
either O +
the O +
sn O +
-1 O +
or O +
sn O +
-2 O +
position O -
. O +

Technically O +
this O +
was O +
not O +
possible O -
. O +

We O +
can O -
not O +
conclude O -
, O +
therefore O -
, O +
that O +
the O +
difference O +
in O +
transacylation O +
using O +
these O +
two O +
substrates O +
is O +
the O +
sole O +
result O +
of O +
the O +
position O +
of O +
the O +
acyl O +
group O -
. O +

Since O +
some O +
1-oleoyl O +
LPG O +
was O +
transacylated O +
in O +
samples O +
containing O +
1-oleoyl O +
LPG O +
and O +
dialkyl O +
PC O +
( O -
data O +
not O +
shown O -
) O +
it O +
appears O +
that O +
the O +
TA B-Gene +
does O +
not O +
exclude O +
naturally O +
occurring O +
2-acyl O +
LPG O +
that O +
has O +
an O +
unsaturated O +
acyl O +
chain O +
as O +
substrate O -
. O +

The O +
question O +
then O +
arose O -
, O +
is O +
the O +
TA B-Gene +
specific O +
for O +
LPG O +
or O +
can O +
other O +
lysolipids O +
serve O +
as O +
substrates O -
. O +

Fig. O +
8 O +
shows O +
that O +
none O +
of O +
the O +
1-acyl O +
lysolipids O +
examined O +
were O +
substrates O +
at O +
10 O +
or O +
100 O +
μM O +
concentrations O -
. O +

Further O -
, O +
when O +
these O +
lysolipids O +
were O +
mixed O +
at O +
a O +
concentration O +
equal O +
to O +
LPG O -
, O +
inhibition O +
was O +
seen O -
. O +

While O +
not O +
studied O +
further O -
, O +
this O +
could O +
be O +
a O +
competitive O +
type O +
inhibition O +
or O +
the O +
result O +
of O +
surface O +
dilution O +
of O +
LPG O +
in O +
the O +
lipid O +
aggregate O -
. O +

4 O +
Discussion O +
The O +
results O +
presented O +
here O +
show O +
that O +
the O +
TA B-Gene +
that O +
converts O +
LPG O +
to O +
BMP O +
is O +
intramolecular O +
involving O +
the O +
transfer O +
of O +
the O +
acyl O +
group O +
from O +
one O +
LPG O +
to O +
another O -
. O +

The O +
enzyme B-Gene -
, O +
previously O +
shown O +
to O +
be O +
independent O +
of O +
ATP O +
and O +
CoA O +
[ O -
8 O -
] O +
, O +
most O +
likely O +
involves O +
an O +
acyl O +
enzyme B-Gene +
intermediate O -
, O +
although O +
this O +
point O +
can O -
not O +
be O +
proven O +
since O +
both O +
acceptor O +
and O +
donor O +
are O +
always O +
present O -
. O +

The O +
physical O +
state O +
of O +
the O +
substrate O +
appears O +
to O +
play O +
a O +
significant O +
role O +
in O +
the O +
reaction O -
. O +

The O +
1-myristoyl O +
LPG O +
is O +
reported O +
to O +
have O +
a O +
high O +
critical O +
micellar O +
concentration O +
( O -
CMC O -
) O +
ranging O +
from O +
160 O +
to O +
3000 O +
μM O -
, O +
depending O +
on O +
the O +
presence O +
of O +
salt O +
[ O -
20 O -
] O +
. O +

Under O +
the O +
conditions O +
used O +
in O +
our O +
standard O +
assay O -
, O +
10 O +
μM O +
LPG O -
, O +
most O +
substrate O -
, O +
if O +
not O +
all O -
, O +
is O +
monomeric O -
. O +

The O +
presence O +
of O +
diradyl O +
lipid O +
or O +
bile O +
acid O +
would O +
lead O +
to O +
partitioning O +
of O +
the O +
LPG O +
into O +
a O +
lipid O +
aggregate O +
such O +
as O +
a O +
bilayer O +
vesicle O +
or O +
a O +
mixed O +
micelle O -
. O +

If O +
so O -
, O +
the O +
enzyme B-Gene +
appears O +
to O +
prefer O +
a O +
lipid O -
/ O -
H2 O +
O O +
interface O +
over O +
monomolecular O +
dispersions O +
of O +
LPG O -
. O +

The O +
unusual O +
dependence O +
of O +
transacylation O +
on O +
both O +
the O +
LPG O +
and O +
PC O +
concentration O +
is O +
consistent O +
with O +
this O +
interpretation O +
( O -
Fig. O +
1 O +
) O -
. O +

Where O +
increasing O +
amounts O +
of O +
POPC O +
( O -
1–100 O +
μM O -
) O +
are O +
added O +
to O +
a O +
fixed O +
amount O +
of O +
LPG O +
( O -
30 O +
μM O -
; O +
Fig. O +
1B O +
) O -
, O +
two O +
considerations O +
must O +
be O +
made O -
, O +
first O +
the O +
intermicellar O +
concentration O +
( O -
IMC O -
) O +
of O +
LPG O +
partitioning O +
into O +
POPC O -
, O +
and O +
second O +
the O +
surface O +
dilution O +
of O +
1-myristoyl O +
LPG O +
in O +
POPC O -
. O +

The O +
fact O +
that O +
POPC O +
does O +
not O +
increase O +
transacylation O +
until O +
the O +
threshold O +
of O +
10 O +
μM O +
is O +
reached O -
, O +
but O +
continues O +
to O +
stimulate O +
to O +
100 O +
μM O -
, O +
suggests O +
that O +
the O +
partitioning O +
of O +
LPG O +
into O +
the O +
lipid O +
interface O -
, O +
the O +
IMC O -
, O +
has O +
more O +
influence O +
on O +
transacylation O +
than O +
does O +
substrate O +
dilution O -
. O +

Comparison O +
of O +
POPC O +
and O +
POPE O +
( O -
Fig. O +
1B O +
) O +
also O +
suggests O +
that O +
not O +
all O +
lipid O -
/ O -
H2 O +
O O +
interfaces O +
support O +
transacylation O -
. O +

POPE O -
, O +
a O +
lipid O +
known O +
to O +
form O +
a O +
Hex O +
II O +
phase O +
[ O -
21 O -
] O +
, O +
was O +
without O +
effect O -
, O +
either O +
the O +
result O +
of O +
little O +
LPG O +
partitioning O +
into O +
the O +
POPE O +
or O +
a O +
lipid O +
polymorphic O +
structure O -
, O +
presumably O +
Hex O +
II O -
, O +
that O +
the O +
TA B-Gene +
is O +
unable O +
to O +
productively O +
bind O -
. O +

When O +
a O +
different O +
matrix O +
is O +
present O +
and O +
PE O +
is O +
added O +
with O +
DOC O -
, O +
stimulation O +
is O +
observed O +
( O -
Fig. O +
3 O +
) O -
. O +

We O +
recognize O +
that O +
these O +
interpretations O +
are O +
speculative O +
without O +
data O +
on O +
the O +
lipid O +
structures O +
involved O -
. O +

They O +
do O +
provide O -
, O +
however O -
, O +
a O +
reasonable O +
approach O +
to O +
the O +
understanding O +
of O +
the O +
nature O +
of O +
the O +
lipid O +
mixtures O +
used O -
. O +

Previous O +
work O +
by O +
us O +
and O +
others O +
suggested O +
that O +
the O +
conversion O +
of O +
LPG O +
to O +
BMP O +
involves O +
transferring O +
an O +
acyl O +
chain O +
from O +
a O +
diacyl O +
phospholipid O +
[ O -
8,11–13 O -
] O +
. O +

Those O +
results O +
were O +
obtained O +
with O +
sub O -
- O -
μM O +
concentrations O +
of O +
LPG O +
and O +
transacylation O +
was O +
dependent O +
on O +
added O +
phospholipid O -
. O +

No O +
attempt O +
was O +
made O +
in O +
those O +
experiments O -
, O +
however O -
, O +
to O +
demonstrate O +
the O +
transfer O +
of O +
a O +
radiolabeled O +
fatty O +
acid O +
to O +
BMP O -
. O +

In O +
unpublished O +
experiments O +
we O +
found O +
that O +
a O +
few O +
percent O +
of O +
radiolabeled O +
fatty O +
acid O +
are O +
transferred O +
to O +
BMP O +
from O +
diradyl O +
phospholipids O -
, O +
relative O +
to O +
the O +
total O +
amount O +
of O +
BMP O +
synthesized O -
. O +

How O +
do O +
the O +
results O +
presented O +
here O +
reconcile O +
with O +
those O +
of O +
others O -
? O +

One O +
possible O +
explanation O +
is O +
that O +
multiple O +
transacylases B-Gene +
were O +
present O +
in O +
the O +
lysosomal O +
preparation O +
used O +
by O +
others O -
, O +
but O +
not O +
in O +
our O +
partially O +
purified O +
TA B-Gene -
. O +

For O +
example O -
, O +
Huterer O +
and O +
Wherett O +
showed O +
that O +
a O +
preparation O +
of O +
rat O +
liver O +
lysosomes O +
transferred O +
[ O -
3 O +
H O -
] O -
oleate O +
from O +
PC O +
to O +
form O +
BMP O +
[ O -
22 O -
] O +
. O +

However O -
, O +
the O +
vast O +
majority O +
of O +
the O +
oleate O +
was O +
released O +
as O +
a O +
free O +
oleate O +
and O +
less O +
than O +
1 O -
% O +
was O +
recovered O +
in O +
BMP O -
. O +

Further O -
, O +
the O +
amount O +
of O +
BMP O +
formed O +
from O +
LPG O +
was O +
far O +
in O +
excess O +
of O +
the O +
amount O +
of O +
oleate O +
incorporated O -
. O +

These O +
data O +
are O +
consistent O +
with O +
our O +
results O +
here O +
that O +
show O +
little O -
, O +
if O +
any O -
, O +
BMP O +
is O +
formed O +
by O +
the O +
transfer O +
of O +
an O +
acyl O +
group O +
from O +
diradyl O +
lipids O -
. O +

The O +
different O +
transacylases B-Gene +
described O +
can O +
be O +
classified O +
as O +
follows:1 O -
. O +

acyl B-Gene -
- I-Gene -
CoA I-Gene +
acyltransferases I-Gene -
; O +
2 O -
. O +

CoA B-Gene +
independent I-Gene +
transacylases I-Gene -
; O +
3 O -
. O +
lysophospholipases B-Gene -
; O +
4 O -
. O +

LPG B-Gene +
transacylases I-Gene +
( O -
TA O -
) O -
. O +

The O +
acyl B-Gene -
- I-Gene -
CoA I-Gene +
acyltransferase I-Gene +
employs O +
an O +
acyl O -
- O -
CoA O +
formed O +
by O +
acyl B-Gene -
- I-Gene -
CoA I-Gene +
synthetase I-Gene +
in O +
microsomes O +
and O +
is O +
optimal O +
at O +
pH O +
7.5 O +
[ O -
23 O -
] O +
. O +

These O +
characteristics O +
make O +
it O +
clearly O +
different O +
from O +
the O +
activity O +
described O +
here O -
. O +

The O +
CoA B-Gene +
independent I-Gene +
transacylase I-Gene +
is O +
an O +
enzyme O +
that O +
transfers O +
an O +
acyl O +
group O +
from O +
the O +
sn O +
-2 O +
position O +
of O +
a O +
diradyl O +
phospholipid O +
to O +
a O +
lysolipid O +
[ O -
24 O -
] O +
. O +

If O +
that O +
were O +
the O +
enzyme B-Gene +
involved O +
we O +
would O +
expect O +
that O +
PG O +
would O +
be O +
formed O +
from O +
LPG O +
yet O +
none O +
was O +
detected O +
( O -
data O +
not O +
shown O -
) O -
. O +

The O +
transfer O +
of O +
the O +
acyl O +
group O +
only O +
to O +
the O +
head O +
group O +
( O -
prime O -
) O +
glycerol O +
is O +
different O +
from O +
other O +
CoA B-Gene +
independent I-Gene +
transacylases I-Gene -
. O +

The O +
third O -
, O +
lysophospholipase B-Gene -
, O +
has O +
one O +
similarity O +
to O +
the O +
activity O +
reported O +
here O -
; O +
two O +
molecules O +
of O +
the O +
same O +
lysolipid O +
are O +
used O +
to O +
form O +
one O +
diradyl O +
phospholipid O +
[ O -
25 O -
] O +
. O +

This O +
enzyme O +
is O +
different O +
from O +
the O +
TA B-Gene +
in O +
two O +
important O +
respects O -
, O +
however O -
. O +

First O -
, O +
we O +
find O +
no O +
evidence O +
for O +
lysophospholipase B-Gene +
activity O +
in O +
the O +
TA B-Gene -
, O +
based O +
on O +
the O +
lack O +
of O +
fatty O +
acid O +
released O +
( O -
data O +
not O +
shown O -
) O -
. O +

Second O -
, O +
the O +
LPC O -
: O -
LPC O +
transacylase B-Gene +
has O +
a O +
broad O +
substrate O +
specificity O +
and O +
can O +
use O +
LPG O -
, O +
but O +
in O +
that O +
case O +
PG O -
, O +
not O +
BMP O -
, O +
is O +
formed O +
[ O -
26 O -
] O +
. O +

The O +
TA B-Gene +
described O +
here O -
, O +
therefore O -
, O +
appears O +
to O +
be O +
unique O -
. O +

How O +
do O +
the O +
findings O +
reported O +
here O +
fit O +
with O +
the O +
proposed O +
role O +
of O +
the O +
LPG B-Gene +
transacylase I-Gene +
in O +
Scheme O +
1 O +
? O +

Scheme O +
2 O +
provides O +
a O +
modification O +
of O +
the O +
TA B-Gene +
reaction O +
proposed O +
in O +
step O +
2 O +
of O +
Scheme O +
1 O +
. O +

Rather O +
than O +
utilizing O +
a O +
diacyl O +
phospholipid O +
in O +
transacylation O -
, O +
a O +
second O +
molecule O +
of O +
LPG O +
is O +
the O +
acyl O +
donor O +
with O +
the O +
production O +
of O +
glycerophosphoglycerol O +
( O -
GPG O -
) O +
in O +
addition O +
to O +
BMP O -
. O +

The O +
major O +
factor O +
that O +
can O -
not O +
be O +
accommodated O +
is O +
the O +
failure O +
of O +
the O +
TA B-Gene +
to O +
use O +
unsaturated O +
fatty O +
acids O +
significantly O -
. O +

We O +
must O +
conclude O +
that O +
polyunsaturated O +
fatty O +
acids O +
such O +
as O +
arachidonate O +
[ O -
7 O -
] O +
or O -
, O +
in O +
particular O -
, O +
docosahexanoate O +
[ O -
27 O -
] O +
are O +
incorporated O +
by O +
some O +
other O +
mechanism O -
. O +

Until O +
the O +
mechanism O +
of O +
stereochemical O +
rearrangement O +
is O +
defined O -
, O +
this O +
question O +
of O +
polyunsaturated O +
fatty O +
acid O +
incorporation O +
remains O +
open O -
. O +

Acknowledgements O +
This O +
work O +
was O +
supported O +
in O +
part O +
by O +
National O +
Institutes O +
of O +
Health O +
HL-50395 O +
and O +
National O +
Cancer O +
Institute O +
Comprehensive O +
Cancer O +
Center O +
of O +
Wake O +
Forest O +
Grant O +
CA-12197 O -
. O +

Use O +
of O +
the O +
Tissue O +
Culture O +
Core O +
Laboratory O +
is O +
gratefully O +
acknowledged O -
. O +

We O +
especially O +
thank O +
Dr. O +
Mike O +
Thomas O +
and O +
Mike O +
Samuel O +
from O +
Wake O +
Forest O +
University O +
for O +
their O +
technical O +
support O +
in O +
examining O +
the O +
MS O +
samples O -
, O +
and O +
Dr. O +
Nick O +
Ralston O +
and O +
Dr. O +
Koji O +
Shinozaki O +
for O +
their O +
advice O +
and O +
assistance O +
in O +
the O +
laboratory O -
. O +

The O +
authors O +
attempted O +
to O +
evaluate O +
different O +
reagents O +
in O +
order O +
to O +
quantify O +
the O +
amino O +
groups O +
of O +
the O +
platelet O +
membrane O -
. O +

The O +
study O +
was O +
carried O +
out O +
by O +
the O +
action O +
of O +
different O +
aldehydes O +
and O +
acid O +
anhydrides O -
. O +

The O +
use O +
of O +
2,4,6-trinitrobenzenesulfonic O +
acid O +
made O +
possible O +
an O +
approach O +
by O +
electrophoresis O +
and O +
chemical O +
assay O -
. O +

The O +
results O +
showed O +
an O +
increase O +
in O +
the O +
surface O +
charge O +
corresponding O +
to O +
a O +
mean O +
number O +
of O +
amino O +
groups O +
varying O +
from O +
1.86.10 O -
( O -
5 O -
) O +
groups O +
with O +
citraconic O +
acid O +
to O +
3.94.10 O -
( O -
5 O -
) O +
groups O +
with O +
acetaldehyde O -
. O +

The O +
study O +
on O +
the O +
metabolism O +
after O +
oral O +
administration O +
of O +
chenodeoxycholic O +
acid-24 O -
- O -
14C O +
was O +
performed O +
by O +
analysis O +
of O +
radioactivity O +
that O +
had O +
appeared O +
in O +
bile O +
and O +
feces O +
of O +
male O +
hamsters O -
. O +

The O +
radioactive O +
bile O +
acids O +
were O +
analyzed O +
by O +
thin O +
layer O +
chromatography O +
and O +
identified O +
by O +
the O +
isotope O +
dilution O +
method O -
. O +

In O +
the O +
bile O +
of O +
the O +
hamsters O +
with O +
bile O +
fistula O -
, O +
radioactivity O +
was O +
originated O +
from O +
unchanged O +
chenodeoxycholic O +
acid O +
for O +
the O +
most O +
part O -
, O +
and O +
7-ketolithocholic O +
acid O -
, O +
lithocholic O +
acid O -
, O +
and O +
beta O -
- O -
muricholic O +
acid O +
for O +
the O +
remainder O -
. O +

In O +
the O +
feces O +
lithocholic O +
acid O -
, O +
dehydrolithocholic O +
acid O -
, O +
isolithocholic O +
acid O -
, O +
and O +
unchanged O +
form O +
were O +
identified O -
. O +

After O +
the O +
multiple O +
dosing O +
of O +
chenodeoxycholic O +
acid-24 O -
- O -
14C O +
for O +
6 O +
days O -
, O +
beta O -
- O -
muricholic O +
acid O +
was O +
also O +
identified O +
in O +
the O +
feces O -
. O +

1 O -
. O +

Normal O +
human O +
urine O +
contains O +
small O +
amounts O +
( O -
less O +
than O +
4 O +
mg O -
/ O -
g O +
of O +
creatinine O -
) O +
of O +
2-ethylhydracrylic O +
acid O -
, O +
formed O -
, O +
we O +
believe O -
, O +
by O +
a O +
previously O +
undisclosed O +
endogenous O +
catabolic O +
pathway O +
for O +
the O +
oxidation O +
of O +
a O +
newly O +
described O +
series O +
of O +
R O +
metabolites O +
of O +
isoleucine O -
. O +

2 O -
. O +

Urinary O +
excretion O +
of O +
2-ethylhydracrylic O +
acid O +
is O +
variably O +
increased O +
in O +
defects O +
of O +
isoleucine O +
oxidation O +
at O +
distal O +
steps O +
in O +
the O +
catabolic O +
pathway O +
( O -
3-oxoacyl B-Gene -
- I-Gene -
CoA I-Gene +
thiolase I-Gene +
deficiency O +
and O +
methylmalonyl B-Gene -
- I-Gene -
CoA I-Gene +
mutase I-Gene +
deficiency O -
) O +
and O +
is O +
diminished O +
when O +
proximal O +
steps O +
of O +
the O +
oxidative O +
pathway O +
are O +
blocked O +
as O +
in O +
branched B-Gene -
- I-Gene -
chain I-Gene +
oxo I-Gene +
acid I-Gene +
decarboxylase I-Gene +
deficiency O +
( O -
' O -
maple O -
- O -
syrup O -
- O -
urine O -
' O +
disease O -
) O -
. O +

3 O -
. O +
Precursors O +
of O +
R O -
- O -
pathway O +
metabolites O +
[ O -
R O -
( O -
- O -
) O -
-2-methylbutyrate O +
and O +
2-ethylacrylate O +
] O +
lead O +
to O +
increased O +
2-ethylhydracrylate O +
excretion O +
in O +
the O +
mammal O -
( O -
rat O -
, O +
rabbit O +
and O +
dog O -
) O -
; O +
the O +
corresponding O +
S O +
metabolites O +
[ O -
S O -
( O -
+ O -
) O -
-2-methylbutyric O +
acid O +
and O +
tiglic O +
acid O +
] O -
, O +
when O +
given O +
in O +
equimolar O +
amounts O -
, O +
have O +
little O +
effect O +
on O +
its O +
excretion O -
, O +
suggesting O +
that O +
little O +
or O +
no O +
interconversion O +
between O +
S O +
and O +
R O +
metabolites O +
occurs O +
in O +
vivo O -
. O +

4 O -
. O +
Studies O +
with O +
2H O -
- O -
labelled O +
precursors O +
indicate O +
that O +
conversion O +
of O +
R O +
2-methylbutyrate O +
into O +
2-ethylhydracrylic O +
acid O +
occurs O +
by O +
a O +
direct O +
pathway O +
( O -
apparently O +
via O +
2-ethylacrylic O +
acid O -
) O -
. O +

5 O -
. O +

The O +
further O +
oxidation O +
of O +
2-ethylhydracrylic O +
acid O +
to O +
ethylmalonic O +
acid O +
was O +
demonstrated O -
, O +
and O +
may O +
be O +
analogous O +
to O +
S O -
- O -
metabolite O +
oxidation O +
via O +
methyl O +
malonate O -
. O +

6 O -
. O +

Valine O +
metabolites O +
do O +
not O +
interact O +
with O +
the O +
R O -
= O -
isoleucine O +
pathway O +
under O +
the O +
conditions O +
of O +
these O +
experiments O +
in O +
vivo O -
. O +

In O +
six O +
persons O +
with O +
contact O +
allergy O +
to O +
chrysanthemum O +
of O +
florists O -
, O +
patch O +
tests O +
were O +
performed O +
with O +
25 O +
sequiterpene O +
lactones O -
. O +

Positive O +
responses O +
were O +
observed O +
to O +
15 O +
lactones O -
. O +

The O +
most O +
frequently O +
encountered O +
positive O +
responses O +
were O +
to O +
alantolactone O +
( O -
positive O +
in O +
all O +
cases O -
) O +
and O +
to O +
arbusculin O +
A O -
, O +
8-deoxycumambrin O -
, O +
ambrosin O -
, O +
damsin O +
and O +
psilostachynin O -
. O +

The O +
findings O +
corroborate O +
the O +
assumption O +
that O +
an O +
alpha O -
- O -
methylene O +
group O +
attached O +
to O +
the O +
gamma O -
- O -
lactone O +
ring O +
is O +
an O +
essential O +
prerequisite O +
for O +
allergenic O +
activity O +
of O +
sesquiterpene O +
lactones O -
. O +

Pyrethrum O +
produced O +
a O +
positive O +
reaction O +
in O +
one O +
of O +
the O +
patients O -
, O +
pyrethrins O +
gave O +
negative O +
reactions O +
in O +
all O -
. O +

Some O +
of O +
the O +
chrysanthemum O +
patients O +
were O +
also O +
hypersensitive O +
to O +
turpentine O +
and O +
colophony O +
and O +
to O +
garlic O -
, O +
primin O +
and O +
tars O -
. O +

Depression O +
is O +
a O +
common O +
condition O +
that O +
is O +
often O +
unrecognised O -
, O +
misdiagnosed O +
and/or O +
undertreated O -
. O +

It O +
is O +
associated O +
with O +
substantial O +
direct O -
, O +
indirect O +
and O +
intangible O +
costs O -
. O +

The O +
indirect O +
costs O +
of O +
lost O +
earnings O -
/ O -
productivity O +
and O +
premature O +
death O +
account O +
for O +
the O +
majority O +
of O +
these O +
costs O -
; O +
drug O +
costs O +
account O +
for O +
only O +
about O +
1 O +
to O +
2 O -
% O +
of O +
total O +
costs O +
and O +
about O +
10 O +
to O +
12 O -
% O +
of O +
direct O +
costs O -
. O +

Thus O -
, O +
better O +
recognition O +
and O +
appropriate O +
treatment O +
of O +
depression O +
would O +
increase O +
the O +
direct O +
costs O +
associated O +
with O +
this O +
illness O -
, O +
but O +
would O +
also O +
have O +
the O +
potential O +
to O +
greatly O +
reduce O +
indirect O +
costs O +
and O +
consequently O +
the O +
overall O +
cost O +
of O +
depression O -
. O +

Because O +
of O +
their O +
higher O +
acquisition O +
costs O +
relative O +
to O +
tricyclic O +
antidepressants O +
( O -
TCAs O -
) O -
, O +
there O +
has O +
been O +
much O +
debate O +
about O +
whether O +
the O +
use O +
of O +
sertraline O +
or O +
other O +
selective O +
serotonin O +
reuptake O +
inhibitors O +
( O -
SSRIs O -
) O +
for O +
first O -
- O -
line O +
treatment O +
of O +
depression O +
can O +
be O +
justified O -
. O +

While O +
these O +
agents O +
have O +
similar O +
efficacy O +
to O +
TCAs O -
, O +
they O +
are O +
better O +
tolerated O +
and O +
have O +
a O +
lower O +
risk O +
of O +
death O +
on O +
overdosage O -
. O +

Despite O +
the O +
large O +
economic O +
burden O +
of O +
depression O +
on O +
society O -
, O +
pharmacoeconomic O +
data O +
on O +
sertraline O +
and O +
antidepressant O +
drugs O +
in O +
general O +
are O +
scarce O -
. O +

Most O +
of O +
the O +
available O +
studies O +
on O +
sertraline O +
are O +
limited O +
to O +
considerations O +
of O +
direct O +
costs O +
and O +
do O +
not O +
assess O +
costs O +
from O +
a O +
societal O +
perspective O -
. O +

In O +
addition O -
, O +
a O +
number O +
of O +
studies O +
have O +
significant O +
methodological O +
problems O +
which O +
limit O +
determination O +
of O +
meaningful O +
conclusions O -
. O +

Nonetheless O -
, O +
data O +
from O +
2 O +
more O +
recent O +
studies O +
with O +
fewer O +
methodological O +
problems O +
than O +
earlier O +
studies O +
indicated O +
that O +
sertraline O +
was O +
more O +
cost O -
- O -
effective O +
than O +
TCAs O +
because O +
of O +
fewer O +
psychiatrist O +
consultations O -
, O +
and O +
less O +
costly O +
than O +
fluoxetine O +
because O +
of O +
fewer O +
absences O +
from O +
work O +
and O +
fewer O +
medical O +
consultations O -
. O +

The O +
cost O -
- O -
utility O +
ratio O +
of O +
maintenance O +
therapy O +
of O +
depression O +
with O +
sertraline O +
appears O +
to O +
fall O +
within O +
the O +
range O +
of O +
accepted O +
cost O -
- O -
utility O +
ratios O +
of O +
common O +
healthcare O +
interventions O -
. O +

Thus O -
, O +
studies O +
to O +
date O +
have O +
generally O +
shown O +
that O +
overall O +
treatment O +
costs O +
with O +
sertraline O +
and O +
other O +
SSRIs O +
are O +
no O +
greater O +
than O +
those O +
for O +
TCAs O -
; O +
this O +
is O +
despite O +
the O +
lower O +
acquisition O +
costs O +
of O +
the O +
latter O +
agents O -
. O +

Therefore O -
, O +
it O +
is O +
clear O +
from O +
these O +
data O +
that O +
it O +
is O +
misleading O +
to O +
classify O +
antidepressant O +
agents O +
as O +
expensive O +
or O +
inexpensive O +
based O +
solely O +
on O +
their O +
acquisition O +
costs O -
. O +

Sertraline O -
, O +
therefore O -
, O +
can O +
be O +
considered O +
as O +
a O +
first O -
- O -
line O +
alternative O +
to O +
TCAs O +
and O +
other O +
SSRIs O +
for O +
the O +
treatment O +
of O +
depression O +
on O +
both O +
clinical O +
and O +
pharmacoeconomic O +
grounds O -
. O +

The O +
55-kDa O +
receptor B-Gene +
for I-Gene +
tumor I-Gene +
necrosis I-Gene +
factor I-Gene +
( O -
TR55 B-Gene -
) O +
triggers O +
multiple O +
signaling O +
cascades O +
initiated O +
by O +
adapter B-Gene +
proteins I-Gene +
like O +
TRADD B-Gene +
and O +
FAN B-Gene -
. O +

By O +
use O +
of O +
the O +
primary O +
amine O +
monodansylcadaverine O +
( O -
MDC O -
) O -
, O +
we O +
addressed O +
the O +
functional O +
role O +
of O +
tumor B-Gene +
necrosis I-Gene +
factor I-Gene +
( O -
TNF B-Gene -
) O +
receptor B-Gene +
internalization O +
for O +
intracellular O +
signal O +
distribution O -
. O +

We O +
show O +
that O +
MDC O +
does O +
not O +
prevent O +
the O +
interaction O +
of O +
the O +
p55 B-Gene +
TNF I-Gene +
receptor I-Gene +
( O -
TR55 B-Gene -
) O +
with O +
FAN B-Gene +
and O +
TRADD B-Gene -
. O +

Furthermore O -
, O +
the O +
activation O +
of O +
plasmamembrane O -
- O -
associated O +
neutral O +
sphingomyelinase B-Gene +
activation O +
as O +
well O +
as O +
the O +
stimulation O +
of O +
proline B-Gene -
- I-Gene -
directed I-Gene +
protein I-Gene +
kinases I-Gene +
were O +
not O +
affected O +
in O +
MDC O -
- O -
treated O +
cells O -
. O +

In O +
contrast O -
, O +
activation O +
of O +
signaling B-Gene +
enzymes I-Gene +
that O +
are O +
linked O +
to O +
the O +
" O -
death O +
domain O -
" O +
of O +
TR55 B-Gene -
, O +
like O +
acid B-Gene +
sphingomyelinase I-Gene +
and O +
c B-Gene -
- I-Gene -
Jun I-Gene -
- I-Gene -
N I-Gene -
- I-Gene -
terminal I-Gene +
protein I-Gene +
kinase I-Gene +
as O +
well O +
as O +
TNF B-Gene +
signaling O +
of O +
apoptosis O +
in O +
U937 O +
and O +
L929 O +
cells O -
, O +
are O +
blocked O +
in O +
the O +
presence O +
of O +
MDC O -
. O +

The O +
results O +
of O +
our O +
study O +
suggest O +
a O +
role O +
of O +
TR55 B-Gene +
internalization O +
for O +
the O +
activation O +
of O +
select O +
TR55 B-Gene +
death O +
domain O +
signaling O +
pathways O +
including O +
those O +
leading O +
to O +
apoptosis O -
. O +

Amiodarone O +
( O -
AD O -
) O +
is O +
an O +
effective O +
antidysrythmic O +
drug O -
, O +
however O -
, O +
there O +
can O +
be O +
serious O +
side O +
effects O -
, O +
such O +
as O +
hepatic O +
and O +
neurological O +
alterations O -
, O +
as O +
well O +
as O +
skin O +
photosensitization O -
, O +
as O +
seen O +
in O +
porphyrias O -
. O +

Clinical O +
signs O +
in O +
porphyrias O +
might O +
be O +
triggered O +
by O +
the O +
so O -
- O -
called O +
porphyrinogenic O +
drugs O -
. O +

Without O +
sound O +
basis O -
, O +
Amiodarone O +
has O +
been O +
classified O +
as O +
an O +
unsafe O +
drug O +
for O +
porphyric O +
patients O -
. O +

The O +
aim O +
of O +
this O +
work O +
has O +
been O +
to O +
study O +
the O +
effect O +
of O +
AD O -
, O +
both O +
in O +
vivo O +
and O +
in O +
vitro O -
, O +
on O +
heme O +
metabolism O -
. O +

In O +
the O +
in O +
vivo O +
assays O -
, O +
the O +
activities O +
of O +
5-aminolevulinate B-Gene +
synthetase I-Gene +
( O -
ALA B-Gene -
- I-Gene -
S I-Gene -
) O -
, O +
ALA B-Gene +
dehydratase I-Gene +
( O -
ALA B-Gene -
- I-Gene -
D I-Gene -
) O -
, O +
porphobilinogenase B-Gene +
( O -
PBGase B-Gene -
) O +
and O +
PBG B-Gene -
- I-Gene -
deaminase I-Gene +
( O -
PBG B-Gene -
- I-Gene -
D I-Gene -
) O +
in O +
blood O -
, O +
liver O -
, O +
and O +
kidney O -
; O +
hepatic O +
and O +
fecal O +
porphyrins O -
, O +
urinary O +
ALA O -
, O +
PBG O +
and O +
porphyrins O +
in O +
male O +
mice O +
strain O +
CF1 O +
treated O +
with O +
AD O +
( O -
100 O +
mg O +
i.p O -
. O +

daily O -
) O +
for O +
1 O +
week O +
and O +
1 O +
month O -
, O +
were O +
measured O -
. O +

No O +
significanat O +
differences O +
were O +
found O +
for O +
any O +
of O +
these O +
parameters O +
in O +
the O +
AD O +
treated O +
animals O +
as O +
compared O +
to O +
controls O -
. O +

In O +
the O +
in O +
vitro O +
experiments O +
human O +
blood O -
, O +
and O +
mice O +
blood O -
, O +
liver O -
, O +
and O +
kidney O -
, O +
were O +
used O +
to O +
measure O +
the O +
activities O +
of O +
ALA B-Gene -
- I-Gene -
S I-Gene -
, O +
ALA B-Gene -
- I-Gene -
D I-Gene -
, O +
PBGase B-Gene -
, O +
PBG B-Gene -
- I-Gene -
D I-Gene +
and O +
uroporphyrinogen B-Gene +
decarboxylase I-Gene -
, O +
in O +
the O +
presence O +
of O +
varying O +
concentrations O +
of O +
AD O +
( O -
0.0172 O -
- O -
4.304 O +
mM O -
) O -
. O +

AD O +
did O +
not O +
modify O +
any O +
of O +
the O +
enzyme B-Gene +
activities O -
. O +

All O +
of O +
the O +
above O +
biochemical O +
parameters O +
were O +
studied O +
in O +
17 O +
cardiac O +
patients O +
under O +
AD O +
treatment O +
for O +
3 O +
to O +
20 O +
years O -
. O +

Neither O +
the O +
activities O +
of O +
the O +
heme B-Gene +
enzymes I-Gene -
, O +
nor O +
the O +
levels O +
of O +
precursors O +
and O +
porphyrins O +
in O +
urine O +
and O +
plasma O +
were O +
altered O -
. O +

These O +
findings O +
clearly O +
demonstrate O +
that O +
AD O +
is O +
a O +
pharmacologically O +
safe O +
drug O +
and O +
can O +
be O +
used O +
for O +
the O +
treatment O +
of O +
associated O +
pathologies O +
in O +
porphyrias O -
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
determine O +
the O +
antimutagenicity O +
of O +
WR-1065 O +
added O +
after O +
irradiation O +
of O +
cells O +
of O +
cell O +
lines O +
differing O +
in O +
their O +
ability O +
to O +
rejoin O +
radiation O -
- O -
induced O +
DNA O +
double O -
- O -
strand O +
breaks O +
( O -
DSBs O -
) O -
. O +

The O +
postirradiation O +
antimutagenicity O +
of O +
WR-1065 O +
at O +
the O +
thymidine B-Gene +
kinase I-Gene +
locus O +
was O +
demonstrated O +
for O +
L5178Y O +
( O -
LY O -
) O -
-S1 O +
cells O +
that O +
are O +
deficient O +
in O +
repair O +
of O +
DNA O +
DSBs O -
. O +

Less O +
postirradiation O +
antimutagenicity O +
of O +
WR-1065 O +
was O +
observed O +
in O +
LY O -
- O -
R16 O +
and O +
LY O -
- O -
SR1 O +
cells O -
, O +
which O +
are O +
relatively O +
efficient O +
in O +
DSB O +
repair O -
. O +

Postirradiation O +
treatment O +
with O +
WR-1065 O +
had O +
only O +
a O +
small O +
stimulatory O +
effect O +
on O +
DSB O +
rejoining O -
. O +

A O +
3-h O +
incubation O +
of O +
irradiated O +
LY O +
cells O +
with O +
WR-1065 O +
caused O +
slight O +
changes O +
in O +
the O +
distribution O +
of O +
cells O +
in O +
the O +
phases O +
of O +
the O +
cell O +
cycle O +
that O +
differed O +
between O +
LY O -
- O -
S1 O +
and O +
LY O -
- O -
SR1 O +
cells O -
. O +

Both O +
LY O -
- O -
S1 O +
and O +
LY O -
- O -
SR1 O +
cells O +
were O +
protected O +
against O +
the O +
cytotoxic O +
and O +
mutagenic O +
effects O +
of O +
radiation O +
when O +
WR-1065 O +
was O +
present O +
30 O +
min O +
before O +
and O +
during O +
the O +
irradiation O -
. O +

We O +
conclude O +
that O +
the O +
differential O +
postirradiation O +
effects O +
of O +
WR-1065 O +
in O +
the O +
LY O -
- O -
S1 O +
and O +
LY O -
- O -
SR1 O +
cells O +
are O +
not O +
caused O +
by O +
differences O +
in O +
cellular O +
uptake O +
of O +
the O +
radioprotector O +
or O +
in O +
its O +
radical O +
scavenging O +
activity O -
. O +

Possible O +
mechanisms O +
for O +
the O +
postirradiation O +
antimutagenicity O +
of O +
WR-1065 O +
are O +
discussed O -
. O +

Nitric O +
oxide O +
( O -
NO O -
) O +
and O +
tumor B-Gene +
necrosis I-Gene +
factor I-Gene +
alpha I-Gene +
( O -
TNF B-Gene -
- I-Gene -
alpha I-Gene -
) O +
are O +
the O +
major O +
mediators O +
produced O +
in O +
activated O +
macrophages O +
which O +
contribute O +
to O +
the O +
circulatory O +
failure O +
associated O +
with O +
septic O +
shock O -
. O +

A O +
sesquiterpene O +
lactone O +
compound O +
( O -
dehydrocostus O +
lactone O -
) O +
isolated O +
from O +
the O +
medicinal O +
plant O -
, O +
Saussurea O +
lappa O -
, O +
inhibited O +
the O +
production O +
of O +
NO O +
in O +
lipopolysaccharide O +
( O -
LPS O -
) O -
-activated O +
RAW O +
264.7 O +
cells O +
by O +
suppressing O +
inducible O +
nitric B-Gene +
oxide I-Gene +
synthase I-Gene +
enzyme B-Gene +
expression O -
. O +

This O +
compound O +
also O +
decreased O +
the O +
TNF B-Gene -
- I-Gene -
alpha I-Gene +
level O +
in O +
LPS O -
- O -
activated O +
systems O +
in O +
vitro O +
and O +
in O +
vivo O -
. O +

Thus O -
, O +
dehydrocostus O +
lactone O +
may O +
be O +
a O +
possible O +
candidate O +
for O +
the O +
development O +
of O +
new O +
drugs O +
to O +
treat O +
endotoxemia O +
accompanied O +
by O +
the O +
overproduction O +
of O +
NO O +
and O +
TNF B-Gene -
- I-Gene -
alpha I-Gene -
. O +

The O +
putative O +
biosynthetic O +
gene O +
cluster O +
for O +
the O +
alpha B-Gene -
- I-Gene -
glucosidase I-Gene +
inhibitor O +
acarbose O +
was O +
identified O +
in O +
the O +
producer O +
Actinoplanes O +
sp. O +
50 O -
/ O -
110 O +
by O +
cloning O +
a O +
DNA O +
segment O +
containing O +
the O +
conserved O +
gene O +
for O +
dTDP B-Gene -
- I-Gene -
D I-Gene -
- I-Gene -
glucose I-Gene +
4,6-dehydratase I-Gene -
, O +
acbB. B-Gene +
The O +
two O +
flanking O +
genes O +
were O +
acbA B-Gene +
( O -
dTDP B-Gene -
- I-Gene -
D I-Gene -
- I-Gene -
glucose I-Gene +
synthase I-Gene -
) O +
and O +
acbC B-Gene -
, O +
encoding O +
a O +
protein B-Gene +
with O +
significant O +
similarity O +
to O +
3-dehydroquinate B-Gene +
synthases I-Gene +
( O -
AroB B-Gene +
proteins I-Gene -
) O -
. O +

The O +
acbC B-Gene +
gene O +
was O +
overexpressed O +
heterologously O +
in O +
Streptomyces O +
lividans O +
66 O -
, O +
and O +
the O +
product O +
was O +
shown O +
to O +
be O +
a O +
C7-cyclitol B-Gene +
synthase I-Gene +
using O +
sedo O -
- O -
heptulose O +
7-phosphate O -
, O +
but O +
not O +
ido O -
- O -
heptulose O +
7-phosphate O -
, O +
as O +
its O +
substrate O -
. O +

The O +
cyclization O +
product O -
, O +
2-epi-5-epi O -
- O -
valiolone O +
( O -
( O -
2S,3S,4S,5R O -
) O -
-5- O -
( O -
hydroxymethyl O -
) O -
cyclohexanon-2,3,4,5-tetrol O -
) O -
, O +
is O +
a O +
precursor O +
of O +
the O +
valienamine O +
moiety O +
of O +
acarbose O -
. O +

A O +
possible O +
five O -
- O -
step O +
reaction O +
mechanism O +
is O +
proposed O +
for O +
the O +
cyclization O +
reaction O +
catalyzed O +
by O +
AcbC B-Gene +
based O +
on O +
the O +
recent O +
analysis O +
of O +
the O +
three O -
- O -
dimensional O +
structure O +
of O +
a O +
eukaryotic O +
3-dehydroquinate B-Gene +
synthase I-Gene +
domain O +
( O -
Carpenter O -
, O +
E. O +
P. O -
, O +
Hawkins O -
, O +
A. O +
R. O -
, O +
Frost O -
, O +
J. O +
W. O -
, O +
and O +
Brown O -
, O +
K. O +
A. O +
( O -
1998 O -
) O +
Nature O +
394 O -
, O +
299 O -
- O -
302 O -
) O -
. O +

The O +
mechanism O +
of O +
DNA O +
damage O +
induced O +
by O +
metabolites O +
of O +
nitrobenzene O +
was O +
investigated O +
in O +
relation O +
to O +
the O +
carcinogenicity O +
and O +
reproductive O +
toxicity O +
of O +
nitrobenzene O -
. O +

Nitrosobenzene O -
, O +
a O +
nitrobenzene O +
metabolite O -
, O +
induced O +
NADH O +
plus O +
Cu O -
( O -
II O -
) O -
-mediated O +
DNA O +
cleavage O +
frequently O +
at O +
thymine O +
and O +
cytosine O +
residues O -
. O +

Catalase B-Gene +
and O +
bathocuproine O +
inhibited O +
the O +
DNA O +
damage O -
, O +
suggesting O +
the O +
involvement O +
of O +
H2O2 O +
and O +
Cu O -
( O -
I O -
) O -
. O +

Typical O +
free O +
hydroxyl O +
radical O +
scavengers O +
showed O +
no O +
inhibitory O +
effects O +
on O +
DNA O +
damage O -
. O +

Nitrosobenzene O +
caused O +
the O +
formation O +
of O +
8-oxo-7 O -
, O +
8-dihydro-2'-deoxyguanosine O +
in O +
calf O +
thymus O +
DNA O +
in O +
the O +
presence O +
of O +
NADH O +
and O +
Cu O -
( O -
II O -
) O -
. O +

ESR O +
spectroscopic O +
study O +
has O +
confirmed O +
that O +
nitrosobenzene O +
is O +
reduced O +
by O +
NADH O +
to O +
the O +
phenylhydronitroxide O +
radical O +
even O +
in O +
the O +
absence O +
of O +
Cu O -
( O -
II O -
) O -
. O +

These O +
results O +
suggest O +
that O +
nitrosobenzene O +
can O +
be O +
reduced O +
non O -
- O -
enzymatically O +
by O +
NADH O -
, O +
and O +
the O +
redox O +
cycle O +
reaction O +
resulted O +
in O +
oxidative O +
DNA O +
damage O +
due O +
to O +
the O +
copper O -
- O -
oxygen O +
complex O -
, O +
derived O +
from O +
the O +
reaction O +
of O +
Cu O -
( O -
I O -
) O +
with O +
H2O2 O -
. O +

1 O -
. O +

The O +
urinary O +
metabolic O +
fate O +
of O +
4-fluoroaniline O +
( O -
4-FA O -
) O +
and O +
1- O -
[ O -
13C O -
] O -
-4-fluoroacetanilide O +
( O -
4-FAA O -
) O +
has O +
been O +
studied O +
using O +
NMR O -
- O -
based O +
methods O +
after O +
50 O +
and O +
100 O +
mg O +
kg O -
( O -
-1 O -
) O +
i.p O -
. O +

doses O +
respectively O +
to O +
the O +
male O +
Sprague O -
- O -
Dawley O +
rat O -
. O +

2 O -
. O +
4-FA O +
was O +
both O +
ortho- O +
and O +
para O -
- O -
hydroxylated O -
. O +

The O +
major O +
metabolite O +
produced O +
by O +
ortho O -
- O -
hydroxylation O +
was O +
2-amino-5-fluorophenylsulphate O +
accounting O +
for O +
approximately O +
30 O -
% O +
of O +
the O +
dose O -
. O +

Of O +
the O +
dose O -
, O +
approximately O +
10 O -
% O +
was O +
excreted O +
via O +
para O -
- O -
hydroxylation O +
and O +
the O +
resulting O +
defluorinated O +
metabolites O +
were O +
N O -
- O -
acetylated O +
and O +
excreted O +
as O +
sulphate O +
( O -
major O -
) O -
, O +
glucuronide O +
( O -
minor O -
) O +
and O +
N O -
- O -
acetyl O -
- O -
cysteinyl O +
( O -
minor O -
) O +
conjugates O +
of O +
4-acetamidophenol O +
( O -
paracetamol O -
) O -
. O +

3 O -
. O +

The O +
major O +
route O +
of O +
metabolism O +
of O +
1- O -
[ O -
13C O -
] O -
-4-FAA O +
was O +
N O -
- O -
deacetylation O +
and O +
the O +
metabolites O +
excreted O +
in O +
the O +
urine O +
were O +
qualitatively O +
identical O +
to O +
4-FA O -
. O +

The O +
paracetamol O +
metabolites O +
produced O +
via O +
para O -
- O -
hydroxylation O +
were O +
also O +
a O +
product O +
of O +
N O -
- O -
deacetylation O +
and O +
reacetylation O -
, O +
as O +
the O +
[ O -
13C O -
] O -
-label O +
was O +
not O +
retained O -
. O +

4 O -
. O +

These O +
studies O +
demonstrate O +
the O +
value O +
of O +
[ O -
13C O -
] O -
-labelling O +
in O +
understanding O +
the O +
contribution O +
of O +
N O -
- O -
acetylation O -
, O +
and O +
futile O +
deacetylation O -
- O -
reacetylation O +
reactions O -
, O +
in O +
aniline O +
metabolism O -
. O +

In O +
addition O -
, O +
this O +
work O +
sheds O +
new O +
light O +
on O +
the O +
metabolic O +
lability O +
of O +
certain O +
aromatic O +
fluorine O +
substituents O -
. O +

Masoprocol O +
( O -
nordihydroguaiaretic O +
acid O -
) O +
is O +
a O +
lipoxygenase B-Gene +
inhibitor O +
isolated O +
from O +
the O +
creosote O +
bush O +
and O +
used O +
by O +
native O +
healers O +
to O +
treat O +
type O +
2 O +
diabetes O -
. O +

It O +
has O +
been O +
recently O +
shown O +
to O +
decrease O +
serum O +
glucose O -
, O +
free O +
fatty O +
acid O +
( O -
FFA O -
) O -
, O +
and O +
triglyceride O +
( O -
TG O -
) O +
concentrations O +
in O +
rodent O +
models O +
of O +
type O +
2 O +
diabetes O -
. O +

The O +
current O +
study O +
was O +
initiated O +
to O +
quantify O +
the O +
effects O +
of O +
masoprocol O +
incubation O +
of O +
adipocytes O +
isolated O +
from O +
normal O +
rats O -
. O +

The O +
results O +
indicate O +
that O +
masoprocol O +
significantly O +
increased O +
glucose O +
uptake O +
by O +
adipocytes O +
in O +
both O +
the O +
absence O +
and O +
presence O +
of O +
insulin B-Gene -
. O +

In O +
addition O -
, O +
the O +
maximal O +
rate O +
of O +
insulin B-Gene -
- O -
stimulated O +
glucose O +
transport O +
was O +
increased O +
in O +
adipocytes O +
incubated O +
with O +
masoprocol O +
and O +
the O +
insulin B-Gene +
concentration O +
resulting O +
in O +
a O +
half O -
- O -
maximal O +
glucose O +
transport O +
rate O +
( O -
ED50 O -
) O +
decreased O -
. O +

Finally O -
, O +
isoproterenol O -
- O -
stimulated O +
increases O +
in O +
FFA O +
and O +
glycerol O +
release O +
were O +
significantly O +
decreased O +
in O +
the O +
presence O +
of O +
masoprocol O -
. O +

These O +
results O +
provide O +
an O +
explanation O +
at O +
the O +
cellular O +
level O +
for O +
the O +
observation O +
that O +
masoprocol O +
decreases O +
serum O +
glucose O -
, O +
insulin B-Gene -
, O +
and O +
FFA O +
concentrations O +
in O +
rodent O +
models O +
of O +
type O +
2 O +
diabetes O -
. O +

Free O +
d O +
-amino O +
acids O +
have O +
been O +
shown O +
to O +
be O +
present O +
in O +
a O +
large O +
variety O +
of O +
species O -
, O +
including O +
mammals O +
and O -
, O +
more O +
specifically O -
, O +
humans O +
[ O -
1,2 O -
] O +
. O +

In O +
particular O -
, O +
d O +
-aspartate O +
has O +
drawn O +
special O +
interest O +
since O +
( O -
a O -
) O +
its O +
levels O +
are O +
often O +
found O +
to O +
be O +
the O +
highest O +
amongst O +
d O +
-amino O +
acids O +
[ O -
3 O -
] O +
, O +
( O -
b O -
) O +
recent O +
reports O +
propose O +
some O +
yet O +
unknown O +
neuronal O +
and O +
neuroendocrine O +
roles O +
of O +
d O +
-aspartate O +
[ O -
4,5 O -
] O +
, O +
( O -
c O -
) O +
high O +
levels O +
of O +
d O +
-aspartate O +
in O +
the O +
brain O +
and O +
other O +
tissues O +
of O +
mammals O +
were O +
discovered O +
by O +
several O +
authors O +
[ O -
6–8 O -
] O +
, O +
( O -
d O -
) O +
abnormal O +
levels O +
of O +
d O +
-aspartate O +
have O +
been O +
reported O +
in O +
relation O +
to O +
Alzheimer O -
, O +
senescence O +
and O +
renal O +
diseases O +
[ O -
9,10 O -
] O +
, O +
( O -
e O -
) O +
various O +
levels O +
of O +
d O +
-amino O +
acids O +
are O +
produced O +
during O +
food O +
processing O +
[ O -
11 O -
] O +
, O +
( O -
f O -
) O +
d O +
-aspartate O +
and O +
other O +
chemically O +
related O +
molecules O +
( O -
such O +
as O +
N O +
-methyl O -
- O -
d O +
-aspartate O -
) O +
are O +
widely O +
used O +
as O +
agonists O +
or O +
antagonists O +
of O +
neurochemical O +
transmitters O +
both O +
in O +
in O +
vivo O +
and O +
in O +
vitro O +
studies O +
and O +
( O -
h O -
) O +
some O +
of O +
them O +
might O +
play O +
such O +
a O +
role O +
also O +
in O +
vivo O +
[ O -
4,12,13 O -
] O +
. O +

Despite O +
the O +
growing O +
interest O +
in O +
the O +
biological O +
functions O +
of O +
d O +
-aspartate O -
, O +
little O +
is O +
known O +
about O +
its O +
origin O +
and O +
metabolism O +
in O +
mammals O -
. O +

In O +
this O +
regard O -
, O +
a O +
flavoprotein B-Gene +
with O +
d B-Gene +
-aspartate I-Gene +
oxidase I-Gene +
activity O +
has O +
been O +
purified O -
, O +
characterized O +
and O +
cloned O +
from O +
beef O +
kidney O +
cortex O +
[ O -
14–17 O -
] O +
and O -
, O +
more O +
recently O -
, O +
from O +
human O +
brain O +
[ O -
18 O -
] O +
. O +

The O +
enzyme B-Gene +
from O +
beef O +
kidney O +
cortex O +
( O -
bDASPO B-Gene -
) O +
has O +
been O +
thoroughly O +
investigated O +
as O +
far O +
as O +
primary O +
structure O -
, O +
kinetic O +
mechanism O -
, O +
FAD O +
binding O +
and O +
spectroscopic O +
properties O +
of O +
the O +
free O +
and O +
ligand O -
- O -
bound O +
enzyme B-Gene +
are O +
concerned O +
[ O -
14–16 O -
] O +
. O +

It O +
is O +
a O +
monomer O +
with O +
a O +
molecular O +
weight O +
of O +
37 O +
659 O +
( O -
apo B-Gene -
- I-Gene -
protein I-Gene -
) O +
containing O +
one O +
molecule O +
of O +
flavin O -
. O +

It O +
is O +
isolated O +
as O +
a O +
mixture O +
of O +
an O +
active O +
form O +
containing O +
FAD O +
( O -
FAD B-Gene -
- I-Gene -
bDASPO I-Gene -
) O +
and O +
an O +
inactive O +
form O +
( O -
9–20 O -
% O +
depending O +
on O +
the O +
purification O -
) O +
containing O +
6-OH O -
- O -
FAD O +
( O -
6-OH B-Gene -
- I-Gene -
FAD I-Gene -
- I-Gene -
bDASPO I-Gene -
) O -
. O +

The O +
enzyme B-Gene +
catalyzes O +
the O +
oxidative O +
deamination O +
of O +
dicarboxylic O +
d O +
-amino O +
acids O +
by O +
O2 O +
with O +
the O +
production O +
of O +
H2 O +
O2 O +
, O +
NH3 O +
and O +
the O +
corresponding O +
α O -
- O -
keto O +
acids O -
. O +

The O +
relatively O +
low O +
abundance O +
of O +
the O +
enzyme B-Gene -
, O +
and O +
the O +
consequently O +
long O +
purification O +
procedure O -
, O +
hampered O +
so O +
far O +
the O +
use O +
of O +
this O +
protein B-Gene +
as O +
a O +
tool O +
to O +
study O +
the O +
presence O +
and O +
biological O +
significance O +
of O +
dicarboxylic O +
d O +
-amino O +
acids O +
in O +
organisms O -
. O +

In O +
order O +
to O +
overcome O +
this O +
problem O -
, O +
a O +
procedure O +
to O +
overexpress O +
recombinant B-Gene +
d I-Gene +
-aspartate I-Gene +
oxidase I-Gene +
( O -
rDASPO B-Gene -
) O +
in O +
Escherichia O +
coli O +
has O +
been O +
set O +
up O +
[ O -
17 O -
] O +
. O +

Starting O +
from O +
the O +
latter O +
study O -
, O +
the O +
present O +
paper O +
reports O +
overexpression O +
and O +
purification O +
protocols O +
leading O +
to O +
large O +
amounts O +
of O +
homogeneous O +
and O +
catalytically O +
active O +
rDASPO B-Gene -
. O +

The O +
biochemical O +
characterization O +
of O +
the O +
recombinant B-Gene +
enzyme I-Gene +
shows O +
that O +
rDASPO B-Gene +
possesses O +
the O +
same O +
catalytic O +
properties O +
of O +
bDASPO B-Gene +
and O -
, O +
therefore O -
, O +
can O +
be O +
used O +
to O +
extend O +
the O +
study O +
of O +
the O +
properties O +
of O +
DASPO B-Gene -
. O +

In O +
particular O -
, O +
in O +
this O +
paper O +
we O +
focused O +
our O +
attention O +
on O +
the O +
determination O +
of O +
the O +
redox O +
potential O +
of O +
DASPO B-Gene +
and O +
to O +
possible O +
interactions O +
between O +
the O +
enzyme O +
and O +
a O +
variety O +
of O +
molecules O +
used O +
as O +
agonists O +
or O +
antagonists O +
of O +
neurotransmitters O +
[ O -
12 O -
] O +
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Overexpression O +
and O +
purification O +
of O +
rDASPO B-Gene +
E. O +
coli O +
GI724 O +
cells O -
, O +
carrying O +
the O +
cI O +
repressor O +
gene O +
engineered O +
into O +
bacterial O +
chromosome O +
under O +
the O +
control O +
of O +
the O +
Trp O +
promoter O -
, O +
were O +
freshly O +
transformed O +
with O +
the O +
recombinant O +
plasmid O +
pED O +
carrying O +
the O +
gene O +
for O +
bovine B-Gene +
kidney I-Gene +
d I-Gene +
-aspartate I-Gene +
oxidase I-Gene +
under O +
the O +
control O +
of O +
the O +
λ O +
PL O +
promoter O +
[ O -
17 O -
] O +
. O +

200 O +
ml O +
RM O +
medium O +
( O -
6 O +
g O +
Na2 O +
HPO4 O +
, O +
3 O +
g O +
KH2 O +
PO4 O +
, O +
0.5 O +
g O +
NaCl O -
, O +
1 O +
g O +
NH4 O +
Cl O -
, O +
95.21 O +
mg O +
MgCl2 O +
, O +
20 O +
g O +
casamino O +
acids O -
, O +
10 O +
ml O +
glycerol O +
in O +
1 O +
l O -
) O +
containing O +
100 O +
μg O +
ampicillin O +
ml−1 O +
were O +
inoculated O +
with O +
20 O +
ml O +
overnight O +
precultures O +
of O +
GI724 O +
( O -
pED O -
) O +
and O +
the O +
cells O +
grown O +
at O +
30 O -
° O -
C O +
up O +
to O +
A O +
550 O +
0.5 O -
. O +

The O +
material O +
was O +
used O +
to O +
inoculate O +
6 O +
l O +
of O +
induction O +
medium O +
( O -
6 O +
g O +
Na2 O +
HPO4 O +
, O +
3 O +
g O +
KH2 O +
PO4 O +
, O +
0.5 O +
g O +
NaCl O -
, O +
1 O +
g O +
NH4 O +
Cl O -
, O +
95.21 O +
mg O +
MgCl2 O +
, O +
2 O +
g O +
casamino O +
acids O -
, O +
5 O +
g O +
glucose O +
for O +
1 O +
l O -
) O +
containing O +
100 O +
μg O +
ampicillin O +
ml−1 O +
in O +
a O +
fermenter O +
( O -
BioIndustrie O +
Mantovane O -
, O +
Italy O -
) O +
and O +
the O +
cells O +
grown O +
at O +
30 O -
° O -
C O +
until O +
A O +
550 O +
reached O +
0.5 O -
. O +

Expression O +
was O +
induced O +
by O +
adding O +
tryptophan O +
to O +
a O +
final O +
concentration O +
of O +
100 O +
μg O +
ml−1 O +
and O +
raising O +
the O +
temperature O +
to O +
37 O -
° O -
C O -
. O +

The O +
cells O +
were O +
harvested O +
after O +
16 O +
h O -
, O +
centrifuged O +
at O +
14 O +
000 O -
× O -
g O +
for O +
25 O +
min O -
, O +
resuspended O +
in O +
cold O +
0.9 O -
% O +
NaCl O -
, O +
centrifuged O +
at O +
27 O +
000 O -
× O -
g O +
and O +
the O +
pellet O +
stored O +
at O +
−80 O -
° O -
C O -
. O +

All O +
purification O +
steps O +
were O +
performed O +
at O +
4 O -
° O -
C O +
and O +
all O +
buffers O +
contained O +
0.3 O +
mM O +
EDTA O +
and O +
5 O +
mM O +
sodium O +
potassium O +
tartrate O -
, O +
unless O +
otherwise O +
indicated O -
. O +

Cells O +
were O +
resuspended O +
in O +
2 O +
vols O -
. O +

of O +
50 O +
mM O +
NaPi O -
, O +
pH O +
8.0 O -
, O +
1 O +
mM O +
phenylmethylsulfonyl O +
fluoride O -
, O +
20 O +
μM O +
FAD O -
, O +
sonicated O +
and O +
centrifuged O +
at O +
27 O +
000 O -
× O -
g O +
for O +
30 O +
min O -
. O +

Protamine O +
sulfate O +
was O +
slowly O +
added O +
to O +
a O +
final O +
concentration O +
of O +
0.2 O -
% O +
at O +
0 O -
° O -
C O -
, O +
the O +
material O +
was O +
left O +
at O +
the O +
same O +
temperature O +
for O +
an O +
additional O +
15 O +
min O +
and O +
then O +
centrifuged O +
at O +
27 O +
000 O -
× O -
g O +
for O +
1 O +
h. O +
The O +
supernatant O +
was O +
adjusted O +
to O +
0 O -
. O +
15 O +
M O +
NaPi O -
, O +
pH O +
6.75 O +
and O +
loaded O +
on O +
a O +
Phenyl O -
- O -
Sepharose O +
CL-4B O +
column O +
( O -
13 O -
× O -
2.6 O +
cm O -
) O +
equilibrated O +
in O +
the O +
same O +
buffer O -
. O +

The O +
column O +
was O +
washed O +
with O +
2 O +
vols O -
. O +

of O +
starting O +
buffer O +
and O +
the O +
enzyme O +
eluted O +
with O +
10 O +
mM O +
NaPi O -
, O +
pH O +
8.0 O -
. O +

The O +
active O +
fractions O +
( O -
total O +
volume O +
about O +
2.5 O +
l O -
) O +
were O +
brought O +
to O +
20 O +
μM O +
FAD O -
, O +
50 O +
mM O +
MES O +
pH O +
5.5 O +
using O +
a O +
concentrated O +
solution O +
of O +
this O +
buffer O -
, O +
divided O +
in O +
300 O +
ml O +
aliquots O +
and O +
directly O +
loaded O +
on O +
a O +
S15 O +
strong O +
cationic O +
exchanger O +
membrane O +
adsorber O +
( O -
Sartorius O +
AG O -
, O +
Germany O -
) O +
equilibrated O +
in O +
50 O +
mM O +
MES O -
, O +
pH O +
5.5 O -
. O +

The O +
membrane O +
was O +
washed O +
with O +
10 O +
ml O +
of O +
the O +
starting O +
buffer O +
and O +
eluted O +
with O +
the O +
same O +
buffer O +
containing O +
1 O +
M O +
NaCl O +
in O +
2 O +
ml O +
fractions O -
. O +

The O +
active O +
fractions O +
were O +
pooled O +
and O +
equilibrated O +
in O +
50 O +
mM O +
HEPES O -
, O +
pH O +
8.0 O -
, O +
5 O +
mM O +
sodium O +
potassium O +
tartrate O -
, O +
0.3 O +
mM O +
EDTA O -
, O +
20 O +
μM O +
FAD O +
using O +
an O +
Amicon O -
- O -
PM O +
10 O +
membrane O -
. O +

The O +
pure O +
enzyme B-Gene +
was O +
stored O +
under O +
these O +
conditions O +
at O +
−80 O -
° O -
C O -
. O +

If O +
necessary O -
, O +
excess O +
FAD O +
and O +
tartrate O +
were O +
removed O +
prior O +
to O +
experiments O +
by O +
gel O +
filtration O +
on O +
a O +
PD-10 O +
column O +
( O -
Pharmacia O -
) O +
equilibrated O +
either O +
in O +
50 O +
mM O +
HEPES O -
, O +
pH O +
8.0 O +
or O +
in O +
0.1 O +
M O +
KPi O -
, O +
pH O +
7.0 O -
. O +

In O +
conclusion O -
, O +
the O +
recombinant B-Gene +
protein I-Gene +
was O +
purified O +
following O +
a O +
new O +
procedure O +
greatly O +
simplified O +
as O +
compared O +
to O +
the O +
one O +
used O +
for O +
the O +
enzyme B-Gene +
from O +
beef O +
kidney O +
cortex O +
[ O -
14 O -
] O +
, O +
omitting O +
the O +
heat O -
, O +
gel O +
filtration O +
and O +
Mono O +
Q O +
ion O -
- O -
exchange O +
steps O +
and O +
performing O +
the O +
final O +
ion O -
- O -
exchange O +
step O +
on O +
a O +
S15 O +
strong O +
cationic O +
exchanger O +
membrane O +
adsorber O +
instead O +
of O +
the O +
original O +
Mono O +
S O +
column O -
. O +

The O +
latter O +
modification O +
has O +
the O +
main O +
advantages O +
of O +
avoiding O +
time O +
consuming O +
concentration O +
and O +
equilibration O +
steps O +
and O +
exposure O +
of O +
the O +
enzyme O +
to O +
room O +
temperature O +
during O +
FPLC O +
chromatography O -
. O +

2.2 O +
Activity O +
assay O +
The O +
oxidase O +
activity O +
was O +
determined O +
by O +
the O +
spectrophotometric O +
method O +
set O +
up O +
in O +
[ O -
14 O -
] O +
which O +
couples O +
the O +
production O +
of O +
hydrogen O +
peroxide O +
in O +
the O +
DASPO B-Gene -
- O -
catalyzed O +
reaction O +
with O +
the O +
oxidation O +
of O +
o O +
-dianisidine O +
by O +
horseradish B-Gene +
peroxidase I-Gene +
( O -
ϵ436 O +
= O -
11 O +
610 O +
M−1 O +
cm−1 O +
) O -
. O +

The O +
reaction O +
mixture O +
contained O +
90 O +
μg O +
o O +
-dianisidine-2 O +
HCl O -
, O +
20 O +
nmol O +
FAD O -
, O +
64 O +
μg O +
horseradish B-Gene +
peroxidase I-Gene +
and O +
variable O +
amounts O +
of O +
substrate O +
( O -
routinely O +
10 O +
mM O +
d O +
-aspartate O -
) O +
in O +
1 O +
ml O +
of O +
50 O +
mM O +
KPi O -
, O +
pH O +
7.4 O -
, O +
at O +
25 O -
° O -
C O -
. O +

The O +
reaction O +
was O +
started O +
by O +
addition O +
of O +
variable O +
amounts O +
of O +
rDASPO B-Gene +
( O -
20 O +
ng–4 O +
μg O -
) O +
depending O +
on O +
the O +
substrate O +
tested O -
. O +

1 O +
U O +
of O +
enzyme B-Gene +
is O +
defined O +
as O +
the O +
amount O +
which O +
oxidizes O +
1 O +
μmol O +
substrate O +
min−1 O +
. O +

When O +
a O +
compound O +
was O +
not O +
used O +
as O +
substrate O +
by O +
rDASPO B-Gene +
it O +
was O +
tested O +
as O +
an O +
inhibitor O +
by O +
determining O +
its O +
effect O +
on O +
the O +
rate O +
of O +
oxidation O +
of O +
d O +
-aspartate O +
( O -
using O +
10 O +
mM O +
of O +
both O +
substrate O +
and O +
inhibitor O -
) O -
. O +

2.3 O +
Protein B-Gene +
content O +
Protein B-Gene +
content O +
during O +
the O +
purification O +
steps O +
was O +
estimated O +
using O +
an O +
extinction O +
coefficient O +
of O +
1 O +
for O +
a O +
1 O +
mg O +
ml O +
−1 O +
protein B-Gene +
solution O -
. O +

The O +
purified O +
enzyme B-Gene +
was O +
quantitated O +
using O +
the O +
extinction O +
coefficients O +
previously O +
determined O +
for O +
the O +
various O +
enzyme B-Gene +
forms O -
: O +
ϵ454 O +
= O -
11 O +
810 O +
M−1 O +
cm−1 O +
for O +
holo B-Gene -
- I-Gene -
FAD I-Gene -
- I-Gene -
bDASPO I-Gene +
and O +
ϵ458 O +
= O -
12 O +
300 O +
M−1 O +
cm−1 O +
for O +
l B-Gene +
- I-Gene -
( I-Gene -
+ I-Gene -
) I-Gene -
-tartrate I-Gene -
- I-Gene -
bDASPO I-Gene +
complex O +
[ O -
14 O -
] O +
. O +

2.4 O +
Apo O -
- O -
enzyme O +
preparation O +
Apo O -
- O -
rDASPO O +
was O +
prepared O +
according O +
to O +
the O +
procedure O +
for O +
the O +
selective O +
removal O +
of O +
FAD O +
from O +
bDASPO O +
described O +
in O +
[ O -
14 O -
] O +
. O +

Briefly O -
, O +
2 O +
mg O +
holo B-Gene -
- I-Gene -
enzyme I-Gene +
were O +
dialyzed O +
at O +
4 O -
° O -
C O +
for O +
3 O +
days O +
against O +
500 O +
ml O +
of O +
0.1 O +
M O +
KPi O -
, O +
pH O +
7.0 O -
, O +
0.3 O +
mM O +
EDTA O +
containing O +
3 O +
M O +
KBr O +
and O +
0.5 O -
% O +
charcoal O -
, O +
followed O +
by O +
24 O +
h O +
dialysis O +
against O +
2 O +
l O +
of O +
the O +
same O +
buffer O +
without O +
KBr O +
and O +
charcoal O -
. O +

2.5 O +
Anaerobic O +
reduction O +
of O +
d B-Gene +
-aspartate I-Gene +
oxidase I-Gene +
Anaerobic O +
reduction O +
of O +
rDASPO B-Gene +
was O +
conducted O +
at O +
25 O -
° O -
C O +
in O +
0.1 O +
M O +
KPi O -
, O +
pH O +
7.0 O +
either O +
in O +
the O +
absence O +
or O +
presence O +
of O +
4 O +
mM O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O -
. O +

Anaerobiosis O +
was O +
achieved O +
by O +
alternate O +
evacuation O +
and O +
flushing O +
with O +
argon O +
freed O +
from O +
any O +
residual O +
oxygen O +
using O +
High O +
Capacity O +
Gas O +
Purifier O +
and O +
OMI O +
Indicating O +
Purifier O +
devices O +
( O -
Supelco O -
, O +
USA O -
) O -
. O +

Photoreduction O +
was O +
achieved O +
by O +
irradiating O +
the O +
protein B-Gene +
with O +
a O +
slide O +
projector O +
at O +
0 O -
° O -
C O +
in O +
the O +
presence O +
of O +
10 O +
mM O +
EDTA O -
, O +
0.5 O +
μM O +
5-deazaflavin-3-sulfonate O +
as O +
catalyst O +
and O +
5 O +
μM O +
benzylviologen O +
[ O -
19 O -
] O +
. O +

Following O +
each O +
irradiation O -
, O +
measurements O +
were O +
started O +
when O +
spectral O +
changes O +
in O +
the O +
dark O +
were O +
complete O +
( O -
5–15 O +
min O +
at O +
25 O -
° O -
C O -
) O -
. O +

Alternatively O -
, O +
rDASPO B-Gene +
was O +
reduced O +
by O +
mixing O +
the O +
enzyme B-Gene +
( O -
2 O +
ml O -
) O +
in O +
the O +
main O +
compartment O +
of O +
an O +
anaerobic O +
cuvette O +
with O +
10 O +
mU O +
of O +
xanthine B-Gene +
oxidase I-Gene +
[ O -
20 O -
] O +
. O +

After O +
anaerobiosis O -
, O +
xanthine O +
and O +
benzylviologen O +
were O +
added O +
from O +
a O +
side O +
arm O +
to O +
a O +
final O +
concentration O +
of O +
250 O +
μM O +
and O +
5 O +
μM O -
, O +
respectively O -
, O +
to O +
start O +
the O +
reaction O -
. O +

The O +
concentrations O +
of O +
oxidized O -
, O +
semiquinone O +
and O +
reduced O +
enzyme B-Gene +
at O +
each O +
point O +
of O +
the O +
reduction O +
were O +
calculated O +
from O +
the O +
total O +
enzyme B-Gene +
present O +
and O +
from O +
the O +
absorbance O +
at O +
suitable O +
wavelengths O +
( O -
454 O +
and O +
374 O +
nm O +
for O +
the O +
free O +
enzyme B-Gene +
and O +
458 O +
and O +
374 O +
nm O +
for O +
the O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O +
complex O -
) O +
using O +
the O +
following O +
equation: O -
( O -
1 O -
) O +
ΔA O -
( O -
ox O +
−x O -
) O -
= O -
[ O -
red O -
] O -
( O -
ϵox O +
−ϵred O +
) O -
+ O -
[ O -
sq O -
] O -
( O -
ϵox O +
−ϵsq O +
) O +
were O +
ΔA O +
( O -
ox−x O +
) O +
is O +
the O +
decrease O +
in O +
absorbance O +
in O +
comparison O +
to O +
the O +
spectrum O +
of O +
the O +
oxidized O +
enzyme B-Gene -
, O +
ϵox O +
, O +
ϵsq O +
and O +
ϵred O +
are O +
the O +
extinction O +
coefficients O +
for O +
oxidized O -
, O +
semiquinone O +
and O +
reduced O +
form O +
of O +
the O +
enzyme O +
and O +
[ O -
red O -
] O +
and O +
[ O -
sq O -
] O +
are O +
the O +
molar O +
concentrations O +
of O +
reduced O +
and O +
semiquinone B-Gene +
rDASPO I-Gene -
, O +
respectively O -
. O +

In O +
order O +
to O +
determine O +
the O +
amount O +
of O +
semiquinone O +
thermodynamically O +
stabilized O -
, O +
7.7 O +
μM O +
rDASPO B-Gene +
in O +
0.1 O +
M O +
KPi O -
, O +
pH O +
7.0 O -
, O +
0.5 O +
μM O +
5-deazaflavin-3-sulfonate O -
, O +
10 O +
mM O +
EDTA O +
and O +
5 O +
μM O +
benzylviologen O +
was O +
completely O +
photoreduced O +
anaerobically O +
as O +
described O +
above O +
and O +
mixed O +
with O +
an O +
equimolar O +
amount O +
of O +
concentrated O +
oxidized B-Gene +
enzyme I-Gene +
previously O +
stored O +
in O +
the O +
side O +
arm O +
of O +
the O +
cell O -
. O +

The O +
reaction O +
was O +
followed O +
at O +
25 O -
° O -
C O +
in O +
the O +
dark O +
until O +
no O +
further O +
absorbance O +
changes O +
could O +
be O +
detected O +
( O -
24 O +
h O -
) O +
and O +
the O +
amount O +
of O +
oxidized B-Gene -
, O +
semiquinone B-Gene +
and O +
reduced B-Gene +
enzyme I-Gene +
at O +
equilibrium O +
was O +
calculated O +
as O +
described O +
above O -
. O +

2.6 O +
Determination O +
of O +
redox O +
potentials O +
The O +
redox O +
potential O +
of O +
rDASPO B-Gene +
was O +
determined O +
by O +
a O +
spectrophotometric O +
method O +
employing O +
a O +
reducing O +
system O +
of O +
xanthine O -
, O +
xanthine B-Gene +
oxidase I-Gene +
and O +
a O +
suitable O +
mediator O +
such O +
as O +
benzylviologen O +
[ O -
20 O -
] O +
. O +

Data O +
were O +
plotted O +
according O +
to O +
[ O -
21 O -
] O +
. O +

The O +
amount O +
of O +
oxidized O +
and O +
reduced O +
indicator O +
dye O +
and O +
enzyme B-Gene +
was O +
calculated O +
from O +
the O +
experimentally O +
determined O +
extinction O +
coefficients O +
and O +
isosbestic O +
points O +
at O +
the O +
following O +
wavelengths O -
, O +
depending O +
on O +
the O +
experiment O -
: O +
( O -
a O -
) O +
ITS O +
( O -
600 O +
nm O -
) O -
+rDASPO B-Gene +
( O -
486 O +
nm O -
, O +
isosbestic O +
for O +
ITS O -
) O -
; O +
( O -
b O -
) O +
IDS O +
( O -
610 O +
nm O -
) O -
+rDASPO B-Gene +
( O -
374 O +
and O +
458 O +
nm O -
, O +
the O +
latter O +
being O +
an O +
isosbestic O +
for O +
IDS O -
) O -
; O +
( O -
c O -
) O +
IDS O +
( O -
610 O +
nm O -
) O -
+l O +
- B-Gene -
( I-Gene -
+ I-Gene -
) I-Gene -
-tartrate I-Gene -
- O -
rDASPO B-Gene +
( O -
458 O +
nm O -
) O -
; O +
( O -
d O -
) O +
HNQ O +
( O -
458 O +
nm O -
) O -
+l O +
- O -
( O -
+ O -
) O -
-tartrate O -
- O -
rDASPO B-Gene +
( O -
364 O +
nm O -
) O -
. O +

2.7 O +
Miscellaneous O +
methods O +
Absorption O +
spectra O +
were O +
measured O +
with O +
a O +
Hewlett O +
Packard O +
HP8452 O +
diode O -
- O -
array O +
spectrophotometer O -
. O +

Fluorescence O +
spectra O +
were O +
recorded O +
on O +
a O +
Jasco O +
( O -
Japan O +
Spectroscopy O -
, O +
Japan O -
) O +
FP O +
750 O +
spectrofluorimeter O -
. O +

SDS O -
- O -
PAGE O +
was O +
performed O +
according O +
to O +
[ O -
22 O -
] O +
. O +

N O -
- O -
Terminal O +
amino O +
acid O +
sequence O +
was O +
determined O +
using O +
an O +
Applied O +
BioSystems O +
( O -
Foster O +
City O -
, O +
USA O -
) O +
model O +
477 O -
/ O -
A O +
automatic O +
protein O +
sequencer O -
. O +

Commercial O +
FAD O +
was O +
purified O +
by O +
HPLC O +
as O +
reported O +
in O +
[ O -
14 O -
] O +
. O +

2.8 O +
Materials O +
Xanthine B-Gene +
oxidase I-Gene +
was O +
purchased O +
from O +
Sigma O -
. O +

bDASPO B-Gene +
was O +
purified O +
from O +
beef O +
kidney O +
cortex O +
as O +
described O +
in O +
[ O -
14 O -
] O +
. O +

5-Deazaflavin-3-sulfonate O +
was O +
a O +
generous O +
gift O +
of O +
V. O +
Massey O +
( O -
University O +
of O +
Michigan O -
, O +
Ann O +
Arbor O -
, O +
MI O -
, O +
USA O -
) O -
. O +

All O +
the O +
other O +
chemicals O +
were O +
of O +
the O +
highest O +
purity O +
commercially O +
available O -
. O +

3 O +
Results O +
3.1 O +
Comparison O +
between O +
the O +
properties O +
of O +
rDASPO B-Gene +
and O +
bDASPO B-Gene +
Table O +
1 O +
summarizes O +
the O +
purification O +
protocol O +
of O +
rDASPO B-Gene +
starting O +
from O +
38 O +
g O +
of O +
wet O +
E. O +
coli O +
paste O -
. O +

Since O +
rDASPO B-Gene +
is O +
homogeneous O +
as O +
far O +
as O +
the O +
coenzyme O +
content O +
is O +
concerned O +
( O -
FAD O -
, O +
see O +
below O -
) O -
, O +
while O +
bDASPO B-Gene +
is O +
purified O +
as O +
a O +
mixture O +
of O +
an O +
active O +
FAD O -
- O -
containing O +
and O +
an O +
inactive O +
6-OH O -
- O -
FAD O -
- O -
containing O +
form O -
, O +
the O +
specific O +
activity O +
of O +
rDASPO B-Gene +
( O -
29.1 O +
U O +
mg−1 O +
) O +
is O +
slightly O +
higher O +
than O +
that O +
of O +
bDASPO B-Gene +
( O -
25.3 O +
U O +
mg−1 O +
[ O -
14 O -
] O +
) O -
. O +

As O +
shown O +
in O +
Fig. O +
1 O +
, O +
the O +
molecular O +
mass O +
of O +
rDASPO B-Gene +
is O +
38 O +
kDa O -
, O +
in O +
agreement O +
with O +
that O +
of O +
bDASPO B-Gene -
. O +

The O +
amino O +
acid O +
sequence O +
of O +
the O +
20 O +
N O -
- O -
terminal O +
residues O +
of O +
purified O +
rDASPO B-Gene +
is O +
identical O +
to O +
the O +
one O +
expected O +
from O +
the O +
sequence O +
of O +
bDASPO B-Gene -
. O +

It O +
should O +
be O +
pointed O +
out O +
that O +
the O +
N O -
- O -
terminal O +
Met O +
residue O +
in O +
rDASPO B-Gene +
is O +
free O +
and O +
not O +
blocked O +
as O +
it O +
is O +
in O +
bDASPO B-Gene +
[ O -
16 O -
] O +
. O +

The O +
visible O +
absorption O +
spectra O +
of O +
rDASPO B-Gene +
and O +
bDASPO B-Gene +
at O +
the O +
end O +
of O +
the O +
respective O +
purification O +
procedures O +
are O +
clearly O +
different O -
, O +
since O +
the O +
former O +
lacks O +
both O +
the O +
long O +
wavelength O +
absorption O +
( O -
centered O +
around O +
610 O +
nm O -
) O +
and O +
the O +
pronounced O +
shoulders O +
around O +
440 O -
, O +
360 O +
and O +
340 O +
nm O +
typically O +
observed O +
with O +
bDASPO B-Gene +
( O -
Fig. O +
2 O +
in O +
this O +
paper O +
and O +
Fig. O +
1 O +
of O +
[ O -
14 O -
] O +
) O -
. O +

As O +
reported O +
in O +
[ O -
14 O -
] O +
, O +
such O +
absorption O +
features O +
are O +
due O +
to O +
the O +
presence O +
of O +
variable O +
amounts O +
of O +
6-OH O -
- O -
FAD O +
in O +
bDASPO B-Gene -
. O +

In O +
accordance O -
, O +
the O +
visible O +
absorption O +
spectrum O +
of O +
rDASPO B-Gene +
resembles O +
that O +
of O +
apo B-Gene -
- I-Gene -
bDASPO I-Gene +
reconstituted O +
with O +
FAD O +
( O -
see O +
Fig. O +
6 O +
of O +
[ O -
14 O -
] O +
) O -
, O +
although O +
the O +
latter O +
showed O +
higher O +
absorbance O +
below O +
400 O +
nm O -
, O +
probably O +
a O +
consequence O +
of O +
the O +
harsh O +
conditions O +
used O +
to O +
obtain O +
the O +
complete O +
apo O -
- O -
protein O +
[ O -
14 O -
] O +
. O +

In O +
order O +
to O +
confirm O +
the O +
absence O +
of O +
6-OH O -
- O -
FAD O +
from O +
preparations O +
of O +
rDASPO B-Gene -
, O +
the O +
coenzyme O +
was O +
removed O +
under O +
conditions O +
which O +
allowed O +
the O +
selective O +
removal O +
of O +
FAD O +
( O -
but O +
not O +
of O +
6-OH O -
- O -
FAD O -
) O +
from O +
bDASPO B-Gene +
[ O -
14 O -
] O +
. O +

As O +
expected O -
, O +
no O +
visible O +
absorption O +
was O +
present O +
after O +
removal O +
of O +
FAD O +
( O -
not O +
shown O -
) O -
. O +

The O +
absence O +
of O +
the O +
6-OH O -
- O -
FAD O +
form O +
in O +
rDASPO B-Gene +
strengthens O +
the O +
hypothesis O +
that O +
such O +
a O +
form O +
has O +
no O +
biological O +
significance O +
and O +
is O +
an O +
artifact O +
of O +
the O +
long O +
lasting O +
purification O +
procedure O +
of O +
the O +
enzyme B-Gene +
from O +
the O +
natural O +
source O -
. O +

As O +
it O +
was O +
the O +
case O +
for O +
FAD B-Gene -
- I-Gene -
bDASPO I-Gene -
, O +
rDASPO B-Gene +
shows O +
flavin O +
fluorescence O -
. O +

Binding O +
of O +
apo B-Gene -
- I-Gene -
rDASPO I-Gene +
to O +
FAD O +
quenches O +
its O +
fluorescence O +
to O +
a O +
final O +
86 O -
% O +
intensity O -
, O +
a O +
value O +
only O +
slightly O +
higher O +
than O +
the O +
one O +
observed O +
for O +
FAD B-Gene -
- I-Gene -
bDASPO I-Gene +
( O -
70 O -
% O +
[ O -
14 O -
] O +
) O -
. O +

Titration O +
of O +
rDASPO B-Gene +
with O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O +
( O -
Fig. O +
2 O +
) O +
and O +
sulfite O +
[ O -
23 O -
] O +
( O -
data O +
not O +
shown O -
) O -
, O +
two O +
ligands O +
whose O +
complexes O +
with O +
FAD B-Gene -
- I-Gene -
bDASPO I-Gene +
have O +
been O +
thoroughly O +
characterized O -
, O +
further O +
confirmed O +
that O +
the O +
recombinant B-Gene +
protein I-Gene +
shares O +
the O +
same O +
properties O +
as O +
the O +
FAD O -
- O -
containing O +
form O +
of O +
the O +
enzyme B-Gene +
from O +
the O +
natural O +
source O -
. O +

In O +
fact O -
, O +
the O +
dissociation O +
constants O +
determined O +
for O +
the O +
complexes O +
between O +
rDASPO B-Gene +
and O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O +
or O +
sulfite O +
( O -
4.10 O -
× O -
10−5 O +
M O +
and O +
7.5 O -
× O -
10−6 O +
M O -
, O +
respectively O -
) O +
are O +
very O +
similar O +
to O +
those O +
determined O +
in O +
the O +
case O +
of O +
FAD B-Gene -
- I-Gene -
bDASPO I-Gene +
( O -
2.65 O -
× O -
10−5 O +
M O +
and O +
7.4 O -
× O -
10 O +
−6 O +
M O -
, O +
respectively O +
[ O -
14 O -
] O +
) O -
. O +

3.2 O +
Apo B-Gene -
- I-Gene -
protein I-Gene +
preparation O +
and O +
holo B-Gene -
- I-Gene -
enzyme I-Gene +
reconstitution O +
As O +
reported O +
above O -
, O +
the O +
mild O +
conditions O +
used O +
to O +
remove O +
FAD O +
from O +
rDASPO B-Gene +
produced O +
a O +
complete O +
apo B-Gene -
- I-Gene -
protein I-Gene +
with O +
no O +
residual O +
visible O +
absorption O +
and O +
activity O -
. O +

Reconstitution O +
of O +
holo B-Gene -
- I-Gene -
enzyme I-Gene +
by O +
addition O +
of O +
FAD O +
resulted O +
in O +
a O +
species O +
with O +
a O +
specific O +
activity O +
of O +
90 O -
% O +
as O +
compared O +
to O +
rDASPO B-Gene -
, O +
with O +
a O +
yield O +
of O +
53 O -
% O -
. O +

Such O +
a O +
value O +
is O +
significantly O +
higher O +
than O +
the O +
one O +
obtained O +
in O +
the O +
case O +
of O +
bDASPO B-Gene +
( O -
24 O -
% O -
) O -
, O +
due O +
to O +
the O +
harsher O +
conditions O +
necessary O +
to O +
remove O +
6-OH O -
- O -
FAD O +
from O +
bDASPO B-Gene +
[ O -
14 O -
] O +
. O +

3.3 O +
Redox O +
potential O +
of O +
rDASPO B-Gene +
In O +
order O +
to O +
determine O +
the O +
redox O +
potential O +
of O +
the O +
enzyme B-Gene +
by O +
the O +
spectrophotometric O +
method O +
described O +
by O +
Massey O +
[ O -
20 O -
] O +
it O +
was O +
first O +
necessary O +
to O +
determine O +
the O +
extinction O +
coefficients O +
of O +
the O +
oxidized B-Gene +
( O -
EFAD O -
) O -
, O +
one B-Gene -
- I-Gene -
electron I-Gene +
reduced I-Gene +
( O -
semiquinone O -
, O +
EFAD−⋅ O +
) O +
and O +
two B-Gene -
- I-Gene -
electron I-Gene +
reduced I-Gene +
rDASPO I-Gene +
( O -
EFADH− O +
) O +
both O +
free O +
and O +
in O +
complex O +
with O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O -
. O +

Fig. O +
3 O +
shows O +
the O +
reduction O +
of O +
free O +
rDASPO B-Gene +
using O +
the O +
xanthine O -
/ O -
xanthine B-Gene +
oxidase I-Gene +
reducing O +
system O -
. O +

Almost O +
quantitative O +
formation O +
of O +
red O +
anionic O +
semiquinone O +
( O -
91 O -
% O -
) O +
was O +
observed O +
in O +
the O +
first O +
part O +
of O +
the O +
experiment O -
, O +
followed O +
by O +
complete O +
reduction O +
of O +
the O +
enzyme B-Gene -
. O +

Extinction O +
coefficients O +
at O +
any O +
wavelength O +
could O +
be O +
obtained O +
for O +
the O +
oxidized O +
and O +
fully O +
reduced O +
form O +
from O +
the O +
initial O +
and O +
the O +
final O +
spectrum O -
, O +
respectively O -
, O +
and O +
for O +
the O +
semiquinone O +
by O +
means O +
of O +
plots O +
such O +
as O +
that O +
shown O +
in O +
the O +
inset O +
of O +
Fig. O +
3 O +
. O +

It O +
should O +
be O +
pointed O +
out O +
that O +
when O +
the O +
enzyme B-Gene +
was O +
photoreduced O -
, O +
under O +
the O +
same O +
experimental O +
conditions O -
, O +
a O +
much O +
lower O +
amount O +
of O +
semiquinone O +
was O +
detected O +
( O -
about O +
26 O -
% O +
at O +
maximum O +
formation O -
, O +
data O +
not O +
shown O -
) O -
. O +

The O +
significant O +
difference O +
in O +
the O +
percentage O +
of O +
semiquinone O +
observed O +
during O +
the O +
experiments O +
using O +
different O +
reduction O +
systems O +
suggests O +
that O +
the O +
stabilization O +
of O +
the O +
radical O +
was O +
at O +
least O +
in O +
part O +
kinetic O +
rather O +
than O +
thermodynamic O -
. O +

This O +
was O +
experimentally O +
proved O +
( O -
for O +
the O +
free O +
enzyme B-Gene -
) O +
by O +
mixing O +
equimolar O +
amounts O +
of O +
EFADH− O +
and O +
EFAD O +
in O +
the O +
presence O +
of O +
benzylviologen O +
as O +
mediator O +
and O +
allowing O +
the O +
system O +
to O +
reach O +
complete O +
equilibrium O -
; O +
32 O -
% O +
of O +
red O +
semiquinone O +
was O +
observed O +
after O +
24 O +
h. O +
This O +
value O +
corresponds O +
to O +
a O +
semiquinone O +
formation O +
constant O +
K O +
of O +
0.89 O -
, O +
where O +
[ O -
24,25 O -
] O +
( O -
2 O -
) O +
K= O -
{ O -
2 O -
[ O -
semiquinonemax O +
] O -
/ O -
( O -
1− O -
[ O -
semiquinonemax O +
] O -
) O +

} O -
2 O +
From O +
the O +
relation O +
[ O -
24 O -
] O +
( O -
3 O -
) O +
( O -
E2 O +
° O -
′−E1 O +
° O -
′ O -
) O -
=− O -
( O -
RT O -
/ O -
F O -
) O +
ln O +
K O +

it O +
can O +
be O +
predicted O +
that O +
for O +
the O +
free O +
enzyme B-Gene +
E O +
2 O +
° O -
′ O +
( O -
EFAD−⋅ O +
/EFADH− O +
) O +
is O +
3 O +
mV O +
more O +
positive O +
than O +
E O +
1 O +
° O -
′ O +
( O -
EFAD O -
/ O -
EFAD−⋅ O +
) O -
. O +

When O +
the O +
reduction O +
was O +
performed O +
in O +
the O +
presence O +
of O +
4 O +
mM O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O +
a O +
maximum O +
amount O +
of O +
83 O -
% O +
and O +
46 O -
% O +
was O +
observed O +
using O +
the O +
xanthine O -
/ O -
xanthine B-Gene +
oxidase I-Gene +
or O +
the O +
EDTA O -
/ O -
light O +
reduction O +
method O -
, O +
respectively O -
. O +

Again O -
, O +
extinction O +
coefficients O +
for O +
oxidized O -
, O +
one O -
- O -
electron O +
and O +
two O -
- O -
electron O +
reduced O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O -
- O -
rDASPO B-Gene +
were O +
calculated O +
from O +
the O +
experiment O +
using O +
xanthine O -
/ O -
xanthine B-Gene +
oxidase I-Gene +
( O -
data O +
not O +
shown O -
) O -
. O +

Table O +
2 O +
shows O +
the O +
experimentally O +
determined O +
redox O +
potential O +
of O +
rDASPO B-Gene +
and O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O -
- O -
rDASPO B-Gene +
complex O +
in O +
0.1 O +
M O +
KPi O -
, O +
pH O +
7.0 O -
, O +
25 O -
° O -
C O -
. O +

The O +
redox O +
potential O +
of O +
the O +
free O +
enzyme B-Gene +
was O +
determined O +
using O +
ITS O +
and O +
IDS O +
as O +
indicator O +
dyes O -
. O +

In O +
the O +
case O +
of O +
ITS O +
( O -
Fig. O +
4 O +
) O +
no O +
semiquinone O +
formation O +
was O +
detected O +
and O +
a O +
midpoint O +
potential O +
of O +
−97 O +
mV O +
( O -
slope=1.1 O -
) O +
was O +
calculated O +
from O +
the O +
Minnaert O +
plot O +
shown O +
in O +
inset O +
of O +
Fig. O +
4 O +
. O +

On O +
the O +
contrary O -
, O +
using O +
IDS O +
a O +
significant O +
amount O +
of O +
semiquinone O +
( O -
up O +
to O +
58 O -
% O -
) O +
was O +
detected O -
. O +

This O +
allowed O +
to O +
calculate O +
the O +
redox O +
potentials O +
for O +
each O +
electron O +
using O +
data O +
from O +
the O +
first O +
part O +
of O +
the O +
experiment O +
for O +
E O +
1 O +
° O -
′ O +
( O -
−96 O +
mV O -
, O +
slope=1.9 O -
) O +
and O +
from O +
the O +
second O +
part O +
of O +
the O +
reaction O +
for O +
E O +
2 O +
° O -
′ O +
( O -
−95 O +
mV O -
, O +
slope=2.0 O -
) O +
( O -
Fig. O +
5 O +
and O +
Table O +
2 O +
) O -
. O +

The O +
calculated O +
E O +
m O +
° O -
′ O +
( O -
−95.5 O +
mV O -
) O +
agrees O +
well O +
with O +
the O +
midpoint O +
potential O +
determined O +
with O +
ITS O -
, O +
as O +
does O +
the O +
difference O +
between O +
E O +
2 O +
° O -
′ O +
and O +
E O +
1 O +
° O -
′ O +
( O -
determined O +
+ O -
1 O +
mV O -
, O +
predicted O +
from O +
the O +
semiquinone O +
formation O +
constant O +
+ O -
3 O +
mV O -
) O -
. O +

From O +
the O +
shift O +
in O +
the O +
midpoint O +
potential O +
of O +
FAD O +
( O -
−207 O +
mV O -
, O +
Massey O -
) O +
upon O +
binding O +
to O +
rDASPO B-Gene +
( O -
−97 O +
mV O -
) O +
and O +
the O +
known O +
dissociation O +
constant O +
of O +
FAD O +
for O +
the O +
oxidized O +
protein B-Gene +
( O -
5 O -
× O -
10−8 O +
M O +
[ O -
14 O -
] O +
) O +
a O +
value O +
of O +
1.0 O -
× O -
10−11 O +
M O +
for O +
K O +
red O +
( O -
the O +
dissociation O +
constant O +
of O +
the O +
reduced O +
coenzyme O -
) O +
can O +
be O +
calculated O +
using O +
the O +
following O +
equation O +
[ O -
24 O -
] O +
: O -
( O -
4 O -
) O +
ΔE O -
° O -
′=RT O -
/ O -
nF O -
× O -
ln O +
( O -
Kox O +
/Kred O +
) O +
In O +
the O +
presence O +
of O +
4 O +
mM O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O -
, O +
a O +
concentration O +
100-fold O +
higher O +
than O +
the O +
dissociation O +
constant O +
of O +
the O +
ligand O +
for O +
the O +
oxidized O +
enzyme B-Gene -
, O +
a O +
midpoint O +
potential O +
of O +
−157 O +
( O -
slope=1.1 O -
) O +
and O +
−156 O +
mV O +
( O -
slope=1.1 O -
) O +
was O +
determined O +
for O +
the O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O -
- O -
rDASPO B-Gene +
complex O +
using O +
IDS O +
and O +
HNQ O +
( O -
Table O +
2 O +
and O +
Fig. O +
6 O +
) O +
as O +
indicator O +
dyes O -
, O +
respectively O -
. O +

No O +
detectable O +
formation O +
of O +
semiquinone O +
was O +
observed O -
. O +

Eq. O +
5 O +
[ O -
26 O -
] O +
allows O +
to O +
calculate O +
the O +
dissociation O +
constant O +
of O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O +
for O +
reduced B-Gene +
rDASPO I-Gene +
( O -
K O +
red O +
′=3.6 O -
× O -
10−2 O +
M O -
) O -
: O -
( O -
5 O -
) O +
ΔE O -
° O -
′=RT O -
/ O -
nF O -
× O -
ln O +
{ O -
( O -
1+ O -
[ O -
L O +
] O -
/Kred O +
′ O -
) O -
/ O -
( O -
1+ O -
[ O -
L O +
] O -
/Kox O +
′ O -
) O -
} O +
where O +
ΔE O +
° O -
′ O +
is O +
the O +
difference O +
between O +
the O +
redox O +
potential O +
in O +
the O +
presence O +
and O +
in O +
the O +
absence O +
of O +
the O +
ligand O -
, O +
K O +
red O +
′ O +
is O +
the O +
dissociation O +
constant O +
of O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O +
from O +
reduced B-Gene +
rDASPO I-Gene +
and O +
K O +
ox O +
′ O +
is O +
the O +
known O +
dissociation O +
constant O +
for O +
the O +
same O +
ligand O +
from O +
the O +
oxidized B-Gene +
enzyme I-Gene +
( O -
K O +
ox O +
′ O -
, O +
4.1 O -
× O -
10−5 O +
M O -
, O +
see O +
above O -
) O -
, O +
and O +
[ O -
L O -
] O +
the O +
concentration O +
of O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O +
used O -
. O +

It O +
can O +
be O +
concluded O +
that O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O +
binds O +
also O +
to O +
EFADH− O +
, O +
although O +
with O +
a O +
much O +
lower O +
affinity O +
as O +
compared O +
to O +
EFAD O -
. O +

This O +
result O +
confirms O +
those O +
obtained O +
for O +
another O +
ligand O +
( O -
oxaloacetate O -
) O +
and O +
for O +
the O +
substrate O +
( O -
d O +
-aspartate O -
) O -
, O +
based O +
on O +
kinetic O +
data O +
[ O -
15 O -
] O +
. O +

3.4 O +
Oxidase O +
activity O +
towards O +
neurotransmitter O +
agonists O +
DASPO B-Gene +
is O +
strictly O +
specific O +
for O +
d O +
-amino O +
acids O +
since O +
l O +
-amino O +
acids O +
do O +
not O +
act O +
as O +
substrates O +
or O +
inhibitors O -
. O +

However O -
, O +
it O +
is O +
not O +
strictly O +
specific O +
for O +
d O +
-aspartate O -
, O +
being O +
active O +
also O +
against O +
a O +
variety O +
of O +
other O +
d O +
-amino O +
acids O -
, O +
with O +
a O +
strong O +
preference O +
for O +
dicarboxylic O +
ones O +
[ O -
27,28 O -
] O +
. O +

The O +
availability O +
of O +
large O +
amounts O +
of O +
pure O +
active O +
enzyme B-Gene +
allows O +
to O +
extend O +
the O +
characterization O +
of O +
the O +
substrate O +
specificity O +
of O +
DASPO B-Gene +
to O +
a O +
series O +
of O +
other O +
d O +
-amino O +
acids O +
which O +
are O +
known O +
to O +
possess O +
pharmacological O +
activity O +
as O +
neurotransmitter O +
agonists O +
[ O -
12 O -
] O +
. O +

The O +
apparent O +
kinetic O +
parameters O +
have O +
been O +
obtained O +
under O +
conditions O +
in O +
which O +
DASPO B-Gene +
was O +
shown O +
to O +
follow O +
Michaelis O -
- O -
Menten O +
kinetics O +
with O +
d O +
-aspartate O +
( O -
from O +
2 O +
mM O +
to O +
30 O +
mM O +
[ O -
15 O -
] O +
) O -
. O +

Linear O +
double O +
reciprocal O +
plots O +
were O +
obtained O +
for O +
all O +
substrates O +
in O +
this O +
range O -
. O +

The O +
results O +
obtained O +
are O +
listed O +
in O +
Table O +
3 O +
. O +

It O +
should O +
be O +
pointed O +
out O +
that O +
many O +
of O +
the O +
compounds O +
listed O +
are O +
indeed O +
oxidized O +
at O +
a O +
significant O +
rate O +
by O +
DASPO B-Gene -
. O +

Analysis O +
of O +
the O +
data O +
of O +
Table O +
3 O +
suggests O +
that O +
the O +
compounds O +
can O +
be O +
divided O +
into O +
three O +
groups O -
: O +
the O +
first O +
comprises O +
those O +
which O +
do O +
not O +
seem O +
to O +
interact O +
with O +
DASPO B-Gene -
, O +
since O +
they O +
are O +
neither O +
substrates O +
nor O +
inhibitors O -
; O +
the O +
second O +
contains O +
d O +
-aspartate O +
and O +
N O +
-methyl O -
- O -
d O +
-aspartate O -
, O +
which O +
are O +
by O +
far O +
the O +
best O +
substrates O -
; O +
the O +
third O +
comprises O +
the O +
remaining O +
substrates O -
, O +
which O +
are O +
oxidized O +
at O +
similar O +
rates O +
( O -
apparent O +
turnover O +
number O +
ranging O +
between O +
0.22 O +
and O +
2.2 O +
s−1 O +
) O -
. O +

As O +
regards O +
the O +
latter O +
group O -
, O +
the O +
results O +
suggest O +
that O +
substitution O +
of O +
a O +
sulfonic O +
( O -
d O -
, O -
l O +
-cysteic O +
acid O -
) O +
or O +
phosphonic O +
( O -
d O -
, O -
l O +
-2-amino-3-phosphonopropanoic O +
acid O -
) O +
group O +
for O +
the O +
β O -
- O -
carboxylic O +
group O +
of O +
d O +
-aspartate O +
causes O +
a O +
dramatic O +
decrease O +
in O +
the O +
turnover O +
number O -
. O +

The O +
presence O +
of O +
a O +
second O +
acidic O +
group O -
, O +
however O -
, O +
is O +
not O +
an O +
absolute O +
requirement O -
, O +
since O +
d O +
-aspartate O -
- O -
β O -
- O -
hydroxamate O +
is O +
a O +
substrate O -
. O +

In O +
accordance O -
, O +
d O +
-proline O +
was O +
shown O +
to O +
be O +
a O +
substrate O +
for O +
bDASPO B-Gene +
( O -
apparent O +
turnover O +
number O +
0.4 O +
s−1 O +
, O +
K O +
m O +
9 O -
× O -
10−4 O +
M O +
[ O -
28 O -
] O +
) O +
and O +
d O +
-asparagine O +
and O +
d O +
-glutamine O +
for O +
DASPO B-Gene +
from O +
Octopus O +
but O +
not O +
for O +
bDASPO B-Gene +
[ O -
28 O -
] O +
. O +

An O +
increase O +
in O +
the O +
length O +
of O +
the O +
carbon O +
chain O +
also O +
causes O +
a O +
drop O +
in O +
the O +
oxidation O +
rate O -
, O +
as O +
observed O +
with O +
d O +
-glutamate O -
, O +
d O +
-homocysteic O +
acid O +
and O -
, O +
more O +
dramatically O -
, O +
with O +
d O -
, O -
l O +
-2-amino-4-phosphonobutanoic O +
acid O -
, O +
which O +
is O +
neither O +
a O +
substrate O +
nor O +
an O +
inhibitor O -
. O +

A O +
further O +
decrease O +
in O +
the O +
rate O +
of O +
oxidation O +
is O +
observed O +
with O +
the O +
C6-dicarboxylic O +
compound O +
d O +
-α O -
- O -
aminoadipic O +
acid O -
. O +

As O +
expected O +
from O +
previous O +
studies O +
on O +
a O +
related O +
compound O +
( O -
2,3-diaminosuccinic O +
acid O +
[ O -
29 O -
] O +
) O -
, O +
threo O +
-β O -
- O -
hydroxy O -
- O -
d O +
-aspartate O +
does O +
not O +
interact O +
with O +
DASPO B-Gene +
either O +
as O +
a O +
substrate O +
or O +
an O +
inhibitor O -
. O +

The O +
oxidative O +
activity O +
of O +
DASPO B-Gene +
towards O +
glycyl O -
- O -
d O +
-aspartate O +
is O +
of O +
particular O +
relevance O +
since O +
this O +
compound O +
has O +
been O +
proposed O +
to O +
be O +
involved O +
in O +
synaptic O +
transmission O +
in O +
prefrontal O +
cortex O +
in O +
vivo O +
[ O -
13 O -
] O +
. O +

4 O +
Discussion O +
4.1 O +
Purification O +
and O +
properties O +
of O +
rDASPO B-Gene +
This O +
paper O +
reports O +
overexpression O +
and O +
purification O +
conditions O +
leading O +
to O +
about O +
2 O +
mg O +
pure O +
rDASPO B-Gene +
each O +
g O +
of O +
wet O +
E. O +
coli O +
paste O -
. O +

rDASPO B-Gene +
has O +
been O +
shown O +
to O +
possess O +
the O +
same O +
general O +
biochemical O +
properties O +
of O +
bDASPO B-Gene -
, O +
except O +
that O +
the O +
former O +
contains O +
only O +
FAD O -
, O +
while O +
the O +
latter O +
is O +
a O +
mixture O +
of O +
two O +
forms O -
, O +
an O +
active O +
one O +
containing O +
FAD O +
and O +
an O +
inactive O +
one O +
containing O +
6-OH O -
- O -
FAD O +
( O -
9–20 O -
% O +
depending O +
on O +
the O +
preparation O -
) O +
[ O -
14 O -
] O +
. O +

For O +
such O +
reason O -
, O +
apart O +
from O +
the O +
amount O +
of O +
enzyme B-Gene +
obtained O +
and O +
the O +
ease O +
and O +
quickness O +
of O +
the O +
purification O +
protocol O -
, O +
the O +
procedure O +
reported O +
has O +
the O +
following O +
advantages O +
over O +
the O +
one O +
previously O +
used O +
to O +
obtain O +
bDASPO B-Gene +
from O +
the O +
natural O +
source O +
( O -
beef O +
kidney O +
cortex O -
) O -
: O +
rDASPO B-Gene +
possesses O +
a O +
specific O +
activity O +
higher O +
than O +
bDASPO B-Gene -
, O +
apo B-Gene -
- I-Gene -
protein I-Gene +
preparation O +
requires O +
milder O +
conditions O -
, O +
resulting O +
in O +
a O +
higher O +
yield O +
of O +
reconstitutable O +
holo B-Gene -
- I-Gene -
enzyme I-Gene -
, O +
and O +
spectroscopic O +
studies O +
are O +
facilitated O +
by O +
the O +
absence O +
of O +
a O +
second O +
compound O +
with O +
visible O +
absorption O +
properties O +
which O +
partially O +
overlap O +
those O +
of O +
FAD O -
. O +

The O +
latter O +
feature O +
has O +
been O +
used O +
to O +
determine O +
the O +
redox O +
potential O +
of O +
the O +
enzyme B-Gene +
by O +
the O +
spectrophotometric O +
method O +
set O +
up O +
by O +
Massey O +
[ O -
20 O -
] O +
. O +

4.2 O +
Redox O +
potentials O +
of O +
DASPO B-Gene +
The O +
midpoint O +
potential O +
of O +
DASPO B-Gene +
in O +
0.1 O +
M O +
KPi O -
, O +
pH O +
7.0 O -
, O +
25 O -
° O -
C O +
is O +
−97 O +
mV. O +
Thus O -
, O +
the O +
binding O +
to O +
the O +
apo B-Gene -
- I-Gene -
enzyme I-Gene +
increases O +
the O +
redox O +
potential O +
of O +
the O +
flavin O +
by O +
110 O +
mV O +
as O +
compared O +
to O +
free O +
FAD O -
, O +
a O +
shift O +
which O +
is O +
consistent O +
with O +
the O +
role O +
of O +
the O +
enzyme B-Gene +
as O +
a O +
dehydrogenase B-Gene -
/ O -
oxidase B-Gene -
. O +

Useful O +
comparisons O +
can O +
be O +
made O +
with O +
the O +
redox O +
properties O +
of O +
the O +
closely O +
related O +
well O +
known O +
enzyme B-Gene +
d B-Gene +
-amino I-Gene +
acid I-Gene +
oxidase I-Gene -
, O +
which O +
catalyzes O +
the O +
same O +
reaction O +
catalyzed O +
by O +
DASPO B-Gene +
but O +
with O +
different O +
substrate O +
specificity O -
, O +
being O +
active O +
only O +
towards O +
neutral O +
and O +
basic O +
d O +
-amino O +
acids O +
[ O -
30 O -
] O +
. O +

The O +
general O +
properties O +
of O +
the O +
two O +
enzymes B-Gene +
have O +
been O +
shown O +
to O +
be O +
similar O -
, O +
although O +
their O +
kinetic O +
mechanism O +
is O +
slightly O +
different O +
[ O -
15,30 O -
] O +
. O +

Van O +
den O +
Berghe O +
and O +
Stankovich O +
determined O +
E O +
1 O +
° O -
′ O +
of O +
–98 O +
mV O +
and O +
E O +
2 O +
° O -
′ O +
of O +
117 O +
mV O +
in O +
50 O +
mM O +
KPi O -
, O +
pH O +
7.0 O -
, O +
18 O -
° O -
C O +
for O +
d B-Gene +
-amino I-Gene +
acid I-Gene +
oxidase I-Gene +
[ O -
31 O -
] O +
. O +

Thus O -
, O +
the O +
calculated O +
midpoint O +
potential O +
and O +
the O +
amount O +
of O +
semiquinone O +
stabilized O +
( O -
–108 O +
mV O +
and O +
40 O -
% O -
, O +
respectively O -
) O +
are O +
only O +
slightly O +
different O +
from O +
the O +
ones O +
determined O +
for O +
DASPO B-Gene +
( O -
–97 O +
mV O +
and O +
32 O -
% O -
) O -
. O +

In O +
accordance O -
, O +
the O +
presence O +
of O +
a O +
specific O +
inhibitor O +
causes O +
similar O +
negative O +
shifts O +
in O +
the O +
redox O +
potential O +
of O +
the O +
two O +
enzymes B-Gene +
( O -
39 O +
mV O +
in O +
the O +
case O +
of O +
d B-Gene +
-amino I-Gene +
acid I-Gene +
oxidase I-Gene +
with O +
benzoate O -
, O +
58 O +
mV O +
for O +
DASPO B-Gene +
in O +
the O +
presence O +
of O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O -
) O -
. O +

In O +
conclusion O -
, O +
the O +
redox O +
properties O +
of O +
DASPO B-Gene +
conform O +
to O +
those O +
expected O +
for O +
a O +
typical O +
flavoprotein B-Gene +
oxidase I-Gene +
[ O -
32 O -
] O +
. O +

This O +
is O +
in O +
marked O +
contrast O +
with O +
what O +
has O +
been O +
observed O +
for O +
E. B-Gene +
coli I-Gene +
l I-Gene +
-aspartate I-Gene +
oxidase I-Gene -
, O +
a O +
flavoenzyme B-Gene +
which O +
catalyzes O +
the O +
oxidation O +
of O +
l O +
-aspartate O +
by O +
O2 O +
and O +
can O -
not O +
use O +
d O +
-aspartate O +
as O +
a O +
substrate O -
, O +
whose O +
redox O +
potential O +
( O -
–216 O +
mV O -
) O +
is O +
actually O +
lower O +
than O +
that O +
of O +
free O +
FAD O +
[ O -
33 O -
] O +
. O +

Thus O -
, O +
the O +
redox O +
potential O +
data O +
confirm O +
other O +
experimental O +
evidence O +
which O +
suggests O +
that O -
, O +
although O +
DASPO B-Gene +
and O +
l B-Gene +
-aspartate I-Gene +
oxidase I-Gene +
catalyze O +
the O +
same O +
reaction O +
but O +
with O +
different O +
enantio O -
- O -
specificity O -
, O +
their O +
properties O +
are O +
largely O +
different O +
[ O -
33–35 O -
] O +
. O +

This O +
fact O +
can O +
be O +
ascribed O +
both O +
to O +
the O +
need O +
to O +
assure O +
absolute O +
stereospecificity O +
and O +
to O +
respond O +
to O +
totally O +
different O +
metabolic O +
demands O +
and O +
controls O -
. O +

In O +
fact O -
, O +
the O +
biological O +
role O +
of O +
DASPO B-Gene +
is O +
likely O +
to O +
be O +
mainly O +
catabolic O +
[ O -
36 O -
] O +
, O +
while O +
that O +
of O +
l B-Gene +
-aspartate I-Gene +
oxidase I-Gene +
is O +
exclusively O +
anabolic O -
, O +
since O +
it O +
catalyzes O +
the O +
first O +
step O +
in O +
the O +
de O +
novo O +
biosynthesis O +
of O +
pyridinic O +
nucleotides O +
in O +
several O +
microorganisms O +
and O +
plants O +
[ O -
37 O -
] O +
. O +

4.3 O +
Substrate O +
specificity O +
of O +
DASPO B-Gene +
The O +
investigation O +
of O +
the O +
interaction O +
between O +
DASPO B-Gene +
and O +
dicarboxylic O +
compounds O +
which O +
are O +
known O +
to O +
possess O +
pharmacological O +
activities O +
as O +
agonists O -
/ O -
antagonists O +
for O +
excitatory B-Gene +
amino I-Gene +
acid I-Gene +
receptors I-Gene +
has O +
allowed O +
to O +
identify O +
two O +
new O +
substrates O +
for O +
the O +
enzyme O -
, O +
i.e. O +
d O +
-aspartate O -
- O -
β O -
- O -
hydroxamate O +
and O +
glycyl O -
- O -
d O +
-aspartate O -
, O +
and O +
to O +
determine O +
the O +
kinetic O +
parameters O +
for O +
these O +
and O +
a O +
number O +
of O +
other O +
substrates O -
. O +

The O +
results O +
are O +
of O +
particular O +
interest O +
for O +
two O +
reasons O -
: O +
first O +
of O +
all O -
, O +
the O +
presence O +
of O +
d O +
-aspartate O -
, O +
d O +
-glutamate O -
, O +
N O +
-methyl O -
- O -
d O +
-aspartate O +
and O +
glycyl O -
- O -
d O +
-aspartate O +
have O +
been O +
reported O +
in O +
several O +
organisms O +
[ O -
4–10,13,38 O -
] O +
; O +
secondly O -
, O +
all O +
of O +
the O +
compounds O +
listed O +
in O +
Table O +
3 O +
are O +
used O +
for O +
both O +
in O +
vivo O +
and O +
in O +
vitro O +
studies O +
as O +
agonists O -
/ O -
antagonists O +
for O +
excitatory B-Gene +
amino I-Gene +
acid I-Gene +
receptors I-Gene +
but O +
the O +
metabolic O +
fate O +
of O +
most O -
, O +
if O +
not O +
all O -
, O +
of O +
them O +
is O +
still O +
unknown O -
. O +

Since O +
DASPO B-Gene +
has O +
been O +
shown O +
to O +
be O +
present O +
in O +
a O +
number O +
of O +
tissues O -
, O +
the O +
possibility O +
exists O +
that O +
the O +
effect O +
of O +
such O +
compounds O +
can O +
be O +
influenced O +
both O +
in O +
vivo O +
and O +
in O +
vitro O +
by O +
the O +
amount O +
of O +
DASPO B-Gene +
present O -
. O +

Acknowledgements O +
We O +
wish O +
to O +
thank O +
Prof. O +
Tatjana O +
Simonic O +
for O +
providing O +
E. O +
coli O +
GI724 O +
( O -
pED O -
) O +
cells O -
. O +

This O +
paper O +
was O +
supported O +
by O +
grants O +
from O +
the O +
Ministero O +
della O +
Università O +
e O +
della O +
Ricerca O +
Scientifica O +
and O +
from O +
the O +
Consiglio O +
Nazionale O +
delle O +
Ricerche O +
( O -
Italy O -
) O -
. O +

The O +
cardiotoxic O +
effect O +
of O +
karminomycin O +
and O +
adriamycin O +
administered O +
intravenously O +
for O +
5 O +
times O +
in O +
equitoxic O +
doses O +
constituting O +
equal O +
portions O +
of O +
LD50 O +
of O +
the O +
respective O +
antibiotic O +
on O +
its O +
single O +
intravenous O +
administration O +
was O +
studied O +
on O +
albino O +
mice O -
. O +

Histological O +
examination O +
of O +
the O +
heart O +
showed O +
that O +
almost O +
identical O +
damages O +
of O +
the O +
myocardium O +
occured O +
after O +
administration O +
of O +
karminomycin O +
and O +
adriamycin O +
in O +
doses O +
of O +
0.45 O +
of O +
LD50 O +
( O -
1.5 O +
mg O -
/ O -
kg O -
) O +
and O +
0.3 O +
of O +
LD50 O +
( O -
6.3 O +
mg O -
/ O -
kg O -
) O +
respectively O -
. O +

The O +
character O +
of O +
the O +
damages O +
due O +
to O +
the O +
antibiotics O +
was O +
close O -
, O +
the O +
most O +
significant O +
changes O +
were O +
observed O +
when O +
the O +
animals O +
were O +
sacrificed O +
1 O +
month O +
after O +
the O +
last O +
administration O +
of O +
the O +
drug O -
. O +

The O +
histological O +
method O +
is O +
of O +
value O +
in O +
estimation O +
of O +
the O +
cardiotoxic O +
effect O +
of O +
the O +
drugs O -
, O +
using O +
mice O +
as O +
the O +
model O +
suitable O +
for O +
the O +
investigation O -
. O +

Adriamycin O +
had O +
more O +
pronounced O +
cumulative O +
properties O +
as O +
compared O +
to O +
karminomycin O -
: O +
suppression O +
of O +
the O +
weight O +
gain O +
in O +
the O +
mice O +
and O +
their O +
death O +
rate O +
were O +
higher O +
with O +
the O +
use O +
of O +
adriamycin O -
. O +

Three O +
sialosylated O +
and O +
three O +
neutral O +
glycosphingolipids O +
sharing O +
a O +
common O +
iso O -
- O -
neolacto O +
core O +
were O +
isolated O +
from O +
porcine O +
kidney O +
cortex O -
. O +

They O +
were O +
purified O +
by O +
preparative O +
HPTLC O -
, O +
and O +
were O +
characterized O +
by O +
partial O +
exoglycosidase B-Gene +
hydrolysis O +
followed O +
by O +
thin O +
layer O +
chromatography O +
and O +
immunostaining O +
with O +
anti B-Gene -
- I-Gene -
Galalpha1 I-Gene -
- I-Gene -
->3Gal I-Gene -
, O +
anti B-Gene -
- I-Gene -
type I-Gene +
2 I-Gene +
lactosamine I-Gene +
and O +
anti B-Gene -
- I-Gene -
Lewis I-Gene -
( I-Gene -
x I-Gene -
) I-Gene +
antibodies I-Gene -
, O +
methylation O +
analysis O -
, O +
MALDI O -
- O -
TOF O +
mass O +
spectrometry O +
and O +
1H O -
- O -
NMR O +
spectroscopy O -
. O +

Among O +
neutral O +
glycolipids O -
, O +
one O +
was O +
a O +
known O +
structure O -
, O +
VI3VI'3 O -
( O -
alphaGal O -
) O -
2-iso O -
- O -
nLc8Cer O -
, O +
and O +
two O +
were O +
novel O +
structures O +
differing O +
by O +
the O +
number O +
of O +
Galalpha3Lewis O -
( O -
x O -
) O +
determinants O -
: O +
VI3VI'3 O -
( O -
alphaGal O -
) O -
2V'3alphaFuc O -
- O -
iso O -
- O -
nLc8 O -
, O +
and O +
VI3VI'3 O -
( O -
alphaGal O -
) O -
2 O +
V3V'3 O -
( O -
alphaFuc O -
) O -
2-iso O -
- O -
nLc8 O -
. O +

The O +
single O +
Galalpha3Lewis O -
( O -
x O -
) O +
determinant O +
was O +
found O +
on O +
the O +
6-linked O +
antenna O -
. O +

Among O +
sialosylated O +
glycolipids O -
, O +
two O +
had O +
been O +
previously O +
found O +
in O +
other O +
species O +
and O +
tissues O -
, O +
VI3VI'3 O -
( O -
NeuAc O -
) O -
2-iso O -
- O -
nLc8 O -
, O +
and O +
VI3NeuAcVI'3alphaGal O -
- O -
iso O -
- O -
nLc8 O -
. O +

A O +
novel O +
structure O +
was O +
discovered O +
presenting O +
a O +
Galalpha3Lewis O -
( O -
x O -
) O +
determinant O +
on O +
the O +
6-linked O +
antenna O +
and O +
a O +
N O -
- O -
acetylneuraminic O +
acid O +
on O +
the O +
3-linked O +
antenna O -
, O +
VI3NeuAcVI'3alphaGalV'3alphaFuc O -
- O -
iso O -
- O -
nLc8 O -
. O +

These O +
results O +
indicate O +
that O -
, O +
in O +
vivo O -
, O +
the O +
porcine B-Gene +
kidney I-Gene +
alpha3fucosyltransferase I-Gene +
synthesizes O +
the O +
Gala3Lewis O -
( O -
x O -
) O +
determinant O -
, O +
acting O +
on O +
the O +
6-linked O +
before O +
the O +
3-linked O +
Galalpha3neolactosamine O -
, O +
and O +
appears O +
unable O +
to O +
synthesize O +
the O +
sialosylated O +
Lewis O -
( O -
x O -
) O +
determinant O +
on O +
neolactoseries O +
glycolipids O -
. O +

A O +
monoclonal B-Gene +
antibody I-Gene +
( O -
MAb B-Gene -
) O +
was O +
produced O +
against O +
the O +
p O -
- O -
nitrophenylphosphate O +
derivative O +
of O +
3 O +
alpha O -
, O +
5 O +
beta O -
- O -
lithocholic O +
acid O -
, O +
a O +
transition O -
- O -
state O +
analog O +
for O +
hydrolysis O +
of O +
a O +
steroidal O +
p O -
- O -
nitrophenylcarbonate O -
. O +

The O +
indicated O +
reaction O +
was O +
catalyzed O +
by O +
this O +
Ab B-Gene +
with O +
kinetic O +
constants O +
kcat O +
= O +
4.0 O +
x O +
10 O -
( O -
-2 O -
) O -
/ O -
min O +
and O +
K O -
( O -
m O -
) O +
= O +
3.3 O +
microM O +
at O +
pH O +
9.0 O +
and O +
35 O +
degrees O +
C. O +
The O +
Ab B-Gene +
also O +
hydrolyzed O +
the O +
isomeric O +
p O -
- O -
nitrophenylcarbonate O +
of O +
3 O +
beta O -
, O +
5 O +
beta O -
- O -
lithocholic O +
acid O +
with O +
kcat O +
= O +
8.4 O +
x O +
10 O -
( O -
-2 O -
) O -
/ O -
min O +
and O +
K O -
( O -
m O -
) O +
= O +
1.0 O +
microM. O +
Bovine B-Gene +
serum I-Gene +
albumin I-Gene +
( O -
BSA B-Gene -
) O +
was O +
found O +
to O +
catalyze O +
the O +
same O +
reactions O +
with O +
similar O +
turnover O +
rates O +
and O +
Michaelis O +
constants O +
of O +
15 O +
and O +
14 O +
microM O -
, O +
respectively O -
. O +

Although O +
the O +
BSA B-Gene -
- O -
catalyzed O +
reaction O +
was O +
only O +
weakly O +
inhibited O +
by O +
the O +
phosphate O +
ester O +
TSA O +
( O -
IC50 O +
ca O -
. O +

40 O +
microM O -
) O -
, O +
the O +
Ab B-Gene -
- O -
catalyzed O +
reaction O +
was O +
completely O +
inhibited O +
at O +
less O +
than O +
1 O +
microM O +
of O +
the O +
TSA O -
. O +

The O +
relative O +
rates O +
and O +
efficiencies O +
of O +
the O +
MAb B-Gene -
- O -
catalyzed O +
and O +
BSA B-Gene -
- O -
catalyzed O +
reactions O +
are O +
discussed O +
in O +
the O +
context O +
of O +
the O +
hydrophobic O +
sites O +
and O +
intrinsic O +
reactivity O +
of O +
the O +
protein O +
surfaces O -
, O +
and O +
the O +
induction O +
of O +
groups O +
on O +
the O +
Ab B-Gene +
to O +
enhance O +
the O +
enzymatic O +
function O -
. O +

To O +
clarify O +
the O +
relationship O +
between O +
the O +
occurrence O +
of O +
unusual O +
trihydroxy O +
bile O +
acids O -
, O +
namely O +
hyocholic O +
acid O -
, O +
ursocholic O +
acid O +
( O -
UCA O -
) O -
, O +
and O +
omega O -
- O -
muricholic O +
acid O +
( O -
omega O -
- O -
MCA O -
) O +
in O +
urine O +
and O +
liver O +
disease O +
severity O -
, O +
urinary O +
bile O +
acids O +
were O +
analyzed O +
by O +
gas O -
- O -
liquid O +
chromatography O +
in O +
acute O +
and O +
late O +
phases O +
of O +
acute O +
hepatitis O +
and O +
before O +
and O +
after O +
ursodeoxycholic O +
acid O +
( O -
UDCA O -
) O +
loading O +
in O +
healthy O +
adults O +
and O +
liver O +
cirrhosis O +
patients O -
. O +

In O +
11 O +
patients O +
with O +
acute O +
hepatitis O -
, O +
the O +
occurrence O +
rates O +
and O +
amounts O +
of O +
unusual O +
trihydroxy O +
bile O +
acids O +
were O +
increased O +
in O +
the O +
late O +
( O -
recovery O -
) O +
phase O -
, O +
as O +
compared O +
with O +
those O +
in O +
the O +
early O +
phase O -
. O +

In O +
10 O +
patients O +
with O +
severe O +
acute O +
hepatitis O +
who O +
had O +
prothrombin B-Gene +
times O +
exceeding O +
16 O +
seconds O -
, O +
these O +
bile O +
acids O +
had O +
completely O +
disappeared O +
from O +
the O +
urine O +
in O +
the O +
early O +
phase O +
but O +
reappeared O +
in O +
the O +
late O +
phase O +
in O +
those O +
who O +
had O +
a O +
good O +
outcome O -
, O +
though O +
never O +
in O +
a O +
patient O +
who O +
died O -
. O +

After O +
UDCA O +
administration O +
for O +
a O +
week O -
, O +
the O +
amounts O +
of O +
unusual O +
bile O +
acids O -
, O +
especially O +
UCA O +
and O +
omega O -
- O -
MCA O -
, O +
which O +
are O +
thought O +
to O +
be O +
synthesized O +
through O +
12 O +
alpha- O +
and O +
6 O +
alpha O -
- O -
hydroxylations O -
, O +
respectively O -
, O +
from O +
UDCA O -
, O +
were O +
clearly O +
increased O +
in O +
10 O +
healthy O +
adults O +
but O +
only O +
slightly O +
changed O +
in O +
10 O +
patients O +
with O +
liver O +
cirrhosis O -
. O +

In O +
conclusion O -
, O +
hepatic O +
hydroxylations O +
of O +
dihydroxy O +
bile O +
acids O +
as O +
a O +
detoxification O +
reaction O +
were O +
impaired O +
in O +
severe O +
liver O +
diseases O -
, O +
which O +
may O +
play O +
a O +
role O +
in O +
the O +
intensification O +
and O +
perpetuation O +
of O +
hepatocellular O +
injuries O -
. O +

1 O -
. O +

Bioactivation O +
of O +
sulphamethoxazole O +
( O -
SMX O -
) O +
to O +
chemically O -
- O -
reactive O +
metabolites O +
and O +
subsequent O +
protein B-Gene +
conjugation O +
is O +
thought O +
to O +
be O +
involved O +
in O +
SMX O +
hypersensitivity O -
. O +

We O +
have O +
therefore O +
examined O +
the O +
cellular O +
metabolism O -
, O +
disposition O +
and O +
conjugation O +
of O +
SMX O +
and O +
its O +
metabolites O +
in O +
vitro O -
. O +

2 O -
. O +

Flow O +
cytometry O +
revealed O +
binding O +
of O +
N O -
- O -
hydroxy O +
( O -
SMX O -
- O -
NHOH O -
) O +
and O +
nitroso O +
( O -
SMX O -
- O -
NO O -
) O +
metabolites O +
of O +
SMX O -
, O +
but O +
not O +
of O +
SMX O +
itself O -
, O +
to O +
the O +
surface O +
of O +
viable O +
white O +
blood O +
cells O -
. O +

Cellular O +
haptenation O +
by O +
SMX O -
- O -
NO O +
was O +
reduced O +
by O +
exogenous O +
glutathione O +
( O -
GSH O -
) O -
. O +

3 O -
. O +
SMX O -
- O -
NHOH O +
and O +
SMX O -
- O -
NO O +
were O +
rapidly O +
reduced O +
back O +
to O +
the O +
parent O +
compound O +
by O +
cysteine O +
( O -
CYS O -
) O -
, O +
GSH O -
, O +
human O +
peripheral O +
blood O +
cells O +
and O +
plasma O -
, O +
suggesting O +
that O +
this O +
is O +
an O +
important O +
and O +
ubiquitous O +
bioinactivation O +
mechanism O -
. O +

4 O -
. O +
Fluorescence O +
HPLC O +
showed O +
that O +
SMX O -
- O -
NHOH O +
and O +
SMX O -
- O -
NO O +
depleted O +
CYS O +
and O +
GSH O +
in O +
buffer O -
, O +
and O +
to O +
a O +
lesser O +
extent O -
, O +
in O +
cells O +
and O +
plasma O -
. O +

5 O -
. O +

Neutrophil O +
apoptosis O +
and O +
inhibition O +
of O +
neutrophil O +
function O +
were O +
induced O +
at O +
lower O +
concentrations O +
of O +
SMX O -
- O -
NHOH O +
and O +
SMX O -
- O -
NO O +
than O +
those O +
inducing O +
loss O +
of O +
membrane O +
viability O -
, O +
with O +
SMX O +
having O +
no O +
effect O -
. O +

Lymphocytes O +
were O +
significantly O +
( O -
P<0.05 O -
) O +
more O +
sensitive O +
to O +
the O +
direct O +
cytotoxic O +
effects O +
of O +
SMX O -
- O -
NO O +
than O +
neutrophils O -
. O +

6 O -
. O +

Partitioning O +
of O +
SMX O -
- O -
NHOH O +
into O +
red O +
blood O +
cells O +
was O +
significantly O +
( O -
P<0.05 O -
) O +
lower O +
than O +
with O +
the O +
hydroxylamine O +
of O +
dapsone O -
. O +

7 O -
. O +

Our O +
results O +
suggest O +
that O +
the O +
balance O +
between O +
oxidation O +
of O +
SMX O +
to O +
its O +
toxic O +
metabolites O +
and O +
their O +
reduction O +
is O +
an O +
important O +
protective O +
cellular O +
mechanism O -
. O +

If O +
an O +
imbalance O +
exists O -
, O +
haptenation O +
of O +
the O +
toxic O +
metabolites O +
to O +
bodily O +
proteins B-Gene +
including O +
the O +
surface O +
of O +
viable O +
cells O +
can O +
occur O -
, O +
and O +
may O +
result O +
in O +
drug O +
hypersensitivity O -
. O +

Proline O +
( O -
Pro O -
) O +
and O +
hydroxyproline O +
( O -
Hyp O -
) O +
formed O +
by O +
hydroxylation O +
of O +
Pro O +
during O +
collagen B-Gene +
biosynthesis O +
are O +
commonly O +
found O +
in O +
connective B-Gene +
tissue I-Gene +
proteins I-Gene +
such O +
as O +
collagen B-Gene +
at O +
high O +
concentrations O -
. O +

These O +
amino O +
acids O +
are O +
released O +
after O +
degradation O +
of O +
collagen B-Gene +
and O +
excreted O +
into O +
urine O +
as O +
amino O +
acids O -
, O +
small O +
peptides O +
and O +
large O +
peptides O -
. O +

According O +
to O +
previous O +
reports O +
[ O -
1–4 O -
] O +
, O +
total O +
Hyp O +
excreted O +
in O +
urine O +
is O +
comprised O +
of O +
∼85 O -
% O +
small O +
peptides O +
and O +
1–5 O -
% O +
free O +
Hyp O -
. O +

The O +
main O +
peptide O +
containing O +
Hyp O +
was O +
prolylhydroxyproline O +
( O -
Pro O -
– O -
Hyp O -
) O +
which O +
accounted O +
for O +
about O +
60 O -
% O +
of O +
peptide O +
Hyp O +
or O +
44 O -
% O +
of O +
total O +
urinary O +
Hyp O +
[ O -
2,4 O -
] O +
. O +

The O +
concentration O +
of O +
total O +
urinary O +
Pro O +
and O +
Hyp O +
varied O +
in O +
association O +
with O +
various O +
diseases O +
including O +
bone O +
diseases O +
[ O -
1,5–7 O -
] O +
and O +
tumor O +
[ O -
8–10 O -
] O +
and O +
excretion O +
of O +
dipeptides O +
containing O +
Pro O +
or O +
Hyp O +
increases O +
in O +
patients O +
with O +
disorders O +
involving O +
collagen B-Gene +
metabolism O +
[ O -
11–13 O -
] O +
. O +

Therefore O -
, O +
sensitive O +
and O +
reliable O +
determinations O +
of O +
these O +
metabolites O +
in O +
human O +
urine O +
are O +
useful O +
for O +
understanding O +
of O +
various O +
disorders O -
. O +

Currently O -
, O +
a O +
few O +
methods O +
for O +
the O +
determination O +
of O +
dipeptides O +
that O +
contain O +
Pro O +
or O +
Hyp O +
in O +
urine O +
by O +
gas O +
chromatograpgy O -
– O -
mass O +
spectrometry O +
( O -
GC O -
– O -
MS O -
) O +
[ O -
11–14 O -
] O +
, O +
liquid O +
chromatography O +
( O -
LC O -
) O -
–MS O +
[ O -
15–17 O -
] O +
and O +
high O -
- O -
performance O +
liquid O +
chromatography O +
( O -
HPLC O -
) O +
[ O -
18 O -
] O +
have O +
been O +
reported O -
. O +

However O -
, O +
the O +
GC O -
– O -
MS O +
and O +
LC O -
– O -
MS O +
methods O +
require O +
tedious O +
procedures O +
including O +
a O +
two O -
- O -
step O +
column O +
separation O +
for O +
pre O -
- O -
treatment O +
of O +
urine O +
and O +
further O -
, O +
the O +
GC O -
– O -
MS O +
methods O +
require O +
a O +
two O -
- O -
step O +
derivatization O +
procedure O +
to O +
convert O +
dipeptides O +
into O +
volatile O +
derivatives O +
after O +
pre O -
- O -
treatment O -
. O +

In O +
the O +
HPLC O +
method O +
employing O +
a O +
pre O -
- O -
column O +
derivatization O +
technique O +
with O +
4-chloro-7-nitrobenzofurazan O +
as O +
a O +
fluorescent O +
labelling O +
reagent O -
, O +
a O +
relatively O +
large O +
sample O +
volume O +
( O -
5 O +
ml O -
) O +
is O +
required O +
because O +
of O +
low O +
sensitivity O +
to O +
prolyl O +
dipeptides O -
. O +

Recently O -
, O +
we O +
developed O +
an O +
extremely O +
sensitive O +
fluorescent O +
labelling O +
reagent O -
, O +
4- O -
( O -
5,6-dimethoxy-2-phthalimidinyl O -
) O -
-2-methoxyphenylsulfonyl O +
chloride O +
( O -
DMS O -
- O -
Cl O -
) O -
, O +
which O +
reacts O +
quantitatively O +
with O +
amino O +
acids O +
to O +
form O +
fluorescent O +
sulfonamides O +
( O -
maximum O +
wavelength O -
: O +
318 O +
nm O +
for O +
excitation O +
and O +
392 O +
nm O +
for O +
emission O -
) O -
, O +
and O +
applied O +
the O +
reagent O +
for O +
determination O +
of O +
urinary O +
free O +
Hyp O +
by O +
a O +
pre O -
- O -
column O +
HPLC O +
method O +
[ O -
19 O -
] O +
. O +

In O +
the O +
present O +
study O -
, O +
we O +
found O +
DMS O -
- O -
Cl O +
reacted O +
with O +
prolyl O +
dipeptides O +
to O +
give O +
fluorescent O +
derivatives O -
. O +

In O +
addition O -
, O +
a O +
highly O +
sensitive O +
HPLC O +
method O +
for O +
simultaneous O +
determination O +
of O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O +
in O +
urine O +
by O +
fluorescence O +
detection O +
after O +
pre O -
- O -
column O +
derivatization O +
with O +
DMS O -
- O -
Cl O +
was O +
established O -
. O +

2 O +
Experimental O +
2.1 O +
Chemicals O +
and O +
solvents O +
All O +
chemicals O +
were O +
of O +
analytical O +
reagent O +
grade O -
, O +
unless O +
stated O +
otherwise O -
. O +

DMS O -
- O -
Cl O +
was O +
prepared O +
as O +
described O +
previously O +
[ O -
19 O -
] O +
. O +

o O +
-Phthalaldehyde O +
( O -
OPA O -
) O -
, O +
acetonitrile O +
( O -
HPLC O -
- O -
grade O -
) O +
and O +
Creatinine O +
Test O +
Wako O +
were O +
obtained O +
from O +
Wako O +
Pure O +
Chemicals O +
( O -
Osaka O -
, O +
Japan O -
) O -
. O +

Pro O -
– O -
Asp O -
, O +
Pro O -
– O -
Gln O -
, O +
Pro O -
– O -
Glu O -
, O +
Pro O -
– O -
Leu O -
, O +
Pro O -
– O -
Pro O +
and O +
Pro O -
– O -
Ser O +
were O +
purchased O +
from O +
Kokusan O +
Chemical O +
Works O +
( O -
Tokyo O -
, O +
Japan O -
) O +
and O +
Pro O -
– O -
Ala O -
, O +
Pro O -
– O -
Asn O -
, O +
Pro O -
– O -
Gly O -
, O +
Pro O -
– O -
Hyp O -
, O +

Pro O -
– O -
Ile O -
, O +
Pro O -
– O -
Met O -
, O +
Pro O -
– O -
Phe O -
, O +
Pro O -
– O -
Trp O -
, O +
Pro O -
– O -
Tyr O -
, O +
Pro O -
– O -
Val O +
and O +
3,4-dehydro O -
- O -
dl O +
-proline O +
( O -
internal O +
standard O -
, O +
I.S. O -
) O +
were O +
from O +
Sigma O +
( O -
St. O +
Louis O -
, O +
MO O -
, O +
USA O -
) O -
. O +

l O +
-Amino O +
acids O +
except O +
Asn O -
, O +
Hyp O +
and O +
Ser O +
( O -
Nacalai O +
Tesque O -
, O +
Kyoto O -
, O +
Japan O -
) O +
were O +
purchased O +
from O +
Kyowa O +
Hakko O +
( O -
Tokyo O -
, O +
Japan O -
) O -
. O +

Organic O +
solvents O +
except O +
acetonitrile O +
were O +
of O +
highest O +
purity O +
available O +
and O +
used O +
as O +
received O -
. O +

Bond O +
Elut O +
C18 O +
( O -
100 O +
mg O -
/ O -
1 O +
ml O -
, O +
Varian O -
, O +
CA O -
, O +
USA O -
) O +
was O +
conditioned O +
with O +
2 O +
ml O +
of O +
methanol O +
followed O +
by O +
2 O +
ml O +
of O +
water O +
and O +
1 O +
ml O +
of O +
Na2 O +
HPO4 O +
( O -
50 O +
mM O +
) O +
prior O +
to O +
use O -
. O +

2.2 O +
Instrumental O +
conditions O +
The O +
HPLC O +
system O +
consisted O +
of O +
two O +
LC-10AD O +
HPLC O +
pumps O +
( O -
Shimadzu O -
, O +
Kyoto O -
, O +
Japan O -
) O -
, O +
a O +
CTO-10AC O +
column O +
oven O +
( O -
Shimadzu O -
) O -
, O +
a O +
DGU-14A O +
on O -
- O -
line O +
degasser O +
( O -
Shimadzu O -
) O -
, O +
an O +
SIL-10Axl O +
auto O +
injector O +
( O -
Shimadzu O -
) O -
, O +
an O +
L-7480 O +
fluorescence O +
detector O +
( O -
Hitachi O -
, O +
Tokyo O -
, O +
Japan O -
) O +
and O +
a O +
CLASS O -
- O -
LC10 O +
LC O +
work O -
- O -
station O +
( O -
Shimadzu O -
) O +
with O +
a O +
CBM-10A O +
communications O +
bus O +
module O +
( O -
Shimadzu O -
) O -
. O +

A O +
TSK O -
- O -
guard O +
gel O +
ODS-80Ts O +
( O -
15 O -
× O -
3.2 O +
mm O +
I.D. O -
, O +
Tosoh O -
, O +
Tokyo O -
, O +
Japan O -
) O +
and O +
tandem O +
Nova O +
Pak O +
C18 O +
columns O +
( O -
150 O -
× O -
3.9 O +
mm O +
I.D. O -
, O +
4 O +
μm O -
, O +
Waters O -
, O +
Milford O -
, O +
MA O -
, O +
USA O -
) O +
were O +
used O +
at O +
55 O -
° O -
C O +
with O +
a O +
gradient O +
system O +
of O +
( O -
A O -
) O +
aqueous O +
acetic O +
acid O +
( O -
10 O +
mM O +
) O -
– O -
( O -
B O -
) O +
acetonitrile O -
– O -
aqueous O +
acetic O +
acid O +
( O -
50 O +
mM O +
) O +
( O -
8:2 O -
, O +
v O -
/ O -
v O -
) O -
. O +

The O +
elution O +
program O +
consisted O +
of O +
an O +
isocratic O +
elution O +
of O +
25 O -
% O +
B O +
for O +
20 O +
min O -
, O +
followed O +
by O +
a O +
linear O +
gradient O +
elution O +
from O +
25 O +
to O +
55 O -
% O +
of O +
B O +
for O +
30 O +
min O -
, O +
and O +
finally O +
a O +
stepwise O +
decrease O +
to O +
25 O -
% O +
of O +
B O +
to O +
re O -
- O -
equilibrate O +
the O +
column O +
for O +
10 O +
min O -
. O +

The O +
flow O -
- O -
rate O +
was O +
1 O +
ml O -
/ O -
min O -
. O +

The O +
fluorescence O +
intensities O +
were O +
monitored O +
at O +
excitation O +
and O +
emission O +
wavelengths O +
of O +
318 O +
nm O +
and O +
392 O +
nm O -
, O +
respectively O -
. O +

2.3 O +
Derivatization O +
procedure O +
To O +
a O +
test O +
solution O +
( O -
20 O +
μl O -
) O +
of O +
prolyl O +
dipeptides O -
, O +
Pro O -
, O +
Hyp O +
and O +
the O +
I.S. O +
were O +
placed O +
in O +
a O +
screw O -
- O -
capped O +
glass O +
vial O -
, O +
Na2 O +
HPO4 O +
( O -
50 O +
mM O +
, O +
280 O +
μl O -
) O +
and O +
DMS O -
- O -
Cl O +
( O -
2 O +
mM O +
in O +
acetone O -
, O +
500 O +
μl O -
) O +
were O +
successively O +
added O +
and O +
mixed O -
. O +

The O +
mixture O +
was O +
allowed O +
to O +
stand O +
for O +
20 O +
min O +
at O +
70 O -
° O -
C O -
. O +

After O +
cooling O -
, O +
the O +
reaction O +
mixture O +
was O +
mixed O +
with O +
dichloromethane O +
( O -
0.8 O +
ml O -
) O +
and O +
Na2 O +
CO3 O +
( O -
0.1 O +
M O +
, O +
30 O +
μl O -
) O +
and O +
then O +
centrifuged O +
( O -
500 O +
g O +
) O +
for O +
10 O +
min O -
. O +

An O +
aliquot O +
( O -
10 O +
μl O -
) O +
of O +
the O +
aqueous O +
layer O +
was O +
subjected O +
to O +
HPLC O -
. O +

2.4 O +
Procedure O +
for O +
determination O +
of O +
urinary O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O +
2.4.1 O +
Method O +
A O +
( O -
recommended O +
method O -
) O -
: O +
solid O -
- O -
phase O +
extraction O +
method O +
To O +
human O +
urine O +
( O -
25 O +
μl O -
) O +
were O +
added O +
I.S. O +
( O -
10 O +
μM O +
, O +
25 O +
μl O -
) O -
, O +
Na2 O +
HPO4 O +
( O -
50 O +
mM O +
, O +
150 O +
μl O -
) O +
and O +
OPA O +
[ O -
4 O -
% O -
, O +
w O -
/ O -
v O -
, O +
in O +
acetonitrile O -
– O -
Na2 O +
HPO4 O +
( O -
50 O +
mM O +
) O +
( O -
1:1 O -
, O +
v O -
/ O -
v O -
) O -
, O +
50 O +
μl O -
] O -
. O +

After O +
standing O +
for O +
3 O +
min O -
, O +
the O +
OPA O -
- O -
treated O +
mixture O +
( O -
200 O +
μl O -
) O +
was O +
passed O +
through O +
a O +
Bond O +
Elut O +
C18 O +
column O +
and O +
then O +
the O +
column O +
was O +
washed O +
with O +
acetonitrile O -
– O -
Na2 O +
HPO4 O +
( O -
50 O +
mM O +
) O +
( O -
1:9 O -
, O +
v O -
/ O -
v O -
, O +
800 O +
μl O -
) O -
. O +

The O +
effluent O +
with O +
the O +
OPA O -
- O -
treated O +
mixture O +
and O +
the O +
washings O +
were O +
mixed O -
. O +

The O +
mixture O +
( O -
300 O +
μl O -
) O +
was O +
reacted O +
with O +
DMS O -
- O -
Cl O +
( O -
2 O +
mM O +
in O +
acetone O -
, O +
500 O +
μl O -
) O +
at O +
70 O -
° O -
C O +
for O +
20 O +
min O -
. O +

The O +
reaction O +
mixture O +
was O +
mixed O +
with O +
dichloromethane O +
( O -
0.8 O +
ml O -
) O +
and O +
Na2 O +
CO3 O +
( O -
0.1 O +
M O +
, O +
30 O +
μl O -
) O +
and O +
then O +
centrifuged O +
( O -
500 O +
g O +
) O +
for O +
10 O +
min O -
. O +

The O +
aqueous O +
layer O +
( O -
10 O +
μl O -
) O +
was O +
subjected O +
to O +
HPLC O -
. O +

The O +
Bond O +
Elut O +
C18 O +
column O +
was O +
used O +
at O +
least O +
20 O +
times O +
by O +
washing O +
twice O +
sequentially O +
with O +
methanol O +
and O +
water O +
( O -
2 O +
ml O +
each O -
) O +
after O +
each O +
use O -
. O +

2.4.2 O +
Method O +
B O -
: O +
solvent O +
extraction O -
- O -
stripping O +
method O +
To O +
human O +
urine O +
( O -
20 O +
μl O -
) O +
were O +
added O +
I.S. O +
( O -
10 O +
μM O +
, O +
20 O +
μl O -
) O -
, O +
Na2 O +
HPO4 O +
( O -
50 O +
mM O +
, O +
260 O +
μl O -
) O +
and O +
OPA O +
( O -
4 O -
% O -
, O +
w O -
/ O -
v O -
, O +
in O +
acetone O -
, O +
50 O +
μl O -
) O -
. O +

After O +
standing O +
for O +
3 O +
min O -
, O +
DMS O -
- O -
Cl O +
( O -
2 O +
mM O +
in O +
acetone O -
, O +
450 O +
μl O -
) O +
was O +
successively O +
added O +
and O +
mixed O -
. O +

The O +
mixture O +
was O +
allowed O +
to O +
stand O +
for O +
20 O +
min O +
at O +
70 O -
° O -
C O -
. O +

After O +
cooling O -
, O +
the O +
reaction O +
mixture O +
was O +
acidified O +
with O +
HCl O +
( O -
5 O +
M O +
, O +
50 O +
μl O -
) O -
, O +
saturated O +
with O +
NaCl O +
( O -
ca O -
. O +
150 O +
mg O -
) O +
and O +
then O +
extracted O +
with O +
dichloromethane O +
( O -
1 O +
ml O -
) O -
. O +

The O +
organic O +
layer O +
( O -
1 O +
ml O -
) O +
was O +
mixed O +
with O +
Na2 O +
CO3 O +
( O -
10 O +
mM O +
, O +
300 O +
μl O -
) O +
and O +
then O +
centrifuged O +
( O -
500 O +
g O +
) O +
for O +
10 O +
min O -
. O +

The O +
aqueous O +
layer O +
( O -
10 O +
μl O -
) O +
was O +
subjected O +
to O +
HPLC O -
. O +

3 O +
Results O +
and O +
discussion O +
3.1 O +
Chromatographic O +
separation O +
DMS O -
- O -
Cl O +
reacted O +
with O +
prolyl O +
dipeptides O +
in O +
a O +
basic O +
medium O +
to O +
give O +
the O +
corresponding O +
fluorescent O +
derivatives O +
( O -
Fig. O +
1 O +
) O -
. O +

The O +
separation O +
of O +
the O +
derivatives O +
of O +
prolyl O +
dipeptides O +
( O -
16 O +
species O -
) O -
, O +
Pro O -
, O +
Hyp O +
and O +
I.S. O +
labelled O +
with O +
DMS O -
- O -
Cl O +
were O +
examined O +
by O +
use O +
of O +
tandem O +
reversed O -
- O -
phase O +
columns O +
and O +
gradient O +
elution O -
. O +

A O +
typical O +
chromatogram O +
of O +
the O +
reaction O +
mixture O +
of O +
a O +
standard O +
solution O +
is O +
shown O +
in O +
Fig. O +
2 O +
. O +

The O +
peaks O +
due O +
to O +
12 O +
species O +
of O +
prolyl O +
dipeptides O +
( O -
retention O +
time O -
: O +
Pro O -
– O -
Asn O -
, O +
14.8 O -
; O +
–Gln O -
, O +
16.2 O -
; O +
–Hyp O -
, O +
17.1 O -
; O +
–Glu O -
, O +
23.9 O -
; O +
–Gly O -
, O +
27.0 O -
; O +
–Ala O -
, O +
33.8 O -
; O +
–Pro O -
, O +
35.0 O -
; O +
–Tyr O -
, O +
37.7 O -
; O +
–Met O -
, O +
42.1 O -
; O +
–Val O -
, O +
43.7 O -
; O +
–Trp O -
, O +
47.3 O -
; O +
–Phe O -
, O +
49.1 O +
min O -
) O -
, O +
Pro O +
( O -
34.4 O +
min O -
) O -
, O +
Hyp O +
( O -
12.2 O +
min O -
) O +
and O +
I.S. O +
( O -
31.0 O +
min O -
) O +
were O +
separate O +
from O +
each O +
other O +
and O +
the O +
reagent O +
blank O +
components O -
, O +
although O +
the O +
peaks O +
due O +
to O +
Pro O -
– O -
Asp O +
( O -
18.6 O +
min O -
) O +
and O +
Pro O -
– O -
Ser O +
( O -
18.7 O +
min O -
) O +
and O +
those O +
due O +
to O +
Pro O -
– O -
Ile O +
( O -
47.9 O +
min O -
) O +
and O +
Pro O -
– O -
Leu O +
( O -
48.0 O +
min O -
) O +
overlapped O -
. O +

As O +
the O +
chromatographic O +
separation O +
of O +
DMS O +
derivatives O +
of O +
prolyl O +
dipeptides O -
, O +
Pro O -
, O +
Hyp O +
and O +
I.S. O +
was O +
affected O +
by O +
the O +
pH O +
in O +
the O +
mobile O +
phase O -
, O +
the O +
effect O +
of O +
the O +
pH O +
was O +
examined O +
using O +
acetate O +
buffer O +
[ O -
10 O +
mM O +
for O +
mobile O +
phase O +
( O -
A O -
) O +
and O +
50 O +
mM O +
for O +
mobile O +
phase O +
( O -
B O -
) O -
, O +
pH O +
4.0–6.0 O -
] O +
instead O +
of O +
acetic O +
acid O -
. O +

As O +
shown O +
in O +
Fig. O +
3 O +
, O +
the O +
retention O +
times O +
of O +
all O +
peaks O +
became O +
shorter O +
with O +
increased O +
pH O +
and O +
the O +
prolyl O +
dipeptide O +
peaks O +
overlapped O +
at O +
pH O +
greater O +
than O +
pH O +
4.5 O -
. O +

The O +
pH O +
of O +
acetic O +
acid O +
( O -
10 O +
mM O +
) O +
in O +
mobile O +
phase O +
was O +
about O +
3.4 O -
. O +

3.2 O +
Labelling O +
reaction O +
conditions O +
A O +
standard O +
solution O +
of O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O +
( O -
10 O +
μM O +
each O -
) O +
was O +
used O +
to O +
determine O +
the O +
optimum O +
labelling O +
conditions O -
. O +

The O +
reaction O +
of O +
Hyp O +
with O +
DMS O -
- O -
Cl O +
was O +
complete O +
within O +
5 O +
min O +
regardless O +
of O +
the O +
temperature O +
( O -
labelling O +
yield O -
: O +
99.7 O -
% O -
) O +
[ O -
19 O -
] O +
. O +

However O -
, O +
the O +
labelling O +
reactions O +
of O +
prolyl O +
dipeptides O +
with O +
DMS O -
- O -
Cl O +
were O +
incomplete O +
under O +
the O +
above O +
conditions O -
, O +
while O +
the O +
reactions O +
of O +
Pro O +
and O +
I.S. O +
with O +
DMS O -
- O -
Cl O +
were O +
similar O +
to O +
that O +
of O +
Hyp O -
. O +

Therefore O -
, O +
the O +
effect O +
of O +
the O +
reaction O +
time O +
on O +
the O +
labelling O +
reaction O +
was O +
examined O +
at O +
various O +
temperatures O -
. O +

The O +
results O +
obtained O +
for O +
Pro O -
– O -
Hyp O +
are O +
shown O +
in O +
Fig. O +
4 O +
. O +

The O +
maximum O +
peak O +
area O +
was O +
obtained O +
from O +
the O +
reactions O +
performed O +
at O +
above O +
70 O -
° O -
C O -
, O +
for O +
10 O +
min O -
. O +

Similar O +
results O +
were O +
obtained O +
from O +
other O +
prolyl O +
dipeptides O -
. O +

Consequently O -
, O +
subsequent O +
labelling O +
reactions O +
for O +
prolyl O +
dipeptides O -
, O +
Pro O -
, O +
Hyp O +
and O +
I.S. O +
with O +
DMS O -
- O -
Cl O +
were O +
carried O +
out O +
at O +
70 O -
° O -
C O +
for O +
20 O +
min O -
. O +

The O +
reaction O +
mixture O +
was O +
stable O +
for O +
at O +
least O +
48 O +
h O +
at O +
room O +
temperature O -
. O +

As O +
the O +
labelling O +
reaction O +
of O +
prolyl O +
dipeptides O -
, O +
Pro O -
, O +
Hyp O +
and O +
I.S. O +
with O +
DMS O -
- O -
Cl O +
proceeded O +
in O +
a O +
basic O +
medium O -
, O +
the O +
effect O +
of O +
the O +
pH O +
of O +
phosphate O +
buffer O +
( O -
50 O +
mM O +
) O +
on O +
the O +
labelling O +
reaction O +
was O +
examined O -
. O +

The O +
results O +
for O +
Pro O -
– O -
Hyp O -
, O +
Pro O -
– O -
Gly O -
, O +
Pro O -
– O -
Pro O +
and O +
I.S. O +
are O +
shown O +
in O +
Fig. O +
5 O +
. O +

Each O +
peak O +
exhibited O +
a O +
maximum O +
and O +
constant O +
area O +
in O +
the O +
range O +
of O +
pH O +
8–10 O -
. O +

Similar O +
results O +
were O +
obtained O +
from O +
other O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O -
. O +

The O +
effect O +
of O +
the O +
anionic O +
component O +
of O +
the O +
buffer O +
solution O +
was O +
also O +
examined O +
using O +
acetate O -
, O +
borate O +
and O +
phosphate O +
buffer O +
( O -
50 O +
mM O +
, O +
pH O +
8) O -
. O +

The O +
maximum O +
peak O +
areas O +
of O +
prolyl O +
dipeptides O +
were O +
obtained O +
in O +
phosphate O +
buffer O +
( O -
peak O +
area O +
relative O +
to O +
phosphate O +
buffer O -
: O +
acetate O +
buffer O -
, O +
75–98 O -
% O -
; O +
borate O +
buffer O -
, O +
91–100 O -
% O +
except O +
61 O -
% O +
for O +
Pro O -
– O -
Tyr O -
) O -
. O +

Therefore O -
, O +
Na2 O +
HPO4 O +
( O -
50 O +
mM O +
, O +
pH O +
ca O -
. O +

9.3 O -
) O +
was O +
adopted O -
. O +

When O +
the O +
effect O +
of O +
the O +
concentration O +
of O +
Na2 O +
HPO4 O +
( O -
10–100 O +
mM O +
) O +
was O +
examined O -
, O +
the O +
maximum O +
and O +
constant O +
peak O +
areas O +
were O +
obtained O +
at O +
a O +
concentration O +
of O +
more O +
than O +
25 O +
mM O +
. O +

The O +
concentration O +
of O +
DMS O -
- O -
Cl O +
was O +
determined O +
by O +
the O +
peak O +
areas O +
due O +
to O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O +
( O -
100 O +
μM O +
each O -
) O -
. O +

The O +
maximum O +
peak O +
areas O +
were O +
obtained O +
at O +
more O +
than O +
1.5 O +
mM O +
DMS O -
- O -
Cl O -
. O +

Dichloromethane O +
extraction O +
was O +
carried O +
out O +
to O +
remove O +
excess O +
DMS O -
- O -
Cl O -
, O +
which O +
was O +
suspected O +
of O +
causing O +
the O +
guard O +
column O +
to O +
degrade O -
. O +

The O +
extraction O +
was O +
achieved O +
after O +
addition O +
of O +
Na2 O +
CO3 O +
( O -
0.1 O +
M O +
, O +
30 O +
μl O -
) O +
because O +
parts O +
of O +
the O +
derivatives O +
of O +
prolyl O +
dipeptides O +
that O +
eluted O +
after O +
the O +
derivatives O +
of O +
Pro O -
– O -
Ala O +
on O +
the O +
HPLC O +
column O +
were O +
lost O +
with O +
dichloromethane O +
extraction O +
without O +
Na2 O +
CO3 O +
. O +

3.3 O +
Linearity O +
and O +
detection O +
limit O +
Linearity O +
was O +
studied O +
over O +
wide O +
ranges O +
of O +
concentration O +
of O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O +
( O -
between O +
0.1 O +
and O +
100 O +
μM O +
each O -
) O -
. O +

The O +
peak O -
- O -
area O +
ratios O +
of O +
analytes O +
to O +
I.S. O +
were O +
linear O +
in O +
the O +
concentration O +
ranges O +
investigated O +
( O -
r O +
> O -
0.999 O +
each O -
) O -
. O +

When O +
the O +
precision O +
was O +
tested O +
using O +
standard O +
solutions O +
( O -
1 O -
, O +
10 O +
and O +
100 O +
μM O +
each O -
) O -
, O +
the O +
relative O +
standard O +
deviations O +
( O -
RSDs O -
, O +
n O +
= O -
10 O -
) O +
were O +
less O +
than O +
4.1 O -
% O -
. O +

The O +
detection O +
limits O +
( O -
S O -
/ O -
N=3 O -
) O +
for O +
prolyl O +
dipeptides O +
were O +
1–5 O +
fmol O -
/ O -
injection O -
. O +

3.4 O +
Pretreatment O +
of O +
urine O +
and O +
HPLC O +
chromatograms O +
For O +
determination O +
of O +
urinary O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O +
by O +
pre O -
- O -
column O +
HPLC O -
, O +
OPA O +
treatment O +
[ O -
20 O -
] O +
was O +
employed O +
to O +
eliminate O +
primary O +
amino O +
compounds O +
coexisting O +
with O +
analytes O +
in O +
urine O -
. O +

However O -
, O +
the O +
reaction O +
mixture O +
of O +
urine O +
with O +
OPA O +
was O +
colored O +
darkly O -
. O +

Therefore O -
, O +
two O +
methods O -
, O +
method O +
A O +
( O -
solid O -
- O -
phase O +
extraction O -
) O +
and O +
method O +
B O +
( O -
solvent O +
extraction O -
- O -
stripping O -
) O +
described O +
in O +
Section O +
2.4 O +
were O +
tested O +
to O +
remove O +
the O +
colored O +
products O -
. O +

The O +
colored O +
products O +
were O +
retained O +
on O +
the O +
Bond O +
Elut O +
C18 O +
column O +
in O +
method O +
A O +
and O +
were O +
not O +
extracted O +
with O +
dichloromethane O +
at O +
acidic O +
pH O +
in O +
method O +
B. O +
The O +
typical O +
chromatograms O +
of O +
a O +
standard O +
solution O +
and O +
urine O +
obtained O +
according O +
to O +
the O +
procedures O +
of O +
methods O +
A O +
and O +
B O +
are O +
shown O +
in O +
Fig. O +
6A O +
and O +
B O +
and O +
Fig. O +
7A O +
and O +
B O +
, O +
respectively O -
. O +

As O +
shown O +
in O +
Fig. O +
6A O +
, O +
some O +
prolyldipeptides O +
( O -
Pro O -
– O -
Tyr O -
, O +
–Val O -
, O +
–Met O -
, O +
–Trp O -
, O +
–Ile O -
, O +
–Leu O +
and O +
–Phe O -
) O +
were O +
unable O +
to O +
be O +
measured O +
by O +
method O +
A O -
, O +
because O +
these O +
peptides O +
were O +
retained O +
on O +
the O +
Bond O +
Elut O +
C18 O +
column O +
under O +
the O +
conditions O +
used O -
. O +

When O +
urine O +
was O +
analyzed O +
by O +
method O +
A O -
, O +
peaks O +
due O +
to O +
Pro O -
– O -
Hyp O -
, O +
Pro O -
– O -
Gly O -
, O +
Pro O -
– O -
Pro O -
, O +
Pro O +
and O +
Hyp O +
at O +
retention O +
times O +
of O +
17.1 O -
, O +
27.0 O -
, O +
35.0 O -
, O +
34.3 O +
and O +
12.2 O +
min O -
, O +
respectively O -
, O +
were O +
observed O +
( O -
Fig. O +
6B O +
) O -
. O +

In O +
contrast O -
, O +
for O +
method O +
B O -
, O +
all O +
prolyl O +
dipeptides O +
in O +
a O +
standard O +
solution O +
were O +
detected O +
( O -
Fig. O +
7A O +
) O -
. O +

However O -
, O +
the O +
seven O +
prolyl O +
dipeptides O +
that O +
could O +
not O +
be O +
measured O +
by O +
method O +
A O +
were O +
not O +
recognized O +
in O +
urine O +
( O -
Fig. O +
7B O +
) O -
, O +
although O +
the O +
three O +
prolyl O +
dipeptides O +
mentioned O +
above O +
were O +
recognized O +
in O +
urine O -
. O +

Despite O +
these O +
issues O -
, O +
urinary O +
Pro O -
– O -
Hyp O -
, O +
Pro O -
– O -
Gly O -
, O +
Pro O -
– O -
Pro O -
, O +
Pro O -
, O +
Hyp O +
and O +
I.S. O +
were O +
separated O +
from O +
the O +
reagent O +
blank O +
and O +
other O +
urinary O +
components O +
( O -
Figs. O +
6B O +
and O +
7B O +
) O -
. O +

These O +
urinary O +
analytes O +
were O +
identified O +
by O +
comparing O +
the O +
retention O +
times O +
with O +
those O +
of O +
standard O +
solutions O +
and O +
also O +
by O +
co O -
- O -
chromatography O +
of O +
a O +
standard O +
solution O +
and O +
urine O -
. O +

3.5 O +
Recovery O +
and O +
precision O +
Recovery O +
tests O +
were O +
examined O +
by O +
means O +
of O +
both O +
methods O +
using O +
three O +
urine O +
samples O +
spiked O +
with O +
various O +
amounts O +
of O +
standard O +
Pro O -
– O -
Hyp O +
( O -
urinary O +
concentration O -
: O +
25 O -
, O +
50 O -
, O +
100 O -
, O +
250 O +
and O +
500 O +
μM O +
) O -
, O +
Pro O -
– O -
Gly O -
, O +
Pro O -
– O -
Pro O -
, O +
Hyp O +
( O -
0.5 O -
, O +
1 O -
, O +
2 O -
, O +
5 O +
and O +
10 O +
μM O +
each O -
) O +
and O +
Pro O +
( O -
1 O -
, O +
2 O -
, O +
4 O -
, O +
10 O +
and O +
20 O +
μM O +
) O -
. O +

The O +
relationships O +
between O +
the O +
peak O -
- O -
area O +
ratios O +
of O +
analytes O +
to O +
I.S. O +
and O +
the O +
concentrations O +
of O +
analytes O +
were O +
linear O -
. O +

According O +
to O +
method O +
A O -
, O +
the O +
regression O +
equations O +
for O +
standard O +
solutions O +
without O +
urine O +
were O +
y O +
= O -
0.1300x O +
+ O -
0.1183 O +
( O -
r O +
= O -
0.9999 O -
) O +
for O +
Pro O -
– O -
Hyp O -
, O +
y O +
= O -
0.1384x O +
−0.0001 O +
( O -
r O +
= O -
0.9999 O -
) O +
for O +
Pro O -
– O -
Gly O -
, O +
y O +
= O -
0.1069x O +
+ O -
0.0020 O +
( O -
r O +
= O -
0.9998 O -
) O +
for O +
Pro O -
– O -
Pro O -
, O +
y O +
= O -
0.1135x O +
+ O -
0.0735 O +
( O -
r O +
= O -
0.9994 O -
) O +
for O +
Pro O +
and O +
y O +
= O -
0.1140x O +
+ O -
0.0066 O +
( O -
r O +
= O -
0.9996 O -
) O +
for O +
Hyp O -
, O +
where O +
y O +
is O +
the O +
peak O -
- O -
area O +
ratio O +
of O +
analyte O +
to O +
I.S. O +
and O +
x O +
is O +
the O +
concentration O +
of O +
analyte O +
( O -
μM O +
) O -
. O +

The O +
recoveries O +
were O +
obtained O +
from O +
the O +
slope O +
ratios O +
of O +
regression O +
equations O +
of O +
analytes O +
with O -
/ O -
without O +
urine O -
. O +

The O +
slopes O +
of O +
regression O +
equations O +
and O +
the O +
recoveries O +
by O +
methods O +
A O +
and O +
B O +
are O +
shown O +
in O +
Table O +
1 O +
. O +

The O +
recoveries O +
of O +
the O +
analytes O +
except O +
Pro O -
– O -
Gly O +
by O +
method O +
A O +
were O +
almost O +
100 O -
% O -
, O +
while O +
those O +
by O +
method O +
B O +
were O +
very O +
low O -
. O +

In O +
method O +
B O -
, O +
some O +
organic O +
solvents O +
such O +
as O +
chloroform O -
, O +
benzene O -
, O +
ethyl O +
acetate O +
and O +
diethyl O +
ether O +
instead O +
of O +
dichloromethane O +
were O +
also O +
used O -
. O +

However O -
, O +
the O +
maximum O +
peak O +
areas O +
of O +
DMS O -
- O -
derivatives O +
were O +
obtained O +
with O +
use O +
of O +
dichloromethane O -
. O +

In O +
addition O -
, O +
when O +
the O +
concentration O +
of O +
Na2 O +
CO3 O +
( O -
1 O -
, O +
5 O -
, O +
10 O +
and O +
20 O +
mM O +
) O +
for O +
stripping O +
of O +
the O +
derivatives O +
of O +
prolyl O +
dipeptides O +
was O +
examined O -
, O +
maximum O +
peak O +
areas O +
were O +
obtained O +
by O +
use O +
of O +
more O +
than O +
5 O +
mM O +
Na2 O +
CO3 O +
. O +

These O +
results O +
suggest O +
that O +
method O +
A O +
is O +
appropriate O +
for O +
the O +
determination O +
of O +
urinary O +
prolyl O +
dipeptides O -
. O +

Incidentally O -
, O +
when O +
the O +
recoveries O +
of O +
standard O +
prolyl O +
dipeptides O -
, O +
Pro O -
, O +
Hyp O +
( O -
0.02 O -
, O +
0.2 O -
, O +
2 O +
and O +
10 O +
nmol O +
each O -
) O +
and O +
I.S. O +
from O +
Bond O +
Elut O +
C18 O +
were O +
examined O -
, O +
the O +
recoveries O +
were O +
96.1–101.1 O -
% O +
( O -
except O +
the O +
seven O +
species O +
prolyl O +
dipeptides O +
mentioned O +
above O -
) O -
. O +

Therefore O -
, O +
for O +
determination O +
of O +
urinary O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O -
, O +
method O +
A O +
was O +
employed O +
and O +
the O +
regression O +
equations O +
in O +
water O +
described O +
above O +
were O +
used O -
. O +

However O -
, O +
the O +
estimated O +
values O +
of O +
urinary O +
Pro O -
– O -
Gly O +
were O +
corrected O +
using O +
the O +
mean O +
value O +
( O -
0.866 O -
, O +
n O +
= O -
6 O -
) O +
of O +
recovery O +
derived O +
from O +
additional O +
experiments O +
using O +
another O +
three O +
urine O +
samples O +
( O -
the O +
recoveries O -
: O +
85.8 O -
, O +
85.9 O +
and O +
86.8 O -
% O -
) O -
. O +

The O +
within O -
- O -
day O +
and O +
between O -
- O -
day O +
precisions O +
of O +
method O +
A O +
were O +
evaluated O +
using O +
three O +
urine O +
samples O -
. O +

The O +
within O -
- O -
day O +
precision O +
was O +
examined O +
with O +
ten O +
replicate O +
assays O +
in O +
each O +
one O +
day O +
and O +
the O +
between O -
- O -
day O +
precision O +
by O +
assays O +
on O +
five O +
different O +
days O -
. O +

As O +
shown O +
in O +
Table O +
2 O +
, O +
RSDs O +
of O +
the O +
within O -
- O -
day O +
and O +
between O -
- O -
day O +
precisions O +
were O +
1.5–4.8 O +
and O +
1.7–5.8 O -
% O -
, O +
respectively O -
. O +

3.6 O +
Selection O +
of O +
I.S. O +
Some O +
secondary O +
amino O +
acids O +
( O -
10 O +
μM O +
each O -
) O +
were O +
examined O +
to O +
select O +
I.S. O +
Although O +
the O +
peaks O +
due O +
to O +
l O +
-azetidine-2-calboxylic O +
acid O -
, O +
l O +
-thioproline O -
, O +
isonipecotic O +
acid O -
, O +
nipecotic O +
acid O +
and O +
dl O +
-pipecolic O +
acid O +
were O +
eluted O +
at O +
23.0 O -
, O +
34.7 O -
, O +
36.9 O -
, O +
39.9 O +
and O +
42.0 O +
min O -
, O +
respectively O -
, O +
those O +
peaks O +
overlapped O +
with O +
peaks O +
due O +
to O +
urinary O +
components O -
. O +

The O +
peak O +
due O +
to O +
3,4-dehydro O -
- O -
dl O +
-proline O +
( O -
31.0 O +
min O -
) O +
was O +
successfully O +
separated O +
from O +
those O +
of O +
urinary O +
components O -
. O +

3.7 O +
Influence O +
of O +
amino O +
acids O +
The O +
influence O +
of O +
amino O +
acids O +
on O +
determination O +
of O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O +
by O +
method O +
A O +
was O +
examined O +
with O +
urine O +
spiked O +
with O +
25 O +
species O +
of O +
primary O +
amino O +
acids O +
( O -
Ala O -
, O +
Arg O -
, O +
Asp O -
, O +
Asn O -
, O +
Cit O -
, O +
Cys O -
, O +
Cys O -
– O -
Cys O -
, O +
Glu O -
, O +
Gln O -
, O +
Gly O -
, O +
His O -
, O +
Hse O -
, O +
Ile O -
, O +
Leu O -
, O +
Lys O -
, O +
Met O -
, O +
Orn O -
, O +
Phe O -
, O +
Ser O -
, O +
Thr O -
, O +
Trp O -
, O +
Tyr O -
, O +
Val O -
, O +
γ O -
- O -
aminobutyric O +
acid O +
and O +
ϵ-aminocaproic O +
acid O -
, O +
5 O +
nmol O +
each O -
) O -
. O +

These O +
amino O +
acids O +
did O +
not O +
interfere O +
with O +
the O +
determination O +
of O +
Pro O -
– O -
Hyp O -
, O +
Pro O -
– O -
Gly O -
, O +
Pro O -
– O -
Pro O -
, O +
Pro O +
and O +
Hyp O -
. O +

3.8 O +
Determination O +
of O +
urinary O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O +
The O +
concentrations O +
of O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O +
in O +
urine O +
from O +
ten O +
healthy O +
volunteers O +
( O -
Japanese O +
staff O +
and O +
students O +
in O +
our O +
laboratory O -
) O +
who O +
were O +
eating O +
self O -
- O -
selected O +
diets O +
were O +
measured O +
by O +
method O +
A. O +
Overnight O +
urine O +
was O +
collected O +
in O +
the O +
early O +
morning O +
and O +
stored O +
at O +
−20 O -
° O -
C O +
until O +
use O -
. O +

The O +
concentrations O +
of O +
urinary O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O +
are O +
given O +
in O +
Table O +
3 O +
. O +

The O +
mean O +
values O +
( O -
mean±SD O -
) O +
of O +
urinary O +
Pro O -
– O -
Hyp O -
, O +
Pro O -
– O -
Gly O -
, O +
Pro O -
– O -
Pro O -
, O +
Pro O +
and O +
Hyp O +
were O +
97.6±28.2 O -
, O +
2.74±1.48 O -
, O +
2.08±1.13 O -
, O +
6.71±3.34 O +
and O +
2.30±1.59 O +
nmol O -
/ O -
mg O +
creatinine O -
, O +
respectively O -
. O +

When O +
the O +
concentration O +
of O +
Hyp O +
in O +
hydrolysed O +
urine O +
( O -
total O +
Hyp O -
) O +
was O +
measured O +
according O +
to O +
the O +
method O +
reported O +
previously O +
[ O -
20 O -
] O +
, O +
the O +
concentration O +
ratios O +
( O -
% O -
, O +
mean±SD O -
) O +
of O +
Pro O -
– O -
Hyp O +
and O +
free O +
Hyp O +
to O +
total O +
Hyp O +
were O +
45.7–64.5 O -
% O +
( O -
53.1±6.7 O -
% O -
) O +
and O +
0.4–2.2 O -
% O +
( O -
1.3±0.7 O -
% O -
) O -
, O +
respectively O -
. O +

These O +
values O +
were O +
similar O +
to O +
the O +
values O +
reported O +
previously O +
[ O -
2,3,19 O -
] O +
. O +

The O +
proposed O +
method O +
for O +
the O +
determination O +
of O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O +
in O +
urine O +
is O +
highly O +
sensitive O +
and O +
reliable O -
. O +

As O +
the O +
sensitive O +
and O +
reliable O +
determination O +
of O +
these O +
components O +
can O +
provide O +
useful O +
information O +
for O +
diagnosis O +
and O +
prognosis O +
of O +
diseases O -
, O +
the O +
proposed O +
method O +
may O +
be O +
useful O +
for O +
biochemical O +
and O +
clinical O +
research O -
. O +

Further O +
clinical O +
research O +
including O +
a O +
determination O +
of O +
bone O +
metastasis O +
stages O +
in O +
cancer O +
patients O +
is O +
now O +
progressing O +
in O +
our O +
laboratories O -
. O +

The O +
eight O +
enzymes B-Gene +
of O +
the O +
tricarboxylic O +
acid O +
( O -
TCA O -
) O +
cycle O +
are O +
encoded O +
by O +
at O +
least O +
15 O +
different O +
nuclear O +
genes O +
in O +
Saccharomyces O +
cerevisiae O -
. O +

We O +
have O +
constructed O +
a O +
set O +
of O +
yeast O +
strains O +
defective O +
in O +
these O +
genes O +
as O +
part O +
of O +
a O +
comprehensive O +
analysis O +
of O +
the O +
interactions O +
among O +
the O +
TCA B-Gene +
cycle I-Gene +
proteins I-Gene -
. O +

The O +
15 O +
major O +
TCA O +
cycle O +
genes O +
can O +
be O +
sorted O +
into O +
five O +
phenotypic O +
categories O +
on O +
the O +
basis O +
of O +
their O +
growth O +
on O +
nonfermentable O +
carbon O +
sources O -
. O +

We O +
have O +
previously O +
reported O +
a O +
novel O +
phenotype O +
associated O +
with O +
mutants O +
defective O +
in O +
the O +
IDH2 O +
gene O +
encoding O +
the O +
Idh2p B-Gene +
subunit I-Gene +
of O +
the O +
NAD+-dependent B-Gene +
isocitrate I-Gene +
dehydrogenase I-Gene +
( O -
NAD B-Gene -
- I-Gene -
IDH I-Gene -
) O -
. O +

Null O +
and O +
nonsense O +
idh2 O +
mutants O +
grow O +
poorly O +
on O +
glycerol O -
, O +
but O +
growth O +
can O +
be O +
enhanced O +
by O +
extragenic O +
mutations O -
, O +
termed O +
glycerol O +
suppressors O -
, O +
in O +
the O +
CIT1 O +
gene O +
encoding O +
the O +
TCA B-Gene +
cycle I-Gene +
citrate I-Gene +
synthase I-Gene +
and O +
in O +
other O +
genes O +
of O +
oxidative O +
metabolism O -
. O +

The O +
TCA O +
cycle O +
mutant O +
collection O +
was O +
utilized O +
to O +
search O +
for O +
other O +
genes O +
that O +
can O +
suppress O +
idh2 O +
mutants O +
and O +
to O +
identify O +
TCA O +
cycle O +
genes O +
that O +
display O +
a O +
similar O +
suppressible O +
growth O +
phenotype O +
on O +
glycerol O -
. O +

Mutations O +
in O +
7 O +
TCA O +
cycle O +
genes O +
were O +
capable O +
of O +
functioning O +
as O +
suppressors O +
for O +
growth O +
of O +
idh2 O +
mutants O +
on O +
glycerol O -
. O +

The O +
only O +
other O +
TCA O +
cycle O +
gene O +
to O +
display O +
the O +
glycerol O -
- O -
suppressor O -
- O -
accumulation O +
phenotype O +
was O +
IDH1 O -
, O +
which O +
encodes O +
the O +
companion O +
Idh1p O +
subunit O +
of O +
NAD B-Gene -
- I-Gene -
IDH I-Gene -
. I-Gene +

These O +
results O +
provide O +
genetic O +
evidence O +
that O +
NAD B-Gene -
- I-Gene -
IDH I-Gene +
plays O +
a O +
unique O +
role O +
in O +
TCA O +
cycle O +
function O -
. O +

A O +
mixture O +
of O +
oligosaccharides O +
produced O +
by O +
beta B-Gene -
- I-Gene -
galactosidase I-Gene +
using O +
lactose O +
as O +
a O +
substrate O +
was O +
fractionated O +
according O +
to O +
degree O +
of O +
polymerization O +
using O +
gel O +
filtration O -
, O +
followed O +
by O +
high O -
- O -
pH O +
anion O -
- O -
exchange O +
chromatography O -
. O +

The O +
fractions O +
obtained O +
were O +
analyzed O +
using O +
monosaccharide O +
analysis O -
, O +
methylation O +
analysis O -
, O +
mass O +
spectrometry O -
, O +
and O +
NMR O +
spectroscopy O -
. O +

Twelve O +
novel O +
non O -
- O -
reducing O +
oligosaccharides O +
were O +
characterized O -
, O +
namely O -
, O +
[ O -
beta O -
- O -
D O -
- O -
Galp- O -
( O -
1 O -
- O -
->4 O -
) O -
] O -
n O -
- O -
alpha O -
- O -
D O -
- O -
Glcp- O +
( O -
1<-->1 O -
) O -
-beta O -
- O -
D O -
- O -
Galp O -
[ O -
- O -
( O -
4<--1 O -
) O -
-beta O -
- O -
D O -
- O -
Galp O -
] O -
m O -
, O +
with O +
n O -
, O +
m O +
= O +
( O -
1 O -
, O +
2 O -
, O +
3 O -
, O +
or O +
4 O -
) O +
and O +
beta O -
- O -
D O -
- O -
Galp- O -
( O -
1 O -
- O -
->2 O -
) O -
-alpha O -
- O -
D O -
- O -
Glcp- O +
( O -
1<-->1 O -
) O -
-beta O -
- O -
D O -
- O -
Galp O -
. O +

Concentration O +
of O +
L O -
- O -
cystathionine O +
was O +
distinctly O +
increased O +
in O +
rabbit O +
brain O +
within O +
the O +
period O +
of O +
maximal O +
action O +
of O +
drugs O -
, O +
stimulating O +
the O +
central O +
nervous O +
system O +
( O -
phenamine O -
, O +
strychnine O +
corasole O -
) O -
. O +

A O +
distinct O +
decrease O +
in O +
content O +
of O +
L O -
- O -
cystathionine O +
was O +
observed O +
within O +
one O +
hour O +
after O +
the O +
administration O +
of O +
strychnine O +
and O +
corasole O -
. O +

Lactosylceramide B-Gene +
synthase I-Gene +
is O +
an O +
enzyme B-Gene +
that O +
catalyzes O +
the O +
transfer O +
of O +
galactose O +
from O +
UDP O -
- O -
Gal O +
to O +
glucosylceramide O -
, O +
and O +
thus O +
participates O +
in O +
the O +
biosynthesis O +
of O +
most O +
glycolipids O +
in O +
mammals O -
. O +

We O +
have O +
isolated O +
and O +
sequenced O +
the O +
cDNA O +
clone O +
encoding O +
human O +
lactosylceramide B-Gene +
synthase I-Gene -
. O +

The O +
deduced O +
amino O +
acid O +
sequence O +
of O +
the O +
human O +
lactosylceramide B-Gene +
synthase I-Gene +
showed O +
94.2 O -
% O +
identity O +
with O +
rat O +
lactosylceramide B-Gene +
synthase I-Gene -
. O +

Northern O +
blotting O +
analysis O +
revealed O +
that O +
lactosylceramide B-Gene +
synthase I-Gene +
mRNA O +
was O +
expressed O +
in O +
various O +
tissues O -
, O +
with O +
the O +
highest O +
level O +
in O +
brain O +
and O +
adrenal O +
gland O -
. O +

Microsomal O +
cytochrome B-Gene +
P450-dependent I-Gene +
lauric B-Gene +
acid I-Gene +
hydroxylase I-Gene +
activities O +
were O +
characterized O +
in O +
liver O -
, O +
kidney O -
, O +
and O +
intestinal O +
mucosa O +
of O +
the O +
sea O +
bass O +
( O -
Dicentrarchus O +
labrax O -
) O -
. O +

Microsomes O +
from O +
these O +
organs O +
generated O +
( O -
omega-1 O -
) O -
-hydroxylauric O +
acid O +
and O +
a O +
mixture O +
of O +
positional O +
isomers O +
including O +
( O -
omega O -
) O -
- O -
, O +
( O -
omega-2 O -
) O -
- O -
, O +
( O -
omega-3 O -
) O -
- O +
and O +
( O -
omega-4 O -
) O -
-hydroxylauric O +
acids O -
, O +
which O +
were O +
identified O +
by O +
RP O -
- O -
HPLC O +
and O +
GC O -
- O -
MS O +
analysis O -
. O +

Peroxisome O +
proliferators O -
, O +
such O +
as O +
clofibrate O +
and O +
especially O +
di O -
( O -
2-ethylhexyl O -
) O +
phthalate O -
, O +
increased O +
kidney O +
microsomal O +
lauric B-Gene +
acid I-Gene +
hydroxylase I-Gene +
activities O -
. O +

The O +
synthesis O +
of O +
11-hydroxylauric O +
acid O +
was O +
enhanced O +
5.3-fold O +
in O +
kidney O +
microsomes O -
. O +

Liver O +
microsomal O +
lauric B-Gene +
acid I-Gene +
hydroxylase I-Gene +
activities O +
were O +
weakly O +
affected O +
and O +
no O +
significant O +
induction O +
was O +
found O +
in O +
small O +
intestine O +
microsomes O +
from O +
clofibrate O +
or O +
di O -
( O -
2-ethylhexyl O -
) O +
phthalate O -
- O -
treated O +
fish O -
. O +

The O +
differences O +
in O +
lauric O +
acid O +
metabolisation O +
and O +
the O +
tissue O -
- O -
specific O +
induction O +
by O +
peroxisome O +
proliferators O +
suggest O +
the O +
involvement O +
of O +
several O +
P450s B-Gene +
in O +
this O +
reaction O -
. O +

Incubations O +
of O +
liver O +
and O +
kidney O +
microsomes O +
with O +
lauric O +
acid O +
analogues O +
( O -
11- O +
or O +
10-dodecynoic O +
acids O -
) O +
resulted O +
in O +
a O +
time- O +
and O +
concentration O -
- O -
dependent O +
loss O +
of O +
lauric B-Gene +
acid I-Gene +
hydroxylase I-Gene +
activities O -
. O +

The O +
induction O +
of O +
these O +
activities O +
in O +
fish O +
by O +
phthalates O -
, O +
which O +
are O +
widely O -
- O -
distributed O +
environmental O +
pollutants O -
, O +
may O +
be O +
taken O +
into O +
consideration O +
for O +
the O +
development O +
of O +
new O +
biomarkers O -
. O +

6-Chloro-7-arylamino-5,8-isoquinolinediones O +
were O +
newly O +
synthesized O +
and O +
evaluated O +
for O +
in O +
vitro O +
cytotoxic O +
activities O +
against O +
five O +
human O +
solid O +
tumor O +
cell O +
lines O -
. O +

Among O +
them O -
, O +
5b O -
, O +
5c O +
and O +
5d O +
exhibited O +
potent O +
activities O +
against O +
the O +
cell O +
lines O +
HCT-15 O +
and O +
SK O -
- O -
MEL-2 O -
. O +

We O +
developed O +
a O +
novel O +
fluorometric O +
assay O +
method O +
for O +
the O +
measurement O +
of O +
glycosyltransferase B-Gene +
activities O +
using O +
mono- O +
and O +
di O -
- O -
saccharides O +
aminated O +
and O +
tagged O +
with O +
7-hydroxycoumarin-3-carboxylic O +
acid O +
( O -
coumarin O -
) O +
as O +
substrates O -
, O +
N O -
- O -
acetylglucosamine O +
( O -
GlcNAc O -
) O -
-coumarin O +
for O +
beta1,4-galactosyltransferase B-Gene +
from O +
bovine O +
milk O +
and O +
Gal O +
beta1 O -
- O -
4GlcNAc O -
- O -
coumarin O +
for O +
alpha2,3- B-Gene +
and O +
alpha2,6-sialyltransferases B-Gene +
from O +
rat O +
liver O -
. O +

Using O +
Gal O +
beta1 O -
- O -
3GlcNAc O +
and O +
Gal O +
beta1 O -
- O -
4Glc O -
- O -
NAc O -
- O -
coumarin O -
, O +
alpha1,3 B-Gene -
/ I-Gene -
4- I-Gene +
and O +
alpha1,3-fucosyltransferase B-Gene +
activities O +
were O +
also O +
determined O -
, O +
respectively O -
. O +

These O +
enzymatic O +
products O +
liberated O +
by O +
the O +
reactions O +
of O +
glycosyltransferases B-Gene +
in O +
the O +
presence O +
of O +
sugar O +
nucleotides O -
, O +
were O +
separated O +
by O +
a O +
normal O +
phase O +
or O +
an O +
ion O -
- O -
pair O +
reversed O +
phase O +
HPLC O +
with O +
an O +
isocratic O +
elution O +
and O +
fluorescence O +
detection O -
. O +

We O +
applied O +
this O +
assay O +
method O +
to O +
determine O +
the O +
glycosyltransferase B-Gene +
activities O +
in O +
8 O +
kinds O +
of O +
human O +
tumor O +
cell O +
lines O -
, O +
including O +
the O +
cell O +
lines O +
derived O +
from O +
hepatocytes O +
( O -
HuH-7 O -
, O +
HepG2 O -
) O -
, O +
colonic O +
cells O +
( O -
Colo205 O -
, O +
HT-29 O -
) O -
, O +
myelocytes O +
( O -
HL-60 O -
, O +
U-937 O -
) O -
, O +
B O -
- O -
lymphocytes O +
( O -
Daudi O -
) O +
and O +
T O -
- O -
lymphocytes O +
( O -
Jurkat O -
) O -
. O +

This O +
assay O +
method O +
is O +
accurate O +
and O +
easy O +
compared O +
with O +
other O +
isotopic O +
and O +
non O -
- O -
isotopic O +
assay O +
methods O -
, O +
and O +
is O +
sensitive O +
enough O +
to O +
measure O +
glycosyltransferase B-Gene +
activities O +
in O +
cell O +
homogenates O -
. O +

Anandamide O +
( O -
N O -
- O -
arachidonoylethanolamine O -
) O +
and O +
six O +
fatty O +
acid O +
ethanolamides O +
were O +
synthesized O +
and O +
their O +
pharmacological O +
effects O +
in O +
mice O +
were O +
assessed O +
using O +
catalepsy O -
, O +
hypothermia O +
and O +
pentobarbital O -
- O -
induced O +
sleep O +
prolongation O +
as O +
indices O -
. O +

The O +
effects O +
of O +
phenylmethylsulfonyl O +
fluoride O +
( O -
PMSF O -
) O +
pretreatment O +
on O +
anandamide O +
effects O +
were O +
also O +
evaluated O +
and O +
discussed O +
in O +
relation O +
to O +
inhibition O +
of O +
anandamide B-Gene +
amidohydrolase I-Gene +
in O +
mouse O +
brain O +
and O +
liver O -
. O +

The O +
cataleptogenic O +
effect O +
of O +
anandamide O +
( O -
ED50=6.0 O +
mg O -
/ O -
kg O -
, O +
i.v O -
. O -
) O +
was O +
4 O +
to O +
6 O +
times O +
more O +
active O +
than O +
those O +
of O +
N O -
- O -
oleoyl- O +
( O -
ED50=26.5 O +
mg O -
/ O -
kg O -
, O +
i.v O -
. O -
) O +
and O +
N O -
- O -
linoleoylethanolamine O +
( O -
ED50=37.5 O +
mg O -
/ O -
kg O -
, O +
i.v O -
. O -
) O -
, O +
although O +
the O +
peak O +
time O +
in O +
the O +
effect O +
was O +
observed O +
within O +
1 O +
min O +
after O +
i.v O -
. O +

administration O -
. O +

None O +
of O +
the O +
saturated O +
fatty O +
acid O +
ethanolamides O +
( O -
N O -
- O -
myristoyl- O -
, O +
N O -
- O -
palmitoyl- O -
, O +
N O -
- O -
stearoyl- O +
and O +
N O -
- O -
arachidoylethanolamine O -
) O +
showed O +
a O +
positive O +
response O +
in O +
the O +
cataleptogenic O +
effect O +
even O +
at O +
a O +
dose O +
up O +
to O +
40 O +
mg O -
/ O -
kg O +
i.v O -
. O +

Anandamide O -
, O +
N O -
- O -
linoleoyl- O -
, O +
N O -
- O -
oleoyl- O +
and O +
N O -
- O -
myristoylethanolamine O +
( O -
10 O +
mg O -
/ O -
kg O -
, O +
i.v O -
. O -
) O +
produced O +
a O +
significant O +
hypothermia O +
( O -
0.19 O +
to O +
0.59 O +
degrees O +
C O -
) O +
at O +
5 O +
to O +
15 O +
min O +
after O +
administration O -
. O +

The O +
duration O +
of O +
the O +
effects O +
of O +
these O +
ethanolamides O +
was O +
also O +
relatively O +
short O -
. O +

Anandamide O -
, O +
N O -
- O -
linoleoyl- O -
, O +
N O -
- O -
oleoyl- O +
and O +
N O -
- O -
palmitoylethanolamine O +
( O -
5 O +
or O +
10 O +
mg O -
/ O -
kg O -
, O +
i.v O -
. O -
) O +
significantly O +
prolonged O +
pentobarbital O -
- O -
induced O +
sleeping O +
time O +
by O +
148 O -
- O -
207 O -
% O +
of O +
control O +
sleeping O +
time O -
. O +

The O +
cataleptogenic O +
effect O +
of O +
anandamide O +
was O +
markedly O +
potentiated O +
by O +
pretreatment O +
of O +
mice O +
with O +
PMSF O +
( O -
100 O +
mg O -
/ O -
kg O -
, O +
i.p O -
. O -
) O -
. O +

The O +
ED50 O +
( O -
mg O -
/ O -
kg O -
, O +
i.v O -
. O -
) O +
of O +
anandamide O +
was O +
0.48 O +
( O -
0.24 O -
- O -
0.96 O -
) O +
in O +
PMSF O -
- O -
pretreated O +
mice O -
. O +

The O +
pretreatment O +
of O +
mice O +
with O +
PMSF O +
significantly O +
decreased O +
the O +
metabolic O +
clearance O +
rate O +
of O +
anandamide O +
in O +
microsomal O +
fractions O +
of O +
liver O +
and O +
brain O -
. O +

Thus O -
, O +
the O +
Vmax O -
/ O -
Km O +
values O +
of O +
brain O +
and O +
hepatic O +
microsomes O +
were O +
26 O +
and O +
10 O -
% O -
, O +
respectively O -
, O +
as O +
compared O +
with O +
those O +
of O +
control O +
mice O -
. O +

The O +
present O +
study O +
demonstrated O +
that O +
anandamide O +
and O +
N O -
- O -
acylethanolamines O +
of O +
unsaturated O +
fatty O +
acids O +
exhibited O +
cannabinoid O -
- O -
like O +
effects O +
in O +
mice O -
, O +
and O +
that O +
anandamide B-Gene +
amidohydrolase I-Gene +
has O +
an O +
important O +
role O +
in O +
the O +
pharmacological O +
effects O +
of O +
anandamide O +
in O +
vivo O -
. O +

Localized O +
1H O +
NMR O +
homonuclear O +
J O +
editing O +
spectroscopy O +
was O +
used O +
to O +
measure O +
the O +
concentration O +
of O +
2-pyrrolidinone O +
( O -
PRDN O -
) O +
in O +
the O +
human O +
occipital O +
lobe O +
of O +
five O +
normal O +
and O +
six O +
epileptic O +
subjects O +
taking O +
vigabatrin O -
. O +

PRDN O +
is O +
a O +
lactam O +
cyclization O +
product O +
of O +
gamma O -
- O -
aminobutyric O +
acid O +
( O -
GABA O -
) O -
. O +

From O +
a O +
localized O +
volume O +
of O +
13.5 O +
cm3 O +
in O +
the O +
occipital O +
cortex O -
, O +
the O +
concentration O +
of O +
PRDN O +
ranged O +
from O +
0.2 O +
to O +
0.3 O +
micromol O -
/ O -
g O +
in O +
normal O +
subjects O -
, O +
whereas O +
in O +
epileptic O +
subjects O +
on O +
vigabatrin O +
PRDN O +
was O +
elevated O +
to O +
0.6 O +
+ O -
/- O +

0.1 O +
micromol O -
/ O -
g O -
. O +

The O +
elevated O +
PRDN O +
in O +
patients O +
on O +
vigabatrin O +
was O +
in O +
accord O +
with O +
raised O +
GABA O +
levels O +
compared O +
with O +
normals O -
. O +

1H O +
NMR O +
measurements O +
of O +
PRDN O +
will O +
be O +
important O +
in O +
assessment O +
of O +
the O +
role O +
of O +
this O +
metabolite O +
for O +
improved O +
seizure O +
control O -
. O +

Phosphatoquinones O +
A O +
and O +
B O +
were O +
isolated O +
from O +
the O +
cultured O +
broth O +
of O +
Streptomyces O +
sp. O +
TA-0363 O +
and O +
their O +
structures O +
were O +
elucidated O +
by O +
spectroscopic O +
analyses O -
. O +

Phosphatoquinones O +
A O +
and O +
B O +
inhibited O +
the O +
protein B-Gene +
tyrosine I-Gene +
phosphatase I-Gene +
activity O +
prepared O +
from O +
human O +
Ball-1 O +
cells O +
with O +
IC50 O +
of O +
28 O +
microM O +
and O +
2.9 O +
microM O -
, O +
respectively O -
. O +

The O +
biosynthesis O +
of O +
polyketomycin O +
was O +
investigated O +
by O +
feeding O +
13C O -
- O -
labeled O +
acetate O +
and O +
propionate O +
to O +
the O +
growing O +
cultures O +
of O +
Streptomyces O +
diastatochromogenes O +
Tu O +
6028 O -
. O +

13C O +
NMR O +
spectral O +
analysis O +
demonstrated O +
the O +
polyketide O +
origin O +
of O +
the O +
aglycone O +
and O +
the O +
dimethylsalicyloyl O +
moieties O -
. O +

The O +
O O -
- O -
methyl O +
group O +
and O +
6-CH3 O +
of O +
the O +
aglycone O +
as O +
well O +
as O +
3B O -
- O -
CH3 O +
of O +
L O -
- O -
axenose O +
and O +
3C O -
- O -
CH3 O +
of O +
the O +
salicyloyl O +
residue O +
were O +
labeled O +
by O +
feeding O +
L- O -
[ O -
methyl-13C O -
] O -
methionine O -
. O +

Both O +
deoxysugars O +
emerged O +
from O +
D O -
- O -
glucose O -
. O +

The O +
biosynthesis O +
of O +
the O +
aglycone O +
and O +
the O +
assembly O +
of O +
the O +
glycoside O +
are O +
discussed O -
. O +

The O +
polyketomycin O +
producing O +
strain O +
may O +
be O +
a O +
candidate O +
for O +
further O +
exploration O +
in O +
combinatorial O +
biosynthesis O -
. O +

The O +
effect O +
of O +
thirteen O +
different O +
fungal O +
azaphilones O -
, O +
which O +
have O +
a O +
common O +
6-iso O -
- O -
chromane O -
- O -
like O +
ring O -
, O +
was O +
tested O +
on O +
cholesteryl B-Gene +
ester I-Gene +
transfer I-Gene +
protein I-Gene +
( O -
CETP B-Gene -
) O +
activity O +
in O +
vitro O -
. O +

Chaetoviridin O +
B O +
showed O +
the O +
most O +
potent O +
inhibitory O +
activity O +
with O +
an O +
IC50 O +
value O +
of O +
< O +
6.2 O +
microM O -
, O +
followed O +
by O +
sclerotiorin O +
with O +
an O +
IC50 O +
value O +
of O +
19.4 O +
microM. O +
Rotiorin O -
, O +
chaetoviridin O +
A O +
and O +
rubrorotiorin O +
had O +
moderate O +
inhibitory O +
activity O +
( O -
IC50 O +
; O +
30 O +
approximately O +
40 O +
microM O -
) O -
, O +
but O +
others O +
showed O +
very O +
weak O +
or O +
no O +
inhibitory O +
activity O -
. O +

The O +
relationship O +
between O +
the O +
structures O +
and O +
their O +
inhibitory O +
activity O +
indicated O +
that O +
the O +
presence O +
of O +
an O +
electrophilic O +
ketone O -
( O -
s O -
) O +
and/or O +
enone O -
( O -
s O -
) O +
at O +
both O +
C-6 O +
and O +
C-8 O +
positions O +
in O +
the O +
isochromane O -
- O -
like O +
ring O +
is O +
essential O +
for O +
eliciting O +
CETP B-Gene +
inhibitory O +
activity O -
. O +

The O +
transfer O +
activity O +
of O +
both O +
CE O +
and O +
TG O +
was O +
inhibited O +
by O +
sclerotiorin O +
to O +
approximately O +
the O +
same O +
extent O +
( O -
IC50 O -
: O +
14.4 O +
and O +
10.3 O +
microM O -
, O +
respectively O -
) O -
. O +

A O +
model O +
of O +
the O +
reaction O +
suggested O +
that O +
sclerotiorin O +
reacts O +
with O +
a O +
primary O +
amine O +
of O +
amino O +
acids O +
such O +
as O +
lysine O +
in O +
the O +
protein O +
to O +
form O +
a O +
covalent O +
bond O -
. O +

Six O +
new O +
( O -
1 O -
- O -
6 O -
) O +
and O +
three O +
known O +
( O -
7 O -
- O -
9 O -
) O +
sesquiterpene O +
esters O +
were O +
isolated O +
from O +
the O +
roots O +
of O +
Celastrus O +
orbiculatus O -
. O +

The O +
structures O +
of O +
the O +
new O +
compounds O +
were O +
elucidated O +
as O +
1beta O -
- O -
acetoxy-6alpha O -
- O -
furoyloxy-9alpha O -
- O -
benzoyl O +
oxydihydro O -
- O -
beta O -
- O -
agarofur O +
an O +
( O -
1 O -
) O -
, O +
1beta O -
- O -
acetoxy-6alpha O -
- O -
benzoyloxy-9alpha O -
- O -
furoyloxydih O +
ydro O -
- O -
beta O -
- O -
agarofur O +
an O +
( O -
2 O -
) O -
, O +
1beta O -
- O -
acetoxy-6alpha O -
, O +
9alpha O -
- O -
difuroyloxydihydro O -
- O -
beta O -
- O -
agarofuran O +
( O -
3 O -
) O -
, O +
1beta O -
, O +
2beta O -
- O -
diacetoxy-6alpha O -
- O -
furoyloxy-9alpha O -
- O -
benzo O +
yloxydihydro O -
- O -
beta O -
- O -
agarof O +
uran O +
( O -
4 O -
) O -
, O +
1beta O -
- O -
acetoxy-2beta O -
, O +
6alpha O -
- O -
difuroyloxy-9alpha O -
- O -
benzoyloxydihydro O -
- O -
beta O +
-agarofuran O +
( O -
5 O -
) O -
, O +
and O +
1beta O -
- O -
acetoxy-2beta,6alpha O -
, O +
9alpha O -
- O -
tribenzoyloxydihydro O -
- O -
beta O -
- O -
agarofuran O +
( O -
6 O -
) O -
. O +

Compounds O +
4 O -
, O +
5 O -
, O +
and O +
7 O -
- O -
9 O +
were O +
shown O +
to O +
be O +
more O +
active O +
than O +
verapamil O +
in O +
reversing O +
vinblastine O +
resistance O +
in O +
multidrug O -
- O -
resistant O +
KB O -
- O -
V1 O +
cells O -
. O +

Late O -
- O -
onset O +
drinking O +
is O +
a O +
common O +
problem O +
in O +
elderly O +
people O +
related O +
to O +
stress O +
induced O +
by O +
social O +
isolation O -
. O +

Experiments O +
were O +
performed O +
in O +
order O +
to O +
evaluate O +
the O +
effects O +
of O +
alprazolam O -
, O +
a O +
benzodiazepine O +
agonist O +
anxiolytic O -
, O +
on O +
the O +
free O -
- O -
choice O +
ethanol O +
consumption O +
in O +
aged O +
rats O +
subjected O +
to O +
isolation O +
stress O -
. O +

The O +
animals O +
we O +
offered O +
a O +
two O -
- O -
bottle O +
choice O +
consumption O +
( O -
one O +
of O +
0.2 O -
% O +
saccharin O +
and O +
the O +
other O +
with O +
10 O -
% O +
ethanol O -
/ O -
0.2 O -
% O +
saccharin O -
) O +
and O +
then O +
exposed O +
to O +
4 O +
days O +
of O +
isolation O +
stress O +
on O +
an O +
irregular O -
, O +
unpredictable O +
schedule O -
. O +

Stress O +
resulted O +
in O +
significant O +
increase O +
in O +
ethanol O +
consumption O -
. O +

Treatment O +
with O +
alprazolam O +
( O -
1 O +
mg O -
/ O -
Kg O -
) O +
partially O +
reversed O +
this O +
adverse O +
effect O +
of O +
stress O -
. O +

The O +
elucidation O +
of O +
N O +
-glycans O +
in O +
plants O +
has O +
raised O +
increasing O +
interest O +
in O +
the O +
past O +
years O +
due O +
to O +
several O +
physiological O +
roles O +
which O +
could O +
be O +
attributed O +
to O +
these O +
structures O -
: O +
correct O +
folding O -
, O +
biological O +
activity O +
and O +
stability O +
of O +
proteins B-Gene +
can O +
be O +
affected O +
by O +
the O +
presence O +
of O +
N O +
-glycans O +
( O -
Driouich O -
, O +
Gonnet O -
, O +
Makkie O -
, O +
Laine O -
, O +
& O +
Faye O -
, O +
1989 O -
; O +
Sheldon O -
, O +
& O +
Bowles O -
, O +
1992 O -
; O +
Nagai O -
, O +
& O +
Yamaguchi O -
, O +
1993 O -
) O +
. O +

Moreover O -
, O +
the O +
involvement O +
of O +
N O +
-linked O +
oligosaccharides O +
in O +
plant O +
development O +
was O +
demonstrated O +
( O -
Ettlinger O -
, O +
Schindler O -
, O +
& O +
Lehle O -
, O +
1986 O -
) O +
. O +

Besides O +
these O +
physiological O +
roles O -
, O +
N O +
-glycans O +
can O +
influence O +
the O +
immunogenicity O +
of O +
glycoproteins B-Gene -
, O +
representing O +
antigenic O +
epitopes O +
by O +
themselves: O -
( O -
i O -
) O +
The O +
injection O +
of O +
horseradish B-Gene +
peroxidase I-Gene +
( O -
HRP B-Gene -
) O +
into O +
rabbits O +
resulted O +
in O +
polyclonal O +
anti O -
- O -
HRP B-Gene +
antiserum O +
which O +
also O +
reacted O +
with O +
many O +
other O +
plant O +
glycoproteins B-Gene +
carrying O +
glycans O +
similar O +
to O +
those O +
from O +
horseradish B-Gene +
peroxidase I-Gene -
. O +

β1,2-xylose O -
, O +
present O +
in O +
all O +
the O +
glycoprotein B-Gene -
– I-Gene -
glycans I-Gene +
of O +
the O +
study O -
, O +
but O +
absent O +
in O +
mammalian O +
organisms O -
, O +
was O +
supposed O +
to O +
be O +
responsible O +
for O +
the O +
observed O +
cross O -
- O -
reactivity O +
( O -
Faye O -
, O +
Johnson O -
, O +
Sturm O -
, O +
& O +
Chrispeels O -
, O +
1993 O -
) O +
. O +

( O -
ii O -
) O +
The O +
crossreactivity O +
of O +
a O +
polyclonal O +
antiserum O +
against O +
HRP B-Gene +
with O +
other O +
plant O +
glycoproteins B-Gene +
and O +
with O +
bee B-Gene -
- I-Gene -
venom I-Gene +
phospholipase I-Gene +
A2 I-Gene +
, O +
due O +
to O +
a O +
common O +
carbohydrate O +
epitope O +
could O +
be O +
demonstrated O -
. O +

( O -
Prenner O -
, O +
Mach O -
, O +
Glössl O -
, O +
& O +
März O -
, O +
1992 O +
; O +
Wilson O -
, O +
Harthill O -
, O +
Mullin O -
, O +
Ashford O -
, O +
& O +
Altmann O -
, O +
1998 O -
) O -
. O +

Chemical O +
defucosylation O +
as O +
well O +
as O +
ELISA O +
inhibition O +
experiments O +
indicated O +
that O +
α1,3-fucose O +
is O +
sufficient O +
to O +
create O +
an O +
immunogenic O +
epitope O -
. O +

The O +
assumption O +
that O +
N O +
-glycans O +
or O +
parts O +
of O +
these O +
structures O +
can O +
not O +
only O +
represent O +
antigenic O -
, O +
but O +
also O +
allergenic O +
epitopes O +
was O +
confirmed O +
by O +
Tretter O -
, O +
Altmann O -
, O +
Kubelka O -
, O +
März O -
, O +
and O +
Becker O +
( O -
1993 O -
) O +
; O +
in O +
the O +
case O +
of O +
bee O -
- O -
venom O +
allergic O +
patients O -
, O +
the O +
reactivity O +
of O +
IgE O +
antibodies B-Gene +
to O +
glycopeptides B-Gene +
of O +
phospholipase B-Gene +
A2 I-Gene +
was O +
demonstrated O -
; O +
the O +
proximal O +
α1,3-fucose O +
residue O +
was O +
identified O +
as O +
the O +
IgE O -
- O -
reactive O +
determinant O -
. O +

The O +
involvement O +
of O +
carbohydrate O +
structures O +
in O +
food O +
allergies O +
is O +
presently O +
discussed O +
quite O +
controversial O -
. O +

However O -
, O +
there O +
is O +
increasing O +
evidence O +
that O +
certain O +
carbohydrates O -
, O +
especially O +
N O +
-glycans O -
, O +
might O +
play O +
a O +
role O +
in O +
these O +
adverse O +
food O +
reactions O +
( O -
Aalberse O -
, O +
Koshte O -
, O +
& O +
Clemens O -
, O +
1981 O -
) O +
, O +
deduced O +
from O +
the O +
following O +
observations O -
: O +
many O +
proteins O +
which O +
are O +
of O +
allergological O +
importance O +
are O +
glycosylated O -
; O +
many O +
allergic O +
individuals O +
show O +
hypersensitivity O +
to O +
various O +
types O +
of O +
allergens O +
which O +
are O +
not O +
taxonomically O +
related O -
, O +
thus O +
suggesting O +
common O -
, O +
ubiquitous O +
structures O +
as O +
glycans O -
; O +
and O +
finally O -
, O +
many O +
pollen O +
allergic O +
patients O +
are O +
also O +
sensitive O +
to O +
certain O +
food O +
stuffs O -
, O +
which O +
also O +
implies O +
common O +
structural O +
epitopes O +
( O -
Möller O +
et O +
al. O -
, O +
1997 O -
) O +
. O +

In O +
immunological O +
investigations O -
, O +
mostly O +
indirect O +
methods O +
are O +
applied O +
which O +
shall O +
prove O +
the O +
involvement O +
of O +
glycans O +
in O +
allergic O +
reactions O -
, O +
such O +
as O +
deglycosylation O -
, O +
lectin B-Gene +
binding O +
and O +
compositional O +
analysis O +
( O -
Petersen O -
, O +
Becker O -
, O +
Moll O -
, O +
Blümke O -
, O +
& O +
Schlaak O -
, O +
1995 O -
; O +
Batanero O -
, O +
Villalba O -
, O +
Monsalve O -
, O +
& O +
Rodriguez O -
, O +
1996 O -
; O +
Tsuji O +
et O +
al. O -
, O +
1997 O -
) O +
; O +
however O -
, O +
structural O +
information O +
is O +
a O +
prerequisite O +
for O +
making O +
correct O +
conclusions O +
about O +
the O +
allergenicity O +
of O +
N O +
-glycans O +
or O +
epitopes O -
, O +
respectively O -
. O +

We O +
report O +
here O +
on O +
the O +
structural O +
elucidation O +
of O +
the O +
N O +
-linked O +
oligosaccharides O +
in O +
tomato O +
fruit O -
, O +
which O +
shall O +
help O +
to O +
understand O +
some O +
observed O +
cross O -
- O -
reactivities O +
reported O +
recently O +
by O +
Petersen O -
, O +
Vieths O -
, O +
Aulepp O -
, O +
Schlaak O -
, O +
and O +
Becker O +
( O -
1996 O -
) O +
. O +

2 O +
Results O +
2.1 O +
Preparation O +
of O +
N O +
-glycans O +
from O +
tomato O +
fruit O +
To O +
isolate O +
the O +
protein B-Gene +
fraction O +
from O +
tomato O +
fruit O -
, O +
two O +
procedures O +
were O +
carried O +
out O +
alternatively O -
: O +
on O +
the O +
one O +
hand O -
, O +
the O +
tomatoes O +
were O +
homogenized O +
in O +
an O +
appropriate O +
extraction O +
buffer O +
and O +
the O +
proteins B-Gene +
were O +
precipitated O +
by O +
addition O +
of O +
ammonium O +
sulfate O -
. O +

On O +
the O +
other O +
hand O -
, O +
a O +
low O -
- O -
temperature O +
acetone O +
powder O +
method O -
, O +
first O +
described O +
by O +
Clements O +
( O -
1965 O -
) O +
, O +
was O +
employed O -
; O +
the O +
proteins B-Gene +
precipitated O +
in O +
acetone O -
, O +
whereas O +
small O +
hydrophobic O +
compounds O +
( O -
flavonoids O -
, O +
carotinoids O -
) O +
as O +
well O +
as O +
most O +
of O +
the O +
salts O +
were O +
effectively O +
removed O -
; O +
the O +
proteins B-Gene +
were O +
extracted O +
from O +
the O +
resulting O +
powder O -
, O +
yielding O +
concentrations O +
of O +
180–310 O +
μg O -
/ O -
ml O +
as O +
determined O +
according O +
to O +
Bradford O +
( O -
1976 O -
) O +
; O +
these O +
values O +
are O +
in O +
the O +
same O +
order O +
of O +
magnitude O +
with O +
those O +
reported O +
by O +
Vieths O -
, O +
Schöning O -
, O +
Brockmann O -
, O +
and O +
Aulepp O +
( O -
1992 O -
) O +
, O +
who O +
used O +
this O +
procedure O +
for O +
the O +
preparation O +
of O +
several O +
fruit O +
and O +
vegetable O +
extracts O -
. O +

A O +
cation O -
- O -
exchange O +
chromatography O +
eliminated O +
most O +
of O +
the O +
by O -
- O -
products O +
in O +
the O +
sample O -
. O +

The O +
binding O +
fraction O +
was O +
assayed O +
for O +
the O +
amount O +
of O +
N O +
-acetylglucosamine O +
by O +
OPA O -
- O -
aminosugar O +
analysis O -
, O +
yielding O +
170–260 O +
nmol O +
GlcNAc O -
, O +
dependent O +
on O +
the O +
sample O -
. O +

From O +
these O +
values O +
it O +
could O +
be O +
deduced O +
that O +
about O +
85–130 O +
nmol O +
of O +
N O +
-glycans O +
are O +
present O +
in O +
the O +
glycopeptide B-Gene +
fractions O +
( O -
assuming O +
2 O +
moles O +
of O +
GlcNAc O -
/ O -
mol O +
of O +
oligosaccharide O -
) O -
. O +

The O +
oligosaccharides O +
were O +
released O +
from O +
the O +
glycopeptides B-Gene +
using O +
N B-Gene +
-glycosidase I-Gene +
A I-Gene -
, O +
separated O +
from O +
peptides B-Gene +
and O +
residual O +
glycopeptides B-Gene +
by O +
reverse O -
- O -
phase O +
chromatography O +
and O +
derivatized O +
with O +
the O +
fluorescent O +
tag O +
2-aminopyridine O -
. O +

2.2 O +
Separation O +
and O +
structural O +
elucidation O +
of O +
the O +
N O +
-linked O +
oligosaccharides O +
The O +
pyridylaminated O +
oligosaccharides O +
were O +
first O +
size O -
- O -
fractionated O +
on O +
MicroPak O +
AX-5 O +
( O -
Fig. O +
1 O +
Fig. O +
1 O +
A O -
) O -
; O +
11 O +
fractions O +
were O +
manually O +
collected O +
and O +
rechromatographed O +
if O +
necessary O -
. O +

Individual O +
fractions O +
were O +
subjected O +
to O +
reverse O -
- O -
phase O +
HPLC O -
, O +
yielding O +
a O +
total O +
of O +
sixteen O +
subfractions O +
( O -
additionally O -
, O +
an O +
aliquot O +
of O +
the O +
total O +
glycan O +
pool O +
was O +
applied O +
to O +
the O +
reverse O -
- O -
phase O +
system O -
, O +
see O +
Fig. O +
1 O +
B O -
) O -
. O +

The O +
elution O +
position O +
of O +
each O +
isolated O +
oligosaccharides O +
was O +
determined O +
on O +
both O +
columns O +
and O +
compared O +
to O +
those O +
from O +
reference O +
oligosaccharides O -
. O +

The O +
individual O +
peaks O +
were O +
then O +
subjected O +
to O +
exoglycosidase B-Gene +
treatment O +
using O +
α B-Gene -
- I-Gene -
mannosidase I-Gene -
, O +
β B-Gene -
- I-Gene -
N I-Gene +
-acetylhexosaminidase I-Gene +
and O +
endoglycosidase B-Gene +
H. I-Gene +
The O +
digests O +
were O +
again O +
chromatographed O +
on O +
reverse O -
- O -
phase O +
and O +
MicroPak O +
to O +
monitor O +
the O +
change O +
in O +
the O +
elution O +
behavior O +
( O +
Tables O +
1 O +
and O +
2 O +
) O -
. O +

Whenever O +
possible O -
, O +
a O +
tentatively O +
identified O +
peak O +
was O +
coinjected O +
with O +
the O +
corresponding O +
reference O +
oligosaccharide O +
to O +
verify O +
the O +
identical O +
elution O +
behavior O -
. O +

In O +
the O +
following O -
, O +
the O +
structural O +
assignment O +
of O +
each O +
peak O +
is O +
described O -
; O +
the O +
proposed O +
structures O +
are O +
depicted O +
in O +
Table O +
3 O +
. O +

2.3 O +
Complex O +
and O +
truncated O +
complex O +
glycans O +
The O +
retention O +
data O +
of O +
oligosaccharide O +
1-A O -
, O +
a O +
minor O +
component O +
present O +
in O +
all O +
the O +
tomato O +
samples O -
, O +
did O +
not O +
fit O +
with O +
any O +
of O +
the O +
available O +
reference O +
compounds O -
. O +

However O -
, O +
the O +
glycan O +
exhibited O +
resistance O +
to O +
α B-Gene -
- I-Gene -
mannosidase I-Gene +
treatment O -
. O +

The O +
identity O +
could O +
be O +
presumed O +
from O +
complete O +
digestion O +
of O +
MMF3 O +
from O +
phospholipase B-Gene +
A2 I-Gene +
with O +
α B-Gene -
- I-Gene -
mannosidase I-Gene -
, O +
resulting O +
in O +
a O +
peak O +
with O +
the O +
same O +
retention O +
behavior O +
as O +
oligosaccharide O +
1-A O +
on O +
both O +
columns O -
. O +

1-A O +
is O +
therefore O +
presumed O +
to O +
be O +
00F3 O +
. O +

Oligosaccharide O +
1-B O +
also O +
was O +
resistant O +
to O +
α B-Gene -
- I-Gene -
mannosidase I-Gene -
. I-Gene +

Together O +
with O +
its O +
size O +
and O +
having O +
the O +
same O +
retention O +
time O +
on O +
reverse O -
- O -
phase O +
HPLC O +
as O +
the O +
product O +
of O +
α B-Gene -
- I-Gene -
mannosidase I-Gene +
digestion O +
of O +
the O +
major O +
structure O +
of O +
horseradish B-Gene +
peroxidase I-Gene +
( O -
MMXF3 O +
) O -
, O +
1-B O +
was O +
deduced O +
to O +
be O +
00XF3 O +
. O +

The O +
third O +
peak O +
present O +
in O +
the O +
first O +
MicroPak O +
fraction O -
, O +
1-C O +
, O +
showed O +
a O +
remarkably O +
high O +
retention O +
time O +
on O +
reverse O -
- O -
phase O +
( O -
11.0 O +
glucose O +
units O -
) O +
and O +
sensitivity O +
to O +
α B-Gene -
- I-Gene -
mannosidase I-Gene -
, O +
resulting O +
in O +
a O +
reduction O +
of O +
the O +
retention O +
time O +
to O +
8.5 O +
glucose O +
units O -
. O +

This O +
corresponds O +
to O +
the O +
retention O +
time O +
of O +
completely O +
digested O +
MMX B-Gene +
from O +
zucchini O +
ascorbate B-Gene -
– I-Gene -
oxidase I-Gene +
( O -
Altmann O -
, O +
1998 O -
) O +
. O +

Coelution O +
of O +
the O +
limited O +
digestion O +
product O +
from O +
the O +
reference O +
oligosaccharide O +
with O +
1-C O +
yields O +
a O +
single O -
, O +
homogenous O +
peak O +
as O +
calculated O +
from O +
addition O +
of O +
the O +
peak O +
areas O -
; O +
1-C O +
was O +
therefore O +
found O +
to O +
be O +
M0X O +
. O +

Peak O +
2 O +
from O +
MicroPak O +
gave O +
a O +
single O +
peak O +
on O +
reverse O -
- O -
phase O -
, O +
which O +
was O +
sensitive O +
to O +
α B-Gene -
- I-Gene -
mannosidase I-Gene -
; O +
two O +
peaks O -
, O +
lacking O +
one O +
and O +
two O +
mannose O +
residues O +
as O +
deduced O +
from O +
the O +
retention O +
behavior O +
on O +
MicroPak O +
HPLC O -
, O +
were O +
obtained O -
. O +

The O +
second O +
peak O +
on O +
the O +
size O +
fractionation O +
column O +
exhibited O +
the O +
same O +
retention O +
time O +
as O +
fraction O +
1 O +
of O +
phospholipase B-Gene +
A2 I-Gene +
. O +

Therefore O -
, O +
the O +
structure O +
of O +
peak O +
2 O +
was O +
assumed O +
to O +
be O +
MM O +
. O +

This O +
was O +
confirmed O +
by O +
coinjection O +
of O +
MM O +
( O -
prepared O +
from O +
bovine O +
fibrin O -
) O -
, O +
resulting O +
in O +
a O +
single O +
peak O -
. O +

Furthermore O -
, O +
the O +
α B-Gene -
- I-Gene -
mannosidase I-Gene +
digest O +
of O +
fibrin B-Gene +
MM O +
behaved O +
exactly O +
the O +
same O +
way O +
as O +
the O +
digest O +
of O +
peak O +
2 O +
on O +
both O +
HPLC O +
columns O -
. O +

Oligosaccharide O +
3-A O +
exhibited O +
the O +
same O +
elution O +
behavior O +
in O +
both O +
HPLC O +
systems O +
as O +
the O +
reference O +
oligosaccharide O +
from O +
pineapple O +
stem O +
bromelain B-Gene -
, O +
M0XF3 O +
. O +

α B-Gene -
- I-Gene -
mannosidase I-Gene +
digestion O +
of O +
3-A O +
resulted O +
in O +
a O +
single O +
peak O -
, O +
which O +
coeluted O +
with O +
compound O +
1-B O +
( O -
5.2 O +
glucose O +
units O +
on O +
reverse O -
- O -
phase O +
HPLC O -
) O -
. O +

Peak O +
3-B O +
was O +
identified O +
based O +
on O +
its O +
size O +
and O +
retention O +
times O +
before O +
and O +
after O +
α B-Gene -
- I-Gene -
mannosidase I-Gene +
digestions O +
in O +
comparison O +
with O +
the O +
standard O +
MMX O +
from O +
fraction O +
1 O +
of O +
ascorbate B-Gene +
oxidase I-Gene -
. O +

Partial O +
digestion O +
with O +
α B-Gene -
- I-Gene -
mannosidase I-Gene +
resulted O +
in O +
a O +
peak O +
which O +
coeluted O +
with O +
compound O +
1-C. O +
The O +
final O +
proof O +
of O +
peak O +
identity O +
was O +
again O +
provided O +
by O +
coinjection O +
of O +
the O +
MMX O +
reference O +
compound O -
. O +

Peak O +
4 O -
, O +
which O +
appeared O +
to O +
be O +
non O -
- O -
homogenous O +
on O +
MicroPak O +
eluted O +
as O +
one O +
major O +
peak O +
( O -
> O -
85 O -
% O -
) O +
on O +
the O +
reverse O -
- O -
phase O +
column O -
. O +

The O +
minor O +
components O +
( O -
at O +
least O +
five O +
peaks O -
) O +
were O +
present O +
in O +
minute O +
quantities O +
and O +
could O +
not O +
be O +
analyzed O +
further O -
. O +

The O +
major O +
peak O +
was O +
subjected O +
to O +
α B-Gene -
- I-Gene -
mannosidase I-Gene +
digestion O -
, O +
yielding O +
two O +
signals O +
on O +
reverse O -
- O -
phase O +
HPLC O +
with O +
retention O +
times O +
of O +
5.1 O +
and O +
4.4 O +
glucose O +
units O -
, O +
thus O +
indicating O +
the O +
presence O +
of O +
two O +
mannose O +
residues O +
in O +
the O +
structure O -
. O +

The O +
first O +
peak O +
on O +
reverse O -
- O -
phase O +
coeluted O +
with O +
compound O +
1-A O -
, O +
thus O +
indicating O +
peak O +
4 O +
to O +
represent O +
MMF3 O +
. O +

This O +
assumption O +
could O +
be O +
proved O +
by O +
( O -
i O -
) O +
coinjection O +
of O +
phospholipase B-Gene +
A2 I-Gene +
-compound O +
5A O +
( O -
MMF3 O +
) O -
, O +
resulting O +
in O +
a O +
single O +
peak O +
and O +
( O -
ii O -
) O +
by O +
digesting O +
the O +
reference O +
compound O +
with O +
α B-Gene -
- I-Gene -
mannosidase I-Gene -
, O +
yielding O +
the O +
same O +
two O +
degradation O +
products O +
as O +
for O +
peak O +
4 O -
. O +

The O +
major O +
oligosaccharide O +
( O -
5 O -
) O +
in O +
all O +
the O +
samples O -
, O +
representing O +
47–59 O -
% O +
of O +
the O +
total O +
N O +
-glycan O +
amount O -
, O +
was O +
shown O +
to O +
be O +
susceptible O +
to O +
α B-Gene -
- I-Gene -
mannosidase I-Gene +
digestion O -
, O +
resulting O +
in O +
two O +
peaks O -
: O +
the O +
first O +
eluted O +
at O +
retention O +
times O +
identical O +
to O +
those O +
from O +
oligosaccharide O +
3-A O +
and O +
the O +
M0XF3 O +
reference O +
compound O -
, O +
the O +
second O +
coeluted O +
with O +
oligosaccharide O +
1-B O -
, O +
already O +
being O +
elucidated O +
as O +
00XF3 O +
. O +

Furthermore O -
, O +
additional O +
evidence O +
for O +
the O +
peak O +
being O +
MMXF3 O +
was O +
obtained O +
from O +
coinjection O +
of O +
the O +
reference O +
oligosaccharide O +
from O +
horseradish B-Gene +
peroxidase I-Gene -
, O +
yielding O +
a O +
single O +
peak O -
. O +

Fraction O +
6 O +
from O +
MicroPak O +
gave O +
two O +
peaks O +
on O +
the O +
reverse O -
- O -
phase O +
column O +
with O +
relative O +
retention O +
times O +
of O +
4.7 O +
and O +
5.8 O +
glucose O +
units O -
, O +
respectively O -
. O +

These O +
peaks O +
were O +
digestible O +
by O +
β B-Gene -
- I-Gene -
N I-Gene +
-acetyl I-Gene -
- I-Gene -
hexosaminidase I-Gene +
to O +
a O +
common O +
new O +
compound O -
, O +
exhibiting O +
the O +
same O +
elution O +
behavior O +
as O +
compound O +
5 O -
. O +

Furthermore O -
, O +
hornbeam O +
GnGnXF3 O +
digestion O +
with O +
the O +
same O +
enzyme B-Gene +
resulted O +
in O +
formation O +
of O +
the O +
two O +
peaks O +
mentioned O +
above O -
. O +

Again O -
, O +
the O +
final O +
proof O -
, O +
that O +
the O +
two O +
peaks O +
represent O +
MGnXF3 O +
and O +
GnMXF3 O +
was O +
accomplished O +
by O +
coinjection O +
of O +
the O +
corresponding O +
oligosaccharides O +
obtained O +
from O +
limited O +
β B-Gene -
- I-Gene -
N I-Gene +
-acetylglucosaminidase I-Gene +
digestion O +
of O +
hornbeam O +
pollen O +
GnGnXF3 O +
. O +

Oligosaccharide O +
8 O +
also O +
gave O +
one O +
major O +
peak O +
on O +
reverse O -
- O -
phase O +
HPLC O -
. O +

An O +
initial O +
hexosaminidase B-Gene +
digestion O +
resulted O +
in O +
the O +
presence O +
of O +
the O +
peaks O +
with O +
4.8 O +
and O +
5.8 O +
glucose O +
units O +
on O +
reverse O -
- O -
phase O -
, O +
thus O +
presumably O +
representing O +
the O +
above O +
mentioned O +
components O +
MGnXF3 O +
and O +
GnMXF3 O +
. O +

Complete O +
digestion O +
with O +
β B-Gene -
- I-Gene -
N I-Gene +
-acetyl I-Gene -
- I-Gene -
hexosaminidase I-Gene +
yielded O +
a O +
single O +
peak O -
, O +
coeluting O +
with O +
compound O +
5 O +
and O +
the O +
reference O +
compound O +
MMXF3 O +
. O +

Hence O -
, O +
oligosaccharide O +
8 O +
can O +
be O +
designated O +
to O +
be O +
GnGnXF3 O +
. O +

2.4 O +
Oligomannosidic O +
glycans O +
From O +
the O +
relative O +
retention O +
times O +
on O +
MicroPak O +
of O +
7.7 O -
, O +
8.7 O -
, O +
9.7 O +
and O +
10.6 O +
glucose O +
units O -
, O +
oligomannosidic O +
glycans O +
were O +
predicted O -
. O +

This O +
surmise O +
was O +
verified O +
by O +
performing O +
α B-Gene -
- I-Gene -
mannosidase I-Gene +
digestions O +
of O +
these O +
compounds O -
: O +
each O +
fraction O +
was O +
accessible O +
to O +
α B-Gene -
- I-Gene -
mannosidase I-Gene -
, O +
resulting O +
in O +
the O +
same O +
two O +
peaks O +
( O -
exhibiting O +
relative O +
retention O +
times O +
of O +
3.7 O -
/ O -
8.7 O +
and O +
2.9 O -
/ O -
7.2 O +
glucose O +
units O +
on O +
MicroPak O +
and O +
Hypersil O +
ODS O -
, O +
respectively O -
; O +
Table O +
1 O +
) O +
for O +
all O +
four O +
fractions O -
. O +

The O +
assumption O +
of O +
these O +
peaks O +
being O +
Manα1–6Manβ1–4GlcNAcβ1–4GlcNAc O -
– O -
pyridylamine O +
and O +
Manβ1–4GlcNAcβ1–4GlcNAc O -
– O -
pyridylamine O +
was O +
confirmed O +
by O +
a O +
limited O +
α B-Gene -
- I-Gene -
mannosidase I-Gene +
digest O +
of O +
MM O -
, O +
which O +
yielded O +
the O +
same O +
two O +
peaks O -
. O +

Furthermore O -
, O +
endoglycosidase B-Gene +
H I-Gene -
- O -
digests O +
of O +
the O +
peaks O +
7 O +
and O +
9–11 O +
resulted O +
in O +
the O +
formation O +
of O +
pyridylamino O -
– O -
GlcNAc O +
( O -
3.5 O +
glucose O +
units O +
on O +
reverse O -
- O -
phase O +
column O -
) O -
, O +
also O +
proving O +
the O +
presence O +
of O +
oligomannosidic O +
structures O -
. O +

Additionally O -
, O +
the O +
authentic O +
oligosaccharides O +
from O +
soybean O +
7S O +
-glycoprotein O +
were O +
used O +
to O +
confirm O +
the O +
identities O +
of O +
the O +
four O +
above O -
- O -
mentioned O +
peaks O -
. O +

Coelution O +
of O +
peaks O +
7 O -
, O +
9 O +
and O +
10 O +
was O +
observed O +
with O +
the O +
corresponding O +
reference O +
compounds O +
Man6 O +
GlcNAc2 O +
–Man8 O +
GlcNAc2 O +
. O +

Peak O +
9 O +
consisted O +
of O +
two O +
structural O +
isomers O +
( O -
M7.1 O +
and O +
M7.2 O +
) O -
, O +
occurring O +
in O +
relative O +
amounts O +
of O +
45 O +
and O +
55 O -
% O +
( O -
for O +
sample O +
NotAP2 O +
( O +
Table O +
4 O +
) O -
) O -
, O +
respectively O -
. O +

Man8 O +
GlcNAc2 O +
is O +
a O +
homogenous O +
peak O +
on O +
reverse O -
- O -
phase O +
( O -
4.7 O +
GcU O -
) O -
, O +
which O +
can O +
be O +
therefore O +
assigned O +
to O +
be O +
the O +
M8.1 O +
-isomer O -
. O +

The O +
elution O +
behavior O +
of O +
peak O +
11 O +
corresponds O +
to O +
published O +
data O +
( O -
Tomiya O +
et O +
al. O -
, O +
1991 O +
; O +
Kubelka O -
, O +
Altmann O -
, O +
Kornfeld O -
, O +
& O +
März O -
, O +
1994 O -
) O +
and O +
can O +
therefore O +
assigned O +
to O +
be O +
the O +
Man9 O +
-isomer O +
M9.1 O +
. O +

Additional O +
confirmation O +
of O +
the O +
results O +
was O +
obtained O +
by O +
MALDI O -
– O -
TOF O +
analysis O +
of O +
individual O +
HPLC O +
fractions O -
. O +

Fig. O +
2 O +
Fig. O +
2 O +
shows O +
the O +
mass O +
spectrum O +
of O +
fraction O +
5 O -
, O +
identified O +
as O +
MMXF3 O +
; O +
Table O +
5 O +
summarizes O +
the O +
results O -
, O +
which O +
corroborate O +
the O +
assignments O +
based O +
upon O +
two O -
- O -
dimensional O +
mapping O -
. O +

2.5 O +
Analysis O +
of O +
tomatoes O +
from O +
two O +
varieties O -
. O +

Analysis O +
of O +
red O +
and O +
green O +
tomatoes O +
Red O +
Notoro O -
- O -
type O +
tomatoes O +
were O +
subjected O +
to O +
the O +
two O +
different O +
isolation O +
procedures O +
in O +
order O +
to O +
monitor O +
the O +
impact O +
of O +
sample O +
preparation O +
on O +
the O +
glycan O +
pattern O +
in O +
terms O +
of O +
quality O +
and O +
quantity O -
. O +

Furthermore O -
, O +
red O +
and O +
green O +
San O +
Marzano O -
- O -
type O +
fruits O +
were O +
analyzed O +
to O +
distinguish O +
differences O +
in O +
the O +
glycan O +
pattern O +
due O +
to O +
the O +
variety O +
and O +
the O +
stage O +
of O +
ripening O -
, O +
respectively O -
. O +

Table O +
4 O +
shows O +
the O +
condensed O +
results O +
in O +
terms O +
of O +
relative O +
abundances O +
of O +
individual O +
fractions O +
on O +
the O +
total O +
N O +
-glycan O +
amounts O -
. O +

It O +
could O +
be O +
demonstrated O +
that O +
irrespective O +
of O +
the O +
preparation O +
method O +
very O +
similar O +
results O +
were O +
obtained O -
; O +
San O +
Marzano O -
- O -
type O +
tomatoes O +
contain O +
the O +
same O +
sixteen O +
structures O +
and O +
also O +
the O +
relative O +
quantities O +
were O +
rather O +
similar O +
in O +
the O +
examined O +
varieties O -
. O +

Interestingly O -
, O +
also O +
the O +
state O +
of O +
ripening O +
does O +
not O +
seem O +
to O +
have O +
a O +
significant O +
impact O +
on O +
the O +
appearance O +
of O +
the O +
glycan O +
pattern O +
in O +
terms O +
of O +
quality O +
and O +
quantity O +
although O +
it O +
has O +
to O +
be O +
stated O +
that O +
more O +
samples O +
have O +
to O +
be O +
analyzed O +
for O +
a O +
statistical O +
interpretation O -
. O +

3 O +
Discussion O +
The O +
N O +
-glycans O +
of O +
tomato O +
fruit O +
were O +
structurally O +
elucidated O -
, O +
thereby O +
comparing O +
two O +
varieties O +
as O +
well O +
as O +
two O +
stages O +
of O +
ripening O -
. O +

The O +
low O +
protein B-Gene +
content O +
of O +
tomatoes O +
and O +
the O +
high O +
amount O +
of O +
free O +
sugars O +
and O +
polysaccharides O +
( O -
Seymour O -
, O +
Colquhoun O -
, O +
DuPont O -
, O +
Parsely O -
, O +
& O +
Selvendran O -
, O +
1990 O -
; O +
York O -
, O +
Kumar O +
Kolli O -
, O +
Orlando O -
, O +
Albersheim O -
, O +
& O +
Darvill O -
, O +
1997 O -
) O +
complicated O +
the O +
effective O +
isolation O +
of O +
the O +
protein B-Gene +
fraction O -
. O +

However O -
, O +
the O +
employed O +
low O -
- O -
temperature O +
acetone O +
powder O +
method O +
proved O +
to O +
be O +
very O +
efficient O +
for O +
this O +
application O -
: O +
several O +
by O -
- O -
products O +
are O +
effectively O +
removed O -
, O +
the O +
resulting O +
powder O +
can O +
be O +
stored O +
for O +
several O +
months O +
at O +
−20 O -
° O -
C O +
and O -
, O +
although O +
not O +
of O +
relevance O +
in O +
the O +
present O +
study O -
, O +
protein B-Gene +
denaturation O +
is O +
minimized O +
due O +
to O +
the O +
extremely O +
low O +
temperature O +
during O +
isolation O -
, O +
yielding O +
extracts O +
of O +
high O +
immunochemical O +
activity O +
( O -
Vieths O -
, O +
Schöning O -
, O +
& O +
Baltes O -
, O +
1992 O -
) O +
. O +

In O +
the O +
further O +
sample O +
preparation O -
, O +
two O +
steps O +
shall O +
be O +
briefly O +
addressed O -
: O +
borohydride O +
reduction O -
, O +
which O +
was O +
employed O +
in O +
order O +
to O +
prevent O +
residual O +
free O +
sugars O +
from O +
subsequent O +
derivatization O +
which O +
proved O +
its O +
necessity O +
in O +
the O +
case O +
of O +
grass O +
pollen O +
extracts O +
where O +
several O +
artefactic O +
peaks O +
appeared O +
on O +
the O +
chromatogramms O +
without O +
this O +
step O +
( O -
F. O +
Altmann O -
, O +
personal O +
communication O -
) O -
. O +

Second O -
, O +
N B-Gene +
-glycosidase I-Gene +
A I-Gene +
from O +
almonds O +
was O +
used O +
for O +
the O +
deglycosylation O +
of O +
the O +
glycopeptides B-Gene -
, O +
which O +
is O +
important O -
, O +
since O +
the O +
( O -
more O -
) O +
frequently O +
used O +
N B-Gene +
-glycosidase I-Gene +
F I-Gene +
from O +
Flavobacterium O +
meningosepticum O +
can O -
not O +
cleave O +
glycans O +
containing O +
fucose O +
linked O +
α1–3 O +
to O +
Asn O -
– O -
GlcNAc O +
( O -
Tretter O -
, O +
Altmann O -
, O +
& O +
März O -
, O +
1991 O -
; O +
Altmann O -
, O +
Schweiszer O -
, O +
& O +
Weber O -
, O +
1995 O -
) O +
. O +

The O +
methodology O +
for O +
the O +
structural O +
characterization O -
, O +
using O +
two O -
- O -
dimensional O +
HPLC O +
in O +
combination O +
with O +
exoglycosidase B-Gene +
digestions O -
, O +
was O +
first O +
introduced O +
by O +
Tomiya O +
et O +
al. O +
( O -
1988 O -
) O +
and O +
has O +
been O +
employed O +
for O +
glycoprotein B-Gene -
– O -
glycans O +
from O +
various O +
sources O +
( O -
Takahashi O +
et O +
al. O -
, O +
1986 O -
; O +
Kubelka O +
et O +
al. O -
, O +
1994 O -
; O +
Ohsuga O +
et O +
al. O -
, O +
1996 O -
) O +
. O +

Complex O -
- O -
type O +
structures O -
, O +
most O +
of O +
them O +
truncated O +
and O +
exhibiting O +
α1–3 O +
linked O +
fucose O +
and/or O +
β1–2 O +
linked O +
xylose O -
, O +
as O +
well O +
as O +
oligomannosidic O +
glycans O +
were O +
detected O -
. O +

Most O +
of O +
these O +
structures O +
have O +
been O +
reported O +
to O +
occur O +
in O +
other O +
plant O +
glycoproteins B-Gene -
; O +
MMXF3 O +
, O +
addressed O +
to O +
be O +
the O +
typical O +
vacuole O -
- O -
type O +
plant O +
N O +
-glycan O +
( O -
Sturm O -
, O +
1995 O -
) O +
and O +
the O +
most O +
abundant O +
oligosaccharide O +
in O +
tomato O +
fruit O -
, O +
has O +
also O +
been O +
found O +
in O +
horseradish B-Gene +
peroxidase I-Gene +
( O -
Kurosaka O +
et O +
al. O -
, O +
1991 O -
) O +
, O +
a O +
protease B-Gene +
inhibitor O +
from O +
barbados O +
pride O +
( O -
Caesalpinia O +
Pulcherrima O +
Sw O -
. O -
) O +
seeds O +
( O -
Hase O +
et O +
al. O -
, O +
1986 O -
) O +
, O +
Sophora O +
japonica O +
lectin B-Gene +
( O -
Fournet O +
et O +
al. O -
, O +
1987 O -
) O +
and O +
ricin B-Gene +
D I-Gene +
from O +
the O +
seeds O +
of O +
castor O +
plants O +
( O -
Ricinus O +
communis O +
) O +
( O -
Kimura O +
et O +
al. O -
, O +
1988 O -
) O +
. O +

M0XF3 O +
, O +
another O +
structure O +
which O +
occurs O +
in O +
relatively O +
high O +
amounts O +
in O +
tomato O +
( O -
17–22 O -
% O -
) O -
, O +
has O +
been O +
reported O +
for O +
both O +
pineapple O +
stem O +
bromelain B-Gene +
( O -
Van O +
Kuik O +
et O +
al. O -
, O +
1986 O -
) O +
and O +
barley O +
peroxidase B-Gene +
( O -
Johannson O -
, O +
Rasmussen O -
, O +
Harthill O -
, O +
& O +
Welinder O -
, O +
1992 O -
) O +
. O +

Small O +
α1,3-fucosylated O +
and/or O +
β1,2-xylosylated O +
glycans O +
that O +
are O +
minor O +
fractions O +
in O +
tomato O -
, O +
have O +
recently O +
also O +
been O +
found O +
in O +
other O +
plants O -
; O +
MMX O +
was O +
found O +
to O +
be O +
the O +
most O +
abundant O +
N O +
-glycan O +
in O +
rice O +
α B-Gene -
- I-Gene -
amylase I-Gene +
from O +
germinated O +
seedlings O +
( O -
Hayashi O +
et O +
al. O -
, O +
1990 O -
) O +
and O +
also O +
represents O +
the O +
complex O +
oligosaccharide O +
side O +
chain O +
of O +
the O +
bean O +
storage O +
protein B-Gene +
phaseolin B-Gene +
( O -
Sturm O -
, O +
van O +
Kuik O -
, O +
Vliegenthart O -
, O +
& O +
Chrispeels O -
, O +
1987 O -
) O -
. O +

M0X O +
accounts O +
for O +
15 O -
% O +
of O +
the O +
N O +
-glycans O +
of O +
barley O -
( B-Gene -
1–3,1–4 I-Gene -
) I-Gene -
-β I-Gene -
- I-Gene -
d I-Gene +
-glucan I-Gene +
4-glucanohydrolase I-Gene +
isoenzyme I-Gene +
EII O +
( O -
Harthill O -
, O +
& O +
Thomsen O -
, O +
1995 O -
) O +
, O +
whereas O +
MMF3 O +
was O +
found O +
to O +
be O +
a O +
minor O +
fraction O +
of O +
soybean O +
peroxidase B-Gene +
( O -
Gray O -
, O +
Yun O +
Yang O -
, O +
Hull O -
, O +
Venzke O -
, O +
& O +
Montgomery O -
, O +
1996 O -
) O +
. O +

Three O +
structures O +
that O +
exhibit O +
outer O -
- O -
arm O +
GlcNAc O +
residues O +
and O +
represent O +
6–14 O -
% O +
of O +
the O +
N O +
-glycans O +
in O +
tomato O +
fruit O -
, O +
have O +
been O +
previously O +
reported O +
for O +
lactase B-Gene +
from O +
sycamore O +
cells O +
( O -
Harthill O -
, O +
& O +
Thomsen O -
, O +
1995 O -
) O +
. O +

GnMXF3 O +
and O +
MGnXF3 O +
were O +
also O +
found O +
to O +
be O +
present O +
in O +
red O +
kidney O +
bean O +
Fe B-Gene -
( I-Gene -
III I-Gene -
) I-Gene -
–Zn I-Gene -
( I-Gene -
II I-Gene -
) I-Gene +
purple I-Gene +
acid I-Gene +
phosphatase I-Gene +
( O -
Stahl O +
et O +
al. O -
, O +
1994 O -
) O +
. O +

Oligomannosidic O +
structures O -
, O +
accounting O +
for O +
only O +
3–9 O -
% O +
of O +
the O +
N O +
-glycans O +
in O +
tomato O +
fruit O -
, O +
are O +
wide O -
- O -
spread O +
among O +
plants O +
( O -
e.g. O +
soybean O +
agglutinin B-Gene +
( O -
Dorland O -
, O +
van O +
Halbeek O -
, O +
Vliegenthart O -
, O +
Lis O -
, O +
& O +
Sharon O -
, O +
1981 O -
) O +
, O +
phaseolin B-Gene +
of O +
the O +
common O +
bean O +
( O -
Sturm O +
et O +
al. O -
, O +
1987 O -
) O +
, O +
rice O +
α O -
- O -
amylase O +
( O -
Hayashi O +
et O +
al. O -
, O +
1990 O -
) O +
, O +
α B-Gene -
- I-Gene -
amylase I-Gene +
inhibitor O +
from O +
white O +
kidney O +
bean O +
( O -
Phasolus O +
vulgaris O -
) O +
( O -
Yamaguchi O -
, O +
Funaoka O -
, O +
& O +
Iwamoto O -
, O +
1992 O -
) O +
, O +
but O +
are O +
also O +
found O +
in O +
insect O -
, O +
yeast O +
and O +
mammalian O +
glycoproteins B-Gene -
. O +

α-1,3-Fucosylation O +
of O +
the O +
innermost O +
N O +
-acetylglucosamine O +
residue O -
, O +
a O +
typical O +
feature O +
of O +
N O +
-glycans O +
from O +
plants O +
but O +
also O +
from O +
insects O -
, O +
was O +
found O +
in O +
8 O +
of O +
the O +
16 O +
tomato O +
N O +
-linked O +
oligosaccharides O -
, O +
accounting O +
for O +
86–90 O -
% O +
of O +
the O +
N O +
-glycan O +
pool O +
in O +
tomato O +
fruits O -
. O +

Such O +
fucosyl O +
residues O +
as O +
well O +
as O +
β1,2-linked O +
xylosyl O +
residues O +
are O +
not O +
present O +
in O +
mammalian O +
glycoproteins B-Gene +
and O +
therefore O +
render O +
plant O +
glycoproteins B-Gene +
immunogenic O +
( O -
Wilson O +
et O +
al. O -
, O +
1998 O -
) O +
. O +

In O +
fact O -
, O +
even O +
IgE O +
antibodies B-Gene +
may O +
be O +
directed O +
against O +
this O +
epitope O -
. O +

Owing O +
to O +
their O +
widespread O +
occurrence O -
, O +
α1,3-fucosylated O +
N O +
-glycans O +
( O -
with O +
or O +
without O +
xylose O -
) O +
constitute O +
a O +
highly O +
cross O -
- O -
reactive O +
carbohydrate O +
determinant O +
detected O +
in O +
a O +
wide O +
variety O +
of O +
plant O +
as O +
well O +
as O +
insect O +
allergens O +
( O -
Tretter O +
et O +
al. O -
, O +
1993 O -
; O +
Garcia O -
- O -
Casado O +
et O +
al. O -
, O +
1996 O -
; O +
Jankiewicz O -
, O +
Aulepp O -
, O +
Altmann O -
, O +
Foetisch O -
, O +
& O +
Vieths O -
, O +
1998 O -
) O +
. O +

As O +
far O +
as O +
tomatoes O +
are O +
concerned O -
, O +
Petersen O +
et O +
al. O +
( O -
1996 O -
) O +
reported O +
the O +
reactivity O +
of O +
IgE O +
antibodies B-Gene +
of O +
grass O +
pollen O +
allergic O +
individuals O +
to O +
tomato O +
extracts O -
. O +

Lectin B-Gene +
blotting O +
of O +
proteins B-Gene +
and O +
ELISA O +
inhibition O +
experiments O +
using O +
glycopeptides B-Gene +
of O +
known O +
glycan O +
structures O +
suggested O +
the O +
presence O +
of O +
carbohydrate O +
IgE O +
epitopes O +
with O +
an O +
α1,3-fucose O +
residue O -
. O +

The O +
characterization O +
of O +
the O +
tomato O +
N O +
-glycans O +
presented O +
in O +
this O +
work O -
, O +
revealing O +
a O +
high O +
degree O +
of O +
α1,3-fucosylated O +
structures O +
in O +
the O +
fruit O -
, O +
offers O +
the O +
structural O +
explanation O +
for O +
these O +
findings O -
. O +

4 O +
Experimental O +
4.1 O +
Materials O +
Red O +
tomatoes O +
( O -
variety O +
Notoro O -
) O +
were O +
bought O +
in O +
a O +
retail O +
shop O -
; O +
red O +
and O +
green O +
tomatoes O +
( O -
variety O +
San O +
Marzano O -
) O +
were O +
obtained O +
from O +
RIKILT O -
- O -
DLO O -
, O +
Netherlands O -
. O +

N B-Gene +
-glycosidase I-Gene +
A I-Gene +
from O +
almonds O +
and O +
endoglycosidase B-Gene +
H I-Gene +
from O +
Streptomyces O +
plicatus O +
were O +
purchased O +
from O +
Boehringer O +
Mannheim O -
. O +

β B-Gene -
- I-Gene -
N I-Gene +
-acetylglucosaminidase I-Gene +
( O -
jack O +
bean O -
) O -
, O +
α B-Gene -
- I-Gene -
mannosidase I-Gene +
( O -
jack O +
bean O -
) O +
and O +
pepsin B-Gene +
( O -
from O +
porcine O +
stomach O +
mucosa O -
) O +
were O +
obtained O +
from O +
Sigma O -
. O +

2-aminopyridine O -
, O +
sodium O +
cyanoborohydride O -
, O +
dithioerythritol O -
, O +
benzamidine O +
and O +
PMSF O +
were O +
obtained O +
from O +
Sigma O -
. O +

4.2 O +
Precipitation O +
of O +
proteins B-Gene +
using O +
a O +
low O -
- O -
temperature O +
acetone O +
powder O +
method O +
The O +
extracts O +
were O +
prepared O +
in O +
a O +
similar O +
manner O +
to O +
that O +
described O +
by O +
Vieths O -
, O +
Schöning O -
, O +
and O +
Petersen O +
( O -
1994 O -
) O +
: O +
200 O +
g O +
of O +
tomato O +
fruit O +
were O +
homogenized O +
in O +
400 O +
ml O +
of O +
ice O -
- O -
cold O +
acetone O +
on O +
dry O +
ice O -
. O +

Another O +
400 O +
ml O +
of O +
ice O -
- O -
cold O +
acetone O +
were O +
added O +
and O +
the O +
sample O +
was O +
kept O +
on O +
dry O +
ice O +
overnight O +
with O +
occasional O +
stirring O +
during O +
the O +
first O +
few O +
hours O -
. O +

The O +
resulting O +
precipitate O +
was O +
filtered O +
through O +
sintered O +
glass O +
and O +
washed O +
twice O +
with O +
acetone O +
and O +
once O +
with O +
acetone O -
/ O -
diethylether O +
( O -
1:1 O -
, O +
v O -
/ O -
v O -
) O +
at O +
−20 O -
° O -
C O -
. O +

The O +
sediment O +
was O +
lyophilized O -
. O +

4 O +
g O +
of O +
acetone O +
powder O +
were O +
taken O +
up O +
in O +
150 O +
ml O +
phosphate O +
buffered O +
saline O +
( O -
10 O +
mM O +
phosphate O +
pH O +
7.4 O -
; O +
0.15 O +
M O +
NaCl O -
) O +
and O +
stirred O +
at O +
4 O -
° O -
C O +
for O +
60 O +
min O -
. O +

After O +
centrifugation O +
( O -
20000 O +
rpm O -
, O +
20 O +
min O -
, O +
0 O -
° O -
C O -
) O -
, O +
the O +
supernatant O +
was O +
filtered O +
( O -
0.45 O +
μm O -
) O -
, O +
extensively O +
dialyzed O +
against O +
double O -
- O -
distilled O +
water O +
( O -
membrane O +
3.5 O +
kD O +
cut O -
- O -
off O -
) O +
overnight O +
and O +
lyophilized O -
. O +

4.3 O +
Ammonium O +
sulfate O +
precipitation O +
As O +
an O +
alternative O +
to O +
the O +
above O -
- O -
mentioned O +
procedure O -
, O +
ammonium O +
sulfate O +
precipitation O +
was O +
per O -
- O -
formed O -
: O +
to O +
200 O +
g O +
of O +
tomato O +
fruit O +
400 O +
ml O +
of O +
extraction O +
buffer O +
( O -
10 O +
mM O +
phosphate O +
pH O +
7.4 O -
, O +
150 O +
mM O +
NaCl O -
, O +
1 O +
mM O +
EDTA O -
, O +
1 O +
mM O +
benzamidine O -
, O +
1 O +
mM O +
DTE O -
, O +
0.1 O +
mM O +
PMSF O -
) O +
was O +
added O +
and O +
the O +
sample O +
was O +
homogenized O -
. O +

Centrifugation O +
was O +
carried O +
out O +
at O +
20000 O +
rpm O +
( O -
20 O +
min O -
, O +
4 O -
° O -
C O -
) O -
. O +

Solid O +
ammonium O +
sulfate O +
was O +
added O +
to O +
the O +
supernatant O +
to O +
a O +
final O +
concentration O +
of O +
80 O -
% O +
saturation O -
. O +

The O +
mixture O +
was O +
stirred O +
at O +
4 O -
° O -
C O +
for O +
3 O +
h O -
, O +
centrifuged O +
( O -
20000 O +
rpm O -
, O +
20 O +
min O -
, O +
4 O -
° O -
C O -
) O +
and O +
the O +
pellet O +
was O +
dialyzed O +
against O +
double O -
- O -
distilled O +
water O +
and O +
lyophilized O -
. O +

4.4 O +
Purification O +
of O +
N O +
-glycans O +
The O +
lyophilisate O +
was O +
dissolved O +
in O +
5 O -
% O +
v O -
/ O -
v O +
formic O +
acid O +
and O +
digested O +
with O +
pepsin B-Gene +
( O -
2 O -
% O -
, O +
w O -
/ O -
w O -
) O +
for O +
48 O +
h O +
at O +
37 O -
° O -
C O -
. O +

( O -
Another O +
1 O -
% O +
w O -
/ O -
w O +
pepsin B-Gene +
was O +
added O +
after O +
24 O +
h O -
) O -
. O +

After O +
centrifugation O +
( O -
10000 O +
rpm O -
, O +
10 O +
min O -
) O -
, O +
the O +
supernatant O +
was O +
adjusted O +
to O +
pH O +
2.5 O +
and O +
chromatographed O +
on O +
an O +
ion O -
- O -
exchange O +
SP650-M O +
column O -
, O +
1 O -
× O -
5 O +
cm O +
( O -
Toso O +
Haas O -
) O -
, O +
equilibrated O +
with O +
5 O -
% O +
acetic O +
acid O -
. O +

After O +
application O +
of O +
the O +
sample O -
, O +
the O +
column O +
was O +
rinsed O +
with O +
40 O +
ml O +
5 O -
% O +
acetic O +
acid O -
. O +

The O +
glycopeptide B-Gene +
fraction O +
was O +
eluted O +
with O +
1 O +
M O +
ammonia O +
( O -
collection O +
of O +
2 O +
ml O +
fractions O -
) O -
. O +

Carbohydrate O -
- O -
positive O +
fractions O -
, O +
detected O +
using O +
the O +
orcinol O -
– O -
sulfuric O +
acid O +
reagent O +
according O +
to O +
Winzler O +
( O -
1955 O -
) O +
, O +
were O +
pooled O +
and O +
lyophilized O -
. O +

The O +
sample O +
was O +
taken O +
up O +
in O +
1 O +
ml O +
water O -
; O +
the O +
pH O +
was O +
adjusted O +
to O +
9 O +
with O +
ammonia O -
. O +

100 O +
μl O +
of O +
a O +
2 O -
% O +
w O -
/ O -
v O +
sodium O +
borohydride O +
solution O +
was O +
added O +
and O +
the O +
sample O +
was O +
incubated O +
at O +
room O +
temperature O +
overnight O -
. O +

After O +
addition O +
of O +
acetic O +
acid O +
and O +
evaporation O -
, O +
this O +
step O +
was O +
repeated O +
twice O +
with O +
1 O -
% O +
v O -
/ O -
v O +
acetic O +
acid O +
in O +
methanol O +
and O +
twice O +
with O +
MeOH O -
. O +

The O +
sample O +
was O +
dissolved O +
in O +
100 O +
μl O +
citrate O -
/ O -
phosphate O +
pH O +
5.0 O +
and O +
digested O +
with O +
0.5 O +
mU O +
of O +
N B-Gene +
-glycosidase I-Gene +
A I-Gene +
for O +
37 O -
° O -
C O +
for O +
48 O +
h. O +
Oligosaccharides O +
were O +
separated O +
from O +
residual O +
glycopeptides B-Gene +
and O +
peptides B-Gene +
using O +
a O +
reverse O -
- O -
phase O +
cartridge O +
as O +
described O +
by O +
Dell O +
et O +
al. O +
( O -
Dell O +
et O +
al. O -
, O +
1993 O -
) O +
. O +

The O +
glycans O +
were O +
labelled O +
with O +
2-aminopyridine O +
according O +
to O +
Hase O -
, O +
Ibuki O -
, O +
and O +
Ikenaka O +
( O -
1984 O -
) O +
. O +

To O +
remove O +
the O +
excess O +
of O +
reagent O -
, O +
a O +
gelfiltration O +
step O +
was O +
performed O +
using O +
a O +
1 O -
× O -
40 O +
cm O +
Sephadex O +
G15 O +
column O -
, O +
equilibrated O +
with O +
1 O -
% O +
w O -
/ O -
v O +
acetic O +
acid O -
. O +

4.5 O +
Fractionation O +
of O +
pyridylaminated O +
oligosaccharides O +
by O +
two O -
- O -
dimensional O +
HPLC O +
A O +
Shimadzu O +
module O +
system O -
, O +
consisting O +
of O +
a O +
system O +
controller O -
, O +
a O +
pump O +
and O +
a O +
fluorescence O +
detector O +
was O +
used O -
. O +

Separations O +
of O +
the O +
pyridylamino O -
- O -
oligosaccharides O +
using O +
two O +
different O +
HPLC O +
columns O +
were O +
performed O +
at O +
room O +
temperature O -
. O +

Glucose O +
oligomers O +
were O +
used O +
in O +
both O +
systems O +
for O +
calibration O +
and O +
as O +
internal O +
standards O -
. O +

Elution O +
volumes O +
of O +
the O +
samples O +
were O +
expressed O +
in O +
glucose O +
units O +
according O +
to O +
Lee O -
, O +
Lee O -
, O +
Tomiya O -
, O +
and O +
Takahashi O +
( O -
1990 O -
) O +
. O +

Fractionation O +
according O +
to O +
size O +
was O +
accomplished O +
on O +
a O +
MicroPak O +
AX-5 O +
column O +
( O -
4 O -
× O -
300 O +
mm O -
, O +
VARIAN O -
) O -
; O +
the O +
eluents O +
were O +
as O +
follows O -
: O +
( O -
A O -
) O +
3 O -
% O +
w O -
/ O -
v O +
acetic O +
acid O -
, O +
triethylamine O +
pH O +
7.3 O -
: O +
acetonitrile O +
35:65 O -
, O +
v O -
/ O -
v O +
and O +
( O -
B O -
) O +
3 O -
% O +
w O -
/ O -
v O +
acetic O +
acid O -
, O +
triethylamine O +
pH O +
7.3 O -
: O +
acetonitrile O +
50:50 O -
, O +
v O -
/ O -
v O -
. O +

A O +
linear O +
gradient O +
of O +
0–60%B O +
in O +
30 O +
min O +
at O +
a O +
flow O +
rate O +
of O +
1 O +
ml O -
/ O -
min O +
was O +
applied O -
. O +

Further O +
separation O +
was O +
achieved O +
by O +
reverse O -
- O -
phase O +
HPLC O +
on O +
a O +
5 O +
μm O +
hypersil O +
ODS O +
column O +
( O -
Shandon O -
) O -
. O +

The O +
column O +
was O +
equilibrated O +
with O +
0.1 O +
M O +
ammonium O +
acetate O +
pH O +
4.0 O +
and O +
eluted O +
with O +
a O +
linear O +
gradient O +
of O +
0–7.5 O -
% O +
( O -
by O +
vol O -
. O -
) O +
methanol O +
in O +
25 O +
min O +
at O +
a O +
flow O +
rate O +
of O +
1.5 O +
ml O -
/ O -
min O -
. O +

In O +
both O +
systems O -
, O +
pyridylaminated O +
oligosaccharides O +
were O +
detected O +
by O +
fluorescence O +
using O +
excitation O +
and O +
emission O +
wavelengths O +
of O +
320 O +
and O +
400 O +
nm O -
, O +
respectively O -
. O +

4.6 O +
Exoglycosidase B-Gene +
digestions O +
Generally O -
, O +
about O +
50–100 O +
pmol O +
of O +
oligosaccharide O +
were O +
incubated O +
for O +
20 O +
h O +
at O +
37 O -
° O -
C O -
. O +

The O +
following O +
buffers O +
and O +
enzyme B-Gene +
quantities O +
were O +
used O -
: O +
50 O +
mU O +
α B-Gene -
- I-Gene -
mannosidase I-Gene +
in O +
50 O +
mM O +
sodium O +
acetate O -
, O +
pH O +
4.2 O +
containing O +
0.1 O +
mM O +
ZnCl2 O +
to O +
achieve O +
complete O +
removal O +
of O +
α O -
- O -
linked O +
mannose O +
residues O -
; O +
5 O +
mU O +
of O +
α B-Gene -
- I-Gene -
mannosidase I-Gene +
to O +
selectively O +
remove O +
α1,3-linked O +
mannose O +
residues O -
; O +
2 O +
mU O +
β B-Gene -
- I-Gene -
N I-Gene +
-acetylhexosaminidase I-Gene +
( O -
for O +
partial O +
hydrolysis O -
) O +
or O +
10 O +
mU O +
of O +
the O +
enzyme B-Gene +
for O +
complete O +
hydrolysis O -
, O +
using O +
0.1 O +
M O +
sodium O +
citrate O -
, O +
pH O +
5.0 O -
; O +
1 O +
mU O +
endoglycosidase B-Gene +
H I-Gene +
in O +
0.1 O +
M O +
sodium O +
citrate O -
/ O -
phosphate O -
, O +
pH O +
5.0 O -
. O +

4.7 O +
Preparation O +
of O +
reference O +
oligosaccharides O +
Pyridylaminated O +
oligosaccharides O +
used O +
as O +
reference O +
substances O +
were O +
prepared O +
from O +
the O +
following O +
sources O -
: O +
Manα1–6 O -
( O -
Manα1–3 O -
) O -
Manβ1–4GlcNAcβ1–4GlcNAc O +
( O -
MM O -
) O +
from O +
bovine O +
fibrin B-Gene +
( O -
Staudacher O -
, O +
Kubelka O -
, O +
& O +
März O -
, O +
1992 O -
) O +
; O +
Manα1–6 O -
( O -
Manα1–3 O -
) O -
( O -
Xylβ1–2 O -
) O -
Manβ1–4GlcNAcβ1–4GlcNAc O +
( O -
MMX O -
) O +
from O +
zucchini O +
ascorbate B-Gene +
oxidase I-Gene +
( O -
Altmann O -
, O +
1998 O -
) O +
; O +
Manα1–6 O -
( O -
Manα1–3 O -
) O -
Manβ1–4GlcNAcβ1–4 O -
( O -
Fucα1–3 O -
) O -
GlcNAc O +
( O -
MMF3 O +
) O +
from O +
honeybee O +
venom O +
phospholipase B-Gene +
A2 I-Gene +
( O -
Kubelka O +
et O +
al. O -
, O +
1993 O -
) O +
; O +
Manα1–6 O -
( O -
Xylβ1–2 O -
) O -
Manβ1–4GlcNAcβ1–4 O -
( O -
Fucα1–3 O -
) O -
GlcNAc O +
( O -
M0XF3 O +
) O +
from O +
pineapple O +
stem O +
bromelain B-Gene +
( O -
Van O +
Kuik O +
et O +
al. O -
, O +
1986 O -
) O +
; O +
Manα1–6 O -
( O -
Manα1–3 O -
) O -
( O -
Xylβ1–2 O -
) O -
Manβ1–4GlcNAcβ1–4 O -
( O -
Fucα1–3 O -
) O -
GlcNAc O +
( O -
MMXF3 O +
) O +
from O +
horseradish B-Gene +
peroxidase I-Gene +
( O -
Kurosaka O +
et O +
al. O -
, O +
1991 O -
) O +
; O +
GlcNAcβ1–2Manα1–6 O -
( O -
GlcNAcβ1–2Manα1–3 O -
) O -
( O -
Xylβ1–2 O -
) O -
Manβ1–4GlcNAcβ1–4 O -
( O -
Fucα1–3 O -
) O -
GlcNAc O +
( O -
GnGnXF3 O +
) O +
from O +
hornbeam O +
pollen O +
( O -
Wilson O -
, O +
& O +
Altmann O -
, O +
1998 O -
) O +
; O +
Man6 O +
GlcNAc2 O +
[ O -
M6.1 O -
] O -
1 O +
Codes O +
for O +
oligomannose O +
structures O +
according O +
to O +
Tomiya O +
et O +
al. O +
( O -
1991 O -
) O +
. O +

1 O +
, O +
Man7 O +
GlcNAc2 O +
[ O -
M7.1 O -
] O -
1 O +
, O +
[ O -
M7.2 O -
] O -
1 O +
, O +
and O +
Man8 O +
GlcNAc2 O +
[ O -
M8.1 O -
] O -
1 O +
from O +
soybean O +
7S B-Gene +
-glycoprotein I-Gene +
( O -
Neeser O -
, O +
Vedovo O -
, O +
Mutsaers O -
, O +
& O +
Vliegenthart O -
, O +
1985 O -
) O +
. O +

The O +
structures O +
of O +
the O +
reference O +
oligosaccharides O +
were O +
confirmed O +
by O +
methylation O +
analysis O +
( O -
data O +
not O +
shown O -
) O -
. O +

For O +
column O +
calibration O -
, O +
pyridylaminated O +
isomaltooligosaccharides O +
were O +
prepared O +
from O +
partially O +
hydrolyzed O +
dextran O -
. O +

4.8 O +
Matrix O -
- O -
assisted O +
laser O +
desorption O -
/ O -
ionization O +
– O +
time O +
of O +
flight O +
– O +
mass O +
spectrometry O +
MALDI O -
– O -
TOF O -
– O -
MS O +
data O +
was O +
obtained O +
using O +
a O +
Dynamo O +
instrument O +
( O -
Thermo O +
Bioanalysis O -
, O +
UK O -
) O -
, O +
operating O +
in O +
the O +
positiv O -
- O -
ion O +
linear O +
mode O -
. O +

About O +
5–10 O +
pmol O +
of O +
pyridylaminated O +
tomato O +
N O +
-glycans O +
( O -
individual O +
reverse O -
- O -
phase O +
HPLC O +
fractions O -
) O +
were O +
repeatedly O +
dried O +
under O +
nitrogen O +
to O +
remove O +
buffer O +
components O -
; O +
the O +
samples O +
were O +
finally O +
dissolved O +
in O +
6 O +
μl O +
water O +
and O +
3 O +
μl O +
matrix O +
solution O +
( O -
2 O -
% O +
2,5-dihydroxybenzoic O +
acid O +
in O +
water O +
containing O +
30 O -
% O +
acetonitrile O +
and O +
0,5 O +
mM O +
NaCl O -
) O -
. O +

Aliquots O +
of O +
1 O +
μl O +
were O +
applied O +
on O +
the O +
target O +
and O +
allowed O +
to O +
dry O -
. O +

Mass O +
spectra O +
were O +
obtained O +
by O +
averaging O +
20 O +
single O +
spectra O -
. O +

External O +
mass O +
calibration O +
was O +
performed O +
with O +
pyridylaminated O +
GlcNAc2 O +
Man3 O +
GlcNAc2 O +
( O -
MNa+ O +
= O -
1418,2 O +
Da O -
) O +
which O +
was O +
prepared O +
from O +
bovine O +
fibrin B-Gene +
as O +
described O +
( O -
Altmann O -
, O +
Schwihla O -
, O +
Staudacher O -
, O +
Glössl O -
, O +
& O +
März O -
, O +
1995 O -
) O +
. O +

4.9 O +
HPLC O -
- O -
analysis O +
of O +
OPA O -
- O -
aminosugars O +
An O +
aliquot O +
of O +
the O +
glycopeptide B-Gene +
fraction O +
was O +
hydrolyzed O +
with O +
4 O +
M O +
TFA O +
and O +
aminosugar O +
analysis O +
by O +
reverse O -
- O -
phase O +
chromatography O +
was O +
performed O +
as O +
described O +
by O +
Altmann O +
( O -
1992 O -
) O +
. O +

Acknowledgements O +

We O +
thank O +
Hubert O +
Noteborn O -
, O +
RILILT O -
- O -
DLO O +
for O +
supplying O +
us O +
with O +
the O +
tomato O +
samples O +
and O +
Thomas O +
Dalik O +
for O +
performing O +
the O +
aminosugar O +
analyses O -
. O +

This O +
work O +
was O +
financed O +
by O +
the O +
EU O -
- O -
project O +
AIR3-CT94 O -
- O -
2311 O -
. O +

2-Nitrofluorene O +
( O -
NF O -
) O +
is O +
an O +
air O +
pollutant O +
which O +
has O +
been O +
used O +
as O +
a O +
model O +
substance O +
of O +
nitrated O +
polycyclic O +
aromatic O +
hydrocarbons O +
( O -
nitro O -
- O -
PAHs O -
) O +
[ O -
1 O -
, O +
2 O -
] O +
. O +

NF O +
enters O +
in O +
vivo O +
into O +
an O +
oxidative O +
or O +
a O +
reductive O +
metabolic O +
pathway O -
, O +
depending O +
on O +
the O +
route O +
of O +
administration O +
[ O -
3–5 O -
] O +
. O +

Oral O +
administration O +
results O +
mainly O +
in O +
reduced O +
metabolites O +
[ O -
5 O -
] O +
, O +
e.g. O -
, O +
2-aminofluorene O +
( O -
AF O -
) O +
and O +
2-acetylaminofluorene O +
( O -
AAF O -
) O -
, O +
both O +
are O +
carcinogens O -
. O +

It O +
is O +
reported O +
that O +
NF O +
induces O +
DNA O +
adduct O +
formation O +
in O +
vivo O +
with O +
dG O -
- O -
C8-AF O +
as O +
one O +
of O +
the O +
characterized O +
DNA O +
adducts O +
[ O -
6 O -
, O +
7 O -
] O +
. O +

dG O -
- O -
C8-AF O -
, O +
together O +
with O +
other O +
known O +
AF- O +
and O +
AAF O -
- O -
related O +
DNA O +
adducts O +
( O -
i.e. O -
, O +
dG O -
- O -
C8-AAF O -
, O +
dG O -
- O -
N O +
2 O +
-AAF O -
, O +
etc O -
. O -
) O +
have O +
been O +
suspected O +
to O +
be O +
pre O -
- O -
mutagenic O +
or O +
toxic O +
[ O -
8 O -
] O +
. O +

Carcinogens O +
have O +
been O +
shown O +
to O +
induce O +
DNA O +
adducts O +
[ O -
6 O -
, O +
7 O -
, O +
9 O -
, O +
10 O -
] O +
. O +

Exposures O +
of O +
human O +
populations O +
to O +
complex O +
mixtures O +
with O +
known O +
or O +
suspected O +
risk O +
of O +
inducing O +
cancer O +
is O +
also O +
associated O +
with O +
formation O +
of O +
DNA O +
adducts O +
[ O -
11–13 O -
] O +
. O +

High O +
levels O +
of O +
DNA O +
adducts O +
in O +
normal O +
human O +
colonic O +
mucosa O +
is O +
significantly O +
associated O +
with O +
colorectal O +
cancer O +
[ O -
14 O -
] O +
. O +

In O +
polluted O +
areas O -
, O +
the O +
seasonal O +
change O +
of O +
DNA O +
adducts O +
in O +
human O +
lymphocytes O +
varies O +
with O +
the O +
seasonal O +
changes O +
of O +
air O +
pollutants O +
[ O -
15 O -
] O +
. O +

Thus O -
, O +
DNA O +
adducts O +
may O +
be O +
used O +
as O +
biomarkers O +
for O +
genotoxic O +
risk O -
. O +

DNA O +
adducts O +
have O +
different O +
stabilities O +
owing O +
to O +
factors O +
such O +
as O +
DNA O +
repair O +
and O +
chemical O +
instability O -
. O +

No O +
uniform O +
correlation O +
is O +
found O +
between O +
adduct O +
persistence O +
and O +
tumor O +
induction O -
. O +

However O -
, O +
it O +
is O +
postulated O +
that O +
the O +
persistent O +
DNA O +
adducts O +
represent O +
dormant O +
lesions O +
that O +
may O +
become O +
fixed O +
as O +
mutations O +
long O +
after O +
exposure O +
to O +
the O +
carcinogen O +
and O +
contribute O +
to O +
the O +
malignant O +
transformation O +
as O +
a O +
result O +
of O +
cell O +
division O +
[ O -
16 O -
] O +
. O +

Measurement O +
of O +
DNA O +
adducts O +
from O +
carcinogenic O +
alkenylbenzenes O +
in O +
preweanling O +
male O +
B6C3F1 O +
mice O +
suggests O +
the O +
virtual O +
absence O +
of O +
DNA O +
repair O +
for O +
these O +
adducts O +
[ O -
17 O -
] O +
. O +

This O +
has O +
been O +
postulated O +
to O +
play O +
a O +
role O +
in O +
the O +
carcinogenicity O +
of O +
safrole O +
and O +
related O +
alkenylbenzenes O +
in O +
newborn O +
mice O +
[ O -
17–20 O -
] O +
. O +

Further O +
experiments O +
show O +
that O +
rapid O +
repair O +
of O +
O O +
6 O +
-methylguanine O -
- O -
DNA O +
adducts O +
protects O +
transgenic O +
mice O +
from O +
N O +
-methylnitrosourea O -
- O -
induced O +
thymic O +
lymphomas O +
[ O -
21 O -
] O +
. O +

It O +
has O +
also O +
been O +
reported O +
that O +
increased O +
platinum O +
removal O +
from O +
total O +
genomic O +
DNA O +
was O +
associated O +
with O +
increased O +
cisplatin O +
resistance O +
in O +
human O +
ovarian O +
cancer O +
cell O +
lines O +
[ O -
22 O -
] O +
. O +

A O +
recently O +
published O +
long O -
- O -
term O +
tumor O +
study O +
on O +
Wistar O +
rats O +
showed O +
that O +
NF O +
induces O +
tumors O +
in O +
the O +
liver O -
, O +
kidney O +
and O +
forestomach O -
. O +

DNA O +
adducts O +
are O +
formed O +
at O +
higher O +
levels O +
during O +
the O +
early O +
stage O +
of O +
NF O +
administration O +
in O +
these O +
tumor O -
- O -
target O +
organs O +
compared O +
with O +
some O +
non O -
- O -
tumor O +
target O +
organs O +
( O -
heart O -
, O +
spleen O +
and O +
glandular O +
stomach O -
) O +
[ O -
23 O -
] O +
. O +

However O -
, O +
NF O +
and O +
also O +
a O +
lot O +
of O +
other O +
carcinogens O +
induce O +
DNA O +
adducts O +
in O +
both O +
tumor O -
- O -
target O +
and O +
non O -
- O -
tumor O +
target O +
tissues O -
. O +

It O +
is O +
thus O +
of O +
significance O +
to O +
know O +
the O +
biochemical O +
characteristics O +
and O +
mutagenic O +
effects O +
of O +
the O +
individual O +
DNA O +
adduct O +
induced O +
by O +
carcinogens O -
. O +

Better O +
correlation O +
may O +
be O +
achieved O +
when O +
an O +
individual O +
DNA O +
adduct O +
is O +
compared O +
with O +
tumor O +
formation O -
. O +

The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
investigate O +
the O +
formation O +
and O +
persistence O +
and O +
the O +
characterization O +
of O +
DNA O +
adducts O +
during O +
and O +
after O +
a O +
long O -
- O -
term O +
administration O +
of O +
NF O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Animal O +
experiment O +
Male O +
Wistar O +
rats O +
from O +
Möllegaard O +
Breeding O +
Center O +
( O -
Skensved O -
, O +
Denmark O -
) O +
with O +
a O +
body O +
weight O +
of O +
approximately O +
90 O +
g O -
, O +
were O +
used O +
for O +
the O +
experiment O -
. O +

The O +
rats O +
were O +
housed O +
in O +
wire O -
- O -
bottomed O +
cages O +
under O +
standardized O +
conditions O +
of O +
light O +
( O -
12 O +
h O +
light O +
and O +
dark O +
cycle O -
) O -
, O +
humidity O +
( O -
55–60 O -
% O -
) O +
and O +
temperature O +
( O -
21±1 O -
° O -
C O -
) O -
. O +

The O +
rats O +
were O +
acclimatized O +
for O +
1 O +
week O +
before O +
the O +
start O +
of O +
the O +
experiment O -
. O +

During O +
the O +
entire O +
experiment O -
, O +
the O +
rats O +
had O +
access O +
to O +
food O +
and O +
water O +
ad O +
libitum O -
. O +

The O +
rats O +
were O +
randomly O +
divided O +
into O +
four O +
groups O -
. O +

Three O +
groups O +
were O +
fed O +
diets O +
supplemented O +
with O +
different O +
concentrations O +
of O +
NF O +
which O +
were O +
0.24 O +
mmol O +
( O -
LD O -
= O -
low O +
dose O -
) O -
, O +
0.95 O +
mmol O +
( O -
MD O -
= O -
medium O +
dose O -
) O +
and O +
2.37 O +
mmol O +
( O -
HD O -
= O -
high O +
dose O -
) O +
per O +
kg O +
diet O -
, O +
respectively O -
. O +

One O +
group O +
was O +
fed O +
basal O +
diet O +
( O -
R3 O -
, O +
Ewos O -
, O +
Södertälje O -
, O +
Sweden O -
) O +
as O +
a O +
control O +
group O -
. O +

The O +
rats O +
were O +
fed O +
NF O -
- O -
supplemented O +
diets O +
continuously O +
for O +
11 O +
months O -
, O +
thereafter O -
, O +
all O +
groups O +
were O +
fed O +
basal O +
diet O +
for O +
a O +
further O +
13 O +
months O -
. O +

The O +
tumor O +
results O +
of O +
this O +
study O +
were O +
previously O +
reported O +
[ O -
23 O -
] O +
. O +

In O +
the O +
present O +
study O -
, O +
DNA O +
adducts O +
were O +
not O +
detected O +
in O +
the O +
LD O +
group O -
. O +

Different O +
tissues O -
, O +
i.e. O -
, O +
liver O -
, O +
kidney O -
, O +
forestomach O -
, O +
glandular O +
stomach O +
and O +
spleen O -
, O +
were O +
collected O +
for O +
DNA O +
adduct O +
analysis O -
. O +

The O +
early O +
stage O +
DNA O +
adduct O +
levels O +
were O +
obtained O +
from O +
three O +
rats O +
after O +
10 O +
days O +
of O +
HD O +
NF O +
administration O -
. O +

The O +
later O +
stage O +
DNA O +
adduct O +
analysis O +
was O +
focused O +
on O +
the O +
samples O +
which O +
were O +
obtained O +
from O +
three O +
rats O +
that O +
were O +
killed O +
shortly O +
before O +
the O +
cessation O +
of O +
the O +
HD O +
NF O +
diet O +
( O -
11 O +
months O -
) O -
. O +

The O +
persistence O +
of O +
DNA O +
adduct O +
levels O +
in O +
the O +
liver O +
after O +
the O +
termination O +
of O +
NF O +
administration O +
was O +
monitored O +
in O +
the O +
MD O +
group O -
. O +

2.2 O +
DNA O +
adduct O +
analyses O +
Tissues O +
from O +
the O +
rat O +
were O +
homogenized O +
in O +
a O +
buffer O +
of O +
1 O -
% O +
SDS O -
, O +
1 O +
mM O +
EDTA O +
and O +
10 O +
mM O +
Tris O -
– O -
HCl O +
( O -
pH O +
7.4 O -
) O +
while O +
kept O +
cold O +
on O +
an O +
ice O +
bed O -
. O +

After O +
RNAse B-Gene +
and O +
proteinase B-Gene +
K I-Gene +
digestion O -
, O +
DNA O +
was O +
extracted O +
by O +
the O +
phenol O +
and O +
chloroform O +
and O +
then O +
hydrolyzed O +
by O +
micrococcal O +
nuclease O +
and O +
spleen O +
phosphodiesterase B-Gene -
. O +

DNA O +
adducts O +
were O +
enriched O +
by O +
butanol O +
extraction O +
in O +
the O +
presence O +
of O +
tetrabutylammonium O +
chloride O -
. O +

DNA O +
adducts O +
were O +
then O +
labeled O +
with O +
[ O -
γ-32 O +
P O +
] O -
ATP O +
by O +
polynucleotide B-Gene +
kinase I-Gene -
. O +

The O +
method O +
used O +
was O +
originally O +
from O +
Beach O +
and O +
Gupta O +
[ O -
24 O -
] O +
with O +
small O +
modifications O +
in O +
different O +
steps O +
[ O -
25 O -
, O +
26 O -
] O +
. O +

32 O +
P O +
-HPLC O -
- O -
analyses O +
of O +
postlabeled O +
DNA O +
adducts O +
were O +
performed O +
by O +
injecting O +
the O +
total O +
unrefined O +
32 O +
P O +
-labeling O +
mixture O +
into O +
the O +
32 O +
P O +
-HPLC O -
. O +

In O +
each O +
analysis O -
, O +
2.8 O +
μg O +
of O +
DNA O +
( O -
5 O +
μCi O -
) O +
was O +
injected O -
. O +

A O +
DeltaPak O -
™ O +
5 O +
μm O +
C18–100 O +
Å O +
column O -
, O +
with O +
a O +
0.5 O +
ml O -
/ O -
min O +
flow O +
rate O +
of O +
2 O +
M O +
ammonium O +
formate O -
, O +
0.4 O +
M O +
formic O +
acid O +
( O -
pH O +
4.5 O -
) O +
with O +
a O +
linear O +
gradient O +
of O +
0–35 O -
% O +
acetonitrile O +
( O -
0–70 O +
min O -
) O +
was O +
used O +
for O +
the O +
separation O +
of O +
phosphorylated O +
nucleotides O +
and O +
adducts O -
. O +

The O +
32 O +
P O +
-HPLC O +
method O +
for O +
analyses O +
of O +
postlabeled O +
DNA O +
adducts O +
is O +
described O +
in O +
detail O +
elsewhere O +
[ O -
25 O -
, O +
26 O -
] O +
. O +

2.3 O +
Detection O +
of O +
NF O -
- O -
DNA O +
adducts O +
after O +
different O +
enrichment O +
procedures O +
Butanol O +
extraction O +
and O +
nuclease B-Gene +
P1 I-Gene +
( O -
Sigma O -
, O +
St. O +
Louis O -
, O +
MO O -
) O +
treatment O +
were O +
run O +
in O +
parallel O +
for O +
the O +
comparison O +
of O +
enrichment O +
efficiency O +
of O +
the O +
NF O -
- O -
DNA O +
adducts O -
. O +

Liver O +
samples O +
were O +
collected O +
from O +
rats O +
receiving O +
11 O +
months O +
of O +
HD O +
NF O +
feeding O -
. O +

In O +
the O +
nuclease B-Gene +
P1 I-Gene +
enrichment O +
procedure O -
, O +
normal O +
nucleotides O +
were O +
dephosphorylated O +
by O +
40 O +
min O +
37 O -
° O -
C O +
incubation O +
with O +
nuclease B-Gene +
P1 I-Gene +
( O -
in O +
1 O +
mM O +
ZnCI2 O +
) O +
in O +
1 O +
μg O -
/ O -
μg O +
DNA O +
level O -
. O +

The O +
hydrolysates O +
were O +
thereafter O +
evaporated O +
to O +
dryness O +
and O +
redissolved O +
in O +
water O +
for O +
32 O +
P O +
-labeling O +
as O +
described O +
above O -
. O +

2.4 O +
Identification O +
of O +
NF O -
- O -
DNA O +
adducts O +
DNA O +
adducts O +
formed O +
in O +
the O +
liver O +
after O +
11-month O +
HD O +
NF O +
administration O +
were O +
co O -
- O -
chromatographed O +
with O +
DNA O +
adduct O +
standards O -
: O +
dGp O -
- O -
C8-AF O -
, O +
dGp O -
- O -
C8-AAF O +
and O +
dGp O -
- O -
N O +
2 O +
-AAF O +
( O -
Fig. O +
1 O +
) O -
. O +

The O +
DNA O +
adduct O +
standards O +
were O +
kindly O +
supplied O +
by O +
Dr. O +
F.A. O +
Beland O -
, O +
National O +
Center O +
for O +
Toxicological O +
Research O -
, O +
Jefferson O -
, O +
AR O -
, O +
USA O -
. O +

3 O +
Results O +
Four O +
DNA O +
adducts O +
( O -
DNA O +
adduct O +
A O -
, O +
B O -
, O +
C O +
and O +
D O -
) O +
were O +
found O +
in O +
rat O +
tissues O +
after O +
10 O +
days O +
as O +
well O +
as O +
11 O +
months O +
of O +
HD O +
NF O +
feeding O -
. O +

Fig. O +
2 O +
shows O +
representative O +
32 O +
P O +
-HPLC O +
chromatograms O +
of O +
DNA O +
adducts O +
formed O +
in O +
the O +
liver O -
, O +
kidney O +
and O +
spleen O +
after O +
10 O +
days O +
( O -
Fig. O +
2 O +
a O -
– O -
c O -
) O +
and O +
11 O +
months O +
( O -
Fig. O +
2 O +
d O -
– O -
f O -
) O +
of O +
HD O +
NF O +
feeding O -
. O +

DNA O +
adducts O +
A O +
and O +
B O +
increased O +
dramatically O +
in O +
the O +
liver O +
and O +
kidney O +
during O +
the O +
period O +
of O +
NF O +
administration O -
. O +

Adducts O +
C O +
and O +
D O +
showed O +
less O +
marked O +
changes O +
over O +
time O -
. O +

Fig. O +
3 O +
shows O +
representative O +
chromatograms O +
of O +
DNA O +
adducts O +
formed O +
in O +
forestomach O +
and O +
glandular O +
stomach O +
after O +
10 O +
days O +
of O +
HD O +
NF O +
administration O -
. O +

A O +
dramatic O +
difference O +
was O +
seen O +
between O +
these O +
two O +
tissues O +
regarding O +
DNA O +
adduct O +
levels O +
which O +
was O +
mainly O +
caused O +
by O +
high O +
DNA O +
adduct O +
D O +
level O +
in O +
the O +
forestomach O -
. O +

DNA O +
adducts O +
A O +
and O +
C O +
were O +
not O +
detectable O +
either O +
in O +
the O +
forestomach O +
or O +
the O +
glandular O +
stomach O -
. O +

Fig. O +
4 O +
displays O +
the O +
DNA O +
adduct O +
levels O +
in O +
different O +
tissues O +
after O +
10 O +
days O +
( O -
upper O -
) O +
and O +
11 O +
months O +
( O -
lower O -
) O +
of O +
HD O +
NF O +
feeding O -
, O +
respectively O -
. O +

After O +
10 O +
days O +
of O +
NF O +
feeding O -
, O +
the O +
levels O +
of O +
DNA O +
adducts O +
A O -
, O +
B O +
and O +
C O +
were O +
much O +
lower O +
compared O +
to O +
11 O +
months O +
of O +
NF O +
feeding O -
. O +

Adduct O +
D O -
, O +
which O +
was O +
a O +
major O +
DNA O +
adduct O +
especially O +
in O +
the O +
liver O +
at O +
early O +
stage O +
( O -
10 O +
days O -
) O +
of O +
NF O +
feeding O -
, O +
did O +
not O +
increase O +
significantly O +
over O +
time O +
( O -
10 O +
days O +
to O +
11 O +
months O -
) O -
. O +

Adducts O +
A O +
and O +
B O -
, O +
on O +
the O +
other O +
hand O -
, O +
increased O +
dramatically O +
during O +
the O +
NF O +
feeding O +
and O +
consequently O -
, O +
became O +
dominant O +
adducts O +
in O +
the O +
liver O +
and O +
kidney O +
after O +
11 O +
months O +
of O +
NF O +
feeding O -
. O +

Compared O +
to O +
the O +
liver O +
and O +
kidney O -
, O +
spleen O +
showed O +
a O +
different O +
adduct O +
pattern O +
in O +
which O +
adduct O +
A O +
was O +
not O +
detectable O -
. O +

Fig. O +
5 O +
shows O +
the O +
DNA O +
adduct O +
levels O +
formed O +
in O +
the O +
forestomach O +
and O +
glandular O +
stomach O +
after O +
10 O +
days O +
of O +
HD O +
NF O +
feeding O -
. O +

A O +
significant O +
difference O +
was O +
seen O +
with O +
respect O +
to O +
the O +
level O +
of O +
adduct O +
D O +
in O +
these O +
two O +
tissues O -
. O +

DNA O +
adducts O +
A O +
and O +
C O +
were O +
not O +
found O +
in O +
these O +
tissues O -
. O +

To O +
characterize O +
the O +
four O +
major O +
DNA O +
adducts O +
induced O +
by O +
NF O -
, O +
32 O +
P O +
-HPLC O +
co O -
- O -
chromatography O +
was O +
performed O -
. O +

DNA O +
adduct O +
D O +
co O -
- O -
migrated O +
with O +
dG O -
- O -
C8-AF O +
and O +
DNA O +
adduct O +
C O +
co O -
- O -
migrated O +
with O +
dG O -
- O -
N O +
2 O +
-AAF O -
. O +

Neither O +
DNA O +
adduct O +
A O +
nor O +
B O +
co O -
- O -
migrated O +
with O +
any O +
of O +
the O +
three O +
adduct O +
standards O +
( O -
Fig. O +
6 O +
) O -
. O +

Higher O +
levels O +
of O +
DNA O +
adduct O +
A O +
and O +
C O +
were O +
detected O +
after O +
nuclease B-Gene +
P1 I-Gene +
treatment O +
compared O +
to O +
the O +
butanol O +
extraction O -
. O +

On O +
the O +
other O +
hand O -
, O +
DNA O +
adducts O +
B O +
and O +
D O +
were O +
not O +
detectable O +
after O +
nuclease O +
P1 O +
treatment O +
( O -
Fig. O +
7 O +
) O -
. O +

The O +
decline O +
of O +
total O +
NF O -
- O -
DNA O +
adducts O +
in O +
the O +
rat O +
liver O +
after O +
the O +
withdrawal O +
of O +
MD O +
NF O +
administration O +
showed O +
a O +
biphasic O +
manner O +
( O -
Fig. O +
8 O +
) O -
. O +

The O +
pattern O +
of O +
DNA O +
adduct O +
removal O +
for O +
different O +
DNA O +
adducts O +
varied O -
. O +

Adducts O +
B O +
and O +
D O +
showed O +
a O +
sharp O +
drop O +
1 O +
month O +
after O +
the O +
withdrawal O +
of O +
NF O +
feeding O -
. O +

DNA O +
adduct O +
D O -
, O +
in O +
the O +
later O +
stage O +
of O +
the O +
period O -
, O +
reached O +
an O +
undetectable O +
level O -
. O +

On O +
the O +
other O +
hand O -
, O +
DNA O +
adducts O +
A O +
and O +
C O +
showed O +
a O +
slow O +
decline O -
. O +

DNA O +
adduct O +
A O +
maintained O +
a O +
high O +
level O +
after O +
11 O +
months O +
on O +
the O +
basal O +
diet O +
( O -
Fig. O +
8 O +
) O -
. O +

4 O +
Discussion O +
A O +
long O -
- O -
term O +
NF O +
feeding O +
to O +
rats O +
induces O +
tumors O +
in O +
the O +
liver O -
, O +
kidney O +
and O +
forestomach O +
[ O -
23 O -
] O +
. O +

Both O +
DNA O +
adduct O +
levels O +
and O +
tumor O +
formation O +
showed O +
a O +
dose O -
- O -
dependent O +
manner O +
[ O -
23 O -
] O +
. O +

DNA O +
adduct O +
levels O +
after O +
short O -
- O -
term O +
( O -
days O -
) O +
NF O +
administration O +
were O +
associated O +
with O +
the O +
locations O +
of O +
tumors O +
up O +
to O +
2 O +
years O +
later O +
[ O -
23 O -
] O +
. O +

In O +
the O +
present O +
experiment O -
, O +
four O +
major O +
DNA O +
adducts O -
, O +
named O +
as O +
DNA O +
adduct O +
A O -
, O +
B O -
, O +
C O +
and O +
D O -
, O +
were O +
found O +
in O +
the O +
liver O +
and O +
kidney O +
after O +
10 O +
days O +
and O +
11 O +
months O +
of O +
NF O +
feeding O -
. O +

The O +
levels O +
of O +
different O +
NF O -
- O -
DNA O +
adducts O +
increased O +
with O +
varied O +
rates O +
during O +
the O +
period O +
of O +
NF O +
feeding O -
. O +

In O +
one O +
of O +
the O +
non O -
- O -
tumor O +
target O +
tissues O -
, O +
spleen O -
, O +
adducts O +
B O -
, O +
C O -
, O +
and O +
D O +
were O +
detected O +
at O +
low O +
levels O +
after O +
short- O +
or O +
long O -
- O -
term O +
of O +
NF O +
feeding O -
. O +

Glandular O +
stomach O -
, O +
as O +
another O +
non O -
- O -
tumor O +
target O +
tissue O -
, O +
showed O +
only O +
low O +
levels O +
of O +
DNA O +
adducts O +
B O +
and O +
D O +
after O +
10 O +
days O +
of O +
NF O +
feeding O -
. O +

DNA O +
adduct O +
formation O +
in O +
forestomach O +
after O +
11-month O +
NF O +
administration O +
could O +
not O +
be O +
analysed O +
since O +
multiple O +
tumors O +
which O +
generally O +
covered O +
the O +
forestomach O +
membrane O +
were O +
formed O +
in O +
this O +
tissue O +
in O +
almost O +
all O +
the O +
NF O -
- O -
dosed O +
rats O +
( O -
HD O -
, O +
MD O +
and O +
LD O +
group O -
) O -
. O +

At O +
the O +
early O +
stage O -
, O +
DNA O +
adduct O +
D O -
, O +
which O +
co O -
- O -
migrated O +
with O +
dG O -
- O -
C8-AF O -
, O +
constituted O +
a O +
large O +
part O +
of O +
total O +
NF O -
- O -
DNA O +
adducts O -
, O +
especially O +
in O +
the O +
liver O -
. O +

At O +
the O +
later O +
stage O +
of O +
NF O +
feeding O -
, O +
DNA O +
adducts O +
A O +
and O +
B O +
increased O -
, O +
becoming O +
the O +
major O +
part O +
of O +
total O +
DNA O +
adducts O -
, O +
while O +
DNA O +
adduct O +
D O +
( O -
dG O -
- O -
C8-AF O -
) O +
did O +
not O +
increase O +
significantly O +
compared O +
to O +
the O +
level O +
at O +
the O +
early O +
stage O -
. O +

Expressed O +
as O +
a O +
percentage O +
of O +
total O +
DNA O +
adducts O -
, O +
DNA O +
adduct O +
D O +
( O -
dG O -
- O -
C8-AF O -
) O +
decreased O +
from O +
42 O +
( O -
10-day O +
NF O +
administration O -
) O +
to O +
10 O -
% O +
of O +
total O +
DNA O +
adducts O +
( O -
11-month O +
NF O +
administration O -
) O +
in O +
the O +
liver O +
during O +
the O +
feeding O +
period O -
. O +

The O +
rat O +
stomach O +
consists O +
of O +
two O +
parts O -
, O +
i.e. O -
, O +
the O +
forestomach O +
and O +
the O +
glandular O +
stomach O -
. O +

A O +
dramatically O +
higher O +
DNA O +
adduct O +
level O +
was O +
detected O +
in O +
the O +
forestomach O -
, O +
corresponding O +
to O +
the O +
high O +
tumor O +
incidence O +
in O +
this O +
tissue O -
, O +
compared O +
to O +
the O +
level O +
of O +
DNA O +
adducts O +
in O +
the O +
glandular O +
stomach O -
, O +
a O +
non O -
- O -
tumor O +
target O +
tissue O +
of O +
NF O +
[ O -
23 O -
] O +
. O +

In O +
the O +
high O +
dose O +
group O -
, O +
most O +
of O +
the O +
rats O +
grew O +
liver O +
tumors O +
while O +
they O +
were O +
still O +
on O +
NF O +
diet O +
or O +
not O +
long O +
after O +
the O +
termination O +
of O +
NF O +
diet O -
. O +

Samples O +
were O +
unable O +
to O +
be O +
collected O +
for O +
certain O +
period O +
after O +
the O +
termination O +
of O +
NF O +
diet O -
. O +

MD O +
group O +
of O +
rats O +
grew O +
tumors O +
in O +
a O +
scattered O +
time O +
points O +
generally O +
after O +
the O +
termination O +
of O +
NF O +
diet O -
. O +

Liver O +
samples O +
from O +
the O +
MD O +
group O +
were O +
therefore O +
chosen O +
for O +
the O +
study O +
of O +
DNA O +
adduct O +
persistence O -
. O +

The O +
use O +
of O +
mature O +
rats O +
minimizes O +
the O +
significance O +
of O +
DNA O +
adduct O +
dilution O +
through O +
cell O +
proliferation O +
in O +
the O +
liver O -
. O +

The O +
early O +
rapid O +
diminution O +
of O +
DNA O +
adducts O +
followed O +
by O +
a O +
slower O +
rate O +
of O +
elimination O +
was O +
seen O +
for O +
adducts O +
B O +
and O +
D O +
( O -
but O +
not O +
for O +
adducts O +
A O +
and O +
C O -
) O -
. O +

The O +
biphasic O +
removal O +
is O +
consistent O +
with O +
what O +
observed O +
in O +
rat O +
tissues O +
after O +
in O +
vivo O +
administration O +
of O +
substances O +
that O +
form O +
bulky O +
adducts O +
[ O -
16 O -
, O +
27–30 O -
] O +
. O +

The O +
two O -
- O -
step O +
removal O +
process O +
may O +
be O +
attributed O +
to O +
the O +
heterogeneity O +
in O +
efficiency O +
of O +
DNA O +
repair O -
, O +
with O +
adducts O +
in O +
some O +
genomic O +
regions O +
being O +
more O +
accessible O +
to O +
DNA O +
repair O +
than O +
these O +
in O +
others O +
[ O -
31 O -
, O +
32 O -
] O +
. O +

Among O +
the O +
four O +
major O +
DNA O +
adducts O +
induced O +
by O +
NF O -
, O +
adduct O +
D O +
and O +
C O +
co O -
- O -
migrated O +
with O +
dG O -
- O -
C8-AF O +
and O +
dG O -
- O -
N O +
2 O +
-AAF O -
, O +
respectively O -
. O +

DNA O +
adducts O +
A O +
and O +
B O +
did O +
not O +
co O -
- O -
migrate O +
with O +
any O +
of O +
the O +
adduct O +
standards O +
used O -
. O +

Some O +
characteristics O +
of O +
the O +
four O +
NF O -
- O -
DNA O +
adducts O +
are O +
summarized O +
in O +
Table O +
1 O +
. O +

For O +
DNA O +
adduct O +
enrichment O -
, O +
generally O -
, O +
butanol O +
extraction O +
is O +
used O +
for O +
aromatic O +
amines O -
- O -
DNA O +
adducts O +
and O +
nuclease B-Gene +
P1 I-Gene +
is O +
used O +
for O +
PAHs O -
- O -
DNA O +
adducts O -
. O +

The O +
values O +
of O +
DNA O +
adduct O +
A O +
and O +
C O +
were O +
much O +
higher O +
after O +
nuclease B-Gene +
P1 I-Gene +
treatment O +
compared O +
to O +
that O +
of O +
butanol O +
extraction O -
. O +

On O +
the O +
other O +
hand O -
, O +
DNA O +
adducts O +
B O +
and O +
D O +
were O +
undetectable O +
when O +
the O +
nuclease B-Gene +
P1 I-Gene +
enrichment O +
procedure O +
was O +
used O -
. O +

DNA O +
adduct O +
A O +
as O +
an O +
unknown O +
major O +
NF O +
adduct O +
may O +
be O +
the O +
same O +
DNA O +
adduct O +
as O +
that O +
described O +
by O +
Wierckx O +
et O +
al. O +
[ O -
7 O -
] O +
. O +

This O +
DNA O +
adduct O +
could O +
possibly O +
represent O +
an O +
oxidative O +
NF O +
metabolite O +
reacted O +
with O +
DNA O -
, O +
either O +
via O +
a O +
ring O +
epoxide O +
or O +
via O +
a O +
reaction O +
with O +
the O +
hydroxyl O +
group O -
. O +

It O +
was O +
reported O +
that O +
OH O -
- O -
NFs O +
are O +
potent O +
genotoxins O +
with O +
a O +
hydroxy O +
function O +
at O +
position O +
7 O +
or O +
9 O +
of O +
NF O -
, O +
while O +
hydroxylization O +
at O +
position O +
5 O +
makes O +
a O +
detoxification O +
product O +
[ O -
33 O -
] O +
. O +

DNA O +
adduct O +
B O -
, O +
which O +
was O +
sensitive O +
to O +
nuclease B-Gene +
P1 I-Gene +
hydrolyzation O -
, O +
could O +
possibly O +
be O +
an O +
arylamine O +
DNA O +
adduct O +
[ O -
34 O -
, O +
35 O -
] O +
. O +

Another O +
possibility O +
is O +
that O +
DNA O +
adduct O +
B O +
is O +
the O +
bis O -
- O -
phosphate O +
of O +
DNA O +
adduct O +
A. O +
Upon O +
nuclease B-Gene +
P1 I-Gene +
treatment O -
, O +
DNA O +
adduct O +
B O +
is O +
converted O +
to O +
DNA O +
adduct O +
A. O +
Since O +
DNA O +
adduct O +
levels O +
varied O +
after O +
different O +
enrichment O +
procedures O +
( O -
Fig. O +
7 O +
) O -
, O +
it O +
is O +
therefore O +
of O +
importance O +
to O +
relate O +
DNA O +
adduct O +
levels O +
to O +
specific O +
enrichment O +
procedures O -
. O +

Culp O +
et O +
al. O +
[ O -
36 O -
] O +
demonstrates O +
a O +
biphasic O +
removal O +
of O +
DNA O +
adducts O +
in O +
the O +
rat O +
liver O +
after O +
administration O +
of O +
AAF O -
. O +

The O +
present O +
study O +
dealt O +
with O +
NF O -
, O +
which O +
is O +
mainly O +
but O +
not O +
completely O +
metabolized O +
to O +
AF O +
and O +
AAF O +
in O +
rats O +
[ O -
2 O -
, O +
3 O -
, O +
5 O -
] O +
. O +

Two O +
DNA O +
adducts O -
, O +
i.e. O -
, O +
dG O -
- O -
C8-AF O +
and O +
dG O -
- O -
N O +
2 O +
-AAF O -
, O +
were O +
induced O +
in O +
the O +
rat O +
liver O +
both O +
by O +
NF O +
( O -
present O +
study O -
) O +
and O +
AAF O +
[ O -
36 O -
] O +
. O +

Although O +
the O +
strain O +
of O +
the O +
rats O +
and O +
length O +
of O +
administration O +
are O +
different O +
between O +
the O +
present O +
study O +
and O +
the O +
AAF O +
study O +
[ O -
36 O -
] O +
, O +
the O +
persistence O +
of O +
the O +
two O +
common O +
DNA O +
adducts O +
is O +
rather O +
consistent O -
. O +

Three O +
out O +
of O +
the O +
four O +
NF O -
- O -
DNA O +
adducts O +
were O +
still O +
detectable O +
in O +
rat O +
liver O +
after O +
the O +
rats O +
were O +
on O +
basal O +
diet O +
for O +
11 O +
months O -
. O +

The O +
long O +
persistence O +
of O +
NF O -
- O -
DNA O +
adducts O +
may O +
increase O +
their O +
chances O +
to O +
be O +
fixed O +
as O +
mutations O -
. O +

In O +
conclusion O -
, O +
the O +
air O +
pollutant O +
NF O +
induces O +
mainly O +
four O +
DNA O +
adducts O -
. O +

Two O +
DNA O +
adducts O -
, O +
i.e. O -
, O +
adducts O +
C O +
and O +
D O -
, O +
are O +
characterized O +
as O +
dG O -
- O -
N O +
2 O +
-AAF O +
and O +
dG O -
- O -
C8-AF O -
, O +
respectively O -
. O +

DNA O +
adducts O +
A O +
and O +
B O -
, O +
with O +
structures O +
unknown O -
, O +
are O +
the O +
major O +
NF O -
- O -
DNA O +
adducts O +
after O +
11 O +
months O +
of O +
NF O +
feeding O -
. O +

NF O -
- O -
DNA O +
adducts O +
persist O +
long O +
after O +
the O +
withdrawal O +
of O +
NF O -
, O +
especially O +
DNA O +
adducts O +
A O +
and O +
C O +
which O +
are O +
repaired O +
only O +
to O +
a O +
minor O +
extent O +
over O +
a O +
period O +
that O +
corresponds O +
to O +
approximately O +
half O +
the O +
life O +
time O +
of O +
the O +
rats O -
. O +

Three O +
out O +
of O +
the O +
four O +
NF O -
- O -
DNA O +
adducts O +
are O +
still O +
detectable O +
in O +
the O +
rat O +
liver O +
11 O +
months O +
after O +
the O +
withdrawal O +
of O +
NF O +
feeding O -
. O +

Further O +
characterization O +
of O +
individual O +
NF O -
- O -
DNA O +
adducts O +
may O +
help O +
to O +
elucidate O +
the O +
mechanism O +
of O +
NF O -
- O -
induced O +
carcinogenesis O -
. O +

Acknowledgements O +
The O +
authors O +
wish O +
to O +
express O +
their O +
gratitude O +
to O +
Mary O -
- O -
Ann O +
Zetterqvist O +
for O +
skillful O +
technical O +
assistance O -
. O +

This O +
study O +
was O +
supported O +
by O +
grants O +
from O +
Swedish O +
Environmental O +
Protection O +
Agency O +
and O +
Swedish O +
Cancer O +
Society O -
. O +

Nausea O +
and O +
vomiting O +
are O +
frequent O +
side O +
effects O +
caused O +
by O +
cancer O +
chemotherapeutic O +
agents O -
. O +

Traditional O +
Chinese O +
herbal O +
drugs O +
with O +
anti O -
- O -
emetic O +
potential O +
can O +
be O +
used O +
to O +
prevent O +
them O -
. O +

However O -
, O +
the O +
effects O +
of O +
anti O -
- O -
emetic O +
active O +
principles O +
of O +
these O +
crude O +
drugs O +
need O +
to O +
be O +
studied O +
using O +
modern O +
pharmacological O +
methods O -
. O +

One O +
of O +
the O +
difficul­ties O +
in O +
testing O +
for O +
anti O -
- O -
emetic O +
activity O +
of O +
natural O +
prod­ucts O +
is O +
the O +
selection O +
of O +
adequate O +
animal O +
models O -
. O +

We O +
previously O +
reported O +
anti O -
- O -
emetic O +
principles O +
from O +
Magnolia O +
obovata O +
bark O -
, O +
Zingiber O +
officinale O +
rhizome O +
( O -
Kawai O +
et O +
al. O -
, O +
1994 O -
) O -
, O +
Inula O +
linariaefolia O +
flowers O +
and O +
Forsythia O +
suspensa O +
fruits O +
( O -
Kinoshita O +
et O +
al. O -
, O +
1996 O -
) O -
, O +
and O +
Poria O +
cocos O +
( O -
Tai O +
et O +
al. O -
, O +
1995 O -
) O +
using O +
frogs O +
as O +
test O +
sub­jects O -
. O +

The O +
long O +
emetic O +
latency O +
of O +
frogs O +
induced O +
by O +
the O +
emetic O +
agent O +
was O +
not O +
suitable O +
for O +
testing O +
many O +
samples O +
within O +
a O +
short O +
period O +
of O +
time O -
. O +

Therefore O -
, O +
we O +
studied O +
a O +
new O +
screening O +
method O +
using O +
chicks O +
for O +
anti O -
- O -
emetic O +
ac­tivity O +
( O -
Akita O +
et O +
al. O -
, O +
1998 O -
) O +
to O +
overcome O +
these O +
difficulties O -
. O +

The O +
present O +
paper O +
describes O +
the O +
screening O +
of O +
31 O +
ex­tracts O +
from O +
8 O +
traditional O +
Chinese O +
herbal O +
drugs O +
for O +
anti­emetic O +
activities O -
, O +
using O +
young O +
chicks O -
, O +
and O +
the O +
identifica­tion O +
of O +
some O +
of O +
the O +
active O +
principles O +
contained O +
in O +
Po­gostemon O +
cablin O +
( O -
Blanco O -
) O +
Benth O -
. O +

Materials O +
and O +
Methods O +
Materials O +

The O +
dry O +
plant O +
materials O +
used O +
here O +
were O +
commercial O +
products O -
. O +

Alpinia O +
katsumadai O +
seeds O -
, O +
Alpinia O +
officina­rum O +
rhizome O -
, O +
Amomum O +
kravanh O +
fruits O -
, O +
Amomum O +
tsao O -
- O -
ko O +
fruits O -
, O +
Amomum O +
xanthioides O +
fruits O -
, O +
Eupato­rium O +
fortunei O +
leaves O +
and O +
stem O -
, O +
and O +
Nelumbo O +
nucifera O +
seeds O +
were O +
purchased O +
from O +
Kotaro O +
Pharmaceutical O +
Co. O -
, O +
Ltd. O +
( O -
Osaka O -
, O +
Japan O -
) O -
. O +

Pogostemon O +
cab O -
/ O -
in O +
leaves O +
were O +
purchased O +
from O +
Kinokuniya O +
Kanyakkyoku O +
( O -
To­kyo O -
, O +
Japan O -
) O -
. O +

Spectrometry O +
and O +
chromatography O +
lH_and13C O -
- O -
NMRspectrawererecorded O +
usingaJEOL O +
GSX-400 O +
spectrometer O +
in O +
CDCl3 O +
or O +
DMSO O -
- O -
d6 O +
with O +
tet­ramethylsilane O +
as O +
an O +
internal O +
standard O -
. O +

Kieselgel O +
60 O +
F254-precoated O +
plates O +
were O +
employed O +
for O +
thin O -
- O -
layer O +
chromatography O +
( O -
TLC O -
) O -
. O +

Column O +
chromatography O +
was O +
carried O +
out O +
on O +
70 O -
- O -
230 O +
mesh O +
silica O +
gel O -
. O +

HPLC O +
was O +
per­formed O +
using O +
an O +
SSC-3100-J O +
pump O +
with O +
an O +
Oyo O -
- O -
Bunko O +
Uvilog O +
7 O +
UV O +
detector O -
. O +

HR O -
- O -
MS O +
and O +
EI O -
- O -
MS O +
were O +
ob­tained O +
using O +
a O +
JEOL O +
JMX O -
- O -
DX O +
302 O -
. O +

0944 O -
- O -
7113 O -
/ O -
99106 O -
/ O -
02 O -
- O -
089 O +
$ O +
12.0010 O +
Y. O +
Yang O +
et O +
al. O +

Animals O +
nally O +
at O +
a O +
volume O +
of O +
10 O +
rnl O -
/ O -
kg O -
. O +

After O +
10 O +
min O -
, O +
copper O +
sul­ O +
Young O +
male O +
chicks O +
( O -
4 O +
days O +
of O +
age O -
) O +
weighing O +
25 O -
- O -
35 O +
g O +
fate O +
anhydride O +
was O +
administered O +
orally O +
at O +
50 O +
mg O -
/ O -
kg O -
, O +
each O +
were O +
purchased O +
from O +
Goto O +
Furanjo O +
Co. O -
, O +
Ltd. O +
( O -
Sai­then O +
the O +
number O +
of O +
retching O +
( O -
an O +
emetic O +
action O +
without O +
tama O -
, O +
Japan O -
) O -
. O +

vomiting O +
gastric O +
materials O -
) O +
was O +
recorded O +
during O +
the O +
next O +
10 O +
min O -
. O +

The O +
results O +
were O +
judged O +
by O +
the O +
decrease O +
in O +
Bioassay O +
of O +
anti O -
- O -
emetic O +
activity O +
number O +
of O +
retching O +
in O +
contrast O +
with O +
those O +
of O +
control O -
. O +

The O +
young O +
chicks O +
were O +
divided O +
into O +
1 O -
- O -
3 O +
groups O +
con O +
­The O +
inhibition O +
( O -
% O -
) O +
was O +
calculated O +
as O +
follows O -
: O +
sisting O +
of O +
six O +
each O -
, O +
and O +
each O +
young O +
chick O +
was O +
set O +
asi­de O +
for O +
10 O +
min O +
to O +
stabilize O +
in O +
large O +
beakers O +
at O +
25 O -
° O -
C O -
. O +

The O +
Inhibition O +
( O -
% O -
) O +
= O +
[ O -
( O -
A O -
- O -
B O -
) O -
A O -
] O +
X O +
100 O +
sample O +
was O +
dissolved O +
in O +
0.9 O +
% O +
saline O +
containing O +
5 O +
% O +
A O -
: O +
control O +
frequency O +
of O +
retching O +
DMSO O +
and O +
1 O +
% O +
Tween O +
80 O +
and O +
administered O +
abdomi O -
- O -
B O -
: O +
frequency O +
retching O +
after O +
sample O +
treatment O +
Table1 O -
. O +

Screeningtestofmedicinalplantsforanti O -
- O -
emeticeffectagainstcoppersulfate O -
- O -
inducedemesisinyoungchicks O -
. O +

Crude O +
drugs O +
Extracts O +
No. O +
of O +
young O +
chicks O +
No. O +
of O +
retches O +
Inhibition O +
( O -
mean O +
± O +
S.E.M. O -
) O +
( O -
% O +
) O +
control O +

6 O +
69.8 O +
± O +
3.19 O +
Pogostemon O +
cab O -
/ O -
in O +
n O -
- O -
hexane O +
6 O +
28.9 O +
± O +
4.31 O +

* O -
* O -
* O +
58.6 O +
CHCl3 O +
6 O +
45.8 O +
± O +
6.75 O -
" O -
' O +
34.4 O +
MeOH O +
6 O +
47.8 O +
± O +
6.39 O -
" O +
31.5 O +
control O +
6 O +
70.6 O +
± O +
1.25 O +
Alpinia O +
katsumadai O +
n O -
- O -
hexane O +
6 O +
52.4 O +
±3.39 O -
* O -
* O +
25.8 O +
CHCl3 O +
6 O +
28.0 O +
± O +
5.09 O +

* O +

* O +

* O +
60.3 O +
MeOH O +
6 O +
18.4 O +
± O +
0.93 O +

* O -
* O -
* O +
73.9 O +
H2O O +
6 O +
46.2 O +
± O +
8.12 O +
34.6 O +
control O +
6 O +
48.8 O +
± O +
4.34 O +
Amomum O +
tsao O -
- O -
ko O +
n O -
- O -
hexane O +
6 O +
46.6 O +
± O +
3.29 O +
4.5 O +
CHCl3 O +
6 O +
36.6 O +
± O +
5.39 O +
25.6 O +
MeOH O +
6 O +
22.2 O +
± O +
3.28 O +

* O +

* O -
* O +
54.5 O +
H2O O +
6 O +
39.3 O +
± O +
7.23 O +
19.5 O +
control O +
6 O +
75.9 O +
± O +
1.38 O +
Amomum O +
kravanh O +
n O -
- O -
hexane O +
6 O +
78.6 O +
± O +
3.14 O +
-3.6 O +
CHCl3 O +
6 O +
36.0 O +
± O +
5.96 O -
* O -
* O +
52.6 O +
MeOH O +
6 O +
70.0 O +
± O +
11.0 O +
7.8 O +
H2O O +
6 O +
52.0 O +
±2.98 O -
" O +
31.5 O +
control O +
6 O +
64.5 O +
± O +
4.46 O +
Amomum O +
xanthioides O +
n O -
- O -
hexane O +
6 O +
41.8 O +
± O +
9.05 O -
* O +
35.2 O +
CHCI3 O +
6 O +
29.8 O +
± O +
3.94 O +

* O +

* O +
* O +

53.8 O +
MeOH O +
6 O +
34.8 O +
± O +
8.47 O -
* O +
46.0 O +
H2O O +
6 O +
43.5 O +
± O +
7.70 O -
' O -
: O -
' O +
32.6 O +
control O +
6 O +
68.2±2.31 O +
Eupatorium O +
[ O -
ortunei O +
n O -
- O -
hexane O +
6 O +
61.3 O +
± O +
6.68 O +
10.1 O +
CHCI3 O +
6 O +
46.3 O +
± O +
7.32 O +
32.1 O +
MeOH O +
6 O +
50.8 O +
± O +
2.42 O +

* O -
* O +
* O +
25.5 O +
H2O O +
6 O +
54.2 O +
± O +
3.16 O -
* O +
20.5 O +
control O +
6 O +
86.8 O +
± O +
3.69 O +
Nelumbo O +
nucifera O +
n O -
- O -
hexane O +
6 O +
75.3 O +
± O +
9.81 O +
13.2 O +
CHCl3 O +
6 O +
63.2 O +
±3.06 O -
* O -
" O +
27.2 O +
MeOH O +
6 O +
77.6 O +
± O +
2.98 O +
10.6 O +
H2O O +
6 O +
71.6 O +
± O +
5.83 O +
17.6 O +
control O +
6 O +
44.5 O +
± O +
2.33 O +
Alpinia O +
officinarum O +
n O -
- O -
hexane O +
6 O +
37.5 O +
± O +
4.19 O +
15.7 O +
CHel3 O +
6 O +
24.2 O +
± O +
3.23 O +

* O +

* O -
* O +
45.6 O +
MeOH O +
6 O +
32.7 O +
± O +
3.74 O -
* O +
26.5 O +
H2O O +
6 O +
31.2 O +
± O +
4.26 O -
* O +
29.9 O +
Significantly O +
different O +
from O +
the O +
control O +
value O -
, O +
" O -
p O +
< O +
0.05 O -
, O +
" O -
" O -
p O +
< O +
0.01 O -
, O +
* O -
, O -
' O +
" O -
p O +
< O +
0.001 O -
. O +

fate O -
- O -
induced O +
emesis O +
in O +
young O +
chicks O -
. O +

Drugs O +
Dose O +
No. O +
of O +
young O +
chicks O +
No O +
. O +

of O +
retches O +
Inhibition O +
( O -
mg O -
/ O -
kg O -
) O +
( O -
rnean O +
e O +
SEM O -
) O +
( O -
% O -
) O +
control O +
6 O +
47 O +
.8 O +
: O -
! O -
: O +
6.14 O +
Fr O -
. O +

1 O +
150 O +
6 O +
37.4:!:5.17 O +
21.8 O +
Fr O -
. O +

2 O +
150 O +
6 O +
11.6 O -
: O -
! O +

: O +

7.08 O -
· O -
· O -
· O -
· O +
75 O -
. O +
7 O +
Fr O -
. O +

3 O +
150 O +
6 O +
7.6 O +
: O -
! O +

: O +
1.25 O +

* O -
* O -
" O +
84.1 O +
control O +
6 O +
45 O +
.0 O +
: O -
! O -
: O +
8.45 O +
Fr O -
. O +

4 O +
150 O +
6 O +
31.2:!:3.36 O +
30.7 O +
Fr O -
. O +

5 O +
150 O +
6 O +
25 O -
. O +
7 O -
: O -
! O +

: O +
6.92 O +
42.9 O +
Fr O -
. O +

6 O +
150 O +
6 O +
28.4 O +
: O -
! O +

: O +
6.95 O +
36.9 O +
control O +
6 O +
47.8 O +
: O -
! O -
: O +
6.14 O +
Fr O -
. O +

7 O +
150 O +
6 O +
21 O -
. O +
6 O +
: O -
! O +

: O +
4.25 O +
" O -
* O +
54.8 O +
Fr O -
. O +

8 O +
150 O +
6 O +
38.2 O +
: O -
! O +

: O +

7.87 O +
20.1 O +
Significantly O +
different O +
from O +
the O +
control O +
value O -
, O +
* O -
p O +
< O +
0.05 O -
, O +

* O -
* O -
p O +
< O +
0.01 O -
, O +
" O +

* O -
* O +
p O +
< O +
0.001 O -
. O +

Table O +
3 O -
. O +

Anti O -
- O -
emetic O +
effects O +
of O +
compounds O +
1 O -
- O -
5 O +
against O +
sulfate O -
- O -
induced O +
emesis O +
in O +
young O +
chicks O -
. O +

Drugs O +
Dose O +
No. O +
of O +
young O +
chicks O +
No. O +
of O +
retches O +
Inhibition O +
( O -
mg O -
/ O -
kg O -
) O +
( O -
mean O +
a O +
SEM O -
) O +
( O -
% O +
) O +
control O +
6 O +
60.0 O +
: O -
! O +

: O +
4.73 O +
patchouli O +
alcohol O +
( O -
1 O -
) O +
10 O +
6 O +
54.5 O +
: O -
! O -
: O +
7.58 O +
9.2 O +
20 O +
6 O +
50.3 O +
: O -
! O +

: O +
6.90 O +
16.2 O +
50 O +
6 O +
36.0 O -
: O -
! O +

: O +
3.69 O +

* O -
" O +
40.0 O +
70 O +
6 O +
25.4 O -
: O -
! O +

: O +

2.80 O +

* O +

* O -
" O +
57.7 O +
control O +
5 O +
67.2 O +
: O -
! O -
: O +
2.81 O +
pogostol O +
( O -
2 O -
) O +
10 O +
5 O +
40.8 O +
: O -
! O +

: O +
4.79 O +

* O +

* O +
39.3 O +
20 O +
5 O +
38.8 O +
: O -
! O +

: O +
8.73 O -
* O +
42.3 O +
50 O +
5 O +
38.2 O -
: O -
! O +

: O +
6.13 O -
" O -
* O +
43.2 O +
control O +
6 O +
55.7 O -
: O -
! O -
: O +
4.6 O +
stigmast-4-en-10 O +
6 O +
54.9 O -
: O -
! O -
: O +
8.80 O +
1.4 O +
3-one O +
( O -
3 O -
) O +
20 O +
6 O +
39.6 O +
: O -
! O -
: O +

7.48 O +
28.9 O +
50 O +
6 O +
24.7 O +
: O -
! O +

: O +
1.21 O +
" O -
> O -
' O -
* O +
55.7 O +
control O +
6 O +
67.5 O +
: O -
! O -
: O +
6.63 O +
retusin O +
( O -
4 O -
) O +
10 O +
6 O +
49.0 O -
: O -
! O -
: O +
6.97 O +
27.4 O +
20 O +
6 O +
48.0 O -
: O -
! O -
: O +

4.97 O -
* O +
28.9 O +
50 O +
6 O +
36.7:!:3.21 O -
* O -
* O +
45.6 O +
control O +
5 O +
56.6 O +
: O -
! O -
: O +
3.93 O +
pachypodol O +
( O -
5 O -
) O +
10 O +
5 O +
53.4 O -
: O -
! O -
: O +
3.93 O +
5.7 O +
20 O +
5 O +
44.6 O -
: O -
! O +

: O +
7.27 O +
21.2 O +
50 O +
5 O +
28.0 O +
: O -
! O +

: O +
3.09 O -
' O -
' O -
' O -
' O -
* O +
50.5 O +
Significantly O +
different O +
from O +
the O +
control O +
value O -
, O +
" O -
p O +
< O +
0.05 O -
, O +
* O -
" O -
p O +
< O +
0.01 O -
, O +
* O +

* O -
" O -
p O +
< O +
0.001 O -
. O +

Statistical O +
analysis O +
was O +
concentrated O +
to O +
yield O +
n O -
- O -
hexane O -
, O +
CHCI3 O -
, O +
MeOH O -
, O +
All O +
numerical O +
data O +
were O +
expressed O +
as O +
the O +
mean O +
: O -
t O +
and O +
water O +
extracts O -
, O +
respectively O -
. O +

S.E.M. O +
The O +
statistical O +
significance O +
of O +
the O +
difference O +
was O +
determined O +
by O +
an O +
unpaired O +
student O -
's O +
z O -
- O -
test O -
, O +
Isolation O +
and O +
purification O +
of O +
the O +
anti O -
- O -
emetic O +
principles O +
from O +
Pogostemon O +
cablin O +
Preparation O +
of O +
extract O +
The O +
crushed O +
dry O +
leaves O +
of O +
Pogostemon O +
cablin O +
( O -
1 O +
kg O -
) O +
Crusheddryplantmaterials O -
( O -
1kg O -
) O -
wereextractedthree O +
wereextractedsuccessivelywithn O -
- O -
hexane O -
, O -
CHCI3,and O +
timessuccessively O +
with4In O -
- O -
hexane O -
, O -
CHCI3,MeOH O +
MeOH O -
, O +
andeach O +
extractwasexaminedforanti O -
- O -
emetic O +
and O +
water O +
at O +
room O +
temperature O +
for O +
24 O +
h. O +

Each O +
extract O +
activity O +
using O +
young O +
chicks O -
. O +

The O +
n O -
- O -
hexane O +
extract O +
Y. O +
Yang O +
et O +
al. O +
patchouli O +
alcohol O -
( O -
1 O -
) O +
pogostol O +
( O -
2 O -
) O +
sigmast-4-en-3-one O +
( O -
3 O -
) O +
OCHa O +
OH O +
HaCO O +
HaCO O +
OCHa O +
OCH3 O +
OH0 O +
OH0 O +
pachypodol O +
( O -
5 O -
) O +
retusin O -
( O -
4 O -
) O +
Fig. O +
1 O -
. O +

The O +
structures O +
of O +
active O +
compounds O +
isolated O +
from O +
Pogostemon O +
cab O -
/ O -
in O +
Benth O +
which O +
showed O +
the O +
highest O +
anti O -
- O -
emetic O +
activity O +
( O -
58.6 O +
% O -
) O +
was O +
chromatographed O +
on O +
a O +
silica O +
gel O +
column O +
( O -
n O -
- O -
hex­ane O -
: O +
EtOAc O -
) O -
, O +
and O +
8 O +
fractions O +
( O -
fr O -
, O +
1 O -
- O -
8 O -
) O +
obtained O -
. O +

Each O +
fraction O +
was O +
tested O +
for O +
anti O -
- O -
emetic O +
activity O -
, O +
and O +
fro O +
2 O -
, O +
fro O +
3 O -
, O +
fro O +
7 O +
showed O +
positive O +
activity O +
( O -
Table O +
2 O -
) O -
. O +

Fraction O +
2 O +
was O +
subjected O +
to O +
HPLC O +
using O +
a O +
silica O +
gel O +
co­lumn O +
[ O -
Silica-4251-N O +
10 O +
0 O +
X O +
250 O +
mm O -
, O +
n O -
- O -
Hexane­EtOAc O +
( O -
11:1 O -
) O -
] O -
, O +
and O +
compound O +
1 O +
( O -
l.72 O -
g O -
) O +
was O +
obtained O +
and O +
identified O +
as O +
patchouli O +
alcohol O +
by O +
comparison O +
with O +
published O +
spectral O +
data O +
( O -
Barton O +
et O +
al. O -
, O +
1987 O -
) O -
. O +

An O +
active O +
fraction O -
, O +
fro O +
3 O -
, O +
was O +
chromatographed O +
on O +
a O +
silica O +
gel O +
column O +
( O -
n O -
- O -
hexane O -
: O +
acetone O -
) O +
and O +
HPLC O +
using O +
a O +
silica O +
gel O +
column O +
[ O -
Silica-4251-N O +
100 O +
X O +
250 O -
mm O -
, O +
n­Hexane O -
- O -
EtOAc O +
( O -
5:1 O -
) O -
] O -
. O +

Compounds O +
2 O +
( O -
79.7 O +
mg O -
) O +
and O +
3 O +
( O -
41.3 O +
mg O -
) O +
were O +
identified O +
as O +
pogostol O +
and O +
stigmast-4­en O -
- O -
S O -
- O -
one O +
by O +
comparison O +
with O +
published O +
spectral O +
data O +
( O -
Hikino O +
et O +
al. O -
, O +
1968 O -
; O +
Greca O +
et O +
al. O -
, O +
1990 O -
) O -
. O +

Fraction O +
7 O +
was O +
subjected O +
to O +
on O +
HPLC O +
using O +
a O +
silica O +
gel O +
column O +
[ O -
Silica-4251-N O +
100 O +
X O +
250 O -
mm O -
, O +
n O -
- O -
Hexane­acetone O +
( O -
75:25 O -
) O -
] O -
, O +
and O +
compounds O +
4 O +
( O -
62.6 O +
mg O -
) O +
and O +
5 O +
( O -
48.0 O +
mg O -
) O +
were O +
obtained O +
and O +
examined O +
by O +
MS O -
, O +
lH O -
_ O +
and O +
13C O -
- O -
NMR O -
, O +
DEPT O +
experiment O -
, O +
IH_13C O +
COSY O -
, O +
IH_13C O +
long O +
range O +
COSY O +
( O -
COLOq O +
and O +
the O +
difference O +
of O +
Overhauser O +
enhancement O +
( O -
nOe O -
) O +
spectra O -
. O +

These O +
obser­ O +
vations O +
suggested O +
that O +
compounds O +
4 O +
and O +
5 O +
were O +
retusin O +
and O +
pachypodol O -
, O +
respectively O -
. O +

Results O +
and O +
Discussion O +
As O +
shown O +
in O +
Table O +
1,20 O +
extracts O +
significantly O +
inhibited O +
emetic O +
action O +
induced O +
by O +
CUS04 O +
in O +
young O +
chicks O -
. O +

The O +
n O -
- O -
hexane O -
, O +
CHCl3 O +
and O +
MeOH O +
extracts O +
of O +
Pogostemon O +
cablin O +
showed O +
significant O +
inhibition O +
at O +
a O +
dose O +
of O +
300 O +
mg O -
/ O -
kg O -
. O +

Patchouli O +
alcohol O +
( O -
1 O -
) O -
, O +
pogostol O +
( O -
2 O -
) O -
, O +
stigmast-4­en-3-one O +
( O -
3 O -
) O -
, O +
retusin O +
( O -
4 O -
) O +
and O +
pachypodol O +
( O -
5 O -
) O +
previously O +
isolated O +
from O +
the O +
n O -
- O -
hexane O +
extract O +
( O -
Barton O +
et O +
al. O -
, O +
1987 O -
; O +
Hinoki O +
et O +
al. O -
, O +
1968 O -
; O +
Greca O +
et O +
al. O -
, O +
1990 O -
; O +
Dominquez O +
et O +
al. O -
, O +
1968 O -
; O +
Valesi O +
et O +
al. O -
, O +
1972 O -
) O +
also O +
showed O +
anti O -
- O -
emetic O +
activity O +
Patchouli O +
alcohol O +
( O -
1 O -
) O +
was O +
active O +
at O +
two O +
doses O +
of O +
50 O +
mg O -
/ O -
kg O +
and O +
70 O +
mg O -
/ O -
kg O -
. O +

Pogostol O +
( O -
2 O -
) O +
significantly O +
inhibit­ed O +
emetic O +
action O +
at O +
three O +
doses O +
of O +
10 O +
mg O -
/ O -
kg-50 O +
mg O -
/ O -
kg O -
. O +

Stigmast-4-en-3-one O +
( O -
3 O -
) O +
and O +
pachypodol O +
( O -
5 O -
) O +
showed O +
anti O -
- O -
emetic O +
activity O +
at O +
doses O +
of O +
50 O +
mg O -
/ O -
kg O -
. O +

Retusin O +
( O -
4 O -
) O +
inhibited O +
emetic O +
action O +
at O +
two O +
doses O +
of O +
20 O +
mg O -
/ O -
kg O +
and O +
50 O +
mg O -
/ O -
kg O -
. O +

Pogostemon O +
cablin O +
is O +
one O +
of O +
the O +
traditional O +
Chinese O +
medicines O +
used O +
mainly O +
for O +
the O +
treatment O +
of O +
dyspepsia O -
, O +
vomiting O -
, O +
diarrhea O +
and O +
poor O +
appetite O -
. O +

It O +
is O +
also O +
known O +
that O +
inward O +
Ca2 O -
+ O +
influx O +
through O +
the O +
cell O +
membranes O +
may O +
induce O +
excessive O +
excitation O +
of O +
smooth O +
muscles O -
, O +
and O +
excessive O +
contraction O +
of O +
digestive O +
organ O +
muscles O +
may O +
cause O +
vomiting O +
and O +
diarrhea O -
. O +

Therefore O -
, O +
the O +
Ca2 O +
+ O +
antagonist O +
is O +
expected O +
to O +
alleviate O +
those O +
symptoms O +
by O +
depressing O +
excessive O +
contraction O +
of O +
digestive O +
organ O +
muscles O -
. O +

It O +
has O +
been O +
reported O +
that O +
patchouli O +
alcohol O +
showed O +
Ca2 O -
+ O +
antagonist O +
activity O +
in O +
vitro O +
( O -
Ichikawa O +
et O +
al. O -
, O +
1989 O -
) O -
. O +

These O +
results O +
indicate O +
that O +
the O +
anti O -
- O -
emetic O +
activity O +
of O +
patchouli O +
alcohol O +
may O +
be O +
due O +
to O +
depressing O +
excessive O +
contraction O +
of O +
digestive O +
organ O +
muscles O +
by O +
in­hibition O +
of O +
inward O +
Ca2 O -
+ O +
influx O +
through O +
the O +
cell O +
embra­nes O -
. O +

Patchouli O +
alcohol O +
contained O +
abundantly O +
in O +
Po­gostemon O +
cablin O +
( O -
> O +
0.1 O +
% O -
) O +
may O +
playa O +
main O +
role O +
in O +
anti O -
- O -
emetic O +
effect O +
clinically O +
in O +
view O +
of O +
its O +
traditional O +
use O +
in O +
Chinese O +
medicine O -
. O +

Acknowledgements O +
The O +
authors O +
would O +
like O +
to O +
thank O +
Professor O +
emeritus O +
Shoji O +
Shibata O -
, O +
University O +
of O +
Tokyo O -
, O +
for O +
his O +
encouragement O -
. O +

This O +
study O +
was O +
partly O +
supported O +
by O +
a O +
Sasakawa O +
Scientific O +
Research O +
Grant O +
from O +
the O +
Japan O +
Science O +
Society O +
( O -
1996 O -
- O -
7 O -
) O -
. O +

Anti O -
- O -
emetic O +
principles O +
of O +
Pogostemon O +
cablin O +

SCH66336 O -
, O +
( O -
+ O -
) O +
4- O -
{ O -
2- O -
[ O -
4- O -
( O -
8-chloro-3 O -
, O +
10-dibromo-6 O -
, O +
11-dihydro-5H O -
- O -
benzo O +
[ O -
5,6 O -
] O +
cyclohepta O +
[ O -
1,2-b O -
] O +
pyridin-11-yl O -
) O -
-1-piperidinyl O -
] O -
-2-oxoethyl O -
} O -
-1-piperidinecarboxamide O +
( O -
Fig. O +
1 O +
) O -
, O +
is O +
a O +
potent O +
inhibitor O +
of O +
farnesyl B-Gene +
protein I-Gene +
transferase I-Gene +
( O -
FPT B-Gene -
) O -
. O +

FPT B-Gene +
catalyzes O +
the O +
initial O +
step O +
in O +
the O +
post O -
- O -
translational O +
processing O +
of O +
the O +
ras O +
gene O -
, O +
that O +
is O -
, O +
the O +
transfer O +
of O +
the O +
15-carbon O +
farnesyl O +
group O +
onto O +
a O +
cysteine O +
residue O +
in O +
the O +
carboxy O +
terminal O +
of O +
all O +
Ras B-Gene +
proteins I-Gene +
[ O -
1–6 O -
] O +
. O +

The O +
farnesylation O +
step O +
appears O +
to O +
be O +
essential O +
for O +
Ras B-Gene +
proteins I-Gene +
to O +
become O +
membrane O -
- O -
associated O +
and O +
induces O +
cell O +
transformation O +
[ O -
4 O -
] O +
. O +

In O +
normal O +
cells O -
, O +
Ras B-Gene +
protein I-Gene +
in O +
its O +
active O +
GTP O -
- O -
bound O +
state O +
initiates O +
several O +
intracellular O +
signaling O +
pathways O +
that O +
lead O +
to O +
cell O +
proliferation O +
and O +
differentiation O -
. O +

The O +
signal O +
is O +
terminated O +
by O +
the O +
hydrolysis O +
of O +
GTP O +
to O +
the O +
inactive O +
GDP O -
- O -
bound O +
form O +
of O +
the O +
Ras B-Gene +
protein I-Gene +
[ O -
7 O -
] O +
. O +

The O +
capacity O +
of O +
certain O +
oncogenic O +
forms O +
of O +
Ras B-Gene +
to O +
hydrolyze O +
GTP O +
to O +
GDP O +
is O +
greatly O +
reduced O -
, O +
leading O +
to O +
continuous O +
intracellular O +
signaling O +
which O +
results O +
in O +
alteration O +
of O +
cellular O +
proliferation O +
and O +
differentiation O +
[ O -
4,8 O -
] O +
. O +

Oncogenic O +
forms O +
of O +
Ras B-Gene +
proteins I-Gene +
have O +
been O +
reported O +
to O +
be O +
associated O +
with O +
nearly O +
one O -
- O -
third O +
of O +
all O +
human O +
cancers O -
, O +
including O +
50 O -
% O +
of O +
colon O +
cancers O +
and O +
90 O -
% O +
of O +
pancreatic O +
cancers O +
[ O -
4 O -
] O +
. O +

Blocking O +
the O +
farnesylation O +
step O +
by O +
inhibiting O +
FPT B-Gene +
is O +
an O +
attractive O +
target O +
for O +
the O +
discovery O +
of O +
compounds O +
with O +
anti O -
- O -
tumor O +
activity O +
[ O -
9 O -
] O +
. O +

This O +
form O +
of O +
therapy O +
has O +
enormous O +
potential O +
because O +
of O +
the O +
prevalance O +
of O +
mutated O +
ras B-Gene +
gene O +
in O +
human O +
cancers O +
[ O -
4,10 O -
] O +
. O +

In O +
vivo O +
studies O +
in O +
nude O +
mice O +
demonstrated O +
that O +
SCH O +
66336 O +
has O +
a O +
potent O +
oral O +
activity O +
profile O +
in O +
a O +
wide O +
array O +
of O +
human O +
tumor O +
xenograft O +
models O +
including O +
tumors O +
of O +
colon O -
, O +
lung O -
, O +
pancreas O -
, O +
prostate O -
, O +
and O +
urinary O +
bladder O +
origin O +
[ O -
11 O -
] O +
. O +

When O +
used O +
to O +
treat O +
Ha B-Gene -
- I-Gene -
Ras I-Gene +
transgenic O +
mice O +
with O +
spontaneously O +
occurring O +
tumors O +
prior O +
to O +
tumor O +
onset O -
, O +
SCH O +
66336 O +
delayed O +
tumor O +
onset O -
, O +
reduced O +
the O +
average O +
number O +
of O +
tumors O +
per O +
mouse O +
and O +
reduced O +
the O +
average O +
tumor O +
weight O +
per O +
animal O +
[ O -
11 O -
] O +
. O +

In O +
a O +
therapeutic O +
mode O -
, O +
where O +
gavage O +
treatment O +
was O +
initiated O +
after O +
the O +
transgenic O +
mice O +
had O +
developed O +
palpable O +
tumors O -
, O +
significant O +
tumor O +
regression O +
was O +
induced O +
by O +
SCH O +
66336 O +
in O +
a O +
dose O -
- O -
dependent O +
fashion O +
[ O -
11 O -
] O +
. O +

The O +
issue O +
of O +
chirality O +
has O +
emerged O +
as O +
a O +
major O +
theme O +
in O +
drug O +
design O +
and O +
discovery O +
[ O -
12,13 O -
] O +
. O +

Since O +
enantiomers O +
often O +
differ O +
in O +
pharmacological O +
activity O -
, O +
toxicity O +
and O +
pharmacokinetics O +
characteristics O -
, O +
it O +
is O +
important O +
that O +
enantiomeric O +
drug O +
candidates O +
be O +
evaluated O +
in O +
an O +
optically O +
pure O +
form O -
. O +

SCH O +
66336 O +
is O +
a O +
single O +
enantiomer O +
which O +
contains O +
one O +
chiral O +
center O -
. O +

During O +
the O +
discovery O +
stage O +
of O +
this O +
compound O -
, O +
it O +
was O +
of O +
interest O +
to O +
determine O +
its O +
pharmacokinetics O +
and O +
possible O +
chiral O +
inversion O +
in O +
animals O +
prior O +
to O +
administration O +
in O +
humans O -
. O +

Therefore O -
, O +
these O +
studies O +
were O +
initiated O +
to O +
develop O +
HPLC O +
methods O +
for O +
its O +
determination O +
in O +
cynomolgus O +
monkey O +
plasma O +
and O +
for O +
the O +
evaluation O +
of O +
its O +
chiral O +
inversion O +
in O +
rat O +
and O +
cynomolgus O +
monkey O +
plasma O +
that O +
had O +
been O +
dosed O +
with O +
SCH O +
66336 O -
. O +

2 O +
Experimental O +
2.1 O +
Reagents O +
Hexane O -
, O +
methanol O -
, O +
acetonitrile O -
, O +
methylene O +
chloride O -
, O +
ethanol O -
, O +
diethyl O +
amine O +
and O +
sodium O +
bicarbonate O +
were O +
purchased O +
from O +
Fisher O +
Scientific O +
( O -
Fair O +
Lawn O -
, O +
NJ O -
, O +
USA O -
) O -
. O +

SCH O +
66336 O -
, O +
SCH O +
66337 O +
( O -
enantiomer O +
of O +
SCH O +
66336 O -
) O +
and O +
SCH O +
66347 O +
( O -
internal O +
standard O +
for O +
the O +
chiral O +
assay O -
) O +
were O +
provided O +
by O +
Schering O -
- O -
Plough O +
Research O +
Institute O +
( O -
Kenilworth O -
, O +
NJ O -
, O +
USA O -
) O -
. O +

Azatadine O +
maleate O +
( O -
internal O +
standard O +
for O +
the O +
achiral O +
assay O -
) O +
was O +
obtained O +
from O +
U.S. O +
Pharmacopeial O +
Convention O -
, O +
Inc. O +
( O -
Rockville O -
, O +
MD O -
, O +
USA O -
) O -
. O +

2.2 O +
Calibration O +
standards O +
For O +
the O +
achiral O +
HPLC O +
analysis O -
, O +
stock O +
solution O +
of O +
SCH O +
66336 O +
was O +
prepared O +
in O +
methanol O +
at O +
200 O +
μg O -
/ O -
ml O -
; O +
the O +
internal O +
standard O +
was O +
prepared O +
in O +
water O +
at O +
100 O +
μg O -
/ O -
ml O -
. O +

The O +
stock O +
solutions O +
were O +
stored O +
at O +
−20 O -
° O -
C O -
. O +

Eight O +
calibration O +
standards O +
( O -
at O +
0.1 O -
, O +
0.2 O -
, O +
0.5 O -
, O +
1 O -
, O +
2 O -
, O +
5 O -
, O +
10 O -
, O +
and O +
20 O +
μg O -
/ O -
ml O -
) O +
were O +
prepared O +
in O +
triplicate O +
on O +
each O +
of O +
three O +
validation O +
days O -
. O +

Three O +
sets O +
of O +
quality O +
control O +
samples O +
( O -
QC O +
samples O -
) O +
at O +
concentration O +
of O +
0.2 O +
( O -
low O -
) O -
, O +
1.5 O +
( O -
medium O -
) O +
and O +
15 O +
μg O -
/ O -
ml O +
( O -
high O -
) O +
were O +
prepared O +
in O +
bulk O +
from O +
separate O +
weighing O -
, O +
aliquotted O +
and O +
stored O +
at O +
−20 O -
° O -
C O +
for O +
use O +
during O +
the O +
entire O +
validation O +
and O +
sample O +
analysis O -
. O +

For O +
the O +
chiral O +
HPLC O +
assay O -
, O +
stock O +
solutions O +
of O +
SCH O +
66336 O -
, O +
SCH O +
66337 O +
and O +
SCH O +
66347 O +
were O +
prepared O +
in O +
methanol O +
at O +
100 O +
μg O -
/ O -
ml O +
and O +
stored O +
at O +
−20 O -
° O -
C O -
. O +

Three O +
sets O +
of O +
quality O +
control O +
samples O +
at O +
concentration O +
of O +
0.4 O +
( O -
low O -
) O -
, O +
2.5 O +
( O -
medium O -
) O +
and O +
8.0 O +
μg O -
/ O -
ml O +
( O -
high O -
) O +
were O +
prepared O +
in O +
bulk O +
from O +
separate O +
weighings O -
, O +
aliquotted O +
and O +
stored O +
at O +
−20 O -
° O -
C O +
for O +
use O +
during O +
the O +
entire O +
validation O +
and O +
sample O +
analysis O -
. O +

2.3 O +
Sample O +
preparation O +
For O +
the O +
achiral O +
assay O -
, O +
a O +
0.2-ml O +
volume O +
of O +
monkey O +
plasma O +
standard O -
, O +
QC O +
sample O +
or O +
unknown O +
was O +
placed O +
into O +
a O +
15-ml O +
screw O -
- O -
capped O +
test O +
tube O +
containing O +
0.2 O +
ml O +
of O +
internal O +
standard O +
solution O +
( O -
2 O +
μg O -
/ O -
ml O -
) O -
. O +

Saturated O +
sodium O +
bicarbonate O +
solution O +
( O -
0.3 O +
ml O -
) O +
was O +
added O +
followed O +
by O +
4.0 O +
ml O +
of O +
30 O -
% O +
( O -
v O -
/ O -
v O -
) O +
methylene O +
chloride O +
in O +
hexane O -
, O +
mixed O +
on O +
a O +
mechanical O +
vortexer O +
for O +
10 O +
min O +
and O +
centrifuged O -
. O +

The O +
organic O +
layer O +
was O +
transferred O +
into O +
15-ml O +
conical O +
test O +
tubes O +
and O +
20 O +
μl O +
of O +
0.8 O +
M O +
HCl O +
in O +
methanol O +
was O +
added O -
. O +

The O +
samples O +
were O +
evaporated O +
to O +
dryness O +
at O +
40 O -
° O -
C O +
under O +
a O +
gentle O +
stream O +
of O +
nitrogen O -
, O +
the O +
residue O +
was O +
reconstituted O +
in O +
0.2 O +
ml O +
of O +
mobile O +
phase O +
and O +
50 O +
μl O +
was O +
injected O +
onto O +
the O +
HPLC O +
column O +
for O +
analysis O -
. O +

For O +
the O +
chiral O +
analysis O -
, O +
a O +
0.2-ml O +
volume O +
of O +
rat O +
or O +
monkey O +
plasma O +
standard O -
, O +
QC O +
sample O -
, O +
or O +
unknown O +
was O +
applied O +
onto100 O +
mg O +
of O +
the O +
solid O -
- O -
phase O +
extraction O +
( O -
SPE O -
) O +
cartridge O +
ethyl O +
Bond O +
Elute O +
cartridge O +
which O +
has O +
been O +
pre O -
- O -
washed O +
with O +
3 O +
ml O +
of O +
methanol O +
and O +
3 O +
ml O +
of O +
water O -
. O +

The O +
SPE O +
cartridge O +
was O +
washed O +
with O +
2 O +
ml O +
of O +
water O +
and O +
2 O +
ml O +
of O +
10 O -
% O +
( O -
v O -
/ O -
v O -
) O +
acetonitrile O +
in O +
water O -
. O +

The O +
compounds O +
were O +
eluted O +
with O +
3 O +
ml O +
of O +
acetonitrile O -
. O +

The O +
eluate O +
was O +
evaporated O +
to O +
dryness O +
under O +
nitrogen O +
and O +
the O +
residue O +
was O +
reconstituted O +
with O +
0.5 O +
ml O +
of O +
mobile O +
phase O -
; O +
a O +
0.1 O +
ml O +
aliquot O +
was O +
injected O +
onto O +
the O +
HPLC O +
column O +
for O +
analysis O -
. O +

2.4 O +
Chromatographic O +
conditions O +
The O +
HPLC O +
system O +
consisted O +
of O +
a O +
Shimadzu O +
LC-10 O +
AD O +
pump O +
and O +
a O +
Waters O +
486 O +
absorbance O +
detector O +
set O +
at O +
280 O +
nm O -
. O +

The O +
achiral O +
separation O +
was O +
accomplished O +
on O +
a O +
Spherisorb O +
CN O -
, O +
5 O +
μm O -
, O +
150 O -
× O -
4.6 O +
mm O +
column O +
which O +
was O +
preceded O +
by O +
an O +
on O -
- O -
line O +
filter O -
. O +

The O +
Millennium O +
2020 O +
Chromatography O +
Manager O +
Soft O +
System O +
was O +
used O +
for O +
data O +
handling O -
. O +

The O +
mobile O +
phase O +
consisted O +
of O +
0.02 O +
M O +
potassium O +
phosphate O +
( O -
pH O +
4 O -
) O -
–acetonitrile O +
( O -
65:35 O -
, O +
v O -
/ O -
v O -
) O -
, O +
and O +
was O +
delivered O +
at O +
0.9 O +
ml O -
/ O -
min O -
. O +

The O +
chiral O +
HPLC O +
method O +
involved O +
the O +
use O +
of O +
a O +
Chiral O +
Pak O +
AD O +
column O +
( O -
Chiral O +
Technologies O -
, O +
Eaton O -
, O +
PA O -
) O +
set O +
at O +
39 O -
° O -
C O +
and O +
a O +
mobile O +
phase O +
of O +
hexane O -
– O -
ethanol O -
– O -
diethylamine O +
( O -
30:70:0.2 O -
, O +
v O -
/ O -
v O -
/ O -
v O -
) O +
at O +
a O +
flow O +
of O +
0.8 O +
ml O -
/ O -
min O -
. O +

2.5 O +
Administration O +
of O +
SCH O +
66336 O +
Six O +
male O +
cynomolgus O +
monkeys O +
were O +
dosed O +
orally O +
with O +
a O +
100-mg O +
experimental O +
tablet O +
of O +
SCH O +
66336 O +
( O -
approximately O +
15 O +
mg O -
/ O -
kg O -
) O +
for O +
pharmacokinetic O +
evaluation O -
. O +

Also O -
, O +
rats O +
and O +
cynomolgus O +
monkeys O +
were O +
given O +
SCH O +
66336 O +
at O +
a O +
single O +
oral O +
dose O +
of O +
300 O +
and O +
120 O +
mg O -
/ O -
kg O -
, O +
respectively O -
, O +
as O +
a O +
suspension O +
in O +
0.4 O -
% O +
methylcellulose O +
for O +
the O +
evaluation O +
of O +
chiral O +
inversion O +
of O +
SCH O +
66336 O -
. O +

Blood O +
samples O +
were O +
collected O +
at O +
intervals O +
after O +
dosing O -
, O +
centrifuged O +
and O +
plasma O +
stored O +
at O +
−20 O -
° O -
C O +
pending O +
analysis O -
. O +

Plasma O +
concentrations O +
equal O +
to O +
or O +
above O +
the O +
limit O +
of O +
quantitation O +
( O -
LOQ O -
, O +
0.1 O +
μg O -
/ O -
ml O -
) O +
were O +
used O +
for O +
pharmacokinetic O +
analysis O +
using O +
model O -
- O -
independent O +
methods O +
[ O -
14 O -
] O +
. O +

The O +
maximum O +
plasma O +
concentration O +
( O -
C O +
max O +
) O +
and O +
time O +
of O +
maximum O +
plasma O +
concentration O +
( O -
T O +
max O +
) O +
were O +
the O +
observed O +
values O -
. O +

The O +
area O +
under O +
the O +
plasma O +
concentration O -
– O -
time O +
curve O +
from O +
time O +
zero O +
to O +
the O +
time O +
of O +
the O +
final O +
measurable O +
sample O +
[ O -
AUC O -
( O -
tf O -
) O -
] O +
was O +
calculated O +
using O +
the O +
linear O +
trapezoidal O +
method O -
, O +
and O +
was O +
extrapolated O +
to O +
infinity O +
( O -
I O +
) O +
according O +
to O +
the O +
following O +
equation O -
: O -
AUC O -
( O -
I O +
) O -
= O -
AUC O -
( O -
tf O -
) O -
+C O +
( O -
tf O -
) O -
/ O -
k O +
where O +
C O +
( O -
tf O -
) O +
is O +
the O +
estimated O +
concentration O +
at O +
tf O +
using O +
the O +
above O +
regression O -
. O +

3 O +
Results O +
3.1 O +
Achiral O +
HPLC O +
Typical O +
chromatograms O +
of O +
drug O -
- O -
free O +
monkey O +
plasma O +
and O +
plasma O +
spiked O +
with O +
SCH O +
66336 O +
and O +
the O +
internal O +
standard O +
azatadine O +
maleate O +
are O +
illustrated O +
in O +
Fig. O +
2 O +
. O +

The O +
retention O +
times O +
of O +
SCH O +
66336 O +
and O +
the O +
internal O +
standard O +
were O +
approximately O +
7.2 O +
and O +
10.5 O +
min O -
, O +
respectively O -
. O +

There O +
were O +
no O +
endogenous O +
peaks O +
in O +
plasma O +
of O +
six O +
undosed O +
monkeys O +
that O +
coeluted O +
with O +
SCH O +
66336 O +
or O +
the O +
internal O +
standard O -
, O +
indicating O +
that O +
the O +
method O +
was O +
selective O -
. O +

The O +
linearity O +
of O +
the O +
assay O +
was O +
evaluated O +
over O +
a O +
concentration O +
range O +
of O +
0.1–20 O +
μg O -
/ O -
ml O -
. O +

Linear O +
regression O +
parameters O +
of O +
the O +
peak O +
height O +
ratios O +
versus O +
concentrations O +
along O +
with O +
back O -
- O -
calculated O +
concentrations O +
of O +
nine O +
calibration O +
curves O +
are O +
presented O +
in O +
Table O +
1 O +
. O +

The O +
results O +
showed O +
highly O +
reproducible O +
calibration O +
curves O +
with O +
correlation O +
coefficients O +
of O +
> O -
0.99 O -
, O +
indicating O +
that O +
the O +
response O +
was O +
linear O +
over O +
the O +
concentration O +
range O +
studied O -
. O +

Intra O -
- O -
day O +
precision O +
and O +
accuracy O +
were O +
evaluated O +
at O +
SCH O +
66336 O +
concentrations O +
of O +
0.2 O -
, O +
1.5 O +
and O +
15 O +
μg O -
/ O -
ml O -
. O +

Six O +
samples O +
were O +
analyzed O +
at O +
each O +
concentration O +
on O +
the O +
same O +
day O -
. O +

The O +
results O +
showed O +
satisfactory O +
intra O -
- O -
day O +
precision O +
and O +
accuracy O +
as O +
indicated O +
by O +
a O +
coefficient O +
of O +
variation O +
( O -
CV O -
) O +
of O +
< O -
2.5 O -
% O +
and O +
a O +
bias O +
of O +
< O -
5.1 O -
% O +
( O -
Table O +
2 O +
) O -
. O +

Inter O -
- O -
day O +
precision O +
and O +
accuracy O +
were O +
evaluated O +
at O +
the O +
same O +
concentrations O +
as O +
above O +
and O +
the O +
samples O +
were O +
analyzed O +
on O +
three O +
separate O +
days O -
. O +

The O +
results O +
demonstrated O +
satisfactory O +
inter O -
- O -
day O +
precision O +
and O +
accuracy O +
as O +
shown O +
by O +
CV O +
and O +
bias O +
values O +
of O +
< O -
3.4 O -
% O +
and O +
< O -
6.1 O -
% O -
, O +
respectively O +
( O -
Table O +
3 O +
) O -
. O +

The O +
LOQ O -
, O +
defined O +
as O +
the O +
lowest O +
concentration O +
in O +
the O +
calibration O +
curve O +
that O +
could O +
be O +
determined O +
with O +
acceptable O +
precision O +
and O +
accuracy O -
, O +
was O +
0.1 O +
μg O -
/ O -
ml O -
. O +

At O +
this O +
concentration O -
, O +
the O +
precision O +
and O +
accuracy O +
from O +
the O +
back O -
- O -
calculated O +
concentrations O +
were O +
satisfactory O +
( O -
CV=5 O -
% O -
, O +
bias O +
0 O -
% O -
; O +
Table O +
1 O +
) O -
. O +

The O +
recovery O +
was O +
consistent O +
over O +
a O +
concentration O +
range O +
of O +
0.2–15 O +
μg O -
/ O -
ml O +
( O -
> O -
83 O -
% O -
) O -
. O +

The O +
recovery O +
of O +
the O +
internal O +
standard O +
at O +
the O +
concentration O +
used O +
( O -
2.0 O +
μg O -
/ O -
ml O -
) O +
was O +
88.7 O -
% O -
. O +

The O +
stability O +
of O +
SCH O +
66336 O +
in O +
plasma O +
was O +
evaluated O +
through O +
three O +
freeze O -
– O -
thaw O +
cycles O +
at O +
concentrations O +
of O +
0.2 O -
, O +
1.5 O +
and O +
15 O +
μg O -
/ O -
ml O -
. O +

The O +
samples O +
were O +
thawed O +
in O +
a O +
water O +
bath O +
at O +
room O +
temperature O +
and O +
frozen O +
within O +
5 O +
min O +
of O +
thawing O +
in O +
each O +
cycle O -
. O +

After O +
three O +
cycles O -
, O +
the O +
changes O +
from O +
nominal O +
concentrations O +
were O +
−5.0 O -
, O +
+ O -
13.3 O +
and O +
+ O -
12.7 O -
% O +
for O +
the O +
0.2 O -
, O +
1.5 O +
and O +
15 O +
μg O -
/ O -
ml O -
, O +
respectively O -
, O +
demonstrating O +
that O +
SCH O +
66336 O +
was O +
stable O +
in O +
plasma O +
through O +
three O +
freeze O -
– O -
thaw O +
cycles O -
. O +

Long O -
- O -
term O +
stability O +
was O +
determined O +
following O +
316 O +
days O +
of O +
storage O +
at O +
−20 O -
° O -
C O +
at O +
the O +
concentrations O +
above O -
. O +

The O +
changes O +
from O +
the O +
nominal O +
concentrations O +
ranged O +
from O +
0.7–5.0 O -
% O +
indicating O +
that O +
SCH O +
66336 O +
was O +
stable O +
in O +
plasma O +
for O +
at O +
least O +
316 O +
days O -
. O +

In O -
- O -
process O +
stability O +
was O +
performed O +
for O +
up O +
to O +
72 O +
h O +
after O +
sample O +
processing O -
. O +

Three O +
sets O +
of O +
processed O +
plasma O +
samples O +
at O +
the O +
above O +
SCH O +
66336 O +
concentrations O +
were O +
analyzed O +
after O +
storage O +
at O +
room O +
temperature O +
for O +
72 O +
h. O +
The O +
changes O +
from O +
nominal O +
concentrations O +
were O +
−5.0 O -
, O +
2.0 O +
and O +
3.3 O -
% O +
for O +
the O +
0.2 O -
, O +
1.5 O +
and O +
15 O +
μg O -
/ O -
ml O -
, O +
respectively O -
, O +
demonstrating O +
that O +
SCH O +
66336 O +
was O +
stable O +
under O +
the O +
conditions O +
evaluated O -
. O +

3.2 O +
Chiral O +
HPLC O +
Typical O +
chromatograms O +
of O +
drug O -
- O -
free O +
rat O +
and O +
cynomolgus O +
monkey O +
plasma O +
and O +
plasma O +
spiked O +
with O +
the O +
internal O +
standard O -
, O +
SCH O +
66336 O +
and O +
its O +
enantiomer O +
SCH O +
66337 O +
are O +
illustrated O +
in O +
Figs. O +
3 O +
and O +
4 O +
, O +
respectively O -
. O +

The O +
retention O +
times O +
of O +
SCH O +
66337 O -
, O +
SCH O +
66336 O +
and O +
the O +
internal O +
standard O +
were O +
approximately O +
5.7 O -
, O +
8.3 O +
and O +
13.4 O +
min O -
, O +
respectively O -
. O +

There O +
were O +
no O +
endogenous O +
peaks O +
in O +
plasma O +
of O +
undosed O +
rats O +
or O +
monkeys O +
that O +
coeluted O +
with O +
SCH O +
66337 O -
, O +
SCH O +
66336 O +
or O +
the O +
internal O +
standard O -
, O +
indicating O +
that O +
the O +
method O +
was O +
selective O -
. O +

The O +
linearity O +
was O +
evaluated O +
over O +
a O +
concentration O +
range O +
of O +
0.25–10 O +
μg O -
/ O -
ml O -
, O +
the O +
correlation O +
coefficients O +
were O +
> O -
0.99 O +
indicating O +
that O +
the O +
response O +
was O +
linear O +
over O +
the O +
concentration O +
range O +
studied O +
( O -
Tables O +
4 O +
and O +
5 O +
) O -
. O +

Intra O -
- O -
day O +
precision O +
and O +
accuracy O +
were O +
evaluated O +
at O +
plasma O +
SCH O +
66337 O +
and O +
SCH O +
66336 O +
concentrations O +
of O +
0.4 O -
, O +
2.5 O +
and O +
8.0 O +
μg O -
/ O -
ml O -
. O +

Three O +
samples O +
were O +
analyzed O +
at O +
each O +
concentration O +
on O +
the O +
same O +
day O -
; O +
the O +
results O +
are O +
shown O +
in O +
Table O +
6 O +
. O +

Intra O -
- O -
day O +
precision O +
and O +
accuracy O +
were O +
satisfactory O +
as O +
indicated O +
by O +
a O +
CV O +
of O +
< O -
13 O -
% O +
and O +
a O +
bias O +
of O +
< O -
12 O -
% O +
for O +
both O +
enantiomers O -
. O +

The O +
LOQ O +
was O +
0.25 O +
μg O -
/ O -
ml O -
; O +
at O +
this O +
concentration O -
, O +
the O +
precision O +
and O +
accuracy O +
from O +
the O +
back O -
- O -
calculated O +
concentrations O +
were O +
satisfactory O +
( O -
CV O +
< O -
14 O -
% O -
, O +
bias=6 O -
% O -
) O -
. O +

The O +
recovery O +
values O +
at O +
10 O +
μg O -
/ O -
ml O +
for O +
SCH O +
66337 O -
, O +
SCH O +
66336 O +
and O +
the O +
internal O +
standard O +
were O +
83 O -
, O +
80 O +
and O +
79 O -
% O -
, O +
respectively O -
. O +

4 O +
Discussion O +
SCH O +
66336 O +
belongs O +
to O +
the O +
tricyclic O +
class O +
of O +
FPT B-Gene +
inhibitors O +
which O +
are O +
structurally O +
distinct O +
from O +
other O +
reported O +
FPT B-Gene +
inhibitors O -
, O +
many O +
of O +
which O +
were O +
derived O +
from O +
peptidomimetic O +
approaches O +
[ O -
15,16 O -
] O +
. O +

These O +
differences O -
, O +
including O +
the O +
absence O +
of O +
a O +
sulfhydryl O +
function O -
, O +
are O +
likely O +
to O +
contribute O +
to O +
the O +
favorable O +
oral O +
pharmacokinetic O +
properties O +
of O +
the O +
tricyclic O +
class O -
. O +

Initial O +
compounds O +
in O +
this O +
series O -
, O +
such O +
as O +
SCH O +
44342 O +
( O -
IC50 O +
= O -
250 O +
nM O +
) O -
, O +
displayed O +
less O +
than O +
optimal O +
pharmacokinetic O +
properties O +
in O +
the O +
mouse O -
, O +
including O +
a O +
very O +
rapid O +
oxidative O +
metabolism O +
[ O -
15 O -
] O +
. O +

Blocking O +
the O +
susceptible O +
metabolic O +
sites O +
on O +
SCH O +
44342 O +
greatly O +
improved O +
the O +
pharmacokinetic O +
properties O +
of O +
compounds O +
in O +
this O +
series O -
. O +

SCH O +
66336 O +
was O +
the O +
lead O +
compound O +
that O +
emerged O +
from O +
these O +
efforts O -
. O +

In O +
addition O +
to O +
improved O +
metabolic O +
stability O -
, O +
its O +
intrinsic O +
potency O +
was O +
also O +
improved O +
as O +
indicated O +
by O +
an O +
FPT B-Gene +
IC50 O +
of O +
1.9 O +
nM O +
. O +

Due O +
to O +
these O +
improvements O -
, O +
SCH O +
66336 O +
persisted O +
in O +
mouse O +
serum O +
at O +
concentrations O +
greater O +
than O +
its O +
IC50 O +
for O +
Ha B-Gene -
- I-Gene -
Ras I-Gene +
processing O +
in O +
Cos O +
cells O +
for O +
over O +
16 O +
h O +
following O +
a O +
single O +
oral O +
dose O +
of O +
25 O +
mg O -
/ O -
kg O +
[ O -
11 O -
] O +
. O +

We O +
have O +
attempted O +
to O +
improve O +
the O +
sensitivity O +
of O +
the O +
achiral O +
HPLC O +
method O +
by O +
solid O -
- O -
phase O +
extraction O +
on O +
ethyl O +
column O -
. O +

However O -
, O +
because O +
of O +
the O +
high O +
plasma O +
background O -
, O +
the O +
sensitivity O +
was O +
reduced O +
( O -
LOQ O +
was O +
0.25 O +
μg O -
/ O -
ml O -
) O -
. O +

Gas O +
chromatography O +
( O -
GC O -
) O +
with O +
electron O +
capture O +
detection O +
( O -
ECD O -
) O +
appeared O +
to O +
be O +
a O +
suitable O +
mean O +
for O +
developing O +
a O +
sensitive O +
assay O -
, O +
since O +
the O +
compound O +
contains O +
three O +
halogens O +
( O -
Fig. O +
1 O +
) O -
. O +

Because O +
SCH O +
66336 O +
was O +
non O -
- O -
volatile O -
, O +
the O +
GC O +
column O +
temperature O +
needed O +
to O +
be O +
kept O +
above O +
320 O -
° O -
C O +
to O +
observe O +
a O +
signal O -
. O +

However O -
, O +
the O +
compound O +
was O +
thermally O +
unstable O +
at O +
this O +
high O +
temperature O -
. O +

The O +
achiral O +
analytical O +
method O +
was O +
used O +
to O +
characterize O +
the O +
pharmacokinetic O +
profile O +
of O +
SCH O +
66336 O +
in O +
the O +
cynomolgus O +
monkey O +
treated O +
orally O +
with O +
a O +
100-mg O +
experimental O +
capsule O +
of O +
SCH O +
66336 O -
. O +

SCH O +
66336 O +
was O +
quantifiable O +
in O +
plasma O +
between O +
2 O +
and O +
24 O +
h O +
after O +
oral O +
administration O +
( O -
Fig. O +
5 O +
) O -
. O +

The O +
mean O +
C O +
max O +
of O +
SCH O +
66336 O +
was O +
6.82 O +
μg O -
/ O -
ml O +
which O +
was O +
attained O +
at O +
a O +
mean O +
T O +
max O +
of O +
7.67 O +
h. O +

The O +
area O +
under O +
the O +
plasma O +
concentration O -
– O -
time O +
curve O +
( O -
AUC0–24 O +
h O +
) O +
was O +
84.5 O +
μg O +
h O -
/ O -
ml O +
( O -
Table O +
7 O +
) O -
. O +

Enantiomers O +
of O +
biologically O +
active O +
molecules O +
may O +
differ O +
in O +
potency O -
, O +
pharmacological O +
action O -
, O +
metabolism O -
, O +
toxicity O +
and O +
pharmacokinetics O +
[ O -
12 O -
] O +
. O +

Therefore O -
, O +
it O +
is O +
highly O +
desirable O +
that O +
only O +
the O +
active O +
enantiomer O +
be O +
the O +
drug O +
candidate O -
. O +

The O +
tools O +
for O +
chiral O +
resolution O +
have O +
been O +
progressively O +
improving O +
by O +
the O +
development O +
of O +
a O +
great O +
variety O +
of O +
chiral O +
HPLC O -
- O -
stationary O +
phases O -
. O +

Chiral O +
phases O +
containing O +
cavities O +
such O +
as O +
cyclodextrins O +
or O +
cellulose O +
derivatives O +
have O +
played O +
a O +
significant O +
role O +
in O +
the O +
area O +
of O +
chiral O +
resolution O +
[ O -
13 O -
] O +
. O +

The O +
chiral O +
recognition O +
of O +
cavity O -
- O -
containing O +
stationary O +
phases O +
is O +
believed O +
to O +
be O +
a O +
result O +
of O +
the O +
insertion O +
of O +
the O +
aromatic O +
portion O +
of O +
the O +
solute O +
into O +
the O +
chiral O +
cavity O -
, O +
in O +
addition O +
to O +
hydrogen O +
bonding O +
interactions O -
. O +

A O +
great O +
number O +
of O +
chiral O +
drugs O +
have O +
been O +
resolved O +
on O +
cyclodextrin O +
( O -
cyclobond O -
) O -
, O +
cellulose O +
( O -
chiralcel O -
) O +
or O +
amylose O +
( O -
chiralpak O -
) O +
based O +
columns O -
. O +

Several O +
chiral O +
HPLC O +
columns O +
were O +
evaluated O +
for O +
the O +
separation O +
of O +
SCH O +
66336 O +
and O +
SCH O +
66336 O +
including O +
Cyclobond O +
1 O -
, O +
Chiralcel O +
OD O +
( O -
cellulose O +
carbamate O +
derivative O -
) O +
and O +
Chiralpak O +
AD O +
( O -
amylose O +
carbamate O +
derivative O -
) O -
. O +

The O +
Cyclobond O +
1 O +
and O +
Chiralcel O +
OD O +
columns O +
gave O +
broad O +
peaks O +
with O +
asymmetric O +
peak O +
shape O +
( O -
tailing O -
) O +
without O +
baseline O +
separations O -
. O +

The O +
Chiralpak O +
AD O +
column O +
was O +
selected O +
because O +
of O +
symmetrical O +
peaks O +
and O +
baseline O +
separation O +
resulting O +
in O +
a O +
better O +
sensitivity O -
. O +

The O +
chiral O +
HPLC O +
method O +
was O +
used O +
to O +
evaluate O +
the O +
possible O +
chiral O +
inversion O +
of O +
SCH O +
66336 O +
in O +
animals O -
. O +

It O +
should O +
be O +
pointed O +
out O +
that O +
SCH O +
66336 O +
administered O +
to O +
animals O +
contained O +
approximately O +
1.5–2.0 O -
% O +
SCH O +
66337 O +
as O +
an O +
impurity O -
. O +

In O +
rat O +
plasma O -
, O +
SCH O +
66337 O +
concentrations O +
were O +
below O +
the O +
LOQ O -
, O +
while O +
the O +
concentrations O +
of O +
SCH O +
66336 O +
ranged O +
from O +
5.5–25.0 O +
μg O -
/ O -
ml O -
. O +

In O +
cynomolgus O +
monkey O +
plasma O -
, O +
the O +
concentrations O +
of O +
SCH O +
66336 O +
were O +
within O +
the O +
range O +
of O +
0.32– O +
28.9 O +
μg O -
/ O -
ml O -
, O +
while O +
those O +
for O +
SCH O +
66337 O +
were O +
within O +
the O +
range O +
of O +
below O +
the O +
LOQ O +
to O +
0.9 O +
μg O -
/ O -
ml O -
. O +

The O +
ratios O +
of O +
the O +
concentrations O +
of O +
SCH O +
66337 O +
to O +
SCH O +
66337 O +
in O +
the O +
samples O +
that O +
contained O +
quantifiable O +
levels O +
of O +
both O +
analytes O +
were O +
within O +
the O +
range O +
of O +
2.5–3 O -
% O -
, O +
which O +
is O +
similar O +
to O +
the O +
ratio O +
seen O +
as O +
an O +
impurity O +
in O +
SCH O +
66336 O -
. O +

Therefore O -
, O +
it O +
is O +
concluded O +
that O +
SCH O +
66336 O +
is O +
not O +
subjected O +
to O +
chiral O +
inversion O +
in O +
rats O +
and O +
cynomolgus O +
monkeys O -
. O +

In O +
conclusion O -
, O +
the O +
HPLC O +
assay O +
for O +
the O +
determination O +
of O +
SCH O +
66336 O +
in O +
cynomolgus O +
monkey O +
plasma O +
was O +
shown O +
to O +
be O +
accurate O +
and O +
reliable O +
over O +
a O +
concentration O +
range O +
of O +
0.1 O +
to O +
20 O +
μg O -
/ O -
ml O +
with O +
an O +
average O +
CV O +
of O +
6 O -
% O +
and O +
an O +
average O +
bias O +
of O +
7 O -
% O -
. O +

The O +
assay O +
was O +
used O +
successfully O +
to O +
monitor O +
plasma O +
concentrations O +
of O +
SCH O +
66336 O +
in O +
cynomolgus O +
monkey O -
. O +

A O +
reliable O +
chiral O +
HPLC O +
method O +
was O +
also O +
developed O +
to O +
separate O +
SCH O +
66336 O +
from O +
its O +
enantiomer O +
SCH O +
66337 O +
in O +
monkey O +
and O +
rat O +
plasma O -
. O +

Chiral O +
HPLC O +
analysis O +
indicated O +
that O +
SCH O +
66336 O +
was O +
not O +
subjected O +
to O +
chiral O +
inversion O +
in O +
rats O +
and O +
cynomolgus O +
monkeys O -
. O +

The O +
growing O +
demand O +
for O +
peptides O +
with O +
biological O -
, O +
pharmaceutical O +
and O +
food O +
ingredients O +
applications O +
requires O +
the O +
development O +
of O +
efficient O +
synthetic O +
methods O +
[ O -
1 O -
] O +
. O +

Recently O -
, O +
the O +
successful O +
performance O +
of O +
enzymatic O +
peptide O +
synthesis O +
in O +
heterogenous O +
substrate O +
mixtures O +
[ O -
2–5 O -
] O +
has O +
provided O +
a O +
new O +
and O +
efficient O +
route O +
to O +
peptide O +
syntheses O -
. O +

It O +
was O +
found O +
that O +
some O +
amino O +
acid O +
amides O +
can O +
form O +
supercooled O +
liquid O +
mixtures O +
with O +
N O +
-carbobenzyloxy O -
- O -
l O +
-tyrosine O +
ethyl O +
ester O +
( O -
CBZ O -
- O -
Tyroet O -
) O +
and O +
acetyl O -
- O -
l O +
-tyrosine O +
ethyl O +
ester O +
( O -
Ac O -
- O -
Tyroet O -
) O -
, O +
in O +
which O +
enzymic O +
catalysis O +
of O +
transesterfication O +
reactions O +
can O +
take O +
place O -
. O +

For O +
example O -
, O +
the O +
dipeptide O +
( O -
N O +
-CBZ O -
- O -
Tyr O -
- O -
leuNH O -
) O +
was O +
obtained O +
in O +
the O +
supercooled O +
liquid O +
mixtures O +
of O +
l O +
-leucinamide O +
with O +
CBZ O -
- O -
Tyroet O +
when O +
subtilisin B-Gene +
or O +
α B-Gene -
- I-Gene -
chymotrypsin I-Gene +
were O +
used O -
. O +

However O -
, O +
the O +
enzymatic O +
peptide O +
synthesis O +
in O +
the O +
absence O +
of O +
solvent O +
depends O +
on O +
the O +
ability O +
of O +
the O +
mixtures O +
to O +
form O +
supercooled O +
liquid O +
mixtures O +
[ O -
2–5 O -
] O +
. O +

For O +
instance O -
, O +
supercooled O -
- O -
liquid O +
mixtures O +
can O -
not O +
be O +
formed O +
on O +
mixing O +
l O +
-leucinamide O +
and O +
N O +
-trifluoroacetyl O -
- O -
l O +
-tyrosine O +
ethyl O +
ester O +
( O -
TFAc O -
- O -
Tyroet O -
) O +
and O +
no O +
dipeptide O +
can O +
be O +
obtained O -
. O +

It O +
is O +
therefore O +
important O +
to O +
understand O +
the O +
mechanism O +
of O +
the O +
formation O +
of O +
supercooled O +
liquid O +
in O +
the O +
mixtures O +
of O +
amino O +
acid O +
amides O +
and O +
tyrosine O +
derivatives O -
. O +

As O +
part O +
of O +
the O +
systematic O +
study O +
of O +
amino O +
acid O +
derivatives O -
, O +
the O +
proton O +
relaxation O +
behaviour O +
and O +
crystal O +
structure O +
of O +
l O +
-leucinamide O +
[ O -
6 O -
, O +
7 O -
] O +
and O +
the O +
proton O +
relaxation O +
of O +
l O +
-alaninamide O +
[ O -
8 O -
] O +
has O +
been O +
studied O -
. O +

It O +
was O +
found O +
that O +
methyl O +
group O +
and O +
amino O +
group O +
rotations O +
are O +
the O +
main O +
spin O -
- O -
lattice O +
relaxation O +
mechanisms O -
. O +

In O +
this O +
paper O -
, O +
we O +
examine O +
the O +
NMR O +
proton O +
relaxation O +
behaviours O +
of O +
three O +
tyrosine O +
derivatives O -
, O +
namely O -
, O +
Ac O -
- O -
Tyroet O -
, O +
CBZ O -
- O -
Tyroet O -
, O +
TFAc O -
- O -
Tyroet O +
( O -
Fig. O +
1 O +
) O -
, O +
and O +
their O +
mixtures O +
with O +
l O +
-leucinamide O +
in O +
order O +
to O +
understand O +
the O +
molecular O +
dynamics O +
of O +
these O +
compounds O +
and O +
the O +
contributions O +
of O +
molecular O +
motions O +
in O +
the O +
formation O +
of O +
supercooled O +
liquids O -
. O +

2 O +
Experimental O +
2.1 O +
Sample O +
preparation O +
2.1.1 O +
N O -
- O -
carbobenzyloxy O -
- O -
l O +
-tyrosine O +
ethyl O +
ester O +
( O -
CBZ O -
- O -
Tyroet O -
) O +
CBZ O -
- O -
Tyroet O +
was O +
prepared O +
from O +
the O +
corresponding O +
free O +
acid O +
using O +
the O +
thionyl O +
chloride O +
method O +
[ O -
9 O -
] O +
. O +

A O +
10 O +
g O +
N O +
-carbobenzyloxy O -
- O -
l O +
-tyrosine O +
( O -
Sigma O -
) O +
was O +
dissolved O +
in O +
absolute O +
ethanol O +
( O -
BDH O -
) O +
and O +
2.8 O +
ml O +
of O +
thionyl O +
chloride O +
( O -
Sigma O -
) O +
was O +
slowly O +
added O +
in O -
. O +

The O +
reaction O +
was O +
carried O +
out O +
at O +
40 O -
° O -
C O +
for O +
2 O +
h O +
in O +
a O +
water O +
bath O +
located O +
in O +
a O +
fume O +
cupboard O -
, O +
followed O +
by O +
rotary O +
evaporation O -
. O +

The O +
products O +
were O +
then O +
dissolved O +
in O +
ethyl O +
acetate O +
( O -
BDH O -
) O +
and O +
washed O +
by O +
0.1 O +
M O +
aqueous O +
sodium O +
hydrogen O +
carbonate O +
( O -
Sigma O -
) O +
solution O +
3 O +
or O +
4 O +
times O +
to O +
remove O +
non O -
- O -
reacted O +
N O +
-carbobenzyloxy O -
- O -
l O +
-tyrosine O -
. O +

To O +
dry O +
the O +
ethyl O +
acetate O +
solution O -
, O +
an O +
excess O +
of O +
magnesium O +
sulphate O +
( O -
BDH O -
) O +
was O +
added O -
, O +
followed O +
by O +
filtration O +
and O +
rotary O +
evaporation O -
. O +

The O +
CBZ O -
- O -
Tyroet O +
was O +
then O +
crystallised O +
from O +
hot O +
ethyl O +
acetate O +
and O +
petroleum O +
ether O +
( O -
BDH O -
) O -
. O +

A O +
deuterated O +
sample O +
( O -
D2-CBZ O -
- O -
Tyroet O -
) O +
was O +
prepared O +
by O +
stirring O +
the O +
CBZ O -
- O -
Tyroet O +
in O +
D2 O +
O O +
( O -
Fluorochem O -
) O +
for O +
ca O -
. O +

2 O +
h O -
, O +
followed O +
by O +
freeze O -
- O -
drying O -
. O +

This O +
process O +
was O +
repeated O +
3 O +
times O +
to O +
ensure O +
that O +
all O +
the O +
exchangeable O +
protons O +
are O +
replaced O +
by O +
deuterium O -
. O +

The O +
samples O +
were O +
stored O +
in O +
a O +
desiccator O +
over O +
di O -
- O -
phosphorus O +
pentoxide O +
at O +
room O +
temperature O -
. O +

The O +
moisture O +
content O +
was O +
0.1 O +
wt.% O +
as O +
measured O +
by O +
Karl O -
– O -
Fischer O +
titration O -
. O +

2.1.2 O +
N O -
- O -
trifluoroacetyl O -
- O -
l O +
-tyrosine O +
ethyl O +
ester O +
( O -
TFAc O -
- O -
Tyroet O -
) O +
TFAc O -
- O -
Tyroet O +
was O +
prepared O +
by O +
trifluoroacetylation O +
of O +
l O +
-tyrosine O +
ethyl O +
ester O +
( O -
Sigma O -
) O +
with O +
ethyl O +
trifluoroacetate O +
( O -
Sigma O -
) O -
, O +
in O +
the O +
presence O +
of O +
tetramethyl O +
guanidine O +
( O -
Sigma O -
) O +
[ O -
10 O -
] O +
. O +

A O +
20 O +
g O +
l O +
-tyrosine O +
ethyl O +
ester O +
was O +
dissolved O +
in O +
120 O +
ml O +
of O +
absolute O +
ethanol O -
, O +
1.2 O +
ml O +
of O +
tetramethyl O +
guanidine O +
followed O +
by O +
12.5 O +
ml O +
of O +
ethyl O +
trifluoroacetate O +
was O +
added O -
. O +

The O +
mixture O +
was O +
stirred O +
at O +
room O +
temperature O +
for O +
5 O +
h O +
in O +
a O +
fume O +
cupboard O -
. O +

When O +
the O +
synthesis O +
had O +
been O +
completed O -
, O +
15 O +
g O +
Dowex O +
50X2 O -
- O -
400 O +
( O -
Sigma O -
) O +
followed O +
by O +
2 O +
g O +
Norit O -
- O -
A O +
activated O +
carbon O +
( O -
Sigma O -
) O +
was O +
added O -
. O +

The O +
mixture O +
was O +
stirred O +
for O +
a O +
further O +
15 O +
min O -
. O +

The O +
mixture O +
was O +
filtered O +
through O +
diatomaceous O +
earth O +
( O -
Sigma O -
) O +
and O +
followed O +
by O +
rotary O +
evaporation O -
. O +

The O +
TFAc O -
- O -
Tyroet O +
was O +
recrystallised O +
from O +
hot O +
dichloromethane O +
( O -
BDH O -
) O +
and O +
ethanol O -
. O +

The O +
moisture O +
content O +
was O +
0.18 O +
wt.% O +
as O +
measured O +
by O +
Karl O -
– O -
Fischer O +
titration O -
. O +

The O +
deuterated O +
TFAc O -
- O -
Tyroet O +
( O -
D2-TFAc O -
- O -
Tyroet O -
) O +
was O +
prepared O +
in O +
the O +
same O +
way O +
as O +
the O +
D2-CBZ O -
- O -
Tyroet O -
. O +

2.1.3 O +
Acetyl O -
- O -
l O +
-tyrosine O +
ethyl O +
ester O +
( O -
Ac O -
- O -
Tyroet O -
) O +
Ac O -
- O -
Tyroet O +
was O +
purchased O +
from O +
Sigma O +
and O +
used O +
without O +
any O +
further O +
treatment O -
. O +

The O +
moisture O +
content O +
was O +
6.5 O +
wt.% O +
as O +
measured O +
by O +
Karl O -
– O -
Fischer O +
titration O -
. O +

The O +
deuterated O +
Ac O -
- O -
Tyroet O +
( O -
D2-Ac O -
- O -
Tyroet O -
) O +
was O +
prepared O +
in O +
the O +
same O +
way O +
as O +
the O +
D2-CBZ O -
- O -
Tyroet O -
. O +

2.2 O +
Solid O +
state O +
NMR O +
measurements O +
All O +
the O +
proton O +
NMR O +
relaxation O +
measurements O +
were O +
carried O +
out O +
on O +
a O +
Bruker O +
MSL-100 O +
spectrometer O +
operating O +
at O +
a O +
proton O +
frequency O +
of O +
100.13 O +
MHz O +
over O +
the O +
temperature O +
range O +
between O +
110 O +
and O +
350 O +
K. O +
Experiments O +
were O +
always O +
started O +
from O +
the O +
lowest O +
temperature O -
. O +

T O +
2 O +
was O +
measured O +
directly O +
from O +
the O +
free O +
induction O +
decay O +
( O -
FID O -
) O +
following O +
a O +
90 O -
° O +
pulse O -
. O +

A O +
90 O -
° O +
pulse O +
length O +
of O +
1 O +
μs O +
was O +
used O +
and O +
the O +
receiver O +
deadtime O +
following O +
the O +
pulse O +
was O +
5 O +
μs O -
. O +

The O +
proton O +
second O +
moment O +
was O +
calculated O +
from O +
the O +
FID O +
assuming O +
Gaussian O +
line O +
shapes O +
[ O -
11 O -
] O +
. O +

The O +
spin O -
- O -
lattice O +
relaxation O +
time O +
( O -
T O +
1 O +
) O +
was O +
measured O +
via O +
the O +
inversion O +
recovery O +
( O -
180x O +
° O -
-τ O +
-90x O +
° O -
-detect O -
) O +
method O +
[ O -
12 O -
] O +
. O +

The O +
signal O +
intensity O +
at O +
the O +
beginning O +
of O +
each O +
FID O +
was O +
recorded O -
, O +
a O +
total O +
of O +
48 O +
data O +
points O +
were O +
collected O -
. O +

In O +
order O +
to O +
ensure O +
that O +
the O +
spread O +
of O +
τ O +
values O +
was O +
sufficient O +
to O +
test O +
for O +
the O +
existence O +
of O +
multi O -
- O -
exponential O +
relaxation O -
, O +
the O +
values O +
of O +
τ O +
were O +
chosen O +
according O +
to O +
τ O +
= O -
A O +
×10 O -
( O -
n O +
−1 O -
) O -
/ O -
12 O +
, O +
where O +
A O +
is O +
a O +
constant O +
varying O +
between O +
1–4 O +
ms O -
, O +
depending O +
on O +
the O +
estimate O +
of O +
T O +
1 O +
, O +
and O +
n O +
is O +
the O +
number O +
of O +
data O +
points O -
. O +

The O +
spin O -
- O -
lattice O +
relaxation O +
times O +
in O +
the O +
rotating O +
frame O -
, O +
T O +
1ρ O +
, O +
were O +
determined O +
by O +
spin O -
- O -
locking O +
the O +
magnetization O +
in O +
the O +
rotating O +
frame O +
for O +
a O +
suitable O +
period O +
and O +
monitoring O +
the O +
intensity O +
of O +
the O +
resulting O +
FID O +
( O -
90 O -
° O -
-spin O -
- O -
lock O -
- O -
acquire O -
) O +
[ O -
13 O -
] O +
. O +

The O +
spin O -
- O -
locking O +
field O +
strength O +
were O +
40 O +
kHz O +
equivalent O +
to O +
a O +
90 O -
° O +
pulse O +
length O +
of O +
6.25 O +
μs O -
. O +

The O +
spin O -
- O -
locking O +
time O +
varied O +
from O +
400 O +
μs O +
to O +
51.2 O +
ms O -
. O +

Single O +
point O +
sampling O +
was O +
used O -
, O +
10 O +
μs O +
after O +
spin O -
- O -
locking O +
pulse O -
. O +

Dependent O +
on O +
the O +
length O +
of O +
the O +
T O +
1ρ O +
, O +
48–128 O +
data O +
points O +
were O +
collected O +
for O +
each O +
experiment O -
. O +

Co O -
- O -
added O +
were O +
2–4 O +
scans O +
to O +
improve O +
the O +
signal O +
to O +
noise O +
ratio O +
in O +
both O +
T O +
1 O +
and O +
T O +
1ρ O +
measurements O -
. O +

All O +
data O +
were O +
analyzed O +
using O +
TableCurve O +
( O -
Jandel O +
Scientific O -
) O +
which O +
is O +
a O +
simultaneous O +
multiple O +
non O -
- O -
linear O +
curve O -
- O -
fitting O +
program O +
and O +
uses O +
the O +
Levenburg O -
– O -
Marquardt O +
algorithm O +
to O +
minimize O +
the O +
sum O +
of O +
squares O +
of O +
the O +
deviations O +
between O +
a O +
calculated O +
summation O +
curve O +
and O +
the O +
observed O +
data O +
points O +
[ O -
14 O -
] O +
. O +

3 O +
Results O +
and O +
discussion O +
3.1 O +
Pure O +
tyrosine O +
derivatives O +
3.1.1 O +
Second O +
moment O +
The O +
transverse O +
relaxation O +
processes O +
of O +
the O +
three O +
tyrosine O +
derivatives O +
can O +
be O +
fitted O +
by O +
a O +
single O +
Gaussian O +
process O -
. O +

Fig. O +
2 O +
shows O +
the O +
temperature O +
dependence O +
of O +
the O +
second O +
moments O +
for O +
the O +
three O +
tyrosine O +
derivatives O -
. O +

Generally O -
, O +
the O +
second O +
moments O +
( O -
M O +
2 O +
) O +
reflect O +
the O +
strength O +
of O +
static O +
dipolar O +
interactions O +
in O +
the O +
system O -
. O +

The O +
general O +
decrease O +
in O +
second O +
moment O +
with O +
increasing O +
temperature O +
is O +
probably O +
due O +
to O +
lattice O +
expansion O +
rather O +
than O +
motional O +
averaging O +
since O +
no O +
clear O +
transition O +
is O +
observed O -
. O +

The O +
lower O +
average O +
value O +
of O +
second O +
moment O +
observed O +
for O +
TFAc O -
- O -
Tyroet O +
compared O +
to O +
Ac O -
- O -
Tyroet O +
is O +
due O +
to O +
the O +
lower O +
density O +
of O +
protons O +
in O +
the O +
sample O -
. O +

The O +
lowest O +
second O +
moments O +
are O +
shown O +
by O +
CBZ O -
- O -
Tyroet O -
, O +
these O +
may O +
be O +
due O +
to O +
the O +
bulky O +
benzene O +
ring O +
substituent O +
causing O +
poor O +
crystal O +
packing O +
and O +
reducing O +
the O +
intermolecular O +
contribution O +
to O +
the O +
second O +
moment O -
. O +

3.1.2 O +
Spin O -
- O -
lattice O +
relaxation O +
in O +
the O +
laboratory O +
frame O +
The O +
T O +
1 O +
s O +
of O +
tyrosine O +
derivatives O +
were O +
measured O +
over O +
the O +
temperature O +
range O +
130–360 O +
K. O +
The O +
relaxation O +
time O +
can O +
be O +
fitted O +
to O +
a O +
single O +
exponential O +
in O +
all O +
cases O -
. O +

The O +
variation O +
of O +
R O +
1 O +
with O +
temperature O +
is O +
shown O +
in O +
Fig. O +
3 O +
. O +

R O +
1 O +
of O +
Ac O -
- O -
Tyroet O +
shows O +
two O +
well O -
- O -
resolved O +
R O +
1 O +
maxima O +
at O +
170 O +
and O +
320 O +
K. O +
This O +
indicates O +
that O +
the O +
spin O -
- O -
lattice O +
relaxation O +
is O +
mainly O +
driven O +
by O +
two O +
independent O +
motions O -
, O +
one O +
of O +
which O +
is O +
effective O +
below O +
250 O +
K O +
and O +
the O +
other O +
one O +
is O +
effective O +
above O +
that O +
temperature O -
. O +

Previous O +
studies O +
on O +
the O +
proton O +
relaxation O +
of O +
amino O +
acid O +
amides O +
suggest O +
that O +
methyl O +
groups O +
and O +
their O +
reorientations O +
are O +
expected O +
to O +
be O +
important O +
in O +
relaxing O +
the O +
system O +
[ O -
6 O -
, O +
8 O -
] O +
. O +

The O +
low O -
- O -
temperature O +
relaxation O +
rate O +
maximum O +
of O +
Ac O -
- O -
Tyroet O +
occurs O +
at O +
within O +
about O +
30 O -
° O -
C O +
of O +
temperature O +
as O +
in O +
l O +
-leucinamide O +
( O -
200 O +
K O -
) O +
[ O -
6 O -
] O +
. O +

Therefore O -
, O +
the O +
effective O +
motion O +
that O +
occurs O +
below O +
250 O +
K O +
is O +
likely O +
to O +
be O +
the O +
methyl O +
group O +
rotation O -
. O +

To O +
identify O +
the O +
relaxation O +
process O +
at O +
high O +
temperature O -
, O +
the O +
spin O -
- O -
lattice O +
relaxation O +
times O +
of O +
deuterated O +
Ac O -
- O -
Tyroet O +
were O +
measured O -
. O +

The O +
temperature O +
dependence O +
of O +
relaxation O +
is O +
similar O +
for O +
both O +
protonated O +
and O +
deuterated O +
Ac O -
- O -
Tyroet O +
and O +
shown O +
in O +
Fig. O +
4 O +
. O +

This O +
phenomenon O +
is O +
also O +
observed O +
in O +
the O +
T O +
1 O +
of O +
deuterated O +
CBZ O -
- O -
Tyroet O +
and O +
TFAc O -
- O -
Tyroet O -
. O +

This O +
implies O +
that O +
motions O +
closely O +
related O +
to O +
NH O +
or O +
OH O +
or O +
residual O +
H2 O +
O O +
can O +
be O +
eliminated O +
( O -
see O +
Section O +
2.1 O +
) O -
. O +

The O +
most O +
likely O +
motion O +
left O +
for O +
relaxing O +
the O +
system O +
is O +
a O +
benzene O +
ring O +
flip O +
motion O -
. O +

Therefore O +
the O +
methyl O +
group O +
reorientation O +
and O +
benzene O +
ring O +
flip O +
are O +
assumed O +
to O +
be O +
the O +
major O +
relaxation O +
mechanisms O +
for O +
Ac O -
- O -
Tyroet O -
. O +

The O +
data O +
were O +
fitted O +
to O +
an O +
expression O +
which O +
was O +
found O +
to O +
be O +
very O +
useful O +
in O +
the O +
previous O +
studies O +
[ O -
6 O -
, O +
8 O -
] O +
: O -
( O -
1 O -
) O +
R1obs O +
= O -
1 O +
T1 O +
= O -
2 O +
3 O +
Pa O +
M2a O +
τa O +
1+ω2 O +
τ2 O +
a O +
+ O -
4τa O +
1 O -
+ O -
4ω2 O +
τ2 O +
a O +
+ O -
2 O +
3 O +
Pb O +
M2b O +
τb O +
1+ω2 O +
τ2 O +
b O +
+ O -
4τb O +
1 O -
+ O -
4ω2 O +
τ2 O +
b O +
. O +

This O +
is O +
an O +
extension O +
of O +
the O +
well O -
- O -
known O +
relaxation O +
expression O +
of O +
Kubo O +
and O +
Tomita O +
[ O -
15 O -
] O +
to O +
two O +
independent O +
relaxation O +
processes O -
. O +

ω O +
/2π O +
is O +
the O +
frequency O +
of O +
measurement O +
in O +
Hertz O -
; O +
τ O +
is O +
the O +
correlation O +
time O +
of O +
the O +
molecular O +
motion O +
responsible O +
for O +
spin O -
- O -
lattice O +
relaxation O +
and O +
M O +
2 O +
is O +
the O +
second O +
moment O +
modulated O +
by O +
the O +
corresponding O +
motion O -
. O +

P O +
a O +
and O +
P O +
b O +
are O +
the O +
relative O +
populations O +
of O +
methyl O +
protons O +
and O +
protons O +
on O +
the O +
aromatic O +
ring O -
. O +

They O +
are O +
6 O -
/ O -
17 O +
and O +
4 O -
/ O -
17 O +
for O +
Ac O -
- O -
Tyroet O -
. O +

It O +
is O +
also O +
assumed O +
that O +
the O +
temperature O +
dependence O +
of O +
the O +
correlation O +
time O +
is O +
exponential O -
, O +
hence: O -
( O -
2 O -
) O +
τ O -
= O -
τ0 O +
exp O +
Ea O +
RT O +
. O +

Fig. O +
3 O +
shows O +
the O +
good O +
agreement O +
between O +
the O +
calculated O +
curve O +
and O +
experimental O +
data O +
for O +
Ac O -
- O -
Tyroet O -
. O +

The O +
optimized O +
motional O +
parameters O +
of O +
M O +
2 O +
, O +
τ O +
0 O +
and O +
E O +
a O +
are O +
summarised O +
in O +
Table O +
1 O +
. O +

The O +
activation O +
energy O +
E O +
a O +
, O +
corresponding O +
to O +
the O +
low O +
temperature O +
motion O -
, O +
is O +
11.8 O +
kJ O -
/ O -
mol O +
which O +
is O +
in O +
good O +
agreement O +
with O +
that O +
found O +
for O +
methyl O +
groups O +
in O +
l O +
-leucinamide O +
( O -
10.9 O +
kJ O -
/ O -
mol O -
) O +
[ O -
6 O -
] O +
. O +

However O -
, O +
the O +
second O +
moment O +
obtained O +
is O +
about O +
1.0 O -
× O -
108 O +
s−2 O +
which O +
is O +
smaller O +
than O +
that O +
from O +
l O +
-leucinamide O +
( O -
2.7 O -
× O -
108 O +
s−2 O +
) O -
. O +

Examination O +
of O +
the O +
chemical O +
formula O +
of O +
Ac O -
- O -
Tyroet O +
shows O +
two O +
methyl O +
groups O -
; O +
one O +
of O +
which O +
is O +
bonded O +
to O +
a O +
carbonyl O +
carbon O +
and O +
the O +
other O +
one O +
is O +
next O +
to O +
a O +
CH2 O +
group O -
. O +

The O +
rotations O +
of O +
the O +
two O +
methyl O +
groups O +
are O +
expected O +
to O +
behave O +
differently O -
; O +
the O +
one O +
bonded O +
to O +
a O +
carbonyl O +
carbon O +
has O +
a O +
larger O +
distance O +
between O +
methyl O +
group O +
and O +
other O +
protons O -
. O +

The O +
behaviour O +
of O +
this O +
methyl O +
group O +
is O +
expected O +
to O +
be O +
similar O +
to O +
those O +
in O +
methionine O +
methyl O +
d O +
-α O -
- O -
galacturonic O +
acid O +
methyl O +
ester O +
[ O -
16 O -
] O +
or O +
methylpyranisides O +
[ O -
17 O -
, O +
18 O -
] O +
. O +

This O +
type O +
of O +
methyl O +
group O +
is O +
less O +
hindered O -
, O +
with O +
a O +
estimated O +
activation O +
energy O +
of O +
6 O +
kJ O -
/ O -
mol O +
and O +
pre O -
- O -
exponential O +
term O +
of O +
2 O -
× O -
10−13 O +
s O +
[ O -
16 O -
] O +
. O +

At O +
100 O +
MHz O -
, O +
this O +
type O +
of O +
methyl O +
group O +
has O +
a O +
relaxation O +
maximum O +
at O +
about O +
80 O +
K. O +
The O +
maximum O +
observed O +
at O +
170 O +
K O +
is O +
therefore O +
likely O +
to O +
be O +
due O +
to O +
the O +
motion O +
of O +
the O +
more O +
hindered O +
group O -
, O +
CH2 O +
–CH3 O +
. O +

In O +
this O +
case O -
, O +
the O +
value O +
of O +
P O +
a O +
in O +
Eq. O +
( O -
1 O -
) O +
should O +
be O +
3 O -
/ O -
17 O +
instead O +
of O +
6 O -
/ O -
17 O -
, O +
and O +
M O +
2a O +
should O +
be O +
2.0 O -
× O -
108 O +
s−2 O +
which O +
is O +
much O +
more O +
consistent O +
with O +
other O +
data O -
. O +

The O +
second O +
motion O +
controlling O +
the O +
relaxation O +
at O +
high O +
temperature O +
( O -
maximum O +
at O +
320 O +
K O -
) O +
was O +
assumed O +
to O +
be O +
a O +
benzene O +
ring O +
flip O -
. O +

The O +
second O +
moment O +
obtained O +
from O +
the O +
curve O +
fitting O +
( O -
2.7 O -
× O -
107 O +
s−2 O +
) O +
is O +
an O +
order O +
of O +
magnitude O +
smaller O +
than O +
that O +
from O +
the O +
methyl O +
group O +
rotation O -
, O +
but O +
is O +
in O +
broad O +
agreement O +
with O +
that O +
found O +
in O +
phenylalanine O +
( O -
M O +
2 O +
: O -
1.3 O -
× O -
107 O +
s−2 O +
) O +
[ O -
19 O -
] O +
. O +

The O +
maximum O +
of O +
relaxation O +
rate O +
occurs O +
at O +
255 O +
K O +
for O +
benzene O +
ring O +
flipping O +
motion O +
in O +
phenylalanine O +
[ O -
19 O -
] O +
. O +

In O +
Ac O -
- O -
Tyroet O -
, O +
there O +
is O +
a O +
hydroxyl O +
group O +
on O +
the O +
end O +
of O +
benzene O +
ring O -
, O +
which O +
is O +
hydrogen O -
- O -
bonded O +
to O +
a O +
amide O +
group O +
in O +
a O +
neighbouring O +
molecule O +
[ O -
20 O -
] O +
and O +
thus O -
, O +
restricting O +
the O +
motion O +
of O +
the O +
ring O -
. O +

Since O +
the O +
rotation O +
is O +
more O +
restricted O -
, O +
the O +
rate O +
maximum O +
is O +
likely O +
to O +
occur O +
at O +
a O +
higher O +
temperature O -
. O +

Fig. O +
3 O +
also O +
shows O +
the O +
temperature O +
dependence O +
of O +
spin O -
- O -
lattice O +
relaxation O +
rate O +
of O +
CBZ O -
- O -
Tyroet O -
. O +

Following O +
the O +
results O +
obtained O +
in O +
Ac O -
- O -
Tyroet O -
, O +
the O +
rotational O +
motion O +
of O +
the O +
methyl O +
group O +
as O +
the O +
origin O +
of O +
spin O -
- O -
lattice O +
relaxation O +
in O +
the O +
laboratory O +
frame O +
at O +
low O +
temperature O +
is O +
also O +
assumed O -
. O +

The O +
data O +
suggest O +
that O +
the O +
relaxation O +
at O +
high O +
temperature O +
is O +
relatively O +
efficient O +
( O -
Fig. O +
3 O +
insert O -
) O -
, O +
indicating O +
a O +
second O +
effective O +
motion O +
occurring O +
above O +
220 O +
K O -
, O +
although O +
no O +
obvious O +
relaxation O +
rate O +
maximum O +
was O +
seen O -
. O +

The O +
second O +
motion O +
is O +
also O +
assumed O +
to O +
be O +
the O +
benzene O +
ring O +
flipping O -
. O +

The O +
observed O +
temperature O +
dependence O +
of O +
R O +
1 O +
was O +
therefore O +
fitted O +
to O +
Eqs. O +
( O -
1 O -
) O +
and O +
( O -
2 O -
) O +
with O +
a O +
P O +
a O +
value O +
of O +
3 O -
/ O -
21 O +
and O +
a O +
P O +
b O +
value O +
of O +
9 O -
/ O -
21 O -
. O +

Good O +
agreement O +
between O +
the O +
fitted O +
curve O +
and O +
experimental O +
data O +
was O +
obtained O -
. O +

Examination O +
of O +
the O +
activation O +
energy O +
and O +
pre O -
- O -
exponential O +
term O +
of O +
methyl O +
group O +
rotation O +
shows O +
good O +
agreement O +
between O +
CBZ O -
- O -
Tyroet O +
and O +
Ac O -
- O -
Tyroet O +
( O -
Table O +
1 O +
) O -
. O +

However O -
, O +
the O +
second O +
moment O +
obtained O +
from O +
assuming O +
both O +
methyl O +
groups O +
were O +
active O +
in O +
Ac O -
- O -
Tyroet O +
is O +
about O +
half O +
of O +
that O +
from O +
CBZ O -
- O -
Tyroet O -
. O +

This O +
further O +
suggests O +
that O +
the O +
methyl O +
group O +
bonded O +
to O +
the O +
carbonyl O +
carbon O +
in O +
Ac O -
- O -
Tyroet O +
is O +
less O +
hindered O +
and O +
does O +
not O +
have O +
contribution O +
to O +
the O +
relaxation O +
at O +
170 O +
K. O +
Effectively O -
, O +
the O +
system O +
is O +
relaxed O +
by O +
only O +
one O +
methyl O +
group O -
. O +

In O +
contrast O +
to O +
Ac O -
- O -
Tyroet O +
where O +
there O +
is O +
an O +
R O +
1 O +
maximum O +
at O +
320 O +
K O -
, O +
there O +
are O +
no O +
obvious O +
high O +
temperature O +
R O +
1 O +
maxima O +
in O +
CBZ O -
- O -
Tyroet O -
. O +

Inspection O +
of O +
the O +
chemical O +
structure O +
of O +
the O +
two O +
molecules O +
shows O +
the O +
presence O +
of O +
two O +
benzene O +
rings O +
in O +
CBZ O -
- O -
Tyroet O -
, O +
one O +
of O +
which O +
is O +
restricted O +
by O +
a O +
hydroxyl O +
group O +
and O +
the O +
other O +
one O +
is O +
not O -
. O +

The O +
relatively O +
free O +
benzene O +
ring O +
motion O +
is O +
expected O +
to O +
relax O +
the O +
system O +
efficiently O +
at O +
the O +
temperature O +
below O +
320 O +
K. O +
It O +
is O +
very O +
likely O +
that O +
the O +
relaxation O +
mechanism O +
occurring O +
at O +
higher O +
temperature O +
comprises O +
two O +
ring O +
flip O +
motions O +
having O +
different O +
activation O +
energies O -
, O +
the O +
non O -
- O -
hydrogen O -
- O -
bonded O +
benzene O +
ring O +
flipping O +
at O +
lower O +
temperature O -
. O +

The O +
presence O +
of O +
unrestricted O +
benzene O +
ring O +
motion O +
is O +
manifest O +
in O +
the O +
differences O +
in O +
proton O +
T O +
1 O +
value O +
of O +
CBZ O -
- O -
Tyroet O +
( O -
1.75 O +
s O -
) O +
and O +
Ac O -
- O -
Tyroet O +
( O -
3.56 O +
s O -
) O +
at O +
250 O +
K. O +
However O -
, O +
the O +
fitting O +
procedure O +
was O +
unable O +
to O +
discriminate O +
two O +
motions O +
and O +
only O +
one O +
motion O +
was O +
assumed O +
in O +
the O +
fit O -
. O +

T O +
1 O +
s O +
of O +
TFAc O -
- O -
Tyroet O +
were O +
measured O +
over O +
the O +
temperature O +
range O +
of O +
150–360 O +
K. O +
The O +
variation O +
of O +
the O +
spin O -
- O -
lattice O +
relaxation O +
rate O +
with O +
temperature O +
is O +
shown O +
in O +
Fig. O +
3 O +
. O +

In O +
contrast O +
to O +
the O +
Ac O -
- O -
Tyroet O +
and O +
CBZ O -
- O -
Tyroet O -
, O +
it O +
shows O +
only O +
one O +
maximum O +
at O +
around O +
170 O +
K. O +
This O +
indicates O +
the O +
presence O +
of O +
a O +
motion O +
whose O +
correlation O +
time O +
is O +
about O +
10−9 O +
s O +
at O +
170 O +
K. O +
Following O +
the O +
previous O +
study O -
, O +
the O +
motion O +
occurring O +
at O +
170 O +
K O +
is O +
likely O +
to O +
be O +
the O +
methyl O +
group O +
rotation O -
. O +

The O +
observed O +
R O +
1 O +
is O +
therefore O +
fitted O +
to O +
the O +
Eqs. O +
( O -
1 O -
) O +
and O +
( O -
2 O -
) O +
assuming O +
that O +
only O +
methyl O +
rotation O +
is O +
present O -
. O +

In O +
this O +
case O -
, O +
P O +
a O +
in O +
the O +
Eq. O +
( O -
1 O -
) O +
is O +
3 O -
/ O -
14 O +
for O +
the O +
TFAc O -
- O -
Tyroet O -
. O +

Good O +
agreement O +
was O +
found O +
between O +
the O +
experimental O +
data O +
and O +
the O +
fitted O +
curve O -
. O +

The O +
calculated O +
relaxation O +
parameters O +
for O +
methyl O +
group O +
reorientation O +
are O +
summarised O +
in O +
Table O +
1 O +
. O +

The O +
calculated O +
relaxation O +
parameters O +
for O +
methyl O +
group O +
rotation O +
in O +
TFAc O -
- O -
Tyroet O +
are O +
in O +
good O +
agreement O +
with O +
those O +
of O +
CBZ O -
- O -
Tyroet O +
and O +
Ac O -
- O -
Tyroet O -
, O +
confirming O +
the O +
assumption O +
made O +
as O +
to O +
the O +
origin O +
of O +
the O +
relaxation O -
. O +

However O -
, O +
the O +
flipping O +
motion O +
of O +
benzene O +
ring O +
in O +
the O +
TFAc O -
- O -
Tyroet O +
is O +
not O +
observed O +
in O +
the O +
temperature O +
range O +
studied O -
, O +
indicating O +
that O +
the O +
motion O +
is O +
significantly O +
hindered O -
. O +

The O +
hindered O +
motion O +
is O +
presumably O +
due O +
to O +
the O +
presence O +
of O +
the O +
perfluorinated O +
group O -
. O +

This O +
lack O +
of O +
motion O +
may O +
have O +
a O +
role O +
in O +
the O +
failure O +
of O +
this O +
compound O +
to O +
form O +
mixtures O +
with O +
amino O +
acid O +
amides O -
. O +

3.1.3 O +
Spin O -
- O -
lattice O +
relaxation O +
in O +
the O +
rotating O +
frame O +
T O +
1ρ O +
of O +
protonated O +
and O +
deuterated O +
Ac O -
- O -
Tyroet O +
were O +
measured O +
at O +
spin O -
- O -
locking O +
field O +
of O +
40 O +
kHz O +
in O +
the O +
temperature O +
range O +
130–290 O +
K O -
, O +
single O -
- O -
exponential O +
T O +
1ρ O +
relaxation O +
was O +
observed O -
. O +

The O +
dependence O +
of O +
R O +
1ρ O +
on O +
temperature O +
shown O +
in O +
Fig. O +
5 O +
clearly O +
illustrates O +
that O +
the O +
system O +
is O +
mainly O +
relaxed O +
by O +
two O +
motions O -
, O +
one O +
motion O +
is O +
effective O +
below O +
240 O +
K O +
and O +
the O +
other O +
one O +
is O +
effective O +
above O +
it O -
. O +

Furthermore O -
, O +
the O +
curves O +
for O +
Ac O -
- O -
Tyroet O +
and O +
D2-Ac O -
- O -
Tyroet O +
are O +
similar O +
at O +
temperatures O +
below O +
240 O +
K O -
, O +
however O -
, O +
the O +
higher O +
temperature O +
motion O +
is O +
affected O +
by O +
replacing O +
exchangeable O +
protons O +
with O +
deuterium O -
. O +

The O +
data O +
can O +
be O +
fitted O +
to O +
equations O +
similar O +
to O +
those O +
used O +
in O +
the O +
T O +
1 O +
analysis O +
[ O -
21 O -
] O +
: O -
( O -
3 O -
) O +
R1ρ O +
= O -
1 O +
T1ρ O +
= O -
Pa O +
M2a O +
τa O +
1 O -
+ O -
4ω2 O +
τ2 O +
a O +
+ O -
Pb O +
M2b O +
τb O +
1 O -
+ O -
4ω2 O +
τ2 O +
b O +
. O +

This O +
equation O +
is O +
generally O +
valid O +
when O +
τ O +
a O -
, O -
b O +
< O -
T O +
2 O +
and O +
B O +
1 O +
≫B O +
L O +
[ O -
22 O -
] O +
; O +
B O +
1 O +
is O +
the O +
spin O -
- O -
locking O +
field O +
and O +
B O +
L O +
, O +
the O +
local O +
dipolar O +
field O -
. O +

In O +
the O +
experiments O -
, O +
B O +
1 O +
of O +
40 O +
kHz O +
was O +
used O +
and O +
the O +
averaged O +
local O +
dipolar O +
field O +
for O +
Ac O -
- O -
Tyroet O +
was O +
52 O +
kHz O -
, O +
thus O -
, O +
B O +
1 O +
< O -
B O +
L O +
which O +
does O +
not O +
meet O +
the O +
requirement O -
. O +

Therefore O -
, O +
account O +
must O +
be O +
taken O +
for O +
the O +
effects O +
of O +
the O +
local O +
dipolar O +
field O -
. O +

McCall O +
and O +
Douglass O +
[ O -
23 O -
] O +
have O +
suggested O +
using O +
an O +
equation O +
of O +
the O +
form O +
ω O +
2 O +
= O -
ω O +
1 O +
2 O +
+ O -
ω O +
L O +
2 O +
, O +
where O +
ω O +
L O +
/2π O +
is O +
the O +
local O +
dipolar O +
field O +
which O +
equals O +
to O +
square O +
root O +
of O +
one O +
third O +
of O +
second O +
moment O -
. O +

From O +
the O +
T O +
1 O +
of O +
Ac O -
- O -
Tyroet O -
, O +
the O +
effect O +
of O +
benzene O +
ring O +
motion O +
was O +
detected O +
at O +
320 O +
K O -
, O +
it O +
is O +
reasonable O +
to O +
assume O +
that O +
the O +
motion O +
below O +
240 O +
K O +
is O +
benzene O +
ring O +
motion O +
since O +
the O +
measurement O +
of O +
spin O -
- O -
lattice O +
relaxation O +
in O +
the O +
rotating O +
frame O +
has O +
the O +
effect O +
of O +
shifting O +
the O +
relaxation O +
maxima O +
into O +
a O +
lower O +
temperature O +
range O -
. O +

Therefore O -
, O +
P O +
a O +
in O +
Eq. O +
( O -
3 O -
) O +
is O +
4 O -
/ O -
17 O +
for O +
Ac O -
- O -
Tyroet O +
and O +
4 O -
/ O -
15 O +
for O +
D2-Ac O -
- O -
Tyroet O -
. O +

Since O +
the O +
second O +
motion O +
is O +
difficult O +
to O +
identify O +
positively O -
, O +
a O +
P O +
b O +
value O +
of O +
13 O -
/ O -
17 O +
for O +
Ac O -
- O -
Tyroet O +
and O +
11 O -
/ O -
15 O +
for O +
D2-Ac O -
- O -
Tyroet O +
is O +
assumed O +
for O +
the O +
curve O +
fitting O -
. O +

Fig. O +
5 O +
shows O +
the O +
quality O +
of O +
the O +
fitting O -
. O +

The O +
results O +
of O +
the O +
fitting O +
are O +
summarised O +
in O +
Table O +
1 O +
. O +

The O +
values O +
of O +
M O +
2 O +
, O +
E O +
a O +
and O +
τ O +
0 O +
are O +
the O +
same O +
within O +
experimental O +
error O +
for O +
both O +
protonated O +
and O +
deuterated O +
samples O +
in O +
the O +
temperature O +
range O +
below O +
240 O +
K O -
, O +
indicating O +
that O +
deuteration O +
has O +
little O +
effect O +
on O +
this O +
motion O -
. O +

Supposing O +
that O +
the O +
benzene O +
ring O +
flip O +
is O +
responsible O +
for O +
the O +
T O +
1ρ O +
relaxation O +
in O +
this O +
temperature O +
range O -
, O +
therefore O -
, O +
the O +
temperature O +
dependence O +
of O +
R O +
1ρ O +
curve O +
can O +
be O +
predicted O +
from O +
the O +
relaxation O +
parameters O +
( O -
within O +
the O +
error O +
range O -
) O +
of O +
benzene O +
flipping O +
motion O +
obtained O +
from O +
T O +
1 O +
. O +

Fig. O +
5 O +
shows O +
the O +
predicted O +
curve O -
. O +

Clearly O -
, O +
the O +
fitted O +
curve O +
does O +
not O +
agree O +
very O +
well O +
with O +
the O +
predicted O +
one O -
; O +
the O +
fitted O +
curve O +
is O +
wider O +
than O +
the O +
predicted O +
one O -
. O +

This O +
may O +
arise O +
because O +
the O +
fitting O +
of O +
the O +
T O +
1 O +
data O +
is O +
rather O +
poor O -
, O +
the O +
peak O +
is O +
rather O +
weak O +
and O +
is O +
at O +
the O +
end O +
of O +
the O +
temperature O +
range O -
. O +

The O +
pre O -
- O -
exponential O +
factor O +
found O +
for O +
the O +
T O +
1 O +
data O +
is O +
also O +
very O +
small O -
. O +

This O +
suggests O +
that O +
the O +
T O +
1ρ O +
data O +
are O +
more O +
reliable O -
. O +

In O +
contrast O +
to O +
the O +
motion O +
at O +
lower O +
temperature O -
, O +
the O +
higher O +
temperature O +
motion O +
is O +
affected O +
by O +
replacing O +
exchangeable O +
protons O +
with O +
deuterium O -
. O +

Fig. O +
5 O +
shows O +
that O +
deuterated O +
sample O +
is O +
relaxed O +
more O +
efficiently O +
in O +
this O +
temperature O +
region O -
. O +

This O +
must O +
be O +
due O +
to O +
the O +
decrease O +
in O +
the O +
number O +
of O +
protons O +
to O +
be O +
relaxed O +
by O +
the O +
motion O +
[ O -
6 O -
, O +
15 O -
] O +
. O +

The O +
motion O +
that O +
becomes O +
apparent O +
may O +
be O +
a O +
motion O +
involving O +
a O +
large O +
part O +
of O +
the O +
molecule O -
. O +

However O -
, O +
its O +
origin O +
is O +
not O +
certain O +
so O +
the O +
motion O +
will O +
be O +
referred O +
to O +
simply O +
as O +
the O +
third O +
motion O -
. O +

T O +
1ρ O +
of O +
solid O +
CBZ O -
- O -
Tyroet O +
was O +
measured O +
over O +
the O +
temperature O +
range O +
150–340 O +
K O +
and O +
the O +
dependence O +
of O +
R O +
1ρ O +
on O +
temperature O +
is O +
shown O +
in O +
Fig. O +
6 O +
. O +

Relaxation O +
of O +
CBZ O -
- O -
Tyroet O +
( O -
Fig. O +
6 O +
) O +
is O +
similar O +
to O +
that O +
of O +
Ac O -
- O -
Tyroet O +
( O -
Fig. O +
5 O +
) O -
. O +

One O +
motion O +
occurs O +
below O +
270 O +
K O +
and O +
the O +
other O +
one O +
is O +
effective O +
at O +
higher O +
temperature O -
. O +

As O +
with O +
Ac O -
- O -
Tyroet O -
, O +
benzene O +
ring O +
flipping O +
and O +
the O +
third O +
mode O +
of O +
motion O +
are O +
assumed O +
to O +
account O +
for O +
the O +
R O +
1ρ O +
of O +
CBZ O -
- O -
Tyroet O -
. O +

The O +
data O +
are O +
therefore O +
fitted O +
to O +
Eq. O +
( O -
3 O -
) O +
with O +
a O +
P O +
a O +
value O +
of O +
9 O -
/ O -
21 O +
and O +
a O +
P O +
b O +
of O +
12 O -
/ O -
21 O +
for O +
CBZ O -
- O -
Tyroet O -
. O +

The O +
local O +
dipolar O +
field O -
, O +
ω O +
L O +
, O +
( O -
44 O +
kHz O -
) O +
has O +
also O +
been O +
taken O +
into O +
account O -
. O +

A O +
fit O +
of O +
Eq. O +
( O -
3 O -
) O +
to O +
the O +
temperature O +
dependence O +
of O +
R O +
1ρ O +
of O +
CBZ O -
- O -
Tyroet O +
gives O +
a O +
pre O -
- O -
exponential O +
factor O +
of O +
7.0 O -
× O -
10−10 O +
for O +
the O +
motion O +
effective O +
below O +
270 O +
K. O +
This O +
value O +
is O +
too O +
high O +
for O +
the O +
motion O +
at O +
low O +
temperature O -
. O +

Usually O -
, O +
this O +
is O +
indicative O +
of O +
a O +
distribution O +
of O +
correlation O +
time O +
[ O -
24 O -
, O +
25 O -
] O +
. O +

From O +
the O +
discussion O +
of O +
T O +
1 O +
of O +
CBZ O -
- O -
Tyroet O -
, O +
two O +
benzene O +
rings O +
are O +
present O +
in O +
the O +
CBZ O -
- O -
Tyroet O -
. O +

Therefore O -
, O +
the O +
relaxation O +
below O +
270 O +
K O +
can O +
be O +
treated O +
simply O +
as O +
the O +
sum O +
of O +
two O +
individual O +
motions O +
corresponding O +
to O +
restricted O +
and O +
unrestricted O +
benzene O +
ring O +
flipping O +
motions O +
and O +
thus O -
, O +
the O +
R O +
1ρ O +
below O +
290 O +
K O +
may O +
be O +
written O +
as: O -
( O -
4 O -
) O +
R1ρ O +
= O -
1 O +
T1ρ O +
= O -
Pa O +
M2a O +
τa O +
1 O -
+ O -
4ω2 O +
τ2 O +
a O +
+ O +
τb O +
1 O -
+ O -
4ω2 O +
τ2 O +
b O +
where O +
τ O +
a O +
and O +
τ O +
b O +
correspond O +
to O +
correlation O +
times O +
of O +
the O +
unrestricted O +
and O +
restricted O +
benzene O +
ring O +
flipping O +
motions O -
. O +

The O +
fitted O +
results O +
are O +
listed O +
in O +
Table O +
1 O +
. O +

Fig. O +
6 O +
shows O +
the O +
good O +
agreement O +
between O +
the O +
fitted O +
curve O +
and O +
the O +
experimental O +
data O -
. O +

The O +
calculated O +
activation O +
energy O +
and O +
the O +
pre O -
- O -
exponential O +
term O +
for O +
the O +
restricted O +
benzene O +
ring O +
motion O +
in O +
CBZ O -
- O -
Tyroet O +
is O +
in O +
good O +
agreement O +
with O +
those O +
in O +
Ac O -
- O -
Tyroet O +
although O +
large O +
uncertainties O +
occurred O +
in O +
the O +
curve O +
fitting O +
( O -
Table O +
1 O +
) O -
. O +

The O +
activation O +
energy O +
obtained O +
for O +
the O +
unrestricted O +
motion O +
is O +
lower O +
than O +
that O +
of O +
restricted O +
one O -
, O +
which O +
is O +
expected O -
. O +

The O +
third O +
motion O +
appearing O +
at O +
higher O +
temperatures O +
is O +
affected O +
by O +
deuterium O +
replacement O +
of O +
exchangeable O +
proton O -
, O +
which O +
is O +
similar O +
to O +
the O +
observation O +
made O +
for O +
Ac O -
- O -
Tyroet O -
. O +

However O -
, O +
since O +
such O +
a O +
small O +
part O +
of O +
the O +
curve O +
was O +
observable O +
no O +
reliable O +
fitted O +
data O +
could O +
be O +
obtained O -
. O +

The O +
variation O +
of O +
R O +
1ρ O +
of O +
TFAc O -
- O -
Tyroet O +
and O +
D2-TFAc O -
- O -
Tyroet O +
with O +
temperature O +
is O +
shown O +
in O +
Fig. O +
7 O +
. O +

The O +
proton O +
spin O -
- O -
lattice O +
relaxation O +
in O +
the O +
rotating O +
frame O +
of O +
both O +
protonated O +
and O +
deuterated O +
samples O +
is O +
increasingly O +
efficient O +
below O +
240 O +
K O +
and O +
no O +
relaxation O +
rate O +
maximum O +
was O +
seen O -
. O +

This O +
is O +
in O +
contrast O +
to O +
the O +
results O +
from O +
Ac O -
- O -
Tyroet O +
and O +
CBZ O -
- O -
Tyroet O +
where O +
benzene O +
ring O +
motion O +
was O +
observed O +
at O +
200 O +
K. O +
In O +
the O +
T O +
1 O +
of O +
TFAc O -
- O -
Tyroet O +
analysis O -
, O +
methyl O +
group O +
reorientation O +
was O +
found O +
to O +
be O +
the O +
only O +
relaxation O +
mechanism O -
. O +

It O +
is O +
expected O +
that O +
it O +
is O +
also O +
responsible O +
for O +
T O +
1ρ O +
relaxation O +
at O +
very O +
low O +
temperature O -
. O +

The O +
temperature O +
at O +
which O +
the O +
maximum O +
occurs O +
is O +
predicted O +
to O +
be O +
around O +
92 O +
K O +
using O +
the O +
relaxation O +
parameters O +
for O +
methyl O +
group O +
rotation O +
found O +
in O +
the O +
T O +
1 O +
analysis O -
. O +

To O +
confirm O +
this O -
, O +
T O +
1ρ O +
of O +
TFAc O -
- O -
Tyroet O +
was O +
measured O +
between O +
110 O +
to O +
140 O +
K O +
and O +
it O +
was O +
found O +
that O +
the O +
relaxation O +
becomes O +
more O +
efficient O +
as O +
the O +
temperature O +
is O +
decreased O +
( O -
see O +
the O +
insert O +
Fig. O +
7 O +
) O -
. O +

Therefore O -
, O +
the O +
only O +
relaxation O +
mechanism O +
for O +
the O +
T O +
1ρ O +
of O +
TFAc O -
- O -
Tyroet O +
can O +
be O +
reasonably O +
assigned O +
to O +
methyl O +
group O +
rotation O -
. O +

This O +
is O +
consistent O +
with O +
the O +
observation O +
made O +
in O +
the O +
T O +
1 O +
analysis O +
and O +
suggests O +
that O +
the O +
crystal O +
structure O +
results O +
in O +
a O +
more O +
rigid O +
molecule O +
than O +
in O +
the O +
other O +
compounds O -
. O +

This O +
may O +
be O +
the O +
cause O +
of O +
the O +
failure O +
to O +
form O +
a O +
supercooled O +
liquid O +
mixture O +
with O +
l O +
-leucinamide O -
. O +

3.2 O +
Mixtures O +
of O +
l O +
-leucinamide O -
/ O -
tyrosine O +
derivatives O +
l O +
-leucinamide O +
can O +
spontaneously O +
form O +
supercooled O +
liquid O +
mixtures O +
with O +
CBZ O -
- O -
Tyroet O +
and O +
Ac O -
- O -
Tyroet O -
. O +

However O -
, O +
the O +
melts O +
of O +
l O +
-leuNH O -
/ O -
TFAc O -
- O -
Tyroet O +
do O +
not O +
supercool O +
but O +
rather O +
crystallise O +
into O +
separated O +
phases O -
. O +

The O +
mixtures O +
containing O +
1:1 O +
l O +
-leucinamide O -
/ O -
tyrosine O +
derivatives O +
were O +
studied O +
by O +
the O +
temperature O +
dependence O +
of O +
proton O +
spin O -
- O -
lattice O +
relaxation O +
time O +
in O +
the O +
laboratory O +
frame O -
. O +

For O +
the O +
supercooled O +
liquid O +
mixture O +
of O +
l O +
-leuNH O -
/ O -
CBZ O -
- O -
Tyroet O -
, O +
a O +
single O +
exponential O +
T O +
1 O +
relaxation O +
was O +
found O +
in O +
the O +
temperature O +
range O +
below O +
330 O +
K O -
, O +
above O +
that O +
temperature O -
, O +
a O +
slightly O +
double O +
exponential O +
recovery O +
of O +
magnetization O +
was O +
detected O -
. O +

For O +
the O +
supercooled O +
liquid O +
mixture O +
of O +
l O +
-leuNH O -
/ O -
Ac O -
- O -
Tyroet O -
, O +
a O +
slightly O +
double O +
exponential O +
recovery O +
of O +
magnetization O +
was O +
detected O +
above O +
345 O +
K. O +
The O +
behaviour O +
of O +
spin O -
- O -
lattice O +
relaxation O +
of O +
a O +
two O -
- O -
component O +
system O +
depends O +
on O +
the O +
spin O +
diffusion O +
rate O +
between O +
the O +
components O -
. O +

When O +
the O +
spin O +
diffusion O +
rate O +
is O +
faster O +
than O +
the O +
rate O +
at O +
which O +
spin O +
energy O +
flows O +
from O +
the O +
spin O +
to O +
lattice O -
, O +
averaging O +
of O +
the O +
spatial O +
inhomogeneities O +
of O +
the O +
spin O -
- O -
lattice O +
relaxation O +
occurs O +
and O +
results O +
in O +
an O +
observed O +
single O +
relaxation O +
time O -
. O +

The O +
spin O +
diffusion O +
rate O +
is O +
dependent O +
on O +
the O +
strength O +
of O +
homonuclear O +
dipolar O +
interactions O +
which O -
, O +
in O +
turn O -
, O +
depends O +
on O +
both O +
the O +
distance O +
between O +
nuclei O +
and O +
molecular O +
mobilities O -
. O +

At O +
below O +
300 O +
K O -
, O +
the O +
transverse O +
relaxation O +
of O +
the O +
mixture O +
comprises O +
a O +
Gaussian O +
and O +
an O +
exponential O +
process O -
, O +
above O +
300 O +
K O +
it O +
is O +
exponential O -
. O +

A O +
single O +
exponential O +
spin O -
- O -
lattice O +
relaxation O +
is O +
observed O +
below O +
300 O +
K. O +
This O +
is O +
due O +
to O +
the O +
strong O +
static O +
dipolar O +
interactions O -
, O +
which O +
exist O +
in O +
this O +
temperature O +
regime O -
. O +

When O +
the O +
temperature O +
is O +
above O +
330 O +
K O -
, O +
the O +
dipolar O +
interactions O +
are O +
weakened O +
as O +
the O +
result O +
of O +
molecular O +
motion O -
, O +
consequently O -
, O +
the O +
spin O +
diffusion O +
rate O +
is O +
slow O -
, O +
resulting O +
in O +
non O -
- O -
exponential O +
recovery O +
of O +
T O +
1 O +
. O +

However O -
, O +
in O +
the O +
temperature O +
range O +
between O +
300 O +
to O +
330 O +
K O -
, O +
the O +
single O +
exponential O +
T O +
1 O +
relaxation O +
observed O +
in O +
the O +
mixture O +
of O +
LeuNH O -
/ O -
CBZ O -
- O -
Tyroet O +
is O +
not O +
the O +
result O +
of O +
strong O +
static O +
interactions O +
since O +
the O +
transverse O +
relaxation O +
of O +
the O +
mixture O +
LeuNH O -
/ O -
CBZ O -
- O -
Tyroet O +
is O +
an O +
exponential O +
process O -
. O +

The O +
single O +
exponential O +
T O +
1 O +
observed O +
in O +
this O +
case O +
may O +
be O +
due O +
to O +
the O +
strong O +
intra- O +
and O +
intermolecular O +
interactions O +
resulting O +
from O +
the O +
fact O +
that O +
molecules O +
in O +
the O +
mixtures O +
are O +
in O +
close O +
contact O +
to O +
each O +
other O -
. O +

The O +
spin O -
- O -
lattice O +
relaxation O +
behaviour O +
of O +
both O +
the O +
mixtures O +
was O +
treated O +
as O +
a O +
single O +
exponential O +
process O +
in O +
the O +
temperature O +
range O +
150–360 O +
K O +
since O +
only O +
a O +
few O +
data O +
show O +
the O +
double O -
- O -
exponential O +
behaviour O -
, O +
and O +
fitting O +
our O +
data O +
to O +
a O +
single O +
exponential O +
function O +
does O +
not O +
affect O +
the O +
analysis O +
drastically O -
. O +

Fig. O +
8 O +
Fig. O +
9 O +
show O +
the O +
spin O -
- O -
lattice O +
relaxation O +
rates O +
of O +
the O +
mixtures O +
LeuNH O -
/ O -
Ac O -
- O -
Tyroet O +
and O +
LeuNH O -
/ O -
CBZ O -
- O -
Tyroet O +
plotted O +
against O +
temperature O -
. O +

Clearly O -
, O +
two O +
independent O +
dominant O +
relaxation O +
mechanisms O +
were O +
detected O -
, O +
one O +
of O +
which O +
is O +
effective O +
below O +
250 O +
K O +
and O +
the O +
other O +
one O +
is O +
effective O +
above O +
that O +
temperature O -
. O +

The O +
methyl O +
group O +
rotation O +
is O +
expected O +
to O +
be O +
responsible O +
for O +
the O +
relaxation O +
at O +
low O +
temperature O +
[ O -
6 O -
] O +
. O +

To O +
clarify O +
the O +
high O +
temperature O +
relaxation O +
mechanism O -
, O +
the O +
spin O -
- O -
lattice O +
relaxation O +
times O +
of O +
a O +
deuterated O +
supercooled O +
liquid O +
mixture O +
of O +
l O +
-leuND O -
/ O -
D2-CBZ O -
- O -
Tyroet O +
( O -
Fig. O +
9 O +
) O +
were O +
measured O +
in O +
the O +
temperature O +
range O +
140–360 O +
K O +
and O +
plotted O +
against O +
temperature O -
. O +

Relatively O +
efficient O +
relaxation O +
was O +
still O +
found O +
at O +
high O +
temperature O -
. O +

This O +
suggests O +
that O +
the O +
spin O -
- O -
lattice O +
relaxation O +
at O +
high O +
temperature O +
is O +
not O +
only O +
due O +
to O +
the O +
motions O +
of O +
NH2 O +
or O +
OH O -
, O +
but O +
also O +
some O +
other O +
contributions O -
. O +

Inspection O +
of O +
the O +
spin O -
- O -
lattice O +
relaxation O +
times O +
of O +
the O +
pure O +
CBZ O -
- O -
Tyroet O +
and O +
Ac O -
- O -
Tyroet O +
shows O +
that O +
the O +
benzene O +
ring O +
flipping O +
motion O +
is O +
expected O +
in O +
this O +
temperature O +
range O -
. O +

However O -
, O +
the O +
strength O +
of O +
the O +
relaxation O +
in O +
the O +
mixtures O +
is O +
much O +
larger O +
than O +
that O +
could O +
be O +
generated O +
by O +
the O +
benzene O +
ring O +
flipping O -
, O +
since O +
this O +
is O +
a O +
weaker O +
relaxation O +
source O +
than O +
the O +
methyl O +
group O +
rotation O +
( O -
Fig. O +
4 O +
) O -
. O +

The O +
system O +
is O +
likely O -
, O +
in O +
this O +
case O -
, O +
to O +
be O +
relaxed O +
by O +
the O +
molecular O +
tumbling O +
motion O +
since O +
considerable O +
line O +
narrowing O +
was O +
observed O +
in O +
the O +
FID O +
in O +
this O +
temperature O +
range O -
. O +

Therefore O -
, O +
it O +
is O +
reasonable O +
to O +
assume O +
that O +
rapid O +
molecule O +
tumbling O +
is O +
the O +
major O +
relaxation O +
mechanism O +
for O +
the O +
spin O -
- O -
lattice O +
relaxation O +
of O +
the O +
system O +
at O +
high O +
temperature O -
. O +

The O +
experimental O +
data O +
were O +
then O +
fitted O +
in O +
Eq. O +
( O -
1 O -
) O +
. O +

P O +
a O +
is O +
the O +
methyl O +
group O +
proton O +
population O -
, O +
the O +
value O +
is O +
9 O -
/ O -
35 O +
for O +
the O +
mixture O +
of O +
l O +
-leuNH O -
/ O -
CBZ O -
- O -
Tyroet O +
and O +
9 O -
/ O -
31 O +
for O +
l O +
-leuNH O -
/ O -
Ac O -
- O -
Tyroet O -
. O +

P O +
b O +
is O +
set O +
to O +
unity O +
since O +
all O +
the O +
protons O +
in O +
the O +
mixture O +
contribute O +
to O +
the O +
relaxation O -
. O +

Figs. O +
8 O +
and O +
9 O +
show O +
the O +
good O +
agreement O +
between O +
the O +
fitted O +
curves O +
and O +
experimental O +
data O -
. O +

The O +
results O +
are O +
given O +
in O +
Table O +
2 O +
. O +

The O +
second O +
moment O +
calculated O +
for O +
methyl O +
group O +
rotation O +
is O +
in O +
the O +
same O +
order O +
of O +
magnitude O +
as O +
those O +
in O +
pure O +
solids O -
. O +

However O -
, O +
the O +
activation O +
energy O +
of O +
the O +
methyl O +
group O +
rotation O +
in O +
the O +
mixture O +
is O +
smaller O +
than O +
those O +
found O +
for O +
the O +
pure O +
solids O -
. O +

The O +
molecules O +
in O +
supercooled O +
liquid O +
mixtures O +
are O +
loosely O +
packed O -
. O +

As O +
a O +
consequence O -
, O +
rotation O +
of O +
methyl O +
group O +
might O +
be O +
less O +
hindered O +
compared O +
to O +
the O +
corresponding O +
crystal O +
state O -
. O +

This O +
might O +
be O +
the O +
reason O +
for O +
the O +
low O +
activation O +
energy O +
observed O -
. O +

The O +
relaxation O +
rates O +
of O +
these O +
mixtures O +
at O +
low O +
temperature O +
can O +
be O +
predicted O +
from O +
the O +
corresponding O +
crystals O +
assuming O +
that O +
methyl O +
group O +
rotation O +
is O +
the O +
relaxation O +
mechanism O -
. O +

The O +
predictions O +
shown O +
in O +
Figs. O +
8 O +
and O +
9 O +
differ O +
from O +
the O +
experimental O +
values O -
. O +

This O +
indicates O +
the O +
effects O +
of O +
molecular O +
arrangement O +
on O +
the O +
methyl O +
group O +
rotation O -
. O +

In O +
contrast O +
to O +
the O +
mixtures O +
of O +
l O +
-leuNH O -
/ O -
CBZ O -
- O -
Tyroet O +
and O +
l O +
-leuNH O -
/ O -
Ac O -
- O -
Tyroet O -
, O +
the O +
mixture O +
of O +
l O +
-leuNH O -
/ O -
TFAc O -
- O -
Tyroet O +
does O +
not O +
form O +
a O +
supercooled O +
liquid O -
. O +

The O +
T O +
1 O +
of O +
a O +
mixture O +
of O +
l O +
-leuNH O -
/ O -
TFAc O -
- O -
Tyroet O +
( O -
1:1 O -
) O +
were O +
measured O +
over O +
the O +
temperature O +
range O +
150–360 O +
K. O +
Unlike O +
the O +
liquid O +
mixtures O -
, O +
double O +
exponential O +
relaxation O +
times O +
were O +
found O +
for O +
the O +
temperature O +
range O +
studied O -
. O +

The O +
short O +
T O +
1 O +
component O +
varied O +
between O +
0.08 O +
to O +
0.69 O +
s O +
and O +
the O +
long O +
T O +
1 O +
component O +
varied O +
between O +
0.3 O +
to O +
10 O +
s. O +
The O +
double O +
exponential O +
behaviour O +
of O +
spin O -
- O -
lattice O +
relaxation O +
indicates O +
that O +
the O +
mixture O +
of O +
l O +
-leuNH O -
/ O -
TFAc O -
- O -
Tyroet O +
is O +
a O +
two O +
phase O +
system O +
and O +
that O +
the O +
spin O +
diffusion O +
between O +
the O +
two O +
components O +
is O +
slow O +
on O +
the O +
time O +
scale O +
of O +
T O +
1 O +
. O +

The O +
temperature O +
dependence O +
of O +
relaxation O +
rate O +
of O +
both O +
components O +
is O +
shown O +
in O +
Fig. O +
10 O +
. O +

A O +
comparison O +
of O +
both O +
the O +
relaxation O +
times O +
with O +
the O +
pure O +
components O +
of O +
l O +
-leuNH O +
and O +
TFAc O -
- O -
Tyroet O +
shows O +
that O +
the O +
long O +
relaxation O +
component O +
coincides O +
well O +
with O +
the O +
R O +
1 O +
of O +
TFAc O -
- O -
Tyroet O +
and O +
that O +
the O +
short O +
component O +
is O +
close O +
to O +
the O +
R O +
1 O +
of O +
l O +
-leuNH O -
. O +

From O +
this O +
observation O -
, O +
it O +
can O +
be O +
inferred O +
that O +
the O +
mixture O +
of O +
l O +
-leuNH O -
/ O -
TFAc O -
- O -
Tyroet O +
behaves O +
as O +
if O +
both O +
components O +
were O +
in O +
their O +
pure O +
states O -
. O +

This O +
suggestion O +
is O +
confirmed O +
by O +
the O +
proportion O +
of O +
the O +
two O +
components O -
. O +

At O +
temperatures O +
above O +
260 O +
K O -
, O +
the O +
proportion O +
of O +
short O +
T O +
1 O +
component O +
comprises O +
about O +
50 O -
% O -
. O +

This O +
agrees O +
very O +
well O +
with O +
the O +
proton O +
population O +
of O +
l O +
-leuNH O -
. O +

The O +
short O +
T O +
1 O +
represents O +
the O +
population O +
of O +
l O +
-leuNH O +
protons O -
, O +
and O +
the O +
long O +
T O +
1 O +
represents O +
that O +
of O +
the O +
TFAc O -
- O -
Tyroet O +
protons O -
. O +

This O +
is O +
in O +
contrast O +
to O +
the O +
liquid O +
mixtures O +
where O +
the O +
mixtures O +
act O +
differently O +
from O +
their O +
pure O +
states O -
. O +

At O +
low O +
temperature O +
( O -
below O +
210 O +
K O -
) O +
there O +
is O +
significant O +
deviation O +
of O +
the O +
LeuNH O +
data O +
in O +
the O +
mixture O +
from O +
the O +
pure O +
state O -
, O +
both O +
apparent O +
population O +
and O +
relaxation O +
rate O +
deviate O -
. O +

This O +
may O +
be O +
due O +
to O +
long O +
range O +
spin O +
diffusion O +
effects O +
at O +
this O +
temperature O -
. O +

The O +
ability O +
to O +
form O +
supercooled O +
liquid O +
mixture O +
can O +
be O +
related O +
to O +
the O +
molecular O +
dynamics O +
of O +
the O +
pure O +
substrates O -
. O +

A O +
comparison O +
of O +
the O +
dynamics O +
of O +
these O +
tyrosine O +
derivatives O +
shows O +
that O +
the O +
benzene O +
ring O +
flipping O +
motion O +
and O +
the O +
third O +
motion O +
are O +
absent O +
in O +
the O +
fluorine O +
substituted O +
compound O -
. O +

The O +
reason O +
remains O +
unclear O -
. O +

The O +
preliminary O +
X O -
- O -
ray O +
data O +
did O +
not O +
show O +
strong O +
interactions O +
between O +
the O +
fluorine O +
atoms O +
and O +
the O +
benzene O +
ring O -
, O +
which O +
agrees O +
with O +
the O +
conclusions O +
from O +
UV O +
and O +
Raman O +
spectra O -
. O +

The O +
absence O +
of O +
benzene O +
ring O +
flipping O +
and O +
the O +
third O +
motion O +
in O +
the O +
fluorinated O +
compound O +
implies O +
that O +
the O +
level O +
of O +
order O +
in O +
this O +
crystal O +
is O +
higher O +
than O +
those O +
in O +
the O +
other O +
compounds O +
studied O -
. O +

On O +
crystallisation O +
there O +
will O +
be O +
only O +
one O +
molecular O +
conformation O +
( O -
with O +
respect O +
to O +
the O +
benzene O +
ring O -
) O +
that O +
is O +
possible O -
. O +

Formation O +
of O +
a O +
crystal O +
is O +
therefore O +
only O +
a O +
matter O +
of O +
the O +
whole O +
molecule O +
assuming O +
the O +
correct O +
orientation O +
with O +
respect O +
to O +
its O +
neighbours O +
and O +
packing O +
closely O -
. O +

In O +
the O +
case O +
of O +
Ac O -
- O -
Tyroet O +
there O +
is O +
variability O +
in O +
the O +
conformation O +
with O +
respect O +
to O +
the O +
benzene O +
ring O +
in O +
molecules O +
in O +
the O +
crystal O -
. O +

This O +
will O +
mean O +
that O -
, O +
in O +
effect O -
, O +
the O +
benzene O +
rings O +
will O +
occupy O +
a O +
greater O +
volume O +
than O +
if O +
they O +
were O +
static O +
( O -
in O +
the O +
case O +
of O +
TFAc O -
- O -
Tyroet O -
) O +
and O +
therefore O -
, O +
the O +
intermolecular O +
distances O +
will O +
be O +
greater O +
than O +
in O +
the O +
fluorinated O +
analogue O -
. O +

This O +
in O +
turn O +
implies O +
a O +
weaker O +
intermolecular O +
interactions O -
. O +

This O +
suggestion O +
is O +
supported O +
by O +
the O +
fact O +
that O +
fluorine O +
substitution O +
increases O +
the O +
melting O +
point O +
of O +
the O +
crystal O +
from O +
about O +
78 O -
° O -
C O +
to O +
175 O -
° O -
C O -
. O +

The O +
presence O +
of O +
highly O +
mobile O -
, O +
non O -
- O -
rigid O +
molecules O +
are O +
also O +
likely O +
to O +
inhibit O +
crystal O +
formation O -
. O +

In O +
the O +
presence O +
of O +
another O +
solute O -
, O +
this O +
is O +
likely O +
to O +
lead O +
to O +
the O +
formation O +
of O +
supercooling O +
systems O +
since O +
only O +
weak O +
interactions O +
in O +
solute O +
will O +
be O +
enough O +
to O +
prevent O +
crystallisation O -
. O +

Similar O +
observations O +
of O +
the O +
effects O +
of O +
fluorination O +
have O +
been O +
made O +
by O +
Dow O +
et O +
al. O +
[ O -
26 O -
] O +
. O +

It O +
was O +
found O +
that O +
fluorine O -
- O -
substituted O +
lipids O +
form O +
solids O +
on O +
cooling O +
in O +
30–60 O +
min O -
, O +
whereas O +
unsubstituted O +
lipids O +
require O +
a O +
cooling O +
period O +
of O +
hours O +
or O +
days O -
. O +

It O +
was O +
also O +
shown O +
that O +
less O +
mobility O +
was O +
associated O +
with O +
fluorine O -
- O -
substituted O +
lipids O +
[ O -
26 O -
] O +
. O +

4 O +
Conclusions O +
The O +
proton O +
relaxation O +
behaviour O +
of O +
three O +
tyrosine O +
derivatives O -
: O +
Ac O -
- O -
Tyroet O -
, O +
CBZ O -
- O -
Tyroet O -
, O +
TFAc O -
- O -
Tyroet O +
and O +
their O +
mixtures O +
with O +
l O +
-leucinamide O +
was O +
studied O -
. O +

The O +
extension O +
of O +
the O +
well O -
- O -
known O +
relaxation O +
expression O +
of O +
Kubo O +
and O +
Tomita O +
to O +
several O +
independent O +
relaxation O +
processes O +
was O +
used O +
to O +
identify O +
the O +
relaxation O +
mechanisms O +
and O +
estimate O +
the O +
relaxation O +
parameters O -
. O +

It O +
was O +
found O +
that O +
methyl O +
group O +
rotation O +
is O +
important O +
for O +
relaxing O +
the O +
system O +
at O +
low O +
temperature O +
in O +
both O +
the O +
pure O +
state O +
and O +
mixtures O -
. O +

In O +
addition O -
, O +
both O +
benzene O +
ring O +
flipping O +
and O +
a O +
third O +
motion O +
were O +
found O +
to O +
be O +
the O +
relaxation O +
mechanisms O +
for O +
Ac O -
- O -
Tyroet O +
and O +
CBZ O -
- O -
Tyroet O -
, O +
however O -
, O +
these O +
motions O +
are O +
absent O +
in O +
TFAc O -
- O -
Tyroet O -
. O +

In O +
the O +
mixtures O -
, O +
molecular O +
tumbling O +
motion O +
is O +
responsible O +
for O +
relaxing O +
the O +
supercooled O +
liquids O +
l O +
-leuNH O -
/ O -
CBZ O -
- O -
Tyroet O +
and O +
l O +
-leuNH O -
/ O -
Ac O -
- O -
Tyroet O -
. O +

However O -
, O +
this O +
motion O +
is O +
absent O +
in O +
the O +
mixture O +
l O +
-leuNH O -
/ O -
TFAc O -
- O -
Tyroet O -
. O +

The O +
absence O +
of O +
benzene O +
ring O +
flipping O +
motion O +
and O +
the O +
third O +
motion O +
in O +
the O +
pure O +
tyrosine O +
derivatives O +
may O +
affect O +
its O +
ability O +
to O +
form O +
a O +
supercooled O +
liquid O +
with O +
l O +
-leucinamide O -
. O +

Acknowledgements O +
The O +
authors O +
wish O +
to O +
acknowledge O +
funding O +
from O +
the O +
BBSRC O +
competitive O +
strategic O +
grant O -
. O +

Y.L. O +
Wang O +
wishes O +
to O +
thank O +
the O +
BBSRC O +
for O +
provision O +
of O +
a O +
studentship O -
. O +

d O +
-Penicillamine O +
( O -
d O +
-pen O -
) O +
is O +
a O +
drug O +
used O +
in O +
the O +
treatment O +
of O +
patients O +
with O +
rheumatoid O +
arthritis O +
( O -
RA O -
) O -
, O +
cystinuria O +
and O +
Wilson O -
's O +
disease O -
. O +

A O +
small O +
molecule O -
, O +
similar O +
in O +
structure O +
to O +
cysteine O +
( O -
see O +
Fig. O +
2 O +
) O -
, O +
it O +
has O +
a O +
sulfhydryl O +
group O +
that O +
allows O +
it O +
to O +
couple O +
covalently O +
to O +
proteins B-Gene +
( O -
Coleman O +
et O +
al. O -
, O +
1988 O +
) O -
, O +
resulting O +
in O +
slow O +
elimination O +
from O +
the O +
body O -
. O +

Its O +
mechanism O +
of O +
action O +
in O +
RA O +
remains O +
unclear O -
, O +
but O +
its O +
variable O +
and O +
unpredictable O +
efficacy O -
, O +
coupled O +
with O +
a O +
relatively O +
high O +
incidence O +
of O +
side O -
- O -
effects O -
, O +
has O +
led O +
to O +
a O +
decline O +
in O +
its O +
use O +
in O +
recent O +
years O -
. O +

Such O +
side O -
- O -
effects O +
include O +
the O +
development O +
of O +
a O +
number O +
of O +
autoimmune O +
disorders O +
including O +
lupus O +
erythematosus O -
, O +
pemphigus O -
, O +
Goodpasture O -
's O +
syndrome O -
, O +
neuromyotonia O +
and O +
myasthenia O +
gravis O +
( O -
MG O -
; O +
Fernandes O +
et O +
al. O -
, O +
1980 O +
) O -
. O +

d O +
-Pen O +
is O +
not O +
the O +
only O +
drug O +
capable O +
of O +
inducing O +
autoimmune O +
disease O -
, O +
but O +
it O +
is O +
almost O +
alone O +
in O +
its O +
ability O +
to O +
cause O +
autoimmune O +
MG O -
. O +

As O +
with O +
other O +
drug O -
- O -
induced O +
disorders O -
, O +
d O +
-pen O -
- O -
induced O +
MG O +
is O +
associated O +
with O +
the O +
development O +
of O +
autoantibodies B-Gene -
, O +
in O +
this O +
case O +
to O +
the O +
acetylcholine B-Gene +
receptor I-Gene +
( O -
AChR B-Gene -
) O +
( O -
Russell O +
and O +
Lindstrom O -
, O +
1978 O +
) O -
. O +

The O +
avidity O +
and O +
specificities O +
of O +
these O +
autoantibodies B-Gene +
in O +
d O +
-pen O -
- O -
induced O +
MG O +
are O +
similar O +
to O +
those O +
found O +
in O +
early O -
- O -
onset O +
patients O +
( O -
EOMG O -
) O -
, O +
particularly O +
early O +
in O +
the O +
course O +
of O +
the O +
disease O +
( O -
Vincent O +
and O +
Newsom O -
- O -
Davis O -
, O +
1982 O +
; O +
Heidenreich O +
et O +
al. O -
, O +
1988 O +
) O -
; O +
however O -
, O +
the O +
MG O +
normally O +
remits O +
within O +
6 O +
months O +
of O +
stopping O +
the O +
drug O -
, O +
with O +
a O +
concomitant O +
fall O +
in O +
the O +
anti O -
- O -
AChR B-Gene +
antibody B-Gene +
titer O +
( O -
Vincent O +
et O +
al. O -
, O +
1978 O +
; O +
Kuncl O +
et O +
al. O -
, O +
1986 O +
) O -
, O +
whereas O +
idiopathic O +
MG O +
is O +
usually O +
long O -
- O -
lasting O -
. O +

Delamere O +
et O +
al. O +
( O -
1983 O -
) O +
and O +
Garlepp O +
et O +
al. O +
( O -
1983 O -
) O +
reported O +
that O -
, O +
in O +
contrast O +
with O +
other O +
MG O +
subgroups O -
, O +
the O +
condition O +
is O +
associated O +
with O +
HLA O -
- O -
DR1 O -
, O +
though O +
its O +
rarity O +
means O +
that O +
the O +
numbers O +
of O +
patients O +
studied O +
are O +
small O -
. O +

How O +
d O +
-pen O +
induces O +
MG O +
is O +
unclear O -
. O +

Administration O +
of O +
the O +
drug O +
to O +
experimental O +
animals O +
did O +
not O +
result O +
in O +
the O +
production O +
of O +
anti O -
- O -
AChR B-Gene +
antibodies B-Gene -
, O +
although O +
they O +
showed O +
an O +
augmented O +
antibody B-Gene +
response O +
to O +
immunization O +
with O +
AChR B-Gene +
and O +
the O +
resulting O +
MG O +
signs O +
were O +
sometimes O +
more O +
severe O +
( O -
Bever O +
et O +
al. O -
, O +
1984 O +
) O -
. O +

The O +
size O +
of O +
the O +
molecule O +
and O +
its O +
reactive O +
sulfhydryl O +
group O +
suggest O +
that O +
the O +
drug O +
is O +
acting O +
as O +
a O +
hapten O +
and/or O +
modifying O +
self O +
protein B-Gene -
( O -
s O -
) O -
/ O -
peptide O -
( O -
s O -
) O -
, O +
thereby O +
creating O +
neo O -
- O -
epitope O -
( O -
s O -
) O -
. O +

Indeed O -
, O +
coupling O +
of O +
d O +
-pen O +
to O +
an O +
unidentified O +
serum B-Gene +
protein I-Gene +
has O +
been O +
demonstrated O +
in O +
patients O +
on O +
d O +
-pen O +
therapy O +
( O -
Laycock O +
et O +
al. O -
, O +
1994 O +
) O -
, O +
though O +
its O +
significance O +
for O +
autoimmunity O +
is O +
not O +
clear O -
. O +

To O +
examine O +
the O +
role O +
of O +
d O +
-pen O +
in O +
MG O -
, O +
we O +
have O +
isolated O +
a O +
number O +
of O +
CD3 O -
+ O +
, O +
CD4 O -
+ O +
T O +
cell O +
clones O +
from O +
the O +
peripheral O +
blood O +
mononuclear O +
cells O +
( O -
PBMC O -
) O +
of O +
a O +
patient O +
with O +
d O +
-pen O -
- O -
induced O +
MG O +
that O +
respond O +
to O +
the O +
drug O +
in O +
vitro O +
together O +
with O +
HLA O -
- O -
DR1 O -
+ O +
PBMC O -
. O +

We O +
provide O +
evidence O +
that O +
the O +
drug O +
is O +
acting O +
by O +
coupling O +
directly O +
to O +
the O +
MHC O +
class O +
II O -
/ O -
peptide O +
complex O -
, O +
and O +
discuss O +
how O +
this O +
might O +
result O +
in O +
the O +
development O +
of O +
MG O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Patient O +
details O +
We O +
studied O +
a O +
68-year O +
old O +
woman O +
( O -
D O -
- O -
P1 O -
) O +
with O +
erosive O +
seropositive O +
RA O +
( O -
HLA O +
A1,32 O -
; O +
B8,35 O -
; O +
C4,701 O -
; O +
DR1,3,DR52a O -
; O +
DQ2,5 O -
) O +
who O +
had O +
been O +
on O +
d O +
-pen O +
treatment O +
for O +
9 O +
months O +
before O +
she O +
developed O +
right O -
- O -
sided O +
ptosis O -
. O +

Six O +
months O +
later O -
, O +
single O +
fiber O +
electromyography O +
in O +
the O +
affected O +
orbicularis O +
oculi O +
muscle O +
showed O +
markedly O +
increased O +
jitter O -
, O +
consistent O +
with O +
a O +
defect O +
in O +
neuromuscular O +
transmission O -
. O +

Her O +
anti O -
- O -
AChR B-Gene +
antibody B-Gene +
titer O +
was O +
3.2 O +
nM O -
, O +
confirming O +
the O +
diagnosis O +
of O +
MG O -
: O +
the O +
d O +
-pen O +
treatment O +
was O +
therefore O +
stopped O -
. O +

At O +
this O +
time O -
, O +
we O +
took O +
a O +
blood O +
sample O +
from O +
which O +
d O +
-pen O -
- O -
specific O +
lines O +
and O +
clones O +
were O +
obtained O -
. O +

The O +
recovery O +
of O +
her O +
mainly O +
ocular O +
symptoms O +
was O +
slow O -
; O +
about O +
two O +
years O +
after O +
d O +
-pen O +
treatment O +
started O -
, O +
she O +
was O +
given O +
a O +
short O +
course O +
of O +
oral O +
corticosteroids O +
before O +
they O +
resolved O +
completely O +
within O +
9 O +
further O +
months O -
. O +

2.2 O +
Generation O +
of O +
primary O +
T O +
cell O +
lines O +
d O +
-Pen O +
HCl O +
( O -
Sigma O -
, O +
Poole O -
, O +
UK O -
) O +
was O +
dissolved O +
in O +
sterile O +
water O +
and O +
aliquots O +
stored O +
at O +
−70 O -
° O -
C O -
. O +

The O +
cellular O +
toxicity O +
of O +
the O +
drug O +
was O +
determined O +
by O +
inhibition O +
of O +
PHA O +
( O -
Difco O +
Laboratories O -
, O +
Detroit O -
, O +
USA O -
) O -
-induced O +
proliferation O +
of O +
PBMCs O +
from O +
healthy O +
controls O +
by O +
increasing O +
concentrations O +
of O +
d O +
-pen O -
; O +
doses O +
of O +
100–500 O +
μg O -
/ O -
ml O +
were O +
found O +
to O +
be O +
optimal O -
, O +
and O +
toxicity O +
was O +
seen O +
at O +
doses O +
of O +
1 O +
mg O -
/ O -
ml O +
and O +
above O -
. O +

PBMCs O +
were O +
separated O +
from O +
heparinized O +
blood O +
on O +
Lymphoprep O +
( O -
Nycomed O -
, O +
Oslo O -
, O +
Norway O -
) O -
, O +
washed O +
and O +
cultured O +
at O +
2 O -
× O -
106 O +
/1 O +
ml O +
well O +
( O -
Nunc O -
, O +
Roskilde O -
, O +
Denmark O -
) O +
with O +
100–500 O +
μg O -
/ O -
ml O +
d O +
-pen O +
in O +
RPMI O +
( O -
Hyclone O -
, O +
Cramlington O -
, O +
UK O -
) O +
supplemented O +
with O +
5 O -
% O +
heat O -
- O -
inactivated O +
human O +
serum O +
( O -
Blood O +
Transfusion O +
Service O -
, O +
Oxford O -
, O +
UK O -
) O -
, O +
l O +
-glutamine O +
( O -
Gibco O +
Life O +
Technologies O -
, O +
Paisley O -
, O +
Scotland O -
) O +
and O +
50 O +
μg O -
/ O -
ml O +
gentamycin O +
( O -
Gibco O -
) O -
, O +
i.e. O -
, O +
without O +
penicillin O -
. O +

After O +
7 O +
days O -
, O +
stimulation O +
was O +
assessed O +
by O +
culturing O +
triplicate O +
samples O +
( O -
5 O -
% O -
) O +
from O +
each O +
well O +
with O +
1 O +
μCi O +
of O +
3 O +
H O +
thymidine O +
( O -
Amersham O +
International O -
, O +
Amersham O -
, O +
UK O -
) O +
for O +
18 O +
h O -
, O +
followed O +
by O +
harvesting O +
onto O +
filter O +
mats O +
( O -
Wallac O -
, O +
Turku O -
, O +
Finland O -
) O +
and O +
counting O +
on O +
a O +
Betaplate O +
flatbed O +
liquid O +
scintillation O +
counter O +
( O -
Wallac O -
) O -
. O +

A O +
response O +
was O +
considered O +
positive O +
when O +
the O +
activity O +
was O +
greater O +
than O +
twice O +
the O +
control O +
value O -
, O +
i.e. O -
, O +
the O +
stimulation O +
index O +
( O -
SI O -
) O +
was O +
> O -
2 O -
. O +

We O +
expanded O +
positive O +
wells O +
into O +
lines O +
using O +
a O +
cycle O +
of O +
fortnightly O +
restimulation O +
with O +
autologous O +
30 O +
Gy O -
- O -
irradiated O +
PBMC O +
( O -
PBMCx O -
) O +
and O +
d O +
-pen O -
, O +
and O +
supplementing O +
with O +
20U O +
IL-2 B-Gene +
( O -
Biotest O +
( O -
UK O -
) O -
, O +
Solihull O -
, O +
UK O -
) O +
approximately O +
every O +
72 O +
h O +
thereafter O -
. O +

Specificity O +
of O +
the O +
lines O +
for O +
the O +
drug O +
was O +
confirmed O +
by O +
culturing O +
3 O -
× O -
104 O +
T O +
cells O +
with O +
1 O -
× O -
105 O +
PBMCx O +
pretreated O +
with O +
500 O +
μg O -
/ O -
ml O +
d O +
-pen O +
for O +
4 O +
h O +
at O +
37 O -
° O -
C O +
in O +
RPMI O -
/ O -
5 O -
% O +
human O +
serum O +
and O +
then O +
washed O +
twice O +
before O +
being O +
used O +
in O +
the O +
assay O -
. O +

2.3 O +
Isolation O +
of O +
d O +
-pen O -
- O -
specific O +
T O +
cell O +
clones O +
One O +
of O +
the O +
d O +
-pen O -
- O -
specific O +
lines O +
derived O +
from O +
patient O +
D O -
- O -
P1 O +
was O +
cloned O +
by O +
limiting O +
dilution O +
in O +
Terasaki O +
wells O +
( O -
Nunc O -
) O +
using O +
PBMCx O +
prepulsed O +
with O +
500 O +
μg O -
/ O -
ml O +
d O +
-pen O +
as O +
the O +
stimulus O -
. O +

Proliferating O +
clones O +
were O +
expanded O +
with O +
IL-2 B-Gene +
and O +
fortnightly O +
restimulation O +
with O +
PHA O +
and O +
allogeneic O +
PBMCx O -
, O +
and O +
then O +
assayed O +
for O +
a O +
response O +
to O +
d O +
-pen O -
, O +
as O +
described O +
above O -
. O +

Specificity O +
was O +
confirmed O +
by O +
comparing O +
the O +
response O +
to O +
d O +
-pen O +
with O +
that O +
to O +
the O +
isomer O -
, O +
l O +
-penicillamine O -
, O +
and O +
the O +
analogue O -
, O +
d O +
-cysteine O +
( O -
both O +
at O +
500 O +
μg O -
/ O -
ml O -
; O +
Sigma O -
) O -
. O +

Surface O +
phenotype O +
was O +
determined O +
by O +
FACS O +
analysis O +
( O -
Becton O +
Dickinson O -
, O +
Oxford O -
, O +
UK O -
) O +
using O +
conventional O +
two O +
color O +
staining O +
with O +
anti B-Gene -
- I-Gene -
CD3 I-Gene +
( O -
OKT3 B-Gene -
) O +
directly O +
conjugated O +
to O +
fluorescein O +
isothiocyanate O +
( O -
FITC O -
; O +
gift O +
of O +
S.J. O +
Curnow O -
) O +
and O +
anti B-Gene -
- I-Gene -
CD4 B-Gene +
and O +
-CD8 O +
conjugated O +
to O +
phycoerythrin B-Gene +
( O -
Dako O -
, O +
High O +
Wycombe O -
, O +
UK O -
) O -
. O +

2.4 O +
Class O +
II O +
restriction O +
The O +
restricting O +
class O +
II O +
isotype O +
was O +
determined O +
by O +
adding O +
the O +
following O +
class O +
II O -
- O -
blocking O +
mAbs O +
to O +
the O +
presenting O +
cells O +
in O +
the O +
standard O +
assay O -
: O +
mouse O +
anti O -
- O -
human O +
DR O +
( O -
L243 O -
; O +
gift O +
of O +
H. O +
McDevitt O -
) O -
, O +
anti O -
- O -
human O +
DP O +
( O -
gift O +
of O +
F. O +
Brodsky O -
) O +
or O +
anti O -
- O -
human O +
DQ O +
( O -
L2 O -
; O +
gift O +
of O +
D. O +
Altmann O -
) O -
. O +

Comparing O +
the O +
ability O +
of O +
HLA O -
- O -
sharing O +
PBMCx O +
to O +
present O +
d O +
-pen O +
to O +
the O +
clones O +
then O +
identified O +
the O +
allele O -
. O +

2.5 O +
Cytokine B-Gene +
profile O +
The O +
supernatant O +
from O +
T O +
cell O +
clones O +
cultured O +
with O +
PBMCx's±d O +
-pen O +
was O +
analyzed O +
for O +
interferon B-Gene -
- I-Gene -
γ I-Gene +
( O -
IFN B-Gene -
- I-Gene -
γ I-Gene -
) O +
and O +
interleukin-4 B-Gene +
( O -
IL-4 B-Gene -
) O +
by O +
ELISA O +
( O -
Pharmingen O -
, O +
San O +
Diego O -
, O +
CA O -
) O +
according O +
to O +
the O +
manufacturer O -
's O +
instructions O -
. O +

2.6 O +
TCR O +
gene O +
usage O +
T B-Gene +
cell I-Gene +
receptors I-Gene +
were O +
cloned O +
using O +
the O +
anchored O +
polymerase B-Gene +
chain O +
reaction O +
( O -
Moss O +
et O +
al. O -
, O +
1993 O +
) O -
. O +

Briefly O -
, O +
cDNA O +
was O +
synthesized O +
from O +
5 O +
μg O +
of O +
RNA O +
using O +
AMV O -
- O -
RT O +
and O +
an O +
oligo O +
dT O +
primer O -
. O +

cDNA O +
was O +
precipitated O +
three O +
times O +
using O +
4 O +
M O +
ammonium O +
acetate O +
and O +
an O +
oligo O +
dG O +
homopolymer O +
tail O +
added O +
using O +
TdT. O +
cDNA O +
was O +
then O +
amplified O +
using O +
an O +
anchor O +
primer O +
and O +
primers O +
complementary O +
to O +
TCRA O +
and O +
TCRB O +
constant O +
regions O -
. O +

PCR O +
products O +
were O +
then O +
cloned O +
into O +
M13mp18 O +
and O +
sequenced O -
. O +

2.7 O +
Requirement O +
for O +
human O +
serum O +
and O +
antigen O +
processing O +
for O +
antigenicity O +
Fresh O +
PBMCs O +
were O +
washed O +
and O +
kept O +
in O +
serum O -
- O -
free O +
medium O +
before O +
irradiation O +
and O +
pulsing O +
in O +
plain O +
RPMI O -
, O +
in O +
5 O -
% O +
human O +
or O +
fetal O +
calf O +
serum O +
( O -
Tissue O +
Culture O +
Services O -
, O +
Buckingham O -
, O +
UK O -
) O +
or O +
in O +
serum O -
- O -
free O +
AIM O +
V O -
® O +
medium O +
( O -
Gibco O -
) O +
which O +
contains O +
human O +
albumin B-Gene -
, O +
transferrin B-Gene +
and O +
insulin B-Gene -
. O +

The O +
PBMCx O +
were O +
then O +
counted O +
so O +
that O +
any O +
cell O +
losses O +
could O +
be O +
corrected O -
. O +

We O +
also O +
tested O +
B O +
cell O +
lines O -
, O +
including O +
the O +
homozygous O +
DR1 O +
line O +
EHM O +
and O +
one O +
raised O +
from O +
the O +
patient O +
herself O -
; O +
they O +
were O +
pretreated O +
with O +
50 O +
μg O -
/ O -
ml O +
of O +
mitomycin O +
C O +
( O -
Sigma O -
) O +
and O +
washed O +
before O +
co O -
- O -
culture O +
with O +
the O +
T O +
cells O -
. O +

The O +
requirement O +
for O +
antigen O +
processing O +
was O +
determined O +
by O +
preincubating O +
the O +
presenting O +
cells O +
with O +
chloroquine O +
( O -
Sigma O -
) O +
for O +
30 O +
min O +
before O +
pulsing O +
with O +
500 O +
μg O -
/ O -
ml O +
d O +
-pen O +
for O +
4 O +
h O -
, O +
after O +
which O +
the O +
cells O +
were O +
washed O +
and O +
plated O +
routinely O -
. O +

To O +
confirm O +
their O +
subsequent O +
viability O -
, O +
we O +
checked O +
their O +
capacity O +
to O +
present O +
peptide O +
antigen O +
to O +
a O +
well O +
characterized O +
T O +
cell O +
clone O -
, O +
TB-2 O -
, O +
that O +
recognizes O +
a O +
fragment O +
of O +
the O +
α O +
subunit O +
of O +
the O +
AChR B-Gene -
, O +
α:144–163 O -
, O +
presented O +
by O +
DR52a O +
( O -
Nagvekar O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

3 O +
Results O +
3.1 O +
Initial O +
T O +
cell O +
responses O +
to O +
d O +
-pen O +
In O +
a O +
preliminary O +
screen O +
using O +
d O +
-pen O +
at O +
500 O +
μg O -
/ O -
ml O -
, O +
we O +
found O +
positive O +
responses O +
by O +
PBL O +
T O +
cells O +
( O -
SI>2 O -
) O +
in O +
four O +
of O +
five O +
RA O +
patients O +
with O +
recent O +
onset O +
d O +
-pen O +
MG O +
( O -
SIs O +
3–12 O -
) O -
; O +
in O +
one O +
of O +
four O +
RA O +
patients O +
without O +
MG O +
or O +
anti O -
- O -
AChR B-Gene +
antibodies B-Gene +
despite O +
d O +
-pen O +
treatment O +
( O -
SI O +
4.1 O -
) O -
; O +
in O +
zero O +
of O +
three O +
patients O +
with O +
idiopathic O +
EOMG O +
and O +
in O +
4 O +
of O +
11 O +
healthy O +
controls O +
( O -
SI O +
2.3 O -
, O +
4.5 O -
, O +
4.8 O +
and O +
15.0 O -
) O -
. O +

All O +
of O +
the O +
d O +
-pen O +
MG O +
patients O +
had O +
HLA O -
- O -
DR1 O -
, O +
as O +
did O +
the O +
one O +
other O +
responder O +
with O +
RA O -
. O +

However O -
, O +
none O +
of O +
the O +
healthy O +
responders O +
was O +
DR1 O -
+ O +
; O +
some O +
of O +
their O +
responses O +
might O +
conceivably O +
be O +
related O +
to O +
prior O +
exposure O +
to O +
penicillin O -
. O +

Only O +
one O +
of O +
the O +
responder O +
d O +
-pen O +
MG O +
patients O +
( O -
D O -
- O -
P1 O -
; O +
SI O +
4.3 O -
) O +
was O +
tested O +
before O +
taking O +
corticosteroids O -
; O +
as O +
she O +
was O +
readily O +
available O +
for O +
further O +
sampling O -
, O +
T O +
cell O +
lines O +
were O +
initiated O +
from O +
her O +
for O +
detailed O +
characterization O +
of O +
this O +
response O -
. O +

3.2 O +
Selecting O +
d O +
-pen O -
- O -
responsive O +
T O +
cell O +
lines O +
and O +
clones O +
from O +
patient O +
D O -
- O -
P1 O +
Several O +
T O +
cell O +
lines O +
were O +
successfully O +
raised O +
and O +
maintained O +
by O +
culturing O +
with O +
d O +
-pen O +
at O +
500 O +
μg O -
/ O -
ml O -
. O +

Three O +
findings O +
established O +
that O +
this O +
drug O +
was O +
not O +
merely O +
acting O +
as O +
a O +
non O -
- O -
specific O +
mitogen O -
. O +

Firstly O -
, O +
two O +
well O -
- O -
characterized O +
AChR B-Gene -
- O -
specific O +
T O +
cell O +
clones O -
, O +
TB-2 O +
and O +
PM O -
- O -
A1 O -
, O +
failed O +
to O +
show O +
any O +
proliferative O +
response O +
to O +
d O +
-pen O +
at O +
50–500 O +
μg O -
/ O -
ml O +
( O -
not O +
shown O -
) O -
. O +

Secondly O -
, O +
the O +
drug O -
- O -
specific O +
lines O +
also O +
responded O +
optimally O +
to O +
autologous O +
APC O +
preincubated O +
with O +
the O +
drug O +
for O +
4 O +
h O +
and O +
then O +
washed O +
thoroughly O -
, O +
while O +
unpulsed O +
autologous O +
APC O +
failed O +
to O +
stimulate O -
. O +

Thirdly O -
, O +
there O +
was O +
no O +
response O +
when O +
the O +
APC O +
were O +
HLA O -
- O -
mismatched O +
( O -
see O +
below O -
) O -
. O +

3.3 O +
Characteristics O +
of O +
d O +
-pen O -
- O -
specific O +
T O +
cell O +
clones O +
The O +
d O +
-pen O -
- O -
specific O +
line O +
that O +
showed O +
the O +
greatest O +
response O +
to O +
the O +
drug O +
was O +
cloned O +
by O +
limiting O +
dilution O +
in O +
the O +
presence O +
of O +
d O +
-pen O -
- O -
prepulsed O +
autologous O +
PBMCx O -
. O +

Among O +
the O +
175 O +
clones O +
grown O -
, O +
40 O -
% O +
( O -
70 O -
) O +
responded O +
to O +
d O +
-pen O +
( O -
SI>5 O -
) O -
, O +
showing O +
that O +
there O +
was O +
a O +
high O +
precursor O +
frequency O +
of O +
d O +
-pen O -
- O -
specific O +
T O +
cells O +
in O +
the O +
line O -
. O +

Some O +
10 O +
clones O +
were O +
chosen O +
for O +
further O +
study O -
; O +
they O +
were O +
all O +
CD3 O -
+ O +
CD4 O -
+ O +
and O +
behaved O +
identically O +
in O +
all O +
experiments O -
, O +
responding O +
to O +
autologous O +
PBMCx O +
preincubated O +
with O +
d O +
-pen O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
( O -
Fig. O +
1 O +
) O -
. O +

Moreover O -
, O +
the O +
clones O +
were O +
highly O +
specific O +
for O +
l O +
-pen O -
, O +
as O +
shown O +
by O +
their O +
failure O +
to O +
respond O +
to O +
the O +
analogues O +
d O +
-pen O +
and O +
d O +
-cysteine O +
( O -
Fig. O +
2 O +
) O -
. O +

The O +
10 O +
clones O +
tested O +
all O +
proved O +
to O +
be O +
restricted O +
to O +
HLA O -
- O -
DR1 O -
. O +

An O +
isotype O -
- O -
specific O +
anti O -
- O -
HLA O -
- O -
DR O +
mAb B-Gene +
almost O +
completely O +
blocked O +
the O +
responses O +
of O +
these O +
clones O +
( O -
Fig. O +
3 O +
a O -
) O -
; O +
furthermore O -
, O +
they O +
all O +
recognized O +
d O +
-pen O -
- O -
pulsed O +
PBMCx O +
from O +
a O +
number O +
of O +
healthy O +
DR1 O -
+ O +
individuals O +
( O -
Fig. O +
3 O +
b O -
) O -
. O +

The O +
two O +
clones O +
tested O +
were O +
both O +
phenotypically O +
Th1 O -
, O +
producing O +
large O +
amounts O +
of O +
IFN B-Gene -
- I-Gene -
γ I-Gene +
( O -
2 O -
× O -
104 O +
pg O -
/ O -
ml O -
) O -
, O +
but O +
no O +
detectable O +
IL-4 B-Gene +
( O -
not O +
shown O -
) O -
. O +

They O +
proved O +
to O +
have O +
identical O +
TCR O +
gene O +
usage O -
, O +
namely O +
Vα4.1 O -
, O +
Jα1.3 O -
, O +
Vβ6.1 O -
, O +
Jβ2.3 O -
, O +
suggesting O +
that O +
they O +
are O +
sister O +
clones O -
. O +

Intriguingly O -
, O +
this O +
β O +
chain O +
sequence O +
shares O +
a O +
PG O +
motif O +
in O +
the O +
CDR3 O +
region O +
( O -
Fig. O +
4 O +
) O +
with O +
a O +
previously O +
characterized O +
AChR B-Gene +
ε O -
- O -
specific O +
T O +
cell O +
clone O +
isolated O +
from O +
a O +
patient O +
with O +
EOMG O +
( O -
Hill O +
et O +
al. O -
, O +
1999 O +
) O -
. O +

3.4 O +
Potential O +
` O -
carrier O -
' O +
molecules O +
for O +
d O +
-pen O +
To O +
determine O +
whether O +
the O +
d O +
-pen O +
was O +
coupling O +
to O +
a O +
serum B-Gene +
protein I-Gene -
, O +
PBMCx O +
were O +
pulsed O +
with O +
d O +
-pen O +
in O +
the O +
presence O +
or O +
absence O +
of O +
serum O -
. O +

Regardless O +
of O +
whether O +
we O +
used O +
5 O -
% O +
human O +
or O +
fetal O +
calf O +
serum O -
, O +
serum O -
- O -
free O +
AIM O +
V O -
® O +
medium O +
( O -
containing O +
human O +
albumin B-Gene -
, O +
transferrin B-Gene +
and O +
insulin B-Gene -
) O +
or O +
even O +
plain O +
RPMI O -
, O +
the O +
PBMCx O +
all O +
stimulated O +
the O +
two O +
T O +
cell O +
clones O +
tested O +
very O +
efficiently O +
( O -
Fig. O +
5 O +
) O -
. O +

This O +
result O +
suggested O +
that O +
the O +
drug O +
was O +
coupling O +
to O +
pre O -
- O -
existing O +
cellular B-Gene +
proteins I-Gene -
, O +
whether O +
internal O +
or O +
on O +
the O +
surface O -
. O +

To O +
determine O +
whether O +
these O +
require O +
further O +
processing O -
, O +
we O +
tested O +
the O +
effects O +
of O +
chloroquine O -
, O +
a O +
potent O +
lysosomotropic O +
inhibitor O +
of O +
antigen O +
processing O +
( O -
Ziegler O +
and O +
Unanue O -
, O +
1982 O +
) O -
. O +

As O +
a O +
standard O -
, O +
we O +
used O +
the O +
response O +
of O +
clone O +
TB-2 O +
to O +
both O +
the O +
full O -
- O -
length O +
AChR B-Gene +
α B-Gene +
subunit I-Gene +
( O -
α:1–437 B-Gene -
) O -
, O +
which O +
requires O +
processing O -
, O +
and O +
its O +
peptide O -
, O +
α:144–163 O -
, O +
which O +
does O +
not O +
( O -
Fig. O +
6 O +
) O -
. O +

Pretreatment O +
of O +
PBMCx O +
with O +
chloroquine O +
had O +
no O +
detectable O +
effect O +
on O +
the O +
responses O +
to O +
d O +
-pen O +
or O +
α:144–163 O +
at O +
doses O +
that O +
almost O +
completely O +
abolished O +
those O +
to O +
the O +
full O -
- O -
length O +
α:1–437 B-Gene +
( O -
Fig. O +
6 O +
b O -
) O -
, O +
clearly O +
showing O +
that O +
the O +
key O +
molecules O +
modified O +
by O +
d O +
-pen O +
do O +
not O +
require O +
subsequent O +
processing O -
. O +

Thus O -
, O +
these O +
data O +
strongly O +
suggest O +
that O +
d O +
-pen O +
is O +
acting O +
by O +
directly O +
coupling O +
to O +
a O +
component O +
of O +
the O +
MHC O -
/ O -
peptide O +
complex O -
. O +

It O +
was O +
therefore O +
intriguing O +
that O +
two O +
different O +
DR1 O -
+ O +
EBV O -
- O -
B O +
cell O +
lines O +
( O -
one O +
of O +
them O +
autologous O -
) O +
consistently O +
failed O +
to O +
` O -
present O -
' O +
d O +
-pen O +
to O +
the O +
clones O -
; O +
this O +
deficiency O +
was O +
not O +
corrected O +
by O +
pre O -
- O -
culturing O +
the O +
EBV O -
- O -
B O +
cells O +
in O +
human O +
serum O +
rather O +
than O +
the O +
FCS O +
in O +
which O +
these O +
cells O +
were O +
normally O +
maintained O +
( O -
Fig. O +
7 O +
) O -
. O +

The O +
autologous O +
B O +
cell O +
line O -
, O +
which O +
also O +
has O +
HLA O -
- O -
DR52a O -
, O +
presented O +
specific O +
peptides O +
very O +
well O +
to O +
the O +
DR52a O -
- O -
restricted O +
clone O +
TB-2 O +
when O +
tested O +
in O +
parallel O -
, O +
confirming O +
its O +
efficient O +
antigen O -
- O -
presenting O +
ability O -
. O +

Thus O -
, O +
these O +
results O +
suggest O +
that O +
these O +
T O +
cells O +
are O +
recognizing O +
a O +
modification O +
of O +
some O +
resident O +
peptide O -
, O +
rather O +
than O +
of O +
the O +
DR1 O +
itself O -
, O +
and O +
that O +
this O +
peptide O +
differs O +
in O +
the O +
PBMC O +
and O +
the O +
B O +
cell O +
lines O -
. O +

4 O +
Discussion O +
In O +
this O +
study O +
on O +
d O +
-pen O -
- O -
induced O +
MG O -
, O +
we O +
report O +
the O +
isolation O +
and O +
characterization O +
of O +
CD4 O -
+ O +
Th1 O +
cell O +
clones O +
specific O +
for O +
d O +
-pen O -
, O +
which O +
recognized O +
DR1 O -
+ O +
APC O +
preincubated O +
with O +
the O +
drug O -
. O +

Our O +
evidence O +
suggests O +
that O +
it O +
is O +
acting O +
by O +
directly O +
modifying O +
pre O -
- O -
existing O +
MHC O +
molecules O +
and/or O +
resident O +
peptides O +
on O +
the O +
APC O +
surface O -
, O +
though O +
the O +
nature O +
of O +
this O +
modification O +
still O +
requires O +
elucidation O -
. O +

Responses O +
of O +
these O +
T O +
cells O +
became O +
significant O +
at O +
approximately O +
50 O +
μg O -
/ O -
ml O +
of O +
d O +
-pen O -
, O +
and O +
optimal O +
at O +
500 O +
μg O -
/ O -
ml O -
; O +
the O +
latter O +
is O +
very O +
similar O +
to O +
that O +
previously O +
used O +
in O +
vitro O +
for O +
d O +
-pen O -
- O -
specific O +
T O +
cells O +
isolated O +
from O +
experimental O +
animals O +
immunized O +
with O +
the O +
drug O +
( O -
O'Donnell O +
and O +
Coleman O -
, O +
1992 O +
) O -
. O +

It O +
apparently O +
contrasts O +
with O +
the O +
peak O +
levels O +
of O +
about O +
5 O +
μg O -
/ O -
ml O +
measured O +
in O +
the O +
peripheral O +
blood O +
of O +
patients O +
taking O +
750 O +
mg O -
/ O -
day O +
( O -
Brooks O +
et O +
al. O -
, O +
1984 O +
) O -
. O +

However O -
, O +
much O +
higher O +
doses O +
are O +
usually O +
required O +
in O +
culture O +
than O +
in O +
vivo O -
, O +
as O +
has O +
been O +
observed O +
previously O +
with O +
other O +
drugs O +
such O +
as O +
sulfonamides O -
, O +
carbamazepine O +
and O +
phenytoin O +
( O -
Mauri O -
- O -
Hellweg O +
et O +
al. O -
, O +
1995 O +
) O -
, O +
as O +
well O +
as O +
with O +
d O +
-pen O +
itself O +
( O -
O'Donnell O +
and O +
Coleman O -
, O +
1992 O +
) O -
. O +

It O +
therefore O +
seems O +
likely O +
that O -
, O +
in O +
vivo O -
, O +
the O +
drug O +
becomes O +
concentrated O +
in O +
specialized O +
microenvironments O +
or O +
reactive O +
under O +
conditions O +
that O +
are O +
not O +
reproduced O +
in O +
culture O -
, O +
and/or O +
that O +
prolonged O +
exposure O +
is O +
required O -
. O +

It O +
is O +
well O +
recognized O +
that O +
d O +
-pen O +
can O +
couple O +
directly O +
to O +
proteins B-Gene -
, O +
forming O +
disulfide O +
bonds O +
with O +
free O +
cysteine O +
residues O +
( O -
Coleman O +
et O +
al. O -
, O +
1988 O +
): O +
it O +
can O +
also O +
break O +
pre O -
- O -
existing O +
disulfide O +
bonds O -
, O +
and O +
so O +
unfold O +
proteins O +
or O +
disaggregate O +
complexes O -
. O +

Several O +
published O +
reports O +
demonstrate O +
that O +
it O +
couples O +
directly O +
to O +
the O +
surface O +
of O +
presenting O +
cells O +
of O +
experimental O +
animals O +
in O +
vivo O -
, O +
though O +
the O +
identity O +
of O +
the O +
target O +
protein B-Gene -
( O -
s O -
) O +
has O +
not O +
been O +
determined O -
. O +

At O +
doses O +
of O +
125–1000 O +
μg O -
/ O -
ml O -
, O +
d O +
-pen O +
rapidly O +
couples O +
directly O +
to O +
the O +
surface O +
of O +
rat O +
macrophages O -
, O +
a O +
process O +
that O +
is O +
not O +
affected O +
by O +
cell O +
fixation O +
or O +
chloroquine O -
, O +
but O +
is O +
enhanced O +
by O +
oxidizing O +
agents O +
( O -
O'Donnell O +
et O +
al. O -
, O +
1991 O +
) O -
. O +

These O +
cells O +
take O +
up O +
the O +
labeled O +
drug O +
in O +
a O +
dose- O +
and O +
time O -
- O -
dependent O +
manner O +
and O +
retain O +
it O +
for O +
over O +
24 O +
h. O +
In O +
contrast O -
, O +
although O +
lymphocytes O +
rapidly O +
acquire O +
labeled O +
d O +
-pen O -
, O +
they O +
also O +
lose O +
it O +
completely O +
within O +
2 O +
h O +
( O -
Binderup O +
and O +
Arrigoni O -
- O -
Martelli O -
, O +
1979 O +
) O -
. O +

Our O +
present O +
results O +
also O +
suggest O +
that O +
d O +
-pen O +
is O +
acting O +
by O +
coupling O +
directly O +
to O +
the O +
APC O -
, O +
and O +
it O +
seems O +
logical O +
to O +
suppose O +
that O +
its O +
target O +
is O +
the O +
class O +
II O -
/ O -
peptide O +
complex O -
. O +

Since O +
there O +
is O +
a O +
well O -
- O -
known O +
association O +
with O +
HLA O -
- O -
DR1 O +
in O +
d O +
-pen O -
- O -
induced O +
MG O +
( O -
Garlepp O +
et O +
al. O -
, O +
1983 O +
) O -
, O +
the O +
uniform O +
restriction O +
of O +
our O +
clones O +
to O +
this O +
allele O +
argues O +
strongly O +
for O +
their O +
disease O -
- O -
relevance O -
. O +

This O +
would O +
be O +
further O +
supported O +
if O +
the O +
same O +
modification O +
were O +
already O +
present O +
in O +
vivo O +
on O +
the O +
APC O +
of O +
DR1 O -
+ O +
MG O +
patients O +
taking O +
d O +
-pen O -
, O +
and O +
recognizable O +
by O +
the O +
D O -
- O -
P1 O +
T O +
cells O -
. O +

We O +
were O +
unable O +
to O +
test O +
this O +
possibility O +
because O +
our O +
patient O +
had O +
stopped O +
the O +
treatment O +
before O +
enrolment O +
in O +
the O +
study O -
. O +

Several O +
other O +
drugs O -
/ O -
haptens O +
are O +
known O +
to O +
couple O +
either O +
to O +
peptides O +
resident O +
in O +
the O +
MHC O +
groove O +
or O +
directly O +
to O +
MHC O +
molecules O -
. O +

Examples O +
of O +
the O +
former O +
include O +
trinitrophenyl O +
( O -
TNP O -
) O +
and O +
penicillin O +
which O +
both O +
couple O +
to O +
lysine O +
residues O +
( O -
Martin O +
et O +
al. O -
, O +
1992 O +
; O +
Padovan O +
et O +
al. O -
, O +
1997 O +
) O -
, O +
and O +
nickel O +
which O +
couples O +
to O +
histidines O +
( O -
Romagnoli O +
et O +
al. O -
, O +
1992 O +
) O -
, O +
while O +
gold O +
salts O +
are O +
thought O +
to O +
directly O +
modify O +
the O +
class O +
II O +
molecule O +
( O -
Sinigaglia O -
, O +
1994 O +
) O -
. O +

Although O +
further O +
work O +
is O +
required O +
to O +
determine O +
which O +
of O +
these O +
two O +
possibilities O +
applies O +
to O +
d O +
-pen O -
, O +
it O +
is O +
worthy O +
of O +
note O +
that O +
HLA O -
- O -
DR1 O +
is O +
the O +
only O +
human O +
DR O +
molecule O +
that O +
has O +
an O +
unpaired O +
cysteine O +
residue O -
. O +

It O +
is O +
at O +
position O +
30 O +
in O +
the O +
floor O +
of O +
the O +
peptide O -
- O -
binding O +
groove O +
( O -
Stern O +
et O +
al. O -
, O +
1994 O +
) O -
, O +
where O +
modification O +
of O +
analogous O +
amino O +
acids O +
in O +
other O +
HLA O +
alleles O +
can O +
dramatically O +
alter O +
T O +
cell O +
recognition O +
of O +
the O +
epitope O +
peptides O +
( O -
Krieger O +
et O +
al. O -
, O +
1991 O +
; O +
Boehncke O +
et O +
al. O -
, O +
1993 O +
) O -
. O +

Work O +
on O +
the O +
class O +
I O +
allele O +
HLA O -
- O -
B27 O +
also O +
suggests O +
that O +
oxidative O +
modification O +
of O +
the O +
unusual O +
free O +
sulfhydryl O +
group O +
( O -
67 O +
Cys O +
) O +
on O +
this O +
HLA O +
molecule O +
can O +
directly O +
influence O +
its O +
immunogenicity O +
( O -
Archer O +
et O +
al. O -
, O +
1990 O +
) O -
. O +

The O +
failure O +
of O +
the O +
d O +
-pen O -
- O -
treated O +
B O +
cell O +
lines O +
to O +
stimulate O +
our O +
clones O +
is O +
intriguing O +
and O +
argues O +
that O +
the O +
drug O +
was O +
modifying O +
distinctive O +
resident O +
peptides O +
in O +
the O +
autologous O +
PBMC O +
that O +
are O +
not O +
identical O +
in O +
the O +
B O +
cell O +
lines O -
. O +

It O +
would O +
therefore O +
be O +
interesting O +
to O +
identify O +
the O +
key O +
cell O +
type O +
in O +
the O +
PBMC O +
( O -
e.g. O -
, O +
macrophage O +
or O +
dendritic O +
cell O -
) O -
. O +

One O +
might O +
then O -
, O +
in O +
principle O -
, O +
take O +
advantage O +
of O +
this O +
failure O +
by O +
comparing O +
the O +
peptides O +
that O +
react O +
with O +
labeled O +
d O +
-pen O +
in O +
these O +
cells O +
and O +
in O +
the O +
B O +
cell O +
lines O -
, O +
though O +
they O +
may O +
be O +
too O +
heterogeneous O +
to O +
allow O +
precise O +
identification O +
of O +
the O +
key O +
epitope O -
( O -
s O -
) O -
. O +

Remarkably O -
, O +
however O -
, O +
one O +
resident O +
AChR B-Gene +
peptide O +
has O +
already O +
been O +
identified O +
in O +
a O +
DR3 O -
+ O +
B O +
cell O +
line O +
( O -
Chicz O +
et O +
al. O -
, O +
1993 O +
) O -
. O +

The O +
d O +
-pen O -
- O -
specific O +
clones O +
characterized O +
here O +
could O +
provide O +
important O +
clues O +
to O +
the O +
pathogenesis O +
of O +
both O +
drug O -
- O -
induced O +
and O +
idiopathic O +
MG O -
. O +

The O +
first O +
obvious O +
mechanism O +
is O +
that O +
d O +
-pen O -
- O -
modified O +
peptides O +
activate O +
T O +
cells O +
that O +
can O +
cross O -
- O -
react O +
with O +
epitopes O +
derived O +
from O +
the O +
AChR B-Gene -
, O +
though O +
it O +
is O +
hard O +
to O +
envisage O +
the O +
exact O +
nature O +
of O +
such O +
cross O -
- O -
reactions O -
, O +
and O -
, O +
as O +
yet O -
, O +
there O +
is O +
no O +
direct O +
evidence O +
for O +
them O -
. O +

In O +
fact O -
, O +
the O +
clone O +
we O +
tested O +
showed O +
no O +
detectable O +
recognition O +
of O +
either O +
AChR B-Gene +
or O +
its O +
α B-Gene -
, O +
γ B-Gene +
or O +
ε B-Gene +
subunits I-Gene +
after O +
these O +
were O +
pre O -
- O -
incubated O +
with O +
d B-Gene +
-pen I-Gene +
( O -
not O +
shown O -
) O -
, O +
though O +
some O +
of O +
the O +
69 O +
other O +
clones O +
may O +
be O +
sufficiently O +
sensitive O +
to O +
do O +
so O -
. O +

We O +
also O +
tested O +
five O +
patients O +
with O +
d O +
-pen O -
- O -
induced O +
MG O +
for O +
recognition O +
of O +
the O +
untreated O +
AChR B-Gene +
α B-Gene -
- I-Gene -
subunit I-Gene +
( O -
present O +
in O +
all O +
isoforms O -
) O -
, O +
the O +
fetal B-Gene -
- I-Gene -
specific I-Gene +
γ I-Gene +
and O +
the O +
adult B-Gene -
- I-Gene -
specific I-Gene +
ε I-Gene -
. O +

Interestingly O -
, O +
in O +
four O +
of O +
these O +
five O +
cases O -
, O +
we O +
saw O +
responses O +
to O +
the O +
ε B-Gene +
rather O +
than O +
the O +
other O +
subunits B-Gene +
( O -
not O +
shown O -
) O -
. O +

Since O +
the O +
present O +
case O +
( O -
D O -
- O -
P1 O -
) O +
again O +
appeared O +
to O +
be O +
representative O -
, O +
we O +
went O +
on O +
to O +
isolate O +
clones O +
that O +
proved O +
to O +
be O +
specific O +
for O +
the O +
ε:201–219 O +
sequence O +
( O -
Hill O +
et O +
al. O -
, O +
1999 O +
) O -
. O +

This O +
also O +
appears O +
to O +
be O +
a O +
dominant O +
epitope O +
for O +
EOMG O +
patients O +
and O +
is O +
presented O +
by O +
the O +
candidate O +
susceptibility O +
allele O -
, O +
DR52a O +
( O -
Hill O +
et O +
al. O -
, O +
1999 O +
) O -
. O +

Thus O -
, O +
one O +
might O +
hypothesize O +
that O +
AChR B-Gene -
- O -
cross O -
- O -
reactive O +
T O +
cells O +
initially O +
activated O +
by O +
d O +
-pen O +
lead O -
, O +
by O +
a O +
process O +
of O +
determinant O +
spreading O -
, O +
to O +
responsiveness O +
to O +
the O +
ε B-Gene +
subunit I-Gene +
that O +
then O +
induces O +
a O +
pathogenic O +
autoantibody B-Gene +
response O -
, O +
as O +
in O +
idiopathic O +
MG O -
. O +

These O +
T O +
cells O +
would O +
be O +
well O +
equipped O +
to O +
help O +
in O +
the O +
generation O +
of O +
complement O -
- O -
fixing O +
antibodies B-Gene +
by O +
virtue O +
of O +
their O +
Th1 O +
cytokine B-Gene +
profile O -
. O +

However O -
, O +
whereas O +
this O +
response O +
appears O +
to O +
be O +
self O -
- O -
perpetuating O +
in O +
EOMG O -
, O +
the O +
antibody B-Gene +
titers O +
usually O +
fall O +
upon O +
withdrawal O +
of O +
d O +
-pen O -
, O +
with O +
concomitant O +
remission O +
of O +
symptoms O -
. O +

A O +
second O +
possibility O +
is O +
that O +
d O +
-pen O +
directly O +
` O -
haptenates O -
' O +
AChR B-Gene +
and/or O +
AChR B-Gene +
fragments O +
that O +
then O +
activate O +
pathogenic O +
T O +
cells O -
. O +

Hence O -
, O +
it O +
is O +
interesting O +
that O +
the O +
above O +
ε:201–219 O +
sequence O +
includes O +
an O +
unpaired O +
210 O +
Cys O +
at O +
p6 O +
in O +
the O +
epitope O +
core O +
( O -
Beeson O +
et O +
al. O -
, O +
1993 O +
) O -
. O +

This O +
residue O +
appears O +
to O +
be O +
important O +
for O +
T O +
cell O +
recognition O -
, O +
since O +
pre O -
- O -
exposure O +
to O +
d O +
-pen O +
prevented O +
this O +
peptide O +
from O +
stimulating O +
another O +
ε201–219-specific O +
clone O +
from O +
an O +
EOMG O +
patient O +
( O -
unpublished O +
observations O -
) O -
. O +

Hence O -
, O +
this O +
sequence O +
itself O +
may O +
be O +
an O +
alternative O +
target O +
for O +
d O +
-pen O +
modification O -
. O +

In O +
either O +
case O -
, O +
it O +
is O +
a O +
particularly O +
intriguing O +
possibility O +
that O +
d O +
-pen O +
is O +
mimicking O +
the O +
action O +
of O +
an O +
as O +
yet O +
unidentified O +
natural O +
` O -
counterpart O -
' O +
that O +
is O +
responsible O +
for O +
initiating O +
the O +
idiopathic O +
disease O -
. O +

An O +
analogous O +
process O +
has O +
been O +
implicated O +
in O +
other O +
conditions O +
presenting O +
with O +
autoimmune O +
features O +
such O +
as O +
the O +
plant O +
amino O +
acid O -
, O +
canavanine O -
, O +
in O +
SLE O -
, O +
and O +
an O +
analogue O +
of O +
l O +
-tryptophan O -
, O +
1,1′-ethylidenebis O -
[ O -
l O +
-tryptophan O -
] O +
that O +
is O +
thought O +
to O +
induce O +
Eosinophilia O -
– O -
Myalgia O +
syndrome O +
( O -
Yoshida O +
and O +
Gershwin O -
, O +
1993 O +
) O -
. O +

Although O +
definitive O +
proof O +
that O +
these O +
agents O +
are O +
responsible O +
for O +
causing O +
disease O +
is O +
awaited O -
, O +
the O +
latter O +
compound O +
has O +
been O +
shown O +
to O +
be O +
incorporated O +
into O +
self B-Gene -
- I-Gene -
proteins I-Gene -
, O +
apparently O +
creating O +
novel O +
epitopes O +
( O -
Buss O +
et O +
al. O -
, O +
1996 O +
) O -
. O +

Anti O -
- O -
hapten O +
responses O +
have O +
also O +
been O +
implicated O +
in O +
active O +
ankylosing O +
spondylitis O +
by O +
the O +
isolation O +
of O +
HLA O -
- O -
B27-restricted O +
cytotoxic O +
T O +
cells O +
that O +
recognize O +
both O +
APC O +
treated O +
with O +
the O +
compound O +
homocysteine O +
and O +
B O +
cells O +
infected O +
with O +
Salmonella O +
typhimurium O +
( O -
Gao O +
et O +
al. O -
, O +
1996 O +
) O -
. O +

In O +
summary O -
, O +
the O +
isolation O +
and O +
characterization O +
of O +
these O +
d O +
-pen O -
- O -
specific O +
T O +
cell O +
clones O +
should O +
provide O +
a O +
useful O +
experimental O +
system O +
with O +
which O +
to O +
elucidate O +
the O +
basis O +
of O +
hapten O +
recognition O +
by O +
human O +
T O +
cells O -
, O +
and O +
perhaps O +
also O +
the O +
mechanisms O +
of O +
drug O -
- O -
induced O +
autoimmune O +
disease O -
. O +

Ultimately O +
it O +
may O +
also O +
provide O +
insights O +
into O +
the O +
factors O +
involved O +
in O +
the O +
initiation O +
of O +
idiopathic O +
MG O -
. O +

Acknowledgements O +

We O +
are O +
very O +
grateful O +
to O +
several O +
colleagues O +
for O +
referring O +
patients O +
or O +
providing O +
mAbs B-Gene -
, O +
to O +
donor O +
D O -
- O -
P1 O +
and O +
to O +
Drs O -
. O +

E. O +
Sim O -
, O +
J. O +
Coleman O +
and O +
A. O +
Vincent O +
for O +
invaluable O +
suggestions O +
and O +
advice O -
. O +

MEH O +
was O +
supported O +
by O +
the O +
Medical O +
Research O +
Council O +
of O +
Great O +
Britain O -
. O +

Human O +
fascioliasis O -
, O +
caused O +
by O +
Fasciola O +
hepatica O -
, O +
is O +
a O +
great O +
worldwide O +
health O +
problem O +
( O -
CHEN O +
& O +
MOTT O -
, O +
1990 O -
; O +
ESTEBAN O +
et O +
al. O -
, O +
1998e O -
) O -
. O +

Several O +
areas O +
have O +
been O +
de- O +
scribed O +
as O +
presenting O +
true O +
human O +
endemics O -
, O +
ranging O +
from O +
low O +
to O +
very O +
high O +
prevalences O +
and O +
intensities O +
( O -
MAS O -
- O -
COMA O +
al. O -
, O +
1999a O -
) O -
. O +

Studies O +
carried O +
out O +
in O +
recent O +
years O +
have O +
demonstrated O +
that O +
the O +
most O +
important O +
human O +
fascioliasis O +
endemic O +
regions O +
are O +
located O +
in O +
South O +
America O +
( O -
MAS O -
- O -
COMAetfl O -
/ O -
. O -
, O +
1995 O -
, O +
1999a O -
; O +
WHO O -
, O +
1995;HlLLYER O +
& O +
APT O -
, O +
1997 O -
; O +
ESTEBAN O +
et O +
al. O -
, O +
1998e O -
) O -
. O +

Coprological O +
( O -
MAS O -
- O -
COMA O +
al. O -
, O +
1995 O -
; O +
ESTEBAN O +
al. O -
, O +
1997a O -
, O +
1997b O -
) O +
and O +
immunological O +
surveys O +
( O -
HILLYER O +
et O +
al. O -
, O +
1992 O -
; O +
BJORLAND O +
et O +
al. O -
, O +
1995 O -
; O +
MAS O -
- O -
COMA O +
et O +
al. O -
, O +
1995 O -
; O +
O'NEILL O +
et O +
al. O -
, O +
1998 O -
) O -
, O +
concerning O +
either O +
a O +
given O +
locality O +
or O +
only O +
a O +
very O +
few O -
, O +
have O +
shown O +
that O +
the O +
Northern O +
Bolivian O +
Altiplano O -
, O +
between O +
Lake O +
Titicaca O +
and O +
the O +
valley O +
of O +
the O +
city O +
of O +
La O +
Paz O -
, O +
presents O +
high O +
human O +
prevalences O +
and O +
intensities O -
. O +

Concerning O +
the O +
intermediate O +
snail O +
host O +
involved O -
, O +
despite O +
initial O +
reports O +
of O +
2 O +
different O +
lymnaeid O +
transmit- O +
ting O +
species O +
( O -
Lymnaea O +
matrix O +
and O +
L. O +
cubensis O -
) O +
in O +
the O +
Bolivian O +
Altiplano O +
( O -
UENO O +
et O +
al. O -
, O +
1975 O -
) O -
, O +
it O +
has O +
been O +
recently O +
demonstrated O +
that O +
only O +
1 O +
transmitting O +
species O +
is O +
there O -
. O +

Shell O +
morphology O +
and O +
visceral O +
mass O +
anatomy O +
( O -
OVIEDO O +
et O +
al. O -
, O +
1995 O -
) O -
, O +
and O +
molecular O +
( O -
BARGUES O +
& O +
MAS- O +
COMA O -
, O +
1997 O -
; O +
BARGUES O +
et O +
al. O -
, O +
1997 O -
) O +
and O +
isoenzyme B-Gene +
( O -
JABBOUR O -
- O -
ZAHAB O +
et O +
al. O -
, O +
1997 O -
) O +
studies O +
have O +
proved O +
that O +
this O +
species O +
is O +
the O +
European O +
L. O +
truncatula O -
, O +
most O +
probably O +
introduced O +
by O +
Spanish O +
colonizers O +
long O +
ago O -
. O +

Investigations O +
carried O +
out O +
in O +
the O +
Northern O +
Bolivian O +
Altiplano O +
have O +
shown O +
that O +
there O +
are O +
different O +
animal O +
species O +
which O +
play O +
the O +
role O +
of O +
reservoirs O +
and O +
others O +
that O +
are O +
potential O +
definitive O +
hosts O +
( O -
UENO O +
& O +
MORALES O -
, O +
1973 O -
; O +
UENO O +
et O +
al. O -
, O +
1975 O -
; O +
MAS O -
- O -
COMA O +
et O +
al. O -
, O +
1995 O -
, O +
1997 O -
; O +
HILLYER O +
et O +
al. O -
, O +
1996 O -
; O +
BUCHON O +
et O +
al. O -
, O +
1997 O -
; O +
FUENTES O +
et O +
al. O -
, O +
1997 O -
; O +
GROCK O +
et O +
al. O -
, O +
1998 O -
) O -
. O +

Sheep O +
may O +
be O +
consid- O +
ered O +
the O +
most O +
important O +
reservoir O +
( O -
GROCK O +
et O +
al. O -
, O +
1998 O -
) O -
, O +
followed O +
by O +
cattle O +
( O -
BUCHON O +
et O +
al. O -
, O +
1997 O -
) O -
. O +

Pigs O +
and O +
donkeys O +
represent O +
effective O +
secondary O +
reservoir O +
hosts O +
of O +
the O +
parasite O +
in O +
this O +
area O +
and O +
must O +
also O +
be O +
taken O +
into O +
account O +
within O +
preventive O +
and O +
control O +
measures O +
( O -
MAS- O +
Address O +
for O +
correspondence O -
: O +
Professor O +
Dr O +
Jose O -
- O -
Guillermo O +
Esteban O -
, O +
Department O +
of O +
Parasitology O -
, O +
Faculty O +
of O +
Pharmacy O -
, O +
University O +
of O +
Valencia O -
, O +
Av O -
. O +

Vicente O +
Andres O +
Estelies O +
s O -
/ O -
n O -
, O +
46100 O +
Burjassot O -
- O -
Valencia O -
, O +
Spain O -
; O +
phone O +
+ O -
34 O +
96 O +
3864298 O -
, O +
fax O +
+ O -
34 O +
96 O +
3864769 O -
, O +
e O -
- O -
mail O +
jguillermo O -
. O +

esteban@uv.es O +
COMA O +
al. O -
, O +
1997 O -
) O -
. O +

Horses O -
, O +
goats O -
, O +
llamas O +
and O +
alpacas O -
, O +
as O +
well O +
as O +
rabbits O -
, O +
hares O +
and O +
rodents O -
, O +
do O +
not O +
participate O +
in O +
the O +
transmission O +
( O -
FUENTES O +
et O +
al. O -
, O +
1997 O -
; O +
MAS O -
- O -
COMA O +
et O +
al. O -
, O +
1997 O -
) O -
. O +

The O +
aim O +
of O +
this O +
paper O +
is O +
to O +
present O +
and O +
analyse O +
the O +
results O +
obtained O +
in O +
31 O +
coprological O +
surveys O +
including O +
different O +
Altiplanic O +
localities O -
. O +

The O +
purpose O +
is O +
to O +
obtain O +
a O +
general O +
overview O +
of O +
human O +
infection O +
prevalences O +
and O +
intensities O +
throughout O +
the O +
endemic O +
zone O -
. O +

This O +
is O +
the O +
first O +
time O +
that O +
such O +
a O +
large O +
epidemiological O +
study O +
of O +
a O +
human O +
fascioliasis O +
area O +
has O +
been O +
carried O +
out O -
. O +

Materials O +
and O +
Methods O +
This O +
study O +
was O +
conducted O +
in O +
the O +
Department O +
of O +
La O +
Paz O -
, O +
Bolivia O -
, O +
and O +
more O +
specifically O +
in O +
a O +
region O +
of O +
the O +
Northern O +
Bolivian O +
Altiplano O -
, O +
between O +
Lake O +
Titicaca O +
and O +
the O +
valley O +
of O +
the O +
city O +
of O +
La O +
Paz O -
, O +
at O +
a O +
very O +
high O +
altitude O +
( O -
3800 O -
- O -
4200 O +
m O -
) O +
( O -
Figure O -
) O -
. O +

The O +
surface O +
area O +
and O +
human O +
population O +
characteristics O +
of O +
this O +
zone O +
have O +
already O +
been O +
summarized O +
m O +
a O +
balantidiasis O +
study O +
concerning O +
the O +
same O +
area O +
( O -
ESTEBAN O +
etal O -
. O -
, O +
1998b O -
) O -
. O +

A O +
total O +
of O +
31 O +
coprological O +
surveys O +
were O +
carried O +
out O +
in O +
24 O +
localities O +
over O +
the O +
6-year O +
period O +
1992 O -
- O -
97 O +
( O -
Table O +
1 O -
) O -
. O +

These O +
surveys O +
involved O +
2723 O +
Aymara O +
subjects O +
( O -
1483 O +
males O -
, O +
1240 O +
females O -
) O +
aged O +
1 O -
- O -
100 O +
years O +
( O -
mean O +
SD O -
, O +
10 O -
- O -
9 O +
7 O -
- O -
5 O +
years O -
) O -
, O +
among O +
whom O +
were O +
2521 O +
students O +
( O -
1350 O +
boys O -
, O +
1171 O +
girls O -
) O +
aged O +
5 O +
to O +
19 O +
years O +
( O -
9 O -
- O -
6 O +
-7 O +
years O -
) O +
from O +
the O +
schools O +
of O +
these O +
24 O +
localities O -
. O +

These O +
surveys O +
were O +
carried O +
out O +
so O +
that O +
the O +
sample O +
size O +
in O +
each O +
school O +
was O +
representative O +
of O +
both O +
the O +
student O +
enrolment O +
in O +
the O +
school O +
( O -
at O +
least O +
50 O -
% O -
) O +
and O +
the O +
number O +
of O +
children O +
present O +
on O +
the O +
day O +
of O +
the O +
survey O +
( O -
at O +
least O +
75 O -
% O -
) O -
. O +

In O +
Chijipata O +
Alto O +
and O +
Huacullani O -
, O +
where O +
high O +
prevalences O +
in O +
the O +
schools O +
were O +
detected O -
, O +
surveys O +
were O +
extended O +
to O +
total O +
inhabitants O +
and O +
involved O +
202 O +
subjects O +
( O -
133 O +
males O -
, O +
69 O +
females O -
) O +
aged O +
1 O +
to O +
100 O +
years O +
( O -
26 O -
- O -
7 O +
0 O -
- O -
1 O +
years O -
) O -
. O +

Surveys O +
were O +
performed O +
so O +
that O +
the O +
sample O +
size O +
was O +
always O +
at O +
least O +
20 O -
% O +
of O +
the O +
subject O +
number O +
of O +
each O +
locality O -
. O +

None O +
of O +
the O +
children O +
that O +
participated O +
in O +
these O +
community O +
surveys O +
was O +
included O +
in O +
the O +
school O +
surveys O +
of O +
the O +
same O +
localities O -
. O +

All O +
the O +
surveys O +
were O +
made O +
on O +
randomly O +
selected O +
persons O +
on O +
a O +
given O +
day O +
among O +
all O +
participating O +
subjects O -
. O +

One O +
stool O +
sample O +
per O +
subject O +
was O +
collected O +
from O +
all O +
participating O +
individuals O +
and O +
personal O +
data O +
( O -
name O -
, O +
sex O -
, O +
and O +
age O -
) O +
were O +
noted O -
. O +

The O +
relatively O +
low O +
receptivity O +
of O +
Aymara O +
adults O -
, O +
related O +
to O +
their O +
ethnic O +
and O +
religious O +
characteristics O +
( O -
ESTEBAN O +
et O +
al. O -
, O +
1998b O -
) O -
, O +
made O +
it O +
impos- O +
sible O +
to O +
obtain O +
multiple O +
stool O +
specimens O +
collected O +
at O +
2- O +
or O +
132 O +
JOSE O -
- O -
GUILLERMO O +
ESTEBAN O +
ETAL O -
. O +

Figure O -
. O +

Map O +
showing O +
the O +
location O +
of O +
the O +
24 O +
localities O +
surveyed O +
m O +
the O +
Northern O +
Bolivian O +
Altiplano O -
. O +

Closed O +
circles O -
, O +
localities O +
with O +
fascioliasis O -
; O +
open O +
circles O -
, O +
localities O +
in O +
which O +
fascioliasis O +
was O +
not O +
detected O -
. O +

3-day O +
intervals O -
. O +

Each O +
stool O +
sample O +
was O +
examined O +
using O +
the O +
Kato O -
- O -
Katz O +
technique O +
( O -
KATZ O +
et O +
al. O -
, O +
1972 O -
) O +
for O +
hel- O +
minth O +
eggs O +
and O -
, O +
if O +
possible O -
, O +
direct O +
and O +
concentration O +
MIF O +
( O -
SAPERO O +
& O +
LAWLESS O -
, O +
1953 O -
; O +
BLAGG O +
et O +
al. O -
, O +
1955 O -
) O -
, O +
formol O -
- O -
ether O +
concentration O +
( O -
KNIGHT O +
et O +
al. O -
, O +
1976 O -
) O -
, O +
and O +
modified O +
Ziehl O -
- O -
Neelsen O +
( O -
HENRIKSEN O +
& O +
POHLENZ O -
, O +
1981 O -
) O +
techniques O +
were O +
applied O +
in O +
order O +
to O +
cover O +
all O +
the O +
protozoan O +
spectrum O -
. O +

Statistical O +
analyses O +
were O +
done O +
using O +
SPSS O +
6.1 O +
( O -
SPSS O +
Institute O -
, O +
Chicago O -
, O +
IL O -
, O +
USA O -
) O +
for O +
Windows O -
. O +

Statistical O +
comparison O +
of O +
categorical O +
variables O +
was O +
carried O +
out O +
with O +
X2 O +
or O +
Fisher O -
's O +
exact O +
tests O -
. O +

Normally O +
distributed O +
data O +
were O +
analysed O +
using O +
Student O -
's O +
t O -
- O -
test O +
and O +
analysis O +
of O +
variance O +
( O -
ANOVA O -
) O -
. O +

Mann O -
- O -
Whitney O +
utest O +
and O +
Kruskal O -
- O -
Wallis O +
test O +
( O -
Jf O -
) O +
were O +
used O +
for O +
non O -
- O -
normally O +
distributed O +
data O -
. O +

Prevalences O +
and O +
intensities O +
m O +
the O +
same O +
schoolchildren O +
studied O +
in O +
different O +
years O +
were O +
compared O +
with O +
McNemar O +
and O +
Wilcoxon O +
signed O -
- O -
rank O +
tests O -
, O +
respectively O -
. O +

Values O +
of O +
P O +
< O +
0 O -
- O -
05 O +
were O +
taken O +
as O +
significant O -
. O +

This O +
study O +
was O +
conducted O +
with O +
the O +
agreement O +
of O +
the O +
Secretaria O +
Nacional O +
de O +
Salud O +
del O +
Ministerio O +
de O +
Desar- O +
rollo O +
Humano O +
( O -
La O +
Paz O -
, O +
Bolivia O -
) O +
and O +
was O +
performed O +
in O +
collaboration O +
with O +
the O +
INLASA O +
Institute O +
in O +
La O +
Paz O -
. O +

All O +
investigations O +
were O +
made O +
with O +
the O +
consent O +
of O +
the O +
subjects O +
or O -
, O +
in O +
the O +
case O +
of O +
young O +
children O -
, O +
their O +
guardians O -
. O +

Results O +
Prevalences O +

The O +
total O +
prevalence O +
of O +
fascioliasis O +
in O +
the O +
2723 O +
subjects O +
studied O +
was O +
15 O -
- O -
4 O -
% O -
. O +

The O +
maximum O +
prevalences O +
in O +
the O +
school O +
and O +
community O +
surveys O +
were O +
obtained O +
in O +
Chiji- O +
pata O +
Alto O +
( O -
68 O -
- O -
2 O -
% O +
and O +
65 O -
- O -
4 O -
% O -
, O +
respectively O +
in O +
1996 O -
) O -
, O +
whereas O +
in O +
some O +
other O +
school O +
surveys O +
F. O +
hepatica O +
infec- O +
tion O +
was O +
not O +
even O +
detected O +
( O -
Table O +
1 O -
) O -
. O +

Significant O +
differ- O +
ences O +
between O +
prevalence O +
rates O +
both O +
among O +
combined O +
school O +
surveys O +
and O +
among O +
combined O +
community O +
surveys O +
( O -
P O +
= O +
0 O -
- O -
0001 O +
by O +
Fisher O -
's O +
exact O +
test O -
, O +
and O +
x2=312 O -
, O +
P O +
= O +
0 O -
- O -
0001 O -
, O +
respectively O -
) O +
were O +
detected O -
. O +

Comparison O +
analysis O +
of O +
prevalence O +
rates O +
detected O +
in O +
the O +
surveys O +
carried O +
out O +
in O +
the O +
same O +
school O +
( O -
i.e. O -
, O +
Acha- O +
cachi O -
, O +
Chijipata O +
Alto O +
and O +
Huacullani O -
) O +
or O +
in O +
the O +
same O +
community O +
( O -
i.e. O -
, O +
Huacullani O -
) O +
in O +
different O +
years O +
showed O +
no O +
statistical O +
differences O -
. O +

Moreover O -
, O +
no O +
statistical O +
differ- O +
ences O +
were O +
detected O +
between O +
prevalences O +
among O +
the O +
same O +
schoolchildren O +
analysed O +
in O +
different O +
years O -
. O +

Discrepancies O +
in O +
the O +
results O +
were O -
, O +
however O -
, O +
observed O +
when O +
comparing O +
the O +
total O +
prevalences O +
( O -
including O +
the O +
different O +
years O -
) O +
obtained O +
in O +
the O +
school O +
and O +
community O +
surveys O +
in O +
the O +
same O +
locality O -
: O +
in O +
Chijipata O +
Alto O +

no O +
signifi- O +
ca O -
nt O +
difference O +
was O +
observed O +
( O -
60 O -
- O -
5 O -
% O +
in O +
the O +
2 O +
combined O +
school O +
surveys O +
vs. O +
65 O -
- O -
4 O -
% O +
in O +
the O +
community O -
) O -
, O +
whereas O +
in O +
Huacullani O +
( O -
33 O -
- O -
8 O -
% O +
for O +
the O +
3 O +
combined O +
school O +
surveys O +
vs. O +
16 O -
- O -
5 O -
% O +
for O +
the O +
2 O +
combined O +
community O +
surveys O -
) O +
a O +
signifi- O +
ca O -
nt O +
difference O +
was O +
detected O +
( O -
% O -
2 O +
= O +
19 O -
- O -
06 O -
, O +
P O +
= O +
0 O -
- O -
0001 O -
) O -
. O +

Similar O +
results O +
were O +
obtained O +
when O +
comparing O +
the O +
pre- O +
valences O +
obtained O +
in O +
the O +
school O +
survey O +
and O +
the O +
commu- O +
nity O +
survey O +
in O +
the O +
same O +
locality O +
carried O +
out O +
in O +
the O +
same O +
year O +
1996 O -
: O +
in O +
Chijipata O +
Alto O +
there O +
was O +
no O +
significant O +
difference O +
( O -
68 O -
- O -
2 O -
% O +
in O +
the O +
school O +
vs. O +
65 O -
- O -
4 O -
% O +
in O +
the O +
com- O +
munity O -
) O -
, O +
whereas O +
in O +
Huacullani O +
( O -
34 O -
- O -
8 O -
% O +
in O +
the O +
school O +
vs. O +
18 O -
- O -
4 O -
% O +
in O +
the O +
community O -
) O +
a O +
significant O +
difference O +
was O +
detected O +
( O -
/2 O +
= O +
8 O -
- O -
89 O -
, O +
P O +
= O +
0 O -
- O -
0029 O -
) O -
. O +

The O +
distribution O +
of O +
prevalences O +
according O +
to O +
sex O +
and O +
age O -
- O -
groups O +
in O +
the O +
school O +
surveys O +
and O +
also O +
in O +
the O +
com- O +
munity O +
surveys O +
is O +
shown O +
in O +
Table O +
2 O -
. O +

In O +
relation O +
to O +
sex O -
, O +
a O +
significant O +
difference O +
was O +
detected O +
neither O +
among O +
schools O -
, O +
nor O +
among O +
communities O -
, O +
and O +
a O +
similar O +
result O +
was O +
obtained O +
when O +
considering O +
the O +
total O +
of O +
the O +
subjects O +
studied O +
in O +
all O +
the O +
surveys O -
. O +

In O +
the O +
school O +
surveys O -
, O +
the O +
distribution O +
of O +
prevalences O +
according O +
to O +
age O -
- O -
groups O +
did O +
show O +
significant O +
differences O +
Cy2 O +
= O +
19 O -
- O -
00 O -
, O +
P O +
= O +
0 O -
- O -
0001 O -
) O +
when O +
comparing O +
age O -
- O -
groups O +
established O +
according O +
to O +
school O +
criteria O -
: O +
age O +
5 O -
- O -
8 O +
years O -
, O +
basic O +
level O -
, O +
9 O -
- O -
12 O +
years O -
, O +
intermediate O -
; O +
13 O -
- O -
19 O +
years O -
, O +
medium O +
level O +
and O +
students O +
still O +
in O +
school O +
but O +
eligible O +
for O +
military O +
service O -
. O +

The O +
highest O +
prevalences O +
were O +
de- O +
Table O +
1 O -
. O +

The O +
study O +
populations O +
of O +
the O +
schools O +
and O +
communities O +
surveyed O +
in O +
Bolivia O +
and O +
the O +
prevalences O +
and O +
intensities O +
from O +
faecal O +
egg O +
counts O +
off O -
. O +

hepatica O +
Locality O +
Survey O +
year O +
; O +
Male O +
mple O +
studie O -
< O +
Female O +
i O +
Total O +
Age O +
Range O +
( O -
years O -
) O +
Meai O +
tt O -
( O -
SD O -
) O +
Prevalence% O +
( O -
CI O -
) O -
1 O -
' O +
Inl O +
Range O +
: O -
ensity O +
( O -
epg O -
) O -
' O +
AM O +
GM O +
Schools O +
Achacachi O -
( O -
I O -
) O -
3 O +
1996 O +
48 O +
44 O +
92 O +
5 O -
- O -
13 O +
8 O -
- O -
7 O +
( O -
2 O -
- O -
1 O -
) O +
6 O -
- O -
5 O +
( O -
5 O -
- O -
0 O -
) O +
48 O -
- O -
336 O +
139 O +
106 O +
Achacachi O -
( O -
1 O -
) O +
1997 O +
42 O +
45 O +
87 O +
6 O -
- O -
13 O +
9 O -
- O -
1 O +
( O -
1 O -
- O -
7 O -
) O +
1 O -
- O -
1 O +
( O -
2 O -
- O -
2 O -
) O +
240 O +
- O +
- O +
Acbocalla O -
( O -
ll O -
) O +
1996 O +
92 O +
96 O +
188 O +
5 O -
- O -
16 O +
8 O -
- O -
8 O +
( O -
2 O -
- O -
6 O -
) O +
5 O -
- O -
3 O +
( O -
3 O -
- O -
2 O -
) O +
48 O -
- O -
744 O +
304 O +
226 O +
Ancocagua O +
( O -
9 O -
) O +
1997 O +
85 O +
83 O +
168 O +
5 O -
- O -
19 O +
10 O -
- O -
6 O +
( O -
3 O -
- O -
4 O -
) O +
5 O -
- O -
9 O +
( O -
3 O -
- O -
6 O -
) O +
24 O -
- O -
4512 O +
1229 O +
332 O +
Aygachi O -
( O -
16 O -
) O +
1994 O +
68 O +
37 O +
105 O +
5 O -
- O -
17 O +
11 O -
- O -
1 O +
( O -
2 O -
- O -
8 O -
) O +
17 O -
- O -
1 O +
( O -
7 O -
- O -
2 O -
) O +
24 O -
- O -
1200 O +
320 O +
179 O +
BelYayes O -
( O -
17 O -
) O +
1994 O +
26 O +
17 O +
43 O +
5 O -
- O -
12 O +
8 O -
- O -
5 O +
( O -
1 O -
- O -
9 O -
) O +
7 O -
- O -
0 O +
( O -
7 O -
- O -
6 O -
) O +
72 O -
- O -
144 O +
112 O +
108 O +
Caleria O -
( O -
15 O -
) O +
1993 O +
29 O +
22 O +
51 O +
6 O -
- O -
14 O +
9 O -
- O -
1 O +
( O -
2 O -
- O -
3 O -
) O +
5 O -
- O -
9 O +
( O -
6 O -
- O -
5 O -
) O +
24 O -
- O -
48 O +
40 O +
38 O +
Causaya O +
( O -
24 O -
) O +
1995 O +
22 O +
37 O +
59 O +
5 O -
- O -
18 O +
10 O -
- O -
6 O +
( O -
2 O -
- O -
8 O -
) O +
ND'1 O +
- O +
- O +
- O +
Chambi O +
Grande O +
( O -
23 O -
) O +
1995 O +
9 O +
16 O +
25 O +
5 O -
- O -
12 O +
7.4 O +
( O -
1 O -
- O -
6 O -
) O +
12 O -
- O -
0 O +
( O -
12 O -
- O -
7 O -
) O +
240 O -
- O -
840 O +
496 O +
435 O +
Chijipata O +
Alto O +
( O -
4 O -
) O +
1996 O +
11 O +
11 O +
22 O +
5 O -
- O -
10 O +
7 O -
- O -
5 O +
( O -
1 O -
- O -
3 O -
) O +
68 O -
- O -
2 O +
( O -
19 O -
- O -
5 O -
) O +
24 O -
- O -
3000 O +
613 O +
211 O +
Chijipata O +
Alto O +
( O -
4 O -
) O +
1997 O +
29 O +
25 O +
54 O +
5 O -
- O -
15 O +
8 O -
- O -
7 O +
( O -
2 O -
- O -
4 O -
) O +
57 O -
- O -
4 O +
( O -
13 O -
- O -
2 O -
) O +
24 O -
- O -
2424 O +
477 O +
240 O +
Cohana O +
( O -
18 O -
) O +
1994 O +
97 O +
70 O +
167 O +
5 O -
- O -
16 O +
10 O -
- O -
4 O +
( O -
2 O -
- O -
6 O -
) O +
3 O -
- O -
6 O +
( O -
2 O -
- O -
8 O -
) O +
24 O -
- O -
120 O +
72 O +
60 O +
Corapata O +
( O -
10 O -
) O +
1993 O +
43 O +
42 O +
85 O +
5 O -
- O -
16 O +
10 O -
- O -
2 O +
( O -
2 O -
- O -
7 O -
) O +
17 O -
- O -
6 O +
( O -
8 O -
- O -
1 O -
) O +
48 O -
- O -
480 O +
198 O +
157 O +
Cuyahuani O -
( O -
3 O -
) O +
1996 O +
57 O +
54 O +
111 O +
5 O -
- O -
16 O +
10 O -
- O -
7 O +
( O -
2 O -
- O -
8 O -
) O +
6 O -
- O -
3 O +
( O -
4 O -
- O -
5 O -
) O +
72 O -
- O -
600 O +
300 O +
206 O +
Huacullani O +
( O -
21 O -
) O +
1992 O +
70 O +
53 O +
123 O +
5 O -
- O -
15 O +
10 O -
- O -
0 O +
( O -
1 O -
- O -
9 O -
) O +
38 O -
- O -
2 O +
( O -
8 O -
- O -
6 O -
) O +
24 O -
- O -
2160 O +
283 O +
134 O +
Huacullani O +
( O -
21 O -
) O +
1993 O +
141 O +
115 O +
256 O +
5 O -
- O -
19 O +
10 O -
- O -
8 O +
( O -
3 O -
- O -
4 O -
) O +
31 O -
- O -
2 O +
( O -
5 O -
- O -
7 O -
) O +
24 O -
- O -
5064 O +
705 O +
323 O +
Huacullani O +
( O -
21 O -
) O +
1996 O +
65 O +
70 O +
135 O +
8 O -
- O -
15 O +
11 O -
- O -
5 O +
( O -
1 O -
- O -
5 O -
) O +
34 O -
- O -
8 O +
( O -
8 O -
- O -
0 O -
) O +
24 O -
- O -
4368 O +
347 O +
168 O +
Huatajata O +
( O -
2 O -
) O +
1996 O +
102 O +
91 O +
193 O +
5 O -
- O -
12 O +
7 O -
- O -
8 O +
( O -
1 O -
- O -
7 O -
) O +
ND'1 O +
- O +
- O +
- O +
Iquiaca O +
( O -
8) O +
1995 O +
71 O +
62 O +
133 O +
5 O -
- O -
14 O +
9.4 O +
( O -
2 O -
- O -
3 O -
) O +
9 O -
- O -
0 O +
( O -
4 O -
- O -
9 O -
) O +
48 O -
- O -
2448 O +
415 O +
147 O +
Kajchiri O +
( O -
13 O -
) O +
1994 O +
10 O +
11 O +
21 O +
5 O -
- O -
10 O +
8 O -
- O -
0 O +
( O -
1 O -
- O -
7 O -
) O +
9 O -
- O -
5 O +
( O -
12 O -
- O -
6 O -
) O +
168 O +
168 O +
168 O +
Kharapata O +
( O -
5 O -
) O +
1996 O +
48 O +
49 O +
97 O +
5 O -
- O -
15 O +
9 O -
- O -
5 O +
( O -
2 O -
- O -
2 O -
) O +
11 O -
- O -
3 O -
( O -
6 O -
- O -
3 O -
) O +
24 O -
- O -
216 O +
85 O +
59 O +
Lacaya O +
Baja O +
( O -
20 O -
) O +
1997 O +
39 O +
32 O +
71 O +
5 O -
- O -
12 O +
8 O -
- O -
1 O +
( O -
2 O -
- O -
0 O -
) O +
28 O -
- O -
2 O +
( O -
10 O -
- O -
5 O -
) O +
24 O -
- O -
1224 O +
302 O +
208 O +
Oketiti O -
( O -
7 O -
) O +
1995 O +
9 O +
11 O +
20 O +
5 O -
- O -
9 O +
6 O -
- O -
6 O +
( O -
1 O -
- O -
1 O -
) O +
10 O -
- O -
0 O -
( O -
13 O -
- O -
1 O -
) O +
288 O +
- O +
- O +
Pantini O +
( O -
6 O -
) O +
1995 O +
19 O +
14 O +
33 O +
5 O -
- O -
13 O +
8 O -
- O -
9 O +
( O -
1 O -
- O -
6 O -
) O +
30 O -
- O -
3 O +
( O -
15 O -
- O -
7 O -
) O +
24 O -
- O -
648 O +
230 O +
139 O +
Quiripujo O +
( O -
19 O -
) O +
1993 O +
25 O +
18 O +
43 O +
5 O -
- O -
12 O +
7 O -
- O -
7 O +
( O -
2 O -
- O -
0 O -
) O +
20 O -
- O -
9 O +
( O -
12 O -
- O -
1 O -
) O +
24 O -
- O -
240 O +
102 O +
78 O +
Ticuyo O +
( O -
14 O -
) O +
1995 O +
29 O +
3 O +
32 O +
6 O -
- O -
12 O +
9 O -
- O -
4 O +
( O -
1 O -
- O -
8 O -
) O +
Niy1 O +
- O +
- O +
- O +
Tuni O +
( O -
12 O -
) O +
1994 O +
13 O +
12 O +
25 O +
5 O -
- O -
10 O +
7 O -
- O -
5 O +
( O -
1 O -
- O -
5 O -
) O +
ND'1 O +
- O +
- O +
- O +
Yanarico O +
( O -
22 O -
) O +
1995 O +
51 O +
31 O +
82 O +
5 O -
- O -
16 O +
9 O -
- O -
7 O +
( O -
2 O -
- O -
5 O -
) O +
7 O -
- O -
3 O +
( O -
5 O -
- O -
6 O -
) O +
72 O -
- O -
120 O +
96 O +
93 O +
Total O +
1992 O -
- O -
97 O +
1350 O +
1171 O +
2521 O +
5 O -
- O -
19 O +
9 O -
- O -
6 O +
( O -
2 O -
- O -
7 O -
) O +
14 O -
- O -
8 O -
( O -
1 O -
- O -
4 O -
) O +
24 O -
- O -
5064 O +
419 O +
185 O +
Communities O +
Chijipata O +
Alto O +
( O -
4 O -
) O +
1996 O +
17 O +
9 O +
26 O +
6 O -
- O -
75 O +
25 O -
- O -
8 O +
( O -
20 O -
- O -
8 O -
) O +
65 O -
- O -
4 O -
( O -
18 O -
- O -
3 O -
) O +
48 O -
- O -
4440 O +
1345 O +
678 O +
Huacullani O +
( O -
21 O -
) O +
1996 O +
80 O +
45 O +
125 O +
1 O -
- O -
70 O +
22 O -
- O -
9 O +
( O -
17 O -
- O -
9 O -
) O +
18 O -
- O -
4 O +
( O -
6 O -
- O -
8 O -
) O +
24 O -
- O -
1608 O +
253 O +
140 O +
Huacullani O +
( O -
21 O -
) O +
1997 O +
36 O +
15 O +
51 O +
2 O -
- O -
100 O +
35 O -
- O -
4 O +
( O -
22 O -
- O -
6 O -
) O +
11 O -
- O -
8 O -
( O -
8 O -
- O -
8 O -
) O +
24 O -
- O -
264 O +
144 O +
113 O +
Total O +
1996 O -
- O -
97 O +
133 O +
69 O +
202 O +
1 O -
- O -
100 O +
26 O -
- O -
7 O +
( O -
20 O -
- O -
1 O -
) O +
22 O -
- O -
8 O +
( O -
5 O -
- O -
8 O -
) O +
24 O -
- O -
4440 O +
660 O +
250 O +
Total O +
surveys O +
1992 O -
- O -
97 O +
1483 O +
1240 O +
2723 O +
1 O -
- O -
100 O +
10 O -
- O -
9 O +
( O -
7 O -
- O -
5 O -
) O +
15 O -
- O -
4 O -
( O -
1 O -
- O -
4 O -
) O +
24 O -
- O -
5064 O +

446 O +
191 O +
' O -
Number O +
m O +
map O +
( O -
see O +
Figure O -
) O -
. O +

' O -
' O -
Confidence O +
interval O +
( O -
95 O -
% O -
) O -
. O +

' O -
Eggs O +
per O +
gram O +
of O +
faeces O +
( O -
AM O -
, O +
arithmetic O +
mean O -
; O +
GM O -
, O +
geometric O +
mean O -
) O -
. O +

' O -
' O -
Not O +
detected O -
. O +

154 O +
JOSE O -
- O -
GUILLERMO O +
ESTEBAN O +
ETAL O -
. O +

Table O +
2 O -
. O +

Prevalences O +
and O +
intensities O +
of O +
fasciolia- O +
sis O -
, O +
by O +
sex O +
and O +
age O -
- O -
group O -
, O +
in O +
the O +
school O +
and O +
com- O +
munity O +
surveys O +
in O +
Bolivia O +
Prevalence O +
Intensity O +
( O -
epg O -
) O +
b O -
) O +
% O +
( O -
CI O -
) O -
3 O +
Range O +
AM O +
GM O +
Schools O +
Sex O +
Boys O +
14 O -
- O -
5 O +
( O -
1 O -
- O -
9 O -
) O +
24 O -
- O -
3408 O +
323 O +
159 O +
Girls O +
15 O -
- O -
2 O +
( O -
2 O -
- O -
1 O -
) O +
24 O -
- O -
5064 O +
528 O +
219 O +
Age O -
- O -
group O +
( O -
years O -
) O +
5 O -
- O -
8 O +
10 O -
- O -
8 O +
( O -
2 O -
- O -
0 O -
) O +
24 O -
- O -
4512 O +
377 O +
202 O +
9 O -
- O -
12 O +
17 O -
- O -
0 O +
( O -
2 O -
- O -
1 O -
) O +
24 O -
- O -
5064 O +
446 O +
191 O +
13 O -
- O -
19 O +
17 O -
- O -
9 O -
( O -
3 O -
- O -
8 O -
) O +
24 O -
- O -
4488 O +
401 O +
147 O +
Communities O +
Sex O +
Males O +
20 O -
- O -
3 O +
( O -
6 O -
- O -
8 O -
) O +
24 O -
- O -
4440 O +
753 O +
280 O +
Females O +
27 O -
- O -
5 O +
( O -
10 O -
- O -
5 O -
) O +
48 O -
- O -
3758 O +
525 O +
212 O +
Age O -
- O -
group O +
( O -
years O -
) O +
1 O -
- O -
10 O +
29 O -
- O -
3 O -
( O -
11 O -
- O -
7 O -
) O +
24 O -
- O -
4440 O +
796 O +
198 O +
11 O -
- O -
20 O +
43 O -
- O -
8 O -
( O -
17 O -
- O -
2 O -
) O +
48 O -
- O -
3768 O +
825 O +
410 O +
21 O -
- O -
40 O +
13 O -
- O -
8 O +
( O -
8 O -
- O -
4 O -
) O +
72 O -
- O -
864 O +
373 O +
263 O +
> O -
40 O +
13 O -
- O -
3 O +
( O -
9 O -
- O -
9 O -
) O +
24 O -
- O -
1608 O +
368 O +
147 O +
" O -
Confidence O +
interval O +
( O -
95 O -
% O -
) O -
. O +

' O -
' O -
Eggs O +
per O +
gram O +
of O +
faeces O +
( O -
AM O -
, O +
arithmetic O +
mean O -
; O +
GM O -
, O +
geometric O +
mean O -
) O -
. O +

tected O +
in O +
the O +
age O -
- O -
groups O +
9 O -
- O -
12 O +
years O +
( O -
17 O -
- O -
0 O -
% O -
) O +
and O +
13 O -
- O -
19 O +
years O +
( O -
17 O -
- O -
9 O -
% O -
) O +
( O -
Table O +
2 O -
) O -
. O +

In O +
the O +
community O +
surveys O -
, O +
significant O +
differences O +
( O -
/2 O +
= O +
14 O -
- O -
5 O -
, O +
P O +
= O +
0 O -
- O -
0023 O -
) O +
were O +
also O +
detected O -
, O +
with O +
highest O +
prevalences O +
in O +
the O +
age O -
- O -
groups O +
1 O +
- O +
10 O +
years O +
( O -
29 O -
- O -
3 O -
% O -
) O +
and O +
11 O -
- O -
20 O +
years O +
( O -
43 O -
- O -
8 O -
% O -
) O +
( O -
Table O +
2 O -
) O -
. O +

Intensities O +
Intensity O +
of O +
infection O -
, O +
measured O +
as O +
epg O +
by O +
the O +
Kato- O +
Katz O +
technique O -
, O +
in O +
school O +
and O +
community O +
surveys O +
is O +
shown O +
in O +
Table O +
1 O -
. O +

Absolute O +
egg O +
counts O +
in O +
the O +
total O +
individuals O +
surveyed O +
with O +
detectable O +
infection O +
ranged O +
from O +
24 O +
to O +
5064 O +
epg O -
, O +
with O +
arithmetic O +
and O +
geometric O +
means O +
of O +
446 O +
and O +
191 O +
epg O -
, O +
respectively O -
. O +

Significant O +
differences O +
were O +
detected O +
among O +
the O +
different O +
school O +
surveys O +
( O -
.H O +
= O +
51 O -
- O -
82 O -
, O +
P O +
= O +
0 O -
- O -
0005 O -
) O +
as O +
well O +
as O +
among O +
the O +
different O +
community O +
surveys O +
= O +
12 O -
- O -
66 O -
, O +
P O +
= O +
0 O -
- O -
0018 O -
) O -
. O +

Comparison O +
analysis O +
of O +
intensities O +
detected O +
in O +
school O +
surveys O +
carried O +
out O +
in O +
different O +
years O +
in O +
the O +
same O +
locality O +
did O +
not O +
show O +
statistical O +
differences O +
in O +
the O +
case O +
of O +
Chiji- O +
pata O +
Alto O -
, O +
but O +
it O +
did O +
in O +
that O +
of O +
Huacullani O +
( O -
F O +
= O +
4 O -
- O -
80 O -
, O +
P O +
= O +
0 O -
- O -
009 O -
) O -
. O +

In O +
the O +
latter O -
, O +
however O -
, O +
no O +
significant O +
differ- O +
ence O +
was O +
detected O +
between O +
the O +
results O +
obtained O +
in O +
the O +
2 O +
community O +
surveys O -
. O +

No O +
significant O +
differences O +
were O +
detected O +
between O +
intensities O +
among O +
the O +
same O +
school- O +
children O +
analysed O +
in O +
different O +
years O -
. O +

When O +
comparing O +
the O +
intensity O +
values O +
obtained O +
in O +
the O +
school O +
and O +
community O +
surveys O +
in O +
the O +
same O +
locality O -
, O +
the O +
combined O +
results O +
showed O +
significant O +
differences O +
between O +
the O +
school O +
and O +
the O +
community O +
in O +
Chijipata O +
Alto O +
(= O +
229 O -
- O -
5 O -
, O +
P O +
= O +
0 O -
- O -
0123 O -
) O +
but O +
not O +
between O +
the O +
school O +
and O +
the O +
community O +
in O +
Huacullani O -
. O +

Similar O +
results O +
were O +
obtained O +
when O +
comparing O +
the O +
intensity O +
values O +
obtained O +
in O +
the O +
school O +
survey O +
and O +
community O +
survey O +
carried O +
out O +
in O +
a O +
given O +
locality O +
in O +
the O +
same O +
year O -
: O +
significant O +
differences O +
in O +
Chijipata O +
Alto O +
( O -
( O -
7=75 O -
- O -
0 O -
, O +
P O +
= O +
0 O -
- O -
0472 O -
) O -
, O +
but O +
not O +
in O +
Huacullani O -
. O +

Intensities O +
according O +
to O +
sex O +
and O +
age O -
- O -
groups O +
in O +
the O +
school O +
and O +
community O +
surveys O +
are O +
shown O +
in O +
Table O +
2 O -
. O +

No O +
significant O +
differences O +
according O +
to O +
sex O +
were O +
detected O +
in O +
the O +
total O +
study O +
and O +
in O +
the O +
community O +
surveys O -
, O +
but O +
the O +
significantly O +
higher O +
F. O +
hepatica O +
egg O +
counts O +
for O +
the O +
girls O +
in O +
the O +
school O +
surveys O +
( O -
t O +
= O +
2 O -
- O -
59 O -
, O +
P O +
= O +
0 O -
- O -
010 O -
) O +
is O +
worth O +
men- O +
tioning O -
. O +

The O +
analyses O +
according O +
to O +
age O -
- O -
groups O +
did O +
not O +
show O +
any O +
significant O +
difference O -
. O +

Discussion O +
The O +
prevalences O +
and O +
intensities O +
obtained O +
by O +
coprolo- O +
gical O +
methods O +
in O +
this O +
study O +
are O +
the O +
highest O +
known O +
up O +
to O +
the O +
present O -
. O +

These O +
results O +
are O +
even O +
more O +
noteworthy O +
when O +
taking O +
into O +
consideration O +
the O +
fact O +
that O +
the O +
localities O +
surveyed O +
in O +
the O +
Northern O +
Bolivian O +
Altiplano O +
were O +
se- O +
lected O +
only O +
because O +
of O +
their O +
geographical O +
situation O -
, O +
in O +
order O +
to O +
cover O +
a O +
wide O +
geographical O +
area O -
. O +

The O +
probability O +
of O +
detecting O +
high O +
infection O +
rates O +
of O +
fascioliasis O +
was O +
not O +
taken O +
into O +
account O +
and O +
thus O +
survey O +
efforts O +
were O +
not O +
concentrated O +
on O +
the O +
subzones O +
presenting O +
the O +
highest O +
human O +
fascioliasis O +
rates O -
. O +

Owing O +
to O +
the O +
important O +
clinical O +
and O +
pathogenic O +
effects O +
of O +
fascioliasis O +
( O -
CHEN O +
& O +
MOTT O -
, O +
1990 O -
; O +
MAS O -
- O -
COMA O +
et O +
al. O -
, O +
1999a O -
, O +
m O +
press O -
) O -
, O +
the O +
analyses O +
of O +
prevalences O +
and O +
intensities O +
obtained O +
allow O +
us O +
to O +
conclude O +
that O +
the O +
Northern O +
Bolivian O +
Altiplano O +
must O +
be O +
catalogued O +
as O +
a O +
true O +
human O +
fascioliasis O +
endemic O +
area O -
. O +

The O +
term O +
outbreak O +
sometimes O +
used O +
for O +
this O +
area O +
( O -
BJORLAND O +
et O +
al. O -
, O +
1995 O -
) O +
may O +
consequently O +
be O +
used O +
only O +
when O +
a O +
temporary O +
prevalence O +
increase O +
in O +
a O +
given O +
Altiplanic O +
locality O +
is O +
detected O -
. O +

Differences O +
detected O +
between O +
the O +
results O +
of O +
the O +
pre- O +
valences O +
obtained O +
in O +
different O +
localities O +
are O +
not O +
related O +
to O +
different O +
seasons O +
and O +
may O +
be O +
linked O +
to O +
the O +
patchy O +
distribution O +
of O +
the O +
transmission O +
foci O -
, O +
marked O +
by O +
the O +
presence O +
of O +
the O +
necessary O +
freshwater O +
lymnaeids O -
, O +
as O +
well O +
as O +
to O +
the O +
Aymara O +
children O -
's O +
tendency O +
not O +
to O +
travel O +
far O -
. O +

The O +
lack O +
of O +
seasonality O +
in O +
the O +
prevalences O +
detected O +
contrasts O +
with O +
the O +
well O -
- O -
known O +
seasonal O +
transmission O +
characteristics O +
of O +
fascioliasis O +
in O +
other O +
parts O +
of O +
the O +
world O -
. O +

This O +
may O +
be O +
explained O +
by O +
the O +
absence O +
of O +
marked O +
climatic O +
differences O +
between O +
the O +
different O +
seasons O +
in O +
the O +
Northern O +
Altiplano O -
. O +

The O +
non O -
- O -
significant O +
differences O +
in O +
prevalences O +
by O +
sex O +
and O +
the O +
fact O +
that O +
all O +
ages O +
are O +
susceptible O +
to O +
infection O +
( O -
positive O +
cases O +
from O +
2 O +
to O +
70 O +
years O -
) O -
, O +
despite O +
the O +
fact O +
that O +
the O +
subjects O +
aged O +
< O -
20 O +
years O +
are O +
those O +
with O +
a O +
higher O +
infection O +
risk O -
, O +
could O +
be O +
explained O +
by O +
the O +
lack O +
of O +
gender O +
role O +
differences O +
and O +
by O +
the O +
ingestion O +
of O +
several O +
aquatic O +
vegetables O +
( O -
MAS O -
- O -
COMAeta O -
/ O -
. O -
, O +
1995 O -
) O +
as O +
a O +
risk O +
factor O +
for O +
F. O +
hepatica O +
infection O -
. O +

These O +
results O +
agree O +
with O +
a O +
few O +
studies O +
performed O +
in O +
areas O +
of O +
Egypt O +
( O -
FARAG O +
et O +
al. O -
, O +
1979 O -
) O -
, O +
Peru O +
( O -
KNOBLOCH O +
et O +
al. O -
, O +
1985 O -
; O +
SCHEZ O +
et O +
al. O -
, O +
1993 O -
) O +
and O +
Chile O +
( O -
APT O +
et O +
al. O -
, O +
1993 O -
) O -
. O +

The O +
very O +
high O +
egg O +
counts O +
are O +
worth O +
noting O +
when O +
compared O +
with O +
the O +
epg O +
normally O +
found O +
to O +
date O +
in O +
human O +
fascioliasis O +
diagnosis O -
: O +
1 O -
- O -
4 O +
epg O +
( O -
BENDEZet O +
al. O -
, O +
1982 O -
; O +
KNOBLOCH O +
et O +
al. O -
, O +
1985 O -
) O +
is O +
the O +
most O +
common O -
; O +
a O +
case O +
with O +
440 O +
epg O +
( O -
AKAHANE O +
et O +
al. O -
, O +
1975 O -
) O +
may O +
be O +
considered O +
as O +
rare O -
. O +

However O -
, O +
the O +
prospective O +
study O +
by O +
SAMPAIO O +
SILVA O +
( O -
1990 O -
) O +
provided O +
a O +
geometric O +
mean O +
( O -
range O -
) O +
of O +
233 O +
( O -
25- O +
2100 O -
) O +
epg O -
, O +
which O +
was O +
the O +
highest O +
epg O +
count O +
known O +
up O +
to O +
our O +
study O -
. O +

With O +
the O +
exception O +
of O +
a O +
few O +
localities O -
, O +
the O +
distribution O +
of O +
intensities O +
corresponds O +
to O +
the O +
distribution O +
of O +
preva- O +
lences O -
, O +
and O +
the O +
scarce O +
disagreements O +
in O +
some O +
localities O +
may O +
be O +
explained O +
by O +
the O +
few O +
children O +
coming O +
from O +
the O +
very O +
few O +
surrounding O +
zones O +
including O +
transmission O +
foci O -
. O +

Intensity O +
results O +
obtained O +
in O +
schools O +
and O +
communities O +
surveyed O +
more O +
than O +
once O -
, O +
in O +
different O +
seasons O +
and O +
throughout O +
different O +
years O -
, O +
as O +
well O +
as O +
those O +
obtained O +
in O +
the O +
school O +
and O +
community O +
surveys O +
in O +
the O +
same O +
locality O +
are O +
difficult O +
to O +
interpret O -
. O +

Similarly O -
, O +
the O +
significantly O +
higher O +
F. O +
hepatica O +
egg O +
counts O +
for O +
the O +
girls O +
in O +
the O +
school O +
surveys O +
are O +
surprising O -
. O +

Concerning O +
intensity O +
in O +
humans O -
, O +
a O +
relationship O +
between O +
the O +
number O +
of O +
fluke O +
adults O +
and O +
eggs O +
in O +
faeces O +
has O +
never O +
been O +
studied O -
. O +

Data O +
from O +
animals O +
suggest O +
that O +
a O +
direct O +
relation O +
does O +
not O +
necessarily O +
exist O +
( O -
CHEN O +
& O +
MOTT O -
, O +
1990 O -
) O -
. O +

It O +
is O +
evident O +
that O +
further O +
studies O +
on O +
this O +
aspect O +
are O +
needed O -
. O +

Intensity O +
data O +
according O +
to O +
age O -
- O -
groups O +
show O +
that O +
egg O +
output O +
counts O +
decrease O +
with O +
an O +
increase O +
of O +
age O -
. O +

In O +
3 O +
persons O +
aged O +
> O -
60 O +
years O -
, O +
egg O +
counts O +
of O +
24 O -
- O -
168 O +
epg O +
were O +
found O -
. O +

Consequently O -
, O +
adult O +
subjects O +
either O +
maintain O +
the O +
parasites O +
acquired O +
when O +
young O +
or O +
can O +
be O +
newly O +
infected O +
HUMAN O +
FASCIOLIASIS O +
IN O +
BOLIVIA O +
155 O +
as O +
the O +
consequence O +
of O +
inhabiting O +
a O +
zone O +
of O +
high O +
infection O +
risk O -
. O +

A O +
case O +
of O +
a O +
2-year O -
- O -
old O +
child O +
shedding O +
48 O +
epg O +
is O +
worth O +
mentioning O -
, O +
as O +
it O +
is O +
the O +
youngest O +
human O +
fascioliasis O +
case O +
reported O +
so O +
far O -
. O +

The O +
human O +
health O +
problem O +
of O +
this O +
distomatosis O +
in O +
the O +
Northern O +
Bolivian O +
Altiplano O +
is O +
related O +
to O +
the O +
hygienic- O +
sanitation O +
status O +
of O +
the O +
human O +
population O -
. O +

The O +
numer- O +
ous O +
different O +
protozoan O +
and O +
helminth O +
species O +
detected O +
in O +
the O +
area O +
surveyed O +
and O +
the O +
multiple O +
parasite O +
infections O +
detected O -
, O +
including O +
F. O +
hepatica O +
infection O -
, O +
in O +
the O +
same O +
subjects O +
( O -
ESTEBAN O +
et O +
al. O -
, O +
1996 O -
, O +
1997a O -
; O +
1998a O -
, O +
1998b O -
) O +
are O +
illustrative O +
of O +
this O +
situation O -
. O +

Acknowledgements O +
Collaboration O +
by O +
Dr O +
J. O +
A. O +
Oviedo O +
( O -
Valencia O -
, O +
Spain O -
) O +
and O +
Miss O +
W. O +
Strauss O -
, O +
N. O +
lihoshi O -
, O +
M. O +
Magarinos O +
and O +
Dr O +
C. O +
Aguirre O +
( O -
La O +
Paz O -
, O +
Bolivia O -
) O +
is O +
acknowledged O -
. O +

Thanks O +
are O +
also O +
given O +
to O +
the O +
following O +
Bolivian O +
institutions O +
in O +
La O +
Paz O -
: O +
Direccion O +
Nacional O +
de O +
Epidemiologia O +
of O +
the O +
Ministerio O +
de O +
Prevision O +
Social O +
y O +
Salud O +
Plica O -
; O +
ComitRegional O +
de O +
Zoonosis O +
and O +
Centro O +
Piloto O +
of O +
the O +
Unidad O +
Sanitaria O +
La O +
Paz O -
; O +
and O +
Office O +
of O +
the O +
Pan O +
American O +
Health O +
Organization O -
. O +

This O +
work O +
was O +
supported O +
by O +
funding O +
from O +
the O +
STD O +
Program O +
of O +
the O +
Commission O +
of O +
the O +
European O +
Communities O +
( O -
DG O +
XII O -
: O +
Science O -
, O +
Research O +
and O +
Development O -
) O +
( O -
Contract O +
no. O +
TS3- O +
CT94 O -
- O -
0294 O -
) O -
, O +
Brussels O -
, O +
EU O -
, O +
by O +
the O +
Program O +
of O +
Scientific O +
Co- O +
operation O +
with O +
Latin O +
America O -
, O +
Institute O +
de O +
Cooperaci O +
Ibero- O +
americana O -
, O +
Agencia O +
Espanola O +
de O +
Cooperaci O +
Intemacional O +
( O -
ICI O -
- O -
AECI O -
) O +
and O +
by O +
Projects O +
no. O +
UE96 O -
- O -
0001 O +
and O +
no. O +
PM97- O +
0099 O +
of O +
the O +
Direccion O +
General O +
de O +
Investigacion O +
Cientifica O +
y O +
Tnica O +
( O -
DGICYT O -
) O -
, O +
Spanish O +
Ministry O +
of O +
Education O +
and O +
Science O -
, O +
Madrid O -
. O +

Modular O +
polyketide B-Gene +
synthases I-Gene +
( O -
PKSs B-Gene -
) O +
are O +
responsible O +
for O +
producing O +
a O +
large O +
number O +
of O +
12 O -
, O +
14- O +
and O +
16-membered O +
macrolide O +
antibiotics O +
including O +
methymycin O -
, O +
erythromycin O +
and O +
tylosin O -
. O +

These O +
large O -
, O +
multifunctional O +
enzymes B-Gene +
( O -
> O -
300,000 O +
kDa O -
) O +
catalyze O +
the O +
biosynthesis O +
of O +
polyketide O +
macrolactones O +
through O +
multistep O +
pathways O +
involving O +
decarboxylative O +
condensations O +
between O +
acyl O +
thioesters O +
fol- O +
lowed O +
by O +
cycles O +
of O +
varying O +
B O -
- O -
carbon O +
processing O +
[ O -
l O -
] O -
. O +

The O +
ability O +
to O +
control O +
aspects O +
of O +
polyketide O +
biosynthesis O -
, O +
such O +
as O +
monomer O +
selection O -
, O +
degree O +
of O +
B O -
- O -
carbon O +
processing O +
and O +
stereoselectivity O -
, O +
by O +
genetic O +
manipulation O +
of O +
PKSs B-Gene +
has O +
stimulated O +
great O +
interest O +
in O +
the O +
combinatorial O +
engineering O +
of O +
novel O +
antibiotics O +
[ O -
2,3 O -
] O -
. O +

Picromycin O +
( O -
1 O -
; O +
Figure O +
1 O -
) O +
is O +
of O +
par- O +
ticular O +
interest O +
for O +
such O +
use O +
because O +
of O +
its O +
close O +
structural O +
relationship O +
to O +
ketolide O +
compounds O +
( O -
e.g. O +
HMR O +
3004 O -
) O -
, O +
a O +
new O +
class O +
of O +
semisynthetic O +
macrolides O +
with O +
activity O +
against O +
pathogens O +
resistant O +
to O +
erythromycin O +
[ O -
4 O -
] O -
. O +

Genetic O +
systems O +
that O +
allow O +
rapid O +
engineering O +
of O +
the O +
picromycin O +
PKS B-Gene +
would O +
therefore O +
be O +
valuable O +
for O +
creating O +
novel O +
ketolide O +
analogs O +
for O +
pharmaceutical O +
applications O -
. O +

A O +
pivotal O +
development O +
for O +
modular O +
PKS B-Gene +
engineering O +
was O +
the O +
heterologous O +
expression O +
of O +
the O +
erythromycin O +
PKS B-Gene +
( O -
6-deoxyerythronolide B-Gene +
B I-Gene +
synthase I-Gene -
, O +
DEBS B-Gene -
) O +
in O +
Streptomyces O +
coelicolor O +
[ O -
5,6 O -
] O -
. O +

The O +
advantages O +
to O +
this O +
plasmid O -
- O -
based O +
genetic O +
system O +
for O +
DEBS B-Gene +
were O +
that O +
it O +
overcame O +
the O +
tedious O +
and O +
limited O +
techniques O +
for O +
manipulating O +
the O +
natural O +
DEBS B-Gene +
host O +
organism O -
, O +
Saccharopolyspora O +
etythaea O -
, O +
it O +
allowed O +
more O +
facile O +
construction O +
of O +
mutant O +
PKSs B-Gene -
, O +
and O +
it O +
reduced O +
the O +
complexity O +
of O +
PKS B-Gene +
property O +
analysis O +
by O +
pro- O +
viding O +
a O +
leanhost O +
background O -
. O +

This O +
system O +
also O +
expe- O +
dited O +
the O +
construction O +
of O +
the O +
first O +
combinatorial O +
modular O +
polyketide O +
library O +
in O +
Streptomyces O +
[ O -
7 O -
] O -
. O +

Despite O +
the O +
success O +
of O +
this O +
system O -
, O +
as O +
well O +
as O +
the O +
increased O +
number O +
of O +
modular O +
PKS B-Gene +
gene O +
clusters O +
currently O +
available O -
, O +
DEBS B-Gene +
remained O +
the O +
only O +
modular O +
PKS B-Gene +
reported O +
to O +
be O +
expressed O +
in O +
a O +
het- O +
erologous O +
organism O -
. O +

The O +
picromycin O +
gene O +
cluster O +
from O +
Streptomyces O +
venezuelae O +
was O +
recently O +
cloned O +
and O +
sequenced O +
by O +
Sherman O +
and O +
coworkers O +
[ O -
8 O -
] O +
and O +
in O +
our O +
own O +
laboratories O +
( O -
[ O -
9 O -
] O -
; O +
M.C.B. O -
, O +
unpublished O +
observations O -
) O -
. O +

S. O +
venezuelae O +
is O +
unique O +
among O +
macrolide O -
- O -
producing O +
organisms O +
because O +
it O +
produces O +
primary O +
polyketides O +
with O +
two O +
different O +
ring O +
sizes O -
. O +

In O +
addi- O +
tion O +
to O +
the O +
14-membered O +
macrolide O +
picromycin O +
( O -
l O -
) O -
, O +
the O +
12-membered O +
macrolide O +
methymycin O +
( O -
2 O -
; O +
Figure O +
1 O -
) O +
is O +
also O +
produced O -
. O +

Based O +
on O +
the O +
structural O +
similarities O +
between O +
CHBIOL O +
80087 O +
S1074 O -
- O -
5521 O -
( O -
99 O -
) O -
80087 O -
- O -
8 O +
10.1016 O -
/ O -
S1074 O -
- O -
5521 O -
( O -
99 O -
) O -
80087 O -
- O -
8 O +
Elucidating O +
the O +
mechanism O +
of O +
chain O +
termination O +
switching O +
in O +
the O +
picromycin O -
/ O -
methymycin O +
polyketide B-Gene +
synthase I-Gene +
Li O +
Tang O +
Hong O +
Fu O +

Melanie O +
C O +
Betlach O +

Robert O +
McDaniel O +

* O +
mcdaniel@kosan.com O +

KOSAN O +
Biosciences O -
, O +
Inc. O -
, O +
3832 O +
Bay O +
Center O +
Place O -
, O +
Hayward O -
, O +
CA O +
94545 O -
, O +
USA O +

* O +
Correspondence O -
: O +
Robert O +
McDaniel O -
. O +

Background O +
A O +
single O +
modular O +
polyketide B-Gene +
synthase I-Gene +
( O -
PKS B-Gene -
) O +
gene O +
cluster O +
is O +
responsible O +
for O +
production O +
of O +
both O +
the O +
14-membered O +
macrolide O +
antibiotic O +
picromycin O +
and O +
the O +
12-membered O +
macrolide O +
antibiotic O +
methymycin O +
in O +
Streptomyces O +
Venezuelas O +
. O +

Building O +
on O +
the O +
success O +
of O +
the O +
heterologous O +
expression O +
system O +
engineered O +
using O +
the O +
erythromycin O +
PKS B-Gene -
, O +
we O +
have O +
constructed O +
an O +
analogous O +
system O +
for O +
the O +
picromycin O -
/ O -
methymycin O +
PKS B-Gene -
. O +

Through O +
heterologous O +
expression O +
and O +
construction O +
of O +
a O +
hybrid O +
PKS B-Gene -
, O +
we O +
have O +
examined O +
the O +
contributions O +
that O +
the O +
PKS B-Gene -
, O +
its O +
internal O +
thioesterase B-Gene +
domain O +
( O -
pikTE B-Gene -
) O +
and O +
the O +
Pik B-Gene +
TEII I-Gene +
thioesterase B-Gene +
domain O +
make O +
in O +
termination O +
and O +
cyclization O +
of O +
the O +
two O +
polyketide O +
intermediates O -
. O +

Results O +
The O +
picromycin O -
/ O -
methymycin O +
PKS B-Gene +
genes O +
were O +
functionally O +
expressed O +
in O +
the O +
heterologous O +
host O +
Streptomyces O +
lividans O +
, O +
resulting O +
in O +
production O +
of O +
both O +
narbonolide O +
and O +
10-deoxymethynolide O +
( O -
the O +
precursors O +
of O +
picromycin O +
and O +
methymycin O -
, O +
respectively O -
) O -
. O +

Co O -
- O -
expression O +
with O +
the O +
Pik B-Gene +
TEII I-Gene +
thioesterase B-Gene +
led O +
to O +
increased O +
production O +
levels O -
, O +
but O +
did O +
not O +
change O +
the O +
ratio O +
of O +
the O +
two O +
compounds O +
produced O -
, O +
leaving O +
the O +
function O +
of O +
this O +
protein B-Gene +
largely O +
unknown O -
. O +

Fusion O +
of O +
the O +
PKS B-Gene +
thioesterase B-Gene +
domain O +
( O -
pikTE B-Gene -
) O +
to O +
6-deoxyerythronolide B-Gene +
B I-Gene +
synthase I-Gene +
( O -
DEBS B-Gene -
) O +
resulted O +
in O +
formation O +
of O +
only O +
14-membered O +
macrolactones O -
. O +

Conclusions O +
These O +
experiments O +
demonstrate O +
that O +
the O +
PKS B-Gene +
alone O +
is O +
capable O +
of O +
catalyzing O +
the O +
synthesis O +
of O +
both O +
14- O +
and O +
12-membered O +
macrolactones O +
and O +
favor O +
a O +
model O +
by O +
which O +
different O +
macrolactone O +
rings O +
result O +
from O +
a O +
combination O +
of O +
the O +
arrangement O +
between O +
the O +
module O +
5 O +
and O +
module O +
6 O +
subunits O +
in O +
the O +
picromycin O +
PKS B-Gene +
complex O +
and O +
the O +
selectivity O +
of O +
the O +
pikTE B-Gene +
domain O -
. O +

Key O +
words O +
erythromycin O +
methymycin O +
picromycin O +
polyketide I-Gene +
thioesterase I-Gene +

Diltiazem O +
( O -
d O +
-cis O +
-diltiazem O -
) O -
, O +
a O +
benzothiazepine B-Gene +
Ca2 I-Gene -
+ I-Gene +
channel I-Gene +
blocker O -
, O +
has O +
been O +
used O +
for O +
the O +
treatment O +
of O +
ischemic O +
heart O +
disease O -
. O +

The O +
primary O +
mechanism O +
of O +
the O +
anti O -
- O -
ischemic O +
action O +
of O +
d O +
-cis O +
-diltiazem O +
is O +
considered O +
to O +
be O +
its O +
Ca2 B-Gene -
+ I-Gene +
channel I-Gene +
blocking O +
action O -
, O +
which O +
produces O +
improvement O +
of O +
the O +
myocardial O +
oxygen O +
balance O +
between O +
supply O +
and O +
demand O +
by O +
either O +
increasing O +
coronary O +
flow O +
or O +
decreasing O +
cardiac O +
mechanical O +
function O -
, O +
or O +
both O -
. O +

However O -
, O +
l O +
-cis O +
-diltiazem O -
, O +
which O +
is O +
an O +
optical O +
isomer O +
of O +
d O +
-cis O +
-diltiazem O +
with O +
about O +
1 O -
/ O -
20–1 O -
/ O -
100 O +
the O +
Ca2 B-Gene -
+ I-Gene +
channel I-Gene +
blocking O +
action O +
of O +
d O +
-cis O +
-diltiazem O +
( O -
Nasa O +
et O +
al. O -
, O +
1992 O +
; O +
Itogawa O +
et O +
al. O -
, O +
1996 O +
) O -
, O +
and O +
d O +
-cis O +
-diltiazem O +
attenuate O +
the O +
myocardial O +
derangements O +
induced O +
by O +
ischemia O -
– O -
reperfusion O +
to O +
a O +
similar O +
degree O +
( O -
Nasa O +
et O +
al. O -
, O +
1990 O +
) O -
. O +

This O +
fact O +
suggests O +
that O +
the O +
anti O -
- O -
ischemic O +
action O +
of O +
d O +
-cis O +
-diltiazem O +
does O +
not O +
entirely O +
depend O +
on O +
its O +
Ca2 B-Gene -
+ I-Gene +
channel I-Gene +
blocking O +
action O -
, O +
but O +
depends O +
on O +
other O +
unknown O +
actions O -
. O +

Recently O -
, O +
we O +
( O -
Xiao O +
et O +
al. O -
, O +
1997 O +
) O +
have O +
demonstrated O +
that O +
both O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
attenuate O +
the O +
myocardial O +
derangements O +
induced O +
by O +
palmitoyl O -
- O -
l O +
-carnitine O -
, O +
which O +
accumulates O +
in O +
the O +
heart O +
during O +
ischemia O +
and O +
reperfusion O -
, O +
supporting O +
the O +
above O +
suggestion O -
. O +

During O +
ischemia O +
and O +
reperfusion O -
, O +
reactive O +
oxygen O +
species O -
, O +
such O +
as O +
superoxide O +
anion O -
, O +
hydroxyl O +
radical O +
and O +
hydrogen O +
peroxide O +
( O -
H2 O +
O2 O +
) O -
, O +
are O +
generated O +
intra- O +
and O +
extracellularly O +
in O +
the O +
myocardium O +
and O +
endothelium O +
( O -
Hess O +
and O +
Manson O -
, O +
1984 O +
; O +
Lucchesi O -
, O +
1990 O +
; O +
Loesser O +
et O +
al. O -
, O +
1991 O +
) O -
. O +

These O +
reactive O +
oxygen O +
species O +
are O +
considered O +
important O +
in O +
producing O +
irreversible O +
damage O +
in O +
the O +
ischemia O -
- O -
reperfused O +
heart O +
( O -
Hess O +
and O +
Manson O -
, O +
1984 O +
; O +
Lucchesi O -
, O +
1990 O +
; O +
Loesser O +
et O +
al. O -
, O +
1991 O +
) O -
. O +

In O +
fact O -
, O +
oxygen O +
radical O +
scavengers O +
and O +
anti O -
- O -
oxidants O +
protect O +
the O +
myocardium O +
against O +
ischemia O -
– O -
reperfusion O +
damage O +
( O -
Hess O +
and O +
Manson O -
, O +
1984 O +
; O +
Lucchesi O -
, O +
1990 O +
; O +
Loesser O +
et O +
al. O -
, O +
1991 O +
) O -
. O +

We O +
( O -
Hara O +
et O +
al. O -
, O +
1993 O +
; O +
Hara O +
and O +
Abiko O -
, O +
1996 O +
; O +
Kokita O +
and O +
Hara O -
, O +
1996 O +
) O +
have O +
demonstrated O +
that O +
H2 O +
O2 O +
decreases O +
cardiac O +
mechanical O +
function O +
and O +
the O +
tissue O +
levels O +
of O +
high O -
- O -
energy O +
phosphates O +
in O +
the O +
isolated O +
perfused O +
rat O +
heart O -
. O +

According O +
to O +
recent O +
physiological O +
studies O -
, O +
H2 O +
O2 O +
increases O +
the O +
intracellular O +
concentration O +
of O +
Na+ O +
( O -
[ O -
Na+ O +
] O -
i O +
) O +
in O +
the O +
myocardium O +
( O -
Yanagida O +
et O +
al. O -
, O +
1995 O +
) O -
, O +
probably O +
because O +
of O +
an O +
increase O +
in O +
Na+ O +
current O +
in O +
cardiac O +
cells O +
( O -
Bhatnagar O +
et O +
al. O -
, O +
1990 O +
; O +
Ward O +
and O +
Giles O -
, O +
1997 O +
) O -
. O +

The O +
increase O +
in O +
[ O -
Na+ O +
] O -
i O +
activates O +
the O +
Na+ O +
/Ca2 O -
+ O +
exchanger O -
, O +
leading O +
to O +
intracellular O +
Ca2 O -
+ O +
overload O -
, O +
which O +
is O +
responsible O +
for O +
irreversible O +
myocardial O +
derangements O +
( O -
Goldhaber O -
, O +
1996 O +
) O -
. O +

In O +
order O +
to O +
elucidate O +
the O +
mechanisms O +
of O +
action O +
of O +
l O +
-cis O +
-diltiazem O +
responsible O +
for O +
its O +
anti O -
- O -
ischemic O +
effect O +
and O +
to O +
relate O +
its O +
anti O -
- O -
ischemic O +
action O +
to O +
the O +
Ca2 B-Gene -
+ I-Gene +
channel I-Gene +
blocking O +
action O -
, O +
the O +
following O +
two O +
series O +
of O +
experiments O +
were O +
designed O -
. O +

The O +
first O +
series O +
of O +
experiments O +
was O +
performed O +
to O +
determine O +
the O +
effect O +
of O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
on O +
the O +
H2 O +
O2 O +
-induced O +
mechanical O +
dysfunction O -
, O +
decrease O +
in O +
the O +
tissue O +
levels O +
of O +
high O -
- O -
energy O +
phosphates O +
and O +
damage O +
of O +
the O +
cell O +
membrane O -
, O +
and O +
the O +
second O +
series O +
of O +
experiments O +
was O +
carried O +
out O +
to O +
examine O +
the O +
effect O +
of O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
on O +
the O +
H2 O +
O2 O +
-induced O +
increase O +
in O +
[ O -
Na+ O +
] O -
i O +
. O +

2 O +
Methods O +
The O +
protocol O +
of O +
animal O +
experiments O +
in O +
the O +
present O +
study O +
was O +
approved O +
by O +
the O +
` O -
Asahikawa O +
Medical O +
College O +
Committee O +
on O +
Animal O +
Research O -
' O -
. O +

2.1 O +
Heart O +
perfusion O +
( O -
the O +
first O +
series O +
of O +
experiments O -
) O +

Male O +
Sprague O -
– O -
Dawley O +
rats O -
, O +
weighing O +
310–340 O +
g O +
( O -
9–10 O +
weeks O +
old O -
) O -
, O +
were O +
used O +
in O +
the O +
first O +
series O +
of O +
experiments O -
. O +

The O +
rats O +
were O +
anesthetized O +
with O +
sodium O +
pentobarbital O +
( O -
50 O +
mg O +
kg−1 O +
, O +
i.p O -
. O -
) O +
20 O +
min O +
after O +
an O +
injection O +
with O +
heparin O +
( O -
1000 O +
u O +
kg−1 O +
, O +
i.p O -
. O -
) O -
. O +

After O +
thoracotomy O -
, O +
the O +
hearts O +
were O +
rapidly O +
removed O -
, O +
and O +
then O +
retrograde O +
perfusion O +
was O +
started O +
using O +
a O +
cannula O +
inserted O +
into O +
the O +
aorta O +
according O +
to O +
the O +
Langendorff O +
technique O -
. O +

The O +
perfusion O +
buffer O +
was O +
a O +
Krebs O -
– O -
Henseleit O +
bicarbonate O +
( O -
KHB O -
) O +
buffer O +
containing O +
( O -
in O +
mM O -
) O -
: O +
NaCl O -
, O +
118 O -
; O +
KCl O -
, O +
4.7 O -
; O +
KH2 O +
PO4 O +
, O +
1.2 O -
; O +
MgSO4 O +
, O +
1.2 O -
; O +
CaCl2 O +
, O +
2.5 O -
; O +
NaHCO3 O +
, O +
25 O -
; O +
and O +
glucose O -
, O +
11 O -
, O +
equilibrated O +
with O +
a O +
gas O +
mixture O +
of O +
95 O -
% O +
O2 O +
+ O -
5 O -
% O +
CO2 O +
and O +
maintained O +
at O +
37 O -
° O -
C O -
. O +

The O +
oxygen O +
tension O +
of O +
the O +
buffer O +
measured O +
by O +
a O +
blood O +
gas O +
analyzer O +
( O -
Model O +
813 O -
, O +
Instrumentation O +
Laboratory O -
, O +
Lexington O -
, O +
USA O -
) O +
was O +
about O +
550 O +
mm O +
Hg O -
. O +

The O +
hearts O -
, O +
mounted O +
in O +
a O +
water O -
- O -
jacketed O +
chamber O +
( O -
37 O -
° O -
C O -
) O -
, O +
were O +
initially O +
perfused O +
at O +
a O +
constant O +
perfusion O +
pressure O +
of O +
80 O +
cm O +
H2 O +
O. O +
About O +
10 O +
min O +
after O +
constant O +
pressure O +
perfusion O -
, O +
perfusion O +
was O +
switched O +
to O +
constant O +
flow O +
perfusion O +
( O -
10 O +
ml O +
min−1 O +
) O -
, O +
using O +
a O +
microtube O +
pump O +
( O -
Eyela O +
MP-3 O -
, O +
Tokyo O -
- O -
Rikakikai O +
Instruments O -
, O +
Tokyo O -
, O +
Japan O -
) O -
, O +
which O +
was O +
maintained O +
until O +
the O +
end O +
of O +
the O +
experiment O -
. O +

The O +
heart O +
rate O +
was O +
kept O +
constant O +
by O +
pacing O +
the O +
heart O +
at O +
300 O +
beats O +
min−1 O +
with O +
an O +
electronic O +
stimulator O +
( O -
3F46 O -
, O +
San O -
- O -
Ei O +
Instruments O -
, O +
Tokyo O -
, O +
Japan O -
) O +
during O +
the O +
course O +
of O +
the O +
study O -
. O +

Rectangular O +
pulses O +
of O +
2 O +
ms O +
in O +
duration O +
with O +
a O +
voltage O +
of O +
6 O +
V O +
( O -
about O +
3 O -
× O +
the O +
threshold O +
voltage O -
) O +
were O +
applied O +
to O +
the O +
left O +
ventricle O +
for O +
pacing O +
of O +
the O +
heart O -
. O +

As O +
indices O +
of O +
mechanical O +
function O -
, O +
left O +
ventricular O +
systolic O +
pressure O -
, O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
and O +
left O +
ventricular O +
developed O +
pressure O +
were O +
used O -
. O +

The O +
values O +
of O +
left O +
ventricular O +
systolic O +
pressure O +
and O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
were O +
determined O +
from O +
the O +
left O +
ventricular O +
pressure O +
curves O +
recorded O +
continuously O +
during O +
the O +
course O +
of O +
the O +
study O -
, O +
and O +
the O +
left O +
ventricular O +
developed O +
pressure O +
value O +
was O +
calculated O +
as O +
left O +
ventricular O +
systolic O +
pressure O +
minus O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O -
. O +

For O +
measurement O +
of O +
left O +
ventricular O +
pressure O -
, O +
a O +
saline O -
- O -
filled O +
polyethylene O +
cannula O -
, O +
connected O +
to O +
a O +
pressure O +
transducer O -
, O +
was O +
inserted O +
into O +
the O +
left O +
ventricular O +
cavity O +
via O +
the O +
left O +
atrium O -
. O +

2.2 O +
Experimental O +
protocol O +
( O -
the O +
first O +
series O +
of O +
experiments O -
) O +

The O +
hearts O +
were O +
divided O +
into O +
five O +
groups O -
: O +
vehicle O -
, O +
l O +
-cis O +
-diltiazem O +
( O -
5 O +
μM O -
) O -
, O +
l O +
-cis O +
-diltiazem O +
( O -
10 O +
μM O -
) O -
, O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
and O +
d O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
groups O -
. O +

In O +
these O +
groups O -
, O +
the O +
hearts O +
were O +
perfused O +
at O +
a O +
constant O +
flow O +
for O +
75 O +
min O +
( O -
stabilization O +
period O +
for O +
20 O +
min O +
and O +
observation O +
period O +
for O +
55 O +
min O -
) O -
. O +

d O +
-cis O +
-Diltiazem O -
, O +
l O +
-cis O +
-diltiazem O +
or O +
vehicle O +
( O -
KHB O +
buffer O +
for O +
both O +
d O +
-cis O +
-diltiazem O +
and O +
l O +
-cis O +
-diltiazem O +
solutions O -
) O +
was O +
infused O +
into O +
the O +
aortic O +
cannula O +
at O +
a O +
constant O +
flow O +
rate O +
of O +
0.1 O +
ml O +
min−1 O +
for O +
45 O +
min O +
from O +
10 O +
min O +
after O +
the O +
start O +
of O +
observation O +
period O -
. O +

The O +
final O +
concentration O +
of O +
d O +
-cis O +
-diltiazem O +
in O +
the O +
perfusate O +
was O +
set O +
to O +
15 O +
μM O +
and O +
that O +
of O +
l O +
-cis O +
-diltiazem O +
in O +
the O +
perfusate O +
was O +
set O +
to O +
5 O -
, O +
10 O +
or O +
15 O +
μM. O +
H2 O +
O2 O +
was O +
infused O +
into O +
the O +
aortic O +
cannula O +
at O +
a O +
constant O +
flow O +
rate O +
of O +
0.1 O +
ml O +
min−1 O +
for O +
3.5 O +
min O +
from O +
10 O +
min O +
after O +
the O +
start O +
of O +
infusion O +
of O +
d O +
-cis O +
-diltiazem O -
, O +
l O +
-cis O +
-diltiazem O +
or O +
vehicle O -
. O +

The O +
final O +
concentration O +
of O +
H2 O +
O2 O +
in O +
the O +
perfusate O +
was O +
set O +
to O +
600 O +
μM. O +
During O +
the O +
observation O +
period O -
, O +
left O +
ventricular O +
systolic O +
pressure O +
and O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
were O +
continuously O +
recorded O +
and O +
the O +
coronary O +
effluent O +
was O +
collected O +
for O +
determination O +
of O +
lactate B-Gene +
dehydrogenase I-Gene +
( O -
LDH B-Gene -
) O +
released O +
from O +
the O +
myocardium O -
. O +

To O +
measure O +
the O +
tissue O +
levels O +
of O +
high O -
- O -
energy O +
phosphates O -
, O +
the O +
hearts O +
were O +
frozen O +
at O +
the O +
end O +
of O +
experiment O +
( O -
45 O +
min O +
after O +
the O +
start O +
of O +
infusion O +
of O +
vehicle O -
, O +
d O +
-cis O +
-diltiazem O +
or O +
l O +
-cis O +
-diltiazem O -
) O +
with O +
freezing O +
clamps O +
previously O +
chilled O +
in O +
liquid O +
nitrogen O -
. O +

In O +
addition O -
, O +
some O +
hearts O +
in O +
the O +
vehicle O -
, O +
d O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
and O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
groups O +
were O +
frozen O +
immediately O +
before O +
H2 O +
O2 O +
infusion O +
( O -
10 O +
min O +
after O +
the O +
start O +
of O +
infusion O +
of O +
vehicle O -
, O +
d O +
-cis O +
-diltiazem O +
or O +
l O +
-cis O +
-diltiazem O -
) O -
. O +

The O +
frozen O +
myocardial O +
samples O +
were O +
stored O +
in O +
liquid O +
nitrogen O +
( O -
at O +
−196 O -
° O -
C O -
) O +
until O +
the O +
biochemical O +
analysis O +
was O +
performed O -
. O +

2.3 O +
Biochemical O +
analysis O +
( O -
the O +
first O +
series O +
of O +
experiments O -
) O +

The O +
frozen O +
myocardial O +
sample O +
was O +
pulverized O +
in O +
a O +
mortar O +
cooled O +
with O +
liquid O +
nitrogen O -
. O +

A O +
part O +
of O +
the O +
pulverized O +
tissue O +
powder O +
( O -
about O +
0.8–1.0 O +
g O -
) O +
was O +
weighed O +
and O +
put O +
into O +
an O +
oven O +
overnight O -
, O +
in O +
order O +
to O +
measure O +
the O +
tissue O +
water O +
content O +
and O +
dry O +
weight O +
of O +
the O +
tissue O -
. O +

The O +
remainder O +
of O +
the O +
tissue O +
powder O +
was O +
used O +
for O +
determination O +
of O +
the O +
tissue O +
levels O +
of O +
ATP O -
, O +
ADP O -
, O +
AMP O +
and O +
creatine O +
phosphate O -
. O +

ATP O -
, O +
ADP O -
, O +
AMP O +
and O +
creatine O +
phosphate O +
were O +
measured O +
according O +
to O +
standard O +
enzymatic O +
procedures O +
( O -
Bergmeyer O -
, O +
1974a O +
) O -
, O +
using O +
a O +
spectrophotometer O +
( O -
Gilford O +
system O +
2600 O -
, O +
Gilford O +
Instrument O +
Laboratories O -
, O +
Oberlin O -
, O +
USA O -
) O -
. O +

The O +
LDH B-Gene +
activity O +
in O +
the O +
coronary O +
effluent O +
was O +
measured O +
spectrophotometrically O +
according O +
to O +
an O +
enzymatic O +
method O +
( O -
Bergmeyer O -
, O +
1974b O +
) O -
, O +
using O +
an O +
LDH O +
assay O +
kit O +
( O -
Sigma O -
, O +
St. O +
Louis O -
, O +
USA O -
) O -
. O +

2.4 O +
Heart O +
perfusion O +
( O -
the O +
second O +
series O +
of O +
experiments O -
) O +

Male O +
Sprague O -
– O -
Dawley O +
rats O -
, O +
weighing O +
180–210 O +
g O +
( O -
6–7 O +
weeks O +
old O -
) O -
, O +
were O +
used O +
in O +
the O +
second O +
series O +
of O +
experiments O -
. O +

According O +
to O +
the O +
procedure O +
described O +
in O +
the O +
first O +
series O +
of O +
experiments O -
, O +
the O +
isolated O +
hearts O +
were O +
initially O +
perfused O +
by O +
the O +
Langendorff O +
technique O +
at O +
a O +
constant O +
perfusion O +
pressure O +
of O +
80 O +
cm O +
H2 O +
O. O +
About O +
10 O +
min O +
after O +
constant O +
pressure O +
perfusion O -
, O +
perfusion O +
was O +
switched O +
to O +
constant O +
flow O +
perfusion O +
( O -
8.5 O +
ml O +
min−1 O +
) O -
, O +
using O +
a O +
microtube O +
pump O +
( O -
Eyela O +
MP-3 O -
, O +
Tokyo O -
- O -
Rikakikai O +
Instruments O -
) O -
, O +
which O +
was O +
maintained O +
until O +
the O +
end O +
of O +
the O +
experiment O -
. O +

During O +
the O +
first O +
10 O +
min O +
of O +
constant O +
flow O +
perfusion O -
, O +
the O +
hearts O +
were O +
perfused O +
with O +
normal O +
KHB O +
buffer O -
. O +

To O +
obtain O +
23 O +
Na O +
-nuclear O +
magnetic O +
resonance O +
( O -
NMR O -
) O +
spectra O -
, O +
perfusion O +
buffer O +
was O +
then O +
switched O +
to O +
a O +
KHB O +
buffer O +
containing O +
thulium O +
( O -
III O -
) O -
-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis- O -
( O -
methylenephosphonate O -
) O +
[ O -
Tm O -
( O -
DOTP O -
) O -
5− O +
] O +
( O -
a O +
23 O +
Na O +
-NMR O +
shift O +
reagent O -
) O -
, O +
equilibrated O +
with O +
a O +
gas O +
mixture O +
of O +
95 O -
% O +
O2 O +
+ O -
5 O -
% O +
CO2 O +
and O +
maintained O +
at O +
37 O -
° O -
C O -
. O +

The O +
buffer O +
for O +
the O +
study O +
with O +
23 O +
Na O +
-NMR O +
spectra O +
was O +
the O +
same O +
as O +
the O +
normal O +
KHB O +
buffer O -
, O +
except O +
that O +
it O +
contained O +
104 O +
mM O +
NaCl O -
, O +
3.5 O +
mM O +
Na4 O +
HTmDOTP O +
and O +
3.9 O +
mM O +
CaCl2 O +
. O +

The O +
reason O +
for O +
use O +
of O +
3.9 O +
mM O +
CaCl2 O +
was O +
that O +
addition O +
of O +
3.9 O +
mM O +
CaCl2 O +
would O +
produce O +
1 O +
mM O +
free O +
Ca2 O -
+ O +
in O +
the O +
presence O +
of O +
the O +
shift O +
reagent O +
( O -
Buster O +
et O +
al. O -
, O +
1990 O +
) O -
. O +

Although O +
the O +
concentration O +
of O +
free O +
Ca2 O -
+ O +
was O +
lower O +
than O +
that O +
used O +
in O +
the O +
first O +
series O +
of O +
experiments O +
( O -
2.5 O +
mM O -
) O -
, O +
it O +
( O -
1 O +
mM O -
) O +
was O +
chosen O +
to O +
avoid O +
precipitation O +
of O +
the O +
shift O +
reagent O +
( O -
Van O +
Emous O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

The O +
heart O +
rate O +
was O +
kept O +
constant O +
by O +
pacing O +
the O +
heart O +
at O +
300 O +
beats O +
min−1 O +
, O +
using O +
a O +
pair O +
of O +
copper O +
electrodes O +
and O +
an O +
electronic O +
stimulator O +
( O -
SEN-3301 O -
, O +
Nihon O +
Kohden O -
, O +
Tokyo O -
, O +
Japan O -
) O -
. O +

For O +
measurement O +
of O +
left O +
ventricular O +
pressure O -
, O +
a O +
latex O +
balloon O +
connected O +
to O +
a O +
pressure O +
transducer O +
was O +
inserted O +
into O +
the O +
left O +
ventricular O +
cavity O +
via O +
the O +
left O +
atrium O -
. O +

Before O +
experiments O -
, O +
the O +
balloon O +
was O +
inflated O +
with O +
distilled O +
water O +
to O +
achieve O +
an O +
initial O +
end O -
- O -
diastolic O +
pressure O +
of O +
10 O +
mm O +
Hg O -
; O +
thereafter O -
, O +
the O +
volume O +
was O +
kept O +
constant O +
during O +
the O +
course O +
of O +
the O +
study O -
. O +

The O +
hearts O +
perfused O +
with O +
the O +
buffer O +
were O +
placed O +
inside O +
a O +
glass O +
NMR O +
tube O +
( O -
13.4 O +
mm O +
in O +
internal O +
diameter O -
) O +
that O +
was O +
introduced O +
into O +
the O +
NMR O +
probe O +
placed O +
in O +
a O +
superconducting O +
magnet O -
. O +

Because O +
the O +
internal O +
diameter O +
of O +
the O +
glass O +
NMR O +
tube O +
was O +
small O -
, O +
only O +
small O +
hearts O +
were O +
used O +
for O +
the O +
NMR O +
experiments O -
. O +

Therefore O -
, O +
relatively O +
small O +
rats O +
weighing O +
about O +
200 O +
g O +
were O +
used O +
in O +
the O +
second O +
series O +
of O +
experiments O -
. O +

The O +
temperature O +
surrounding O +
the O +
glass O +
NMR O +
tube O +
was O +
maintained O +
at O +
about O +
20 O -
° O -
C O +
by O +
air O +
conditioner O -
, O +
because O +
the O +
apparatus O +
used O +
in O +
the O +
present O +
study O +
is O +
not O +
equipped O +
to O +
provide O +
a O +
temperature O -
- O -
controlled O +
air O +
stream O +
around O +
the O +
NMR O +
tube O -
. O +

Coronary O +
effluent O +
was O +
removed O +
from O +
the O +
NMR O +
glass O +
tube O +
to O +
a O +
level O +
of O +
about O +
10 O +
mm O +
above O +
the O +
heart O -
. O +

Perfusion O +
fluid O +
was O +
not O +
recirculated O -
. O +

2.5 O +
23 O +
Na O +
-NMR O +
measurements O +
( O -
the O +
second O +
series O +
of O +
experiments O -
) O +
23 O +
Na O +
-spectra O +
were O +
obtained O +
using O +
a O +
GX-270 O +
spectrometer O +
( O -
JEOL O -
, O +
Tokyo O -
, O +
Japan O -
) O +
at O +
71.32 O +
MHz O +
with O +
a O +
pulse O +
width O +
of O +
90 O -
° O -
, O +
an O +
interpulse O +
delay O +
of O +
0.5 O +
s O -
, O +
a O +
spectral O +
width O +
of O +
3000 O +
Hz O +
and O +
data O +
size O +
of O +
2048 O -
. O +

The O +
spectrometer O +
was O +
equipped O +
with O +
a O +
6.3-T O +
superconducting O +
magnet O +
and O +
an O +
NMR O +
probe O +
( O -
TU O +
( O -
15 O -
) O -
, O +
JEOL O -
) O +
in O +
which O +
the O +
glass O +
NMR O +
tube O +
was O +
placed O -
. O +

Four O +
glass O +
capillaries O -
, O +
each O +
containing O +
1.67 O +
μmol O +
NaCl O +
in O +
the O +
presence O +
of O +
50 O +
mM O +
Tris O +
form O +
of O +
dysprosium O +
triethylenetetraminehexaacetic O +
acid O +
[ O -
Tris3 O +
Dy O -
( O -
TTHA O -
) O -
·3Tris O -
– O -
HCl O -
] O +
( O -
another O +
23 O +
Na O +
-NMR O +
shift O +
reagent O -
) O -
, O +
were O +
placed O +
inside O +
of O +
the O +
NMR O +
tube O +
as O +
an O +
internal O +
standard O -
. O +

The O +
area O +
of O +
each O +
peak O +
in O +
the O +
23 O +
Na O +
-NMR O +
spectra O +
was O +
analyzed O +
by O +
integration O +
after O +
Gaussian O +
and O +
Lorentzian O +
multiplication O +
and O +
baseline O +
correction O +
using O +
JEOL O +
ALICE2 O +
software O +
( O -
JEOL O +
DATUM O -
, O +
Tokyo O -
, O +
Japan O -
) O -
. O +

The O +
[ O -
Na+ O +
] O -
i O +
of O +
the O +
cardiac O +
cells O +
was O +
calculated O +
by O +
a O +
comparison O +
between O +
the O +
peak O +
area O +
of O +
[ O -
Na+ O +
] O -
i O +
and O +
that O +
of O +
the O +
reference O +
solution O +
in O +
the O +
glass O +
capillaries O -
. O +

2.6 O +
Experimental O +
protocol O +
( O -
the O +
second O +
series O +
of O +
experiments O -
) O +

The O +
hearts O +
were O +
divided O +
into O +
four O +
groups O -
: O +
vehicle O -
, O +
d O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O -
, O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
and O +
tetrodotoxin O +
( O -
3 O +
μM O -
) O +
groups O -
. O +

In O +
these O +
groups O -
, O +
the O +
hearts O +
were O +
perfused O +
with O +
the O +
Tm O -
( O -
DOTP O -
) O -
5− O +
-containing O +
KHB O +
buffer O +
throughout O +
the O +
experiment O +
( O -
stabilization O +
period O +
for O +
10 O +
min O +
and O +
observation O +
period O +
for O +
40 O +
min O -
) O -
. O +

After O +
the O +
stabilization O +
period O -
, O +
d O +
-cis O +
-diltiazem O -
, O +
l O +
-cis O +
-diltiazem O +
or O +
vehicle O +
( O -
KHB O +
buffer O +
for O +
both O +
d O +
-cis O +
-diltiazem O +
and O +
l O +
-cis O +
-diltiazem O -
) O +
was O +
infused O +
into O +
the O +
aortic O +
cannula O +
for O +
40 O +
min O +
at O +
a O +
constant O +
flow O +
rate O +
of O +
0.1 O +
ml O +
min−1 O +
. O +

The O +
final O +
concentration O +
of O +
d O +
-cis O +
-diltiazem O +
and O +
l O +
-cis O +
-diltiazem O +
in O +
the O +
perfusate O +
was O +
set O +
to O +
15 O +
μM O +
and O +
the O +
final O +
concentration O +
of O +
tetrodotoxin O +
in O +
the O +
perfusate O +
was O +
set O +
to O +
3 O +
μM. O +
H2 O +
O2 O +
was O +
infused O +
into O +
the O +
aortic O +
cannula O +
at O +
a O +
constant O +
flow O +
rate O +
of O +
0.1 O +
ml O +
min−1 O +
for O +
4 O +
min O +
from O +
10 O +
min O +
after O +
the O +
start O +
of O +
infusion O +
of O +
l O +
-cis O +
-diltiazem O -
, O +
d O +
-cis O +
-diltiazem O +
or O +
tetrodotoxin O -
. O +

The O +
final O +
concentration O +
of O +
H2 O +
O2 O +
in O +
the O +
perfusate O +
was O +
set O +
to O +
1 O +
mM. O +
Thus O -
, O +
the O +
concentration O +
of O +
H2 O +
O2 O +
used O +
in O +
the O +
second O +
series O +
of O +
experiments O +
was O +
higher O +
than O +
that O +
used O +
in O +
the O +
first O +
series O +
of O +
experiments O -
, O +
because O +
in O +
a O +
preliminary O +
experiment O -
, O +
a O +
high O +
concentration O +
of O +
H2 O +
O2 O +
was O +
needed O +
to O +
induce O +
mechanical O +
dysfunction O +
to O +
a O +
degree O +
similar O +
to O +
that O +
in O +
the O +
first O +
series O +
of O +
experiments O -
. O +

After O +
the O +
experiment O -
, O +
the O +
hearts O +
were O +
put O +
into O +
an O +
oven O +
( O -
80 O -
° O -
C O -
) O +
for O +
48 O +
h O -
, O +
in O +
order O +
to O +
measure O +
the O +
dry O +
weight O +
of O +
the O +
tissue O -
. O +

The O +
volume O +
of O +
intracellular O +
water O +
was O +
assumed O +
to O +
be O +
2.45 O +
ml O +
g−1 O +
dry O +
weight O +
( O -
Askenasy O +
et O +
al. O -
, O +
1995 O +
) O -
. O +

2.7 O +
Direct O +
effect O +
of O +
d O +
-cis O +
-diltiazem O +
and O +
l O +
-cis O +
-diltiazem O +
on O +
the O +
H2 O +
O2 O +
concentration O +
in O +
vitro O +
( O -
another O +
experiment O -
) O +
To O +
determine O +
whether O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
have O +
a O +
direct O +
scavenging O +
effect O +
on O +
H2 O +
O2 O +
, O +
the O +
effect O +
of O +
d O +
-cis O +
-diltiazem O +
and O +
l O +
-cis O +
-diltiazem O +
on O +
the O +
H2 O +
O2 O +
concentration O +
was O +
investigated O +
and O +
compared O +
with O +
that O +
of O +
dimethylthiourea O -
, O +
which O +
has O +
an O +
H2 O +
O2 O +
-scavenging O +
action O +
( O -
Jackson O +
et O +
al. O -
, O +
1985 O +
) O -
. O +

A O +
mixture O +
of O +
H2 O +
O2 O +
( O -
600 O +
μM O -
) O +
and O +
d O +
-cis O +
- O +
or O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
or O +
that O +
of O +
H2 O +
O2 O +
( O -
600 O +
μM O -
) O +
and O +
dimethylthiourea O +
( O -
10 O +
mM O -
) O +
in O +
0.1 O +
M O +
phosphate O +
buffer O +
( O -
pH O +
7.0 O -
) O +
was O +
incubated O +
at O +
37 O -
° O -
C O +
for O +
30 O +
min O -
. O +

The O +
H2 O +
O2 O +
concentration O +
in O +
the O +
buffer O +
was O +
measured O +
according O +
to O +
a O +
spectrophotometric O +
method O +
( O -
Hayashi O +
et O +
al. O -
, O +
1989 O +
) O -
. O +

2.8 O +
Drugs O +
d O +
-cis O +
-Diltiazem O +
( O -
Sigma O -
) O -
, O +
l O +
-cis O +
-diltiazem O +
( O -
Tanabe O +
Seiyaku O -
, O +
Osaka O -
, O +
Japan O -
) O +
and O +
tetrodotoxin O +
( O -
Sankyo O -
, O +
Tokyo O -
, O +
Japan O -
) O +
were O +
dissolved O +
in O +
KHB O +
buffer O +
solution O -
. O +

These O +
agents O +
were O +
infused O +
at O +
a O +
flow O +
rate O +
of O +
0.1 O +
ml O +
min−1 O +
, O +
using O +
an O +
infusion O +
pump O -
, O +
into O +
the O +
inflow O +
tube O +
connected O +
to O +
the O +
side O +
arm O +
of O +
the O +
aortic O +
cannula O -
. O +

H2 O +
O2 O +
( O -
Nacalai O +
Tesque O -
, O +
Kyoto O -
, O +
Japan O -
) O +
was O +
diluted O +
with O +
saline O +
solution O -
. O +

H2 O +
O2 O +
was O +
also O +
infused O +
into O +
the O +
inflow O +
tube O +
at O +
a O +
flow O +
rate O +
of O +
0.1 O +
ml O +
min−1 O +
using O +
another O +
infusion O +
pump O -
. O +

Dimethylthiourea O +
was O +
purchased O +
from O +
Aldrich O +
Chemical O +
( O -
St. O +
Louis O -
, O +
USA O -
) O -
. O +

The O +
reagents O +
and O +
enzymes B-Gene +
used O +
for O +
biochemical O +
analysis O +
were O +
purchased O +
from O +
Sigma O -
. O +

Na4 O +
HTmDOTP O +
was O +
purchased O +
from O +
Magnetic O +
Resonance O +
Solutions O +
( O -
Dallas O -
, O +
USA O -
) O -
. O +

Tris3 O +
Dy O -
( O -
TTHA O -
) O -
·3Tris O -
– O -
HCl O +
( O -
50 O +
mM O -
) O +
was O +
prepared O +
by O +
mixing O +
DyCl3 O +
· O -
6H2 O +
O O +
( O -
Sigma O -
) O +
( O -
50 O +
mM O -
) O +
with O +
H6 O +
TTHA O +
( O -
Sigma O -
) O +
( O -
50 O +
mM O -
) O +
in O +
the O +
Tris O +
buffer O +
( O -
pH O +
7.4 O -
) O -
. O +

2.9 O +
Statistical O +
analysis O +
All O +
values O +
are O +
expressed O +
as O +
means±S.E.M. O +
When O +
changes O +
in O +
left O +
ventricular O +
systolic O +
pressure O -
, O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O -
, O +
left O +
ventricular O +
developed O +
pressure O -
, O +
LDH B-Gene +
release O +
and O +
[ O -
Na+ O +
] O -
i O +
were O +
compared O +
between O +
vehicle O -
- O -
treated O +
and O +
drug O -
- O -
treated O +
groups O -
, O +
statistical O +
analysis O +
was O +
performed O +
with O +
a O +
two O -
- O -
way O +
repeated O +
measures O +
analysis O +
of O +
variance O +
( O -
ANOVA O -
) O +
followed O +
by O +
Dunnett O -
's O +
test O +
for O +
multiple O +
comparisons O -
. O +

If O +
a O +
significant O +
difference O +
was O +
obtained O +
between O +
these O +
groups O -
, O +
further O +
comparisons O +
at O +
each O +
time O +
point O +
were O +
performed O +
by O +
means O +
of O +
Dunnett O -
's O +
test O +
( O -
Fig. O +
1 O +
Figs. O +
3 O -
, O +
4 O +
and O +
6 O +
and O +
8 O +
) O -
. O +

When O +
the O +
tissue O +
levels O +
of O +
energy O +
metabolites O +
in O +
the O +
vehicle O +
group O +
were O +
compared O +
between O +
H2 O +
O2 O +
-untreated O +
and O +
H2 O +
O2 O +
-treated O +
hearts O -
, O +
unpaired O +
Student O -
's O +
t O +
-test O +
was O +
used O +
( O -
Fig. O +
2 O +
Fig. O +
5 O +
) O -
. O +

When O +
the O +
tissue O +
levels O +
of O +
energy O +
metabolites O +
and O +
the O +
H2 O +
O2 O +
concentration O +
were O +
compared O +
between O +
vehicle O -
- O -
treated O +
and O +
drug O -
- O -
treated O +
groups O -
, O +
statistical O +
analysis O +
was O +
performed O +
with O +
a O +
one O -
- O -
way O +
ANOVA O +
followed O +
by O +
Dunnett O -
's O +
test O +
for O +
multiple O +
comparisons O +
( O -
Figs. O +
2 O +
and O +
5 O +
, O +
Table O +
1 O +
) O -
. O +

A O +
difference O +
was O +
considered O +
statistically O +
significant O +
at O +
P O +
< O -
0.05 O -
. O +

3 O +
Results O +
3.1 O +
Effects O +
of O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
on O +
H2 O +
O2 O +
-induced O +
mechanical O +
derangements O +
in O +
the O +
heart O +
Fig. O +
1 O +
shows O +
the O +
effect O +
of O +
various O +
concentrations O +
of O +
l O +
-cis O +
-diltiazem O +
( O -
5 O -
, O +
10 O +
or O +
15 O +
μM O -
) O +
on O +
the O +
H2 O +
O2 O +
-induced O +
mechanical O +
dysfunction O -
. O +

Before O +
the O +
start O +
of O +
the O +
infusion O +
of O +
l O +
-cis O +
-diltiazem O +
( O -
0 O -
, O +
5 O +
and O +
10 O +
min O +
in O +
Fig. O +
1 O +
) O -
, O +
there O +
was O +
no O +
significant O +
difference O +
in O +
the O +
values O +
of O +
left O +
ventricular O +
systolic O +
pressure O +
and O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
between O +
the O +
vehicle O +
and O +
l O +
-cis O +
-diltiazem O +
groups O -
. O +

No O +
concentration O +
of O +
l O +
-cis O +
-diltiazem O +
( O -
5 O -
, O +
10 O +
or O +
15 O +
μM O -
) O +
had O +
a O +
significant O +
action O +
on O +
left O +
ventricular O +
systolic O +
pressure O +
and O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
before O +
H2 O +
O2 O +
infusion O +
( O -
20 O +
min O +
in O +
Fig. O +
1 O +
) O -
. O +

In O +
the O +
vehicle O +
group O -
, O +
H2 O +
O2 O +
produced O +
a O +
temporary O -
, O +
but O +
marked O +
decrease O +
in O +
left O +
ventricular O +
systolic O +
pressure O +
( O -
P O +
< O -
0.001 O +
by O +
ANOVA O -
) O -
, O +
which O +
was O +
followed O +
by O +
incomplete O +
recovery O +
to O +
the O +
initial O +
level O -
. O +

H2 O +
O2 O +
also O +
produced O +
a O +
marked O +
increase O +
in O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
( O -
P O +
< O -
0.001 O +
by O +
ANOVA O -
) O -
, O +
which O +
was O +
accompanied O +
by O +
an O +
increase O +
in O +
left O +
ventricular O +
systolic O +
pressure O -
. O +

The O +
decrease O +
in O +
left O +
ventricular O +
systolic O +
pressure O +
induced O +
by O +
H2 O +
O2 O +
was O +
not O +
significantly O +
modified O +
by O +
any O +
concentration O +
of O +
l O +
-cis O +
-diltiazem O +
( O -
P O +
= O -
0.616 O +
by O +
ANOVA O -
) O -
. O +

In O +
contrast O -
, O +
a O +
high O +
concentration O +
of O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
significantly O +
attenuated O +
the O +
H2 O +
O2 O +
-induced O +
increase O +
in O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
( O -
P O +
< O -
0.05 O +
by O +
ANOVA O +
followed O +
by O +
Dunnett O -
's O +
test O -
) O -
, O +
although O +
lower O +
concentrations O +
of O +
l O +
-cis O +
-diltiazem O +
( O -
5 O +
or O +
10 O +
μM O -
) O +
did O +
not O -
. O +

Fig. O +
2 O +
shows O +
the O +
effects O +
of O +
various O +
concentrations O +
of O +
l O +
-cis O +
-diltiazem O +
( O -
5 O -
, O +
10 O +
or O +
15 O +
μM O -
) O +
on O +
the O +
H2 O +
O2 O +
-induced O +
decrease O +
in O +
the O +
tissue O +
levels O +
of O +
high O -
- O -
energy O +
phosphates O -
. O +

In O +
the O +
vehicle O +
group O -
, O +
H2 O +
O2 O +
decreased O +
the O +
tissue O +
levels O +
of O +
ATP O -
, O +
ADP O +
and O +
creatine O +
phosphate O +
and O +
increased O +
the O +
tissue O +
level O +
of O +
AMP O +
( O -
P O +
< O -
0.05 O -
) O -
. O +

These O +
changes O +
in O +
the O +
tissue O +
levels O +
of O +
high O -
- O -
energy O +
phosphates O +
were O +
not O +
attenuated O +
by O +
lower O +
concentrations O +
of O +
l O +
-cis O +
-diltiazem O +
( O -
5 O +
or O +
10 O +
μM O -
) O -
. O +

However O -
, O +
a O +
high O +
concentration O +
of O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
significantly O +
attenuated O +
the O +
H2 O +
O2 O +
-induced O +
changes O +
in O +
the O +
tissue O +
levels O +
of O +
ATP O -
, O +
AMP O +
and O +
creatine O +
phosphate O +
( O -
P O +
< O -
0.05 O +
by O +
ANOVA O +
followed O +
by O +
Dunnett O -
's O +
test O -
) O -
. O +

These O +
results O +
suggest O +
that O +
at O +
the O +
concentration O +
of O +
15 O +
μM O -
, O +
l O +
-cis O +
-diltiazem O +
attenuates O +
the O +
H2 O +
O2 O +
-induced O +
mechanical O +
and O +
metabolic O +
derangements O +
in O +
the O +
heart O -
. O +

Next O -
, O +
the O +
effect O +
of O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
was O +
compared O +
with O +
that O +
of O +
d O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O -
. O +

Fig. O +
3 O +
shows O +
the O +
effects O +
of O +
d O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
and O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
on O +
the O +
H2 O +
O2 O +
-induced O +
changes O +
in O +
left O +
ventricular O +
systolic O +
pressure O +
and O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O -
. O +

Before O +
the O +
infusion O +
of O +
d O +
-cis O +
- O +
or O +
l O +
-cis O +
-diltiazem O +
( O -
0 O -
, O +
5 O +
and O +
10 O +
min O +
in O +
Fig. O +
3 O +
) O -
, O +
there O +
was O +
no O +
significant O +
difference O +
in O +
the O +
values O +
of O +
left O +
ventricular O +
systolic O +
pressure O +
and O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
among O +
vehicle O -
, O +
d O +
-cis O +
-diltiazem O +
and O +
l O +
-cis O +
-diltiazem O +
groups O -
. O +

Before O +
the O +
H2 O +
O2 O +
infusion O +
( O -
15 O +
and O +
20 O +
min O +
in O +
Fig. O +
3 O +
) O -
, O +
there O +
was O +
a O +
significant O +
decrease O +
in O +
the O +
left O +
ventricular O +
systolic O +
pressure O +
in O +
the O +
d O +
-cis O +
-diltiazem O +
group O +
( O -
P O +
< O -
0.05 O +
by O +
ANOVA O +
followed O +
by O +
Dunnett O -
's O +
test O -
) O -
, O +
while O +
there O +
was O +
no O +
decrease O +
in O +
the O +
l O +
-cis O +
-diltiazem O +
group O -
; O +
left O +
ventricular O +
systolic O +
pressure O +
decreased O +
only O +
in O +
the O +
d O +
-cis O +
-diltiazem O +
group O +
( O -
15–55 O +
min O +
in O +
Fig. O +
3 O +
) O -
. O +

As O +
seen O +
in O +
Fig. O +
1 O +
, O +
in O +
the O +
vehicle O +
group O +
H2 O +
O2 O +
decreased O +
left O +
ventricular O +
systolic O +
pressure O +
( O -
P O +
< O -
0.001 O +
by O +
ANOVA O -
) O +
and O +
increased O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
( O -
P O +
< O -
0.001 O +
by O +
ANOVA O -
) O -
. O +

It O +
is O +
noteworthy O -
, O +
however O -
, O +
that O +
both O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
attenuated O +
significantly O +
the O +
H2 O +
O2 O +
-induced O +
increase O +
in O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
( O -
P O +
< O -
0.05 O +
by O +
ANOVA O +
followed O +
by O +
Dunnett O -
's O +
test O -
) O -
. O +

Fig. O +
4 O +
shows O +
the O +
effects O +
of O +
d O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
and O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
on O +
the O +
H2 O +
O2 O +
-induced O +
decrease O +
in O +
left O +
ventricular O +
developed O +
pressure O -
, O +
which O +
is O +
expressed O +
as O +
left O +
ventricular O +
systolic O +
pressure O +
minus O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O -
. O +

Before O +
the O +
infusion O +
of O +
d O +
-cis O +
- O +
or O +
l O +
-cis O +
-diltiazem O +
( O -
0 O -
, O +
5 O +
and O +
10 O +
min O +
in O +
Fig. O +
4 O +
) O -
, O +
there O +
was O +
no O +
significant O +
difference O +
in O +
the O +
left O +
ventricular O +
developed O +
pressure O +
value O +
among O +
vehicle O -
, O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
groups O -
. O +

Before O +
the O +
H2 O +
O2 O +
infusion O +
( O -
15 O +
and O +
20 O +
min O +
in O +
Fig. O +
4 O +
) O -
, O +
there O +
was O +
a O +
significant O +
decrease O +
in O +
the O +
left O +
ventricular O +
developed O +
pressure O +
in O +
the O +
d O +
-cis O +
-diltiazem O +
group O +
( O -
P O +
< O -
0.05 O +
by O +
ANOVA O +
followed O +
by O +
Dunnett O -
's O +
test O -
) O -
, O +
while O +
there O +
was O +
no O +
decrease O +
in O +
the O +
l O +
-cis O +
-diltiazem O +
group O -
; O +
d O +
-cis O +
-diltiazem O +
alone O +
decreased O +
left O +
ventricular O +
developed O +
pressure O +
( O -
15–55 O +
min O +
in O +
Fig. O +
4 O +
) O -
. O +

In O +
the O +
vehicle O +
group O -
, O +
H2 O +
O2 O +
decreased O +
left O +
ventricular O +
developed O +
pressure O +
markedly O +
( O -
P O +
< O -
0.001 O +
by O +
ANOVA O -
) O -
. O +

l O +
-cis O +
-Diltiazem O +
attenuated O +
significantly O +
the O +
H2 O +
O2 O +
-induced O +
decrease O +
in O +
left O +
ventricular O +
developed O +
pressure O +
( O -
P O +
< O -
0.001 O +
by O +
ANOVA O +
followed O +
by O +
Dunnett O -
's O +
test O -
) O -
, O +
whereas O +
d O +
-cis O +
-diltiazem O +
did O +
not O +
attenuate O +
it O -
, O +
probably O +
because O +
of O +
its O +
cardiodepressive O +
action O -
. O +

Thus O -
, O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
attenuated O +
the O +
H2 O +
O2 O +
-induced O +
changes O +
in O +
both O +
left O +
ventricular O +
developed O +
pressure O +
and O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O -
. O +

Fig. O +
5 O +
shows O +
the O +
tissue O +
levels O +
of O +
ATP O -
, O +
ADP O -
, O +
AMP O +
and O +
creatine O +
phosphate O +
in O +
the O +
vehicle O -
, O +
d O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
and O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
groups O +
before O +
H2 O +
O2 O +
infusion O +
( O -
20 O +
min O +
in O +
Fig. O +
4 O +
) O +
and O +
after O +
the O +
H2 O +
O2 O +
infusion O +
( O -
55 O +
min O +
in O +
Fig. O +
4 O +
) O -
. O +

The O +
tissue O +
levels O +
of O +
ATP O -
, O +
ADP O -
, O +
AMP O +
and O +
creatine O +
phosphate O +
before O +
H2 O +
O2 O +
infusion O +
were O +
similar O +
among O +
the O +
vehicle O -
, O +
d O +
-cis O +
-diltiazem O +
and O +
l O +
-cis O +
-diltiazem O +
groups O +
( O -
P O +
> O -
0.05 O +
by O +
ANOVA O -
) O -
. O +

In O +
the O +
vehicle O +
group O -
, O +
H2 O +
O2 O +
decreased O +
the O +
tissue O +
levels O +
of O +
ATP O -
, O +
ADP O +
and O +
creatine O +
phosphate O -
, O +
and O +
increased O +
the O +
tissue O +
level O +
of O +
AMP O +
( O -
P O +
< O -
0.05 O -
) O -
. O +

These O +
changes O +
in O +
the O +
tissue O +
levels O +
of O +
energy O +
metabolites O +
induced O +
by O +
H2 O +
O2 O +
were O +
significantly O +
attenuated O +
by O +
d O +
-cis O +
-diltiazem O +
( O -
P O +
< O -
0.01 O +
by O +
ANOVA O +
followed O +
by O +
Dunnett O -
's O +
test O -
) O -
. O +

l O +
-cis O +
-Diltiazem O +
also O +
attenuated O +
the O +
H2 O +
O2 O +
-induced O +
changes O +
in O +
the O +
tissue O +
levels O +
of O +
ATP O -
, O +
AMP O +
and O +
creatine O +
phosphate O +
( O -
P O +
< O -
0.01 O +
by O +
ANOVA O +
followed O +
by O +
Dunnett O -
's O +
test O -
) O -
, O +
although O +
it O +
failed O +
to O +
attenuate O +
the O +
H2 O +
O2 O +
-induced O +
decrease O +
in O +
the O +
tissue O +
level O +
of O +
ADP O -
. O +

These O +
results O +
suggest O +
that O +
both O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
attenuate O +
the O +
H2 O +
O2 O +
-induced O +
decrease O +
in O +
high O -
- O -
energy O +
phosphates O +
in O +
the O +
heart O -
. O +

Fig. O +
6 O +
shows O +
the O +
effects O +
of O +
d O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
and O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
on O +
the O +
H2 O +
O2 O +
-induced O +
release O +
of O +
LDH B-Gene -
. O +

In O +
the O +
vehicle O -
, O +
d O +
-cis O +
-diltiazem O +
and O +
l O +
-cis O +
-diltiazem O +
groups O -
, O +
there O +
was O +
no O +
significant O +
difference O +
in O +
the O +
release O +
of O +
LDH B-Gene +
before O +
H2 O +
O2 O +
infusion O -
. O +

In O +
the O +
vehicle O +
group O -
, O +
H2 O +
O2 O +
produced O +
a O +
marked O +
release O +
of O +
LDH B-Gene +
from O +
the O +
myocardium O +
into O +
the O +
effluent O +
( O -
P O +
< O -
0.001 O +
by O +
ANOVA O -
) O -
; O +
the O +
LDH B-Gene +
release O +
reached O +
a O +
maximum O +
21.5 O +
min O +
after O +
the O +
end O +
of O +
H2 O +
O2 O +
infusion O +
( O -
35 O +
min O +
in O +
Fig. O +
6 O +
) O -
. O +

The O +
LDH B-Gene +
release O +
induced O +
by O +
H2 O +
O2 O +
was O +
significantly O +
attenuated O +
by O +
d O +
-cis O +
- O +
or O +
l O +
-cis O +
-diltiazem O +
( O -
P O +
< O -
0.05 O +
by O +
ANOVA O +
followed O +
by O +
Dunnett O -
's O +
test O -
) O -
. O +

These O +
results O +
suggest O +
that O +
both O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
attenuate O +
the O +
H2 O +
O2 O +
-induced O +
damage O +
of O +
the O +
cardiac O +
cell O +
membrane O -
. O +

3.2 O +
Effect O +
of O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
on O +
H2 O +
O2 O +
-induced O +
changes O +
in O +
[ O -
Na+ O +
] O -
i O +
Fig. O +
7 O +
shows O +
typical O +
23 O +
Na O +
spectra O +
for O +
the O +
rat O +
heart O +
in O +
the O +
presence O +
of O +
the O +
23 O +
Na O +
shift O +
reagent O +
Tm O -
( O -
DOTP O -
) O -
5− O +
. O +

H2 O +
O2 O +
( O -
1 O +
mM O -
) O +
was O +
added O +
to O +
the O +
heart O +
for O +
4 O +
min O +
( O -
from O +
15 O +
to O +
19 O +
min O +
in O +
Fig. O +
7 O +
) O -
. O +

It O +
is O +
evident O +
that O +
in O +
the O +
vehicle O +
group O -
, O +
H2 O +
O2 O +
caused O +
an O +
increase O +
in O +
the O +
peak O +
of O +
[ O -
Na+ O +
] O -
i O +
, O +
which O +
was O +
markedly O +
attenuated O +
by O +
d O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O -
, O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
or O +
tetrodotoxin O +
( O -
3 O +
μM O -
) O -
. O +

Fig. O +
8 O +
shows O +
the O +
effects O +
of O +
d O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O -
, O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
and O +
tetrodotoxin O +
( O -
3 O +
μM O -
) O +
on O +
the O +
H2 O +
O2 O +
-induced O +
increase O +
in O +
[ O -
Na+ O +
] O -
i O +
in O +
myocardial O +
cells O -
. O +

In O +
the O +
vehicle O +
group O -
, O +
H2 O +
O2 O +
( O -
1 O +
mM O -
) O +
increased O +
[ O -
Na+ O +
] O -
i O +
markedly O +
( O -
P O +
< O -
0.001 O +
by O +
ANOVA O -
) O +
and O +
the O +
increase O +
reached O +
a O +
maximum O +
20 O +
min O +
after O +
the O +
end O +
of O +
H2 O +
O2 O +
infusion O +
( O -
34 O +
min O +
in O +
Fig. O +
8 O +
) O -
. O +

The O +
increase O +
in O +
[ O -
Na+ O +
] O -
i O +
induced O +
by O +
H2 O +
O2 O +
was O +
almost O +
completely O +
inhibited O +
by O +
d O +
-cis O +
- O +
or O +
l O +
-cis O +
-diltiazem O +
( O -
P O +
< O -
0.05 O +
by O +
ANOVA O +
followed O +
by O +
Dunnett O -
's O +
test O -
) O -
. O +

Tetrodotoxin O +
also O +
attenuated O +
the O +
H2 O +
O2 O +
-induced O +
increase O +
in O +
[ O -
Na+ O +
] O -
i O +
( O -
P O +
< O -
0.05 O +
by O +
ANOVA O +
followed O +
by O +
Dunnett O -
's O +
test O -
) O -
. O +

These O +
results O +
suggest O +
that O +
both O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
attenuate O +
the O +
intracellular O +
accumulation O +
of O +
intracellular O +
Na+ O +
induced O +
by O +
H2 O +
O2 O +
. O +

In O +
the O +
second O +
series O +
of O +
experiments O -
, O +
we O +
also O +
continuously O +
recorded O +
the O +
mechanical O +
function O +
( O -
left O +
ventricular O +
pressure O -
) O +
of O +
the O +
heart O -
, O +
and O +
similar O +
results O +
as O +
in O +
the O +
first O +
series O +
of O +
experiments O +
( O -
Fig. O +
3 O +
) O +
were O +
obtained O -
: O +
H2 O +
O2 O +
decreased O +
left O +
ventricular O +
systolic O +
pressure O +
and O +
increased O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O -
, O +
and O +
the O +
H2 O +
O2 O +
-induced O +
increase O +
in O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
was O +
attenuated O +
by O +
d O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O -
, O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
or O +
tetrodotoxin O +
( O -
data O +
not O +
shown O -
) O -
. O +

If O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
have O +
a O +
Na+ B-Gene +
channel I-Gene +
blocking O +
action O -
, O +
[ O -
Na+ O +
] O -
i O +
in O +
normal O +
cardiac O +
cells O +
( O -
without O +
H2 O +
O2 O +
) O +
should O +
decrease O +
after O +
treatment O +
of O +
the O +
heart O +
with O +
d O +
-cis O +
- O +
or O +
l O +
-cis O +
-diltiazem O -
. O +

However O -
, O +
neither O +
tetrodotoxin O -
, O +
nor O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
changed O +
[ O -
Na+ O +
] O -
i O +
in O +
the O +
normal O +
cardiac O +
cells O -
: O +
[ O -
Na+ O +
] O -
i O +
remained O +
unchanged O +
within O +
the O +
accuracy O +
of O +
the O +
assay O -
. O +

3.3 O +
Effect O +
of O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
on O +
the O +
concentration O +
of O +
H2 O +
O2 O +
in O +
the O +
buffer O +
solution O +
in O +
vitro O +
We O +
examined O +
whether O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
have O +
a O +
direct O +
scavenging O +
effect O +
on O +
H2 O +
O2 O +
in O +
vitro O -
. O +

d O +
-cis O +
- O +
or O +
l O +
-cis O +
-Diltiazem O -
, O +
however O -
, O +
did O +
not O +
modify O +
the O +
H2 O +
O2 O +
concentration O +
in O +
the O +
buffer O +
solution O +
( O -
Table O +
1 O +
) O -
. O +

In O +
contrast O -
, O +
dimethylthiourea O -
, O +
which O +
has O +
a O +
H2 O +
O2 O +
-scavenging O +
action O -
, O +
decreased O +
the O +
H2 O +
O2 O +
concentration O +
markedly O -
. O +

These O +
results O +
suggest O +
that O +
neither O +
d O +
-cis O +
-diltiazem O +
nor O +
l O +
-cis O +
-diltiazem O +
has O +
a O +
direct O +
scavenging O +
action O +
on O +
H2 O +
O2 O +
in O +
vitro O -
. O +

4 O +
Discussion O +
In O +
the O +
present O +
study O -
, O +
we O +
examined O +
the O +
effect O +
of O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
on O +
the O +
H2 O +
O2 O +
-induced O +
myocardial O +
derangements O +
in O +
the O +
isolated O +
perfused O +
rat O +
heart O -
. O +

l O +
-cis O +
-Diltiazem O +
is O +
an O +
optical O +
isomer O +
of O +
d O +
-cis O +
-diltiazem O +
and O +
is O +
about O +
20–100 O +
times O +
less O +
potent O +
than O +
d O +
-cis O +
-diltiazem O +
in O +
its O +
Ca2 B-Gene -
+ I-Gene +
channel I-Gene +
blocking O +
action O +
( O -
Nasa O +
et O +
al. O -
, O +
1992 O +
; O +
Itogawa O +
et O +
al. O -
, O +
1996 O +
) O -
. O +

We O +
used O +
H2 O +
O2 O +
as O +
a O +
substance O +
that O +
may O +
be O +
responsible O +
for O +
ischemic O +
derangements O +
for O +
the O +
following O +
reasons O -
: O +
( O -
1 O -
) O +
H2 O +
O2 O +
and O +
its O +
metabolite O -
, O +
hydroxyl O +
radical O -
, O +
are O +
considered O +
important O +
in O +
the O +
pathogenesis O +
of O +
myocardial O +
damage O +
induced O +
by O +
ischemia O -
– O -
reperfusion O +
( O -
Brown O +
et O +
al. O -
, O +
1988 O +
; O +
Loesser O +
et O +
al. O -
, O +
1991 O +
) O -
; O +
( O -
2 O -
) O +
H2 O +
O2 O +
penetrates O +
the O +
cell O +
membrane O +
and O +
reaches O +
the O +
intracellular O +
site O +
( O -
Fisher O -
, O +
1988 O +
) O -
, O +
and O +
therefore O +
it O +
may O +
produce O +
severe O +
damage O +
to O +
the O +
cell O -
. O +

In O +
the O +
first O +
series O +
of O +
experiments O -
, O +
H2 O +
O2 O +
produced O +
an O +
increase O +
in O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
and O +
a O +
decrease O +
in O +
left O +
ventricular O +
developed O +
pressure O +
( O -
i.e. O -
, O +
mechanical O +
dysfunction O -
) O -
, O +
a O +
decrease O +
in O +
the O +
tissue O +
levels O +
of O +
ATP O +
and O +
creatine O +
phosphate O +
and O +
an O +
increase O +
in O +
the O +
tissue O +
AMP O +
level O +
( O -
i.e. O -
, O +
energy O +
deficiency O -
) O -
, O +
and O +
an O +
increase O +
in O +
LDH B-Gene +
release O +
from O +
the O +
myocardium O +
( O -
i.e. O -
, O +
membrane O +
damage O -
) O -
. O +

These O +
alterations O +
induced O +
by O +
H2 O +
O2 O +
were O +
attenuated O +
by O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O -
. O +

In O +
contrast O +
to O +
l O +
-cis O +
-diltiazem O -
, O +
d O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
failed O +
to O +
attenuate O +
the O +
decrease O +
in O +
left O +
ventricular O +
developed O +
pressure O +
induced O +
by O +
H2 O +
O2 O +
, O +
because O +
d O +
-cis O +
-diltiazem O +
has O +
a O +
potent O +
Ca2 B-Gene -
+ I-Gene +
channel I-Gene +
blocking O +
action O -
, O +
leading O +
to O +
a O +
decrease O +
in O +
mechanical O +
function O -
. O +

In O +
fact O -
, O +
the O +
cardiodepressive O +
action O +
of O +
d O +
-cis O +
-diltiazem O +
was O +
observed O +
before O +
H2 O +
O2 O +
infusion O -
. O +

These O +
results O +
suggest O +
that O +
both O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
protect O +
the O +
myocardium O +
against O +
the O +
H2 O +
O2 O +
-induced O +
derangements O -
, O +
and O +
that O +
their O +
cardioprotective O +
action O +
is O +
not O +
only O +
due O +
to O +
the O +
Ca2 B-Gene -
+ I-Gene +
channel I-Gene +
blocking O +
action O -
. O +

Some O +
radical O +
scavengers O +
or O +
anti O -
- O -
oxidants O +
have O +
been O +
demonstrated O +
to O +
protect O +
the O +
myocardium O +
against O +
oxidative O +
stress O +
( O -
Nakaya O +
et O +
al. O -
, O +
1987 O +
; O +
Weglicki O +
et O +
al. O -
, O +
1990 O +
; O +
Nagy O +
et O +
al. O -
, O +
1996 O +
) O -
. O +

In O +
fact O -
, O +
we O +
have O +
reported O +
that O -
, O +
in O +
the O +
isolated O +
perfused O +
rat O +
heart O -
, O +
catalase B-Gene +
( O -
a O +
H2 O +
O2 O +
scavenger O -
) O +
( O -
Hara O +
et O +
al. O -
, O +
1993 O +
) O +
or O +
propofol O +
( O -
an O +
intravenous O +
anesthetic O +
drug O +
with O +
an O +
anti O -
- O -
oxidant O +
action O -
) O +
( O -
Kokita O +
and O +
Hara O -
, O +
1996 O +
) O +
attenuates O +
the O +
H2 O +
O2 O +
-induced O +
mechanical O +
dysfunction O +
and O +
the O +
decrease O +
in O +
the O +
tissue O +
levels O +
of O +
high O -
- O -
energy O +
phosphates O -
. O +

There O +
is O +
evidence O +
to O +
show O +
that O +
d O +
-cis O +
-diltiazem O +
has O +
an O +
anti O -
- O -
oxidant O +
action O +
( O -
Janero O +
et O +
al. O -
, O +
1988 O +
; O +
Mak O +
and O +
Weglicki O -
, O +
1990 O +
; O +
Weglicki O +
et O +
al. O -
, O +
1990 O +
) O -
, O +
whereas O +
there O +
is O +
no O +
information O +
about O +
the O +
anti O -
- O -
oxidant O +
action O +
of O +
l O +
-cis O +
-diltiazem O -
. O +

The O +
concentration O +
of O +
d O +
-cis O +
-diltiazem O +
required O +
for O +
its O +
anti O -
- O -
oxidant O +
action O +
is O +
much O +
higher O +
than O +
that O +
used O +
in O +
the O +
present O +
study O -
; O +
in O +
the O +
sarcolemmal O +
membrane O -
, O +
the O +
concentration O +
required O +
to O +
inhibit O +
50 O -
% O +
of O +
lipid O +
peroxidation O +
( O -
IC50 O +
) O +
induced O +
by O +
oxygen O +
radicals O +
is O +
510 O +
μM O +
( O -
Janero O +
et O +
al. O -
, O +
1988 O +
) O +
or O +
850 O +
μM O +
( O -
Mak O +
and O +
Weglicki O -
, O +
1990 O +
) O -
. O +

In O +
the O +
present O +
study O -
, O +
neither O +
d O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
nor O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
modified O +
the O +
H2 O +
O2 O +
concentration O +
in O +
the O +
buffer O +
solution O +
in O +
vitro O -
. O +

It O +
is O +
unlikely O -
, O +
therefore O -
, O +
that O +
the O +
protective O +
effect O +
of O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
on O +
the O +
H2 O +
O2 O +
-induced O +
derangements O +
is O +
due O +
to O +
the O +
radical O +
scavenging O +
or O +
anti O -
- O -
oxidant O +
effect O -
. O +

According O +
to O +
recent O +
electrophysiological O +
studies O -
, O +
H2 O +
O2 O +
causes O +
an O +
increase O +
in O +
Na+ O +
current O +
in O +
ventricular O +
myocytes O -
, O +
an O +
increase O +
which O +
is O +
blocked O +
by O +
tetrodotoxin O +
( O -
Bhatnagar O +
et O +
al. O -
, O +
1990 O +
; O +
Ward O +
and O +
Giles O -
, O +
1997 O +
) O -
. O +

Ver O +
Donck O +
and O +
Borgers O +
( O -
1991 O -
) O +
have O +
suggested O +
that O +
the O +
reactive O +
oxygen O +
species O +
causes O +
excessive O +
Na+ O +
entry O +
through O +
the O +
fast O +
Na+ B-Gene +
channel I-Gene -
, I-Gene +
leading O +
to O +
intracellular O +
Ca2 O -
+ O +
overload O +
through O +
the O +
Na+ O +
–Ca2 O -
+ O +
exchange O +
system O -
, O +
and O +
hence O +
myocardial O +
damage O -
. O +

In O +
fact O -
, O +
H2 O +
O2 O +
increases O +
intracellular O +
concentrations O +
of O +
both O +
Na+ O +
and O +
Ca2 O -
+ O +
in O +
the O +
myocardium O +
( O -
Yanagida O +
et O +
al. O -
, O +
1995 O +
) O -
. O +

Interestingly O -
, O +
both O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
have O +
been O +
demonstrated O +
to O +
block O +
the O +
Na+ B-Gene +
channel I-Gene +
( O -
Nakajima O +
et O +
al. O -
, O +
1975 O +
; O +
Itogawa O +
et O +
al. O -
, O +
1996 O +
) O -
. O +

Itogawa O +
et O +
al. O +
( O -
1996 O -
) O +
reported O +
that O +
both O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
inhibited O +
the O +
veratridine O +
( O -
a O +
Na+ B-Gene +
channel I-Gene +
opener O -
) O -
-induced O +
increase O +
in O +
[ O -
Na+ O +
] O -
i O +
and O +
hypercontracture O +
in O +
rat O +
myocytes O +
at O +
the O +
concentration O +
of O +
10 O +
μM O +
or O +
higher O -
. O +

There O +
is O +
a O +
possibility O -
, O +
therefore O -
, O +
that O +
the O +
beneficial O +
effect O +
of O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
on O +
the O +
H2 O +
O2 O +
-induced O +
derangements O +
is O +
due O +
to O +
their O +
blocking O +
effect O +
on O +
the O +
Na+ B-Gene +
channel I-Gene -
. O +

To O +
determine O +
this O +
possibility O -
, O +
we O +
examined O +
the O +
effect O +
of O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
on O +
the O +
H2 O +
O2 O +
-induced O +
increase O +
in O +
[ O -
Na+ O +
] O -
i O +
in O +
the O +
myocardium O +
using O +
an O +
NMR O +
technique O +
( O -
the O +
second O +
series O +
of O +
experiments O -
) O -
. O +

We O +
used O +
a O +
higher O +
concentration O +
of O +
H2 O +
O2 O +
in O +
the O +
second O +
series O +
of O +
experiments O +
than O +
in O +
the O +
first O +
series O +
of O +
experiments O -
: O +
in O +
the O +
second O +
series O +
of O +
experiments O -
, O +
1 O +
mM O +
H2 O +
O2 O +
was O +
applied O +
for O +
4 O +
min O -
, O +
whereas O +
in O +
the O +
first O +
series O +
of O +
experiments O -
, O +
600 O +
μM O +
H2 O +
O2 O +
was O +
applied O +
for O +
3.5 O +
min O -
. O +

This O +
is O +
because O +
in O +
the O +
second O +
series O +
of O +
experiments O -
, O +
a O +
large O +
amount O +
of O +
H2 O +
O2 O +
was O +
needed O +
to O +
induce O +
mechanical O +
dysfunction O +
to O +
a O +
degree O +
similar O +
to O +
that O +
seen O +
in O +
the O +
first O +
series O +
of O +
experiments O -
. O +

The O +
decreased O +
response O +
of O +
the O +
heart O +
to O +
H2 O +
O2 O +
in O +
the O +
second O +
series O +
of O +
experiments O +
may O +
be O +
due O +
to O +
the O +
difference O +
in O +
perfusion O +
conditions O -
, O +
such O +
as O +
lower O +
Ca2 O -
+ O +
concentration O +
and O +
lower O +
temperature O -
, O +
which O +
are O +
determinants O +
of O +
cardioprotection O -
; O +
the O +
concentration O +
of O +
free O +
Ca2 O -
+ O +
( O -
1 O +
mM O -
) O +
in O +
the O +
Tm O -
( O -
DOTP O -
) O -
5− O +
-containing O +
KHB O +
buffer O +
used O +
in O +
the O +
second O +
series O +
of O +
experiments O +
was O +
lower O +
than O +
that O +
( O -
2.5 O +
mM O -
) O +
in O +
the O +
KHB O +
buffer O +
( O -
normal O +
KHB O +
buffer O -
) O +
used O +
in O +
the O +
first O +
series O +
of O +
experiments O -
, O +
and O +
the O +
temperature O +
around O +
the O +
NMR O +
tube O +
( O -
about O +
20 O -
° O -
C O -
) O +
used O +
in O +
the O +
second O +
series O +
of O +
experiments O +
was O +
lower O +
that O +
in O +
the O +
water O -
- O -
jacketed O +
chamber O +
( O -
37 O -
° O -
C O -
) O +
used O +
in O +
the O +
first O +
series O +
of O +
experiments O -
. O +

When O +
the O +
membrane O +
is O +
severely O +
damaged O -
, O +
intracellular O +
Na+ O +
resonance O +
collapses O +
and O +
a O +
broad O +
Na+ O +
resonance O +
appears O +
in O +
the O +
23 O +
Na O +
-NMR O +
spectra O +
because O +
of O +
entry O +
of O +
the O +
shift O +
reagent O +
into O +
the O +
cell O -
, O +
and O +
therefore O +
measurement O +
of O +
[ O -
Na+ O +
] O -
i O +
is O +
impossible O +
( O -
Jansen O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

As O +
shown O +
in O +
Fig. O +
7 O +
, O +
however O -
, O +
no O +
broad O +
Na+ O +
resonance O +
was O +
observed O -
, O +
suggesting O +
that O +
the O +
measurement O +
of O +
[ O -
Na+ O +
] O -
i O +
was O +
appropriate O +
in O +
the O +
present O +
study O -
. O +

The O +
results O +
of O +
the O +
second O +
series O +
of O +
experiments O +
indicate O +
that O +
both O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
attenuate O +
the O +
H2 O +
O2 O +
-induced O +
increase O +
in O +
[ O -
Na+ O +
] O -
i O +
in O +
the O +
heart O -
. O +

Tetrodotoxin O +
( O -
3 O +
μM O -
) O -
, O +
a O +
specific O +
inhibitor O +
of O +
Na+ B-Gene +
channels I-Gene +
( O -
Duff O +
et O +
al. O -
, O +
1988 O +
) O -
, O +
also O +
attenuated O +
the O +
H2 O +
O2 O +
-induced O +
increase O +
in O +
[ O -
Na+ O +
] O -
i O +
in O +
the O +
heart O +
and O +
the O +
H2 O +
O2 O +
-induced O +
myocardial O +
derangements O -
. O +

Therefore O -
, O +
the O +
protective O +
action O +
of O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
may O +
be O +
due O +
to O +
their O +
ability O +
to O +
inhibit O +
the O +
Na+ B-Gene +
channel I-Gene -
. O +

The O +
above O +
view O +
can O +
be O +
supported O +
by O +
our O +
previous O +
findings O +
that O +
tetrodotoxin O +
( O -
Hara O +
et O +
al. O -
, O +
1998 O +
) O -
, O +
lidocaine O +
( O -
Hara O +
et O +
al. O -
, O +
1993 O +
) O +
and O +
dilazep O +
( O -
Hara O +
and O +
Abiko O -
, O +
1996 O +
) O -
, O +
all O +
of O +
which O +
have O +
a O +
Na+ B-Gene +
channel I-Gene +
blocking O +
action O -
, O +
are O +
effective O +
in O +
attenuating O +
the O +
H2 O +
O2 O +
-induced O +
mechanical O +
dysfunction O +
and O +
decrease O +
in O +
the O +
tissue O +
levels O +
of O +
high O -
- O -
energy O +
phosphates O -
. O +

It O +
should O +
be O +
noted O -
, O +
however O -
, O +
that O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
attenuated O +
the O +
H2 O +
O2 O +
-induced O +
mechanical O +
and O +
metabolic O +
derangements O +
incompletely O -
, O +
even O +
when O +
they O +
attenuated O +
the O +
H2 O +
O2 O +
-induced O +
increase O +
in O +
[ O -
Na+ O +
] O -
i O +
completely O -
. O +

It O +
is O +
possible O +
therefore O +
that O +
the O +
harmful O +
action O +
of O +
H2 O +
O2 O +
on O +
the O +
heart O +
is O +
not O +
only O +
due O +
to O +
activation O +
of O +
the O +
fast B-Gene +
Na+ I-Gene +
channel I-Gene -
, O +
but O +
also O +
due O +
to O +
other O +
mechanisms O -
, O +
such O +
as O +
activation O +
of O +
nonselective O +
cation B-Gene +
channels I-Gene +
( O -
Jabr O +
and O +
Cole O -
, O +
1995 O +
) O +
and O +
inactivation O +
of O +
creatine B-Gene +
kinase I-Gene +
( O -
Banerjee O +
et O +
al. O -
, O +
1991 O +
) O -
. O +

According O +
to O +
Nasa O +
et O +
al. O +
( O -
1990 O -
) O +
, O +
d O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
and O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
are O +
capable O +
of O +
attenuating O +
the O +
myocardial O +
derangements O +
induced O +
by O +
ischemia O -
– O -
reperfusion O +
in O +
the O +
isolated O -
, O +
working O +
rat O +
heart O -
. O +

Therefore O -
, O +
the O +
beneficial O +
action O +
of O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
on O +
the O +
H2 O +
O2 O +
-induced O +
changes O +
may O +
contribute O +
to O +
their O +
protective O +
effect O +
on O +
the O +
myocardium O +
against O +
ischemia O -
– O -
reperfusion O +
damage O -
. O +

5 O +
Conclusion O +
Both O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
protect O +
the O +
myocardium O +
against O +
the O +
H2 O +
O2 O +
-induced O +
derangements O +
in O +
the O +
isolated O +
perfused O +
rat O +
heart O -
. O +

The O +
protective O +
action O +
of O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
may O +
be O +
due O +
to O +
inhibition O +
of O +
the O +
H2 O +
O2 O +
-induced O +
increase O +
in O +
[ O -
Na+ O +
] O -
i O +
, O +
at O +
least O +
in O +
part O -
. O +

Acknowledgements O +

We O +
thank O +
Mr. O +
Mitsutoshi O +
Kusakabe O +
for O +
his O +
help O +
in O +
experiments O +
with O +
NMR O +
technique O -
. O +

We O +
also O +
thank O +
Ms. O +
Min O +
Chen O +
for O +
her O +
valuable O +
help O +
during O +
experiments O -
, O +
Mr. O +
Tadahiko O +
Yokoyama O +
for O +
his O +
technical O +
assistance O -
, O +
and O +
Ms. O +
Miwa O +
Kashu O +
and O +
Ms. O +
Kaori O +
Inaba O +
for O +
their O +
secretarial O +
assistance O -
. O +

l O +
-cis O +
-Diltiazem O +
hydrochloride O +
was O +
kindly O +
supplied O +
by O +
Tanabe O +
Seiyaku O +
( O -
Osaka O -
, O +
Japan O -
) O -
. O +

Cordyceps O +
sinensis O +
( O -
Berk O -
. O -
) O +

Sacc O -
. O +

( O -
family O +
Clavicipitaceae O -
) O +
has O +
long O +
been O +
used O +
in O +
Chinese O +
medicine O +
to O +
treat O +
numerous O +
illnesses O -
, O +
promote O +
longevity O -
, O +
relieve O +
exhaustion O +
and O +
increase O +
athletic O +
prowess O +
( O -
Pegler O -
, O +
Yao O +
& O +
Li O -
, O +
1994 O -
; O +
Steinkraus O +
& O +
Whitfield O -
, O +
1994 O -
; O +
Jones O -
, O +
1993 O -
; O +
Tsunoo O -
, O +
Taketomo O -
, O +
Tsuboi O -
, O +
Kamijio O -
, O +
Nemoto O -
, O +
Sasaki O -
, O +
Uchida O -
, O +
Yamashita O -
, O +
Kinjo O +
& O +
Haung O -
, O +
1995 O +
) O -
. O +

The O +
medicinal O +
preparation O +
from O +
the O +
fruiting O +
bodies O +
of O +
C. O +
sinensis O +
is O +
named O +
dong O -
- O -
chong O -
- O -
xia O -
- O -
cao O +
which O +
translates O +
as O +
winter O +
worm O +
and O +
summer O +
grass O -
. O +

C. O +
sinensis O +
infects O +
the O +
larvae O +
of O +
the O +
sphinx O +
moth O -
, O +
Hepialus O +
armoricanus O +
, O +
found O +
only O +
in O +
the O +
highlands O +
of O +
the O +
Himalayan O +
region O -
, O +
and O +
the O +
larva O +
hibernates O +
underground O +
through O +
the O +
winter O -
. O +

The O +
fungus O +
kills O +
the O +
infected O +
host O +
and O +
grows O +
throughout O +
the O +
cadaver O -
, O +
and O +
in O +
the O +
summer O -
, O +
a O +
rod O -
- O -
like O +
stroma O +
of O +
the O +
fungus O +
grows O +
out O +
from O +
the O +
mummified O +
shell O +
of O +
the O +
dead O +
host O -
. O +

Cordyceps O +
species O +
are O +
generally O +
known O +
as O +
the O +
' O -
caterpillar O +
fungus O -
' O +
due O +
to O +
this O +
characteristic O +
parasitism O +
of O +
the O +
living O +
larvae O +
of O +
insects O +
( O -
Pegler O -
, O +
Yao O +
& O +
Li O -
, O +
1994 O -
; O +
Steinkraus O +
& O +
Whitfield O -
, O +
1994 O -
; O +
Jones O -
, O +
1993 O +
) O -
. O +

A O +
number O +
of O +
bioactive O +
constituents O +
from O +
Cordyceps O +
species O +
have O +
been O +
reported O -
. O +

These O +
include O -
: O +
cordycepin O +
( O -
Cunningham O -
, O +
Herchinson O -
, O +
Manson O +
& O +
Spring O -
, O +
1951 O -
; O +
Kredich O +
& O +
Guarino O -
, O +
1960 O +
) O +
and O +
other O +
antibacterial O +
and O +
antitumor O +
adenosine O +
derivatives O +
( O -
Furuya O -
, O +
Hirotani O +
& O +
Matsuzawa O -
, O +
1983 O +
) O -
, O +
ophicordin O -
, O +
an O +
antifungal O +
agent O +
( O -
Kneifel O -
, O +
Srinivasan O +
& O +
Maiti O -
, O +
1957 O +
) O -
, O +
a O +
polysaccharide O +
shown O +
to O +
have O +
antitumor O +
activity O +
( O -
Miyazaki O -
, O +
Oikawa O +
& O +
Yamada O -
, O +
1977 O -
; O +
Yamada O +
et O +
al. O -
, O +
1984 O -
; O +
Ohmori O -
, O +
Tamura O -
, O +
Tsuru O +
& O +
Nomoto O -
, O +
1986 O +
) O -
, O +
an O +
immunopotentiating O +
galactomannan O -
, O +
and O +
l O +
-tryptophan O +
( O -
Zhang O -
, O +
Zhang O -
, O +
Zhu O +
& O +
Chen O -
, O +
1991 O +
) O -
. O +

A O +
recent O +
report O +
indicated O +
that O +
the O +
fruiting O +
body O +
of O +
C. O +
sinensis O +
contained O +
growth O +
inhibitors O +
against O +
tumor O +
cells O +
( O -
K562 O -
, O +
Vero O -
, O +
Wish O -
, O +
Calu-1 O +
and O +
Raji O -
) O +
other O +
than O +
cordycepin O +
and O +
polysaccharides O +
( O -
Kuo O -
, O +
Ching O -
- O -
Yuang O +
Lin O -
, O +
Wei O -
- O -
Jern O +
Tsai O -
, O +
Wu O -
, O +
Chen O +
& O +
Shiao O -
, O +
1994 O +
) O -
. O +

We O +
report O +
herein O +
the O +
isolation O +
and O +
identification O +
of O +
two O +
antitumor O +
compounds O +
from O +
the O +
mycelia O +
of O +
C. O +
sinensis O +
. O +

Activity O +
guided O +
chemical O +
fractionations O +
of O +
the O +
methanol O +
extract O +
of O +
C. O +
sinensis O +
, O +
led O +
to O +
the O +
isolation O +
of O +
a O +
steroidal O +
glycoside O +
5α O +
, O -
8α O +
-epidioxy-24 O -
( O -
R O +
) O -
-methylcholesta-6,22-dien-3β O +
-d O +
-glucopyranoside O +
( O -
1a O +
) O +
and O +
5α O +
, O -
6α O +
-epoxy-24 O -
( O -
R O +
) O -
-methylcholesta-7,22-dien-3β O +
-ol O +
( O -
2 O +
) O -
. O +

Two O +
previously O +
identified O +
compounds O -
, O +
ergosteryl-3-O O +
-β O +
-d O +
-glucopyranoside O +
( O -
3 O +
) O +
and O +
22,23-dihydroergosteryl-3-O O +
-β O +
-d O +
-glucopyranoside O +
( O -
4 O +
) O +
were O +
also O +
isolated O +
during O +
the O +
fractionation O +
of O +
the O +
methanol O +
extract O +
( O -
Shiao O -
, O +
Lin O -
, O +
Lien O -
, O +
Tzean O +
& O +
Lee O -
, O +
1989 O +
) O -
. O +

These O +
ergosterol O +
derivatives O +
were O +
not O +
active O +
against O +
the O +
tumor O +
cell O +
lines O +
used O +
in O +
this O +
study O -
. O +

2 O +
Results O +
and O +
discussion O +
Compounds O +
3 O +
and O +
4 O +
were O +
identified O +
by O +
1 O +
H O +
NMR O +
spectroscopy O +
as O +
ergosteryl-3-O O +
-β O +
-d O +
-glucopyranoside O +
( O -
3 O +
) O +
and O +
22,23-dihydroergosteryl-3-O O +
-β O +
-d O +
-glucopyranoside O +
( O -
4 O +
) O +
previously O +
isolated O +
from O +
the O +
fruiting O +
body O +
of O +
C. O +
sinensis O +
( O -
Shiao O +
et O +
al. O -
, O +
1989 O +
) O -
. O +

Comparison O +
of O +
the O +
1 O +
H O +
NMR O +
spectra O +
of O +
1a O +
with O +
3 O +
and O +
4 O +
suggests O +
that O +
1a O +
was O +
also O +
a O +
glycoside O +
derivative O +
of O +
a O +
sterol O -
. O +

Compound O +
1a O +
was O +
found O +
to O +
have O +
a O +
[ O -
M+NH4 O +
] O -
+ O +
peak O +
from O +
CI O +
of O +
m O +
/z O +
= O -
608 O +
[ O -
C34 O +
H54 O +
O8 O +
+ O -
NH4 O +
] O -
+ O +
with O +
a O +
prominent O +
fragment O +
ion O +
peak O +
at O +
m O +
/z O +
412 O +
in O +
agreement O +
with O +
the O +
proposed O +
presence O +
of O +
a O +
sugar O +
moiety O +
( O -
C6 O +
H12 O +
O6 O +
) O -
. O +

The O +
observation O +
of O +
six O +
methyl O +
signals O +
in O +
the O +
1 O +
H O +
NMR O +
spectrum O +
of O +
1a O +
at O +
δ O +
0.69 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
7.0 O +
Hz O -
) O -
, O +
0.70 O +
( O -
3H O -
, O +
s O +
) O -
, O +
0.71 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.7 O +
Hz O -
) O -
, O +
0.76 O +
( O -
3H O -
, O +
s O +
) O -
, O +
0.79 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.8 O +
Hz O -
) O -
, O +
0.88 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.6 O +
Hz O -
) O +
indicates O +
that O +
the O +
sterol O +
fragment O +
of O +
1a O +
is O +
an O +
ergosterol O +
derivative O -
. O +

The O +
doublet O +
at O +
δ O +
4.2 O +
( O -
1H O -
, O +
d O -
, O +
J O +
= O -
7.8 O +
Hz O -
) O +
indicates O +
that O +
the O +
attachment O +
of O +
the O +
sugar O +
moiety O +
at O +
C3 O +
is O +
in O +
the O +
β O +
-configuration O +
( O -
Shiao O +
et O +
al. O -
, O +
1989 O -
; O +
Ahmed O -
, O +
Ahmed O +
& O +
Malik O -
, O +
1992 O -
; O +
Wasylyk O -
, O +
Martin O -
, O +
Weinheimer O +
& O +
Alam O -
, O +
1989 O +
) O -
, O +
similar O +
to O +
that O +
of O +
the O +
ergosteryl-3-O O +
-β O +
-d O +
-glucopyranoside O +
( O -
3 O +
) O +
and O +
22,23-dihydroergosteryl-3-O O +
-β O +
-d O +
-glucopyranoside O +
( O -
4 O +
) O +
( O -
Shiao O +
et O +
al. O -
, O +
1989 O +
) O -
. O +

The O +
observation O +
of O +
the O +
two O +
doublets O +
at O +
δ O +
6.39 O +
( O -
1H O -
, O +
d O -
, O +
J O +
= O -
8.5 O +
Hz O -
) O +
and O +
6.13 O +
( O -
1H O -
, O +
d O -
, O +
J O +
= O -
8.5 O +
Hz O -
) O -
, O +
approximately O +
1 O +
ppm O +
downfield O +
of O +
the O +
H6 O +
and O +
H7 O +
olefinic O +
protons O +
in O +
3 O +
and O +
4 O +
, O +
suggested O +
that O +
the O +
aglycone O +
of O +
1a O +
is O +
5α O +
, O -
8α O +
-epidioxy-24 O -
( O -
R O +
) O -
-methylcholesta-6,22-diene-3β O +
-ol O +
( O -
1b O +
) O -
. O +

The O +
close O +
comparison O +
of O +
the O +
13 O +
C O +
data O +
of O +
1a O +
with O +
1b O +
listed O +
in O +
Table O +
1 O +
agrees O +
with O +
this O +
proposal O -
. O +

The O +
identity O +
of O +
the O +
sugar O +
moiety O +
in O +
1a O +
was O +
not O +
conclusive O +
from O +
the O +
spectroscopic O +
data O -
. O +

However O +
comparison O +
of O +
the O +
1 O +
H O +
and O +
13 O +
C O +
NMR O +
spectra O +
of O +
1a O +
with O +
the O +
spectra O +
of O +
the O +
glucopyranosides O +
3 O +
and O +
4 O +
suggests O +
that O +
1a O +
is O +
also O +
a O +
glucopyranoside O -
. O +

The O +
synthesis O +
of O +
5α O +
, O -
8α O +
-epidioxy-24 O -
( O -
R O +
) O -
-methylcholesta-6,22-dien-3β O +
-d O +
-glucopyranoside O +
( O -
1a O +
) O +
from O +
ergosterol O +
( O -
6 O +
) O +
was O +
carried O +
out O +
as O +
shown O +
in O +
Scheme O +
1 O +
. O +

Deacetylation O +
of O +
5 O +
( O -
Cerný O -
, O +
Pouzar O -
, O +
Drasar O -
, O +
Budesinsky O +
& O +
Havel O -
, O +
1984 O +
) O +
followed O +
by O +
a O +
Diels O -
– O -
Alder O +
addition O +
of O +
singlet O +
O2 O +
( O -
1 O +
Δg O +
) O +
to O +
the O +
diene O +
in O +
ergosteryl-3-O O +
-β O +
-d O +
-glucopyranoside O +
( O -
3 O +
) O +
( O -
Gunatilaka O -
, O +
Gopichand O -
, O +
Schmitz O +
& O +
Djerassi O -
, O +
1981 O +
) O +
afforded O +
5α O +
, O -
8α O +
-epidioxy-24 O -
( O -
R O +
) O -
-methylcholesta-6,22-dien-3β O +
-d O +
-glucopyranoside O +
( O -
1a O +
) O -
. O +

Comparison O +
of O +
the O +
1 O +
H O +
and O +
13 O +
C O +
NMR O +
of O +
the O +
synthesized O +
molecule O +
both O +
confirmed O +
the O +
proposed O +
identity O +
of O +
the O +
sugar O +
moiety O +
and O +
the O +
stereochemistry O +
of O +
the O +
5α O +
, O -
8α O +
-epideoxy O +
functionality O +
in O +
the O +
isolated O +
compound O +
1a O +
. O +

5α O +
, O -
8α O +
-Epidioxy-24 O -
( O -
R O +
) O -
-methylcholesta-6,22-dien-3β O +
-d O +
-glucopyranoside O +
has O +
previously O +
been O +
isolated O +
from O +
a O +
variety O +
of O +
fungi O +
( O -
including O +
C. O +
sinensis O +
) O +
( O -
Xiao O -
, O +
Liu O +
& O +
Tu O -
, O +
1983 O -
; O +
Takaishi O -
, O +
Adachi O -
, O +
Murakami O -
, O +
Ohashi O -
, O +
Nakano O +
& O +
Tomimatsu O -
, O +
1992 O -
; O +
Tsantrizos O -
, O +
Folkins O -
, O +
Britten O -
, O +
Harpp O -
, O +
Ogilvie O -
, O +
1992 O +
) O -
, O +
lichens O +
( O -
Hirayama O -
, O +
Fujikawa O -
, O +
Yosioka O +
& O +
Kitagawa O -
, O +
1975 O -
; O +
Gonzalez O -
, O +
Barrera O -
, O +
Perez O +
& O +
Padron O -
, O +
1992 O +
) O -
, O +
and O +
marine O +
organisms O +
( O -
Gunatilaka O +
et O +
al. O -
, O +
1981 O -
; O +
Guyot O +
& O +
Durgeat O -
, O +
1981 O +
) O +
and O +
has O +
been O +
shown O +
to O +
have O +
both O +
antitumor O +
( O -
Kahlos O -
, O +
Kangas O +
& O +
Hiltunen O -
, O +
1989 O -
; O +
Kahlos O -
, O +
Hiltunen O +
& O +
Kangas O -
, O +
1989 O -
; O +
Matsueda O -
, O +
Shimoyama O -
, O +
Imaizumi O +
& O +
Tsushima O -
, O +
1982 O -
; O +
Cheng O -
, O +
Nagano O -
, O +
Bang O -
, O +
Ourrison O -
, O +
Beck O -
, O +
1977 O +
) O +
and O +
anti O -
- O -
inflammatory O +
( O -
Yasukawa O +
et O +
al. O -
, O +
1994 O -
, O +
1996 O +
) O +
activity O -
. O +

Formation O +
of O +
1b O +
was O +
shown O +
to O +
be O +
endogenous O +
in O +
fungi O +
and O +
not O +
an O +
artifact O +
of O +
the O +
isolation O +
procedure O +
( O -
Nes O -
, O +
Xu O +
& O +
Haddon O -
, O +
1989 O +
) O -
. O +

The O +
observation O +
of O +
six O +
methyl O +
signals O +
in O +
the O +
1 O +
H O +
NMR O +
spectrum O +
of O +
compound O +
2 O +
, O +
δ O +
0.49 O +
( O -
3H O -
, O +
s O +
) O -
, O +
0.71 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.5 O +
Hz O -
) O -
, O +
0.73 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.5 O +
Hz O -
) O -
, O +
0.81 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.8 O +
Hz O -
) O -
, O +
0.91 O -
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.6 O +
Hz O -
) O -
, O +
0.95 O +
( O -
3H O -
, O +
s O +
) O +
indicates O +
that O +
compound O +
2 O +
is O +
also O +
an O +
ergosterol O +
derivative O -
. O +

The O +
molecular O +
formula O +
for O +
compound O +
2 O +
was O +
determined O +
to O +
be O +
C28 O +
H44 O +
O2 O +
by O +
HRMS O +
( O -
M+ O +
= O -
421.3347 O -
) O -
. O +

The O +
additional O +
oxygen O +
in O +
the O +
molecular O +
formula O +
of O +
2 O +
in O +
comparison O +
to O +
the O +
molecular O +
formula O +
of O +
ergosterol O +
( O -
6 O +
) O +
( O -
C28 O +
H44 O +
O O -
) O +
and O +
the O +
observation O +
in O +
the O +
1 O +
H O +
NMR O +
of O +
a O +
signal O +
at O +
3.50 O +
ppm O +
combined O +
with O +
the O +
loss O +
of O +
an O +
olefinic O +
signal O +
indicates O +
that O +
one O +
of O +
the O +
5,7-diene O +
olefins O +
in O +
6 O +
has O +
been O +
oxidized O +
to O +
the O +
epoxide O -
. O +

The O +
observation O +
of O +
a O +
correlation O +
in O +
the O +
COSY O +
between O +
the O +
trisubstituted O +
epoxy O +
methine O +
signal O +
at O +
3.50 O +
ppm O +
and O +
the O +
olefin O +
methine O +
signal O +
at O +
5.20 O +
ppm O +
is O +
in O +
agreement O +
with O +
this O +
proposal O -
. O +

The O +
observation O +
of O +
cross O -
- O -
peaks O +
in O +
the O +
HMBC O +
between O +
the O +
signal O +
at O +
5.20 O +
ppm O +
with O +
the O +
13 O +
C O +
signals O +
corresponding O +
to O +
C5 O -
, O +
C9 O +
and O +
C14 O +
and O +
the O +
cross O +
peaks O +
for O +
the O +
signal O +
at O +
3.50 O +
ppm O +
with O +
the O +
13 O +
C O +
signals O +
corresponding O +
to O +
C5 O -
, O +
C7 O -
, O +
C8 O +
and O +
C10 O +
indicate O +
the O +
epoxide O +
is O +
in O +
the O +
5,6 O +
position O -
. O +

The O +
downfield O +
chemical O +
shift O +
of O +
the O +
3β O +
-hydroxy O +
methine O +
at O +
3.90 O +
ppm O +
is O +
consistent O +
with O +
the O +
α O +
stereochemistry O +
for O +
the O +
5 O -
, O +
6-epoxy O +
group O +
( O -
Aiello O -
, O +
Fattorusso O -
, O +
Magno O -
, O +
Mayol O +
& O +
Menna O -
, O +
1990 O -
; O +
Isaacs O -
, O +
Berman O +
& O +
Kashman O -
, O +
1991 O -
; O +
Venkateswarlu O -
, O +
Reddy O +
& O +
Rao O -
, O +
1996 O +
) O -
. O +

5α O +
, O +
6α O +
-Epoxy O +
sterols O +
similar O +
to O +
compound O +
2 O +
are O +
unknown O -
. O +

A O +
small O +
number O +
of O +
5α O +
, O +
6α O +
-epoxy O +
sterols O +
have O +
been O +
isolated O +
from O +
marine O +
sponges O +
and O +
corals O +
( O -
Aiello O +
et O +
al. O -
, O +
1990 O -
; O +
Isaacs O -
, O +
Berman O +
& O +
Kashman O -
, O +
1991 O -
; O +
Venkateswarlu O -
, O +
Reddy O +
& O +
Rao O -
, O +
1996 O -
; O +
Kobayashi O +
& O +
Kanda O -
, O +
1991 O +
) O +
and O +
have O +
been O +
shown O +
to O +
have O +
cytotoxic O +
activities O -
. O +

Growth O +
inhibition O +
due O +
to O +
compounds O +
1a O +
, O +
1b O +
, O -
and O +
3 O +
of O +
the O +
malignant O +
cell O +
lines O +
K562 O +
( O -
erythroleukemia O -
) O -
, O +
Jurkat O +
( O -
T O -
- O -
lymphoblastic O -
) O -
, O +
HL-60 O +
( O -
promyelocytic O +
leukemia O -
) O -
, O +
WM1341 O +
( O -
malignant O +
melanoma O -
) O +
and O +
RPMI O +
8226 O +
( O -
multiple O +
myeloma O -
) O +
from O +
the O +
American O +
Tissue O +
Type O +
Collection O +
( O -
ATCC O -
) O +
Rockville O -
, O +
MD O -
, O +
were O +
studied O +
to O +
compare O +
their O +
antitumor O +
activity O -
. O +

The O +
percent O +
inhibition O +
of O +
the O +
proliferation O +
of O +
these O +
five O +
malignant O +
cells O +
lines O +
determined O +
from O +
3 O +
H O -
- O -
thymidine O +
incorporation O +
assays O +
are O +
shown O +
in O +
Fig. O +
1 O -
( O -
a O -
– O -
d O -
) O +
for O +
200 O -
, O +
100 O +
and O +
10 O +
μg O -
/ O -
ml O +
concentrations O +
of O +
compounds O +
3 O +
, O +
1b O +
, O +
and O +
1a O +
. O +

Compound O +
3 O +
which O +
does O +
not O +
contain O +
the O +
5 O -
, O +
8-epoxy O +
functionality O +
showed O +
little O +
to O +
no O +
significant O +
inhibition O +
of O +
proliferation O +
of O +
the O +
tumor O +
cells O -
. O +

Some O +
inhibition O +
of O +
Jurkat O +
and O +
RPMI O +
8226 O +
was O +
detected O +
at O +
200 O +
μg O -
/ O -
ml O -
, O +
the O +
highest O +
concentration O +
in O +
this O +
study O -
. O +

As O +
clearly O +
shown O +
on O +
the O +
graphs O -
, O +
at O +
the O +
lower O +
concentration O -
, O +
the O +
glycoside O +
1a O +
was O +
found O +
to O +
inhibit O +
proliferation O +
of O +
all O +
five O +
malignant O +
cell O +
lines O +
to O +
a O +
greater O +
extent O +
( O -
10–40 O -
% O -
) O +
than O +
the O +
aglycone O +
1b O +
as O +
a O +
control O -
. O +

3 O +
Experimental O +
3.1 O +
General O +
IR O +
spectra O +
were O +
acquired O +
with O +
a O +
Bomen O +
FT O -
- O -
IR O +
Michaelson-100 O +
spectrophotometer O -
. O +

The O +
spectra O +
were O +
obtained O +
either O +
in O +
CHCl3 O +
solution O +
using O +
a O +
0.2 O +
mm O +
thick O +
NaCl O +
cell O -
, O +
or O +
as O +
a O +
solid O +
in O +
KBr O -
, O +
and O +
processed O +
using O +
the O +
Bomen O +
Spectra O +
Calc O +
program O -
. O +

LRMS O +
and O +
HRMS O +
were O +
obtained O +
on O +
a O +
Kratos O -
- O -
AEI O +
model O +
MS-50 O +
spectrometer O -
. O +

All O +
spectra O +
were O +
obtained O +
at O +
an O +
ionization O +
energy O +
of O +
70 O +
eV. O +
1 O +
H O +
NMR O +
spectra O +
were O +
obtained O +
on O +
a O +
Bruker O +
WH-400 O +
spectrometer O -
. O +

13 O +
C O +
and O +
APT O +
were O +
obtained O +
on O +
a O +
Bruker O +
AC-200 O +
spectrometer O -
. O +

HMBC O -
, O +
and O +
HMQC O +
spectra O +
were O +
obtained O +
on O +
a O +
Bruker O +
AMX-500 O +
spectrometer O -
. O +

Silica O +
gel O +
( O -
Art O +
60 O -
, O +
230–400 O +
mesh O -
) O +
for O +
column O +
chromatography O +
( O -
CC O -
) O +
and O +
silica O +
gel O +
( O -
Kieselgel O +
60 O +
F254 O +
) O +
coated O +
on O +
aluminum O +
plates O +
for O +
thin O +
layer O +
chromatography O +
were O +
supplied O +
by O +
Merck O -
. O +

3.2 O +
Fungal O +
material O +

The O +
mycelial O +
sample O +
of O +
C. O +
sinensis O +
was O +
obtained O +
from O +
North O +
American O +
Reishi O -
, O +
Box O +
1780 O -
, O +
Gibsons O -
, O +
British O +
Columbia O -
, O +
Canada O -
, O +
V0N O +
1V0 O -
. O +

3.3 O +
Malignant O +
cell O +
inhibition O +
studies O +
3 O +
H O -
- O -
Thymidine O +
incorporation O +
assays O +
were O +
carried O +
out O +
to O +
determine O +
inhibitory O +
effects O -
. O +

K562 O +
( O -
erythroleukemia O -
) O -
, O +
Jurkat O +
( O -
T O -
- O -
lymphoblastic O -
) O -
, O +
HL-60 O +
( O -
promyelocytic O +
leukemia O -
) O -
, O +
WM1341 O +
( O -
malignant O +
melanoma O -
) O +
and O +
RPMI O +
8226 O +
( O -
multiple O +
myeloma O -
) O +
malignant O +
cell O +
lines O +
were O +
obtained O +
from O +
the O +
American O +
Tissue O +
Type O +
Collection O +
( O -
ATCC O -
) O -
, O +
Rockville O -
, O +
MD O -
. O +

The O +
cell O +
lines O +
were O +
maintained O +
in O +
a O +
medium O +
consisting O +
of O +
RPMI O +
1640 O -
/ O -
FCS O +
10 O -
% O +
at O +
37 O -
° O -
C O +
in O +
an O +
atmosphere O +
of O +
5 O -
% O +
CO2 O +
. O +

Malignant O +
cell O +
lines,106 O +
cells O -
/ O -
ml O +
in O +
96-well O +
round O +
bottom O +
plates O +
( O -
Costar O -
) O -
, O +
were O +
cultured O +
with O +
various O +
concentrations O +
of O +
C. O +
sinensis O +
extracts O +
in O +
a O +
5 O -
% O +
CO2 O +
-air O +
humidified O +
atmosphere O +
at O +
37 O -
° O -
C O -
. O +

After O +
16 O +
h O +
of O +
co O -
- O -
culture O -
, O +
3 O +
H O -
- O -
thymidine O +
( O -
1 O +
MCi O -
/ O -
well O -
, O +
Dupont O -
, O +
Montreal O -
) O +
was O +
added O +
to O +
each O +
well O -
. O +

3 O +
H O -
- O -
Thymidine O +
uptake O +
was O +
measured O +
after O +
6 O +
hours O +
of O +
incubation O +
using O +
a O +
scintillation O +
counter O -
. O +

The O +
inhibitory O +
effect O +
of O +
each O +
extract O +
on O +
tumor O +
cell O +
proliferation O +
was O +
calculated O +
using O +
Eq. O +
1 O +
. O -
( O -
1 O -
) O +

Inhibition O +
percent O +
( O -
% O -
) O +
= O -
Control O +
group O +
( O -
cpm O -
) O -
−Experimental O +
group O +
( O -
cpm O -
) O +
Control O +
group O +
( O -
cpm O -
) O +
×100 O +
3.4 O +
Activity O +
guided O +
fractionation O +
of O +
fungal O +
material O +
The O +
dry O +
mycelium O +
of O +
C. O +
sinensis O +
( O -
150 O +
g O -
) O +
was O +
extracted O +
with O +
MeOH O +
three O +
times O +
( O -
500 O +
ml O -
× O -
3 O -
) O -
. O +

The O +
MeOH O +
extracts O +
were O +
combined O +
and O +
the O +
solvent O +
was O +
removed O +
under O +
reduced O +
pressure O -
. O +

The O +
crude O +
MeOH O +
extract O +
was O +
found O +
to O +
inhibit O +
K562 O +
proliferation O +
by O +
36 O -
% O +
at O +
500 O +
μg O -
/ O -
ml O -
, O +
in O +
the O +
3 O +
H O -
- O -
thymidine O +
incorporation O +
assay O -
. O +

The O +
residue O +
was O +
then O +
redissolved O +
in O +
MeOH O -
/ O -
H2 O +
O O +
( O -
1:1 O -
) O +
and O +
washed O +
with O +
hexanes O -
. O +

Methanol O +
was O +
distilled O +
from O +
the O +
aqueous O +
layer O +
under O +
reduced O +
pressure O -
. O +

The O +
remaining O +
aqueous O +
layer O +
was O +
extracted O +
with O +
EtOAc O -
. O +

Concentration O +
of O +
the O +
combined O +
EtOAc O +
extracts O +
under O +
reduced O +
pressure O +
provided O +
1.57 O +
g O +
of O +
a O +
brown O +
oil O +
( O -
B1 O -
) O -
. O +

This O +
residue O +
was O +
chromatographed O +
on O +
a O +
silica O +
gel O -
- O -
flash O +
column O +
( O -
230–400 O +
mesh O -
, O +
50 O -
× O -
8.0 O +
cm O -
) O -
. O +

The O +
elution O +
was O +
started O +
with O +
CHCl3 O +
and O +
the O +
polarity O +
of O +
solvents O +
was O +
increased O +
stepwise O +
in O +
the O +
following O +
sequence O -
: O +
CHCl3 O +
, O +
CHCl3 O +
/MeOH O +
( O -
8:2 O -
) O -
, O +
CHCl3 O +
/MeOH O +
( O -
5:5 O -
) O -
, O +
CHCl3 O +
/MeOH O +
( O -
2:8 O -
) O +
and O +
MeOH O -
. O +

Fourteen O +
fractions O +
( O -
FA1–FA14 O -
) O +
were O +
collected O +
and O +
dried O +
in O +
vacuo O -
. O +

Only O +
one O +
fraction O +
( O -
FA8 O -
) O +
was O +
found O +
have O +
antitumor O +
activity O -
. O +

Fraction O +
FA8 O +
was O +
further O +
chromatographed O +
on O +
a O +
silicagel O +
flash O -
- O -
column O +
eluted O +
with O +
CHCl3 O +
/MeOH O +
( O -
8:2 O -
) O +
to O +
afford O +
two O +
fractions O +
FB1 O +
and O +
FB2 O +
having O +
an O +
Rf O +
= O -
6.3 O +
and O +
5.4 O -
, O +
respectively O -
. O +

FB1 O +
was O +
a O +
white O +
solid O +
( O -
38 O +
mg O -
) O -
. O +

Recrystallization O +
of O +
FB1 O +
in O +
CHCl3 O +
afforded O +
10 O +
mg O +
of O +
2 O +
as O +
a O +
white O +
powder O -
. O +

Compound O +
2 O +
was O +
found O +
to O +
have O +
61 O -
% O +
antitumor O +
activity O +
against O +
Jurkat O +
cells O +
and O +
36.3 O -
% O +
activity O +
against O +
K562 O +
cells O +
at O +
100 O +
μg O -
/ O -
ml O -
. O +

Fraction O +
FB2 O +
was O +
found O +
to O +
have O +
96 O -
% O +
activity O +
against O +
Jurkat O +
cells O +
and O +
77 O -
% O +
activity O +
against O +
K562 O +
cancer O +
cells O +
at O +
100 O +
μg O -
/ O -
ml O -
. O +

FB2 O +
was O +
further O +
separated O +
by O +
silica O +
gel O +
chromatography O +
eluted O +
with O +
Et2 O +
O O -
: O -
hexanes O -
: O -
MeOH=5:5:1 O +
to O +
afford O +
two O +
fractions O +
FC1 O +
( O -
Rf O +
= O -
6.3 O -
) O +
and O +
3 O +
mg O +
of O +
compound O +
1a O +
( O -
Rf O +
= O -
5.4 O -
) O +
as O +
a O +
white O +
solid O -
. O +

FC1 O +
was O +
further O +
separated O +
by O +
HPLC O +
to O +
give O +
3 O +
and O +
4 O +
. O +

3.4.1 O +
5α O +
, O -
6α O +
-Epoxy-24 O -
( O -
R O +
) O -
-methylcholesta-7,22-dien-3β O +

-ol O +
( O -
2 O +
) O -
. O +

IR O +
( O -
cm−1 O +
, O +
CHCl3 O +
): O +
4685 O -
- O -
3110 O +
( O -
hydroxyl O -
) O -
, O +
2950 O -
, O +
2880 O -
, O +
1673 O -
, O +
1462 O -
; O +
1 O +
H O +
NMR O +
( O -
500 O +
MHz O -
, O +
CDCl3 O +
) O +
δ O +
: O +
0.49 O +
( O -
3H O -
, O +
s O +
, O +
Me-18 O -
) O -
, O +
0.72 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.5 O -
, O +
Me-26 O +
or O +
27 O -
) O -
, O +
0.73 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.5 O -
, O +
Me-26 O +
or O +
27 O -
) O -
, O +
1.2 O +
( O -
2H O -
, O +
m O +
, O +
H17 O -
, O +
H16 O -
) O -
, O +
1.32 O +
( O -
1H O -
, O +
m O +
, O +
H2 O -
) O -
, O +
1.36 O +
( O -
1H O -
, O +
m O +
, O +
H25 O -
) O -
, O +
1.44–1.48 O +
( O -
4H O -
, O +
m O +
, O +
H11 O -
, O +
H11′ O -
, O +
H15 O -
, O +
H1 O -
) O -
, O +
1.58 O +
( O -
1H O -
, O +
m O +
, O +
H12 O -
) O -
, O +
1.64 O +
( O -
1H O -
, O +
m O +
, O +
H16′ O -
) O -
, O +
1.72 O +
( O -
1H O -
, O +
m O +
, O +
H2′ O -
) O -
, O +
1.75 O +
( O -
1H O -
, O +
m O +
, O +
H24 O -
) O -
, O +
1.81 O +
( O -
1H O -
, O +
m O +
, O +
H14 O -
) O -
, O +
1.85 O +
( O -
1H O -
, O +
m O +
, O +
H9 O -
) O -
, O +
1.94 O +
( O -
1H O -
, O +
m O +
, O +
H20 O -
) O -
, O +
1.95 O +
( O -
1H O -
, O +
m O +
, O +
H4 O -
) O -
, O +
3.5 O +
( O -
1H O -
, O +
d O -
, O +
J O +
= O -
5.1 O -
, O +
H-6 O -
) O -
, O +
3.9 O -
( O -
1H O -
, O +
m O +
, O +
H-3 O -
) O -
, O +
5.09 O -
( O -
1H O -
, O +
m O +
, O +
H-22 O -
) O -
, O +
5.11 O +
( O -
1H O -
, O +
m O +
, O +
H-23 O -
) O -
, O +
5.2 O +
( O -
1H O -
, O +
m O +
, O +
H-7 O -
) O -
; O +
13 O +
C O +
NMR O +
( O -
50 O +
MHz O -
, O +
CDCl3 O +
) O +
listed O +
in O +
Table O +
2 O +
; O +
LRMS O +
( O -
EI O -
) O +
m O +
/z O +
( O -
rel O -
. O +

int O -
. O +

% O -
): O +
413 O -
[ O -
M+1 O -
] O -
+ O +
, O +
396 O -
[ O -
M−16 O -
] O -
+ O +
; O +
HRMS O +
( O -
EI O -
) O -
: O +
Calculated O +
for O +
C28 O +
H44 O +
O2 O +
: O +
412.33414 O -
; O +
found O -
: O +
412.33477 O -
. O +

3.4.2 O +
5α O +
, O -
8α O +
-epidioxy-24 O -
( O -
R O +
) O -
-methylcholesta-6,22-dien-3β O +
-d O +
-glucopyranoside O +
( O -
1a O +
) O +
IR O +
( O -
cm−1 O +
, O +
CHCl3 O +
): O +
3580–3055 O +
( O -
hydroxyl O -
) O -
, O +
2950 O -
, O +
2873 O -
, O +
1681 O -
, O +
1458 O -
, O +
1371 O -
; O +
[ O -
α O +
] O -
D O +
( O -
25 O -
° O -
C O -
) O -
: O +
−15.6 O -
° O -
; O +
1 O +
H O +
NMR O +
( O -
500 O +
MHz O -
, O +
CDCl3 O +
) O +
δ O +
: O +
0.70 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.7 O -
, O +
Me-26 O +
or O +
Me-27 O -
) O -
, O +
0.71 O +
( O -
3H O -
, O +
s O +
, O +
Me-18 O -
) O -
, O +
0.72 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.7 O -
, O +
Me-26 O +
or O +
Me-27 O -
) O -
, O +
0.79 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.8 O +
Hz O -
, O +
Me-28 O -
) O -
, O +
0.76 O +
( O -
3H O -
, O +
s O +
, O +
Me-19 O -
) O -
, O +
0.88 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.6 O +
Hz O -
, O +
Me-21 O -
) O -
, O +
1.0–2.0 O +
( O -
19H O -
, O +
m O +
) O -
, O +
2.1 O +
( O -
1H O -
, O +
m O +
) O -
, O +
3.1–3.2 O +
( O -
2H O -
, O +
m O +
, O +
H-2′ O -
, O +
H-3′ O -
) O -
, O +
3.2–3.4 O +
( O -
2H O -
, O +
m O +
, O +
H-4′ O -
, O +
H-5′ O -
) O -
, O +
3.5 O +
( O -
1H O -
, O +
m O +
, O +
H-6a′ O -
) O -
, O +
3.60 O +
( O -
1H O -
, O +
m O +
, O +
H6b′ O -
) O -
, O +
3.85 O +
( O -
1H O -
, O +
m O +
, O +
H-3 O -
) O -
; O +
4.23 O +
( O -
1H O -
, O +
d O -
, O +
J O +
= O -
7.8 O +
Hz O -
, O +
H-1′ O -
) O -
, O +
5.05 O +
( O -
1H O -
, O +
m O +
, O +
H-22 O -
) O -
, O +
5.09 O +
( O -
1H O -
, O +
m O +
, O +
H-23 O -
) O -
, O +
6.13 O +
( O -
1H O -
, O +
d O -
, O +
J O +
= O -
8.5 O +
Hz O -
, O +
H-7 O -
) O -
, O +
6.39 O +
( O -
1H O -
, O +
d O -
, O +
J O +
= O -
8.5 O +
Hz O -
, O +
H-6 O -
) O -
; O +
13 O +
C O +
NMR O +
( O -
50 O +
MHz O -
, O +
CDCl3 O +
): O +
Table O +
2 O +
; O +
LRMS O +
( O -
CIMS O -
) O +
m O +
/z O +
( O -
rel O -
. O +

int O -
. O -
) O -
: O +
608 O -
[ O -
M+NH4 O +
] O -
+ O +
, O +
593 O -
[ O -
M+2 O -
] O -
+ O +
, O +
590 O -
[ O -
M O -
] O -
+ O +
, O +
412 O -
[ O -
M−178 O -
] O -
+ O +
; O +
HRMS O +
( O -
DCIMS O -
) O -
: O +
Calculated O +
for O +
C34 O +
H54 O +
O8 O +
+ O -
NH+ O +
4 O +
: O +
608.41624 O -
; O +
found O -
: O +
608.41572 O -
. O +

3.5 O +
Synthesis O +
of O +
1a O +
from O +
ergosterol O +
( O -
6 O +
) O +
All O +
reactions O +
were O +
carried O +
out O +
under O +
nitrogen O +
atmosphere O +
in O +
flame O -
- O -
dried O +
glassware O +
unless O +
otherwise O +
stated O -
. O +

3.5.1 O +
2,3,4,6-Tetra O -
- O -
O O +
-acetyl-3-O O -
- O -
β O +
-d O +
-glucopyranosyl O -
- O -
ergosta-6,22-dien-5α O +
, O +
8α O +
-epidioxy-3β O +
-ol O +
( O -
5 O +
) O +
To O +
a O +
stirring O +
solution O +
of O +
2,3,4,6-tetra O -
- O -
O O +
-acetyl O -
- O -
α O +
-d O +
-glucosyl O +
trichloroacetimidate O +
( O -
0.172 O +
g O -
, O +
0.4 O +
mmol O -
) O +
in O +
10 O +
ml O +
dry O +
CH2 O +
Cl2 O +
was O +
added O +
4 O +
Å O +
molecular O +
sieves O +
( O -
1 O +
g O -
) O +
followed O +
by O +
ergosterol O +
( O -
6 O +
) O +
( O -
0.2 O +
g O -
, O +
0.5 O +
mmol O -
) O +
as O +
a O +
solid O +
powder O -
. O +

The O +
solution O +
was O +
cooled O +
to O +
0 O -
° O -
C O +
prior O +
to O +
the O +
dropwise O +
addition O +
of O +
BF3 O +
.Et2 O +

O O +
( O -
0.4 O +
ml O +
of O +
stock O +
30 O +
μl O +
in O +
2.5 O +
ml O +
CH2 O +
Cl2 O +
) O -
. O +

Upon O +
the O +
addition O +
of O +
BF3 O +
.Et2 O +

O O +
the O +
solution O +
turned O +
pink O -
, O +
then O +
quickly O +
returned O +
to O +
a O +
clear O +
colourless O +
solution O -
. O +

After O +
10 O +
min O +
the O +
solution O +
was O +
allowed O +
to O +
warm O +
slowly O +
to O +
room O +
temperature O -
. O +

The O +
reaction O +
was O +
quenched O +
with O +
the O +
addition O +
of O +
Et3 O +
N O +
( O -
60 O +
μl O -
) O +
after O +
40 O +
min O -
. O +

The O +
clear O +
solution O +
was O +
diluted O +
with O +
CH2 O +
Cl2 O +
, O +
filtered O +
to O +
remove O +
the O +
molecular O +
sieves O +
and O +
washed O +
twice O +
with O +
H2 O +
O. O +
The O +
organic O +
layer O +
was O +
concentrated O +
under O +
reduced O +
pressure O -
. O +

Column O +
chromatography O +
eluted O +
with O +
5 O -
% O +
MeOH O +
in O +
CHCl3 O +
afforded O +
5 O +
( O -
0.0466 O -
, O +
mmol O -
) O +
in O +
16 O +
% O +
yield O +
( O -
Rf O +
= O -
0.78 O -
, O +
15 O +
% O +
MeOH O +
in O +
CHCl3 O +
) O +
followed O +
by O +
unreacted O +
starting O +
material O +
( O -
0.1192 O +
g O -
, O +
300 O +
mmol O -
) O +
( O -
Rf O +
= O -
0.66 O -
, O +
15 O +
% O +
MeOH O +
in O +
CHCl3 O +
) O -
. O +

1 O +
H O +
NMR O +
( O -
400 O +
MHz O -
, O +
CDCl3 O +
) O +
δ O +
: O +
0.59 O +
( O -
3H O -
, O +
s O +
, O +
Me-18 O -
) O -
, O +
0.79 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.7 O -
, O +
Me-26 O +
or O +
27 O -
) O -
, O +
0.80 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.7 O -
, O +
Me-26 O +
or O +
27 O -
) O -
, O +
0.86 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.9 O -
, O +
Me-28 O -
) O -
, O +
0.88 O +
( O -
3H O -
, O +
s O +
, O +
Me-19 O -
) O -
, O +
1.00 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.5 O -
, O +
Me-21 O -
) O -
, O +
1.7–2.0 O +
( O -
18H O -
, O +
m O +
) O +
1.98 O +
( O -
3H O -
, O +
s O +
) O -
, O +
1.99 O +
( O -
3H O -
, O +
s O +
) O -
, O +
2.01 O +
( O -
3H O -
, O +
s O +
) O -
, O +
2.03 O +
( O -
3H O -
, O +
s O +
) O -
, O +
2.21 O +
( O -
1H O -
, O +
m O +
) O -
, O +
2.40 O -
( O -
1H O -
, O +
m O +
) O -
, O +
3.56 O +
( O -
1H O -
, O +
m O +
, O +
H-3 O -
) O -
, O +
3.66 O +
( O -
1H O -
, O +
m O +
) O -
, O +
4.10 O +
( O -
1H O -
, O +
m O +
) O -
, O +
4.24 O +
( O -
1H O -
, O +
m O +
) O -
, O +
4.60 O +
( O -
1H O -
, O +
d O -
, O +
J O +
= O -
7.7 O -
, O +
H-1′ O -
) O -
, O +
4.94 O +
( O -
1H O -
, O +
m O +
) O -
, O +
5.04 O +
( O -
1H O -
, O +
m O +
) O -
, O +
5.18 O +
( O -
3H O -
, O +
m O +
, O +
H-22 O -
, O +
H-23 O -
) O -
, O +
5.36 O +
( O -
1H O -
, O +
m O +
, O +
H-7 O -
) O -
, O +
5.55 O +
( O -
1H O -
, O +
m O +
, O +
H-6 O -
) O -
; O +
13 O +
C O +
NMR O +
( O -
50 O +
MHz O -
, O +
CDCl3 O +
) O +
12.0 O -
, O +
16.1 O -
, O +
17.6 O -
, O +
19.2 O -
, O +
19.6 O -
, O +
19.6 O -
, O +
19.9 O -
, O +
20.5 O -
, O +
20.6 O -
, O +
20.7 O -
, O +
21.0 O -
, O +
22.9 O -
, O +
28.2 O -
, O +
29.7 O -
, O +
33.0 O -
, O +
33.0 O -
, O +
37.1 O -
, O +
37.4 O -
, O +
38.2 O -
, O +
39.0 O -
, O +
40.3 O -
, O +
42.8 O -
, O +
46.1 O -
, O +
54.5 O -
, O +
55.7 O -
, O +
62.0 O -
, O +
68.5 O -
, O +
71.4 O -
, O +
71.7 O -
, O +
72.8 O -
, O +
78.6 O -
, O +
99.5 O -
, O +
116.1 O -
, O +
119.9 O -
, O +
131.9 O -
, O +
135.4 O -
, O +
139.0 O -
, O +
141.6 O -
, O +
169.2 O -
, O +
169.3 O -
, O +
170.3 O -
, O +
170.6 O -
. O +

3.5.2 O +
Ergosteryl-3-O O +
-β O +
-d O +
-glucopyranoside O +
( O -
3 O +
) O +
To O +
a O +
stirring O +
solution O +
of O +
5 O +
( O -
0.0564 O +
g O -
, O +
0.078 O +
mmol O -
) O +
in O +
20 O +
ml O +
MeOH O +
was O +
added O +
3 O +
ml O +
Et3 O +
N O +
and O +
0.5 O +
ml O +
H2 O +
O. O +
After O +
stirring O +
for O +
48 O +
h O +
the O +
solvent O +
was O +
removed O +
under O +
reduced O +
pressure O -
. O +

The O +
residue O +
was O +
applied O +
to O +
a O +
silica O +
gel O +
column O -
, O +
and O +
eluted O +
with O +
15 O -
% O +
MeOH O +
in O +
CHCl3 O +
( O -
Rf O +
= O -
20.6 O -
) O +
to O +
afford O +
a O +
white O +
solid O -
. O +

Recrystallization O +
from O +
MeOH O +
provided O +
3 O +
( O -
0.0351 O +
g O -
, O +
0.063 O +
mmol O -
) O +
in O +
81 O -
% O +
yield O +
as O +
small O +
white O +
needles O -
. O +

IR O +
( O -
cm−1 O +
, O -
CHCl3 O +
): O +
3400 O -
, O +
2950 O -
, O +
2875 O -
, O +
1681 O -
, O +
1458 O -
, O +
1371 O -
; O +
1 O +
H O +
NMR O +
( O -
400 O +
MHz O -
, O +
DMSO O -
) O +
δ O +
: O +
0.58 O +
( O -
3H O -
, O +
s O +
, O +
Me-18 O -
) O -
, O +
0.79 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.7 O -
, O +
Me-26 O +
or O +
-27 O -
) O -
, O +
0.80 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.7 O -
, O +
Me-26 O +
or O +
-27 O -
) O -
, O +
0.86 O +
( O -
3H O -
, O +
s O +
, O +
Me-19 O -
) O -
, O +
0.88 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.9 O -
, O +
Me-28 O -
) O -
, O +
1.00 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.5 O -
, O +
Me-21 O -
) O -
, O +
1.24 O +
( O -
2H O -
, O +
m O +
) O +
1.45 O +
( O -
1H O -
, O +
m O +
) O -
, O +
1.6 O +
( O -
1H O -
, O +
m O +
) O +
1.68 O +
( O -
1H O -
, O +
m O +
) O -
, O +
1.85 O +
( O -
2H O -
, O +
m O +
) O -
, O +
2.0 O +
( O -
1H O -
, O +
m O +
) O -
, O +
2.18 O +
( O -
1H O -
, O +
m O +
) O -
, O +
2.54 O +
( O -
1H O -
, O +
m O +
) O -
, O +
2.98 O +
( O -
1H O -
, O +
m O +
) O -
, O +
3.13 O +
( O -
1H O -
, O +
m O +
) O -
, O +
3.14 O +
( O -
1H O -
, O +
m O +
) O -
, O +
3.3 O +
( O -
1H O -
, O +
bs O -
) O -
, O +
3.46 O +
( O -
2H O -
, O +
m O +
) O -
, O +
3.61 O +
( O -
1H O -
, O +
m O +
) O -
, O +
4.24 O +
( O -
1H O -
, O +
d O -
, O +
J O +
= O -
7.7 O +
Hz O -
, O +
H-1′ O -
) O -
, O +
5.20 O -
( O -
2H O -
, O +
m O +
, O +
H-22 O -
, O +
H-23 O -
) O -
, O +
5.34 O +
( O -
1H O -
, O +
m O +
, O +
H-7 O -
) O -
, O +
5.52 O +
( O -
1H O -
, O +
m O +
, O +
H-6 O -
) O -
; O +
13 O +
C O +
NMR O +
( O -
50 O +
MHz O -
, O +
CDCl3 O +
, O -
): O +
Table O +
2 O +
. O +

3.5.3 O +
5α O +
, O -
8α O +
-Epidioxy-24 O -
( O -
R O +
) O -
-methylcholesta-6,22-dien-3β O +
-d O +
-glucopyranoside O +
( O -
1a O +
) O +
To O +
a O +
solution O +
of O +
3 O +
( O -
0.0211 O +
g O -
, O +
0.038 O +
mmol O -
) O +
in O +
20 O +
ml O +
dry O +
EtOH O +
was O +
added O +
2 O +
drops O +
of O +
a O +
10 O -
% O +
solution O +
of O +
eosin O +
in O +
EtOH O -
. O +

Oxygen O +
was O +
bubbled O +
through O +
the O +
solution O -
. O +

The O +
reaction O +
vessel O +
was O +
then O +
placed O +
in O +
a O +
silver O +
dewa O +
and O +
irradiated O +
with O +
a O +
500 O +
W O +
tungsten O +
lamp O -
. O +

Water O +
was O +
circulated O +
into O +
the O +
dewar O +
to O +
maintain O +
room O +
temperature O +
for O +
the O +
reaction O -
. O +

After O +
3 O +
h O +
the O +
solution O +
was O +
concentrated O +
under O +
reduced O +
pressure O -
, O +
with O +
the O +
resulting O +
residue O +
applied O +
to O +
a O +
silica O +
gel O +
column O +
what O +
we O +
eluted O +
with O +
15 O -
% O +
MeOH O +
in O +
CHCl3 O +
to O +
afford O +
1a O +
( O -
0.0138 O +
g O -
, O +
0.023 O +
mmol O -
) O +
in O +
62 O -
% O +
yield O +
as O +
a O +
white O +
solid O -
. O +

IR,1 O +
H,13 O +
C O +
and O +
LRMS O +
were O +
identical O +
to O +
spectra O +
of O +
1a O +
isolated O +
from O +
the O +
mycelia O +
of O +
C. O +
sinensis O +
. O +

3.5.4 O +
Synthesis O +
of O +
5α O +
, O -
8α O +
-epidioxy-24 O -
( O -
R O +
) O -
-methylcholesta-6,22-dien-3β O +
-ol O +
( O -
1b O +
) O +
( O -
ergosterol O +
peroxide O -
) O +
from O +
ergosterol O +
( O -
6 O +
) O +
Following O +
the O +
same O +
procedure O +
as O +
used O +
for O +
the O +
preparation O +
of O +
1a O +
from O +
3 O +
, O +
ergosterol O +
( O -
6 O +
) O +
( O -
0.1040 O +
g O +
, O +
0.26 O +
mmol O -
) O +
was O +
oxidized O -
, O +
then O +
purified O +
by O +
silica O +
gel O +
column O +
eluted O +
with O +
15 O -
% O +
EtOAc O +
in O +
CH2 O +
Cl2 O +
to O +
afford O +
1b O +
( O -
0.0932 O +
g O -
, O +
0.22 O +
mmol O -
) O +
in O +
85 O -
% O +
yield O +
as O +
a O +
white O +
solid O -
. O +

1 O +
H O +
NMR O +
( O -
500 O +
MHz O -
, O +
CDCl3 O +
) O +
0.61 O -
( O -
3H O -
, O +
s O +
, O +
Me-18 O -
) O -
, O +
0.67 O +
( O -
3H O -
, O +
s O +
, O +
Me-19 O -
) O -
, O +
0.907 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.67 O +
Hz O -
, O +
Me-26 O +
or O +
27 O -
) O -
, O +
0.913 O -
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.71 O +
Hz O -
, O +
Me-26 O +
or O +
-27 O -
) O -
, O +
0.99 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.78 O +
Hz O -
, O +
Me-28 O -
) O -
, O +
1.00 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.49 O -
, O +
Me-21 O -
) O -
, O +
1.1–2.0 O +
( O -
20H O -
, O +
m O +
) O -
, O +
3.92 O +
( O -
m O -
, O +
1H O -
, O +
H-3 O -
) O -
, O +
5.14 O +
( O -
1H O -
, O +
m O +
, O +
H-23 O -
) O -
, O +
5.25 O +
( O -
1H O -
, O +
m O +
, O +
H-22 O -
) O -
, O +
5.95 O +
( O -
1H O -
, O +
d O -
, O +
J O +
= O -
8.37 O +
Hz O -
, O +
H-6 O -
) O -
, O +
6.29 O +
( O -
1H O -
, O +
d O -
, O +
J O +
= O -
8.47 O +
Hz O -
, O +
H-7 O -
) O -
; O +
13 O +
C O +
NMR O +
( O -
50 O +
MHz O -
, O +
CDCl3 O +
): O +
Table O +
2 O +
. O +

Acknowledgements O +
This O +
work O +
was O +
supported O +
by O +
North O +
American O +
Reishi O +
Inc. O -
, O +
British O +
Columbia O -
. O +

We O +
also O +
thank O +
Dr O +
S. O +
G. O +
Withers O +
for O +
providing O +
2,3,4,6-tetra O -
- O -
O O +
-acetyl O -
- O -
α O +
-d O +
-glucosyltrichloroacetimidate O -
. O +

The O +
biosynthesis O +
of O +
the O +
vitamin O +
biotin O -
, O +
a O +
cofactor O +
in O +
biological O +
carboxylation O +
reactions O -
, O +
occurs O +
in O +
micro O -
- O -
organisms O +
and O +
plants O +
and O +
involves O +
at O +
least O +
four O +
different O +
enzymes B-Gene +
( O -
Eisenberg O -
, O +
1973 O -
; O +
Gloeckler O +
et O +
al O +
. O -
, O +
1990 O -
; O +
Baldet O +
et O +
al O +
. O -
, O +
1993 O -
) O +
. O +

Because O +
biotin O +
synthesis O +
is O +
unique O +
to O +
plants O +
and O +
microorganisms O -
, O +
enzymes B-Gene +
of O +
this O +
pathway O +
are O +
potential O +
targets O +
for O +
the O +
development O +
of O +
antimicrobial O +
drugs O +
and O +
herbicides O +
( O -
Rendina O +
et O +
al O +
. O -
, O +
1999 O -
) O +
. O +

One O +
of O +
these O +
enzymes B-Gene +
is O +
7,8-diaminopelargonic B-Gene +
acid I-Gene +
synthase I-Gene +
( O -
DAPA B-Gene +
synthase I-Gene -
) O -
, O +
an O +
aminotransferase B-Gene +
that O +
catalyses O +
the O +
antepenultimate O +
step O +
in O +
this O +
pathway O -
: O +
the O +
conversion O +
of O +
7-keto-8-aminopelargonic O +
acid O +
( O -
KAPA O -
) O +
to O +
7,8-diaminopelargonic O +
acid O +
( O -
DAPA O -
) O +
( O -
Figure O +
1 O -
) O +
( O -
Stoner O +
& O +
Eisenberg O -
, O +
1975a O -
) O +
. O +

DAPA B-Gene +
synthase I-Gene +
from O +
Escherichia O +
coli O +
is O +
a O +
homodimer O +
with O +
a O +
molecular O +
mass O +
of O +
94 O +
kDa O +
( O -
Stoner O +
& O +
Eisenberg O +
1975a O -
) O +
and O +
contains O +
429 O +
residues O +
per O +
monomer O +
( O -
Otsuka O +
et O +
al O +
. O -
, O +
1988 O -
) O +
. O +

It O +
is O +
unique O +
among O +
aminotransferases B-Gene +
in O +
that O +
it O +
uses O +
S O +
-adenosyl O -
- O -
l O +
-methionine O +
( O -
SAM O -
) O +
as O +
amino O +
group O +
donor O +
( O -
Stoner O +
& O +
Eisenberg O -
, O +
1975a O -
) O +
. O +

DAPA B-Gene +
synthase I-Gene +
uses O +
pyridoxal-5′-phosphate O +
( O -
PLP O -
) O +
as O +
cofactor O +
and O +
hence O +
belongs O +
to O +
the O +
family O +
of O +
vitamin O +
B6 O +
-dependent O +
aminotransferases B-Gene +
( O -
Stoner O +
& O +
Eisenberg O -
, O +
1975a O -
) O +
. O +

In O +
general O +
terms O -
, O +
the O +
mechanism O +
of O +
vitamin O +
B6 O +
-dependent O +
enzymes B-Gene +
is O +
rather O +
well O +
understood O +
( O -
John O -
, O +
1995 O -
; O +
Hayashi O -
, O +
1995 O -
) O +
and O +
it O +
is O +
expected O +
that O +
DAPA B-Gene +
synthase I-Gene +
follows O +
the O +
established O +
overall O +
scheme O +
of O +
PLP O +
catalysis O +
( O -
Figure O +
2 O -
) O +
. O +

PLP O +
binds O +
covalently O +
to O +
the O +
active O +
site O +
lysine O +
residue O +
through O +
a O +
Schiff O +
base O +
linkage O +
( O -
the O +
internal O +
aldimine O -
) O -
. O +

Upon O +
binding O +
of O +
SAM O -
, O +
the O +
substrate O +
for O +
the O +
first O +
part O +
of O +
the O +
catalytic O +
cycle O -
, O +
an O +
external O +
aldimine O +
is O +
formed O +
between O +
the O +
substrate O +
and O +
the O +
cofactor O +
through O +
a O +
transaldimination O +
process O -
. O +

The O +
reaction O +
proceeds O +
through O +
deprotonation O +
of O +
the O +
former O +
Cα O +
carbon O +
of O +
the O +
substrate O -
, O +
leading O +
to O +
the O +
quinonoid O +
intermediate O +
followed O +
by O +
protonation O +
of O +
the O +
C-4′ O +
carbon O -
. O +

It O +
has O +
been O +
shown O +
for O +
aspartate B-Gene +
aminotransferase I-Gene +
that O +
the O +
lysine O +
residue O +
previously O +
covalently O +
bound O +
to O +
the O +
cofactor O +
acts O +
as O +
proton O +
acceptor O +
and O +
donor O +
in O +
these O +
steps O +
( O -
Gehring O -
, O +
1984 O -
; O +
Julin O +
et O +
al O +
. O -
, O +
1989 O -
) O +
. O +

Hydrolysis O +
of O +
the O +
resulting O +
ketimine O +
intermediate O +
gives O +
the O +
keto O +
acid O +
of O +
the O +
first O +
substrate O +
SAM O +
and O +
pyridoxamine O +
phosphate O +
bound O +
to O +
the O +
enzyme B-Gene +
by O +
non O -
- O -
covalent O +
bonds O -
. O +

The O +
second O +
half O +
of O +
the O +
catalytic O +
cycle O +
is O +
in O +
principle O +
a O +
reversal O +
of O +
the O +
first O +
steps O -
. O +

KAPA O -
, O +
the O +
second O +
substrate O -
, O +
binds O +
and O +
receives O +
the O +
amino O +
group O +
from O +
pyridoxamine O +
phosphate O +
as O +
the O +
PLP B-Gene -
- I-Gene -
enzyme I-Gene +
complex I-Gene +
is O +
regenerated O -
. O +

Thus O -
, O +
both O +
substrates O +
have O +
to O +
be O +
accommodated O +
in O +
the O +
same O +
active O +
site O -
, O +
despite O +
differences O +
in O +
size O +
and O +
chemical O +
properties O -
. O +

Although O +
KAPA O +
bears O +
an O +
amino O +
group O -
, O +
DAPA B-Gene +
synthase I-Gene +
uses O +
KAPA O +
only O +
as O +
an O +
amino O +
group O +
acceptor O -
, O +
not O +
as O +
an O +
amino O +
group O +
donor O -
, O +
i.e. O +
KAPA O +
is O +
not O +
transaminated O +
by O +
DAPA B-Gene +
synthase I-Gene +
( O -
Stoner O +
& O +
Eisenberg O -
, O +
1975b O -
) O +
. O +

The O +
three O -
- O -
dimensional O +
structures O +
of O +
more O +
than O +
20 O +
different O +
PLP O -
- O -
dependent O +
enzymes B-Gene +
have O +
been O +
determined O +
( O -
for O +
a O +
recent O +
review O -
, O +
see O +
Jansonius O +
1998 O +
) O -
. O +

Christen O +
and O +
co O -
- O -
workers O +
organised O +
PLP O -
- O -
dependent O +
enzymes B-Gene +
into O +
three O +
different O +
families O -
, O +
α O -
, O +
β O +
and O +
γ O -
, O +
based O +
on O +
the O +
chemical O +
characteristics O +
of O +
the O +
catalysed O +
reaction O +
and O +
attempted O +
to O +
correlate O +
these O +
with O +
amino O +
acid O +
sequence O +
families O +
( O -
Alexander O +
et O +
al O +
. O -
, O +
1994 O -
) O +
. O +

The O +
aminotransferases B-Gene +
belong O +
to O +
the O +
α B-Gene -
- I-Gene -
family I-Gene -
, O +
which O +
hosts O +
enzymes B-Gene +
acting O +
on O +
the O +
carbon O +
atom O +
adjacent O +
to O +
the O +
amino O +
group O +
of O +
the O +
substrate O -
. O +

Another O +
classification O +
based O +
on O +
fold O +
types O +
and O +
sequence O +
comparisons O +
was O +
introduced O +
by O +
Grishin O +
et O +
al. O +
( O -
1995 O -
) O +
. O +

So O +
far O -
, O +
five O +
different O +
folds O +
that O +
can O +
bind O +
PLP O +
have O +
been O +
observed O +
and O +
it O +
has O +
been O +
proposed O +
on O +
the O +
basis O +
of O +
sequence O +
analysis O +
that O +
additional O +
hitherto O +
unknown O +
PLP O -
- O -
binding O +
folds O +
might O +
exist O +
( O -
Grishin O +
et O +
al O +
. O -
, O +
1995 O -
) O +
. O +

Most O +
aminotransferases O +
of O +
known O +
structure O +
belong O +
to O +
fold O +
type O +
I O -
, O +
first O +
described O +
for O +
aspartate O +
aminotransferase O +
( O -
Ford O +
et O +
al O +
. O -
, O +
1980 O -
) O +
. O +

This O +
structural O +
family O +
is O +
characterised O +
by O +
a O +
large O +
domain O +
folded O +
into O +
a O +
central O +
β O -
- O -
sheet O -
, O +
with O +
surrounding O +
loops O +
and O +
helices O +
forming O +
most O +
of O +
the O +
PLP O +
binding O +
site O +
and O +
a O +
smaller O +
domain O +
partly O +
involved O +
in O +
substrate O +
binding O -
. O +

Exceptions O +
are O +
d O +
-amino O +
acid O +
aminotransferase O +
( O -
Sugio O +
et O +
al O +
. O -
, O +
1995 O -
) O +
and O +
branched O +
chain O +
aminotransferase O +
( O -
Okada O +
et O +
al O +
. O -
, O +
1997 O -
) O +
, O +
which O +
fold O +
in O +
a O +
completely O +
different O +
manner O -
. O +

Sequence O +
analysis O +
suggested O +
that O +
DAPA B-Gene +
synthase I-Gene +
may O +
belong O +
to O +
the O +
aminotransferase B-Gene +
subclass I-Gene +
III I-Gene +
of O +
the O +
PLP O +
fold O +
type O +
I O +
family O +
( O -
Metha O +
et O +
al O +
. O -
, O +
1993 O -
) O +
, O +
which O +
includes O +
a O +
number O +
of O +
enzymes B-Gene +
of O +
known O +
structure O -
: O +
ω B-Gene -
- I-Gene -
aminotransferase I-Gene +
( O -
Watanabe O +
et O +
al O +
. O -
, O +
1989 O -
) O +
, O +
ornithine B-Gene +
aminotransferase I-Gene +
( O -
Shah O +
et O +
al O +
. O -
, O +
1997 O -
, O +
Shen O +
et O +
al O +
. O -
, O +
1998 O -
) O +
, O +
2,2-dialkylglycine B-Gene +
decarboxylase I-Gene +
( O -
Toney O +
et O +
al O +
. O -
, O +
1993 O -
, O +
1995 O -
) O +
and O +
glutamate B-Gene +
semialdehyde I-Gene +
aminomutase I-Gene +
( O -
Hennig O +
et O +
al O +
. O -
, O +
1997 O -
) O +
. O +

Here O +
we O +
report O +
the O +
three O -
- O -
dimensional O +
structure O +
of O +
DAPA B-Gene +
synthase I-Gene +
from O +
E. O +
coli O +
at O +
1.8 O +
Å O +
resolution O -
. O +

The O +
structure O +
analysis O +
reveals O +
that O +
this O +
enzyme B-Gene +
indeed O +
is O +
a O +
member O +
of O +
the O +
aspartate B-Gene +
aminotransferase I-Gene +
family O +
of O +
vitamin O +
B6 O +
-dependent O +
enzymes B-Gene -
. O +

A O +
multiple O +
structure O +
alignment O +
suggests O +
that O +
at O +
least O +
six O +
subclasses O -
, O +
which O +
are O +
structurally O +
and O +
evolutionary O +
closely O +
related O -
, O +
exist O +
in O +
this O +
family O -
. O +

Furthermore O -
, O +
the O +
structure O +
of O +
a O +
ternary O +
complex O +
of O +
DAPA B-Gene +
synthase I-Gene +
with O +
the O +
substrate O +
KAPA O -
, O +
bound O +
to O +
the O +
PLP O +
form O +
of O +
the O +
enzyme B-Gene -
, O +
is O +
presented O -
. O +

This O +
structure O +
forms O +
the O +
basis O +
for O +
mechanistic O +
considerations O -
, O +
in O +
particular O +
with O +
respect O +
to O +
substrate O +
recognition O -
. O +

Results O +
Structure O +
determination O +
The O +
structure O +
of O +
DAPA B-Gene +
synthase I-Gene +
was O +
determined O +
to O +
1.8 O +
Å O +
resolution O -
. O +

Despite O +
non O -
- O -
isomorphism O +
between O +
crystals O +
of O +
DAPA B-Gene +
synthase I-Gene -
, O +
two O +
heavy O -
- O -
atom O +
derivatives O +
containing O +
mercury O +
and O +
platinum O -
, O +
respectively O -
, O +
were O +
identified O +
after O +
extensive O +
screening O -
. O +

However O -
, O +
the O +
phases O +
derived O +
from O +
these O +
derivatives O +
were O +
not O +
of O +
sufficient O +
quality O +
to O +
allow O +
tracing O +
of O +
the O +
polypeptide B-Gene +
chain O -
. O +

Therefore O +
multiple O +
anomalous O +
dispersion O +
techniques O -
, O +
using O +
mercury O -
- O -
derivatised O +
crystals O +
were O +
employed O +
to O +
obtain O +
phase O +
information O +
( O -
for O +
data O +
collection O +
and O +
phasing O +
statistics O +
see O +
Table O +
1 O +
) O -
. O +

The O +
initial O +
map O +
at O +
2.0 O +
Å O +
resolution O -
, O +
calculated O +
after O +
solvent O +
flattening O +
and O +
2-fold O +
non O -
- O -
crystallographic O +
averaging O -
, O +
was O +
of O +
excellent O +
quality O +
( O -
Figure O +
3 O -
( O -
a O -
) O -
) O +
and O +
the O +
polypeptide B-Gene +
chain O +
could O +
be O +
readily O +
built O +
into O +
the O +
electron O +
density O -
. O +

After O +
a O +
few O +
refinement O +
cycles O -
, O +
most O +
of O +
the O +
side O -
- O -
chains O +
had O +
been O +
assigned O -
. O +

However O -
, O +
native O +
crystals O +
diffracted O +
to O +
higher O +
resolution O +
( O -
1.8 O +
Å O -
) O +
and O +
it O +
was O +
desirable O +
to O +
use O +
these O +
data O +
for O +
the O +
refinement O -
. O +

Because O +
of O +
the O +
non O -
- O -
isomorphism O +
between O +
crystals O -
, O +
molecular O +
replacement O +
was O +
necessary O +
for O +
finding O +
the O +
correct O +
orientation O +
of O +
the O +
molecule O +
in O +
the O +
native O +
crystal O -
. O +

The O +
solution O +
was O +
verified O +
by O +
strong O +
and O +
well O +
defined O +
density O +
for O +
the O +
cofactor O -
, O +
PLP O -
, O +
which O +
had O +
been O +
excluded O +
from O +
the O +
search O +
model O -
. O +

Two O -
- O -
fold O +
non O -
- O -
crystallographic O +
symmetry O +
was O +
applied O +
in O +
the O +
subsequent O +
refinement O -
, O +
but O +
released O +
in O +
the O +
very O +
last O +
stages O +
causing O +
a O +
slight O +
drop O +
in O +
the O +
free O +
R O +
-value O -
. O +

Figure O +
3 O -
( O -
b O -
) O +
shows O +
a O +
part O +
of O +
the O +
final O +
2F O +
o O +
−F O +
c O +
electron O +
density O +
map O -
, O +
with O +
the O +
refined O +
model O +
superimposed O -
. O +

The O +
final O +
model O +
contains O +
all O +
but O +
one O +
residue O -
, O +
556 O +
water O +
molecules O -
, O +
two O +
PLP O +
molecules O +
covalently O +
linked O +
to O +
Lys274 O +
in O +
each O +
chain O +
and O +
two O +
Na+ O +
. O +

Only O +
the O +
backbone O +
is O +
modelled O +
for O +
the O +
C O -
- O -
terminal O +
residue O +
in O +
both O +
chains O +
( O -
Glu429 O -
) O -
, O +
since O +
the O +
side O -
- O -
chains O +
were O +
disordered O -
. O +

The O +
side O -
- O -
chains O +
in O +
the O +
loop O +
region O +
between O +
residues O +
180 O +
and O +
192 O +
are O +
badly O +
ordered O -
, O +
and O +
in O +
one O +
of O +
the O +
monomers O +
residue O +
183 O +
is O +
not O +
included O +
in O +
the O +
model O -
, O +
since O +
no O +
electron O +
density O +
corresponding O +
to O +
its O +
main O -
- O -
chain O +
atoms O +
was O +
observed O -
. O +

In O +
both O +
chains O +
residue O +
Trp14 O -
, O +
which O +
is O +
positioned O +
in O +
the O +
interior O +
of O +
the O +
protein B-Gene -
, O +
was O +
built O +
as O +
a O +
leucine O +
residue O -
, O +
judged O +
by O +
the O +
electron O +
density O +
and O +
the O +
local O +
environment O +
of O +
the O +
side O -
- O -
chain O -
. O +

This O +
replacement O +
was O +
later O +
supported O +
by O +
N O -
- O -
terminal O +
amino O +
acid O +
sequencing O -
. O +

The O +
model O +
was O +
refined O +
to O +
a O +
final O +
R O +
-factor O +
of O +
17.5 O +
% O +
and O +
a O +
free O +
R O +
-factor O +
of O +
22.6 O +
% O -
. O +

A O +
summary O +
of O +
the O +
refinement O +
statistics O +
is O +
shown O +
in O +
Table O +
2 O +
. O +

Two O +
residues O -
, O +
Trp53 O +
and O +
Ile213 O -
, O +
which O +
both O +
are O +
well O +
defined O +
in O +
the O +
electron O +
density O +
map O -
, O +
appear O +
in O +
the O +
disallowed O +
region O +
of O +
the O +
Ramachandran O +
plot O +
for O +
each O +
subunit O -
. O +

Trp53 O +
is O +
involved O +
in O +
substrate O +
binding O +
and O +
Ile213 O +
is O +
found O +
at O +
a O +
sharp O +
turn O +
in O +
the O +
beginning O +
of O +
a O +
β O -
- O -
strand O +
that O +
takes O +
the O +
chain O +
into O +
the O +
cofactor O +
binding O +
region O -
. O +

The O +
structure O +
of O +
the O +
monomer O +
The O +
monomer O +
of O +
DAPA B-Gene +
synthase I-Gene +
consists O +
of O +
two O +
domains O +
( O -
Figure O +
4 O -
( O -
a O -
) O -
) O +
, O +
a O +
small O +
domain O +
comprising O +
the O +
N O -
- O -
and O +
C O -
- O -
terminal O +
parts O +
of O +
the O +
polypeptide B-Gene +
chain O +
( O -
residues O +
1–49 O +
and O +
330–429 O -
) O +
and O +
a O +
large O +
domain O +
formed O +
by O +
the O +
intervening O +
residues O +
containing O +
the O +
cofactor O +
binding O +
site O -
. O +

A O +
topological O +
description O +
of O +
the O +
structure O +
of O +
DAPA B-Gene +
synthase I-Gene +
is O +
presented O +
in O +
Figure O +
4 O -
( O -
b O -
) O +
. O +

The O +
large O +
domain O +
starts O +
with O +
a O +
helix O -
- O -
loop O -
- O -
helix O +
segment O +
formed O +
by O +
helices O +
α2 O +
and O +
α3 O -
, O +
which O +
takes O +
the O +
chain O +
over O +
the O +
surface O +
of O +
the O +
molecule O +
to O +
the O +
beginning O +
of O +
a O +
seven O -
- O -
stranded O +
β O -
- O -
sheet O -
, O +
the O +
central O +
feature O +
of O +
this O +
domain O -
, O +
which O +
is O +
typical O +
of O +
aminotransferases B-Gene +
( O -
Ford O +
et O +
al O +
. O -
, O +
1980 O -
) O +
. O +

The O +
order O +
of O +
the O +
strands O +
is O +
β4 O -
, O +
β10 O -
, O +
β9 O -
, O +
β8 O -
, O +
β7 O -
, O +
β5 O +
and O +
β6 O -
, O +
where O +
all O +
except O +
β10 O +
are O +
parallel O +
to O +
each O +
other O -
. O +

Towards O +
the O +
exterior O +
of O +
the O +
molecule O +
the O +
sheet O +
is O +
covered O +
by O +
two O +
helices O -
, O +
α5 O +
and O +
α6 O -
, O +
and O +
the O +
loop O +
between O +
strands O +
β8 O +
and O +
β9 O -
. O +

The O +
sheet O +
is O +
further O +
shielded O +
from O +
the O +
solvent O +
by O +
helices O +
α3 O +
and O +
α8 O -
, O +
which O +
pack O +
almost O +
perpendicular O +
to O +
the O +
strands O +
in O +
the O +
β O -
- O -
sheet O -
. O +

Helix O +
α4 O +
and O +
the O +
extended O +
loop O +
between O +
β5 O +
and O +
β6 O +
pack O +
against O +
the O +
sheet O +
on O +
the O +
opposite O +
side O +
and O +
are O +
involved O +
in O +
subunit O -
- O -
subunit O +
interactions O -
. O +

Helices O +
α7-α8 O +
form O +
a O +
helix O -
- O -
loop O -
- O -
helix O +
segment O -
, O +
which O +
follows O +
after O +
the O +
seven O -
- O -
stranded O +
β O -
- O -
sheet O +
and O +
completes O +
the O +
large O +
domain O -
. O +

The O +
C O -
- O -
terminal O +
part O +
of O +
the O +
small O +
domain O +
folds O +
into O +
a O +
β O -
- O -
sheet O +
which O +
is O +
packed O +
against O +
three O +
helices O +
α9 O -
, O +
α10 O +
and O +
α11 O -
, O +
on O +
one O +
side O -
. O +

The O +
other O +
side O +
of O +
the O +
sheet O +
is O +
turned O +
against O +
the O +
large O +
domain O -
, O +
so O +
that O +
a O +
crevice O +
is O +
formed O +
between O +
the O +
two O +
domains O -
, O +
which O +
accommodates O +
the O +
active O +
site O -
. O +

The O +
N O -
- O -
terminal O +
part O +
of O +
the O +
small O +
domain O +
starts O +
with O +
an O +
α O -
- O -
helix O +
followed O +
by O +
three O +
short O +
β O -
- O -
strands O -
, O +
β1 O -
, O +
β2 O +
and O +
β3 O -
, O +
folded O +
into O +
an O +
anti O -
- O -
parallel O +
β O -
- O -
sheet O -
, O +
and O +
then O +
proceeds O +
into O +
the O +
large O +
domain O +
via O +
a O +
connecting O +
peptide O +
segment O -
. O +

This O +
β O -
- O -
sheet O +
is O +
positioned O +
between O +
the O +
C O -
- O -
terminal O +
part O +
of O +
the O +
small O +
domain O +
and O +
the O +
large O +
domain O +
and O +
provides O +
one O +
wall O +
of O +
the O +
active O +
site O -
. O +

The O +
N O -
- O -
terminal O +
β O -
- O -
sheet O +
is O +
extended O +
by O +
a O +
very O +
short O +
strand O -
, O +
created O +
by O +
residues O +
located O +
between O +
strand O +
β13 O +
and O +
helix O +
α10 O +
in O +
the O +
C O -
- O -
terminal O +
part O +
of O +
the O +
domain O -
. O +

Following O +
this O +
interaction O +
the O +
polypeptide B-Gene +
chain O +
proceeds O +
back O +
into O +
the O +
C O -
- O -
terminal O +
part O +
of O +
the O +
small O +
domain O -
, O +
extending O +
its O +
β O -
- O -
sheet O +
by O +
a O +
short O +
anti O -
- O -
parallel O +
β O -
- O -
strand O +
interaction O +
to O +
strand O +
β13 O +
( O -
Figure O +
4 O -
( O -
b O -
) O -
) O +
. O +

Most O +
of O +
the O +
interactions O +
between O +
the O +
C O -
- O -
terminal O +
part O +
of O +
the O +
small O +
domain O +
and O +
the O +
large O +
domain O +
involve O +
strand O +
β11 O -
, O +
the O +
loop O +
following O +
that O +
strand O +
and O +
the O +
loop O +
between O +
β13 O +
and O +
α11 O -
. O +

Arg360 O +
in O +
strand O +
β11 O +
interacts O +
through O +
its O +
side O -
- O -
chain O +
with O +
the O +
main O -
- O -
chain O +
carbonyl O +
groups O +
of O +
residues O +
Gly219 O +
and O +
Met220 O -
, O +
situated O +
in O +
the O +
loop O +
region O +
between O +
β7 O +
and O +
α6 O +
in O +
the O +
large O +
domain O -
. O +

Arg253 O +
in O +
the O +
large O +
domain O +
interacts O +
via O +
its O +
side O -
- O -
chain O +
with O +
the O +
main O -
- O -
chain O +
carbonyl O +
oxygen O +
atoms O +
of O +
Pro401 O +
found O +
between O +
strand O +
β13 O +
and O +
helix O +
α11 O -
, O +
and O +
Ala364 O +
between O +
strands O +
β11 O +
and O +
β12 O -
. O +

It O +
is O +
also O +
hydrogen O +
bonded O +
through O +
its O +
main O -
- O -
chain O +
carbonyl O +
oxygen O +
atom O +
to O +
the O +
phenolic O +
hydroxyl O +
group O +
of O +
Tyr403 O -
. O +

Ile56 O -
, O +
found O +
in O +
the O +
domain O +
interconnection O +
region O -
, O +
provides O +
a O +
main O -
- O -
chain O -
- O -
main O -
- O -
chain O +
interaction O +
with O +
Tyr403 O +
in O +
the O +
small O +
domain O -
. O +

Finally O -
, O +
the O +
side O -
- O -
chain O +
hydroxyl O +
group O +
of O +
Tyr403 O +
is O +
within O +
hydrogen O +
bonding O +
distance O +
of O +
the O +
main O -
- O -
chain O +
carbonyl O +
oxygen O +
atom O +
of O +
Phe251 O +
in O +
the O +
loop O +
between O +
β8 O +
and O +
β9 O -
. O +

All O +
residues O +
involved O +
in O +
this O +
interface O +
except O +
Tyr403 O +
and O +
Ala364 O +
are O +
either O +
conserved O +
or O +
invariant O +
within O +
the O +
DAPA B-Gene +
synthases I-Gene +
( O -
Figure O +
4 O -
( O -
c O -
) O -
) O +
. O +

The O +
domain O -
- O -
domain O +
interface O +
between O +
the O +
N O -
- O -
terminal O +
part O +
of O +
the O +
small O +
domain O +
and O +
the O +
large O +
domain O +
involves O +
hydrogen O +
bond O +
interactions O +
between O +
the O +
main O -
- O -
chain O +
atoms O +
of O +
the O +
C O -
- O -
terminal O +
residues O +
of O +
strand O +
β1 O -
, O +
Ala32 O +
and O +
Gly34 O -
, O +
and O +
main O -
- O -
chain O +
atoms O +
of O +
Tyr59 O +
and O +
the O +
side O -
- O -
chain O +
of O +
Asn60 O -
, O +
which O +
precede O +
helix O +
α2 O +
in O +
the O +
large O +
domain O -
. O +

Tyr17 O -
, O +
located O +
in O +
the O +
loop O +
between O +
α1 O +
and O +
β1 O -
, O +
is O +
hydrogen O -
- O -
bonded O +
through O +
its O +
phenolic O +
oxygen O +
to O +
the O +
side O -
- O -
chain O +
of O +
Asp147 O -
, O +
which O +
is O +
part O +
of O +
the O +
extended O +
loop O +
between O +
strands O +
β5 O +
and O +
β6 O +
of O +
the O +
large O +
domain O -
. O +

Furthermore O -
, O +
two O +
of O +
the O +
residues O +
involved O +
in O +
the O +
domain O +
interconnection O -
, O +
Ser50 O +
and O +
Trp53 O -
, O +
interact O +
through O +
the O +
side O -
- O -
chain O +
hydroxyl O +
and O +
main O -
- O -
chain O +
carbonyl O +
oxygen O +
atom O -
, O +
respectively O -
, O +
with O +
the O +
guanidinium O +
group O +
of O +
Arg253 O +
located O +
between O +
strands O +
β8 O +
and O +
β9 O -
. O +

These O +
three O +
residues O +
and O +
Gly34 O +
are O +
invariant O +
throughout O +
the O +
sequenced O +
DAPA B-Gene +
synthases I-Gene +
( O -
Figure O +
4 O -
( O -
c O -
) O -
) O +
. O +

The O +
DAPA B-Gene +
synthase I-Gene +
dimer O +
In O +
the O +
crystal O -
, O +
a O +
homodimer O +
of O +
DAPA B-Gene +
synthase I-Gene +
( O -
Figure O +
5 O -
) O +
is O +
found O +
with O +
the O +
subunits O +
related O +
by O +
a O +
2-fold O +
non O -
- O -
crystallographic O +
axis O -
. O +

This O +
finding O +
is O +
consistent O +
with O +
solution O +
studies O +
that O +
showed O +
that O +
DAPA B-Gene +
synthase I-Gene +
is O +
active O +
in O +
dimeric O +
form O +
( O -
Stoner O +
& O +
Eisenberg O -
, O +
1975a O -
) O +
. O +

Upon O +
dimerisation O -
, O +
an O +
area O +
of O +
5240 O +
Å2 O +
per O +
subunit O +
is O +
buried O -
, O +
which O +
corresponds O +
to O +
27 O +
% O +
of O +
the O +
total O +
solvent O -
- O -
accessible O +
area O -
. O +

The O +
overall O +
dimension O +
of O +
the O +
dimer O +
is O +
85 O +
Å O -
× O +
60 O +
Å O -
× O -
60 O +
Å. O +
Both O +
subunits O +
are O +
involved O +
in O +
building O +
up O +
the O +
two O +
identical O +
active O +
sites O +
of O +
the O +
DAPA B-Gene +
synthase I-Gene +
dimer O -
, O +
which O +
are O +
positioned O +
approximately O +
20 O +
Å O +
apart O -
. O +

The O +
pattern O +
of O +
subunit O -
- O -
subunit O +
interactions O +
is O +
extensive O +
and O +
residues O +
from O +
both O +
domains O +
are O +
involved O +
in O +
these O +
interactions O -
. O +

In O +
the O +
large O +
domain O +
helix O +
α2 O +
lines O +
up O +
with O +
and O +
packs O +
against O +
α2 O +
from O +
the O +
other O +
monomer O -
, O +
and O +
both O +
form O +
the O +
top O +
of O +
the O +
molecule O -
, O +
as O +
shown O +
in O +
Figure O +
5 O +
. O +

The O +
extended O +
loop O +
following O +
helix O +
α2 O +
protrudes O +
into O +
the O +
neighbouring O +
subunit O -
, O +
forming O +
several O +
strong O +
interactions O +
with O +
loop O +
regions O +
from O +
both O +
domains O +
of O +
that O +
subunit O -
. O +

Helix O +
α3 O -
, O +
which O +
covers O +
the O +
central O +
β O -
- O -
sheet O +
of O +
its O +
own O +
subunit O -
, O +
interacts O +
with O +
residues O +
from O +
the O +
N O -
- O -
terminal O +
part O +
of O +
the O +
small O +
domain O +
from O +
the O +
other O +
subunit O -
. O +

Helix O +
α4 O +
and O +
the O +
loop O +
between O +
β5 O +
and O +
β6 O -
, O +
which O +
protrude O +
from O +
the O +
central O +
β O -
- O -
sheet O +
region O -
, O +
pack O +
against O +
the O +
corresponding O +
residues O +
in O +
the O +
second O +
monomer O +
at O +
an O +
angle O +
of O +
approximately O +
90 O -
° O -
, O +
mainly O +
through O +
hydrophobic O +
interactions O -
. O +

Furthermore O -
, O +
the O +
top O +
end O +
of O +
this O +
part O +
of O +
the O +
sheet O +
involving O +
strands O +
β4 O -
, O +
β10 O +
and O +
β11 O -
, O +
including O +
PLP O +
binding O +
residue O +
Lys274 O -
, O +
and O +
connecting O +
loops O +
form O +
interactions O +
with O +
the O +
other O +
subunit O +
of O +
DAPA B-Gene +
synthase I-Gene -
, O +
in O +
particular O +
with O +
helices O +
α7 O +
and O +
α8 O -
. O +

Dimer O +
interactions O +
formed O +
by O +
the O +
small O +
domain O +
are O +
almost O +
exclusively O +
made O +
up O +
of O +
the O +
N O -
- O -
terminal O +
part O +
in O +
which O +
the O +
N O -
- O -
terminal O +
helix O +
and O +
the O +
following O +
loop O +
folds O +
over O +
the O +
surface O +
of O +
the O +
second O +
monomer O -
. O +

The O +
loop O +
between O +
helix O +
α2 O +
and O +
α3 O +
is O +
of O +
central O +
importance O +
for O +
the O +
subunit O -
- O -
subunit O +
interactions O -
. O +

It O +
interacts O +
with O +
residues O +
located O +
in O +
helix O +
α1 O -
, O +
in O +
the O +
loop O +
between O +
helix O +
α1 O +
and O +
strand O +
β1 O -
, O +
in O +
strand O +
β1 O -
, O +
in O +
the O +
domain O +
interconnection O +
region O -
, O +
in O +
the O +
loop O +
between O +
strands O +
β9 O +
and O +
β10 O -
, O +
and O +
in O +
the O +
loop O +
between O +
helix O +
α10 O +
and O +
strand O +
β13 O +
of O +
the O +
second O +
subunit O -
. O +

The O +
pyridoxal-5′-phosphate O +
binding O +
site O +
The O +
electron O +
density O +
for O +
the O +
cofactor O +
is O +
very O +
well O +
defined O +
and O +
shows O +
clearly O +
that O +
PLP O +
is O +
covalently O +
bound O +
to O +
the O +
active O +
site O +
Lys274 O +
( O -
Figure O +
3 O -
( O -
b O -
) O -
) O +
. O +

The O +
PLP O +
binding O +
site O +
is O +
located O +
between O +
the O +
two O +
domains O +
of O +
the O +
monomer O +
at O +
the O +
interface O +
of O +
the O +
two O +
subunits O +
( O -
Figure O +
6 O -
) O +
. O +

Residues O +
from O +
both O +
subunits O +
are O +
involved O +
in O +
cofactor O +
binding O -
, O +
although O +
each O +
active O +
site O +
cleft O +
is O +
mainly O +
made O +
up O +
of O +
one O +
monomer O -
. O +

The O +
lysine O +
residue O +
covalently O +
attached O +
to O +
PLP O +
is O +
located O +
on O +
the O +
loop O +
between O +
strands O +
β9 O +
and O +
β10 O -
, O +
and O +
points O +
towards O +
the O +
interior O +
of O +
the O +
protein B-Gene +
so O +
that O +
PLP O +
is O +
found O +
on O +
the O +
side O +
of O +
the O +
β O -
- O -
sheet O +
facing O +
the O +
second O +
subunit O +
in O +
the O +
dimer O -
. O +

The O +
cofactor O +
is O +
bound O +
at O +
the O +
bottom O +
of O +
the O +
active O +
site O -
, O +
with O +
its O +
re O +
side O +
facing O +
the O +
solvent O -
. O +

The O +
oxygen O +
atoms O +
of O +
the O +
phosphate O +
group O +
interact O +
with O +
the O +
main O -
- O -
chain O +
amides O +
of O +
Gly112 O +
and O +
Ser113 O -
, O +
and O +
the O +
side O -
- O -
chain O +
of O +
Ser113 O -
, O +
located O +
at O +
the O +
N O +
terminus O +
of O +
helix O +
α4 O -
, O +
thus O +
anchoring O +
PLP O +
firmly O +
to O +
the O +
enzyme B-Gene -
. O +

The O +
negative O +
charges O +
on O +
the O +
phosphate O +
oxygen O +
atoms O +
are O +
partly O +
neutralised O +
by O +
the O +
positive O +
dipole O +
charge O +
of O +
helix O +
α4 O -
. O +

Further O -
, O +
Thr309 O +
from O +
the O +
other O +
subunit O +
forms O +
a O +
hydrogen O +
bond O +
interaction O +
through O +
its O +
main O -
- O -
chain O +
amide O +
to O +
one O +
of O +
the O +
phosphate O +
oxygen O +
atoms O -
. O +

Several O +
well O +
ordered O +
water O +
molecules O +
within O +
hydrogen O +
bond O +
distance O +
of O +
the O +
phosphate O +
oxygen O +
atoms O +
are O +
also O +
found O +
in O +
the O +
active O +
site O +
of O +
the O +
holo B-Gene -
- I-Gene -
enzyme I-Gene -
. O +

The O +
carboxyl O +
group O +
of O +
Asp245 O +
is O +
within O +
hydrogen O +
bonding O +
distance O +
of O +
the O +
pyridine O +
nitrogen O -
. O +

This O +
indicates O +
either O +
that O +
the O +
carboxyl O +
side O -
- O -
chain O +
is O +
protonated O +
and O +
can O +
form O +
a O +
hydrogen O +
bond O +
to O +
the O +
nitrogen O +
atom O +
or O +
that O +
this O +
nitrogen O +
is O +
protonated O -
. O +

The O +
aspartic O +
acid O +
side O -
- O -
chain O +
is O +
kept O +
in O +
place O +
by O +
interactions O +
with O +
the O +
main O -
- O -
chain O +
amide O +
of O +
residue O +
Ile247 O +
and O +
with O +
the O +
side O -
- O -
chain O +
of O +
His145 O -
. O +

No O +
direct O +
interactions O +
with O +
protein B-Gene +
atoms O +
are O +
found O +
for O +
the O +
phenolic O +
hydroxyl O +
group O -
, O +
O-3′ O -
, O +
of O +
the O +
cofactor O -
. O +

There O +
are O -
, O +
however O -
, O +
water O -
- O -
mediated O +
contacts O +
to O +
the O +
side O -
- O -
chain O +
of O +
Glu211 O +
and O +
the O +
main O -
- O -
chain O +
amide O +
of O +
Ala217 O -
. O +

The O +
pyridine O +
ring O +
of O +
PLP O +
is O +
sandwiched O +
between O +
the O +
side O -
- O -
chain O +
of O +
Tyr144 O +
protruding O +
from O +
the O +
active O +
site O -
, O +
which O +
stacks O +
perpendicular O +
to O +
the O +
ring O -
, O +
and O +
Ile247 O -
, O +
which O +
provides O +
support O +
from O +
the O +
si O +
side O +
of O +
the O +
ring O +
facing O +
the O +
protein B-Gene -
. O +

Binding O +
of O +
the O +
substrate O +
KAPA O +
The O +
electron O +
density O +
map O +
for O +
the O +
ternary O +
complex O +
was O +
continuous O +
except O +
for O +
a O +
few O +
disordered O +
loop O +
regions O +
at O +
the O +
surface O +
of O +
the O +
molecule O -
. O +

These O +
regions O +
comprise O +
residues O +
160–168 O +
and O +
300–301 O +
in O +
each O +
subunit O +
with O +
no O +
electron O +
density O +
for O +
the O +
backbone O -
. O +

As O +
in O +
the O +
crystals O +
of O +
the O +
holoenzyme B-Gene -
, O +
the O +
loop O +
comprising O +
residues O +
180–192 O +
has O +
weak O +
electron O +
density O -
, O +
with O +
disordered O +
side O -
- O -
chains O +
for O +
residues O +
180–192 O +
and O +
no O +
electron O +
density O +
for O +
the O +
backbone O +
of O +
residues O +
183–184 O -
. O +

The O +
C O -
- O -
terminal O +
residue O +
was O +
not O +
modelled O +
because O +
of O +
very O +
weak O +
electron O +
density O -
. O +

The O +
stereochemistry O +
of O +
the O +
refined O +
model O +
is O +
reasonable O +
( O -
Table O +
2 O -
) O +
. O +

The O +
Ramachandran O +
plot O +
showed O +
one O +
outlier O -
, O +
residue O +
Ile213 O -
, O +
with O +
well O +
defined O +
electron O +
density O -
. O +

This O +
residue O +
is O +
also O +
found O +
in O +
the O +
disallowed O +
region O +
of O +
the O +
Ramachandran O +
plot O +
for O +
the O +
model O +
of O +
the O +
holoenzyme B-Gene -
. O +

The O +
most O +
characteristic O +
feature O +
of O +
the O +
initial O +
electron O +
density O +
map O +
for O +
the O +
ternary O +
complex O +
was O +
the O +
clear O +
and O +
well O +
defined O +
difference O +
electron O +
density O +
in O +
the O +
active O +
site O +
close O +
to O +
the O +
PLP O +
molecule O -
. O +

A O +
KAPA O +
molecule O +
could O +
be O +
modelled O +
straightforwardly O +
into O +
this O +
difference O +
density O -
. O +

Refinement O +
gave O +
similar O +
B O +
-factors O +
for O +
the O +
atoms O +
of O +
the O +
substrate O +
to O +
those O +
for O +
surrounding O +
protein B-Gene +
atoms O -
, O +
indicating O +
high O +
occupancy O +
of O +
the O +
substrate O +
in O +
the O +
active O +
site O -
. O +

The O +
initial O +
difference O +
electron O +
density O +
for O +
bound O +
KAPA O +
is O +
shown O +
in O +
Figure O +
3 O -
( O -
c O -
) O +
. O +

The O +
substrate O +
is O +
bound O +
in O +
a O +
rather O +
bent O +
fashion O +
in O +
the O +
active O +
site O +
cleft O -
, O +
with O +
the O +
carboxyl O +
tail O +
close O +
to O +
the O +
entrance O +
of O +
the O +
cleft O +
and O +
the O +
polar O +
head O +
group O +
close O +
to O +
the O +
re O +
face O +
of O +
the O +
cofactor O +
at O +
the O +
bottom O +
of O +
the O +
active O +
site O +
( O -
Figure O +
7 O -
) O +
. O +

The O +
polar O +
head O -
/ O -
tail O +
groups O +
anchor O +
the O +
substrate O +
to O +
the O +
protein B-Gene +
through O +
salt O +
bridges O +
and O +
hydrogen O +
bonds O -
, O +
while O +
the O +
hydrophobic O +
carbon O +
chain O +
packs O +
with O +
hydrophobic O +
amino O +
acid O +
side O -
- O -
chains O +
in O +
the O +
active O +
site O +
pocket O -
. O +

The O +
carboxyl O +
group O +
of O +
KAPA O +
forms O +
a O +
salt O +
bridge O +
with O +
the O +
side O -
- O -
chain O +
of O +
the O +
invariant O +
Arg391 O -
. O +

One O +
of O +
the O +
oxygen O +
atoms O +
of O +
this O +
carboxyl O +
groups O +
is O +
also O +
within O +
hydrogen O +
bonding O +
distance O +
of O +
the O +
Nϵ O +
atom O +
of O +
the O +
side O -
- O -
chain O +
of O +
Trp52 O -
. O +

The O +
aliphatic O +
carbon O +
atoms O +
of O +
the O +
KAPA O +
molecule O +
form O +
van O +
der O +
Waals O -
' O +
interactions O +
with O +
the O +
side O -
- O -
chains O +
of O +
residues O +
Tyr17 O -
, O +
Trp53 O -
, O +
Tyr144 O +
and O +
Phe393 O -
. O +

The O +
7-keto O +
oxygen O +
atom O +
of O +
KAPA O +
forms O +
a O +
hydrogen O +
bond O +
to O +
the O +
Nϵ O +
atom O +
of O +
Lys274 O -
, O +
which O +
is O +
covalently O +
linked O +
to O +
the O +
PLP O +
in O +
this O +
ternary O +
complex O -
. O +

The O +
N8 O +
nitrogen O +
atom O +
of O +
the O +
substrate O +
is O +
held O +
in O +
position O +
through O +
hydrogen O +
bonds O +
formed O +
to O +
the O +
hydroxyl O +
group O +
of O +
Tyr17 O -
, O +
and O +
the O +
peptide O +
oxygen O +
of O +
Gly307 O -
. O +

The O +
terminal O +
methyl O +
group O +
of O +
KAPA O +
forms O +
a O +
hydrophobic O +
contact O +
with O +
the O +
side O -
- O -
chain O +
of O +
Trp52 O -
. O +

Very O +
few O +
significant O +
conformational O +
changes O +
occur O +
upon O +
binding O +
of O +
the O +
substrate O -
. O +

The O +
largest O +
changes O +
involve O +
only O +
side O -
- O -
chain O +
movements O -
. O +

They O +
include O +
the O +
side O -
- O -
chain O +
of O +
Tyr17 O -
, O +
which O +
shifts O +
towards O +
the O +
KAPA O +
substrate O -
. O +

The O +
guanidinium O +
group O +
of O +
the O +
side O -
- O -
chain O +
of O +
Arg391 O +
moves O +
about O +
3 O +
Å O +
in O +
order O +
to O +
form O +
a O +
tight O +
salt O +
bridge O +
to O +
the O +
carboxyl O +
group O +
of O +
KAPA O -
. O +

The O +
most O +
pronounced O +
conformational O +
change O +
involves O +
the O +
side O -
- O -
chain O +
of O +
Trp53 O -
, O +
which O +
adopts O +
a O +
position O +
perpendicular O +
to O +
its O +
location O +
in O +
the O +
unliganded O +
protein B-Gene -
. O +

This O +
conformational O +
change O +
has O +
as O +
a O +
consequence O +
that O +
this O +
residue O -
, O +
which O +
had O +
been O +
one O +
of O +
the O +
outliers O +
in O +
the O +
Ramachandran O +
plot O +
for O +
the O +
holoenzyme B-Gene -
, O +
is O +
now O +
located O +
in O +
a O +
favourable O +
region O +
of O +
the O +
Ramachandran O +
plot O -
. O +

The O +
metal O +
binding O +
site O +
A O +
strong O +
peak O +
in O +
electron O +
density O +
( O -
11 O +
times O +
the O +
standard O +
deviation O +
of O +
a O +
F O +
o O +
−F O +
c O +
electron O +
density O +
map O -
) O +
was O +
found O +
located O +
close O +
to O +
a O +
tight O +
turn O +
between O +
helix O +
α3 O +
and O +
strand O +
β4 O -
, O +
formed O +
by O +
residues O +
96 O +
to O +
100 O -
. O +

Observed O +
distances O +
to O +
surrounding O +
protein B-Gene +
atoms O +
( O -
2.3 O +
to O +
2.6 O +
Å O -
) O +
were O +
not O +
consistent O +
with O +
a O +
water O +
molecule O +
in O +
this O +
position O -
. O +

On O +
the O +
basis O +
of O +
peak O +
height O -
, O +
ligand O +
distance O +
and O +
geometry O -
, O +
this O +
difference O +
density O +
was O +
modelled O +
as O +
a O +
sodium O +
ion O -
. O +

Binding O +
of O +
a O +
potassium O +
ion O +
at O +
this O +
site O +
was O +
excluded O -
, O +
since O +
it O +
is O +
not O +
present O +
in O +
the O +
crystallisation O +
solution O -
, O +
whereas O +
sodium O +
is O +
present O +
in O +
high O +
concentration O +
as O +
a O +
buffer O +
counterion O +
( O -
> O -
50 O +
mM O -
) O -
. O +

The O +
ligands O +
to O +
the O +
Na+ O +
form O +
a O +
close O +
to O +
octahedral O +
coordination O +
sphere O -
, O +
with O +
oxygen O +
atoms O +
provided O +
by O +
main O -
- O -
chain O +
carbonyl O +
groups O +
of O +
residues O +
Val96 O -
, O +
Thr99 O -
, O +
Pro100 O +
and O +
Leu103 O +
( O -
Figure O +
8) O +
. O +

Additional O +
ligands O +
are O +
the O +
side O -
- O -
chain O +
of O +
Thr99 O +
and O +
a O +
water O +
molecule O -
. O +

Binding O +
sites O +
for O +
monovalent O +
metal O +
ions O +
have O +
been O +
observed O +
in O +
other O +
vitamin O +
B6 O +
-dependent O +
enzymes B-Gene -
, O +
for O +
instance O +
2,2-dialkylglycine B-Gene +
decarboxylase I-Gene +
( O -
Toney O +
et O +
al O +
. O -
, O +
1993 O -
, O +
1995 O -
) O +
and O +
tryptophanase B-Gene +
( O -
Isupov O +
et O +
al O +
. O -
, O +
1998 O -
) O +
. O +

The O +
metal O +
binding O +
site O +
observed O +
in O +
DAPA B-Gene +
synthase I-Gene +
is O +
identical O +
to O +
site O +
II O +
in O +
the O +
decarboxylase B-Gene -
, O +
with O +
the O +
same O +
set O +
of O +
ligands O -
, O +
four O +
carbonyl O +
oxygen O +
atoms O -
, O +
a O +
threonine O +
side O -
- O -
chain O +
and O +
a O +
water O +
molecule O -
. O +

Because O +
this O +
metal O +
binding O +
site O +
is O +
remote O +
from O +
the O +
active O +
site O +
( O -
> O -
20 O +
Å O -
) O -
, O +
its O +
role O +
is O +
likely O +
to O +
be O +
structural O +
rather O +
than O +
catalytic O -
. O +

Crystal O +
packing O +
DAPA B-Gene +
synthase I-Gene +
crystals O +
grown O +
under O +
the O +
same O +
conditions O +
occur O +
in O +
two O +
space O +
groups O -
, O +
C O +
2 O +
and O +
P O +
21 O +
, O +
with O +
cell O +
dimensions O +
a O +
= O -
130 O +
Å O -
, O +
b O +
= O -
57.5 O +
Å O -
, O +
c O +
= O -
117 O +
Å O +
and O +
β=110 O -
° O -
, O +
and O +
a O +
= O -
58.5 O +
Å O -
, O +
b O +
= O -
55.6 O +
Å O -
, O +
c O +
= O -
117 O +
Å O +
and O +
β=96.9 O -
° O -
, O +
respectively O +
( O -
Käck O +
et O +
al O +
. O -
, O +
1998 O -
) O +
. O +

It O +
was O +
evident O +
that O +
the O +
two O +
space O +
groups O +
were O +
closely O +
related O +
as O +
the O +
crystal O +
lattice O +
could O +
change O +
from O +
C O +
2 O +
to O +
P O +
21 O +
during O +
data O +
collection O -
. O +

This O +
transition O +
can O +
be O +
triggered O +
by O +
cooling O +
the O +
crystal O +
from O +
room O +
temperature O +
to O +
4 O -
° O -
C O -
. O +

Further O -
, O +
the O +
native O +
Patterson O +
map O +
obtained O +
from O +
the O +
P O +
21 O +
crystals O +
had O +
two O +
peaks O +
very O +
close O +
to O +
( O -
1 O -
/ O -
2,1 O -
/ O -
2,1 O -
/ O -
2 O -
) O -
, O +
indicating O +
a O +
pseudo O +
symmetry O +
in O +
the O +
packing O +
pattern O +
( O -
Käck O +
et O +
al O +
. O -
, O +
1998 O -
) O +
. O +

A O +
slight O +
rearrangement O +
of O +
the O +
molecules O +
in O +
the O +
crystal O +
disrupts O +
the O +
perfect O +
alignment O +
between O +
the O +
2-fold O +
molecular O +
axes O +
relating O +
the O +
monomers O +
and O +
the O +
crystallographic O +
dyad O +
and O +
shifts O +
its O +
positions O +
from O +
exactly O +
( O -
1 O -
/ O -
4 O -
, O +
y O +
, O +
0 O -
) O +
and O +
( O -
3 O -
/ O -
4 O -
, O +
y O +
, O +
0 O -
) O -
, O +
resulting O +
in O +
a O +
change O +
from O +
space O +
group O +
C O +
2 O +
to O +
P O +
21 O +
( O -
Figure O +
9 O -
) O +
. O +

The O +
relationship O +
between O +
the O +
two O +
space O +
groups O +
can O +
be O +
described O +
as O +
X O +
C O +
2= O +
−X O +
P O +
21 O +
−Z O +
P O +
21 O +
, O +
Y O +
C O +
2 O -
= O -
Y O +
P O +
21 O +
, O +
Z O +
C O +
2=2X O +
P O +
21 O +
. O +

Discussion O +
Structural O +
relationships O +
between O +
vitamin O +
B6 O +
enzymes B-Gene +
of O +
fold O +
type O +
I O +
In O +
order O +
to O +
analyse O +
structural O +
relationships O +
within O +
the O +
PLP O +
fold O +
type O +
I O +
family O -
, O +
a O +
general O +
search O +
of O +
the O +
Protein O +
Data O +
Bank O +
for O +
PLP O -
- O -
dependent O +
enzymes B-Gene +
topologically O +
similar O +
to O +
DAPA B-Gene +
synthase I-Gene +
was O +
performed O -
, O +
followed O +
by O +
a O +
multiple O +
structural O +
alignment O +
between O +
these O +
( O -
see O +
Materials O +
and O +
Methods O +
for O +
details O -
) O -
. O +

Ten O +
different O +
enzymes B-Gene +
aligned O +
with O +
DAPA B-Gene +
synthase I-Gene +
( O -
Table O +
3 O -
) O +
. O +

The O +
pairwise O +
amino O +
acid O +
identities O +
of O +
structurally O +
aligned O +
elements O +
are O +
presented O +
in O +
Table O +
4 O +
. O +

Furthermore O -
, O +
the O +
relationships O +
based O +
on O +
the O +
structural O +
similarities O +
between O +
these O +
enzymes B-Gene +
are O +
presented O +
in O +
Figure O +
10 O -
( O -
a O -
) O +
( O -
see O +
Materials O +
and O +
Methods O +
for O +
details O -
) O -
. O +

Although O +
the O +
enzymes B-Gene +
in O +
the O +
fold O +
type O +
I O +
class O +
of O +
the O +
vitamin O +
B6 O +
enzyme B-Gene +
superfamily O +
share O +
the O +
same O +
overall O +
fold O -
, O +
only O +
five O +
elements O +
of O +
secondary O +
structure O +
could O +
be O +
structurally O +
aligned O +
between O +
all O +
of O +
them O -
. O +

These O +
elements O +
correspond O +
to O +
strands O +
β4 O -
, O +
β6 O -
, O +
β7 O -
, O +
β8 O +
and O +
β9 O -
, O +
as O +
defined O +
for O +
DAPA B-Gene +
synthase I-Gene +
Figure O +
10 O -
( O -
b O -
) O +
. O +

A O +
slight O +
difference O +
in O +
the O +
twist O +
of O +
the O +
sheet O +
in O +
the O +
different O +
enzymes B-Gene +
prevents O +
alignment O +
of O +
the O +
two O +
outmost O +
strands O +
of O +
the O +
sheet O -
, O +
even O +
though O +
they O +
are O +
present O +
in O +
all O +
structures O -
. O +

Genuinely O +
different O +
areas O +
are O +
loops O +
involved O +
in O +
substrate O +
binding O +
and O +
subunit O -
- O -
subunit O +
interactions O -
. O +

According O +
to O +
the O +
multiple O +
structural O +
alignment O +
these O +
11 O +
enzymes B-Gene +
can O +
be O +
divided O +
into O +
six O +
different O +
subclasses O +
( O -
Figure O +
10 O -
( O -
a O -
) O +
and O +
Table O +
3 O +
) O -
. O +

The O +
largest O +
subclass O +
includes O +
DAPA B-Gene +
synthase I-Gene -
, O +
2,2-dialkylglycine B-Gene +
decarboxylase I-Gene -
, O +
glutamate B-Gene +
semialdehyde I-Gene +
aminomutase I-Gene +
and O +
human O +
ornithine B-Gene +
aminotransferase I-Gene -
, O +
and O +
corresponds O +
to O +
aminotransferases B-Gene +
subclass I-Gene +
III I-Gene +
in O +
Grishin O -
's O +
classification O +
( O -
Grishin O +
et O +
al O +
. O -
, O +
1995 O -
) O +
. O +

Aromatic B-Gene +
amino I-Gene +
acid I-Gene +
aminotransferase I-Gene +
and O +
aspartate B-Gene +
aminotransferase I-Gene +
make O +
up O +
the O +
members O +
of O +
aminotransferases B-Gene +
subclass I-Gene +
I I-Gene -
, O +
and O +
phosphoserine B-Gene +
aminotransferase I-Gene +
is O +
the O +
only O +
representative O +
of O +
the O +
aminotransferase B-Gene +
subclass I-Gene +
V. I-Gene +
There O +
are O +
no O +
coordinates O +
released O +
in O +
the O +
PDB O +
database O +
for O +
enzymes B-Gene +
that O +
might O +
belong O +
to O +
aminotransferase B-Gene +
subclass I-Gene +
II I-Gene +
as O +
defined O +
by O +
Grishin O +
et O +
al O +
. O +

( O -
1995 O -
) O +
. O +

A O +
structure O -
- O -
based O +
classification O +
of O +
the O +
fold O +
type O +
I O +
enzymes B-Gene +
outside O +
the O +
aminotransferase B-Gene +
subclasses O +
had O +
not O +
been O +
addressed O +
earlier O -
. O +

In O +
our O +
comparison O -
, O +
tyrosine B-Gene +
phenol I-Gene -
- I-Gene -
lyase I-Gene +
and O +
tryptophan B-Gene +
indole I-Gene -
- I-Gene -
lyase I-Gene +
form O +
a O +
distinct O +
class O +
( O -
the O +
tyrosine B-Gene +
phenol I-Gene -
- I-Gene -
lyase I-Gene +
subclass O -
) O -
. O +

Cystathionine B-Gene +
β I-Gene -
- I-Gene -
lyase I-Gene +
shows O +
sequence O +
identities O +
in O +
the O +
range O +
of O +
26 O +
% O +
to O +
32 O +
% O +
to O +
metathione B-Gene +
γ I-Gene -
- I-Gene -
lyase I-Gene -
, O +
cystathionine B-Gene +
γ I-Gene -
- I-Gene -
lyase I-Gene -
, O +
O B-Gene +
-acetyl I-Gene -
- I-Gene -
l I-Gene +
-homoserine I-Gene +
sulfhydrylase I-Gene -
, O +
O B-Gene +
-succinylhomoserine I-Gene +
sulphfhydrylase I-Gene -
, O +
and O +
cystathionine B-Gene +
γ I-Gene -
- I-Gene -
synthase I-Gene -
, O +
indicating O +
that O +
they O +
belong O +
to O +
the O +
same O +
structural O +
subclass O +
( O -
the O +
cystathionine B-Gene +
β I-Gene -
- I-Gene -
lyase I-Gene +
subclass O -
) O -
. O +

The O +
larger O +
prokaryotic O +
ornithine B-Gene +
decarboxylase I-Gene +
is O +
the O +
sole O +
representative O +
of O +
its O +
subclass O +
so O +
far O -
. O +

There O +
is O +
a O +
striking O +
correlation O +
between O +
the O +
structure O +
of O +
the O +
N O -
- O -
terminal O +
part O +
of O +
the O +
polypeptide B-Gene +
chain O +
and O +
the O +
subclass O +
definition O +
obtained O +
from O +
the O +
multiple O +
structure O +
alignment O +
within O +
this O +
family O -
. O +

The O +
structure O +
of O +
this O +
chain O +
segment O +
is O +
rather O +
different O +
between O +
the O +
subclasses O -
, O +
but O +
similar O +
within O +
a O +
given O +
subclass O +
( O -
Figure O +
11 O -
) O +
. O +

For O +
instance O -
, O +
the O +
N O -
- O -
terminal O +
β O -
- O -
meander O +
followed O +
by O +
a O +
helix O +
as O +
described O +
for O +
DAPA B-Gene +
synthase I-Gene +
holds O +
for O +
all O +
enzymes B-Gene +
in O +
subclass O +
III O +
( O -
Figure O +
11 O -
( O -
a O -
) O -
) O +
. O +

In O +
the O +
tyrosine B-Gene +
phenol I-Gene -
- I-Gene -
lyase I-Gene +
subclass O +
a O +
helix O +
folds O +
over O +
the O +
hinge O +
region O +
and O +
covers O +
one O +
end O +
of O +
the O +
C O -
- O -
terminal O +
β O -
- O -
sheet O -
. O +

This O +
leaves O +
the O +
entrance O +
to O +
the O +
active O +
site O +
more O +
open O +
than O +
in O +
the O +
subclass B-Gene +
III I-Gene +
enzymes I-Gene -
. O +

An O +
N O -
- O -
terminal O +
arm O +
extends O +
outside O +
the O +
catalytic O +
dimer O +
and O +
is O +
involved O +
in O +
a O +
four O -
- O -
stranded O +
( O -
-sheet O +
built O +
up O +
by O +
two O +
strands O +
from O +
each O +
subunit O +
mediating O +
tetramer O +
formation O +
( O -
Antson O +
et O +
al O +
. O -
, O +
1993 O -
) O +
( O -
Figure O +
11 O -
( O -
b O -
) O -
) O +
. O +

In O +
cystathionine B-Gene -
- I-Gene -
β I-Gene -
- I-Gene -
lyase I-Gene +
( O -
Figure O +
11 O -
( O -
c O -
) O -
) O +
the O +
N O -
- O -
terminus O +
protrudes O +
out O +
from O +
the O +
monomer O +
into O +
the O +
active O +
site O +
of O +
the O +
other O +
monomer O +
in O +
the O +
catalytic O +
dimer O +
and O +
then O +
turns O +
back O +
and O +
folds O +
into O +
an O +
α O -
- O -
helix O +
which O +
packs O +
against O +
the O +
outside O +
of O +
the O +
hinge O +
between O +
the O +
domains O +
in O +
its O +
original O +
subunit O -
. O +

Some O +
of O +
the O +
residues O +
in O +
the O +
N O -
- O -
terminal O +
segment O +
are O +
also O +
involved O +
in O +
tetramer O +
formation O -
. O +

In O +
the O +
aspartate B-Gene +
aminotransferase I-Gene +
and O +
aromatic B-Gene +
amino I-Gene +
acid I-Gene +
aminotransferase I-Gene +
the O +
N O +
terminus O +
starts O +
on O +
the O +
surface O +
of O +
the O +
second O +
subunit O +
and O +
then O +
crosses O +
over O +
the O +
active O +
site O +
cleft O +
before O +
joining O +
the O +
small O +
domain O -
. O +

The O +
N O -
- O -
terminal O +
part O +
of O +
the O +
small O +
domain O +
forms O +
an O +
α O -
- O -
helix O +
which O +
lines O +
the O +
active O +
site O +
entrance O +
and O +
contributes O +
with O +
a O +
β O -
- O -
strand O +
interaction O +
to O +
the O +
C O -
- O -
terminal O +
β O -
- O -
sheet O +
( O -
Figure O +
11 O -
( O -
d O -
) O -
) O +
. O +

Ornithine B-Gene +
decarboxylase I-Gene +
is O +
a O +
larger O +
PLP O -
- O -
dependent O +
enzyme B-Gene +
of O +
which O +
only O +
parts O -
, O +
domain O +
three O +
and O +
domain O +
four O -
, O +
correspond O +
to O +
the O +
fold O +
type B-Gene +
I I-Gene +
enzymes I-Gene -
. O +

The O +
small O +
domain O +
is O +
built O +
up O +
solely O +
by O +
domain O +
four O -
, O +
corresponding O +
to O +
the O +
C O -
- O -
terminal O +
part O +
of O +
the O +
small O +
domain O +
in O +
the O +
smaller O +
fold O +
type B-Gene +
I I-Gene +
enzymes I-Gene -
. O +

The O +
N O -
- O -
terminal O +
domains O +
consist O +
of O +
one O +
independently O +
folded O +
domain O +
followed O +
by O +
a O +
long O +
linker O +
connecting O +
it O +
to O +
the O +
PLP O +
binding O +
domain O +
three O +
( O -
Figure O +
11 O -
( O -
f O -
) O -
) O +
. O +

Finally O -
, O +
the O +
subclass B-Gene +
V I-Gene +
enzymes I-Gene +
seem O +
to O +
lack O +
the O +
N O -
- O -
terminal O +
domain O +
completely O -
. O +

The O +
polypeptide B-Gene +
chain O +
starts O +
at O +
the O +
domain O +
linker O +
region O +
and O +
enters O +
the O +
large O +
domain O +
directly O +
( O -
Figure O +
11 O -
( O -
e O -
) O -
) O +
. O +

The O +
active O +
site O -
: O +
similarities O +
and O +
differences O +
in O +
the O +
fold O +
type B-Gene +
I I-Gene +
enzymes I-Gene +
The O +
active O +
site O +
and O +
in O +
particular O +
the O +
pyridine O +
ring O +
of O +
the O +
PLP O +
cofactor O +
of O +
the O +
fold O +
type B-Gene +
I I-Gene +
enzymes I-Gene +
of O +
known O +
3-D O +
structure O +
superpose O +
very O +
well O +
( O -
Figure O +
12 O -
) O +
. O +

The O +
maximum O +
distance O +
from O +
the O +
Schiff O -
- O -
base O +
nitrogen O +
atom O +
in O +
DAPA B-Gene +
synthase I-Gene +
to O +
the O +
corresponding O +
atom O +
of O +
related O +
enzymes B-Gene +
is O +
1.4 O +
Å O +
( O -
ornithine B-Gene +
decarboxylase I-Gene +
and O +
phosphoserine O +
amino O +
transferase O -
) O -
, O +
and O +
that O +
for O +
the O +
pyridine O +
nitrogen O +
is O +
1.4 O +
Å O +
( O -
phosphoserine B-Gene +
amino I-Gene +
transferase I-Gene -
) O -
. O +

The O +
residues O +
participating O +
in O +
binding O +
of O +
the O +
cofactor O +
are O +
presented O +
in O +
Table O +
5 O +
. O +

It O +
is O +
notable O +
that O -
, O +
despite O +
the O +
similar O +
position O +
of O +
the O +
cofactor O +
in O +
the O +
active O +
site O +
( O -
Figure O +
12 O -
) O +
, O +
the O +
loop O +
between O +
strands O +
β9 O +
and O +
β10 O +
carrying O +
the O +
active O +
site O +
lysine O +
residue O +
is O +
not O +
structurally O +
conserved O -
. O +

In O +
all O +
aminotransferase B-Gene +
subclass I-Gene +
III I-Gene +
enzymes B-Gene +
this O +
loop O +
is O +
shorter O -
, O +
with O +
the O +
consequence O +
that O +
the O +
lysine O +
residue O +
is O +
positioned O +
out O +
of O +
register O +
with O +
the O +
corresponding O +
lysine O +
in O +
the O +
enzymes B-Gene +
belonging O +
to O +
the O +
other O +
subclasses O +
( O -
Figure O +
12 O -
) O +
. O +

This O +
suggests O +
a O +
deletion O +
of O +
one O +
amino O +
acid O +
in O +
the O +
ancestral O +
subclass B-Gene +
III I-Gene +
aminotransferase I-Gene -
. O +

The O +
Nϵ O +
atom O +
of O +
the O +
lysine O +
side O -
- O -
chain O -
, O +
however O -
, O +
is O +
found O +
at O +
approximately O +
the O +
same O +
position O -
. O +

The O +
aspartic O +
acid O +
residue O +
which O +
corresponds O +
to O +
Asp245 O +
in O +
DAPA B-Gene +
synthase I-Gene +
is O +
the O +
only O +
structurally O +
conserved O +
residue O +
in O +
this O +
enzyme B-Gene +
family O -
. O +

This O +
amino O +
acid O +
forms O +
a O +
salt O +
bridge O -
/ O -
hydrogen O +
bond O +
with O +
the O +
pyridine O +
nitrogen O +
and O +
was O +
proposed O +
to O +
provide O +
one O +
of O +
the O +
key O +
interactions O +
for O +
the O +
regulation O +
of O +
the O +
pK O +
a O +
of O +
the O +
aldimine O +
nitrogen O +
( O -
Hayashi O -
, O +
1995 O -
; O +
John O -
, O +
1995 O -
) O +
. O +

Stabilisation O +
of O +
this O +
interaction O +
is O +
provided O +
by O +
a O +
non O -
- O -
conserved O +
pattern O +
of O +
hydrogen O +
bonds O +
to O +
surrounding O +
residues O -
, O +
except O +
in O +
the O +
case O +
of O +
ornithine B-Gene +
decarboxylase I-Gene +
and O +
tryptophanase B-Gene +
in O +
which O +
the O +
aspartic O +
acid O +
only O +
interacts O +
with O +
the O +
pyridine O +
nitrogen O +
of O +
PLP O -
. O +

In O +
DAPA B-Gene +
synthase I-Gene -
, O +
glutamate B-Gene +
semialdehyde I-Gene +
aminomutase I-Gene +
and O +
dialkylglycine B-Gene +
decarboxylase I-Gene +
a O +
histidine O +
residue O +
forms O +
a O +
hydrogen O +
bond O +
to O +
one O +
of O +
the O +
carboxyl O +
oxygen O +
atoms O +
of O +
the O +
aspartic O +
acid O -
. O +

Similar O +
interactions O +
are O +
provided O +
by O +
a O +
histidine O +
from O +
a O +
different O +
loop O +
in O +
the O +
aspartate B-Gene +
and O +
aromatic B-Gene +
amino I-Gene +
acid I-Gene +
aminotransferases I-Gene -
. O +

In O +
the O +
subclass B-Gene +
III B-Gene +
and O +
V B-Gene +
enzymes I-Gene -
, O +
the O +
main O -
- O -
chain O +
amide O +
of O +
the O +
second O +
residue O +
following O +
the O +
aspartic O +
acid O +
is O +
within O +
hydrogen O +
bonding O +
distance O +
( O -
< O -
3.3 O +
Å O -
) O +
to O +
the O +
carboxyl O +
group O +
of O +
this O +
aspartic O +
acid O +
whereas O +
in O +
cystathionine B-Gene +
β I-Gene -
- I-Gene -
lyase I-Gene -
, O +
phosphoserine B-Gene +
aminotransferase I-Gene +
and O +
tyrosine B-Gene +
phenol I-Gene -
- I-Gene -
lyase I-Gene +
the O +
side O -
- O -
chain O +
of O +
this O +
residue O +
( O -
Thr O -
/ O -
Ser O -
) O +
provides O +
an O +
interaction O +
with O +
the O +
same O +
group O -
. O +

In O +
all O +
enzymes B-Gene +
except O +
DAPA B-Gene +
synthase I-Gene -
, O +
the O +
protein B-Gene +
provides O +
a O +
hydrogen O +
bond O +
partner O +
to O +
the O +
phenolic O +
oxygen O -
, O +
O-3′ O -
, O +
of O +
the O +
pyridine O +
ring O -
. O +

The O +
nature O +
and O +
strength O +
of O +
this O +
interaction O +
might O +
influence O +
the O +
pK O +
a O +
of O +
the O +
resulting O +
Schiff O +
base O +
of O +
the O +
cofactor O +
with O +
the O +
catalytic O +
lysine O +
residue O +
( O -
Goldberg O +
et O +
al O +
. O -
, O +
1991 O -
; O +
Inoue O +
et O +
al O +
. O -
, O +
1991 O -
) O +
. O +

As O +
described O -
, O +
a O +
water O -
- O -
mediated O +
interaction O +
with O +
a O +
glutamic O +
acid O +
residue O +
replaces O +
this O +
interaction O +
in O +
DAPA B-Gene +
synthase I-Gene -
. O +

A O +
structural O +
feature O +
distinguishing O +
the O +
subclass B-Gene +
III I-Gene +
aminotransferases I-Gene +
from O +
other O +
fold O +
type O +
I O +
PLP O +
enzymes B-Gene +
is O +
the O +
stacking O +
interactions O +
with O +
the O +
re O +
face O +
of O +
the O +
pyridine O +
ring O +
of O +
PLP O -
. O +

All O +
enzymes B-Gene +
of O +
known O +
structure O +
have O +
aromatic O +
residues O +
in O +
this O +
position O -
, O +
corresponding O +
to O +
Tyr144 O +
in O +
DAPA B-Gene +
synthase I-Gene -
. O +

However O -
, O +
in O +
the O +
subclass B-Gene +
III I-Gene +
aminotransferases I-Gene +
the O +
aromatic O +
residue O +
packs O +
nearly O +
perpendicular O +
to O +
the O +
pyridine O +
ring O +
of O +
the O +
cofactor O -
, O +
while O +
in O +
the O +
other O +
fold O +
type B-Gene +
I I-Gene +
enzymes I-Gene +
the O +
stacking O +
is O +
close O +
to O +
parallel O -
. O +

It O +
has O +
been O +
proposed O +
for O +
aspartate B-Gene +
aminotransferase I-Gene +
that O +
the O +
parallel O +
stacking O -
, O +
which O +
is O +
optimised O +
from O +
nearly O +
parallel O +
to O +
parallel O +
in O +
the O +
external O +
aldimine O +
complex O -
, O +
increases O +
the O +
electron O +
withdrawing O +
effect O +
of O +
the O +
cofactor O +
and O +
favours O +
the O +
formation O +
of O +
the O +
quinonoid O +
intermediate O +
( O -
Ford O +
et O +
al O +
. O -
, O +
1980 O -
; O +
Hayashi O +
et O +
al O +
. O -
, O +
1990 O -
) O +
. O +

In O +
the O +
aminotransferase B-Gene +
subclass I-Gene +
III I-Gene +
enzymes I-Gene -
, O +
the O +
stacking O +
residue O +
is O +
part O +
of O +
the O +
loop O +
between O +
strands O +
β5 O +
and O +
β6 O -
, O +
which O +
narrows O +
the O +
active O +
site O +
entrance O -
. O +

With O +
this O +
conformation O +
of O +
the O +
polypeptide B-Gene +
backbone O -
, O +
the O +
aromatic O +
residue O +
would O +
clash O +
with O +
the O +
main O +
chain O +
if O +
it O +
packed O +
parallel O +
to O +
the O +
ring O -
. O +

In O +
the O +
other O +
fold O +
type B-Gene +
I I-Gene +
enzymes I-Gene +
the O +
loop O +
is O +
replaced O +
by O +
a O +
short O +
helix O +
beginning O +
immediately O +
after O +
the O +
aromatic O +
residue O -
. O +

This O +
difference O +
in O +
backbone O +
conformation O +
enables O +
a O +
parallel O +
stacking O +
to O +
the O +
pyridine O +
ring O +
of O +
the O +
cofactor O +
and O +
leaves O +
the O +
active O +
site O +
much O +
more O +
open O -
. O +

In O +
tryptophanase B-Gene -
, O +
cystathionine B-Gene +
β I-Gene -
- I-Gene -
lyase I-Gene +
and O +
tyrosine B-Gene +
phenol I-Gene -
- I-Gene -
lyase I-Gene +
the O +
active O +
site O +
entrance O +
is O +
instead O +
restricted O +
by O +
a O +
loop O +
protruding O +
from O +
the O +
β O -
- O -
sheet O +
in O +
the O +
small O +
domain O +
whereas O +
the O +
other O +
enzymes B-Gene +
simply O +
have O +
a O +
wider O +
active O +
site O +
entrance O -
. O +

Human O +
ornithine B-Gene +
decarboxylase I-Gene +
is O +
an O +
exception O -
, O +
having O +
an O +
extra O +
C O -
- O -
terminal O +
domain O +
packing O +
against O +
the O +
active O +
site O +
cleft O -
. O +

There O +
are O +
two O +
distinct O +
positions O +
of O +
the O +
phosphate O +
group O +
of O +
PLP O -
; O +
one O +
for O +
the O +
subclass B-Gene +
I I-Gene +
aminotransferases I-Gene +
and O +
one O +
for O +
all O +
the O +
others O +
fold O +
type B-Gene +
I I-Gene +
PLP O +
enzymes B-Gene +
( O -
Figure O +
12 O -
) O +
. O +

This O +
is O +
caused O +
by O +
interactions O +
of O +
phosphate O +
oxygen O +
atoms O +
with O +
an O +
arginine O +
residue O +
( O -
Arg266 O +
in O +
aspartate B-Gene +
aminotransferase I-Gene -
) O +
which O +
result O +
in O +
a O +
different O +
tilt O +
of O +
the O +
cofactor O +
in O +
aspartate B-Gene +
and O +
aromatic B-Gene +
amino I-Gene +
acid I-Gene +
aminotransferases I-Gene +
in O +
relation O +
to O +
the O +
other O +
fold O +
type B-Gene +
I I-Gene +
enzymes I-Gene -
. O +

Substrate O +
recognition O +
In O +
order O +
to O +
locate O +
the O +
active O +
site O +
in O +
DAPA B-Gene +
synthase I-Gene -
, O +
the O +
crystal O +
structure O +
of O +
a O +
ternary O +
complex O +
of O +
the O +
enzyme B-Gene +
with O +
PLP O +
and O +
KAPA O +
was O +
determined O +
( O -
Figure O +
7 O -
) O +
. O +

This O +
complex O +
is O +
unproductive O -
, O +
since O +
it O +
combines O +
the O +
PLP O +
form O +
of O +
the O +
cofactor O +
with O +
the O +
amino O +
group O +
acceptor O +
KAPA O -
, O +
which O +
in O +
the O +
catalytic O +
reaction O +
reacts O +
with O +
the O +
pyridoxamine O +
form O +
of O +
the O +
enzyme B-Gene -
. O +

Since O +
KAPA O +
is O +
an O +
amino O +
acid O -
, O +
the O +
question O +
arises O +
as O +
to O +
why O +
it O +
does O +
not O +
act O +
as O +
amino O +
donor O +
in O +
the O +
reaction O -
, O +
i.e. O +
react O +
with O +
the O +
PLP O +
form O +
of O +
the O +
enzyme B-Gene -
. O +

The O +
structure O +
of O +
the O +
ternary O +
complex O +
provides O +
an O +
immediate O +
answer O -
. O +

In O +
order O +
to O +
react O +
with O +
the O +
C-4′ O +
carbon O +
atom O +
of O +
the O +
cofactor O +
to O +
form O +
the O +
internal O +
aldimine O -
, O +
the O +
N8 O +
amino O +
group O +
of O +
KAPA O +
must O +
bind O +
very O +
closely O +
to O +
this O +
part O +
of O +
the O +
cofactor O +
in O +
an O +
orientation O +
favourable O +
for O +
the O +
reaction O +
to O +
occur O -
. O +

In O +
the O +
complex O -
, O +
the O +
N8 O +
amino O +
group O +
is O +
bound O +
tightly O +
to O +
protein B-Gene +
main O -
- O -
chain O +
and O +
side O -
- O -
chain O +
atoms O +
in O +
such O +
a O +
manner O +
that O +
it O +
points O +
away O +
from O +
the O +
internal O +
aldimine O +
group O -
, O +
thus O +
preventing O +
transamination O +
( O -
Figure O +
7 O -
) O +
. O +

The O +
observed O +
binding O +
of O +
KAPA O +
does O +
however O +
position O +
the O +
seven O -
- O -
carbon O +
atom O +
of O +
KAPA O +
close O +
to O +
the O +
aldimine O +
and O +
thereby O +
facilitates O +
transfer O +
of O +
an O +
amino O +
group O +
to O +
this O +
carbon O +
atom O -
, O +
which O +
would O +
yield O +
the O +
product O -
, O +
7,8-diaminopelargonic O +
acid O -
. O +

An O +
important O +
conclusion O +
to O +
be O +
drawn O +
from O +
the O +
structure O +
of O +
the O +
ternary O +
complex O +
is O +
that O +
in O +
DAPA O +
synthase O -
, O +
as O +
opposed O +
to O +
other O +
enzymes B-Gene +
of O +
this O +
class O +
of O +
vitamin O +
B6 O +
-dependent O +
enzymes B-Gene -
, O +
no O +
domain O -
- O -
domain O +
rotation O +
occurs O +
upon O +
substrate O +
binding O -
. O +

The O +
absence O +
of O +
such O +
large O -
- O -
scale O +
conformational O +
changes O +
is O +
not O +
unique O +
for O +
DAPA B-Gene +
synthase I-Gene +
but O +
has O +
also O +
been O +
shown O +
for O +
another O +
enzyme B-Gene +
in O +
this O +
family O -
, O +
human O +
ornithine B-Gene +
aminotransferase I-Gene +
( O -
Shah O +
et O +
al O +
. O -
, O +
1997 O -
) O +
. O +

The O +
substrate O +
reacting O +
with O +
the O +
PLP O +
form O +
of O +
the O +
enzyme B-Gene +
is O +
SAM O +
and O +
the O +
active O +
site O -
, O +
as O +
seen O +
in O +
the O +
holoenzyme B-Gene +
should O +
therefore O +
be O +
poised O +
to O +
bind O +
SAM O -
. O +

The O +
outer O +
part O +
of O +
the O +
active O +
site O +
pocket O +
is O +
quite O +
open O +
and O +
there O +
are O +
several O +
areas O +
which O +
could O +
provide O +
hydrophobic O +
interactions O +
with O +
the O +
adenine O +
ring O +
and O +
still O +
leave O +
space O +
for O +
the O +
sugar O +
moiety O -
. O +

Therefore O -
, O +
modelling O +
the O +
binding O +
site O +
of O +
SAM O +
in O +
DAPA B-Gene +
synthase I-Gene +
is O +
highly O +
speculative O +
and O +
a O +
reliable O +
model O +
for O +
the O +
enzyme B-Gene -
- B-Gene -
PLP I-Gene -
- I-Gene -
SAM I-Gene +
complex O +
will O +
have O +
to O +
await O +
a O +
crystal O +
structure O +
determination O -
. O +

A O +
more O +
detailed O +
discussion O +
of O +
the O +
reaction O +
mechanism O +
of O +
DAPA B-Gene +
synthase I-Gene +
will O +
require O +
structural O +
information O +
from O +
this O +
and O +
other O +
complexes O +
along O +
the O +
reaction O +
pathway O -
, O +
in O +
combination O +
with O +
the O +
results O +
from O +
site O -
- O -
directed O +
mutagenesis O +
experiments O -
. O +

Materials O +
and O +
methods O +
Crystallisation O +
DAPA B-Gene +
synthase I-Gene +
was O +
expressed O -
, O +
purified O +
and O +
crystallised O +
as O +
described O +
( O -
Käck O +
et O +
al O +
. O -
, O +
1998 O -
) O +
, O +
with O +
one O +
modification O +
in O +
the O +
crystallisation O +
protocol O -
. O +

After O +
one O +
week O +
of O +
equilibration O -
, O +
micro O -
- O -
seeding O +
was O +
employed O +
to O +
increase O +
the O +
reproducibility O +
of O +
crystal O +
formation O -
. O +

At O +
the O +
same O +
time O -
, O +
20–40 O +
μl O +
of O +
4 O +
M O +
sodium O +
chloride O +
was O +
added O +
to O +
the O +
well O +
solution O -
. O +

Crystals O +
of O +
the O +
ternary O +
complex O +
DAPA B-Gene +
synthase I-Gene -
- O -
PLP O -
- O -
KAPA O +
were O +
prepared O +
by O +
soaking O +
crystals O +
of O +
the O +
holoenzyme B-Gene +
overnight O +
in O +
5 O +
mM O +
KAPA O -
, O +
25 O +
% O +
PEG-4000 O -
, O +
20 O +
% O +
MPD O -
, O +
100 O +
mM O +
Hepes O +
( O -
pH O +
7.5 O -
) O -
. O +

The O +
substrate O +
KAPA O +
was O +
synthesised O +
as O +
described O +
( O -
Nudelman O +
et O +
al O +
. O -
, O +
1998 O -
) O +
. O +

Data O +
collection O -
, O +
phasing O +
and O +
model O +
building O +
The O +
cell O +
dimensions O +
differed O +
slightly O +
between O +
crystals O -
, O +
reflecting O +
non O -
- O -
isomorphism O +
between O +
crystals O -
. O +

A O +
large O +
number O +
of O +
different O +
heavy O +
atoms O +
were O +
screened O +
in O +
order O +
to O +
find O +
a O +
useful O +
derivative O -
. O +

Finally O -
, O +
crystals O +
soaked O +
for O +
24 O +
hours O +
at O +
4 O -
° O -
C O +
in O +
25 O +
% O +
polyethylene O +
glycol O +
4000 O -
, O +
22 O +
% O +
2-methyl-2,4 O +
pentanediol O +
and O +
5 O +
mM O +
ethyl O +
mercury O +
thiosalicylate O +
( O -
EMTS O -
) O +
or O +
K2 O +
Pt O -
( O -
NO2 O +
) O -
4 O +
at O +
pH O +
7.5 O +
were O +
isomorphous O +
enough O +
to O +
allow O +
identification O +
of O +
the O +
heavy O -
- O -
atom O +
sites O -
. O +

However O -
, O +
neither O +
the O +
multiple O +
isomorphous O +
replacement O +
electron O +
density O +
map O +
nor O +
the O +
2-fold O +
averaged O +
electron O +
density O +
map O +
was O +
interpretable O -
. O +

Multiple O +
anomalous O +
difference O +
data O +
were O +
therefore O +
collected O +
on O +
a O +
EMTS O -
- O -
soaked O +
crystal O +
with O +
cell O +
dimensions O +
a O +
= O -
58.50 O +
Å O -
, O +
b O +
= O -
56.63 O +
Å O -
, O +
c O +
= O -
121.7 O +
Å O +
and O +
β=96.14 O -
° O -
, O +
space O +
group O +
P O +
21 O +
, O +
at O +
beamline O +
BM O +
14 O +
at O +
the O +
ESRF O +
in O +
Grenoble O -
. O +

Data O +
were O +
collected O +
at O +
three O +
different O +
wavelengths O -
, O +
λ1 O +
( O -
peak O -
) O -
=0.9918 O +
Å O -
, O +
λ2 O +
( O -
inflection O +
point O -
) O -
=1.007 O +
Å O +
and O +
λ3 O +
( O -
high O +
energy O +
remote O -
) O -
=0.8265 O +
Å O +
at O +
100 O +
K O +
to O +
2.0 O +
Å O +
resolution O -
. O +

Data O +
processing O +
and O +
scaling O +
were O +
performed O +
with O +
the O +
programs O +
Denzo O +
and O +
Scalepack O +
( O -
Otwinowski O -
, O +
1993 O -
) O +
. O +

Eight O +
mercury O +
sites O +
were O +
identified O +
by O +
visual O +
inspection O +
of O +
the O +
difference O +
Patterson O +
maps O +
and O +
using O +
difference O +
Fourier O +
methods O +
( O -
for O +
phasing O +
statistics O +
see O +
Table O +
1 O +
) O -
. O +

The O +
five O +
strongest O +
peaks O +
coincided O +
with O +
the O +
binding O +
sites O +
determined O +
earlier O -
, O +
while O +
three O +
minor O +
sites O +
differed O +
in O +
their O +
positions O -
, O +
compared O +
to O +
those O +
previously O +
derived O -
. O +

A O +
map O +
calculated O +
after O +
refinement O +
of O +
the O +
parameters O +
of O +
the O +
mercury O +
positions O +
using O +
mlphare O +
( O -
Otwinowski O -
, O +
1991 O -
) O +
and O +
solvent O +
flattening O +
by O +
DM O +
( O -
Cowtan O +
& O +
Main O -
, O +
1996 O -
) O +
was O +
of O +
excellent O +
quality O -
, O +
and O +
backbone O +
tracing O +
and O +
sequence O +
assignment O +
( O -
Otsuka O +
et O +
al O +
. O -
, O +
1988 O -
) O +
were O +
straighforward O +
for O +
the O +
whole O +
protein B-Gene +
except O +
for O +
two O +
mobile O +
regions O +
containing O +
residues O +
160 O +
to O +
183 O +
and O +
298 O +
to O +
304 O -
, O +
respectively O -
; O +
2-fold O +
averaging O +
did O +
not O +
improve O +
the O +
map O +
significantly O -
. O +

The O +
model O +
was O +
refined O +
using O +
XPLOR O +
( O -
Brünger O +
et O +
al O +
. O -
, O +
1987 O -
) O +
with O +
NCS O +
constraints O +
to O +
R O +
free O +
= O -
35.9 O +
% O +
and O +
R O +
= O -
30.4 O +
% O +
without O +
including O +
mercury O +
atoms O -
. O +

A O +
native O +
data O +
set O +
was O +
collected O +
using O +
a O +
300 O +
mm O +
MAR O +
image O +
plate O +
detector O +
( O -
MAR O +
research O +
Hamburg O -
) O +
at O +
beam O +
line O +
X11 O +
at O +
EMBL O +
in O +
Hamburg O +
to O +
1.8 O +
Å O +
resolution O +
( O -
for O +
data O +
collection O +
statistics O +
see O +
Table O +
1 O +
) O -
. O +

The O +
cell O -
- O -
dimensions O +
of O +
this O +
crystal O +
were O +
a O +
= O -
58.3 O +
Å O -
, O +
b O +
= O -
55.6 O +
Å O -
, O +
c O +
= O -
120.9 O +
Å O +
and O +
β=97.0 O -
° O -
, O +
space O +
group O +
P O +
21 O +
. O +

Diffraction O +
data O +
for O +
the O +
ternary O +
complex O +
DAPA B-Gene +
synthase I-Gene -
- O -
PLP O -
- O -
KAPA O +
were O +
collected O +
at O +
100 O +
K O +
to O +
2.7 O +
Å O +
on O +
a O +
Mar O +
Research O +
image O +
plate O +
mounted O +
on O +
a O +
Rikagu O +
rotating O +
anode O +
operating O +
at O +
50 O +
kV O +
and O +
90 O +
mA. O +
Data O +
were O +
processed O +
and O +
scaled O +
using O +
Denzo O +
and O +
Scalepack O +
software O +
package O +
( O -
Otwinowski O -
, O +
1993 O -
) O +
. O +

Data O +
collection O +
statistics O +
are O +
given O +
in O +
Table O +
1 O +
. O +

The O +
cell O -
- O -
dimensions O +
of O +
this O +
crystal O +
were O +
a O +
= O -
58.0 O +
Å O -
, O +
b O +
= O -
55.9 O +
Å O -
, O +
c O +
= O -
120.8 O +
Å O +
and O +
β=95.7 O -
° O -
. O +

Refinement O +
Because O +
of O +
non O -
- O -
isomorphism O +
between O +
the O +
crystals O -
, O +
molecular O +
replacement O +
had O +
to O +
be O +
used O +
in O +
order O +
to O +
find O +
the O +
position O +
of O +
the O +
native O +
enzyme B-Gene +
in O +
the O +
unit O +
cell O -
. O +

The O +
program O +
AMORE O +
( O -
Navaza O -
, O +
1994 O -
) O +
was O +
used O +
for O +
this O +
task O +
with O +
the O +
dimer O +
as O +
the O +
search O +
molecule O -
. O +

Before O +
refinement O -
, O +
the O +
same O +
set O +
of O +
reflections O +
( O -
in O +
total O +
5 O +
% O +
of O +
the O +
reflection O +
data O -
) O +
were O +
set O +
aside O +
to O +
monitor O +
R O +
free O +
. O +

The O +
top O +
solution O +
( O -
correlation O +
coefficient=76.7 O +
% O -
) O +
gave O +
an O +
R O +
free O +
of O +
37.5 O +
% O +
after O +
an O +
initial O +
rigid O +
body O +
refinement O +
to O +
2.5 O +
Å O +
resolution O +
using O +
the O +
program O +
XPLOR O +
( O -
Brünger O +
et O +
al O +
. O -
, O +
1987 O -
) O +
. O +

A O +
clear O +
and O +
strong O +
difference O +
density O +
was O +
found O +
at O +
the O +
position O +
of O +
the O +
cofactor O -
, O +
PLP O -
, O +
which O +
had O +
not O +
been O +
included O +
in O +
the O +
model O -
, O +
confirming O +
that O +
this O +
was O +
the O +
correct O +
solution O -
. O +

After O +
rigid O +
body O +
refinement O +
the O +
structure O +
was O +
rebuilt O +
using O +
the O +
program O +
O O +
( O -
Jones O +
et O +
al O +
. O -
, O +
1991 O -
) O +
and O +
refined O +
using O +
the O +
maximum O +
likelihood O +
method O +
as O +
implemented O +
in O +
Refmac O +
( O -
Murshudov O +
et O +
al O +
. O -
, O +
1997 O -
) O +
with O +
strong O +
NCS O +
restraints O +
giving O +
R O +
= O -
35.4 O +
% O +
and O +
R O +
free O +
= O -
36.4 O +
% O +
after O +
the O +
first O +
round O +
of O +
refinement O -
. O +

On O +
the O +
basis O +
of O +
a O +
sigma O -
- O -
weighted O +
electron O +
density O +
map O +
calculated O +
subsequently O -
, O +
residues O +
162 O -
- O -
180 O +
and O +
residues O +
298 O -
- O -
303 O +
missing O +
from O +
the O +
previous O +
model O +
could O +
be O +
modelled O -
. O +

After O +
the O +
second O +
round O +
of O +
refinement O +
PLP O +
was O +
included O +
in O +
the O +
model O -
. O +

In O +
subsequent O +
refinement O +
runs O +
the O +
loop O +
region O +
between O +
residue O +
181 O +
and O +
191 O +
was O +
built O -
. O +

In O +
one O +
of O +
the O +
subunits O +
residue O +
183 O +
is O +
still O +
not O +
included O +
in O +
the O +
final O +
model O -
. O +

Eighty O +
water O +
molecules O +
were O +
included O +
after O +
each O +
refinement O +
cycle O +
using O +
the O +
program O +
arp O +
( O -
Lamzin O +
& O +
Wilson O -
, O +
1993 O -
) O +
, O +
resulting O +
in O +
a O +
final O +
number O +
of O +
556 O +
water O +
molecules O +
of O +
which O +
about O +
two O +
thirds O +
follow O +
the O +
NCS O -
. O +

All O +
solvent O +
sites O +
were O +
inspected O +
manually O -
. O +

Non O -
- O -
crystallographic O +
restraints O +
were O +
used O +
until O +
the O +
last O +
stages O +
of O +
the O +
refinement O -
, O +
their O +
release O +
resulted O +
in O +
a O +
slight O +
drop O +
of O +
the O +
free O +
R O +
value O -
. O +

The O +
quality O +
of O +
the O +
final O +
model O +
was O +
assessed O +
with O +
PROCHECK O +
( O -
Laskowski O +
et O +
al O +
. O -
, O +
1993 O -
) O +
. O +

The O +
structure O +
of O +
the O +
ternary O +
complex O +
was O +
determined O +
to O +
2.7 O +
Å O +
by O +
difference O +
Fourier O +
methods O -
. O +

Initial O +
phases O +
were O +
calculated O +
from O +
the O +
refined O +
model O +
of O +
the O +
holoenzyme B-Gene -
, O +
with O +
the O +
water O +
molecules O +
and O +
the O +
sodium O +
ions O +
excluded O -
. O +

A O +
KAPA O +
molecule O +
was O +
fitted O +
into O +
the O +
difference O +
electron O +
density O +
found O +
in O +
the O +
active O +
site O +
close O +
to O +
the O +
PLP O +
cofactor O -
; O +
5 O +
% O +
of O +
the O +
reflection O +
data O +
were O +
excluded O +
from O +
the O +
refinement O +
and O +
used O +
to O +
calculate O +
the O +
free O +
R O +
value O -
. O +

The O +
model O +
of O +
the O +
ternary O +
complex O +
was O +
refined O +
using O +
Refmac O +
( O -
Murshudov O +
et O +
al O +
. O -
, O +
1997 O -
) O +
, O +
starting O +
in O +
the O +
first O +
cycle O +
as O +
a O +
rigid O +
body O +
refinement O -
. O +

Cycles O +
of O +
refinement O +
were O +
followed O +
by O +
manual O +
intervention O +
using O +
the O +
graphics O +
program O +
O O +
( O -
Jones O +
et O +
al O +
. O -
, O +
1991 O -
) O +
. O +

The O +
final O +
model O +
contains O +
94 O +
water O +
molecules O +
and O +
two O +
sodium O +
ions O -
, O +
refinement O +
statistics O +
are O +
given O +
in O +
Table O +
2 O +
. O +

Structural O +
alignments O +
and O +
database O +
searches O +
The O +
program O +
TOP O +
( O -
Lu O -
, O +
1996 O -
) O +
was O +
used O +
for O +
searching O +
the O +
Protein B-Gene +
Data O +
Bank O +
with O +
the O +
large O +
domain O +
of O +
the O +
refined O +
model O +
of O +
DAPA B-Gene +
synthase I-Gene +
as O +
probe O +
and O +
for O +
subsequent O +
superpositions O -
. O +

Exclusion O +
of O +
mutant O +
structures O +
and O +
complexes O +
resulted O +
in O +
15 O +
different O +
PLP O +
enzymes B-Gene +
with O +
identical O +
topology O -
. O +

Five O +
of O +
these O +
were O +
structures O +
of O +
aspartate B-Gene +
aminotransferases I-Gene +
from O +
different O +
sources O -
. O +

As O +
these O +
enzymes B-Gene +
are O +
very O +
similar O -
, O +
only O +
one O +
of O +
these O -
, O +
the O +
E. O +
coli O +
enzyme B-Gene -
, O +
was O +
included O +
in O +
the O +
subsequent O +
multiple O +
structure O +
alignment O -
. O +

For O +
the O +
same O +
reason O -
, O +
only O +
one O +
of O +
the O +
two O +
structures O +
of O +
phosphoserine B-Gene +
aminotransferase I-Gene -
, O +
deposited O +
in O +
the O +
Protein B-Gene +
Data O +
Bank O +
was O +
used O +
in O +
the O +
following O +
multiple O +
structural O +
alignment O -
. O +

Generally O -
, O +
the O +
internal O +
aldimine O +
form O +
of O +
the O +
enzymes B-Gene +
was O +
used O +
in O +
this O +
comparison O -
. O +

The O +
domain O -
- O -
domain O +
orientation O +
as O +
compared O +
with O +
DAPA B-Gene +
synthase I-Gene +
varies O +
substantially O +
between O +
different O +
enzymes B-Gene -
, O +
from O +
27 O -
° O +
rotation O +
for O +
aspartate B-Gene +
aminotransferase I-Gene +
to O +
6 O -
° O +
rotation O +
for O +
ornithine B-Gene +
aminotransferase I-Gene -
. O +

In O +
order O +
to O +
extend O +
the O +
structural O +
alignment O +
and O +
comparison O +
to O +
the O +
whole O +
subunit O +
of O +
these O +
enzymes B-Gene -
, O +
a O +
second O +
topological O +
alignment O +
was O +
carried O +
out O +
using O +
the O +
small O +
domain O +
of O +
DAPA B-Gene +
synthase I-Gene +
as O +
search O +
model O -
. O +

The O +
superposed O +
large O +
and O +
small O +
domains O +
were O +
then O +
artificially O +
connected O +
with O +
the O +
same O +
rotation O +
as O +
in O +
DAPA B-Gene +
synthase I-Gene -
. O +

This O +
set O +
of O +
enzyme B-Gene +
models O +
formed O +
the O +
basis O +
for O +
the O +
multiple O +
structural O +
alignment O +
using O +
the O +
program O +
MAPS O +
( O -
G. O +
Lu O -
, O +
unpublished O -
) O -
. O +

In O +
this O +
program O -
, O +
an O +
initial O +
alignment O +
is O +
carried O +
out O +
using O +
the O +
same O +
algorithm O +
as O +
in O +
TOP O +
( O -
Lu O -
, O +
1996 O -
) O +
. O +

The O +
program O +
then O +
proceeds O +
by O +
minimising O +
a O +
target O +
function O +
made O +
up O +
by O +
the O +
sum O +
of O +
pairwise O +
distances O +
between O +
equivalent O +
Cα O +
atoms O -
. O +

Segments O +
identified O +
as O +
structurally O +
equivalent O +
must O +
fulfil O +
certain O +
criteria O -
: O +
( O -
i O -
) O +
consist O +
of O +
at O +
least O +
three O +
consecutive O +
residues O -
; O +
( O -
ii O -
) O +
the O +
distance O +
between O +
aligned O +
Cα O +
—Cα O +
atoms O +
should O +
not O +
exceed O +
3.8 O +
Å O -
; O +
and O +
( O -
iii O -
) O +
the O +
side O -
- O -
chain O +
should O +
point O +
in O +
a O +
similar O +
direction O +
( O -
the O +
angles O +
formed O +
by O +
the O +
Cα O +
—Cβ O +
bond O +
between O +
equivalent O +
residues O +
should O +
not O +
exceed O +
50 O -
° O -
) O -
. O +

The O +
result O +
of O +
the O +
multiple O +
alignment O +
is O +
presented O +
in O +
terms O +
of O +
aligned O +
residues O +
between O +
all O +
proteins B-Gene +
and O +
an O +
alignment O +
score O +
of O +
r.m.s. O -
/ O -
( O -
N O +
match O +
/N O +
average O +
) O -
a O +
( O -
structure O +
diversity O +
factor O -
) O -
, O +
where O +
a O +
is O +
chosen O +
empirically O +
as O +
1.5 O -
. O +

The O +
structure O +
diversity O +
score O +
can O +
be O +
used O +
to O +
illustrate O +
the O +
structural O +
and O +
possibly O +
evolutionary O +
relationships O +
between O +
the O +
aligned O +
enzymes B-Gene -
. O +

Protein B-Gene +
data O +
bank O +
accession O +
Number O +

The O +
atomic O +
coordinates O +
and O +
observed O +
structure O +
factor O +
amplitudes O +
have O +
been O +
deposited O +
with O +
the O +
Protein B-Gene +
Data O +
Bank O -
, O +
Brookhaven O -
, O +
with O +
accession O +
codes O +
1qj5 O -
, O +
1qj5sf O +
for O +
the O +
enzyme B-Gene -
- O -
PLP O +
and O +
1qj3 O -
, O +
r1qj3sf O +
for O +
the O +
enzyme B-Gene -
- O -
PLP O -
- O -
KAPA O +
complex O -
, O +
respectively O -
. O +

Acknowledgements O +

We O +
thank O +
Ivan O +
M. O +
Turner O +
Sr O +
for O +
excellent O +
technical O +
assistance O +
and O +
Tom O +
Milller O +
for O +
carrying O +
out O +
the O +
N O -
- O -
terminal O +
sequencing O -
. O +

We O +
acknowledge O +
access O +
to O +
synchrotron O +
radiation O +
at O +
the O +
ESRF O -
, O +
Grenoble O -
, O +
France O -
, O +
and O +
thank O +
Dr O +
Andy O +
Thompson O +
at O +
beamline O +
BM14 O +
for O +
assistance O +
and O +
advice O +
with O +
data O +
collection O -
. O +

We O +
also O +
acknowledge O +
access O +
to O +
beamline O +
X11 O -
, O +
EMBL O +
outstation O -
, O +
c O -
/ O -
o O +
DESY O -
, O +
Hamburg O -
. O +

This O +
work O +
was O +
supported O +
by O +
the O +
Swedish O +
Agricultural O +
Research O +
Council O +
and O +
the O +
Swedish O +
Natural O +
Science O +
Research O +
Council O -
. O +

Stilbenes O +
occur O +
naturally O +
in O +
a O +
number O +
of O +
plant O +
families O +
[ O -
1 O -
] O +
but O +
grapes O +
and O +
related O +
products O +
are O +
considered O +
the O +
most O +
important O +
dietary O +
sources O +
of O +
these O +
substances O +
[ O -
2,3 O -
] O +
. O +

Trans O +
-resveratrol O +
and O +
the O +
3-O O -
- O -
β O -
- O -
glucoside O +
of O +
trans O +
-resveratrol O -
, O +
trans O +
-piceid O -
, O +
were O +
recently O +
identified O +
in O +
wine O +
[ O -
4–6 O -
] O +
. O +

Another O +
compound O +
3′-OH O -
- O -
trans O +
-piceid O +
( O -
trans O +
-astringin O -
) O +
has O +
recently O +
been O +
reported O +
to O +
be O +
a O +
constituent O +
of O +
Vitis O +
vinifera O +
cells O +
[ O -
7 O -
] O +
( O -
Fig. O +
1 O +
) O -
. O +

The O +
beneficial O +
role O +
that O +
moderate O +
wine O +
consumption O +
may O +
have O +
in O +
preventing O +
cardiovascular O +
disease O +
is O +
still O +
under O +
debate O +
[ O -
8 O -
] O +
, O +
and O +
great O +
interest O +
has O +
been O +
focused O +
on O +
stilbenes O -
. O +

Trans- O +
astringin O +
has O +
been O +
reported O +
to O +
have O +
antioxidant O +
properties O -
, O +
inhibiting O +
in O +
particular O +
the O +
oxidation O +
of O +
human O +
LDL O +
in O +
vitro O +
[ O -
9 O -
] O +
, O +
but O +
its O +
occurrence O +
in O +
wine O +
has O +
never O +
been O +
reported O -
. O +

The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
develop O +
a O +
simple O +
and O +
sensitive O +
method O +
to O +
determine O +
this O +
occurrence O -
. O +

A O +
HPLC O +
method O +
coupled O +
with O +
fluorimetric O +
detection O +
was O +
developed O +
for O +
this O -
. O +

2 O +
Experimental O +
Methanol O +
and O +
acetic O +
acid O +
were O +
purchased O +
from O +
Carlo O +
Erba O +
( O -
Val O +
de O +
Reuil O -
, O +
France O -
) O +
and O +
Merck O +
( O -
Nogent O +
sur O +
Marne O -
, O +
France O -
) O -
. O +

Trans O +
-astringin O +
was O +
obtained O +
from O +
cell O +
suspension O +
cultures O +
[ O -
10 O -
] O +
and O +
identified O +
unambiguously O +
by O +
MS O +
and O +
NMR O +
as O +
previously O +
described O +
[ O -
7 O -
] O +
. O +

The O +
fluorescence O +
properties O +
of O +
trans O +
-astringin O +
were O +
determined O +
with O +
the O +
1064 O +
Hewlett O -
- O -
Packard O +
spectrofluorimeter O -
. O +

Calibration O +
was O +
performed O +
with O +
solutions O +
of O +
different O +
concentrations O +
of O +
trans O +
-astringin O +
obtained O +
by O +
suitable O +
dilution O +
of O +
methanolic O +
solution O +
at O +
10 O +
mg O -
/ O -
l O -
. O +

Standard O +
solutions O +
were O +
stored O +
at O +
−20 O -
° O -
C O +
and O +
protected O +
from O +
light O -
. O +

The O +
linear O +
regression O +
was O +
Y O +
= O -
499.9x O +
−0.8 O +
( O -
r O +
= O -
0.999 O -
; O +
CV<4.71 O -
) O -
. O +

2.1 O +
HPLC O +
analysis O +
A O +
Hewlett O -
- O -
Packard O +
Model O +
1100 O +
with O +
two O +
low O +
pressure O +
pumps O +
and O +
a O +
1064 O +
Hewlett O -
- O -
Packard O +
fluorimetric O +
detector O +
coupled O +
to O +
an O +
HP O +
Chem O +
Station O +
were O +
used O +
for O +
solvent O +
delivery O +
system O +
and O +
detection O -
. O +

A O +
Hewlett O -
- O -
Packard O +
column O -
, O +
packed O +
with O +
Nucleosil O +
100 O +
C18 O -
, O +
250 O -
× O -
4 O +
mm O -
, O +
5 O +
μm O +
particle O +
size O +
was O +
used O +
for O +
the O +
stationary O +
phase O -
. O +

The O +
eluents O +
were O +
for O +
solvent O +
A O -
, O +
an O +
aqueous O +
solution O +
of O +
20 O +
mM O +
acetic O +
acid O -
, O +
and O +
for O +
solvent O +
B O -
, O +
methanol O +
( O -
HPLC O +
grade O -
) O -
; O +
both O +
were O +
filtered O +
through O +
0.45 O +
μm O +
Millipore O +
filters O -
. O +

Elution O +
was O +
performed O +
with O +
the O +
following O +
gradient O -
: O +
0–5 O +
min O +
98 O -
% O +
solvent O +
A O -
; O +
5–12 O +
min O +
from O +
98 O +
to O +
93 O -
% O +
solvent O +
A O -
; O +
12–18 O +
min O +
from O +
93 O +
to O +
89 O -
% O +
A O -
; O +
18–28 O +
min O +
from O +
89 O +
to O +
85 O -
% O +
A O -
; O +
28–38 O +
min O +
from O +
85 O +
to O +
70 O -
% O -
; O +
38–48 O +
min O +
from O +
70 O +
to O +
60 O -
% O -
; O +
48–55 O +
min O +
from O +
60 O +
to O +
50 O -
% O +
A O -
, O +
55–75 O +
min O +
50 O -
% O +
A. O +

The O +
flow O +
rate O +
was O +
0.5 O +
ml O -
/ O -
min O -
. O +

Ten O +
French O +
wines O +
( O -
5 O +
red O -
, O +
5 O +
white O -
) O +
from O +
the O +
South O +
of O +
France O +
were O +
analyzed O -
. O +

Wine O +
samples O +
were O +
directly O +
injected O +
into O +
the O +
HPLC O +
system O +
after O +
dilution O +
in O +
bi O -
- O -
distilled O +
water O +
and O +
filtration O +
( O -
Millex O -
- O -
FH13 O -
; O +
Millipore O -
; O +
St. O +
Quentin O -
, O +
Yvelines O -
, O +
France O -
) O -
. O +

Dilution O +
of O +
1 O -
/ O -
3 O +
was O +
used O -
, O +
and O +
20 O +
μl O +
were O +
injected O -
. O +

3 O +
Results O +
and O +
discussion O +
The O +
maximum O +
excitation O +
and O +
emission O +
wavelength O +
in O +
a O +
methanolic O +
solution O +
as O +
well O +
as O +
in O +
a O +
mixture O +
of O +
20 O +
mM O +
methanol O -
– O -
acetic O +
acid O +
( O -
v O -
/ O -
v O -
, O +
50:50 O -
) O +
( O -
the O +
composition O +
of O +
the O +
trans O +
-astringin O +
gradient O +
was O +
measured O +
when O +
in O +
the O +
spectrofluorimeter O +
cell O -
) O +
were O +
298 O +
and O +
400 O +
nm O +
respectively O -
. O +

The O +
threshold O +
of O +
detection O +
was O +
defined O +
as O +
the O +
amount O +
of O +
the O +
compound O +
resulting O +
in O +
a O +
peak O +
10-fold O +
higher O +
than O +
the O +
standard O +
deviation O +
of O +
the O +
baseline O +
noise O -
. O +

This O +
was O +
found O +
to O +
be O +
0.03 O +
mg O -
/ O -
l O -
. O +

Chromatograms O +
of O +
trans O +
-astringin O +
and O +
of O +
a O +
red O +
wine O +
sample O +
monitored O +
by O +
fluorescence O +
detection O +
are O +
reported O +
in O +
Fig. O +
2A O +
and O +
B O +
. O +

The O +
retention O +
time O +
was O +
53.7 O +
min O -
. O +

The O +
HPLC O +
separation O +
and O +
the O +
good O +
resolution O +
of O +
the O +
peak O +
without O +
interference O +
allowed O +
the O +
identification O +
of O +
the O +
trans O +
-astringin O -
. O +

A O +
co O -
- O -
chromatographic O +
analysis O +
was O +
also O +
performed O -
; O +
it O +
confirmed O +
the O +
identification O +
of O +
trans O +
-astringin O +
by O +
HPLC O +
with O +
fluorimetric O +
detection O -
. O +

The O +
chromatogram O +
of O +
the O +
wine O +
in O +
which O +
trans O +
-astringin O +
was O +
added O +
is O +
reported O +
in O +
Fig. O +
2C O +
. O +

This O +
progressive O +
gradient O +
run O +
developed O +
here O +
has O +
allowed O +
the O +
analysis O +
of O +
other O +
stilbenes O -
: O +
trans O +
-resveratrol O -
, O +
trans O +
-piceid O +
[ O -
11 O -
] O +
, O +
and O +
other O +
phenolic O +
compounds O +
such O +
as O +
( O -
+ O -
) O -
-catechin O -
, O +
tyrosol O -
, O +
gentisic O +
acid O +
[ O -
12 O -
] O +
. O +

The O +
standard O +
methanolic O +
solution O +
of O +
trans O +
-astringin O +
was O +
stable O +
for O +
at O +
least O +
30 O +
days O +
at O +
−20 O -
° O -
C O +
in O +
the O +
dark O -
. O +

When O +
this O +
solution O +
was O +
exposed O +
to O +
wide O -
- O -
spectrum O +
fluorescent O +
lighting O +
at O +
a O +
light O +
intensity O +
of O +
40 O +
μmol O +
m−2 O +
s−1 O +
at O +
25 O -
° O -
C O -
, O +
no O +
degradation O +
of O +
trans O +
-astringin O +
was O +
observed O +
during O +
the O +
first O +
two O +
h O -
, O +
corresponding O +
to O +
the O +
time O +
of O +
analysis O -
. O +

Therefore O -
, O +
trans O +
-astringin O +
can O +
be O +
handled O +
in O +
the O +
laboratory O +
without O +
very O +
stringent O +
precautions O -
. O +

We O +
found O +
low O +
levels O +
of O +
trans O +
-astringin O +
in O +
the O +
wine O +
analyzed O -
, O +
and O +
the O +
results O +
were O +
confirmed O +
by O +
mass O +
spectrometry O -
. O +

Trans O +
-astringin O +
was O +
extracted O +
from O +
red O +
wine O +
and O +
FAB O -
- O -
MS O +
spectra O +
showed O +
a O +
[ O -
MH O -
] O -
+ O +
peak O +
at O +
m O -
/ O -
z O +
407 O +
( O -
C20 O +
H22 O +
O9 O +
requires O +
406 O -
) O -
. O +

In O +
this O +
research O -
, O +
trans O +
-astringin O +
is O +
reported O +
for O +
the O +
first O +
time O +
to O +
be O +
present O +
in O +
both O +
red O +
and O +
white O +
wines O -
. O +

Concentrations O +
ranged O +
from O +
0.09 O +
mg O -
/ O -
l O +
to O +
0.29 O +
mg O -
/ O -
l O +
for O +
red O +
wines O +
and O +
from O +
0.10 O +
mg O -
/ O -
l O +
to O +
0.22 O +
mg O -
/ O -
l O +
for O +
white O +
wines O -
. O +

To O +
study O +
the O +
reproducibility O -
, O +
the O +
same O +
red O +
and O +
white O +
wine O +
samples O +
were O +
analyzed O +
on O +
five O +
different O +
days O -
. O +

The O +
CV O +
obtained O +
were O +
less O +
than O +
4.72 O -
% O +
for O +
red O +
wines O +
and O +
less O +
than O +
4.23 O -
% O +
for O +
white O +
wines O -
. O +

Fluorimetric O +
detection O +
evidenced O +
low O +
levels O +
of O +
trans O +
-astringin O +
in O +
wine O -
. O +

As O +
already O +
described O +
by O +
Pezet O +
et O +
al. O +
[ O -
13 O -
] O +
for O +
trans- O +
resveratrol O +
and O +
pterostilbene O -
, O +
the O +
use O +
of O +
a O +
fluorimetric O +
detector O +
is O +
well O +
adapted O +
to O +
the O +
low O +
concentrations O +
of O +
stilbenes O +
in O +
wines O -
. O +

In O +
particular O -
, O +
no O +
prior O +
treatment O +
of O +
the O +
wine O +
sample O +
is O +
required O -
. O +

For O +
the O +
ten O +
French O +
wines O +
analyzed O +
here O -
, O +
no O +
large O +
differences O +
were O +
observed O +
between O +
red O +
and O +
white O +
wines O -
, O +
but O +
analysis O +
of O +
more O +
samples O +
of O +
commercial O +
wine O +
is O +
needed O +
to O +
estimate O +
the O +
dietary O +
impact O +
and O +
bioavailability O +
of O +
the O +
trans O +
-astringin O +
in O +
the O +
wines O +
of O +
world O -
. O +

4 O +
Conclusion O +
The O +
present O +
method O +
for O +
the O +
analysis O +
of O +
trans O +
-astringin O +
in O +
wine O +
combines O +
the O +
simplicity O +
of O +
direct O +
HPLC O +
injection O +
with O +
the O +
sensitivity O +
of O +
fluorescence O +
detection O -
. O +

Acknowledgements O +
The O +
authors O +
thank O +
Ray O +
Cooke O +
for O +
revising O +
the O +
English O +
manuscript O +
and O +
F. O +
Gasc O +
for O +
glassware O +
expertise O -
. O +

DNA B-Gene +
topoisomerases I-Gene +
are O +
the O +
enzymes B-Gene +
which O +
regulate O +
the O +
state O +
of O +
DNA O +
topology O -
. O +

The O +
enzymes B-Gene +
are O -
, O +
therefore O -
, O +
important O +
for O +
DNA O +
metabolism O -
, O +
such O +
as O +
replication O -
, O +
recombination O +
and O +
transcription O -
) O +

Nidulalin O +
A O -
( O -
1 O -
) O -
2 O +
and O +
its O +
derivatives O -
, O +
F390B O -
( O -
2 O -
) O +
and O +
C O -
( O -
3 O -
) O -
, O +
were O +
isolated O +
from O +
Penicillium O +
sp. O +
as O +
potent O +
cytotoxic O +
agents O +
( O -
Figure O +
1 O -
) O -
.3 O +
Nidulalin O +
A O -
, O +
a O +
major O +
metabolite O +
of O +
the O +
producing O +
strain O -
, O +
showed O +
potent O +
inhibitory O +
activity O +
against O +
DNA B-Gene +
topoisomerase I-Gene +
II I-Gene -
( O -
Topo B-Gene +
II I-Gene -
) O +
in O +
vitro.4 O +
The O +
antitumor O +
activity O +
of O +
nidulalin O +
A O +
against O +
Colon O +
26 O +
routine O +
adenocarcinoma O +
was O +
evaluated O +
in O +
vivo O -
, O +
however O -
, O +
no O +
antitumor O +
effect O +
was O +
observed O -
. O +

Further O +
investigation O +
revealed O +
that O +
rapid O +
hydrolysis O +
and O +
decarboxylation O +
of O +
the O +
methyl O +
ester O +
moiety O +
of O +
1 O +
by O +
esterases B-Gene +
in O +
murine O +
plasma O +
gave O +
an O +
inactive O +
xanthone O +
derivative O +
4 O -
, O +
which O +
was O +
identical O +
to O +
the O +
compound O +
derived O +
from O +
1 O +
by O +
alkaline O +
hydrolysis O -
. O +

This O +
result O +
prompted O +
us O +
to O +
synthesize O +
stable O +
analogs O +
against O +
hydrolysis O -
. O +

In O +
this O +
communication O -
, O +
we O +
report O +
synthesis O +
and O +
antitumor O +
activity O +
of O +
derivatives O +
of O +
nidulalin O +
A O +
with O +
amide O +
moieties O +
in O +
place O +
of O +
the O +
methoxycarbonyl O +
group O -
. O +

Figure O +
1 O +
MeO2C O +
ORe O +
Nidulalin O +
A O -
( O -
1 O -
) O +
RI O -
= O -
R2 O -
= O -
H O +
F390B O -
( O -
2 O -
) O +
R~=H O -
, O +
R2 O -
= O -
Ac O +
F390C O -
( O -
3 O -
) O +
RI O -
= O -
OH O -
, O +
R2 O -
= O -
H O +
4 O +
0960 O -
- O -
894X O -
/ O -
99 O -
/ O -
$ O +
- O +
see O +
front O +
matter O +
1999 O +
Elsevier O +
Science O +
Ltd. O +
All O +
rights O +
reserved O -
. O +

PII O -
: O +
S0960 O -
- O -
894X O -
( O -
99 O -
) O -
00440 O -
- O -
0 O +
2654 O +
S. O +
Sato O +
et O +
al. O +
/ O +
Bioorg O -
. O +

Med O -
. O +

Chem O -
. O +

Lett O -
. O +

9 O +
( O -
1999 O -
) O +
2653 O -
- O -
2656 O +
Synthesis O +
The O +
syntheses O +
of O +
amide O +
analogs O +
of O +
nidulalin O +
A O +
are O +
outlined O +
in O +
Scheme O +
1 O -
. O +

Direct O +
amidation O +
by O +
methylamine O +
in O +
MeOH O +
afforded O +
approximately O +
4:3 O +
mixture O +
of O +
lactams O +
10a O +
and O +
10b O +
via O +
Michael O +
addition O +
followed O +
by O +
intramolecular O +
aminolysis O -
( O -
Scheme O +
2 O -
) O -
. O +

To O +
avoid O +
lactam O +
formation O -
, O +
nidulalin O +
A O +
was O +
reduced O +
by O +
NaBH4 O +
in O +
MeOH O +
to O +
give O +
a O +
tetrahydroxanthone O +
derivative O +
5 O +
in O +
87 O -
% O +
yield,5 O +
which O +
was O +
treated O +
with O +
1N O +
NaOH O +
followed O +
by O +
acetylation O +
with O +
acetic O +
anhydride O +
in O +
pyridine O +
to O +
give O +
carboxylic O +
acid O +
6 O -
. O +

Condensation O +
of O +
6 O +
with O +
various O +
amines O -
, O +
including O +
ammonia O -
, O +
methylamine O -
, O +
dimethylamine O -
, O +
2-aminoethanol O -
, O +
and O +
pyrrolidine O -
, O +
via O +
acid O +
chloride O +
followed O +
by O +
acetylation O +
of O +
a O +
hydroxyl O +
group O -
, O +
which O +
was O +
generated O +
during O +
amine O +
treatment O -
, O +
gave O +
corresponding O +
amides O +
7a O -
- O -
e O -
, O +
respectively O -
. O +

Oxidation O +
of O +
7a O +
with O +
SeOz O +
in O +
dioxane O +
at O +
65 O +
gave O +
a O +
dihydroxanthone O +
derivative O +
8a O +
in O +
18 O -
% O +
yield O -
. O +

In O +
the O +
same O +
manner O -
, O +
7h O -
- O -
e O +
were O +
converted O +
to O +
8h O -
- O -
e O -
, O +
respectively O -
. O +

The O +
acetyl O +
groups O +
of O +
8a O -
- O -
e O +
were O +
removed O +
by O +
alkaline O +
hydrolysis O +
to O +
give O +
amide O +
analogs O +
9a O -
- O -
e O -
, O +
respectively.6 O +
Scheme O +
1 O +
H O -
~ O -
a O +
" O -
Me,"~ O +
b'c O +
" O -
M~-O~. O +
Y O +
M O +
87 O -
% O +
~ O +
, O -
^,,- O -
, O +
7- O +
i O -
.. O +
91 O -
% O +
.. O +

_ O +
.=. O +
, O +
~w O -
~ O -
v2'~ O -
' O +
OH O +
I'-IU2U O +
OAc O +
Nidulalin O +
A O -
( O -
1 O -
) O +

5 O +
6 O +
65 O -
- O -
97 O +
Yo O +
ROC O +
( O -
~Ac O +
17 O -
- O -
35o O +
Me O -
" O +
" O -
~ O +
-ROo~ O +
OTAc O +
quan O -
. O +

7a O +
R O -
= O -
NH2 O +
8a O +
R O -
= O -
NH2 O +
9a O +
R O -
= O -
NH2 O +
7b O +
R O -
= O -
NHMe O +
8b O +
R O -
= O -
NHMe O +
9b O +
R O -
= O -
NHMe O +
7R O -
= O -
NMe2 O +
8c O +
R O -
= O -
NMe2 O +
9c O +
R O -
= O -
NMe2 O +
7d O +
R O -
= O -
NHCH2CH2OAc O +
8d O +
R O -
= O -
NHCH2CH2OAc O +
9d O +
R O -
= O -
NHCH2CH2OH O +
a O -
) O +
NaBH4 O -
, O +
MeOH O -
, O +
5 O +
b O -
) O +
1N O +
NaOH O -
, O +
5 O +
c O -
) O +
Ac20 O -
, O +
pyridine O -
, O +
rt O +
d O -
) O +
SOCI2 O -
, O +
cat O -
. O +

DMF O -
, O +
CH2CI2 O -
, O +
rt O +
e O -
) O +
aq O -
. O +

amines O -
, O +
5 O +
f O -
) O +
Ac20 O -
, O +
pyridine O -
, O +
rt O +
g O -
) O +
SeO2 O -
, O +
dioxane O -
, O +
65 O +
h O -
) O +

1N O +
NaOH O -
, O +
MeOH O -
, O +
5 O +
Scheme O +
2 O +
a O +
1 O +
a O -
) O +
MeNH2 O -
, O +
MeOH O -
, O +
rt O +
+ O +
M O +
M O +
Me O +
O O -
/ O -
j O +
OH O +
10a O +
10b O +
S. O +
Sato O +
et O +
al. O +
/ O +
Bioorg O -
. O +

Med O -
. O +

Chem O -
. O +

Lett O -
. O +

9 O +
( O -
1999 O -
) O +
2653 O -
- O -
2656 O +
2655 O +
Result O +
and O +
Discussion O +
To O +
test O +
the O +
stability O -
, O +
the O +
amide O +
derivatives O +
were O +
treated O +
with O +
murine O +
plasma O -
. O +

The O +
inactive O +
compound O +
4 O +
was O +
not O +
detected O +
by O +
HPLC O +
analyses O -
, O +
and O +
it O +
was O +
revealed O +
that O +
the O +
amide O +
analogs O +
were O +
stable O +
against O +
esterases B-Gene -
] O +
The O +
biological O +
activities O +
of O +
the O +
semisynthetic O +
compounds O +
of O +
nidulalin O +
A O +
are O +
shown O +
in O +
Table O +
1 O -
. O +

The O +
amide O +
derivatives O +
9a O -
- O -
e O +
retained O +
cytotoxic O +
activity O +
against O +
both O +
human O +
and O +
murine O +
cancer O +
cell O +
lines O +
in O +
vitro O -
. O +

9a O +
inhibited O +
Topo B-Gene +
II I-Gene +
in O +
dose O +
dependent O +
manner O +
with O +
IC~0 O +
value O +
of O +
29gM. O +
Furthermore O -
, O +
9a O +
possessed O +
weak O +
inhibitory O +
activity O +
against O +
topoisomerase B-Gene +
I I-Gene -
( O -
Topo B-Gene +
I I-Gene -
) O +
with O +
ICs0 O +
value O +
of O +
631.tM. O +
In O +
spite O +
of O +
decreased O +
activity O +
against O +
Topo B-Gene +
II I-Gene -
, O +
cytotoxicity O +
of O +
9a O +
was O +
comparable O +
to O +
that O +
of O +
1 O -
. O +

Lactam O +
10a O +
inhibited O +
neither O +
Topo B-Gene +
I I-Gene +
nor O +
Topo B-Gene +
II I-Gene +
since O +
a O +
conjugated O +
dienone O +
moiety O +
was O +
required O +
for O +
inhibitory O +
activity O +
against O +
Topo B-Gene +
II.4 I-Gene +
The O +
reason O +
for O +
the O +
discrepancy O +
between O +
cytotoxicity O +
and O +
inhibitory O +
activity O +
against O +
Topo B-Gene +
I I-Gene +
and O +
Topo B-Gene +
II I-Gene +
of O +
these O +
compounds O +
is O +
not O +
clear O -
. O +

There O +
might O +
be O +
other O +
mechanisms O +
for O +
cytotoxicity O +
of O +
these O +
analogs O +
or O +
instability O +
of O +
1 O +
in O +
cell O +
culture O +
might O +
decrease O +
its O +
cytotoxicity O -
. O +

Table O +
1 O -
. O +

Biological O +
Activities O +
of O +
Nidulalin O +
A O +
Derivatives O +
in O +
vitro O +
Cytotoxicitya O +
Inhibitory O +
Activity O +
ICso O -
( O -
gM O -
) O +
IC,0 O -
( O -
gM O -
) O +
Compound O +
HCT-116 O +
K562 O +
P388 O +
Topo O +
Ib O +
Topo O +
IIc O +
9a O +
0.33 O +
0.59 O +
0.052 O +
63 O +
29 O +
9b O +
1.13 O +
2.26 O +
0.24 O +
> O -
300 O +
132 O +
9 O +
e O +
0.79 O +
0.98 O +
0.15 O +
ndd O +
nd O +
9d O +
7.88 O +
10.61 O +
2.67 O +
102 O +
23 O +
9e O +
1.64 O +
1.52 O +
0.56 O +
nd O +
nd O +
10a O +
19.6 O +
6.31 O +
nd O +
> O -
300 O +
> O -
300 O +
l O -
( O -
Nidulalin O +
A O -
) O +
0.14 O +
0.32 O +
0.024 O +
172 O +
2.2 O +
a O -
) O +
Cells O +
were O +
treated O +
with O +
each O +
compound O +
for O +
72 O +
hours O -
. O +

Cell O +
viability O +
was O +
evaluated O +
by O +
MTT O +
assay O -
, O +
b O -
) O +
Relaxation O +
assay O +
of O +
Topo B-Gene +
I I-Gene +
was O +
performed O +
as O +
shown O +
in O +
ref O -
. O +

8 O -
. O +
c O -
) O +
Decatenation O +
assay O +
of O +
Topo O +
II O +
was O +
performed O +
as O +
shown O +
in O +
ref O -
. O +

9 O -
. O +
d O -
) O +
not O +
determined O +
Table O +
2 O -
. O +

Antitumor O +
Activity O +
of O +
9a O +
in O +
vivo O +
Compound O +
Route O +
IR O -
( O -
% O -
) O -
a O -
( O -
dose O -
) O +
9a O +
iv O +
42b O -
( O -
10mg O -
/ O -
Kg O -
) O +
1 O +
iv O +
24 O -
( O -
20mg O -
/ O -
Kg O -
) O +
a O -
) O +
Tumor O +
growth O +
suppression O +
was O +
determined O +
as O +
shown O +
in O +
note O +
10 O -
. O +

b O -
) O +
P<0.01 O +
by O +
T O -
- O -
test O +
Antitumor O +
activity O +
of O +
9a O +
was O +
evaluated O +
against O +
Colon O +
26 O +
murine O +
tumor O +
model O +
in O +
vivo O -
( O -
Table O +
2 O -
) O -
. O +

9a O -
, O +
at O +
a O +
dose O +
of O +
10mg O -
/ O -
Kg O -
, O +
showed O +
moderate O +
antitumor O +
activity O +
in O +
this O +
model O -
, O +
while O +
1 O +
showed O +
only O +
marginal O +
effect O +
even O +
at O +
a O +
higher O +
dose O +
( O -
20mg O -
/ O -
Kg O -
) O -
. O +

From O +
above O +
results O -
, O +
it O +
is O +
demonstrated O +
that O +
the O +
methoxycarbonyl O +
group O +
modified O +
nidulalin O +
A O +
analogs O +
are O +
stable O +
against O +
esterases B-Gene +
and O +
effective O +
in O +
murine O +
tumor O +
model O +
in O +
vivo O -
. O +

Further O +
evaluation O +
of O +
antitumor O +
activity O +
and O +
synthesis O +
of O +
other O +
stable O +
analogs O +
are O +
underway O -
. O +

Acknowledgement O +

: O +
We O +
thank O +
Dr. O +
Yukio O +
Iino O -
, O +
Toshimi O +
Mizukoshi O -
, O +
Uno O +
Tagami O -
, O +
and O +
Reiko O +
Yuji O +
for O +
measurement O +
of O +
NMR O +
and O +
mass O +
spectra O -
. O +

We O +
are O +
also O +
grateful O +
to O +
Yumiko O +
Fukuda O +
for O +
skillful O +
technical O +
assistance O -
. O +

2656 O +
S. O +
Sato O +
et O +
al. O +
/ O +
Bioorg O -
. O +

Med O -
. O +

Chem O -
. O +

Lett O -
. O +

9 O +
( O -
1999 O -
) O +
2653 O -
- O -
2656 O +

Phytosterol O +
supplements O +
decrease O +
serum O +
cholesterol O +
and O +
may O +
reduce O +
the O +
risk O +
of O +
cardiovascular O +
disease O +
[ O -
1 O -
] O +
. O +

In O +
a O +
feeding O +
trial O +
involving O +
a O +
stanol O -
- O -
supplemented O +
margarine O +
spread O +
[ O -
2 O -
] O +
, O +
a O +
method O +
was O +
needed O +
for O +
sensitive O +
and O +
precise O +
determination O +
of O +
sitosterol O -
, O +
campesterol O -
, O +
stigmasterol O -
, O +
sitostanol O -
, O +
campestanol O -
, O +
lathosterol O -
, O +
and O +
desmosterol O +
in O +
human O +
serum O -
. O +

Quantitation O +
of O +
serum O +
sterols O +
and O +
stanols O +
( O -
5,6-dihydrosterols O -
) O +
is O +
complicated O +
by O +
the O +
presence O +
of O +
numerous O +
other O +
lipids O +
and O +
low O +
concentrations O +
( O -
0.2–13 O +
μg O -
/ O -
ml O -
) O +
of O +
the O +
analytes O +
relative O +
to O +
cholesterol O +
( O -
∼1500–3000 O +
μg O -
/ O -
ml O -
) O -
. O +

A O +
method O +
[ O -
3,4 O -
] O +
previously O +
reported O +
for O +
measurement O +
of O +
phytosterols O -
, O +
stanols O -
, O +
and O +
cholesterol O +
metabolites O +
[ O -
5 O -
] O +
lacked O +
sufficient O +
detail O +
about O +
preparation O +
of O +
serum O +
samples O -
, O +
chromatographic O +
conditions O -
, O +
and O +
analytical O +
sensitivity O -
, O +
and O +
was O +
not O +
readily O +
reproduced O -
. O +

Other O +
reports O +
[ O -
6,7 O -
] O +
do O +
not O +
include O +
validation O +
of O +
the O +
separation O +
and O +
quantification O +
of O +
phytosterols O +
and O +
stanols O +
as O +
well O +
as O +
cholesterol O +
metabolites O +
( O -
e.g. O +
desmosterol O -
, O +
lathosterol O -
) O -
. O +

Sample O +
clean O -
- O -
up O +
was O +
not O +
reported O +
in O +
some O +
of O +
the O +
published O +
methods O -
, O +
and O +
others O +
used O +
thin O -
- O -
layer O +
chromatography O -
. O +

Carryover O +
and O +
column O -
/ O -
injector O +
contamination O +
are O +
problems O +
in O +
the O +
absence O +
of O +
serum O +
sample O +
clean O -
- O -
up O +
prior O +
to O +
chromatography O -
. O +

Very O +
polar O +
compounds O +
( O -
e.g. O +
phospholipids O -
) O +
are O +
an O +
important O +
consideration O +
in O +
sterol O +
analysis O +
when O +
semi O -
- O -
polar O +
or O +
polar O +
stationary O +
phases O +
are O +
employed O -
, O +
especially O +
when O +
analyzing O +
a O +
large O +
number O +
of O +
samples O -
. O +

A O +
60-m O +
capillary O +
column O +
with O +
a O +
moderately O +
polar O +
stationary O +
phase O +
( O -
14 O -
% O +
cyanopropylphenyl–86 O -
% O +
dimethylpolysiloxane O -
) O +
was O +
used O -
, O +
and O +
a O +
one O -
- O -
step O +
solid O -
- O -
phase O +
extraction O +
was O +
added O +
to O +
remove O +
highly O +
polar O +
compounds O +
from O +
the O +
saponified O +
total O +
lipid O +
extract O -
. O +

Epicholesterol O +
was O +
used O +
as O +
an O +
internal O +
standard O -
. O +

Since O +
the O +
primary O +
concern O +
was O +
to O +
detect O +
changes O +
in O +
low O +
levels O +
of O +
serum O +
sterols O +
and O +
stanols O +
as O +
a O +
result O +
of O +
dietary O +
supplementation O -
, O +
we O +
required O +
a O +
very O +
precise O +
assay O -
. O +

Consequently O -
, O +
numerous O +
quality O +
control O +
measures O +
were O +
implemented O -
. O +

In O +
this O +
paper O +
we O +
give O +
a O +
detailed O +
description O +
of O +
the O +
methodology O +
and O +
quality O +
control O +
employed O +
for O +
the O +
precise O +
quantitative O +
analysis O +
of O +
sitosterol O -
, O +
campesterol O -
, O +
stigmasterol O -
, O +
sitostanol O -
, O +
campestanol O -
, O +
lathosterol O -
, O +
and O +
desmosterol O +
in O +
human O +
serum O -
. O +

2 O +
Experimental O +
2.1 O +
Materials O +
2.1.1 O +
Chemicals O +
Epicholesterol O +
was O +
obtained O +
from O +
Steraloids O +
( O -
Wilton O -
, O +
NH O -
, O +
USA O -
) O -
. O +

Beta O -
- O -
sitosterol O -
, O +
campesterol O -
, O +
stigmasterol O -
, O +
sitostanol O -
, O +
fucosterol O -
, O +
lathosterol O -
, O +
lanosterol O -
, O +
and O +
desmosterol O -
, O +
cholestanol O -
, O +
squalene O -
, O +
pyrogallol O -
, O +
cyclohexane O -
, O +
and O +
pyridine O +
were O +
purchased O +
from O +
Sigma O +
Chemical O +
( O -
St. O +
Louis O -
, O +
MO O -
, O +
USA O -
) O -
. O +

Campestanol O +
was O +
from O +
Research O +
Plus O +
( O -
Bayonne O -
, O +
NJ O -
, O +
USA O -
) O -
, O +
and O +
bis O -
( O -
trimethylsilyl O -
) O -
trifluoroacetamide O +
with O +
1 O -
% O +
trimethylchlorosilane O +
( O -
BSTFA O +
w O -
/ O -
1 O -
% O +
TMCS O -
) O +
was O +
obtained O +
from O +
Alltech O +
Associates O +
( O -
Deerfield O -
, O +
IL O -
, O +
USA O -
) O -
. O +

Hexane O -
, O +
chloroform O -
, O +
methanol O -
, O +
isopropanol O -
, O +
sodium O +
chloride O +
( O -
ACS O +
grade O -
) O -
, O +
and O +
potassium O +
hydroxide O +
( O -
NF O -
/ O -
FCC O +
grade O -
) O +
were O +
from O +
Fisher O +
Scientific O +
( O -
Fairlawn O -
, O +
NJ O -
, O +
USA O -
) O -
. O +

Absolute O +
ethanol O +
was O +
obtained O +
from O +
AAPER O +
Alcohol O +
and O +
Chemical O +
( O -
Shelbyville O -
, O +
KY O -
, O +
USA O -
) O -
. O +

All O +
solvents O +
were O +
HPLC O +
grade O +
and O +
used O +
without O +
further O +
purification O -
. O +

2.1.2 O +
Serum O +
samples O +
Serum O +
samples O +
( O -
1–2 O +
ml O -
) O +
frozen O +
in O +
2-ml O +
cryovials O +
were O +
obtained O +
from O +
a O +
human O +
feeding O +
trial O +
conducted O +
at O +
Pennsylvania O +
State O +
University O +
( O -
University O +
Park O -
, O +
PA O -
, O +
USA O -
) O +
and O +
Pennington O +
Biomedical O +
Research O +
Center O +
( O -
Baton O +
Rouge O -
, O +
LA O -
, O +
USA O -
) O -
. O +

Subjects O +
consumed O +
a O +
stanol O -
- O -
supplemented O +
margarine O +
that O +
provided O +
3 O +
g O +
per O +
day O +
stanols O +
and O +
16 O +
g O +
per O +
day O +
fat O +
in O +
a O +
controlled O +
feeding O +
trial O -
; O +
details O +
of O +
the O +
study O +
are O +
reported O +
elsewhere O +
[ O -
2 O -
] O +
. O +

Serum O +
samples O +
were O +
stored O +
at O +
−80 O -
° O -
C O +
until O +
analyzed O -
. O +

2.2 O +
Instrumentation O +
2.2.1 O +
Gas O +
chromatography O +
Gas O +
chromatography O +
was O +
performed O +
with O +
a O +
Perkin O +
Elmer O +
GC O +
Autosystem O -
™ O +
( O -
Perkin O +
Elmer O -
, O +
Norwalk O -
, O +
CT O -
, O +
USA O -
) O -
, O +
an O +
Rtx O -
® O +
-1701 O +
( O -
14 O -
% O +
cyanopropylphenyl–86 O -
% O +
dimethylpolysiloxane O -
) O +
capillary O +
column O +
( O -
60-m O -
× O -
0.25-mm O +
I.D. O -
, O +
0.25-μm O +
film O +
thickness O -
; O +
Restek O -
, O +
Bellefonte O -
, O +
PA O -
, O +
USA O -
) O -
, O +
and O +
a O +
flame O +
ionization O +
detector O +
with O +
hydrogen O +
( O -
45 O +
ml O -
/ O -
min O -
) O +
and O +
air O +
( O -
450 O +
ml O -
/ O -
min O -
) O +
as O +
fuel O +
source O -
. O +

Hydrogen O +
at O +
1.18 O +
ml O -
/ O -
min O +
was O +
the O +
carrier O +
gas O -
. O +

Operating O +
conditions O +
were O -
: O +
injection O +
temperature O -
, O +
280 O -
° O -
C O -
; O +
detector O +
temperature O -
, O +
280 O -
° O -
C O -
; O +
oven O +
temperature O -
, O +
265 O -
° O -
C O -
; O +
split O +
ratio O -
, O +
9:1 O +
( O -
split O +
vent O +
flow O +
9.44 O +
ml O -
/ O -
min O -
) O -
; O +
injection O +
volume O -
, O +
1 O +
μl O -
; O +
head O +
pressure O +
21 O +
p.s.i O -
. O +

Detector O +
signal O +
output O +
was O +
monitored O +
by O +
computer O +
( O -
Dell O +
Dimension O +
XPS O +
D233 O -
; O +
Dell O +
Computer O -
, O +
Round O +
Rock O -
, O +
TX O -
, O +
USA O -
) O +
and O +
all O +
chromatograms O +
and O +
data O +
were O +
generated O +
and O +
processed O +
using O +
Turbochrom O -
™ O +
Workstation O +
version O +
6.0.2.1 O +
software O +
( O -
Perkin O +
Elmer O -
) O -
. O +

2.3 O +
Quality O +
control O +
measures O +
2.3.1 O +
Preparation O +
of O +
glassware O +
All O +
glassware O +
( O -
and O +
other O +
labware O -
, O +
such O +
as O +
stir O +
bars O +
and O +
spatulas O -
) O +
was O +
scrupulously O +
cleaned O +
and O +
rinsed O +
with O +
distilled O +
deionized O +
water O +
and O +
acetone O -
, O +
then O +
immediately O +
before O +
use O -
, O +
rinsed O +
with O +
chloroform O -
, O +
then O +
ethanol O -
, O +
and O +
allowed O +
to O +
air O +
dry O -
. O +

All O +
glass O +
test O +
tubes O +
were O +
silanized O +
with O +
5 O -
% O +
dimethyldicholorosilane O +
in O +
hexane O +
( O -
Sigma O -
) O -
. O +

2.3.2 O +
Other O +
measures O +
to O +
prevent O +
contamination O +
Since O +
sterols O +
are O +
ubiquitous O +
in O +
the O +
lab O +
( O -
e.g. O +
in O +
skin O +
secretions O -
, O +
rubber O +
septa O -
, O +
vegetable O +
oils O +
and O +
fats O -
) O -
, O +
and O +
because O +
the O +
levels O +
of O +
these O +
compounds O +
in O +
serum O +
are O +
low O +
( O -
ng O +
to O +
μg O -
/ O -
ml O -
) O -
, O +
it O +
is O +
essential O +
to O +
prevent O +
sample O +
contamination O +
to O +
preclude O +
falsely O +
elevated O +
values O +
of O +
the O +
analytes O -
. O +

Precautions O +
against O +
cross O -
- O -
contamination O +
are O +
especially O +
necessary O +
in O +
laboratories O +
where O +
vegetable O +
oils O +
or O +
other O +
materials O +
containing O +
significant O +
levels O +
of O +
phytosterols O +
are O +
analyzed O -
. O +

Tight O +
control O +
of O +
measuring O +
volumes O +
and O +
weights O +
is O +
essential O +
to O +
ensure O +
the O +
precision O +
and O +
accuracy O +
of O +
the O +
assay O +
in O +
the O +
ng O +
to O +
μg O +
range O -
. O +

2.3.3 O +
Calibration O +
of O +
pipettes O +
and O +
balances O +
For O +
all O +
critical O +
volume O +
measurements O +
( O -
e.g. O +
standard O +
solutions O -
, O +
serum O +
aliquots O +
taken O +
for O +
analysis O -
) O -
, O +
automatic O +
pipettes O +
were O +
carefully O +
calibrated O +
for O +
accuracy O +
and O +
precision O +
immediately O +
before O +
use O -
, O +
using O +
the O +
solvent O +
of O +
the O +
solution O +
to O +
be O +
dispensed O +
( O -
e.g. O +
chloroform O +
or O +
ethanol O +
for O +
standards O -
, O +
water O +
for O +
serum O -
) O -
, O +
and O +
a O +
five O -
- O -
decimal O +
place O +
analytical O +
balance O -
, O +
calibrated O +
with O +
certified O +
standard O +
weights O -
. O +

The O +
pipetter O +
was O +
held O +
in O +
the O +
hand O +
5 O +
min O +
to O +
warm O +
it O +
to O +
a O +
constant O +
temperature O +
before O +
calibration O -
. O +

To O +
determine O +
accuracy O -
, O +
the O +
weighed O +
volumes O +
were O +
compared O +
to O +
the O +
expected O +
mass O -
, O +
determined O +
from O +
the O +
density O +
of O +
the O +
liquid O +
at O +
the O +
measured O +
temperature O +
of O +
the O +
liquid O +
aliquoted O +
[ O -
8 O -
] O +
. O +

For O +
preparing O +
standard O +
mixtures O +
and O +
for O +
performing O +
standard O +
additions O +
to O +
serum O +
samples O -
, O +
volumetric O +
pipettes O +
were O +
used O -
. O +

2.3.4 O +
Preparation O +
of O +
standard O +
solutions O +
2.3.4.1 O +
Internal O +
standard O +
Test O +
tubes O +
containing O +
internal O +
standard O +
were O +
prepared O +
in O +
batches O -
. O +

Epicholesterol O +
( O -
3 O +
mg O -
) O +
was O +
weighed O +
to O +
the O +
nearest O +
0.01 O +
mg O +
into O +
a O +
1-l O +
volumetric O +
flask O -
, O +
brought O +
to O +
volume O +
with O +
absolute O +
ethanol O -
, O +
and O +
thoroughly O +
mixed O -
. O +

The O +
solution O +
was O +
dispensed O +
in O +
1.6-ml O +
aliquots O +
into O +
each O +
of O +
approximately O +
one O -
- O -
hundred O +
25 O -
× O -
150 O +
mm O +
glass O +
test O +
tubes O +
using O +
a O +
bottle O -
- O -
top O +
dispenser O +
that O +
had O +
been O +
calibrated O +
for O +
accuracy O +
and O +
precision O +
( O -
Section O +
2.3.3 O +
) O -
, O +
yielding O +
5 O +
μg O +
epicholesterol O +
per O +
tube O +
( O -
the O +
exact O +
amount O +
of O +
internal O +
standard O +
was O +
calculated O +
for O +
the O +
exact O +
weights O +
and O +
volumes O +
measured O -
) O -
. O +

The O +
tubes O +
were O +
capped O +
under O +
nitrogen O +
and O +
stored O +
at O +
< O -
10 O -
° O -
C O +
for O +
up O +
to O +
2 O +
months O -
. O +

Immediately O +
prior O +
to O +
use O -
, O +
the O +
solvent O +
was O +
evaporated O +
at O +
60 O -
° O -
C O +
with O +
a O +
stream O +
of O +
nitrogen O -
. O +

2.3.4.2 O +
Reference O +
and O +
calibration O +
standards O +
For O +
each O +
component O -
, O +
a O +
6 O +
μg O -
/ O -
ml O +
stock O +
standard O +
solution O +
was O +
made O -
. O +

Three O +
mg O +
of O +
component O +
was O +
weighed O +
to O +
the O +
nearest O +
0.01 O +
mg O +
and O +
diluted O +
to O +
500 O +
ml O +
in O +
a O +
volumetric O +
flask O -
, O +
using O +
absolute O +
ethanol O +
for O +
sterols O +
and O +
chloroform O +
for O +
stanols O -
. O +

Calibration O +
standard O +
solutions O +
containing O +
30 O +
μg O -
/ O -
ml O +
of O +
the O +
analyte O +
and O +
50 O +
μg O -
/ O -
ml O +
epicholesterol O +
were O +
prepared O +
in O +
batches O -
. O +

Solvent O +
was O +
evaporated O +
at O +
60 O -
° O -
C O +
with O +
a O +
stream O +
of O +
nitrogen O -
, O +
then O +
the O +
mixture O +
was O +
derivatized O +
with O +
1 O +
ml O +
pyridine O -
/ O -
BSTFA O +
as O +
described O +
for O +
samples O +
( O -
Section O +
2.4.4 O +
) O -
. O +

The O +
solution O +
was O +
distributed O +
among O +
ten O +
autosampler O +
vials O +
with O +
volume O +
reduction O +
inserts O +
( O -
∼100 O +
μl O -
/ O -
vial O -
) O +
and O +
stored O +
at O +
−60 O -
° O -
C O -
. O +

These O +
standards O +
were O +
used O +
to O +
determine O +
calibration O +
factors O +
and O +
to O +
check O +
instrument O +
calibration O +
throughout O +
the O +
study O -
. O +

Two O +
reference O +
standard O +
mixtures O +
were O +
prepared O +
and O +
run O +
with O +
each O +
batch O +
of O +
samples O +
to O +
determine O +
run O -
- O -
specific O +
retention O +
times O +
for O +
the O +
analytes O -
. O +
' O +

Reference O +
A O -
' O +
contained O +
5 O +
μg O -
/ O -
ml O +
each O +
of O +
sitosterol O -
, O +
lathosterol O -
, O +
campestanol O -
, O +
stigmasterol O -
, O +
and O +
sitostanol O -
. O +
' O +

Reference O +
B O -
' O +
contained O +
5 O +
μg O -
/ O -
ml O +
each O +
of O +
desmosterol O -
, O +
campesterol O -
, O +
lanosterol O -
, O +
and O +
fucosterol O -
. O +

2.3.5 O +
Preparation O +
of O +
quality O +
control O +
material O +
Accutrol O -
™ O +
Human O +
Serum O +
( O -
normal O -
, O +
lyophilized O -
, O +
# O -
A2034 O -
; O +
Sigma O -
) O +
was O +
used O +
as O +
a O +
control O +
material O -
. O +

No O +
standard O +
serum O +
with O +
certified O +
or O +
reference O +
values O +
for O +
phytosterols O +
could O +
be O +
found O -
, O +
and O +
homogeneous O +
fortification O +
of O +
the O +
serum O +
with O +
sitostanol O +
was O +
not O +
feasible O -
. O +

Because O +
of O +
the O +
potential O +
heterogeneity O +
of O +
reconstituted O +
aliquots O +
of O +
lyophilized O +
serum O +
( O -
due O +
to O +
variable O +
loss O +
of O +
dried O +
material O +
during O +
reconstitution O -
) O -
, O +
and O +
because O +
we O +
required O +
a O +
large O +
number O +
of O +
homogeneous O +
aliquots O +
to O +
adequately O +
monitor O +
assay O +
precision O -
, O +
we O +
prepared O +
a O +
composite O +
of O +
reconstituted O +
Accutrol O -
™ O +
serum O +
and O +
dispensed O +
a O +
batch O +
of O +
380 O +
1.25-ml O +
aliquots O -
. O +

One O -
- O -
hundred O +
vials O +
of O +
the O +
lyophilized O +
Accutrol O -
™ O +
serum O +
( O -
from O +
the O +
same O +
lot O -
) O +
were O +
reconstituted O +
and O +
combined O -
. O +

In O +
batches O +
of O +
ten O +
at O +
a O +
time O -
, O +
vials O +
were O +
removed O +
from O +
the O +
refrigerator O +
and O +
each O +
was O +
reconstituted O +
with O +
5 O +
ml O +
of O +
distilled O +
deionized O +
water O -
, O +
mixed O +
well O -
, O +
and O +
allowed O +
to O +
stand O +
for O +
10–20 O +
min O +
at O +
room O +
temperature O +
( O -
20–23 O -
° O -
C O -
) O -
, O +
then O +
placed O +
in O +
the O +
refrigerator O +
( O -
2–4 O -
° O -
C O -
) O -
. O +

Within O +
3 O +
days O -
, O +
a O +
composite O +
of O +
the O +
reconstituted O +
serum O +
was O +
made O +
in O +
a O +
walk O -
- O -
in O +
cold O +
room O +
( O -
7 O -
° O -
C O -
) O -
. O +

As O +
much O +
as O +
possible O +
of O +
it O +
was O +
transferred O +
from O +
each O +
of O +
the O +
100 O +
serum O +
vials O +
to O +
a O +
500-ml O +
glass O +
reagent O +
bottle O -
, O +
which O +
was O +
then O +
covered O +
and O +
stirred O +
at O +
medium O -
– O -
high O +
speed O +
for O +
1 O +
h. O +
The O +
serum O +
was O +
then O +
dispensed O +
in O +
1.25-ml O +
aliquots O +
into O +
380 O +
2-ml O +
microcentrifuge O +
tubes O +
in O +
batches O +
of O +
ten O +
at O +
a O +
time O -
, O +
using O +
a O +
new O +
pipette O +
tip O +
after O +
every O +
ten O +
samples O -
. O +

The O +
tubes O +
were O +
stored O +
at O +
−80 O -
° O -
C O -
. O +

2.4 O +
Sample O +
preparation O +
2.4.1 O +
Total O +
lipid O +
extraction O +
Serum O +
samples O +
were O +
thawed O +
overnight O +
( O -
12–20 O +
h O -
) O +
at O +
2–4 O -
° O -
C O +
then O +
mixed O +
thoroughly O -
. O +

Using O +
a O +
calibrated O +
pipetter O -
, O +
0.90 O +
ml O +
serum O +
was O +
dispensed O +
into O +
a O +
test O +
tube O +
containing O +
the O +
internal O +
standard O +
( O -
5 O +
μg O +
epicholesterol O -
) O -
. O +

Total O +
lipid O +
was O +
extracted O +
by O +
a O +
modified O +
Folch O +
procedure O +
[ O -
9 O -
] O +
, O +
using O +
chloroform O -
– O -
methanol O +
( O -
2:1 O -
, O +
v O -
/ O -
v O -
) O +
followed O +
by O +
a O +
0.9 O -
% O +
saline O +
wash O -
, O +
as O +
follows O -
. O +

After O +
mixing O +
the O +
sample O -
, O +
0.9 O +
ml O +
of O +
methanol O +
was O +
added O -
, O +
then O +
tubes O +
were O +
capped O +
and O +
vortexed O +
at O +
high O +
speed O +
for O +
15 O +
s. O +
Samples O +
were O +
then O +
shaken O +
for O +
10 O +
min O +
on O +
an O +
orbital O +
shaker O +
at O +
300 O +
rpm O -
. O +

If O +
phases O +
separated O +
before O +
orbital O +
shaking O -
, O +
the O +
tubes O +
were O +
first O +
shaken O +
briefly O +
by O +
hand O -
. O +

Chloroform O +
( O -
2 O -
× O -
9.0 O +
ml O -
) O +
and O +
6.75 O +
ml O +
0.9 O -
% O +
( O -
w O -
/ O -
v O -
) O +
aqueous O +
sodium O +
chloride O +
were O +
added O -
, O +
tubes O +
were O +
capped O +
tightly O +
and O +
vortex O +
mixed O +
at O +
high O +
speed O +
for O +
15 O +
s O -
, O +
then O +
shaken O +
at O +
300 O +
rpm O +
on O +
the O +
orbital O +
shaker O +
for O +
10 O +
min O +
( O -
if O +
phases O +
began O +
to O +
separate O +
before O +
orbital O +
shaking O -
, O +
tubes O +
were O +
first O +
shaken O +
by O +
hand O +
for O +
a O +
few O +
seconds O +
to O +
remix O -
) O -
. O +

Samples O +
were O +
then O +
centrifuged O +
at O +
200 O +
g O +
at O +
20 O -
° O -
C O +
for O +
10 O +
min O +
to O +
facilitate O +
phase O +
separation O -
. O +

2.4.2 O +
Saponification O +
The O +
chloroform O +
( O -
lower O -
) O +
layer O +
from O +
each O +
total O +
lipid O +
extraction O +
was O +
transferred O +
to O +
a O +
25 O -
× O -
150 O +
mm O +
test O +
tube O -
. O +

Care O +
was O +
taken O +
not O +
to O +
transfer O +
any O +
of O +
the O +
emulsion O +
or O +
solid O +
material O +
at O +
the O +
interface O +
between O +
the O +
upper O +
and O +
lower O +
phases O -
, O +
by O +
pushing O +
out O +
any O +
material O +
that O +
entered O +
the O +
pipette O +
tip O +
before O +
drawing O +
in O +
the O +
chloroform O +
solution O -
. O +

A O +
new O +
pipette O +
tip O +
was O +
used O +
for O +
each O +
sample O -
. O +

The O +
total O +
lipid O +
extract O +
was O +
saponified O +
by O +
a O +
modification O +
of O +
a O +
method O +
previously O +
described O +
by O +
Thompson O +
and O +
Merola O +
[ O -
10 O -
] O +
. O +

Solvent O +
was O +
evaporated O +
completely O +
from O +
the O +
total O +
lipid O +
extract O +
at O +
60 O -
° O -
C O +
with O +
a O +
stream O +
of O +
nitrogen O -
. O +

Ethanol O +
with O +
3 O -
% O +
( O -
w O -
/ O -
v O -
) O +
pyrogallol O +
( O -
8 O +
ml O -
) O +
was O +
added O +
to O +
each O +
sample O -
. O +

Tubes O +
were O +
capped O +
and O +
vortexed O +
at O +
high O +
speed O +
for O +
10 O +
s O -
, O +
then O +
0.5 O +
ml O +
of O +
1.28 O +
g O -
/ O -
ml O +
aqueous O +
potassium O +
hydroxide O +
was O +
added O -
. O +

Tubes O +
were O +
capped O +
tightly O -
, O +
vortexed O +
for O +
10 O +
s O +
at O +
high O +
speed O -
, O +
sonicated O +
for O +
30 O +
s O -
, O +
then O +
heated O +
in O +
a O +
test O +
tube O +
rack O +
in O +
a O +
85–89 O -
° O -
C O +
water O +
bath O +
for O +
30 O +
min O -
, O +
ensuring O +
that O +
the O +
bottom O +
half O +
of O +
the O +
tubes O +
were O +
immersed O -
. O +

Tubes O +
( O -
in O +
rack O -
) O +
were O +
shaken O +
and O +
inverted O +
vigorously O +
after O +
1 O -
, O +
2 O -
, O +
5 O -
, O +
10 O -
, O +
15 O -
, O +
20 O -
, O +
25 O -
, O +
and O +
30 O +
min O +
of O +
heating O +
( O -
a O +
second O +
test O +
tube O +
rack O +
was O +
held O +
firmly O +
over O +
the O +
top O +
during O +
shaking O +
to O +
hold O +
the O +
tubes O -
) O -
. O +

The O +
capped O +
tubes O +
were O +
sonicated O +
again O +
for O +
30 O +
s O -
, O +
cooled O +
under O +
running O +
tap O +
water O -
, O +
then O +
slowly O +
opened O -
. O +

Cyclohexane O +
( O -
20 O +
ml O -
) O -
, O +
then O +
12 O +
ml O +
distilled O +
deionized O +
water O +
were O +
added O +
to O +
each O +
sample O -
. O +

Tubes O +
were O +
recapped O -
, O +
shaken O +
vigorously O +
for O +
a O +
few O +
seconds O -
, O +
then O +
rocked O +
15 O +
min O +
on O +
a O +
platform O +
mixer O +
at O +
maximum O +
speed O +
( O -
Thermolyne O +
Vari O -
- O -
Mix O +
platform O +
mixer O -
; O +
Barnstead O -
/ O -
Thermolyne O +
No. O +
48725 O -
) O -
. O +

No O +
residual O +
material O +
was O +
evident O +
in O +
the O +
bottom O +
or O +
on O +
the O +
sides O +
of O +
tubes O +
after O +
shaking O -
. O +

Samples O +
were O +
centrifuged O +
at O +
200 O +
g O +
at O +
20 O -
° O -
C O +
for O +
10 O +
min O +
to O +
accelerate O +
phase O +
separation O -
. O +

For O +
each O +
sample O -
, O +
17.0 O +
ml O +
( O -
2 O -
× O -
8.5 O +
ml O -
) O +
of O +
the O +
cyclohexane O +
( O -
upper O -
) O +
layer O +
was O +
transferred O +
to O +
a O +
25 O -
× O -
150 O +
mm O +
test O +
tube O -
, O +
with O +
care O +
taken O +
not O +
to O +
include O +
any O +
of O +
the O +
black O -
, O +
aqueous O +
phase O -
. O +

Cyclohexane O +
was O +
evaporated O +
at O +
60 O -
° O -
C O +
with O +
a O +
stream O +
of O +
nitrogen O -
. O +

Chloroform O +
( O -
0.5 O +
ml O -
) O +
was O +
added O +
to O +
each O +
sample O -
, O +
then O +
samples O +
were O +
vortexed O +
for O +
10 O +
s O +
at O +
high O +
speed O -
. O +

2.4.3 O +
Solid O -
- O -
phase O +
extraction O +
A O +
modification O +
of O +
the O +
method O +
of O +
Kaluzny O +
et O +
al. O +
[ O -
11 O -
] O +
was O +
used O +
to O +
separate O +
the O +
neutral O +
lipid O +
fraction O +
( O -
containing O +
sterols O +
and O +
stanols O -
) O +
from O +
more O +
polar O +
lipids O -
. O +

Bond O +
Elute O +
LRC O -
® O +
aminopropyl O +
solid O -
- O -
phase O +
extraction O +
( O -
SPE O -
) O +
cartridges O +
10 O +
ml O -
/ O -
500 O +
mg O +
( O -
Varian O +
Associates O -
, O +
Harbor O +
City O -
, O +
CA O -
, O +
USA O -
) O +
were O +
used O -
. O +

The O +
SPE O +
cartridges O +
were O +
attached O +
to O +
a O +
vacuum O +
manifold O +
( O -
Visaprep O +
DL O -
™ O -
; O +
Supelco O -
, O +
Bellefonte O -
, O +
PA O -
, O +
USA O -
) O +
set O +
at O +
slightly O +
less O +
than O +
1″ O +
Hg O +
with O +
valves O +
closed O -
. O +

Cartridges O +
were O +
conditioned O +
with O +
4 O +
ml O +
hexane O -
, O +
which O +
was O +
discarded O -
. O +

A O +
16 O -
× O -
125 O +
mm O +
glass O +
test O +
tube O +
was O +
placed O +
under O +
each O +
outlet O -
. O +

With O +
vacuum O +
valves O +
closed O +
and O +
using O +
a O +
new O +
pipette O +
tip O +
for O +
each O +
sample O -
, O +
sample O +
was O +
transferred O +
into O +
the O +
SPE O +
cartridge O -
, O +
directly O +
onto O +
the O +
adsorbent O -
, O +
repeating O +
until O +
as O +
much O +
as O +
possible O +
had O +
been O +
transferred O -
. O +

With O +
vacuum O +
set O +
at O +
slightly O +
less O +
than O +
1″ O +
Hg O -
, O +
valves O +
were O +
opened O +
one O +
by O +
one O +
until O +
the O +
sample O +
solution O +
had O +
just O +
completely O +
entered O +
the O +
adsorbent O -
, O +
then O +
turned O +
off O +
until O +
all O +
cartridges O +
had O +
been O +
set O -
. O +

Elution O +
solvent O +
( O -
chloroform O -
– O -
isopropanol O -
, O +
2:1 O -
, O +
v O -
/ O -
v O -
, O +
0.5 O +
ml O -
) O +
was O +
added O +
to O +
each O +
cartridge O -
. O +

The O +
solvent O +
was O +
then O +
drawn O +
under O +
vacuum O +
through O +
the O +
cartridges O +
one O +
at O +
a O +
time O +
until O +
it O +
reached O +
just O +
above O +
the O +
column O +
bed O -
, O +
then O +
valve O +
was O +
closed O +
until O +
all O +
samples O +
had O +
been O +
taken O +
to O +
this O +
stage O -
. O +

An O +
additional O +
3.5 O +
ml O +
of O +
the O +
elution O +
solvent O +
was O +
added O +
to O +
each O +
tube O -
, O +
then O +
all O +
valves O +
were O +
opened O +
and O +
the O +
solvent O +
was O +
allowed O +
to O +
pass O +
completely O +
( O -
dropwise O -
) O +
through O +
the O +
cartridges O -
. O +

The O +
vacuum O +
was O +
then O +
increased O +
to O +
draw O +
the O +
columns O +
dry O +
( O -
∼8″ O +
Hg O +
for O +
at O +
least O +
2 O +
min O -
) O -
. O +

2.4.4 O +
Derivatization O +
Solvent O +
was O +
completely O +
evaporated O +
from O +
samples O +
at O +
60 O -
° O -
C O +
with O +
a O +
stream O +
of O +
nitrogen O -
. O +

Freshly O +
prepared O +
derivatization O +
reagent O +
( O -
pyridine O -
– O -
BSTFA O +
with O +
1 O -
% O +
TMCS O -
, O +
1:1 O -
, O +
v O -
/ O -
v O -
) O -
, O +
100 O +
μl O -
, O +
was O +
pipetted O +
into O +
each O +
tube O +
and O +
vortex O +
mixed O +
for O +
10 O +
s. O +

The O +
reagent O +
was O +
then O +
carefully O +
swirled O +
around O +
and O +
∼2″ O +
up O +
the O +
sides O +
of O +
each O +
tube O -
. O +

Tubes O +
were O +
allowed O +
to O +
stand O +
at O +
least O +
1 O +
min O -
, O +
vortex O +
mixed O +
for O +
3 O +
s O -
, O +
then O +
allowed O +
to O +
stand O +
again O +
for O +
at O +
least O +
1 O +
min O -
. O +

Each O +
sample O +
was O +
transferred O +
using O +
a O +
9″ O +
glass O +
pasteur O +
pipette O +
into O +
a O +
100-μl O +
limited O +
volume O +
insert O +
in O +
an O +
autosampler O +
vial O -
, O +
sealed O +
with O +
a O +
PTFE O -
/ O -
silicone O +
septum O +
cap O -
, O +
and O +
stored O +
at O +
< O -
10 O -
° O -
C O +
until O +
assayed O +
by O +
GC O +
( O -
within O +
1 O +
week O -
) O -
. O +

2.4.5 O +
GC O +
analysis O +
and O +
quantitation O +
Analyte O +
retention O +
times O +
were O +
determined O +
using O +
commercially O +
available O +
standards O -
. O +

Analysis O +
of O +
selected O +
serum O +
samples O +
without O +
added O +
epicholesterol O +
internal O +
standard O +
confirmed O +
lack O +
of O +
sample O +
constituents O +
that O +
co O -
- O -
eluted O +
with O +
the O +
internal O +
standard O -
. O +

In O +
routine O +
assays O -
, O +
component O +
peaks O +
were O +
identified O +
by O +
the O +
adjusted O +
retention O +
time O -
, O +
which O +
compensated O +
for O +
any O +
shifts O +
in O +
expected O +
retention O +
times O +
based O +
on O +
that O +
of O +
the O +
internal O +
standard O +
[ O -
12 O -
] O +
. O +

A O +
relative O +
search O +
window O +
( O -
based O +
on O +
a O +
percent O +
of O +
the O +
absolute O +
retention O +
time O -
) O +
was O +
then O +
applied O +
to O +
the O +
adjusted O +
retention O +
time O +
as O +
the O +
criteria O +
for O +
identification O -
. O +

The O +
size O +
of O +
the O +
relative O +
search O +
window O +
was O +
determined O +
based O +
on O +
the O +
degree O +
of O +
absolute O +
retention O +
time O +
shift O +
that O +
was O +
expected O +
during O +
a O +
run O +
and O +
the O +
proximity O +
of O +
other O +
peaks O +
expected O +
in O +
the O +
samples O -
. O +

After O +
determining O +
the O +
method O +
was O +
linear O +
over O +
the O +
expected O +
concentration O +
ranges O +
( O -
below O -
) O -
, O +
analytes O +
were O +
quantified O +
based O +
on O +
a O +
single O +
point O +
response O +
factor O +
( O -
RF O -
) O -
:RF O +
= O -
RC O +
/RIS O +
MC O +
/MIS O +
where O +
R O +
C O +
is O +
the O +
peak O +
area O +
for O +
the O +
component O -
, O +
R O +
IS O +
is O +
the O +
peak O +
area O +
for O +
the O +
internal O +
standard O -
, O +
M O +
C O +
is O +
the O +
amount O +
of O +
component O +
and O +
M O +
IS O +
is O +
the O +
amount O +
of O +
internal O +
standard O +
added O +
to O +
the O +
sample O -
. O +

For O +
each O +
analyte O -
, O +
the O +
RF O +
was O +
determined O +
at O +
3 O +
μg O +
as O +
the O +
average O +
of O +
triplicate O +
analysis O +
of O +
standards O -
. O +

In O +
samples O -
, O +
each O +
component O +
( O -
M O +
C O +
) O +
was O +
determined O +
using O +
the O +
response O +
factor O +
for O +
that O +
component O +
and O +
R O +
C O +
and O +
R O +
IS O +
determined O +
from O +
the O +
GC O +
analysis O -
. O +

Baseline O +
events O +
( O -
timed O +
events O +
in O +
the O +
instrument O +
method O +
which O +
effect O +
integration O +
of O +
peaks O -
) O +
were O +
set O +
up O +
in O +
the O +
standard O +
( O -
routine O -
) O +
Turbochrom O -
™ O +
method O +
file O +
based O +
on O +
optimal O +
consistency O +
of O +
peak O +
integration O +
for O +
the O +
control O +
sample O -
. O +

In O +
sample O +
runs O -
, O +
individual O +
attention O +
was O +
paid O +
to O +
the O +
chromatograms O +
to O +
avoid O +
and O +
correct O +
any O +
obvious O +
integration O +
problems O +
( O -
usually O +
as O +
a O +
result O +
of O +
small O +
peak O +
size O +
and O +
interfering O +
peaks O -
) O -
, O +
by O +
modifying O +
baseline O +
events O +
as O +
necessary O -
. O +

2.5 O +
Linearity O -
, O +
limit O +
of O +
detection O -
, O +
and O +
limit O +
of O +
quantitation O +
studies O +
The O +
expected O +
concentration O +
ranges O +
for O +
desmosterol O -
, O +
lathosterol O -
, O +
campesterol O -
, O +
sitosterol O -
, O +
stigmasterol O -
, O +
campestanol O -
, O +
sitostanol O -
, O +
lanosterol O -
, O +
and O +
fucosterol O +
were O +
tested O +
for O +
linearity O -
. O +

For O +
each O +
compound O -
, O +
standard O +
solutions O +
were O +
made O +
at O +
four O +
or O +
five O +
different O +
concentrations O +
between O +
0.05 O +
μg O -
/ O -
ml O +
and O +
25 O +
μg O -
/ O -
ml O -
. O +

Each O +
standard O +
solution O +
was O +
derivatized O +
and O +
assayed O +
in O +
duplicate O +
at O +
all O +
concentrations O -
, O +
except O +
in O +
quintuplicate O +
at O +
0.75 O +
μg O -
/ O -
ml O +
for O +
desmosterol O -
, O +
lanosterol O -
, O +
fucosterol O -
, O +
campestanol O -
, O +
and O +
sitostanol O +
and O +
at O +
5 O +
μg O -
/ O -
ml O +
for O +
campesterol O -
, O +
sitosterol O -
, O +
and O +
stigmasterol O -
. O +

For O +
each O +
compound O -
, O +
a O +
linear O +
regression O +
was O +
performed O +
on O +
the O +
data O +
( O -
component O -
/ O -
internal O +
standard O +
area O +
ratio O +
vs. O +
component O -
/ O -
internal O +
standard O +
mass O +
ratio O -
) O -
. O +

All O +
curves O +
were O +
linear O -
, O +
above O +
the O +
limit O +
of O +
detection O -
, O +
in O +
the O +
concentration O +
range O +
tested O +
( O -
r O +
2 O +
= O -
0.99 O +
or O +
greater O +
in O +
all O +
cases O -
) O -
. O +

The O +
method O +
limit O +
of O +
detection O +
( O -
MLOD O -
) O +
and O +
limit O +
of O +
quantitation O +
( O -
MLOQ O -
) O +
for O +
sitosterol O -
, O +
campesterol O -
, O +
lathosterol O -
, O +
and O +
desmosterol O +
were O +
determined O +
from O +
results O +
of O +
the O +
repeated O +
analyses O +
( O -
n O +
= O -
55 O -
) O +
of O +
0.9-ml O +
aliquots O +
of O +
the O +
Accutrol O -
™ O +
control O +
serum O +
composite O -
. O +

For O +
each O +
component O -
, O +
the O +
MLOD O +
was O +
calculated O +
as O +
three O +
times O +
the O +
standard O +
deviation O +
of O +
the O +
mean O +
and O +
the O +
MLOQ O +
was O +
estimated O +
as O +
ten O +
times O +
the O +
standard O +
deviation O +
of O +
the O +
mean O +
of O +
the O +
55 O +
measurements O -
. O +

Since O +
sitostanol O +
and O +
campestanol O +
were O +
not O +
present O +
in O +
the O +
control O +
serum O +
and O +
lanosterol O +
and O +
stigmasterol O +
were O +
barely O +
detectable O -
, O +
the O +
MLODs O +
and O +
MLOQs O +
for O +
these O +
components O +
were O +
determined O +
by O +
analysis O +
of O +
the O +
Accutrol O -
™ O +
serum O +
spiked O +
with O +
known O +
amounts O +
of O +
standards O -
, O +
as O +
follows O -
. O +

A O +
chloroform O +
solution O +
containing O +
0.5 O +
μg O -
/ O -
ml O +
of O +
stigmasterol O -
, O +
sitostanol O -
, O +
and O +
lanosterol O +
and O +
1 O +
μg O -
/ O -
ml O +
of O +
campestanol O +
was O +
prepared O -
. O +

One O +
ml O +
of O +
the O +
solution O +
was O +
added O +
to O +
each O +
of O +
seven O +
0.9-ml O +
Accutrol O -
™ O +
composite O +
aliquots O -
, O +
which O +
were O +
then O +
assayed O +
as O +
described O +
above O -
, O +
except O +
for O +
the O +
volume O +
of O +
chloroform O +
added O +
during O +
the O +
total O +
lipid O +
extraction O +
which O +
was O +
reduced O +
by O +
the O +
volume O +
of O +
standard O +
added O -
. O +

MLOD O +
was O +
calculated O +
as O +
three O +
times O +
the O +
standard O +
deviation O +
of O +
the O +
mean O -
, O +
and O +
MLOQ O +
was O +
calculated O +
as O +
ten O +
times O +
the O +
standard O +
deviation O +
of O +
the O +
mean O +
of O +
the O +
seven O +
measurements O -
. O +

We O +
also O +
checked O +
the O +
method O +
performance O +
in O +
assaying O +
smaller O +
serum O +
aliquots O -
, O +
which O +
may O +
be O +
of O +
interest O +
when O +
the O +
sample O +
volume O +
is O +
limited O -
. O +

Seven O +
0.5-ml O +
and O +
seven O +
0.25-ml O +
aliquots O +
of O +
the O +
control O +
serum O +
composite O +
unspiked O +
and O +
spiked O +
with O +
sitostanol O -
, O +
campestanol O -
, O +
stigmasterol O -
, O +
and O +
lanosterol O +
in O +
amounts O +
near O +
the O +
MLOQ O +
determined O +
for O +
analysis O +
of O +
0.9 O +
ml O +
serum O +
were O +
assayed O -
. O +

A O +
chloroform O +
solution O +
of O +
sitostanol O -
, O +
campestanol O -
, O +
stigmasterol O -
, O +
and O +
lanosterol O +
was O +
added O +
to O +
three O +
0.25 O +
ml O +
and O +
three O +
0.5-ml O +
aliquots O +
of O +
the O +
Accutrol O -
™ O +
control O +
composite O +
such O +
that O +
final O +
concentrations O +
were O +
1 O +
μg O -
/ O -
ml O +
campestanol O +
and O +
0.5 O +
μg O -
/ O -
ml O +
sitostanol O -
, O +
stigmasterol O -
, O +
and O +
lanosterol O -
. O +

Additionally O -
, O +
seven O +
serum O +
samples O +
from O +
a O +
clinical O +
feeding O +
trial O +
[ O -
2 O -
] O +
, O +
in O +
which O +
sitostanol O +
was O +
detected O -
, O +
were O +
re O -
- O -
assayed O +
in O +
0.25-ml O +
aliquots O +
and O +
compared O +
to O +
the O +
results O +
from O +
analysis O +
of O +
the O +
0.9-ml O +
aliquots O -
. O +

2.6 O +
Recovery O +
studies O +
Recovery O +
analysis O +
was O +
based O +
on O +
fortification O +
of O +
samples O +
of O +
the O +
control O +
serum O +
composite O -
. O +

For O +
the O +
analytes O +
not O +
present O +
in O +
the O +
control O +
material O -
, O +
fortification O +
was O +
performed O +
at O +
four O +
different O +
concentrations O +
and O +
reported O +
for O +
all O +
concentrations O +
at O +
or O +
above O +
the O +
MLOQ O +
determined O +
for O +
the O +
individual O +
compounds O -
. O +

For O +
the O +
compounds O +
present O +
in O +
the O +
control O +
serum O -
, O +
samples O +
were O +
fortified O +
at O +
one O +
concentration O -
, O +
which O +
was O +
approximately O +
the O +
same O +
as O +
that O +
determined O +
from O +
analysis O +
of O +
the O +
control O +
serum O -
. O +

For O +
these O +
samples O -
, O +
the O +
values O +
calculated O +
for O +
the O +
unfortified O +
control O +
sample O +
analyzed O +
and O +
chromatographed O +
in O +
the O +
same O +
assay O +
were O +
subtracted O +
from O +
the O +
fortified O +
control O +
sample O +
values O +
to O +
determine O +
recovery:%R O -
= O -
Mfc O +
−Mc O +
Mf O +
×100 O +
where O +
% O -
R O +
is O +
percent O +
recovery O -
, O +
M O +
fc O +
is O +
the O +
raw O +
amount O +
in O +
μg O +
of O +
component O +
determined O +
in O +
the O +
fortified O +
sample O -
, O +
M O +
c O +
is O +
the O +
raw O +
amount O +
in O +
μg O +
of O +
component O +
in O +
the O +
unfortified O +
material O -
, O +
and O +
M O +
f O +
is O +
the O +
fortification O +
amount O +
in O +
μg O -
. O +

2.6.1 O +
Precision O +
studies O +
For O +
sitosterol O -
, O +
campesterol O -
, O +
lathosterol O -
, O +
desmosterol O -
, O +
and O +
lanosterol O -
, O +
precision O +
was O +
evaluated O +
from O +
the O +
results O +
of O +
repeated O +
analyses O +
of O +
the O +
control O +
sample O +
( O -
Accutrol O -
™ O -
) O -
. O +

For O +
sitostanol O -
, O +
campestanol O -
, O +
and O +
stigmasterol O -
, O +
precision O +
was O +
estimated O +
from O +
repeated O +
analyses O +
of O +
the O +
control O +
composite O +
spiked O +
with O +
a O +
standard O +
mixture O +
of O +
these O +
components O -
. O +

2.7 O +
Routine O +
quality O +
control O +
Prior O +
to O +
analysis O +
of O +
unknown O +
samples O -
, O +
three O +
assay O +
batches O +
of O +
5–13 O +
aliquots O +
of O +
the O +
serum O +
control O +
material O +
( O -
Section O +
2.3.5 O -
) O +
were O +
analyzed O +
over O +
a O +
period O +
of O +
2 O +
weeks O -
. O +

A O +
control O +
chart O +
showing O +
the O +
mean O +
and O +
tolerance O +
limits O +
( O -
±3 O +
times O +
the O +
standard O +
deviation O -
) O +
was O +
established O +
for O +
each O +
analyte O +
and O +
used O +
to O +
monitor O +
subsequent O +
assays O +
( O -
[ O -
13 O -
] O +
, O +
pp O -
. O +

130–132 O -
) O -
. O +

An O +
aliquot O +
of O +
the O +
control O +
serum O +
composite O +
was O +
assayed O +
with O +
each O +
batch O +
of O +
samples O -
. O +

3 O +
Results O +
and O +
discussion O +
3.1 O +
Chromatograms O +
Representative O +
chromatograms O +
for O +
standards O -
, O +
the O +
control O +
serum O -
, O +
and O +
a O +
serum O +
sample O +
from O +
the O +
diet O +
intervention O +
( O -
which O +
contained O +
sitostanol O +
and O +
campestanol O -
) O +
are O +
shown O +
in O +
Fig. O +
1 O +
. O +

3.2 O +
Retention O +
times O +
and O +
response O +
factors O +
Table O +
1 O +
summarizes O +
the O +
retention O +
times O -
, O +
relative O +
retention O +
times O -
, O +
and O +
response O +
factors O +
for O +
sitosterol O -
, O +
campesterol O -
, O +
stigmasterol O -
, O +
sitostanol O -
, O +
campestanol O -
, O +
desmosterol O -
, O +
lathosterol O -
, O +
and O +
also O +
lanosterol O -
, O +
fucosterol O -
, O +
and O +
squalene O +
using O +
the O +
present O +
method O -
. O +

Whereas O +
absolute O +
retention O +
times O +
sometimes O +
varied O +
up O +
to O +
0.2 O +
min O -
. O +

( O -
e.g. O +
from O +
slight O +
changes O +
in O +
column O +
activity O +
and/or O +
head O +
pressure O -
) O -
, O +
relative O +
retention O +
times O +
were O +
consistent O +
within O +
0.02 O +
min O +
across O +
runs O -
. O +

3.3 O +
Linearity O -
, O +
limits O +
of O +
detection O -
, O +
limits O +
of O +
quantitation O -
, O +
and O +
analytical O +
ranges O +
Table O +
2 O +
summarizes O +
the O +
method O +
linear O +
range O -
, O +
limit O +
of O +
detection O +
( O -
MLOD O -
) O -
, O +
and O +
limit O +
of O +
quantitation O +
( O -
MLOQ O -
) O +
for O +
each O +
component O +
( O -
sitosterol O -
, O +
campesterol O -
, O +
stigmasterol O -
, O +
sitostanol O -
, O +
campestanol O -
, O +
desmosterol O -
, O +
lathosterol O -
, O +
lanosterol O -
) O +
in O +
the O +
present O +
study O -
. O +

The O +
method O +
enabled O +
detection O +
of O +
all O +
components O +
at O +
concentrations O +
of O +
< O -
0.4 O +
μg O -
/ O -
ml O +
( O -
< O -
1 O +
μmol O -
/ O -
l O -
) O -
. O +

The O +
greatest O +
sensitivity O +
was O +
for O +
sitostanol O +
( O -
0.05 O +
μg O -
/ O -
ml O -
; O +
0.1 O +
μmol O -
/ O -
l O -
) O +
and O +
the O +
least O +
for O +
campesterol O +
and O +
campestanol O +
( O -
0.4 O +
μg O -
/ O -
ml O -
; O +
1 O +
μmol O -
/ O -
l O -
) O -
. O +

The O +
decreased O +
sensitivity O +
for O +
campesterol O +
and O +
campestanol O +
was O +
largely O +
due O +
to O +
interfering O +
peaks O +
in O +
the O +
region O +
which O +
limited O +
the O +
reliability O +
of O +
peak O +
area O +
estimates O +
at O +
low O +
analyte O +
levels O -
. O +

The O +
MLOQ O +
ranged O +
from O +
0.2 O +
μg O -
/ O -
ml O +
( O -
0.5 O +
μmol O -
/ O -
l O -
) O +
for O +
sitostanol O +
to O +
1.2 O +
μg O -
/ O -
ml O +
( O -
3 O +
μmol O -
/ O -
l O -
) O +
for O +
campesterol O +
and O +
campestanol O -
. O +

Response O +
was O +
linear O +
in O +
the O +
range O +
analyzed O +
for O +
each O +
component O +
( O -
MLOQ O +
to O +
10 O +
or O +
25 O +
μg O -
/ O -
ml O -
) O -
. O +

The O +
statistically O +
determined O +
MLOD O +
and O +
MLOQ O +
( O -
defined O +
as O +
three O +
and O +
ten O +
times O +
the O +
standard O +
deviation O +
of O +
replicates O -
, O +
respectively O -
; O +
13 O -
, O +
p. O +
80 O -
) O +
included O +
effects O +
of O +
inconsistent O +
automated O +
peak O +
integration O +
due O +
to O +
background O +
interferences O -
. O +

The O +
statistically O +
determined O +
MLOQ O +
for O +
lanosterol O +
was O +
0.1 O +
μg O -
/ O -
ml O -
, O +
and O +
lanosterol O +
was O +
present O +
in O +
the O +
unfortified O +
control O +
serum O +
at O +
approximately O +
this O +
level O -
. O +

However O -
, O +
uncertainty O +
in O +
quantitation O +
of O +
lanosterol O +
occurred O +
due O +
to O +
occasional O +
incomplete O +
resolution O +
from O +
a O +
nearby O +
peak O -
, O +
and O +
the O +
results O +
for O +
55 O +
analyses O +
of O +
the O +
control O +
material O +
and O +
control O +
material O +
spiked O +
with O +
various O +
levels O +
of O +
lanosterol O +
( O -
Table O +
4 O +
) O +
suggested O +
that O +
the O +
practical O +
MLOQ O +
was O +
somewhat O +
higher O +
than O +
0.1 O +
μg O -
/ O -
ml O -
. O +

Therefore O -
, O +
the O +
MLOQ O +
and O +
MLOD O +
for O +
lanosterol O +
reported O +
in O +
Table O +
2 O +
are O +
estimated O +
based O +
on O +
these O +
practical O +
findings O -
. O +

3.4 O +
Recovery O +
Recovery O +
of O +
spiked O +
standards O +
is O +
shown O +
in O +
Table O +
3 O +
and O +
appeared O +
quantitative O +
for O +
lathosterol O -
, O +
campesterol O -
, O +
sitosterol O -
, O +
sitostanol O -
, O +
campestanol O -
, O +
lanosterol O -
, O +
and O +
stigmasterol O -
. O +

Recovery O +
of O +
fortified O +
desmosterol O +
was O +
74 O -
% O -
. O +

The O +
reason O +
for O +
this O +
result O +
is O +
unknown O -
; O +
we O +
did O +
not O +
attempt O +
to O +
repeat O +
the O +
experiment O -
. O +

3.5 O +
Precision O +
Table O +
4 O +
summarizes O +
the O +
mean O -
, O +
standard O +
deviation O -
, O +
and O +
relative O +
standard O +
deviation O +
for O +
sitosterol O -
, O +
campesterol O -
, O +
desmosterol O -
, O +
lathosterol O -
, O +
and O +
lanosterol O +
concentrations O +
assayed O +
in O +
the O +
control O +
material O +
over O +
the O +
course O +
of O +
23 O +
assay O +
batches O +
by O +
two O +
analysts O +
over O +
a O +
2-month O +
period O -
. O +

Because O +
sitostanol O -
, O +
campestanol O -
, O +
and O +
stigmasterol O +
are O +
not O +
components O +
of O +
the O +
Accutrol O -
™ O +
serum O +
and O +
could O +
not O +
be O +
readily O +
and O +
homogeneously O +
fortified O -
, O +
no O +
control O +
data O +
were O +
generated O +
for O +
these O +
compounds O -
. O +

For O +
sitosterol O -
, O +
campesterol O -
, O +
lathosterol O -
, O +
and O +
desmosterol O -
, O +
the O +
standard O +
deviation O +
over O +
all O +
analyses O +
ranged O +
from O +
0.02 O +
μg O -
/ O -
ml O +
( O -
lanosterol O -
) O +
to O +
0.12 O +
μg O -
/ O -
ml O +
( O -
campesterol O -
) O -
. O +

The O +
within O -
- O -
assay O +
standard O +
deviations O +
were O +
similar O +
to O +
the O +
overall O +
RSD O +
for O +
all O +
components O -
. O +

The O +
relative O +
standard O +
deviation O +
for O +
lanosterol O +
was O +
much O +
higher O +
than O +
for O +
other O +
components O +
( O -
14 O -
% O -
) O -
, O +
due O +
to O +
the O +
low O +
concentration O +
in O +
the O +
control O +
sample O +
( O -
0.1 O +
μg O -
/ O -
ml O -
) O -
. O +

Quality O +
control O +
charts O +
for O +
lathosterol O +
and O +
campesterol O +
in O +
the O +
control O +
serum O +
are O +
shown O +
in O +
Fig. O +
2 O +
. O +

3.6 O +
Method O +
performance O +
in O +
assay O +
of O +
smaller O +
volumes O +
of O +
serum O +
Table O +
5 O +
shows O +
data O +
from O +
the O +
analyses O +
of O +
fortified O +
( O -
sitostanol O -
, O +
campestanol O -
, O +
lanosterol O -
, O +
stigmasterol O -
) O +
and O +
unfortified O +
0.25- O -
, O +
0.5- O -
, O +
and O +
0.9-ml O +
aliquots O +
of O +
the O +
control O +
serum O +
composite O -
. O +

All O +
compounds O +
were O +
fortified O +
at O +
concentrations O +
near O +
the O +
MLOQ O +
determined O +
for O +
analysis O +
of O +
0.9 O +
ml O +
( O -
Table O +
2 O +
) O -
. O +

Results O +
for O +
sitosterol O -
, O +
campesterol O -
, O +
lathosterol O -
, O +
desmosterol O -
, O +
sitostanol O -
, O +
and O +
campestanol O +
were O +
similar O +
for O +
all O +
volumes O +
analyzed O -
, O +
suggesting O +
that O +
for O +
these O +
components O -
, O +
sensitivity O +
and O +
precision O +
are O +
not O +
compromised O +
by O +
assaying O +
as O +
low O +
as O +
0.25 O +
ml O -
. O +

In O +
the O +
fortified O +
serum O -
, O +
however O -
, O +
lanosterol O +
and O +
stigmasterol O +
that O +
were O +
measured O +
in O +
the O +
0.9-ml O +
aliquots O +
were O +
undetectable O +
in O +
the O +
smaller O +
aliquots O -
. O +

Table O +
6 O +
summarizes O +
results O +
from O +
analyses O +
of O +
0.25- O +
and O +
0.9-ml O +
aliquots O +
of O +
seven O +
sitostanol O -
- O -
containing O +
serum O +
samples O +
( O -
from O +
the O +
feeding O +
trial O -
) O -
, O +
which O +
were O +
analyzed O +
to O +
compare O +
the O +
sensitivity O +
of O +
the O +
method O +
in O +
measuring O +
naturally O +
occurring O +
( O -
i.e. O +
unfortified O -
) O +
sitostanol O +
in O +
smaller O +
and O +
larger O +
sample O +
volumes O -
. O +

The O +
0.25-ml O +
assay O +
failed O +
to O +
detect O +
sitostanol O +
in O +
four O +
of O +
the O +
seven O +
samples O +
and O +
lanosterol O +
in O +
all O +
seven O +
samples O -
. O +

For O +
sitosterol O +
( O -
mean O +
2.24 O +
μg O -
/ O -
ml O -
) O -
, O +
stigmasterol O +
( O -
not O +
detected O -
) O +
and O +
campestanol O +
( O -
not O +
detected O -
) O +
results O +
were O +
similar O +
in O +
both O +
analyses O -
. O +

For O +
campesterol O -
, O +
lathosterol O -
, O +
and O +
desmosterol O -
, O +
results O +
were O +
somewhat O +
lower O +
( O -
3–25 O -
% O +
on O +
average O -
) O +
for O +
the O +
0.25-ml O +
aliquots O -
. O +

These O +
results O +
suggest O +
that O +
in O +
a O +
range O +
of O +
actual O +
serum O +
samples O +
the O +
sensitivity O +
of O +
the O +
analysis O +
may O +
be O +
reduced O +
when O +
0.25-ml O +
vs. O +
0.9-ml O +
is O +
assayed O -
, O +
especially O +
for O +
lanosterol O +
and O +
sitostanol O -
. O +

4 O +
Conclusions O +
A O +
sensitive O +
and O +
precise O +
method O +
was O +
developed O +
for O +
quantitation O +
of O +
phytosterols O -
, O +
stanols O -
, O +
and O +
selected O +
cholesterol O +
metabolites O +
in O +
human O +
serum O -
. O +

Analytes O +
were O +
detected O +
at O +
levels O +
of O +
120 O +
ng O -
/ O -
ml O +
to O +
6 O +
μg O -
/ O -
ml O +
with O +
standard O +
deviations O +
of O +
0.02 O +
to O +
0.12 O +
μg O -
/ O -
ml O -
. O +

We O +
have O +
communicated O +
the O +
method O +
in O +
detail O +
to O +
facilitate O +
its O +
reproduction O +
in O +
other O +
laboratories O -
. O +

Acknowledgements O +
This O +
work O +
was O +
supported O +
by O +
Fleischmann O -
's O +
Tablespread O +
Company O -
. O +

We O +
gratefully O +
acknowledge O +
technical O +
advice O +
from O +
Dr. O +
Robert O +
Whiton O +
in O +
evaluating O +
method O +
performance O +
parameters O +
and O +
chromatography O +
issues O -
. O +

The O +
majority O +
of O +
adult O +
cancers O +
are O +
carcinomas O +
of O +
epithelial O +
origin O +
with O +
lung O -
, O +
colon O -
, O +
and O +
uterus O +
as O +
the O +
primary O +
sites O -
, O +
which O +
reflects O +
a O +
selective O +
vulnerability O +
of O +
these O +
tissues O +
to O +
carcinogenic O +
insult O +
as O +
a O +
result O +
of O +
frequent O +
exposure O +
to O +
external O +
environment O -
. O +

Indeed O -
, O +
it O +
is O +
estimated O +
that O +
up O +
to O +
80 O +
to O +
90 O -
% O +
of O +
all O +
cancers O +
are O +
attributable O +
to O +
environmental O +
risk O +
factors O -
, O +
including O +
chemicals O -
, O +
radiations O -
, O +
and O +
viruses O -
. O +

The O +
notion O +
that O +
a O +
majority O +
of O +
human O +
cancers O +
have O +
an O +
environmental O +
origin O +
implies O +
an O +
optimistic O +
outlook O +
in O +
terms O +
of O +
cancer O +
prevention O +
since O +
most O +
cancer O -
- O -
causing O +
substances O +
are O +
introduced O +
into O +
the O +
environment O +
by O +
human O +
activities O +
and O +
are O +
hence O -
, O +
controllable O +
or O +
removable O -
. O +

The O +
elimination O +
of O +
environmental O +
carcinogens O +
or O +
at O +
least O +
avoiding O +
exposure O +
to O +
them O +
offers O +
the O +
opportunity O +
to O +
prevent O +
most O +
cancers O -
, O +
which O +
is O +
a O +
basis O +
of O +
primary O +
prevention O -
. O +

Recent O +
advances O +
in O +
our O +
understanding O +
at O +
the O +
cellular O +
and O +
molecular O +
levels O +
of O +
carcinogenesis O +
have O +
led O +
to O +
the O +
development O +
of O +
a O +
new O +
promising O +
strategy O +
for O +
cancer O +
prevention O -
, O +
that O +
is O -
, O +
chemoprevention O +
[ O -
1–3 O -
] O +
. O +

Chemoprevention O +
is O +
defined O +
as O +
the O +
use O +
of O +
specific O +
chemical O +
substances O +
( O -
natural O +
or O +
synthetic O -
) O +
or O +
their O +
mixtures O +
to O +
suppress O -
, O +
retard O -
, O +
or O +
reverse O +
the O +
process O +
of O +
carcinogenesis O -
. O +

It O +
is O +
one O +
of O +
the O +
novel O +
approaches O +
of O +
controlling O +
cancer O +
alternative O +
to O +
therapy O +
that O +
has O +
some O +
limitations O +
and O +
drawbacks O +
in O +
the O +
treatment O +
of O +
patients O -
. O +

The O +
term O +
chemoprevention O +
was O +
initially O +
coined O +
by O +
Michael O +
Sporn O +
who O +
utilized O +
retinoids O +
to O +
halt O +
experimental O +
carcinogenesis O +
[ O -
4 O -
] O +
. O +

Since O +
we O +
are O +
all O +
exposed O +
in O +
greater O +
or O +
lesser O +
degree O +
to O +
environmental O +
carcinogens O +
from O +
diverse O +
sources O -
, O +
it O +
is O +
important O +
to O +
find O +
a O +
way O +
to O +
neutralize O +
these O +
carcinogens O +
or O +
protect O +
against O +
deleterious O +
effects O +
they O +
exert O -
. O +

In O +
this O +
respect O -
, O +
chemoprevention O +
offers O +
a O +
realistic O +
promise O +
of O +
reducing O +
the O +
incidence O +
of O +
human O +
cancer O -
. O +

The O +
primary O +
goal O +
of O +
chemoprevention O +
research O +
is O +
to O +
identify O +
effective O +
agents O +
and/or O +
develop O +
efficient O +
strategies O +
for O +
clinical O +
trials O +
and O +
ultimately O -
, O +
application O +
to O +
human O +
populations O -
. O +

In O +
order O +
to O +
better O +
practice O +
the O +
chemoprevention O -
, O +
one O +
must O +
precisely O +
understand O +
the O +
nature O +
and O +
mechanisms O +
of O +
carcinogenesis O -
. O +

2 O +
Molecular O +
basis O +
of O +
chemoprevention O +
Carcinogenesis O +
is O +
characterized O +
by O +
a O +
complex O +
process O +
that O +
involves O +
a O +
series O +
of O +
individual O +
steps O -
. O +

From O +
the O +
stand O +
point O +
of O +
the O +
experimental O +
carcinogenesis O +
in O +
rodents O -
, O +
tumor O +
development O +
has O +
been O +
generally O +
considered O +
to O +
consist O +
of O +
three O +
distinct O +
steps O -
— O -
initiation O -
, O +
promotion O -
, O +
and O +
progression O +
as O +
depicted O +
in O +
Fig. O +
1 O +
. O +

Initiation O +
is O +
an O +
irreversible O +
event O +
that O +
begins O +
when O +
the O +
cells O +
in O +
normal O +
tissues O +
are O +
exposed O +
to O +
a O +
carcinogen O +
and O +
their O +
genomic O +
DNA O +
undergoes O +
damage O +
that O +
remains O +
unrepaired O +
or O +
misrepaired O -
. O +

In O +
case O +
of O +
chemically O -
- O -
induced O +
carcinogenesis O -
, O +
initiation O +
involves O +
uptake O +
of O +
a O +
given O +
carcinogenic O +
agent O +
with O +
subsequent O +
distribution O +
and O +
transport O +
to O +
organs O +
and O +
tissues O +
where O +
metabolism O +
occurs O -
, O +
the O +
interaction O +
of O +
a O +
reactive O +
metabolite O +
with O +
cellular O +
DNA O +
with O +
subsequent O +
structural O +
alterations O +
in O +
the O +
DNA O +
molecule O -
, O +
and O +
final O +
fixation O +
of O +
the O +
genotoxic O +
damage O +
to O +
cause O +
mutation O -
. O +

The O +
resulting O +
somatic O +
mutation O +
in O +
a O +
damaged O +
cell O +
can O +
be O +
reproduced O +
during O +
mitosis O -
, O +
which O +
gives O +
rise O +
to O +
a O +
clone O +
of O +
mutated O +
cells O -
. O +

Promotion O +
is O +
expansion O +
of O +
the O +
damaged O +
cells O +
to O +
form O +
an O +
actively O +
proliferating O +
multi O -
- O -
cellular O +
premalignant O +
tumor O +
cell O +
population O -
. O +

Progression O +
is O +
the O +
irreversible O +
process O +
which O +
produces O +
a O +
new O +
clone O +
of O +
tumor O +
cells O +
with O +
increased O +
proliferative O +
capacity O -
, O +
invasiveness O -
, O +
and O +
metastatic O +
potential O -
. O +

Conventional O +
classification O +
of O +
chemopreventive O +
agents O -
, O +
first O +
proposed O +
by O +
Wattenberg O +
[ O -
5 O -
] O +
, O +
is O +
based O +
on O +
the O +
underlying O +
mechanisms O +
by O +
which O +
they O +
exert O +
protective O +
effects O +
in O +
a O +
specific O +
stage O +
of O +
multi O -
- O -
step O +
carcinogenesis O -
. O +

According O +
to O +
this O +
system O -
, O +
chemopreventers O +
are O +
subdivided O +
into O +
two O +
major O +
categories O -
, O +
i.e. O -
, O +
blocking O +
agents O +
and O +
suppressing O +
agents O +
( O -
Fig. O +
2 O +
) O -
. O +

Blocking O +
agents O +
are O +
typically O +
those O +
compounds O +
that O +
can O +
inhibit O +
initiation O +
either O +
by O +
inhibiting O +
the O +
formation O +
of O +
carcinogens O +
from O +
precursor O +
molecules O +
or O +
reactive O +
metabolites O +
from O +
the O +
parent O +
carcinogens O -
, O +
or O +
by O +
preventing O +
the O +
ultimate O +
electrophilic O +
and O +
carcinogenic O +
species O +
from O +
interacting O +
with O +
critical O +
cellular O +
target O +
molecules O -
, O +
such O +
as O +
DNA O -
, O +
RNA O -
, O +
and O +
proteins B-Gene -
. O +

Suppressing O +
agents O +
are O +
considered O +
to O +
inhibit O +
malignant O +
expression O +
of O +
initiated O +
cells O -
, O +
in O +
either O +
the O +
promotion O +
or O +
the O +
progression O +
stage O -
. O +

Certain O +
chemopreventive O +
agents O +
( O -
e.g. O -
, O +
curcumin O +
and O +
resveratrol O -
) O +
have O +
more O +
than O +
one O +
defined O +
mechanism O +
of O +
action O -
, O +
and O +
hence O -
, O +
possess O +
both O +
blocking O +
and O +
suppressive O +
properties O +
[ O -
6 O -
] O +
. O +

A O +
vast O +
variety O +
of O +
chemical O +
compounds O +
have O +
been O +
identified O +
to O +
elicit O +
pronounced O +
chemopreventive O +
effects O +
and O +
many O +
of O +
them O +
are O +
of O +
plant O +
origin O +
that O +
are O +
present O +
naturally O +
in O +
our O +
daily O +
foods O +
or O +
have O +
been O +
used O +
for O +
traditional O +
herbal O +
medication O +
[ O -
7–9 O -
] O +
. O +

Some O +
spices O +
or O +
herbs O +
contain O +
bioactive O +
phenolic O +
substances O +
with O +
potent O +
antimutagenic O +
and O +
anticarcinogenic O +
properties O -
. O +

3 O +
Some O +
novel O +
strategies O +
applicable O +
for O +
identifying O +
chemopreventive O +
phytochemicals O +
Numerous O +
phenolic O +
substances O +
present O +
in O +
fruits O +
and O +
vegetables O +
or O +
in O +
medicinal O +
plants O +
have O +
been O +
found O +
to O +
retain O +
potential O +
cancer O +
chemopreventive O +
activities O -
. O +

For O +
most O +
of O +
known O +
chemopreventive O +
phytochemicals O -
, O +
however O -
, O +
their O +
protective O +
effects O +
are O +
based O +
solely O +
on O +
the O +
results O +
from O +
animal O +
tests O -
. O +

Unfortunately O -
, O +
however O -
, O +
the O +
predictive O +
capability O +
of O +
the O +
majority O +
of O +
animal O +
model O +
studies O +
in O +
the O +
evaluation O +
of O +
cancer O +
chemopreventive O +
agents O +
for O +
use O +
in O +
humans O +
is O +
uncertain O +
and O +
often O +
limited O -
. O +

The O +
efficacy O -
, O +
as O +
well O +
as O +
the O +
safety O +
of O +
selected O +
phytochemicals O +
with O +
promising O +
chemopreventive O +
potential O +
should O +
be O +
validated O +
through O +
properly O -
- O -
designed O +
and O +
well O -
- O -
controlled O +
clinical O +
intervention O +
trials O -
. O +

The O +
use O +
of O +
a O +
reliable O +
biomarker O +
as O +
an O +
early O +
surrogate O +
endpoint O +
is O +
pivotal O +
in O +
conducting O +
prospective O +
chemopreventive O +
trials O -
. O +

There O +
have O +
been O +
extensive O +
studies O +
conducted O +
during O +
the O +
past O +
two O +
decades O +
to O +
search O +
for O +
potential O +
naturally O +
occurring O +
cancer O +
chemopreventive O +
agents O +
and O +
some O +
of O +
them O +
hold O +
promise O +
for O +
human O +
use O -
. O +

Antioxidant O +
vitamins O +
or O +
their O +
synthetic O +
derivatives O +
have O +
been O +
frequently O +
investigated O +
for O +
their O +
possible O +
chemopreventive O +
efficacy O +
among O +
normal O +
or O +
high O +
risk O +
( O -
e.g. O -
, O +
smokers O -
, O +
asbestos O +
workers O -
, O +
etc O -
. O -
) O +
populations O -
. O +

While O +
there O +
has O +
been O +
substantial O +
body O +
of O +
evidence O +
from O +
both O +
experimental O +
and O +
epidemiologic O +
studies O +
supporting O +
the O +
beneficial O +
effects O +
of O +
fruits O +
and O +
vegetables O -
, O +
which O +
are O +
good O +
sources O +
of O +
antioxidant O +
vitamins O -
, O +
the O +
chemopreventive O +
effects O +
of O +
dietary O +
supplementation O +
of O +
individual O +
vitamins O +
or O +
their O +
mixtures O +
remain O +
controversial O +
at O +
the O +
present O +
time O -
. O +

We O +
have O +
lessons O +
from O +
the O +
large O -
- O -
scale O +
randomized O -
, O +
double O -
- O -
blind O -
, O +
placebo O -
- O -
controlled O +
Alpha O -
- O -
Tocopherol O -
, O +
Beta O -
- O -
Carotene O +
( O -
ATBC O -
) O +
Cancer O +
Prevention O +
Study O +
that O +
was O +
conducted O +
with O +
about O +
30,000 O +
Finnish O +
male O +
smokers O +
under O +
the O +
joint O +
sponsorship O +
of O +
the O +
US O +
National O +
Cancer O +
Institute O +
and O +
the O +
National O +
Public O +
Health O +
Institute O +
in O +
Finland O -
. O +

In O +
this O +
particular O +
trial O -
, O +
a O +
daily O +
intake O +
of O +
20 O +
mg O +
of O +
beta O -
- O -
carotene O +
was O +
not O +
protective O +
against O +
lung O +
cancer O -
. O +

On O +
the O +
contrary O -
, O +
the O +
cumulative O +
incidence O +
and O +
the O +
mortality O +
of O +
lung O +
cancer O +
increased O -
, O +
compared O +
with O +
those O +
observed O +
among O +
people O +
in O +
the O +
placebo O +
control O +
group O +
[ O -
10 O -
] O +
. O +

The O +
results O +
of O +
this O +
study O +
were O +
contradictory O +
to O +
the O +
beneficial O +
effects O +
of O +
beta O -
- O -
carotene O +
demonstrated O +
in O +
the O +
previous O +
intervention O +
trials O -
, O +
as O +
well O +
as O +
laboratory O +
studies O -
. O +

Nonetheless O -
, O +
the O +
unexpected O +
negative O +
finding O +
in O +
the O +
ATBC O +
study O +
is O +
not O +
surprising O +
and O +
may O +
not O +
be O +
fortuitous O -
. O +

Since O +
the O +
subjects O +
who O +
participated O +
in O +
this O +
study O +
were O +
relatively O +
old O +
( O -
50 O +
to O +
69 O +
years O +
of O +
age O -
) O +
with O +
a O +
smoking O +
habit O -
, O +
it O +
seems O +
likely O +
that O +
the O +
majority O +
of O +
them O +
already O +
had O +
mutated O +
genes O +
( O -
e.g. O -
, O +
p53 O +
tumor O -
- O -
suppressor O +
or O +
ras O +
-oncogenes O -
) O +
or O +
premalignant O +
lesions O +
before O +
starting O +
beta O -
- O -
carotene O +
supplementation O -
, O +
as O +
a O +
result O +
of O +
cigarette O +
smoking O -
. O +

If O +
it O +
is O +
the O +
case O -
, O +
one O +
may O +
not O +
expect O +
the O +
beneficial O +
effects O +
of O +
beta O -
- O -
carotene O +
that O +
is O +
most O +
active O +
in O +
early O +
stages O +
of O +
carcinogenesis O -
. O +

Excess O +
amount O +
of O +
beta O -
- O -
carotene O +
might O +
have O +
met O +
the O +
substantial O +
growth O +
requirement O +
of O +
rapidly O +
proliferating O +
cancerous O +
cells O -
, O +
thereby O +
stimulating O +
their O +
growth O +
rather O +
than O +
suppressing O +
it O -
. O +

In O +
support O +
of O +
this O +
assumption O -
, O +
post O -
- O -
initiation O +
application O +
of O +
this O +
compound O +
stimulated O +
the O +
mammary O +
carcinogenesis O +
in O +
rodents O +
[ O -
11 O -
] O +
. O +

Similarly O -
, O +
dietary O +
supplementation O +
of O +
beta O -
- O -
carotene O +
enhanced O +
the O +
development O +
of O +
papillomas O +
in O +
mice O +
[ O -
12 O -
] O +
, O +
probably O +
via O +
stimulation O +
of O +
the O +
promotion O +
of O +
carcinogenesis O -
. O +

Besides O +
antioxidative O +
vitamins O -
, O +
fruits O +
and O +
vegetables O +
contain O +
countless O +
phytochemicals O +
of O +
less O +
nutritional O +
value O +
but O +
with O +
substantial O +
chemopreventive O +
potential O -
. O +

However O -
, O +
few O +
population O -
- O -
based O +
chemoprevention O +
trials O +
with O +
non O -
- O -
vitamin O +
phytochemicals O +
have O +
been O +
conducted O -
. O +

Rational O +
and O +
successful O +
implementation O +
of O +
chemopreventive O +
strategies O +
rely O +
on O +
the O +
precise O +
understanding O +
of O +
underlying O +
molecular O +
mechanisms O -
. O +

Alterations O +
of O +
carcinogen O +
metabolism O +
and O +
subsequent O +
DNA O +
adduction O +
may O +
represent O +
an O +
important O +
mechanism O +
by O +
which O +
a O +
given O +
phytochemical O +
modulates O +
chemically O -
- O -
induced O +
carcinogenesis O +
in O +
the O +
initiation O +
stage O -
. O +

Modulation O +
of O +
carcinogen O +
metabolism O +
is O +
often O +
considered O +
by O +
many O +
investigators O +
as O +
a O +
mechanistic O +
basis O +
for O +
protective O +
effects O +
of O +
many O +
types O +
of O +
chemopreventive O +
phytochemicals O -
. O +

However O -
, O +
carcinogen B-Gene -
- I-Gene -
metabolizing I-Gene +
enzymes I-Gene +
in O +
general O +
have O +
dual O +
roles O +
and O +
preventive O +
modulation O +
of O +
metabolism O -
, O +
i.e. O -
, O +
suppression O +
of O +
activation O +
or O +
acceleration O +
of O +
detoxification O +
of O +
one O +
carcinogen O -
, O +
may O +
alter O +
the O +
fate O +
of O +
other O +
xenobiotics O +
and O +
endogenous O +
compounds O +
[ O -
13–15 O -
] O +
, O +
which O +
may O +
limit O +
its O +
utilization O +
as O +
a O +
criterion O +
in O +
identifying O +
or O +
defining O +
new O +
chemopreventive O +
agents O -
. O +

Furthermore O -
, O +
inhibition O +
of O +
initiation O +
is O +
unlikely O +
to O +
be O +
a O +
practical O +
approach O +
to O +
chemoprevention O -
, O +
since O +
there O +
are O +
diverse O +
types O +
of O +
initiators O +
present O +
in O +
our O +
environment O +
and O +
it O +
is O +
not O +
feasible O +
to O +
find O +
a O +
chemopreventive O +
agent O +
that O +
can O +
nullify O +
the O +
initiating O +
activities O +
of O +
all O +
the O +
carcinogens O +
to O +
which O +
we O +
are O +
exposed O -
. O +

Therefore O -
, O +
recent O +
chemopreventive O +
strategies O +
are O +
more O +
concerned O +
with O +
identifying O +
substances O +
with O +
antiproliferative O +
or O +
antiprogressive O +
activities O +
that O +
can O +
suppress O +
the O +
transformation O +
of O +
initiated O +
or O +
precancerous O +
cells O +
to O +
malignant O +
ones O -
, O +
rather O +
than O +
search O +
for O +
anti O -
- O -
initiators O -
. O +

Chemopreventive O +
agents O +
that O +
fall O +
into O +
this O +
category O +
include O +
modulators O +
of O +
signal O +
transduction O -
, O +
inhibitors O +
of O +
oncogene O +
activation O -
, O +
inhibitors O +
of O +
polyamine O +
metabolism O -
, O +
enhancers O +
of O +
gap O +
junctional O +
intercellular O +
communication O -
, O +
inhibitors O +
of O +
angiogenesis O -
, O +
etc O -
. O +

[ O -
16 O -
] O +
. O +

Recently O -
, O +
considerable O +
attention O +
has O +
been O +
focused O +
on O +
dietary O +
and/or O +
pharmacological O +
manipulation O +
of O +
apoptosis O +
as O +
a O +
novel O +
and O +
promising O +
strategy O +
for O +
cancer O +
chemoprevention O -
, O +
as O +
well O +
as O +
therapy O +
[ O -
17–19 O -
] O +
. O +

The O +
maintenance O +
of O +
homeostasis O +
in O +
normal O +
mammalian O +
tissues O +
reflects O +
a O +
critical O +
balance O +
between O +
cell O +
proliferation O +
and O +
cell O +
death O +
via O +
apoptosis O -
. O +

In O +
contrast O -
, O +
apoptosis O +
may O +
be O +
inhibited O +
or O +
perturbed O +
in O +
tumors O +
in O +
which O +
the O +
rate O +
of O +
cell O +
proliferation O +
exceeds O +
that O +
of O +
cell O +
loss O -
. O +

If O +
misregulation O +
of O +
apoptosis O +
results O +
in O +
a O +
failure O +
of O +
tissue O +
size O +
regulation O -
, O +
which O +
eventually O +
leads O +
to O +
the O +
malignant O +
transformation O -
, O +
apoptotic O +
cell O +
death O +
could O +
be O +
induced O +
to O +
augment O +
interventions O +
designed O +
to O +
suppress O +
or O +
reverse O +
the O +
development O +
of O +
cancer O -
. O +

Indeed O -
, O +
various O +
chemopreventive O +
and O +
chemotherapeutic O +
agents O +
are O +
now O +
known O +
to O +
exert O +
their O +
antiproliferative O +
or O +
cytostatic O +
effects O +
by O +
inducing O +
apoptosis O +
in O +
( O -
pre O -
) O -
malignant O +
cells O +
[ O -
17–23 O -
] O +
. O +

Selected O +
chemopreventive O +
vitamins O +
or O +
phytochemicals O +
have O +
the O +
propensity O +
to O +
suppress O +
or O +
retard O +
the O +
growth O +
of O +
cancer O +
cells O +
in O +
this O +
way O +
[ O -
[ O -
17 O -
, O +
24 O -
, O +
25 O -
] O +
, O +
and O +
more O +
examples O +
in O +
this O +
review O -
] O -
. O +

Suppression O +
of O +
prostaglandin O +
synthesis O +
through O +
selective O +
inhibition O +
of O +
cyclooxygenase-2 B-Gene +
( O -
COX-2 B-Gene -
) O +
is O +
another O +
promising O +
strategy O +
applicable O +
to O +
identification O +
and O +
development O +
of O +
chemopreventive O +
drugs O -
. O +

Prostaglandins O +
are O +
known O +
to O +
play O +
crucial O +
roles O +
in O +
pathogenesis O +
of O +
malignancy O -
, O +
particularly O +
in O +
colon O +
carcinogenesis O +
and O +
certain O +
nonsteroidal O +
anti O -
- O -
inflammatory O +
drugs O +
( O -
NSAIDs O -
) O -
, O +
such O +
as O +
aspirin O -
, O +
piroxicam O -
, O +
and O +
sulindac O -
, O +
have O +
protective O +
effects O +
on O +
experimental O +
carcinogenesis O +
[ O -
26 O -
, O +
27 O -
] O +
. O +

Furthermore O -
, O +
epidemiologic O +
data O +
indicate O +
a O +
reduced O +
risk O +
of O +
colorectal O +
cancer O +
among O +
individuals O +
who O +
intake O +
aspirin O +
or O +
other O +
NSAIDs O +
on O +
a O +
regular O +
basis O +
[ O -
28 O -
] O +
. O +

Moreover O -
, O +
in O +
patients O +
with O +
familial O +
adenomatous O +
polyposis O -
, O +
the O +
NSAID O +
sulindac O +
caused O +
marked O +
regression O +
of O +
polyps O +
and O +
prevented O +
their O +
recurrence O +
[ O -
29 O -
] O +
. O +

Selected O +
NSAIDs O +
have O +
been O +
reported O +
to O +
suppress O +
growth O +
and O +
proliferation O +
of O +
cancer O +
cells O +
by O +
inducing O +
apoptosis O +
[ O -
30–32 O -
] O +
. O +

Some O +
phenolic O +
substances O +
derived O +
from O +
Zingiberaceae O +
( O -
ginger O +
family O -
) O +
plants O +
have O +
potent O +
anti O -
- O -
inflammatory O +
activity O +
and O +
induce O +
apoptosis O +
in O +
human O +
cancer O +
cell O +
lines O +
[ O -
[ O -
33–36 O -
] O +
; O +
vide O +
infra O -
] O -
. O +

4 O +
Selected O +
chemopreventive O +
dietary O +
and/or O +
medicinal O +
phenolic O +
substances O +
4.1 O +
Capsaicin O +
Capsaicin O +
( O -
trans O +
-8-methyl O -
- O -
N O +
-vanillyl-6-nonenamide O -
; O +
structure O +
shown O +
in O +
Fig. O +
3 O +
) O +
is O +
a O +
principal O +
pungent O +
ingredient O +
present O +
in O +
hot O +
red O +
and O +
chili O +
peppers O +
that O +
belong O +
to O +
the O +
plant O +
genus O +
Capsicum O +
( O -
Solanaceae O -
) O -
. O +

The O +
compound O +
has O +
been O +
tested O +
by O +
many O +
investigators O +
for O +
its O +
effects O +
on O +
experimental O +
carcinogenesis O +
and O +
mutagenesis O +
[ O -
for O +
review O -
, O +
see O +
Refs O -
. O +

[ O -
37 O -
, O +
38 O -
] O +
and O +
references O +
therein O -
] O -
. O +

Data O +
in O +
the O +
literature O +
indicate O +
that O +
capsaicin O +
has O +
a O +
dual O +
role O +
in O +
carcinogenic O +
and O +
mutagenic O +
processes O +
and O +
its O +
effects O +
in O +
some O +
degree O +
relies O +
on O +
the O +
doses O -
, O +
routes O +
of O +
administration O -
, O +
and O +
types O +
of O +
tissues O +
affected O -
. O +

Although O +
the O +
previous O +
studies O +
were O +
mainly O +
focused O +
on O +
evaluation O +
of O +
carcinogenic O +
or O +
co O -
- O -
carcinogenic O +
potential O +
of O +
capsaicin O +
in O +
hot O +
peppers O +
in O +
consideration O +
of O +
its O +
irritancy O -
, O +
the O +
compound O +
has O +
recently O +
been O +
reported O +
to O +
retain O +
protective O +
properties O +
against O +
experimental O +
carcinogenesis O +
and O +
mutagenesis O +
[ O -
37 O -
, O +
38 O -
] O +
. O +

In O +
several O +
instances O -
, O +
it O +
has O +
been O +
demonstrated O +
that O +
capsaicin O +
modulates O +
microsomal O +
cytochrome B-Gene +
P I-Gene +
450-dependent I-Gene +
monooxygenase I-Gene +
activities O -
, O +
thereby O +
affecting O +
metabolism O +
of O +
carcinogens O +
and O +
other O +
xenobiotics O +
[ O -
39–45 O -
] O +
. O +

Capsaicin O +
was O +
found O +
to O +
interact O +
with O +
rat O +
hepatic O +
mixed O -
- O -
function O +
oxidases B-Gene +
as O +
revealed O +
by O +
prolongation O +
of O +
pentobarbital O +
or O +
hexobarbital O +
sleeping O +
time O +
[ O -
39–41 O -
] O +
and O +
inhibition O +
of O +
ethylmorphine B-Gene +
demethylase I-Gene +
activity O -
, O +
as O +
well O +
as O +
production O +
of O +
a O +
type O +
I O +
spectral O +
change O +
[ O -
39 O -
] O +
. O +

The O +
compound O +
also O +
suppresses O +
the O +
activity O +
of O +
rat O +
epidermal O +
aryl B-Gene +
hydrocarbon I-Gene +
hydroxylase I-Gene +
[ O -
42 O -
] O +
that O +
is O +
responsible O +
for O +
the O +
biotransformation O +
of O +
benzo O -
[ O -
a O -
] O -
pyrene O +
and O +
other O +
polyaromatic O +
hydrocarbons O -
. O +

Metabolism O +
and O +
subsequent O +
covalent O +
DNA O +
binding O +
of O +
benzo O -
[ O -
a O -
] O -
pyrene O +
in O +
human O +
and O +
murine O +
keratinocytes O +
were O +
attenuated O +
by O +
capsaicin O +
[ O -
42 O -
] O +
. O +

Taken O +
together O -
, O +
the O +
above O +
findings O +
suggest O +
that O +
capsaicin O +
can O +
influence O +
the O +
initiating O +
activities O +
of O +
certain O +
chemical O +
carcinogens O +
through O +
modulation O +
of O +
their O +
metabolic O +
activation O +
and/or O +
detoxification O -
. O +

Benzo O -
[ O -
a O -
] O -
pyrene O -
- O -
induced O +
pulmonary O +
tumor O +
in O +
mice O +
was O +
inhibited O +
by O +
capsaicin O +
treatment O +
[ O -
43 O -
] O +
. O +

Capsaicin O +
displayed O +
inhibitory O +
effects O +
on O +
metabolism O -
, O +
mutagenicity O +
and/or O +
covalent O +
DNA O +
binding O +
of O +
aflatoxin O +
B1 O +
[ O -
44 O -
] O +
and O +
the O +
tobacco O -
- O -
specific O +
nitrosamine O -
, O +
4- O -
( O -
methylnitrosamino O -
) O -
-1- O -
( O -
3-pyridyl O -
) O -
-1-butanone O +
( O -
NNK O -
) O +
[ O -
45–47 O -
] O +
. O +

Capsaicin O +
and O +
its O +
saturated O +
analog O +
dihydrocapsaicin O +
( O -
Fig. O +
3 O +
for O +
chemical O +
structures O -
) O +
have O +
been O +
shown O +
to O +
inhibit O +
cytochrome B-Gene +
P I-Gene +
450 I-Gene +
2E1 I-Gene +
[ O -
48 O -
, O +
49 O -
] O +
, O +
an O +
isoform B-Gene +
that O +
catalyzes O +
metabolic O +
activation O -
, O +
as O +
well O +
as O +
detoxification O +
of O +
many O +
low O +
molecular O +
weight O +
carcinogens O -
. O +

In O +
agreement O +
with O +
these O +
findings O -
, O +
both O +
compounds O +
inhibited O +
the O +
mutagenicity O +
and/or O +
tumorigenicity O +
of O +
vinyl O +
carbamate O +
and O +
dimethylnitrosamine O +
[ O -
49 O -
] O +
, O +
which O +
are O +
preferentially O +
activated O +
by O +
cytochrome B-Gene +
P I-Gene +
450 I-Gene +
2E1 I-Gene -
. O +

In O +
another O +
study O -
, O +
capsaicin O +
ameliorated O +
the O +
peroxidative O +
changes O +
in O +
rat O +
hepatic O +
and O +
pulmonary O +
tissues O +
induced O +
by O +
chloroform O -
, O +
carbon O +
tetrachloride O -
, O +
or O +
dichloromethane O +
[ O -
50 O -
] O +
. O +

Cytochrome B-Gene +
P I-Gene +
450 I-Gene +
2E1 I-Gene +
again O +
plays O +
a O +
role O +
in O +
activation O +
of O +
these O +
halogenated O +
hydrocarbons O -
. O +

Capsaicin O +
pretreatment O +
also O +
protects O +
against O +
the O +
free O +
radical O -
- O -
induced O +
pulmonary O +
damage O +
in O +
rats O +
exposed O +
to O +
such O +
gaseous O +
chemical O +
irritants O +
as O +
sulfur O +
dioxide O +
and O +
nitrogen O +
dioxide O +
[ O -
51 O -
] O +
. O +

It O +
has O +
been O +
reported O +
that O +
intraperitoneal O +
administration O +
of O +
capsaicin O +
attenuates O +
cyclophosphamide O -
- O -
induced O +
chromosomal O +
aberrations O +
and O +
DNA O +
breaks O +
in O +
mice O +
[ O -
52 O -
] O +
. O +

Although O +
topical O +
application O +
of O +
capsaicin O +
can O +
initially O +
induce O +
ear O +
edema O +
in O +
mice O +
[ O -
53 O -
] O +
, O +
subsequent O +
reapplications O +
of O +
the O +
compound O +
suppressed O +
the O +
inflammatory O +
response O +
[ O -
54 O -
] O +
. O +

Carrageenan O -
- O -
induced O +
inflammation O +
in O +
rats O +
was O +
also O +
ameliorated O +
by O +
capsaicin O +
treatment O +
[ O -
55 O -
] O +
. O +

Furthermore O -
, O +
capsaicin O +
was O +
found O +
to O +
inhibit O +
platelet O +
aggregation O +
[ O -
56–58 O -
] O +
. O +

Another O +
study O -
, O +
however O -
, O +
has O +
demonstrated O +
the O +
stimulation O +
of O +
prostaglandin O +
biosynthesis O +
by O +
capsaicin O +
[ O -
59 O -
] O +
. O +

The O +
observed O +
antiplatelet O +
or O +
anti O -
- O -
inflammatory O +
effects O +
of O +
capsaicin O +
appears O +
to O +
be O +
associated O +
with O +
its O +
interference O +
with O +
phospholipase B-Gene +
A2 I-Gene +
[ O -
60 O -
] O +
, O +
a O +
key O +
enzyme B-Gene +
mediating O +
the O +
inflammatory O +
process O -
. O +

Since O +
tumor O +
promotion O +
is O +
related O +
to O +
inflammation O +
which O +
can O +
stimulate O +
the O +
proliferation O +
of O +
initiated O +
cells O -
, O +
it O +
would O +
be O +
of O +
interest O +
to O +
determine O +
if O +
capsaicin O +
could O +
act O +
as O +
an O +
anti O -
- O -
tumor O +
promoting O +
agent O -
. O +

Capsaicin O +
was O +
found O +
to O +
antagonize O +
the O +
mouse O +
ear O +
edema O +
induced O +
by O +
croton O +
oil O +
[ O -
61 O -
] O +
, O +
lending O +
further O +
support O +
to O +
the O +
above O +
idea O -
. O +

Our O +
preliminary O +
study O +
indicates O +
that O +
topical O +
application O +
of O +
capsaicin O +
along O +
with O +
phorbol O +
ester O +
onto O +
shaven O +
backs O +
of O +
ICR O +
mice O -
, O +
after O +
initiation O +
with O +
7,12-dimethylbenz O -
[ O -
a O -
] O -
anthracene O -
, O +
transiently O +
increased O +
the O +
skin O +
tumor O +
formation O -
, O +
but O +
the O +
overall O +
papillomagenesis O +
did O +
not O +
increase O +
[ O -
62 O -
] O +
. O +

Apparently O -
, O +
some O +
of O +
the O +
tumors O +
became O +
slightly O +
regressed O +
after O +
12 O +
weeks O +
of O +
post O -
- O -
initiation O -
. O +

Epithelial O +
thickening O +
and O +
appearance O +
of O +
atypical O +
cells O +
caused O +
by O +
combination O +
of O +
7,12-dimethylbenz O -
[ O -
a O -
] O -
anthracene O +
and O +
phorbol O +
ester O +
were O +
also O +
reduced O +
by O +
capsaicin O +
treatment O -
. O +

According O +
to O +
a O +
recent O +
study O +
by O +
Morre O +
et O +
al. O +
[ O -
63 O -
] O +
, O +
capsaicin O +
preferentially O +
repressed O +
the O +
growth O +
of O +
some O +
transformed O +
cells O +
of O +
human O +
origin O -
, O +
including O +
HeLa O -
, O +
ovarian O +
carcinoma O -
, O +
mammary O +
adenocarcinoma O -
, O +
and O +
promyelocytic O +
leukemia O +
( O -
HL-60 O -
) O +
cells O +
in O +
culture O -
. O +

The O +
inhibition O +
of O +
cell O +
survival O +
was O +
associated O +
with O +
induction O +
of O +
apoptosis O +
as O +
revealed O +
by O +
characteristic O +
morphological O +
changes O +
and O +
appearance O +
of O +
fragmented O +
nuclear O +
DNA O +
[ O -
63 O -
] O +
. O +

The O +
capsaicin O -
- O -
induced O +
growth O +
inhibition O +
and O +
apoptosis O +
in O +
the O +
aforementioned O +
cells O +
were O +
correlated O +
with O +
inhibition O +
of O +
plasma O +
membrane O +
NADH B-Gene +
oxidase I-Gene +
activity O +
[ O -
63 O -
] O +
. O +

The O +
same O +
investigators O +
have O +
subsequently O +
observed O +
the O +
similar O +
findings O +
with O +
human O +
and O +
mouse O +
melanoma O +
cell O +
lines O +
in O +
terms O +
of O +
growth O +
inhibition O -
, O +
apoptosis O +
induction O -
, O +
and O +
inhibition O +
of O +
plasma O +
membrane O +
NADH B-Gene +
oxidase I-Gene +
[ O -
64 O -
] O +
. O +

Interestingly O -
, O +
direct O +
injection O +
of O +
capsaicin O +
into O +
the O +
B16 O +
mouse O +
melanoma O +
transplanted O +
in O +
C57BL O -
/ O -
6 O +
mice O +
significantly O +
blunted O +
the O +
growth O +
of O +
tumors O +
[ O -
64 O -
] O +
. O +

Capsaicin O -
- O -
induced O +
apoptosis O +
has O +
been O +
suggested O +
to O +
be O +
regulated O +
by O +
Bcl-2 B-Gene +
and O +
the O +
protein B-Gene +
phosphatase I-Gene -
, O +
calcineurin B-Gene +
[ O -
65 O -
] O +
. O +

In O +
another O +
study O -
, O +
capsaicin O -
- O -
induced O +
apoptotic O +
death O +
of O +
cultured O +
human O +
gastric O +
cancer O +
cells O -
, O +
which O +
appeared O +
to O +
be O +
mediated O +
via O +
overexpression O +
of O +
the O +
p53 O +
tumor O +
suppressor O +
gene O +
and/or O +
c O -
- O -
myc O +
proto O -
- O -
oncogene O +
[ O -
66 O -
] O +
. O +

One O +
of O +
the O +
important O +
cellular O +
mediators O +
of O +
cellular O +
processes O +
in O +
response O +
to O +
diversified O +
extracellular O +
stimuli O +
including O +
oxidants O -
, O +
UV O -
, O +
mitogens O -
, O +
cytokines B-Gene -
, O +
viruses O -
, O +
tumor B-Gene +
necrosis I-Gene +
factor I-Gene -
- I-Gene -
α I-Gene +
( O -
TNF B-Gene -
- I-Gene -
α I-Gene -
) O -
, O +
interleukin-1 B-Gene +
( O -
IL-1 B-Gene -
) O -
, O +
etc O -
. O +
is O +
a O +
nuclear B-Gene +
transcription I-Gene +
factor I-Gene +
NF B-Gene -
- I-Gene -
κB I-Gene +
[ O -
67–71 O -
] O +
. O +

Upon O +
activation O +
by O +
external O +
signals O -
, O +
NF B-Gene -
- I-Gene -
κB I-Gene +
is O +
migrated O +
to O +
the O +
nucleus O +
where O +
it O +
binds O +
to O +
a O +
specific O +
segment O +
of O +
DNA O -
, O +
thereby O +
triggering O +
expression O +
of O +
a O +
variety O +
of O +
rapid O -
- O -
response O +
genes O +
involved O +
in O +
some O +
important O +
physiological O +
reactions O -
, O +
such O +
as O +
inflammation O -
, O +
cell O +
adhesion O -
, O +
viral O +
replication O -
, O +
immune O +
response O -
, O +
and O +
proliferation O -
. O +

Reactive O +
oxygen O +
species O +
( O -
ROS O -
) O +
has O +
been O +
suggested O +
as O +
a O +
second O +
messenger O +
in O +
a O +
signal O +
transduction O +
pathway O +
for O +
activation O +
of O +
NF O -
- O -
κB O +
[ O -
72 O -
, O +
73 O -
] O +
. O +

According O +
to O +
the O +
study O +
of O +
Singh O +
et O +
al. O +
[ O -
74 O -
] O +
, O +
capsaicin O +
abrogates O +
the O +
activation O +
of O +
NF B-Gene -
- I-Gene -
κB I-Gene +
by O +
TPA O -
, O +
as O +
well O +
as O +
by O +
TNF B-Gene -
- I-Gene -
α I-Gene -
, O +
which O +
may O +
provide O +
a O +
mechanistic O +
basis O +
for O +
the O +
possible O +
anti O -
- O -
tumor O +
promoting O +
activity O +
of O +
capsaicin O -
. O +

Another O +
eukaryotic B-Gene +
transcription I-Gene +
factor I-Gene +
that O +
is O +
responsive O +
to O +
ROS O +
and O +
is O +
hence O -
, O +
regulated O +
by O +
cellular O +
redox O +
status O +
is O +
activator B-Gene +
protein I-Gene +
1 I-Gene +
( O -
AP-1 B-Gene -
) O +
[ O -
67 O -
] O +
. O +

The O +
regulation O +
of O +
AP-1 B-Gene +
in O +
response O +
to O +
external O +
stimuli O +
is O +
considered O +
to O +
be O +
mediated O +
by O +
members O +
of O +
mitogen B-Gene -
- I-Gene -
activated I-Gene +
protein I-Gene +
kinase I-Gene +
( O -
MAPK B-Gene -
) O +
family O -
, O +
among O +
which O +
c B-Gene -
- I-Gene -
jun I-Gene +
-N I-Gene -
- I-Gene -
terminal I-Gene +
kinase I-Gene +
( O -
JNK B-Gene -
; O +
also O +
known O +
as O +
stress B-Gene -
- I-Gene -
activated I-Gene +
protein I-Gene +
kinase I-Gene +
abbreviated O +
as O +
SAPK B-Gene -
) O +
and O +
extracellular B-Gene +
signal I-Gene -
- I-Gene -
regulated I-Gene +
kinase I-Gene +
( O -
ERK B-Gene -
) O +
isoforms B-Gene +
are O +
best O +
characterized O -
. O +

There O +
is O +
some O +
evidence O +
that O +
JNK B-Gene +
and O +
ERK B-Gene +
exert O +
opposite O +
effects O +
on O +
apoptosis O +
[ O -
75 O -
] O +
. O +

Capsaicin O +
induced O +
apoptosis O +
in O +
cultured O +
Jurkat O +
cells O +
through O +
generation O +
of O +
ROS O +
[ O -
76 O -
] O +
. O +

When O +
treated O +
to O +
these O +
cells O +
at O +
a O +
concentration O +
of O +
300 O +
μM O -
, O +
capsaicin O +
rapidly O +
activated O +
JNK B-Gene -
: O +
the O +
activity O +
was O +
detectable O +
as O +
early O +
as O +
5 O +
min O +
after O +
the O +
treatment O -
, O +
while O +
ERK B-Gene +
activity O +
was O +
not O +
affected O +
under O +
the O +
same O +
experimental O +
conditions O +
[ O -
76 O -
] O +
. O +

Despite O +
the O +
activation O +
of O +
JNK B-Gene +
by O +
capsaicin O -
, O +
there O +
was O +
no O +
induction O +
of O +
AP-1 B-Gene +
activity O -
. O +

On O +
the O +
contrary O -
, O +
capsaicin O +
blocked O +
the O +
TPA O -
- O -
induced O +
AP-1 B-Gene +
activation O +
[ O -
76 O -
] O +
. O +

The O +
latter O +
finding O -
, O +
together O +
with O +
the O +
previous O +
observation O +
by O +
Singh O +
et O +
al. O +
[ O -
74 O -
] O +
on O +
suppression O +
of O +
TPA O -
- O -
induced O +
NF B-Gene -
- I-Gene -
κB I-Gene +
activation O +
by O +
capsaicin O -
, O +
may O +
provide O +
important O +
molecular O +
basis O +
for O +
anti O -
- O -
tumor O +
promoting O +
potential O +
of O +
this O +
vanilloid O -
. O +

4.2 O +
Gingerol O +
and O +
paradol O +
Ginger O +
( O -
Zingiber O +
officinale O +
Roscoe O -
, O +
Zingiberaceae O -
) O +
is O +
among O +
the O +
most O +
frequently O +
and O +
heavily O +
consumed O +
dietary O +
condiments O +
throughout O +
the O +
world O -
. O +

Besides O +
its O +
extensive O +
use O +
as O +
a O +
spice O -
, O +
the O +
rhizome O +
of O +
ginger O +
has O +
also O +
been O +
used O +
in O +
traditional O +
oriental O +
herbal O +
medicine O +
for O +
the O +
management O +
of O +
such O +
symptoms O +
as O +
common O +
cold O -
, O +
digestive O +
disorders O -
, O +
rheumatism O -
, O +
neurologia O -
, O +
colic O +
and O +
motion O -
- O -
sickness O -
. O +

The O +
oleoresin O +
from O +
rhizomes O +
of O +
ginger O +
contains O +
[ O -
6 O -
] O -
-gingerol O +
( O -
1- O -
[ O -
4′-hydroxy-3′-methoxyphenyl O -
] O -
-5-hydroxy-3-decanone O -
) O +
and O +
its O +
homologs O +
as O +
pungent O +
ingredients O +
that O +
have O +
been O +
found O +
to O +
possess O +
many O +
interesting O +
pharmacological O +
and O +
physiological O +
activities O -
, O +
such O +
as O +
anti O -
- O -
inflammatory O -
, O +
analgesic O -
, O +
antipyretic O -
, O +
antihepatotoxic O -
, O +
and O +
cardiotonic O +
effects O +
[ O -
77 O -
, O +
78 O -
] O +
. O +

The O +
chemical O +
structure O +
of O +
[ O -
6 O -
] O -
-gingerol O +
that O +
is O +
known O +
as O +
a O +
major O +
pungent O +
and O +
pharmacologically O +
active O +
principle O +
of O +
ginger O +
is O +
shown O +
in O +
Fig. O +
3 O +
. O +

Gingerol O +
has O +
been O +
found O +
to O +
possess O +
substantial O +
antioxidant O +
activity O +
as O +
determined O +
by O +
inhibition O +
of O +
phospholipid O +
peroxidation O +
induced O +
by O +
the O +
FeCl3 O +
–ascorbate O +
system O +
[ O -
79 O -
] O +
. O +

The O +
antioxidative O +
properties O +
of O +
gingerol O +
and O +
other O +
constituents O +
of O +
ginger O +
have O +
been O +
confirmed O +
in O +
various O +
in O +
vitro O +
and O +
in O +
vivo O +
test O +
systems O +
[ O -
80 O -
, O +
81 O -
] O +
. O +

Gingerol O +
also O +
exerts O +
an O +
inhibitory O +
effect O +
on O +
xanthine B-Gene +
oxidase I-Gene +
[ O -
82 O -
] O +
responsible O +
for O +
generation O +
of O +
superoxide O +
anion O -
. O +

Guh O +
et O +
al. O +
[ O -
83 O -
] O +
reported O +
concentration O -
- O -
dependent O +
inhibition O +
by O +
gingerol O +
of O +
arachidonic O +
acid O -
- O -
induced O +
platelet O +
aggregation O +
and O +
formation O +
of O +
thromboxane O +
B2 O +
and O +
prostaglandin O +
D2 O +
. O +

The O +
compound O +
also O +
completely O +
abolished O +
phosphoinositide O +
breakdown O +
induced O +
by O +
arachidonic O +
acid O -
. O +

Gingerol O -
, O +
shogaol O +
and O +
other O +
structurally O -
- O -
related O +
substances O +
in O +
ginger O +
inhibit O +
prostaglandin O +
and O +
leukotriene O +
biosynthesis O +
through O +
suppression O +
of O +
5-lipoxygenase B-Gene +
or O +
prostaglandin B-Gene +
synthetase I-Gene +
[ O -
84–87 O -
] O +
. O +

Since O +
tumor O +
promotion O +
is O +
closely O +
associated O +
with O +
inflammation O +
and O +
oxidative O +
stress O -
, O +
it O +
is O +
likely O +
that O +
a O +
compound O +
with O +
a O +
strong O +
inhibitory O +
effect O +
on O +
the O +
arachidonic O +
acid O +
metabolism O +
would O +
have O +
anti O -
- O -
tumor O +
promoting O +
potential O -
. O +

In O +
line O +
with O +
this O +
notion O -
, O +
our O +
recent O +
study O +
has O +
demonstrated O +
that O +
gingerol O +
protects O +
TPA O -
- O -
induced O +
ear O +
edema O -
, O +
epidermal O +
ornithine B-Gene +
decarboxylase I-Gene +
( O -
ODC B-Gene -
) O +
activity O -
, O +
and O +
skin O +
tumor O +
promotion O +
in O +
female O +
ICR O +
mice O +
[ O -
88 O -
] O +
. O +

Furthermore O -
, O +
topical O +
application O +
of O +
the O +
ginger O +
extract O +
30 O +
min O +
prior O +
to O +
TPA O +
led O +
to O +
dramatic O +
protection O +
against O +
DMBA O -
- O -
initiated O +
skin O +
carcinogenesis O +
in O +
SENCAR O +
mice O +
[ O -
89 O -
] O +
and O +
suppressed O +
TPA O -
- O -
caused O +
induction O +
of O +
epidermal O +
ODC B-Gene +
and O +
its O +
mRNA O +
expression O -
, O +
as O +
well O +
as O +
cyclooxygenase B-Gene +
( O -
COX B-Gene -
) O +
and O +
lipoxygenase B-Gene +
activities O +
[ O -
89 O -
] O +
. O +

Azoxymethane O -
- O -
induced O +
intestinal O +
carcinogenesis O +
in O +
rats O +
was O +
significantly O +
suppressed O +
by O +
dietary O +
administration O +
of O +
gingerol O +
[ O -
90 O -
] O +
. O +

Gingerol O +
was O +
reported O +
as O +
one O +
of O +
the O +
most O +
active O +
constituents O +
contained O +
in O +
traditional O +
oriental O +
herbal O +
medication O -
, O +
` O -
Keishi O -
- O -
ka O -
- O -
kei O -
- O -
to O -
' O +
that O +
exhibited O +
substantial O +
inhibitory O +
effects O +
on O +
pulmonary O +
metastasis O +
in O +
mice O +
transplanted O +
with O +
B16F10 O +
melanoma O +
cells O +
[ O -
91 O -
] O +
. O +

[ O -
6 O -
] O -
-Paradol O +
( O -
1- O -
[ O -
4′-hydroxy-3′-methoxyphenyl O -
] O -
-3-decanone O -
; O +
Fig. O +
3 O +
) O -
, O +
a O +
pungent O +
compound O +
isolated O +
from O +
the O +
seeds O +
of O +
Grains O +
of O +
Paradise O +
( O -
Aframomum O +
melegueta O +
Roscoe O -
, O +
Zingiberaceae O -
) O -
, O +
as O +
well O +
as O +
from O +
the O +
rhizome O +
of O +
ginger O -
, O +
also O +
attenuated O +
promotion O +
of O +
skin O +
carcinogenesis O +
and O +
TPA O -
- O -
induced O +
ear O +
edema O +
in O +
female O +
ICR O +
mice O +
[ O -
92 O -
] O +
. O +

Both O +
[ O -
6 O -
] O -
-gingerol O +
and O +
[ O -
6 O -
] O -
-paradol O +
induce O +
apoptosis O +
in O +
HL-60 O +
cells O +
[ O -
36 O -
] O +
. O +

4.3 O +
Curcumin O +
Curcumin O +
( O -
diferuloylmethane O -
; O +
Fig. O +
4 O +
) O +
is O +
a O +
yellow O +
odorless O +
pigment O +
isolated O +
from O +
the O +
rhizome O +
of O +
turmeric O +
( O -
Curcuma O +
longa O +
L. O -
, O +
Zingiberaceae O -
) O -
. O +

Curcumin O +
possesses O +
anti O -
- O -
inflammatory O +
and O +
antioxidant O +
properties O +
[ O -
93–102 O -
] O +
. O +

This O +
yellow O -
- O -
coloured O +
compound O +
inhibits O +
mutagenicity O +
of O +
certain O +
chemical O +
carcinogens O +
[ O -
103–105 O -
] O +
and O +
also O +
hampers O +
their O +
covalent O +
DNA O +
binding O +
in O +
vivo O +
[ O -
106 O -
] O +
, O +
as O +
well O +
as O -
, O +
in O +
vitro O +
[ O -
107 O -
, O +
108 O -
] O +
. O +

Curcumin O +
also O +
protected O +
against O +
chemically O -
- O -
induced O +
liver O +
damage O +
in O +
experimental O +
animals O +
[ O -
109 O -
, O +
110 O -
] O +
. O +

Its O +
anticarcinogenic O +
activity O +
was O +
evaluated O +
in O +
many O +
animal O +
tumor O +
models O +
[ O -
reviewed O +
in O +
Refs O -
. O +

[ O -
111–113 O -
] O +
] O -
. O +

One O +
of O +
the O +
most O +
prominent O +
effects O +
curcumin O +
exerts O +
on O +
experimental O +
carcinogenesis O +
is O +
its O +
capability O +
to O +
inhibit O +
tumor O +
promotion O +
[ O -
113–116 O -
] O +
. O +

Thus O -
, O +
curcumin O +
was O +
reported O +
to O +
alleviate O +
TPA O -
- O -
induced O +
skin O +
tumor O +
promotion O +
and O +
epidermal O +
ODC B-Gene +
mRNA O +
expression O +
[ O -
115 O -
] O +
, O +
as O +
well O +
as O -
, O +
ODC B-Gene +
activity O +
[ O -
114 O -
] O +
. O +

Topical O +
application O +
of O +
curcumin O +
onto O +
dorsal O +
skins O +
of O +
mice O +
significantly O +
inhibited O +
epidermal O +
COX B-Gene +
and O +
lipoxygenase B-Gene +
[ O -
117 O -
] O +
. O +

Colonic O +
mucosal O +
COX B-Gene +
and O +
lipoxygenase B-Gene +
activities O +
were O +
suppressed O +
by O +
dietary O +
curcumin O -
, O +
which O +
appears O +
to O +
account O +
for O +
its O +
chemopreventive O +
effects O +
on O +
colon O +
carcinogenesis O -
. O +

Likewise O -
, O +
F344 O +
rats O +
fed O +
curcumin O +
in O +
the O +
diet O +
exhibited O +
reduced O +
catalytic O +
activities O +
of O +
phospholipase B-Gene +
A2 I-Gene +
and O +
phospholipase B-Gene +
Cγ1 I-Gene +
that O +
are O +
involved O +
in O +
arachidonic O +
acid O +
release O +
from O +
cellular O +
phospholipid O +
[ O -
118 O -
] O +
. O +

It O +
also O +
attenuates O +
oxidative O +
DNA O +
damage O +
in O +
mouse O +
epidermis O +
[ O -
116 O -
] O +
and O +
in O +
cultured O +
mouse O +
fibroblast O +
cells O +
[ O -
119 O -
] O +
. O +

The O +
compound O +
was O +
found O +
to O +
suppress O +
the O +
generation O +
of O +
ROS O +
including O +
superoxide O +
and O +
hydrogen O +
peroxide O +
in O +
peritoneal O +
macrophages O +
[ O -
120 O -
, O +
121 O -
] O +
. O +

Its O +
antioxidant O +
effects O +
were O +
confirmed O +
in O +
various O +
systems O -
. O +

It O +
is O +
of O +
interest O +
to O +
note O +
that O +
tetrahydrocurcumin O -
, O +
that O +
is O +
one O +
of O +
the O +
plausible O +
metabolites O +
of O +
curcumin O -
, O +
exhibits O +
stronger O +
antioxidative O +
[ O -
102 O -
] O +
and O +
anti O -
- O -
inflammatory O +
[ O -
97 O -
] O +
activities O +
than O +
does O +
curcumin O -
. O +

Curcumin O +
inhibits O +
lipopolysaccharide- O +
and O +
interferon B-Gene -
- I-Gene -
γ I-Gene -
- O -
induced O +
production O +
of O +
nitric O +
oxide O +
in O +
macrophages O +
[ O -
122 O -
] O +
or O +
nitrite O +
in O +
mouse O +
peritoneal O +
cells O +
[ O -
123 O -
] O +
, O +
possibly O +
by O +
suppression O +
of O +
nitric B-Gene +
oxide I-Gene +
synthase I-Gene -
. O +

More O +
recently O -
, O +
Chan O +
et O +
al. O +
[ O -
124 O -
] O +
have O +
reported O +
the O +
inhibition O +
by O +
curcumin O +
of O +
inducible O +
nitric B-Gene +
oxide I-Gene +
synthase I-Gene +
gene O +
expression O +
in O +
isolated O +
BALB O -
/ O -
c O +
mouse O +
peritoneal O +
macrophages O +
and O +
also O +
in O +
the O +
livers O +
of O +
lipopolysaccharide O -
- O -
injected O +
mice O -
. O +

TPA O -
- O -
induced O +
protein B-Gene +
kinase I-Gene +
C I-Gene +
activation O +
and O +
c B-Gene -
- I-Gene -
jun I-Gene +
expression O +
were O +
markedly O +
suppressed O +
by O +
curcumin O +
in O +
mouse O +
fibroblast O +
cells O +
[ O -
125 O -
] O +
. O +

When O +
applied O +
topically O +
on O +
the O +
dorsal O +
side O +
of O +
mouse O +
skin O -
, O +
curcumin O +
significantly O +
inhibited O +
expression O +
of O +
such O +
proto O -
- O -
oncogenes O +
as O +
c O -
- O -
fos O +
, O +
c B-Gene -
- I-Gene -
jun I-Gene +
, O +
and O +
c O -
- O -
myc O +
[ O -
126 O -
] O +
. O +

Curcumin O +
also O +
exhibited O +
inhibitory O +
effects O +
on O +
epidermal B-Gene +
growth I-Gene +
factor I-Gene +
( O -
EGF B-Gene -
) O +
receptor B-Gene +
kinase I-Gene +
activity O +
in O +
cultured O +
human O +
epidermoid O +
carcinoma O +
A431 O +
[ O -
127 O -
] O +
or O +
NIH3T3 O +
cells O +
[ O -
128 O -
] O +
. O +

Other O +
types O +
of O +
protein B-Gene +
kinases I-Gene +
were O +
also O +
found O +
to O +
be O +
inhibited O +
by O +
this O +
compound O +
in O +
a O +
non O -
- O -
competitive O +
manner O +
[ O -
129 O -
] O +
. O +

The O +
pleiotropic O +
effects O +
of O +
curcumin O +
appear O +
to O +
be O +
mediated O +
at O +
least O +
in O +
part O +
through O +
inhibition O +
of O +
transcription B-Gene +
factors I-Gene +
[ O -
130 O -
] O +
. O +

According O +
to O +
a O +
recent O +
study O +
by O +
Huang O +
et O +
al. O +
[ O -
131 O -
] O +
, O +
curcumin O +
suppresses O +
TPA O -
- O -
responsive O +
element O -
- O -
binding O +
activity O +
of O +
c B-Gene -
- I-Gene -
Jun I-Gene -
/ O -
AP-1 B-Gene -
, I-Gene +
which O +
may O +
account O +
for O +
the O +
anti O -
- O -
tumor O +
promoting O +
effect O +
of O +
this O +
chemopreventive O +
agent O -
. O +

More O +
recently O -
, O +
curcumin O +
has O +
been O +
reported O +
to O +
inhibit O +
TNF B-Gene -
- I-Gene -
α I-Gene -
- O -
induced O +
binding O +
of O +
AP-1 B-Gene +
to O +
DNA O +
in O +
bovine O +
aortic O +
endothelial O +
cells O +
[ O -
132 O -
] O +
. O +

Besides O +
interfering O +
with O +
AP-1 B-Gene +
activation O -
, O +
curcumin O +
has O +
been O +
shown O +
to O +
suppress O +
the O +
activation O +
of O +
NF B-Gene -
- I-Gene -
κB I-Gene +
[ O -
133 O -
] O +
that O +
is O +
another O +
important O +
eukaryotic O +
transcription B-Gene +
factor I-Gene -
. O +

The O +
suppression O +
of O +
protein B-Gene +
kinases I-Gene -
, O +
ODC B-Gene -
, O +
and O +
nuclear B-Gene +
transcription I-Gene +
factors I-Gene +
by O +
curcumin O +
suggests O +
that O +
this O +
phenolic O +
compound O +
can O +
act O +
as O +
a O +
cytostatic O +
agent O +
by O +
interfering O +
with O +
certain O +
signal O +
transduction O +
pathways O +
that O +
are O +
critical O +
for O +
cell O +
growth O +
and O +
proliferation O -
. O +

Indeed O -
, O +
curcumin O +
possesses O +
antiproliferative O +
activity O +
[ O -
134 O -
, O +
135 O -
] O +
and O +
the O +
capability O +
of O +
inducing O +
programmed O +
death O +
or O +
apoptosis O +
in O +
cancer O +
cells O +
[ O -
34 O -
, O +
35 O -
] O +
. O +

Furthermore O -
, O +
curcumin O +
exhibited O +
synergistic O +
effects O +
on O +
induction O +
of O +
differentiation O +
in O +
HL-60 O +
cells O +
when O +
combined O +
with O +
all O -
- O -
trans O +
retinoic O +
acid O +
or O +
1α,25-dihydroxyvitamin O +
D3 O +
[ O -
113 O -
] O +
. O +

It O +
also O +
has O +
a O +
strong O +
inhibitory O +
effect O +
on O +
farnesyl B-Gene +
protein I-Gene +
transferase I-Gene +
[ O -
136 O -
] O +
that O +
plays O +
a O +
crucial O +
role O +
in O +
functional O +
activation O +
of O +
Ras B-Gene +
protein I-Gene -
. O +

A O +
recent O +
study O +
by O +
Ciolino O +
et O +
al. O +
[ O -
137 O -
] O +
has O +
revealed O +
inhibition O +
of O +
cytochrome B-Gene +
P I-Gene +
450 I-Gene +
1A1 I-Gene +
activity O +
and O +
formation O +
of O +
carcinogen O -
- O -
DNA O +
adducts O +
in O +
7,12-dimethylbenz O -
[ O -
a O -
] O -
anthracene O -
- O -
treated O +
human O +
mammary O +
epithelial O +
carcinoma O +
( O -
MCF-7 O -
) O +
cells O +
by O +
competitively O +
binding O +
to O +
the O +
aryl B-Gene +
hydrocarbon I-Gene +
receptor I-Gene -
. O +

Besides O +
preventing O +
malignant O +
transformation O -
, O +
the O +
compound O +
has O +
antimetastatic O +
potential O +
as O +
demonstrated O +
by O +
suppression O +
of O +
matrix B-Gene +
metalloproteinase-9 I-Gene +
in O +
the O +
human O +
hepatocellular O +
carcinoma O +
cell O +
line O +
[ O -
138 O -
] O +
. O +

4.4 O +
Diarylheptanoids O +
structurally O -
- O -
related O +
to O +
curcuminoids O +
Diarylheptanoids O +
structurally O -
- O -
related O +
to O +
curcumin O +
are O +
present O +
in O +
certain O +
plants O +
of O +
ginger O +
family O +
( O -
Zingiberaceae O -
) O +
and O +
have O +
been O +
reported O +
to O +
possess O +
a O +
strong O +
anti O -
- O -
inflammatory O +
activity O -
. O +

For O +
instance O -
, O +
yakuchinone O +
A O +
( O -
1- O -
[ O -
4′-hydroxy-3′-methoxyphenyl O -
] O -
-7-phenyl-3-heptanone O -
) O +
and O +
yakuchinone O +
B O +
( O -
1- O -
[ O -
4′-hydroxy-3′-methoxyphenyl O -
] O -
-7-phenylhept-1-en-3-one O -
) O +
which O +
are O +
present O +
in O +
Alpinia O +
oxyphylla O +
Miquel O +
have O +
been O +
reported O +
to O +
be O +
strong O +
inhibitors O +
of O +
prostaglandin O +
biosynthesis O +
in O +
vitro O +
[ O -
85 O -
, O +
87 O -
] O +
. O +

Like O +
curcumin O -
, O +
these O +
substances O +
have O +
a O +
diarylheptanoid O +
moiety O +
with O +
a O +
carbonyl O +
functional O +
group O +
( O -
refer O +
to O +
the O +
structures O +
in O +
Fig. O +
4 O +
) O +
and O +
are O +
hence O -
, O +
anticipated O +
to O +
exhibit O +
potential O +
cancer O +
chemopreventive O +
activities O -
. O +

Results O +
of O +
our O +
recent O +
study O +
showed O +
that O +
topical O +
application O +
of O +
the O +
methanol O +
extract O +
of O +
A. O +
oxyphylla O +
to O +
the O +
dorsal O +
epidermis O +
of O +
mice O +
during O +
the O +
process O +
of O +
tumor O +
promotion O +
markedly O +
suppressed O +
the O +
papilloma O +
formation O +
[ O -
33 O -
] O +
. O +

The O +
extract O +
also O +
attenuated O +
the O +
mouse O +
ear O +
edema O +
induced O +
by O +
the O +
tumor O +
promoter O -
, O +
TPA O +
[ O -
33 O -
] O +
. O +

Subsequent O +
studies O +
have O +
revealed O +
that O +
yakuchinone O +
A O +
and O +
yakuchinone O +
B O -
, O +
major O +
pungent O +
ingredients O +
derived O +
from O +
A. O +
oxyphylla O +
, O +
can O +
act O +
as O +
anti O -
- O -
tumor O +
promoters O +
as O +
determined O +
by O +
their O +
ability O +
to O +
suppress O +
phorbol O +
ester O -
- O -
induced O +
ODC B-Gene +
activation O +
and O +
papilloma O +
formation O +
in O +
mouse O +
skin O +
[ O -
139 O -
, O +
140 O -
] O +
. O +

TPA O -
- O -
stimulated O +
superoxide O +
generation O +
and O +
TNF B-Gene -
- I-Gene -
α I-Gene +
production O +
in O +
HL-60 O +
cells O +
and O +
on O +
DNA O +
binding O +
of O +
AP-1 B-Gene +
in O +
NIH3T3 O +
cells O +
were O +
also O +
suppressed O +
by O +
the O +
above O +
compounds O +
[ O -
139 O -
, O +
140 O -
] O +
. O +

Furthermore O -
, O +
both O +
yakuchinone O +
A O +
and O +
yakuchinone O +
B O +
induce O +
apoptotic O +
death O +
in O +
HL-60 O +
cells O -
, O +
which O +
accounts O +
for O +
their O +
antiproliferative O +
activity O +
[ O -
139 O -
] O +
. O +

Phenolic O +
diarylheptanoids O +
from O +
Alpinia O +
officinarum O +
Hance O +
( O -
Zingiberaceae O -
) O -
, O +
structurally O +
analogous O +
to O +
yakuchinone O +
A O +
and O +
yakuchinone O +
B O -
, O +
and O +
non O -
- O -
phenolic O +
diarylheptanoids O +
present O +
in O +
a O +
Thai O +
medicinal O +
plant O -
, O +
Curcuma O +
xanthorrhiza O +
( O -
Zingiberaceae O -
) O -
, O +
also O +
exhibit O +
strong O +
anti O -
- O -
inflammatory O +
effects O +
[ O -
86 O -
, O +
141 O -
] O +
. O +

Certain O +
diarylheptanoids O +
isolated O +
from O +
the O +
seeds O +
of O +
Alpinia O +
blepharocalyx O +
K. O +
Schum O +
mitigated O +
collagen- O -
, O +
arachidonic O +
acid- O +
and O +
adenosine O +
diphosphate O -
- O -
induced O +
platelet O +
aggregation O +
of O +
human O +
blood O +
[ O -
142 O -
] O +
and O +
suppressed O +
nitric O +
oxide O +
production O +
in O +
lipopolysaccharide O -
- O -
activated O +
murine O +
macrophages O +
in O +
vitro O +
[ O -
143 O -
] O +
. O +

Bioassay O -
- O -
directed O +
fractionation O +
of O +
the O +
ethanol O +
extract O +
of O +
Curcuma O +
zedoaria O +
( O -
Zingiberaceae O -
) O +
afforded O +
demethoxy- O +
and O +
bisdemethoxycurcumin O -
, O +
as O +
well O +
as O +
curcumin O -
, O +
which O +
were O +
cytotoxic O +
against O +
human O +
ovarian O +
cancer O +
cells O +
[ O -
144 O -
] O +
. O +

The O +
same O +
diarylheptanoids O +
were O +
also O +
found O +
in O +
C. O +
longa O +
L. O +
and O +
displayed O +
topoisomerase B-Gene +
I B-Gene +
and O +
II B-Gene +
inhibitory O +
activity O +
[ O -
145 O -
] O +
. O +

It O +
will O +
be O +
worthwhile O +
investigating O +
chemopreventive O +
effects O +
of O +
these O +
novel O +
diarylheptanoids O -
, O +
particularly O +
with O +
regard O +
to O +
their O +
anti O -
- O -
tumor O +
promotional O +
potential O -
. O +

4.5 O +
Resveratrol O +
Resveratrol O +
( O -
3,5,4′-trihydroxy O -
- O -
trans O +
-stilbene O -
; O +
Fig. O +
5 O +
) O -
, O +
a O +
phytoalexin O +
present O +
in O +
grapes O +
and O +
other O +
plants O -
, O +
has O +
potent O +
antioxidant O +
and O +
anti O -
- O -
inflammatory O +
activities O +
which O +
have O +
been O +
considered O +
to O +
be O +
responsible O +
for O +
beneficial O +
effects O +
of O +
red O +
wine O +
consumption O +
on O +
coronary O +
heart O +
disease O +
[ O -
146–148 O -
] O +
. O +

This O +
triphenolic O +
stilbene O +
has O +
been O +
suggested O +
as O +
a O +
potential O +
cancer O +
chemopreventive O +
agent O +
based O +
on O +
its O +
striking O +
inhibitory O +
effects O +
on O +
diverse O +
cellular O +
events O +
associated O +
with O +
tumor O +
initiation O -
, O +
promotion O -
, O +
and O +
progression O +
[ O -
149 O -
] O +
. O +

Resveratrol O +
has O +
been O +
reported O +
to O +
be O +
a O +
potent O +
inhibitor O +
of O +
hepatic O +
cytochrome B-Gene +
P I-Gene +
450-linked I-Gene +
alkoxyresorufin I-Gene +
O I-Gene +
-dealkylase I-Gene +
activities O +
[ O -
150 O -
] O +
responsible O +
for O +
oxidative O +
metabolism O +
of O +
many O +
carcinogenic O +
polynuclear O +
aromatic O +
carcinogens O -
. O +

It O +
also O +
induces O +
phase-2 B-Gene +
detoxification I-Gene +
enzymes I-Gene -
, O +
such O +
as O +
NAD B-Gene -
( I-Gene -
P I-Gene -
) I-Gene -
H I-Gene -
: I-Gene +
quinone I-Gene +
oxidoreductase I-Gene +
[ O -
149 O -
] O +
. O +

Recent O +
work O +
by O +
Uenobe O +
et O +
al. O +
[ O -
151 O -
] O +
demonstrated O +
an O +
antimutagenic O +
activity O +
of O +
resveratrol O +
against O +
the O +
foodborne O +
heterocyclic O +
amine O -
, O +
3-amino-1,4-dimethyl-5H O -
- O -
pyrido O -
[ O -
4,3-b O +
] O -
indole O +
( O -
Trp O -
- O -
P-1 O -
) O +
in O +
bacteria O -
. O +

Resveratrol O +
attenuated O +
PC12 O +
cell O +
death O +
induced O +
by O +
ter O +
-butyl O +
hydroperoxide O +
in O +
the O +
presence O +
of O +
ferric O +
ion O +
[ O -
152 O -
] O +
or O +
by O +
ethanol O +
[ O -
153 O -
] O +
, O +
and O +
was O +
found O +
to O +
be O +
protective O +
against O +
cytotoxicity O +
and O +
NF B-Gene -
- I-Gene -
κB I-Gene +
activation O +
induced O +
by O +
oxidized B-Gene +
lipoproteins I-Gene +
in O +
PC12 O +
cells O +
[ O -
154 O -
, O +
155 O -
] O +
. O +

In O +
addition O -
, O +
the O +
compound O +
inhibited O +
growth O +
of O +
human O +
breast O +
epithelial O +
cells O +
in O +
culture O +
[ O -
156 O -
] O +
. O +

Proliferation O +
of O +
K-562 O +
human O +
erythroleukemia O +
cells O +
and O +
P-815 O +
murine O +
mastocytoma O +
cells O +
was O +
also O +
suppressed O +
by O +
resveratrol O +
treatment O -
, O +
which O +
might O +
be O +
associated O +
with O +
inhibition O +
of O +
ribonucleotide B-Gene +
reductase I-Gene +
[ O -
157 O -
] O +
. O +

One O +
of O +
the O +
plausible O +
mechanisms O +
that O +
could O +
account O +
for O +
the O +
chemopreventive O +
activity O +
of O +
resveratrol O +
is O +
suppression O +
of O +
prostaglandin O +
biosynthesis O +
catalyzed O +
COX B-Gene -
. O +

Prostaglandins O +
are O +
known O +
to O +
play O +
pivotal O +
roles O +
in O +
pathogenesis O +
of O +
malignancy O -
, O +
particularly O +
in O +
colon O +
and O +
mammary O +
carcinogenesis O +
and O +
suppression O +
of O +
prostaglandin O +
biosynthesis O +
through O +
selective O +
inhibition O +
of O +
COX B-Gene +
is O +
hence O -
, O +
now O +
regarded O +
as O +
an O +
important O +
cancer O +
chemopreventive O +
strategy O -
. O +

Resveratrol O +
was O +
shown O +
to O +
inhibit O +
COX-1 B-Gene +
activity O +
in O +
microsomes O +
derived O +
from O +
sheep O +
seminal O +
vesicles O +
[ O -
149 O -
] O +
. O +

More O +
recently O -
, O +
Subbaramaiah O +
et O +
al. O +
[ O -
158 O -
] O +
have O +
reported O +
that O +
resveratrol O +
inhibits O +
the O +
catalytic O +
activity O +
of O +
the O +
inducible O +
isozyme B-Gene +
COX-2 B-Gene +
in O +
cultured O +
human O +
mammary O +
epithelial O +
cells O +
with O +
and O +
without O +
TPA O +
treatment O -
. O +

Likewise O -
, O +
human O +
recombinant O +
COX-2 B-Gene +
expressed O +
in O +
baculovirus O +
was O +
inhibited O +
by O +
resveratrol O +
[ O -
158 O -
] O +
. O +

Besides O +
inhibiting O +
the O +
catalytic O +
activity O +
of O +
COX-2 B-Gene -
, O +
the O +
compound O +
also O +
blocked O +
TPA O -
- O -
mediated O +
induction O +
of O +
cox B-Gene +
-2 I-Gene +
mRNA O +
in O +
cultured O +
human O +
mammary O +
epithelial O +
cells O +
through O +
repression O +
of O +
AP-1-dependent B-Gene +
transactivation O +
[ O -
158 O -
] O +
. O +

More O +
recently O -
, O +
topical O +
application O +
of O +
resveratrol O +
onto O +
dorsal O +
skin O +
of O +
CD-1 O +
mice O +
led O +
to O +
profound O +
attenuation O +
of O +
oxidative O +
stress O +
and O +
expression O +
of O +
epidermal O +
TGF B-Gene -
- I-Gene -
β1 I-Gene +
and O +
c O -
- O -
fos O +
induced O +
by O +
TPA O -
, O +
but O +
the O +
induction O +
of O +
cox B-Gene +
-1 I-Gene -
, O +
cox B-Gene +
-2 I-Gene -
, O +
c O -
- O -
myc O +
, O +
c B-Gene -
- I-Gene -
jun I-Gene +
and O +
TNF B-Gene -
- I-Gene -
α I-Gene +
mRNAs O +
was O +
not O +
affected O +
[ O -
159 O -
] O +
. O +

As O +
mentioned O +
earlier O -
, O +
some O +
anti O -
- O -
inflammatory O +
chemopreventive O +
agents O +
have O +
been O +
found O +
to O +
suppress O +
growth O +
and O +
proliferation O +
of O +
transformed O +
cells O +
through O +
induction O +
of O +
programmed O +
death O +
or O +
apoptosis O +
[ O -
30–32 O -
] O +
. O +

Although O +
resveratrol O +
exerts O +
anti O -
- O -
inflammatory O +
effects O +
through O +
selective O +
suppression O +
of O +
COX-2 B-Gene -
, O +
little O +
information O +
is O +
available O +
in O +
the O +
literature O +
in O +
regards O +
to O +
its O +
apoptosis O -
- O -
inducing O +
capability O +
in O +
tumor O +
cells O -
. O +

Mgbonyebi O +
et O +
al. O +
[ O -
156 O -
] O +
reported O +
the O +
growth O +
inhibition O +
by O +
resveratrol O +
of O +
several O +
types O +
of O +
human O +
breast O +
epithelial O +
cells O -
, O +
which O +
was O +
independent O +
of O +
estrogen B-Gene +
receptor I-Gene +
status O +
of O +
the O +
cells O -
. O +

Although O +
the O +
antiproliferative O +
activity O +
of O +
resveratrol O +
was O +
demonstrated O +
[ O -
156 O -
] O +
, O +
the O +
mode O +
of O +
cell O +
death O +
induced O +
by O +
this O +
phytochemical O +
was O +
not O +
clarified O +
in O +
the O +
above O +
investigation O -
. O +

Suppression O +
of O +
HL-60 O +
cells O +
by O +
resveratrol O +
was O +
shown O +
to O +
be O +
mediated O +
via O +
induction O +
of O +
apoptosis O +
as O +
determined O +
by O +
nuclear O +
fragmentation O -
, O +
chromatin O +
condensation O -
, O +
a O +
time O -
- O -
related O +
increase O +
in O +
the O +
frequency O +
of O +
subdiploid O +
( O -
apoptotic O -
) O +
cells O -
, O +
and O +
internucleosomal O +
DNA O +
fragmentation O +
[ O -
160 O -
] O +
. O +

Besides O +
suppression O +
of O +
proliferation O -
, O +
the O +
compound O +
induced O +
differentiation O +
of O +
HL-60 O +
cells O +
at O +
concentrations O +
as O +
low O +
as O +
30 O +
μM O -
, O +
which O +
appears O +
to O +
be O +
associated O +
with O +
reversible O +
cell O +
cycle O +
arrest O +
at O +
the O +
S O -
- O -
phase O +
check O +
point O +
[ O -
161 O -
] O +
. O +

Moreover O -
, O +
resveratrol O +
was O +
found O +
to O +
induce O +
apoptosis O +
in O +
HL-60 O +
cells O +
by O +
triggering O +
the O +
CD95 O +
signaling O +
system O +
[ O -
162 O -
] O +
. O +

The O +
growth O +
of O +
estrogen O -
- O -
dependent O +
T47D O +
breast O +
carcinoma O +
cells O +
was O +
also O +
suppressed O +
by O +
resveratrol O +
treatment O +
[ O -
162 O -
] O +
. O +

The O +
latter O +
finding O +
is O +
contradictory O +
to O +
the O +
result O +
of O +
a O +
previous O +
work O +
by O +
Gehm O +
et O +
al. O +
[ O -
163 O -
] O +
, O +
who O +
demonstrated O +
stimulation O +
of O +
T47D O +
cell O +
proliferation O +
by O +
resveratrol O +
through O +
interaction O +
with O +
the O +
estrogen B-Gene +
receptor I-Gene -
. O +

The O +
exact O +
reason O +
for O +
this O +
discrepancy O +
remains O +
unknown O -
. O +

In O +
another O +
study O -
, O +
resveratrol O +
caused O +
estrogen O +
mimic O +
induction O +
of O +
prolactin B-Gene +
secretion O +
in O +
the O +
immortalized O +
pituitary O +
cell O +
line O +
PR1 O -
, O +
but O +
it O +
exhibited O +
neither O +
estrogen B-Gene +
receptor I-Gene +
binding O +
nor O +
growth O +
stimulatory O +
activity O +
in O +
these O +
cells O +
[ O -
164 O -
] O +
. O +

4.6 O +
Epigallocatechin O +
gallate O +
Epidemiologic O -
, O +
as O +
well O +
as O +
laboratory O +
studies O -
, O +
have O +
revealed O +
that O +
increased O +
consumption O +
of O +
green O +
tea O +
has O +
been O +
associated O +
with O +
reduced O +
frequencies O +
of O +
several O +
types O +
of O +
malignant O +
tumors O +
[ O -
165–169 O -
] O +
. O +

Among O +
many O +
polyphenolic O +
compounds O +
isolated O +
from O +
green O +
tea O -
, O +
( O -
− O -
) O -
-epigallocatechin O +
gallate O +
( O -
EGCG O -
; O +
Fig. O +
5 O +
) O +
is O +
believed O +
to O +
be O +
a O +
key O +
active O +
constituent O +
in O +
terms O +
of O +
cancer O +
chemopreventive O +
potential O +
[ O -
113 O -
, O +
165 O -
, O +
170–172 O -
] O +
. O +

The O +
strong O +
antioxidative O +
activity O +
retained O +
in O +
this O +
polyphenol O +
has O +
been O +
confirmed O +
in O +
numerous O +
in O +
vivo O +
and O +
in O +
vitro O +
studies O +
[ O -
173–186 O -
] O +
, O +
which O +
appears O +
to O +
contribute O +
in O +
part O +
to O +
the O +
antimutagenic O +
and O +
anticarcinogenic O +
effects O +
of O +
green O +
tea O -
. O +

Thus O -
, O +
pretreatment O +
of O +
SENCAR O +
mice O +
with O +
EGCG O +
significantly O +
ameliorated O +
TPA O -
- O -
induced O +
infiltration O +
and O +
diminished O +
the O +
formation O +
of O +
hydrogen O +
peroxide O +
and O +
oxidized O +
DNA O +
bases O +
including O +
8-hydroxy-2′-deoxyguanosine O +
( O -
8-OH O -
- O -
dG O -
) O +
and O +
5-hydroxymethyl-2′-deoxyuridine O +
in O +
the O +
skin O +
[ O -
174 O -
] O +
. O +

Likewise O -
, O +
TPA O -
- O -
induced O +
oxidative O +
DNA O +
base O +
modification O +
was O +
inhibited O +
dose O -
- O -
dependently O +
by O +
EGCG O +
in O +
cultured O +
HeLa O +
cells O +
[ O -
175 O -
] O +
. O +

EGCG O +
and O +
structurally O -
- O -
related O +
green O +
tea O +
catechins O +
were O +
found O +
to O +
be O +
stronger O +
inhibitors O +
of O +
lipid O +
peroxidation O +
in O +
rat O +
liver O +
homogenates O +
than O +
such O +
antioxidants O +
as O +
glutathione O -
, O +
ascorbic O +
acid O -
, O +
tocopherol O -
, O +
butylated O +
hydroxytoluene O -
, O +
and O +
butylated O +
hydroxyanisole O +
[ O -
176 O -
] O +
. O +

The O +
antioxidant O +
activities O +
of O +
theaflavins O +
and O +
thearubigin O +
purified O +
from O +
the O +
infusion O +
of O +
black O +
tea O +
leaves O +
were O +
lower O +
than O +
those O +
of O +
green O +
tea O +
polyphenols O +
[ O -
176 O -
] O +
, O +
although O +
the O +
total O +
lyophilized O +
infusion O +
products O +
of O +
green O +
tea O +
and O +
black O +
tea O +
leaves O +
were O +
equally O +
active O -
. O +

EGCG O +
exhibited O +
a O +
strong O +
inhibitory O +
effect O +
on O +
Cu2 O -
+ O +
-mediated O +
oxidation O +
of O +
low B-Gene +
density I-Gene +
lipoprotein I-Gene +
( O -
LDL O -
) O +
in O +
vitro O +
and O +
was O +
again O +
more O +
potent O +
than O +
theaflavin O -
, O +
α O -
- O -
tocopherol O -
, O +
and O +
butylated O +
hydroxytoluene O +
in O +
this O +
regard O +
[ O -
177 O -
] O +
. O +

Kidney O +
slices O +
from O +
rats O +
subjected O +
to O +
oral O +
administration O +
of O +
EGCG O +
( O -
50 O +
mg O -
/ O -
kg O +
body O +
weight O -
) O +
for O +
7 O +
days O +
or O +
fed O +
3 O -
% O +
green O +
tea O +
leaf O +
powder O +
for O +
50 O +
days O +
exhibited O +
lesser O +
extent O +
of O +
ter O +
-butyl O +
hydroperoxide O -
- O -
induced O +
lipid O +
peroxidation O -
, O +
compared O +
with O +
the O +
control O +
animals O +
[ O -
178 O -
] O +
. O +

EGCG O -
, O +
as O +
well O +
as O +
green O +
tea O +
given O +
to O +
rats O +
in O +
drinking O +
water O +
was O +
protective O +
against O +
hepatotoxicity O +
and O +
liver O +
nuclear O +
8-OH O -
- O -
dG O +
formation O +
induced O +
by O +
the O +
carcinogen O +
2-nitropropane O +
[ O -
179 O -
] O +
. O +

Pentachlorophenol O -
- O -
induced O +
hepatic O +
8-OH O -
- O -
dG O +
formation O +
in O +
male O +
B6C3F1 O +
mice O +
was O +
reduced O +
by O +
oral O +
administration O +
of O +
EGCG O +
[ O -
180 O -
] O +
. O +

Peroxynitrite O -
- O -
mediated O +
formation O +
of O +
8-OH O -
- O -
dG O +
in O +
calf O +
thymus O +
DNA O +
and O +
nitration O +
of O +
tyrosine O +
to O +
3-nitrotyrosine O +
were O +
suppressed O +
by O +
EGCG O +
[ O -
181 O -
] O +
. O +

Strand O +
scission O +
in O +
Escherichia O +
coli O +
pUC18 O +
plasmid O +
DNA O +
by O +
gamma O -
- O -
ray O +
or O +
beta O -
- O -
ray O +
was O +
inhibited O +
in O +
the O +
presence O +
of O +
EGCG O -
, O +
which O +
might O +
be O +
attributable O +
to O +
its O +
hydroxyl O +
radical O +
scavenging O +
effect O +
[ O -
182 O -
, O +
183 O -
] O +
. O +

Among O +
the O +
tea O +
flavonoids O +
tested O -
, O +
EGCG O +
exerted O +
the O +
most O +
pronounced O +
protection O +
against O +
oxidation O +
of O +
LDL B-Gene +
as O +
revealed O +
by O +
prolongation O +
of O +
the O +
oxidation O +
time O +
[ O -
184 O -
] O +
. O +

The O +
EGCG O +
was O +
found O +
to O +
block O +
the O +
production O +
of O +
ROS O +
derived O +
from O +
NADPH B-Gene -
- I-Gene -
cytochrome I-Gene +
P I-Gene +
450-mediated I-Gene +
oxidation O +
of O +
the O +
cooked O +
meat O +
carcinogen O -
, O +
2-amino-3-methylimidazo O -
[ O -
4,5-f O +
] O -
quinoline O +
( O -
IQ O -
) O +
[ O -
185 O -
] O +
. O +

The O +
EGCG O +
and O +
epigallocatechin O +
were O +
found O +
to O +
inhibit O +
xanthine B-Gene +
oxidase I-Gene +
[ O -
186 O -
] O +
. O +

The O +
EGCG O +
has O +
also O +
been O +
reported O +
to O +
attenuate O +
the O +
nitric O +
oxide O +
production O +
[ O -
187 O -
, O +
188 O -
] O +
, O +
which O +
appears O +
to O +
be O +
mediated O +
through O +
suppression O +
of O +
inducible B-Gene +
nitric I-Gene +
oxide I-Gene +
synthase I-Gene +
( O -
iNOS B-Gene -
) O +
or O +
its O +
mRNA O +
expression O +
[ O -
187 O -
, O +
189 O -
] O +
. O +

The O +
electrophorectic O +
mobility O +
shift O +
assay O +
revealed O +
that O +
EGCG O +
blunted O +
activation O +
of O +
NF B-Gene -
- I-Gene -
κB I-Gene +
responsible O +
for O +
iNOS B-Gene +
induction O +
[ O -
187 O -
] O +
. O +

These O +
results O +
indicate O +
that O +
EGCG O +
inhibits O +
the O +
binding O +
of O +
NF B-Gene -
- I-Gene -
κB I-Gene +
to O +
iNOS B-Gene +
promoter O -
, O +
thereby O +
hampering O +
the O +
transcription O +
of O +
iNOS B-Gene +
gene O -
. O +

Interferon B-Gene -
- I-Gene -
gamma I-Gene +
and O +
lipopolysaccharide O -
- O -
induced O +
nitrite O +
production O +
in O +
mouse O +
peritoneal O +
cells O +
was O +
also O +
inhibited O +
by O +
EGCG O +
[ O -
190 O -
] O +
. O +

The O +
chemopreventive O +
effects O +
of O +
EGCG O +
and O +
other O +
structurally O -
- O -
related O +
green O +
tea O +
polyphenols O +
have O +
been O +
investigated O +
using O +
diverse O +
rodent O +
tumor O +
models O +
( O -
recently O +
reviewed O +
in O +
Ref O -
. O +

[ O -
191 O -
] O +
) O -
. O +

Thus O -
, O +
EGCG O +
exhibited O +
protective O +
effects O +
against O +
N O +
-ethyl O -
- O -
N O +
′-nitrosoguanidine O -
- O -
induced O +
murine O +
duodenum O +
carcinogenesis O +
[ O -
165 O -
, O +
192 O -
, O +
193 O -
] O +
, O +
N O +
-methyl O -
- O -
N O +
′-nitrosoguanidine O -
- O -
induced O +
rat O +
gastric O +
carcinogenesis O +
[ O -
193 O -
, O +
194 O -
] O +
, O +
diethylnitrosamine O -
- O -
initiated O +
and O +
phenobarbital O -
- O -
promoted O +
formation O +
of O +
hepatic O +
preneoplastic O +
foci O +
in O +
male O +
F344 O +
rats O +
[ O -
195 O -
] O +
, O +
mouse O +
skin O +
carcinogenesis O +
[ O -
170 O -
, O +
196–200 O -
] O +
, O +
tobacco O -
- O -
specific O +
nitrosamine O -
- O -
induced O +
mouse O +
pulmonary O +
tumorigenesis O +
[ O -
[ O -
201 O -
] O +
, O +
reviewed O +
in O +
Ref O -
. O +

[ O -
202 O -
] O +
] O -
, O +
rat O +
sarcoma O +
induction O +
following O +
subcutaneous O +
injection O +
of O +
benzo O -
[ O -
a O -
] O -
pyrene O +
[ O -
203 O -
] O +
, O +
and O +
spontaneous O +
hepatoma O +
formation O +
in O +
C3H O -
/ O -
HeNCrj O +
mice O +
[ O -
204 O -
] O +
. O +

One O +
of O +
the O +
most O +
plausible O +
mechanisms O +
underlying O +
the O +
chemopreventive O +
activity O +
of O +
EGCG O +
is O +
suppression O +
of O +
promotion O +
of O +
carcinogenesis O +
[ O -
170 O -
, O +
193 O -
, O +
196 O -
, O +
197 O -
] O +
examined O +
in O +
animals O +
and O +
also O +
in O +
cultured O +
cells O +
[ O -
205 O -
] O +
. O +

Thus O -
, O +
EGCG O +
has O +
been O +
reported O +
to O +
influence O +
some O +
biochemical O +
events O +
related O +
to O +
tumor O +
promotion O -
, O +
such O +
as O +
suppression O +
of O +
mouse O +
epidermal O +
ODC B-Gene +
activity O +
induced O +
by O +
TPA O +
[ O -
197 O -
] O +
or O +
okadaic O +
acid O +
[ O -
170 O -
] O +
, O +
inhibition O +
of O +
protein B-Gene +
kinase I-Gene +
C I-Gene +
activation O +
induced O +
by O +
teleocidin O +
[ O -
171 O -
] O +
or O +
TPA O +
[ O -
206 O -
] O +
, O +
attenuation O +
of O +
okadaic O +
acid O -
- O -
stimulated O +
production O +
of O +
TNF B-Gene -
- I-Gene -
α I-Gene +
and O +
its O +
mRNA O +
expression O +
in O +
cultured O +
BALB O -
/ O -
3T3 O +
cells O +
[ O -
172 O -
, O +
207 O -
] O +
, O +
inhibition O +
of O +
binding O +
of O +
tumor O +
promoters O +
to O +
the O +
particulate O +
fraction O +
of O +
mouse O +
skin O +
[ O -
170 O -
] O +
or O +
to O +
its O +
receptor B-Gene +
protein I-Gene +
kinase I-Gene +
C I-Gene +
[ O -
206 O -
] O +
, O +
mitigation O +
of O +
TPA O -
- O -
induced O +
oxidative O +
damage O +
in O +
mouse O +
skin O +
[ O -
174 O -
] O +
and O +
cultured O +
cells O +
[ O -
175 O -
] O +
, O +
enhancement O +
of O +
gap O +
junctional O +
intercellular O +
communication O +
[ O -
208 O -
] O +
. O +

The O +
ODC B-Gene +
activity O +
in O +
gastric O +
mucosal O +
cells O +
of O +
N O +
-methyl O -
- O -
N O +
′-nitrosoguanidine O -
- O -
treated O +
rats O +
was O +
also O +
reduced O +
by O +
oral O +
administration O +
of O +
EGCG O +
[ O -
194 O -
] O +
. O +

TPA O -
- O -
induced O +
expression O +
of O +
ODC B-Gene +
gene O -
, O +
protein B-Gene +
kinase I-Gene +
C I-Gene +
gene O -
, O +
and O +
c O -
- O -
myc O +
proto O -
- O -
oncogene O +
in O +
mouse O +
skin O +
was O +
all O +
repressed O +
by O +
topical O +
application O +
of O +
EGCG O +
[ O -
209 O -
] O +
. O +

Likewise O -
, O +
increases O +
in O +
the O +
transcript O +
level O +
of O +
epidermal O +
IL-1α B-Gene +
gene O +
in O +
SENCAR O +
mice O +
treated O +
with O +
different O +
types O +
of O +
tumor O +
promoters O +
were O +
suppressed O +
by O +
topical O +
pretreatment O +
with O +
EGCG O +
[ O -
210 O -
] O +
. O +

In O +
contrast O -
, O +
EGCG O +
alone O +
stimulated O +
the O +
production O +
of O +
IL-1α B-Gene +
and O +
its O +
mRNA O +
expression O +
in O +
human O +
peripheral O +
blood O +
mononuclear O +
cells O +
in O +
culture O +
[ O -
211 O -
] O +
. O +

EGCG O +
abrogated O +
TPA O -
- O -
induced O +
activation O +
of O +
protein B-Gene +
kinase I-Gene +
C I-Gene -
, O +
c B-Gene -
- I-Gene -
jun I-Gene +
expression O -
, O +
and O +
transformation O +
in O +
cultured O +
mouse O +
fibroblasts O +
in O +
culture O +
[ O -
212 O -
] O +
. O +

Very O +
recently O -
, O +
Dong O +
et O +
al. O +
[ O -
213 O -
] O +
reported O +
that O +
EGCG O +
and O +
theaflavins O +
inhibited O +
EGF- B-Gene +
or O +
TPA O -
- O -
induced O +
transformation O +
of O +
JB6 O +
mouse O +
epidermal O +
cell O +
line O +
which O +
was O +
associated O +
with O +
their O +
repression O +
of O +
AP-1-dependent B-Gene +
transcriptional O +
activity O +
and O +
its O +
DNA O +
binding O +
activity O -
. O +

The O +
inhibition O +
of O +
AP-1 B-Gene +
activation O +
by O +
these O +
substances O +
appears O +
to O +
be O +
mediated O +
via O +
down O -
- O -
regulation O +
of O +
JNK B-Gene -
, O +
but O +
not O +
the O +
ERK B-Gene +
pathway O +
[ O -
213 O -
] O +
. O +

The O +
anticarcinogenic O -
, O +
as O +
well O +
as O +
antigenotoxic O +
activities O +
of O +
EGCG O +
have O +
been O +
confirmed O +
in O +
many O +
other O +
in O +
vivo O +
and O +
in O +
vitro O +
bioassays O +
( O -
extensively O +
reviewed O +
in O +
Ref O -
. O +

[ O -
192 O -
] O +
and O +
see O +
references O +
therein O -
) O +
although O +
some O +
studies O +
revealed O +
no O +
protective O +
effects O +
[ O -
214 O -
] O +
. O +

Besides O +
inhibiting O +
the O +
tumor O +
promotion O -
, O +
EGCG O +
administered O +
intraperitoneally O +
and O +
the O +
green O +
tea O +
polyphenol O +
fraction O +
given O +
orally O +
or O +
intraperitoneally O +
caused O +
growth O +
inhibition O +
and/or O +
regression O +
of O +
experimentally O +
induced O +
skin O +
papillomas O +
in O +
mice O +
[ O -
198 O -
] O +
. O +

Topically O +
applied O +
green O +
tea O +
polyphenol O +
fraction O +
also O +
inhibited O +
the O +
progression O +
of O +
papillomas O +
to O +
squamous O +
cell O +
carcinoma O +
[ O -
199 O -
] O +
. O +

Similarly O -
, O +
i.p O -
. O +

injection O +
of O +
this O +
polyphenol O +
caused O +
growth O +
inhibition O +
and O +
regression O +
of O +
tumors O +
arising O +
from O +
human O +
prostate O +
cancer O +
cells O -
, O +
PC-3 O +
and O +
LNCaP O +
104-R O -
, O +
subcutaneously O +
inoculated O +
into O +
nude O +
mice O +
[ O -
215 O -
] O +
. O +

Other O +
structurally O -
- O -
related O +
catechins O -
, O +
such O +
as O +
( O -
− O -
) O -
-epicatechin O +
gallate O -
, O +
were O +
not O +
active O +
in O +
this O +
respect O -
. O +

EGCG O +
also O +
effectively O +
suppressed O +
the O +
growth O +
of O +
human O +
mammary O +
cancer O +
cells O +
( O -
MCF-7 O -
) O +
in O +
athymic O +
mice O +
[ O -
215 O -
] O +
. O +

In O +
line O +
with O +
these O +
in O +
vivo O +
findings O -
, O +
EGCG O +
downregulated O +
the O +
aberrant O +
hyperproliferation O +
of O +
c O -
- O -
myc O +
oncogene O -
- O -
transfected O +
mouse O +
mammary O +
epithelial O +
cells O +
as O +
demonstrated O +
by O +
its O +
ability O +
to O +
suppress O +
the O +
anchorage O -
- O -
independent O +
growth O +
of O +
these O +
cells O +
in O +
soft O +
agar O +
[ O -
216 O -
] O +
. O +

Aberrant O +
hyperproliferation O +
of O +
spontaneously O +
immortalized O +
murine O +
mammary O +
epithelial O +
cells O +
subjected O +
to O +
initiation O +
with O +
a O +
chemical O +
carcinogen O +
or O +
by O +
oncogene O +
transfection O +
and O +
their O +
subsequent O +
growth O +
in O +
syngenic O +
mice O +
were O +
also O +
blocked O +
by O +
EGCG O +
treatment O +
[ O -
217 O -
] O +
. O +

In O +
contrast O +
to O +
the O +
above O +
positive O +
findings O -
, O +
EGCG O +
given O +
as O +
a O +
diet O +
to O +
female O +
Sprague O -
– O -
Dawley O +
rats O +
during O +
the O +
late O +
promotion O +
or O +
progression O +
stages O +
of O +
7,12-dimethylbenz O -
[ O -
a O -
] O -
anthracene O -
- O -
initiated O +
mammary O +
carcinogenesis O +
exhibited O +
no O +
significant O +
protective O +
effects O +
[ O -
218 O -
] O +
. O +

There O +
have O +
been O +
a O +
series O +
of O +
papers O +
published O -
, O +
which O +
deal O +
with O +
the O +
growth O +
inhibitory O +
or O +
antiproliferative O +
activities O +
of O +
green O +
tea O +
polyphenols O +
in O +
numerous O +
types O +
of O +
tumor O +
cells O +
[ O -
[ O -
219 O -
, O +
220 O -
] O +
, O +
and O +
vide O +
infra O -
] O -
. O +

Like O +
other O +
chemopreventive O +
phytochemicals O +
listed O +
above O -
, O +
the O +
growth O +
inhibitory O +
effects O +
of O +
EGCG O +
in O +
cancer O +
cells O +
appears O +
in O +
part O +
to O +
be O +
mediated O +
via O +
apoptosis O -
. O +

Hibasami O +
et O +
al. O +
[ O -
221 O -
] O +
reported O +
that O +
human O +
lymphoid O +
leukemia O +
Molt O +
4B O +
cells O +
exposed O +
to O +
EGCG O +
underwent O +
programmed O +
death O +
as O +
determined O +
by O +
appearance O +
of O +
DNA O +
ladder O +
on O +
agarose O +
gel O +
electrophoresis O -
. O +

Other O +
green O +
tea O +
polyphenols O -
, O +
such O +
as O +
epigallocatechin O +
and O +
epicatechin O +
gallate O -
, O +
also O +
inhibited O +
growth O +
of O +
Molt O +
4B O +
cells O +
via O +
induction O +
of O +
apoptotic O +
death O +
[ O -
221 O -
, O +
222 O -
] O +
. O +

Each O +
of O +
these O +
polyphenols O +
exhibited O +
an O +
inhibitory O +
effect O +
on O +
the O +
growth O +
of O +
human O +
lung O +
cancer O +
cell O +
line O +
PC-9 O -
, O +
possibly O +
through O +
arrest O +
of O +
the O +
cell O +
cycle O +
in O +
the O +
G2 O +
/M O +
phase O +
[ O -
166 O -
, O +
223 O -
] O +
. O +

In O +
a O +
subsequent O +
study O -
, O +
the O +
apoptosis O -
- O -
inducing O +
activity O +
of O +
EGCG O +
in O +
PC-9 O +
cells O +
has O +
been O +
found O +
to O +
be O +
synergistically O +
enhanced O +
by O +
combined O +
treatment O +
with O +
other O +
chemopreventive O +
agents O -
, O +
including O +
sulindac O +
and O +
tamoxifen O +
[ O -
224 O -
] O +
. O +

In O +
another O +
study O -
, O +
EGCG O +
induced O +
apoptosis O +
of O +
human O +
epidermoid O +
carcinoma O +
cell O +
line O +
( O -
A431 O -
) O -
, O +
human O +
carcinoma O +
keratinocyte O +
cell O +
line O +
( O -
HaCaT O -
) O -
, O +
human O +
prostate O +
carcinoma O +
cell O +
line O +
( O -
DU145 O -
) O -
, O +
and O +
mouse O +
lymphoma O +
cell O +
line O +
( O -
L5178Y O -
) O +
and O +
its O +
apoptosis O +
inducing O +
activity O +
was O +
related O +
to O +
the O +
cell O +
cycle O +
arrest O +
in O +
the O +
G0 O +
–G1 O +
phase O +
[ O -
225 O -
] O +
. O +

Antiproliferative O +
activity O +
of O +
EGCG O +
against O +
A431 O +
cells O +
has O +
been O +
attributed O +
to O +
its O +
suppression O +
of O +
EGF B-Gene +
binding O +
to O +
its O +
receptor B-Gene +
and O +
subsequent O +
autophosphorylation O +
of O +
the O +
EGF B-Gene +
receptor I-Gene +
required O +
for O +
EGF B-Gene +
signaling O +
[ O -
226 O -
] O +
. O +

The O +
EGCG O +
and O +
epigallocatechin O +
treated O +
to O +
Ehrlich O +
ascites O +
tumor O +
cells O +
caused O +
significant O +
reduction O +
in O +
cell O +
viability O +
[ O -
227 O -
] O +
. O +

While O +
epigallocatechin O +
suppressed O +
the O +
tyrosine O +
phosphorylation O +
of O +
42 O +
kDa O +
and O +
45 O +
kDa O +
proteins B-Gene +
in O +
treated O +
cells O -
, O +
EGCG O +
was O +
not O +
inhibitory O +
on O +
the O +
protein B-Gene +
tyrosine I-Gene +
kinase I-Gene +
activity O +
[ O -
227 O -
] O +
. O +

The O +
growth O +
of O +
premalignant O +
and O +
malignant O +
cells O +
derived O +
respectively O +
from O +
dysplastic O +
leukoplakia O +
and O +
squamous O +
carcinoma O +
of O +
oral O +
epithelial O +
origin O +
was O +
also O +
inhibited O +
by O +
EGCG O -
, O +
which O +
was O +
considered O +
to O +
be O +
associated O +
with O +
cell O +
cycle O +
arrest O +
in O +
the O +
G1 O +
phase O +
[ O -
228 O -
, O +
229 O -
] O +
. O +

The O +
malignant O +
oral O +
epithelium O +
was O +
less O +
responsive O +
to O +
EGCG O +
than O +
normal O +
and O +
dysplastic O +
cells O +
[ O -
229 O -
] O +
. O +

Treatment O +
of O +
benzo O -
[ O -
a O -
] O -
pyrene O -
- O -
initiated O +
human O +
mammary O +
epithelial O +
184-B5 O +
cells O +
with O +
EGCG O +
led O +
to O +
increases O +
in O +
sub O +
G0 O +
population O +
and O +
apoptotic O +
cell O +
death O -
, O +
which O +
might O +
account O +
for O +
suppression O +
of O +
aberrant O +
proliferation O +
in O +
these O +
cells O +
[ O -
230 O -
] O +
. O +

Human O +
stomach O +
KATO O +
III O +
cells O +
also O +
underwent O +
apoptotic O +
death O +
when O +
exposed O +
to O +
EGCG O +
[ O -
231 O -
] O +
. O +

When O +
different O +
types O +
of O +
polyphenols O +
derived O +
from O +
green O +
tea O +
extracts O +
were O +
treated O +
to O +
human O +
lung O +
and O +
colon O +
cancer O +
cell O +
lines O -
, O +
EGCG O +
and O +
epigallocatechin O +
exhibited O +
strong O +
growth O +
inhibitory O +
effects O +
followed O +
by O +
epicatechin O +
gallate O +
and O +
epicatechin O +
[ O -
232 O -
] O +
. O +

The O +
incubation O +
of O +
the O +
human O +
lung O +
tumor O +
cell O +
line O +
H661 O +
with O +
EGCG O +
resulted O +
in O +
apoptosis O -
, O +
which O +
was O +
considered O +
to O +
be O +
mediated O +
by O +
hydrogen O +
peroxide O +
produced O +
by O +
this O +
polyphenol O +
[ O -
232 O -
] O +
. O +

EGCG O +
was O +
proven O +
to O +
be O +
the O +
most O +
potent O +
green O +
tea O +
catechin O +
in O +
terms O +
of O +
suppressing O +
the O +
growth O +
of O +
several O +
human O +
prostate O +
cancer O +
cell O +
lines O -
, O +
including O +
LNCaP O -
, O +
PC-3 O -
, O +
and O +
DU145 O +
[ O -
233 O -
] O +
. O +

The O +
selective O +
inhibition O +
of O +
5α B-Gene -
- I-Gene -
reductase I-Gene +
by O +
EGCG O +
suggests O +
that O +
its O +
antiproliferative O +
activity O +
against O +
prostate O +
cancer O +
cells O +
is O +
mediated O +
via O +
modulation O +
of O +
androgen O +
action O +
[ O -
234 O -
] O +
. O +

The O +
antiproliferative O +
and O +
apoptosis O -
- O -
inducing O +
effects O +
of O +
EGCG O +
were O +
shown O +
to O +
be O +
specific O +
for O +
tumor O +
cells O +
[ O -
225 O -
, O +
235 O -
] O +
, O +
which O +
was O +
partly O +
associated O +
with O +
its O +
differential O +
modulation O +
of O +
c O -
- O -
myc O +
and O +
c O -
- O -
fos O +
expression O +
[ O -
235 O -
] O +
. O +

EGCG O +
also O +
possesses O +
a O +
potential O +
antimetastatic O +
activity O +
as O +
revealed O +
by O +
inhibition O +
of O +
matrix B-Gene +
metalloproteinase I-Gene +
activity O +
in O +
mouse O +
Lewis O +
lung O +
carcinoma O +
cells O +
[ O -
236 O -
] O +
. O +

Furthermore O -
, O +
administration O +
of O +
EGCG O +
inhibited O +
metastasis O +
of O +
mouse O +
B16 O +
melanoma O +
cells O +
[ O -
237 O -
] O +
. O +

Adhesion O +
of O +
mouse O +
lung O +
carcinoma O +
cells O +
to O +
endothelial O +
cells O +
was O +
also O +
inhibited O +
by O +
EGCG O +
[ O -
238 O -
] O +
. O +

It O +
also O +
reduced O +
the O +
lifespan O +
of O +
cultured O +
monoblastoid O +
leukemia O +
and O +
HT29 O +
colon O +
adenocarcinoma O +
cells O +
through O +
direct O +
inactivation O +
of O +
telomerase B-Gene +
[ O -
239 O -
] O +
, O +
an O +
enzyme B-Gene +
essential O +
for O +
unlocking O +
the O +
proliferation O +
of O +
cancer O +
cells O -
. O +

5 O +
Concluding O +
remarks O +
A O +
wide O +
variety O +
of O +
phenolic O +
substances O +
present O +
in O +
dietary O +
and O +
medicinal O +
plants O +
possess O +
striking O +
antioxidative O +
and O +
anti O -
- O -
inflammatory O +
properties O -
, O +
which O +
to O +
some O +
extent O -
, O +
contribute O +
to O +
their O +
cancer O +
chemopreventive O +
potential O -
. O +

Examples O +
are O +
pungent O +
vanilloids O +
in O +
red O +
pepper O +
and O +
ginger O -
, O +
and O +
diarylheptanoids O +
isolated O +
from O +
certain O +
medicinal O +
plants O +
of O +
ginger O +
family O -
. O +

These O +
phenolic O +
substances O +
have O +
the O +
ability O +
to O +
inhibit O +
mouse O +
skin O +
tumor O +
promotion O +
and O +
to O +
abrogate O +
various O +
biochemical O +
processes O +
induced O +
or O +
mediated O +
by O +
the O +
tumor O +
promoters O +
including O +
TPA O +
and O +
okadaic O +
acid O -
. O +

They O +
also O +
induce O +
apoptosis O +
in O +
premalignant O +
or O +
cancerous O +
cells O -
. O +

Resveratrol O -
, O +
a O +
phytoalexin O +
present O +
in O +
grapes O +
and O +
red O +
wine O +
and O +
EGCG O -
, O +
one O +
of O +
the O +
major O +
antioxidative O +
polyphenols O +
contained O +
in O +
green O +
tea O -
, O +
have O +
been O +
shown O +
to O +
possess O +
a O +
broad O +
spectrum O +
of O +
anticarcinogenic O +
effects O -
. O +

Recent O +
studies O +
have O +
revealed O +
that O +
resveratrol O +
and O +
EGCG O +
suppress O +
growth O +
and O +
proliferation O +
of O +
various O +
types O +
of O +
tumor O +
cells O +
via O +
induction O +
of O +
apoptosis O +
or O +
arrest O +
of O +
a O +
specific O +
phase O +
of O +
the O +
cell O +
cycle O -
. O +

Most O +
of O +
the O +
naturally O +
occurring O +
chemopreventive O +
phenolics O +
exert O +
multifacet O +
action O -
, O +
and O +
any O +
clinical O +
applications O +
using O +
these O +
substances O +
should O +
be O +
based O +
on O +
the O +
precise O +
understanding O +
of O +
the O +
physiologically O +
relevant O +
action O +
mechanism O -
( O -
s O -
) O -
. O +

Acknowledgements O +
This O +
work O +
was O +
supported O +
by O +
a O +
grant O +
from O +
Korea O +
Science O +
Engineering O +
Foundation O +
through O +
the O +
Research O +
Center O +
for O +
New O +
Drug O +
Development O +
of O +
Seoul O +
National O +
University O +
and O +
also O +
by O +
a O +
grant O +
for O +
' O -
98 O +
Good O +
Health O +
R&D O +
project O +
( O -
HMP-96-D-2 O -
- O -
1034 O -
) O +
sponsored O +
by O +
the O +
Ministry O +
of O +
Health O +
and O +
Welfare O -
, O +
Republic O +
of O +
Korea O -
. O +

Guillain O -
- O -
Barré O +
syndrome O +
( O -
GBS O -
) O +
is O +
an O +
acute O +
immune O -
- O -
mediated O +
polyradiculoneuropathy O -
. O +

An O +
infection O +
often O +
precedes O +
the O +
onset O +
of O +
GBS O -
. O +

Although O +
a O +
subtype O +
with O +
primary O +
axonal O +
degeneration O +
has O +
recently O +
been O +
reported O +
[ O -
1 O -
] O +
, O +
the O +
predominant O +
pathogenetic O +
process O +
is O +
considered O +
to O +
be O +
demyelination O -
. O +

Gangliosides O +
are O +
surface O +
membrane O +
antigens O +
distributed O +
predominantly O +
in O +
the O +
nervous O +
system O -
. O +

Antiganglioside B-Gene +
antibodies I-Gene +
are O +
frequently O +
elevated O +
in O +
the O +
acute O +
phase O +
sera O +
of O +
GBS O +
[ O -
2–4 O -
] O +
. O +

Among O +
the O +
gangliosides O -
, O +
LM1 O +
( O -
sialosylneolactotetraosylceramide O -
) O +
is O +
the O +
predominant O +
one O +
in O +
the O +
peripheral O +
nerve O +
myelin O +
[ O -
5 O -
] O +
. O +

Anti B-Gene -
- I-Gene -
LM1 I-Gene +
antibody I-Gene +
may O +
therefore O +
be O +
related O +
to O +
the O +
pathogenesis O +
of O +
GBS O -
. O +

In O +
this O +
paper O -
, O +
we O +
investigate O +
the O +
presence O +
of O +
the O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
antibody I-Gene +
in O +
the O +
serum O +
of O +
patients O +
with O +
GBS O +
and O +
the O +
clinical O +
and O +
electrophysiological O +
features O +
of O +
GBS O +
patients O +
with O +
the O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
IgG I-Gene +
antibody I-Gene -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Patients O -
' O +
sera O +
Serum O +
samples O +
were O +
obtained O +
from O +
140 O +
consecutive O +
patients O +
with O +
acute O +
GBS O +
within O +
two O +
weeks O +
of O +
the O +
onset O +
of O +
neurologic O +
symptoms O -
, O +
24 O +
normal O +
controls O +
and O +
147 O +
disease O +
controls O -
, O +
which O +
included O +
patients O +
with O +
chronic O +
inflammatory O +
demyelinating O +
polyneuropathy O +
( O -
CIDP O -
) O -
, O +
33 O -
; O +
Miller O +
Fisher O +
syndrome O +
( O -
MFS O -
) O -
, O +
47 O -
; O +
other O +
neuropathies O -
, O +
7 O -
; O +
multiple O +
sclerosis O -
, O +
13 O -
; O +
collagen O +
disease O -
, O +
13 O -
; O +
myasthenia O +
gravis O -
, O +
6 O +
and O +
other O +
neurodegenerative O +
disease O -
, O +
28 O -
. O +

All O +
the O +
patients O +
with O +
GBS O +
met O +
the O +
clinical O +
criteria O +
defined O +
by O +
Asbury O +
and O +
Cornblath O +
[ O -
6 O -
] O +
. O +

Except O +
for O +
the O +
subjects O +
with O +
degenerative O +
disorders O +
and O +
normal O +
controls O -
, O +
the O +
serum O +
samples O +
were O +
collected O +
during O +
the O +
acute O +
phase O +
or O +
relapse O -
. O +

2.2 O +
Enzyme B-Gene -
- O -
linked O +
immunosorbent O +
assay O +
An O +
enzyme O -
- O -
linked O +
immunosorbent O +
assay O +
( O -
ELISA O -
) O +
was O +
performed O +
as O +
described O +
elsewhere O +
[ O -
2 O -
] O +
to O +
investigate O +
the O +
serum O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
antibodies I-Gene -
. O +

Ninety O -
- O -
six O -
- O -
well O +
Linbro O +
microtiter O +
plates O +
( O -
Flow O +
Laboratories O -
, O +
McLean O -
, O +
VA O -
, O +
USA O -
) O +
were O +
used O -
. O +

Each O +
well O +
was O +
coated O +
with O +
0.2 O +
μg O +
of O +
antigen O -
, O +
with O +
an O +
uncoated O +
well O +
being O +
used O +
as O +
the O +
control O -
. O +

After O +
incubation O +
with O +
1 O -
% O +
bovine B-Gene +
serum I-Gene +
albumin I-Gene +
( O -
BSA B-Gene -
) O +
in O +
phosphate O -
- O -
buffered O +
saline O +
( O -
PBS O -
) O -
, O +
serum O +
diluted O +
1:40 O +
with O +
1 O -
% O +
BSA B-Gene +
in O +
PBS O +
was O +
added O +
to O +
each O +
well O +
and O +
the O +
plate O +
was O +
incubated O +
at O +
room O +
temperature O +
for O +
1.5 O +
h. O +
After O +
each O +
well O +
had O +
been O +
washed O +
with O +
0.1 O -
% O +
BSA B-Gene +
in O +
PBS O -
, O +
peroxidase B-Gene -
- B-Gene -
conjugated I-Gene +
anti I-Gene -
- I-Gene -
human I-Gene +
IgM B-Gene +
or O +
IgG B-Gene +
antibody I-Gene +
( O -
Cappel O -
, O +
West O +
Chester O -
, O +
PA O -
, O +
USA O -
) O -
, O +
diluted O +
1:200 O +
and O +
1:500 O -
, O +
respectively O -
, O +
with O +
1 O -
% O +
BSA B-Gene +
in O +
PBS O -
, O +
was O +
added O +
to O +
each O +
well O +
and O +
the O +
plate O +
was O +
incubated O +
at O +
room O +
temperature O +
for O +
1.5 O +
h. O +

The O +
wells O +
then O +
were O +
washed O +
with O +
0.1 O -
% O +
BSA B-Gene +
in O +
PBS O +
and O +
a O +
color O +
reaction O +
was O +
obtained O +
by O +
incubation O +
with O +
200 O +
μl O +
of O +
orthophenylenediamine O +
dihydrochloride O +
( O -
40 O +
mg O -
/ O -
dl O +
of O +
phosphate O -
– O -
citrate O +
buffer O -
, O +
pH O +
5.0 O -
) O +
at O +
room O +
temperature O +
for O +
2 O +
min O -
. O +

The O +
reaction O +
was O +
stopped O +
by O +
the O +
addition O +
of O +
8 O +
N O +
H2 O +
SO4 O +
, O +
after O +
which O +
the O +
optical O +
density O +
( O -
OD O -
, O +
492 O +
nm O -
) O +
was O +
read O +
with O +
an O +
ELISA O +
reader O +
( O -
Bio O -
- O -
Rad O -
, O +
Hercules O -
, O +
CA O -
, O +
USA O -
) O -
. O +

Each O +
OD O +
value O +
was O +
corrected O +
by O +
subtracting O +
the O +
OD O +
of O +
a O +
control O +
well O +
that O +
had O +
been O +
processed O +
the O +
same O +
way O -
. O +

Serum O +
with O +
an O +
OD O +
of O +
more O +
than O +
the O +
mean+3 O +
SD O +
of O +
the O +
ODs O +
of O +
the O +
24 O +
normal O +
controls O +
was O +
considered O +
positive O -
. O +

Each O +
serum O +
sample O +
positive O +
for O +
the O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
antibody I-Gene +
was O +
diluted O +
serially O +
from O +
1:40 O +
to O +
1:5120 O +
and O +
ELISA O +
was O +
preformed O +
as O +
described O -
. O +

Anti B-Gene -
- I-Gene -
LM1 I-Gene +
antibody I-Gene +
titer O +
was O +
expressed O +
as O +
the O +
maximal O +
dilution O +
factor O +
that O +
gave O +
a O +
corrected O +
OD O +
of O +
more O +
than O +
0.1 O -
. O +

Serum O +
samples O +
with O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
IgG I-Gene +
antibody I-Gene +
were O +
assayed O +
for O +
antibodies B-Gene +
to O +
several O +
other O +
gangliosides O +
such O +
as O +
GM1 O -
, O +
GM2 O -
, O +
GM3 O -
, O +
GM1b O -
, O +
GD1a O -
, O +
GD1b O -
, O +
GD3 O -
, O +
GalNAc O -
- O -
GD1a O -
, O +
GT1b O +
and O +
GQ1b O -
, O +
and O +
serum O +
samples O +
of O +
all O +
patients O +
with O +
GBS O +
were O +
assayed O +
for O +
anti B-Gene -
- I-Gene -
GQ1b I-Gene +
IgG I-Gene +
antibodies I-Gene -
. O +

Antibodies B-Gene +
against O +
those O +
gangliosides O +
were O +
investigated O +
by O +
the O +
use O +
of O +
ELISA O +
as O +
described O +
previously O +
[ O -
2 O -
] O +
. O +

2.3 O +
Thin O -
- O -
layer O +
chromatogram O +
immunostaining O +
Thin O -
- O -
layer O +
chromatogram O +
( O -
TLC O -
) O +
immunostaining O +
was O +
performed O +
as O +
described O +
elsewhere O +
[ O -
2 O -
] O +
to O +
confirm O +
the O +
serum O +
antibody B-Gene +
reactivities O +
with O +
gangliosides O -
. O +

2.4 O +
Clinical O +
features O +
The O +
clinical O +
and O +
electrophysiological O +
features O +
of O +
GBS O +
patients O +
with O +
the O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
IgG I-Gene +
antibody I-Gene +
were O +
investigated O -
. O +

The O +
clinical O +
grade O +
was O +
determined O +
as O +
described O +
by O +
Hughes O +
et O +
al. O +
[ O -
7 O -
] O +
. O +

Patients O +
were O +
classified O +
electrophysiologically O +
as O +
having O +
either O +
acute O +
inflammatory O +
demyelinating O +
polyradiculoneuropathy O +
( O -
AIDP O -
) O -
, O +
with O +
or O +
without O +
axonal O +
degeneration O +
( O -
AD O -
) O -
, O +
acute O +
motor O +
axonal O +
neuropathy O -
, O +
or O +
acute O +
motor O +
and O +
sensory O +
axonal O +
neuropathy O +
according O +
to O +
the O +
criteria O +
described O +
by O +
Rees O +
et O +
al. O +
[ O -
8 O -
] O +
. O +

Patients O +
who O +
had O +
insufficient O +
evidence O +
of O +
demyelination O +
or O +
axonal O +
degeneration O +
were O +
labeled O +
as O +
unclassifiable O -
. O +

2.5 O +
Statistical O +
analysis O +
The O +
difference O +
in O +
the O +
percentages O +
of O +
anti B-Gene -
- I-Gene -
GQ1b I-Gene +
IgG I-Gene +
antibody I-Gene -
- O -
positive O +
cases O +
among O +
GBS O +
patients O +
with O +
or O +
without O +
the O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
IgG I-Gene +
antibody I-Gene +
was O +
analyzed O +
using O +
the O +
Fisher O -
's O +
exact O +
test O -
. O +

3 O +
Results O +
3.1 O +
Investigation O +
of O +
serum O +
antiganglioside B-Gene +
antibodies I-Gene +
Seven O +
patients O +
with O +
GBS O -
, O +
one O +
with O +
CIDP O +
and O +
two O +
with O +
MFS O +
had O +
the O +
IgG B-Gene +
anti I-Gene -
- I-Gene -
LM1 I-Gene +
antibody I-Gene +
in O +
the O +
serum O +
( O -
Fig. O +
1 O +
) O -
. O +

All O +
the O +
patients O +
with O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
IgG I-Gene +
antibody I-Gene +
titers O +
of O +
1:160 O +
or O +
more O +
were O +
GBS O +
patients O -
. O +

The O +
IgM B-Gene +
anti I-Gene -
- I-Gene -
LM1 I-Gene +
antibody I-Gene +
was O +
detected O +
in O +
only O +
two O +
patients O -
, O +
one O +
with O +
GBS O +
and O +
the O +
other O +
with O +
MFS O -
. O +

The O +
binding O +
of O +
the O +
patients O -
' O +
antibody B-Gene +
to O +
LM1 O +
was O +
confirmed O +
by O +
TLC O -
- O -
immunostaining O +
( O -
Fig. O +
2 O +
) O -
. O +

Follow O -
- O -
up O +
serum O +
samples O +
were O +
available O +
from O +
three O +
patients O +
( O -
patients O +
3 O -
, O +
4 O +
and O +
5 O -
) O -
. O +

Anti B-Gene -
- I-Gene -
LM1 I-Gene +
IgG I-Gene +
antibody I-Gene +
titer O +
decreased O +
over O +
the O +
course O +
of O +
the O +
disease O +
in O +
each O +
patient O -
; O +
1:80 O +
on O +
day O +
2 O +
of O +
neurological O +
onset O +
and O +
1:40 O +
on O +
day O +
7 O +
in O +
patient O +
3 O -
; O +
1:160 O +
on O +
day O +
3 O -
, O +
1:80 O +
on O +
day O +
12 O +
and O +
< O -
1:40 O +
on O +
day O +
25 O +
in O +
patient O +
4 O -
; O +
1:640 O +
on O +
day O +
2 O +
and O +
< O -
1:40 O +
on O +
day O +
22 O +
in O +
patient O +
5 O -
. O +

No O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
antibody I-Gene +
was O +
detected O +
either O +
in O +
the O +
normal O +
or O +
in O +
the O +
disease O +
controls O +
other O +
than O +
CIDP O +
and O +
MFS O -
. O +

Six O +
of O +
seven O +
GBS O +
patients O +
with O +
the O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
IgG I-Gene +
antibody I-Gene +
also O +
had O +
antibodies B-Gene +
against O +
other O +
gangliosides O -
. O +

In O +
particular O -
, O +
five O +
patients O +
had O +
the O +
anti B-Gene -
- I-Gene -
GQ1b I-Gene +
IgG I-Gene +
antibody I-Gene +
( O -
Table O +
1 O +
) O -
. O +

The O +
anti B-Gene -
- I-Gene -
GQ1b I-Gene +
IgG I-Gene +
antibody I-Gene +
was O +
detected O +
in O +
14 O +
of O +
the O +
140 O +
serum O +
samples O +
of O +
patients O +
with O +
GBS O -
. O +

The O +
percentage O +
of O +
anti B-Gene -
- I-Gene -
GQ1b I-Gene +
IgG I-Gene +
antibody I-Gene -
- O -
positive O +
cases O +
was O +
significantly O +
higher O +
in O +
GBS O +
cases O +
with O +
the O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
IgG I-Gene +
antibody I-Gene +
than O +
in O +
those O +
without O +
it O +
( O -
P O +
< O -
0.001 O -
) O -
. O +

3.2 O +
Clinical O +
features O +
of O +
GBS O +
patients O +
with O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
IgG I-Gene +
antibody I-Gene +
Of O +
the O +
seven O +
cases O +
with O +
the O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
IgG I-Gene +
antibody I-Gene -
, O +
respiratory O +
tract O +
infection O +
preceded O +
the O +
onset O +
of O +
GBS O +
in O +
five O +
patients O +
and O +
gastrointestinal O +
tract O +
infection O +
in O +
two O +
patients O -
. O +

All O +
the O +
five O +
patients O +
in O +
whom O +
the O +
onset O +
of O +
GBS O +
was O +
preceded O +
by O +
respiratory O +
tract O +
infection O +
had O +
anti B-Gene -
- I-Gene -
GQ1b I-Gene +
IgG I-Gene +
antibodies I-Gene -
. O +

Four O +
of O +
those O +
five O +
patients O +
had O +
ophthalmoplegia O -
. O +

One O +
of O +
the O +
two O +
patients O +
( O -
patient O +
7 O -
) O +
with O +
preceding O +
gastrointestinal O +
infection O +
had O +
an O +
antibody B-Gene +
to O +
Campylobacter O +
jejuni O +
( O -
C. O +
jejuni O +
) O -
. O +

Electrophysiological O +
examinations O +
showed O +
that O +
four O +
of O +
the O +
seven O +
patients O +
with O +
the O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
IgG I-Gene +
antibody I-Gene +
were O +
of O +
the O +
AIDP O +
type O +
and O +
one O +
patient O +
( O -
patient O +
7 O -
) O +
was O +
of O +
the O +
AIDP O +
type O +
with O +
axonal O +
damage O -
. O +

In O +
the O +
remaining O +
two O +
patients O -
, O +
no O +
abnormal O +
findings O +
were O +
seen O +
electrophysiologically O -
. O +

Plasmapheresis O +
was O +
performed O +
for O +
all O +
those O +
patients O +
with O +
the O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
IgG I-Gene +
antibody I-Gene -
. O +

One O +
month O +
after O +
the O +
onset O +
of O +
neuropathy O -
, O +
six O +
patients O +
had O +
recovered O +
to O +
clinical O +
Grade O +
1 O -
, O +
whereas O +
only O +
patient O +
7 O +
still O +
had O +
Grade O +
4 O -
. O +

4 O +
Discussion O +
We O +
detected O +
the O +
IgG B-Gene +
antibody I-Gene +
to O +
LM1 O +
in O +
the O +
sera O +
of O +
7 O +
out O +
of O +
140 O +
( O -
5 O -
% O -
) O +
GBS O +
patients O -
, O +
1 O +
out O +
of O +
33 O +
( O -
3.0 O -
% O -
) O +
CIDP O +
patients O -
, O +
and O +
2 O +
out O +
of O +
47 O +
( O -
4.3 O -
% O -
) O +
MFS O +
patients O -
. O +

The O +
IgM B-Gene +
antibody I-Gene +
to O +
LM1 O +
was O +
found O +
only O +
in O +
two O +
patients O -
, O +
each O +
with O +
GBS O +
and O +
MFS O -
. O +

The O +
sera O +
of O +
patients O +
with O +
other O +
diseases O +
and O +
of O +
the O +
normal O +
controls O +
did O +
not O +
contain O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
antibodies I-Gene -
. O +

Several O +
research O +
groups O +
have O +
found O +
serum O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
antibodies I-Gene +
in O +
patients O +
with O +
demyelinating O +
neuropathies O +
[ O -
9–11 O -
] O +
, O +
however O -
, O +
the O +
results O +
are O +
conflicting O -
. O +

Fredman O +
et O +
al. O +
[ O -
9 O -
] O +
reported O +
that O +
43 O -
% O +
of O +
GBS O +
patients O -
, O +
67 O -
% O +
of O +
CIDP O +
patients O +
and O +
20 O -
% O +
of O +
the O +
normal O +
controls O +
had O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
antibodies I-Gene -
, O +
mostly O +
of O +
the O +
IgG B-Gene +
type O -
. O +

Ilyas O +
et O +
al. O +
[ O -
10 O -
] O +
reported O +
that O +
23 O -
% O +
of O +
GBS O +
patients O +
and O +
2.3 O -
% O +
of O +
the O +
disease O +
and O +
normal O +
controls O +
had O +
the O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
IgG I-Gene +
antibody I-Gene -
, O +
but O +
no O +
significant O +
elevation O +
of O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
IgM I-Gene +
antibody I-Gene +
titers O +
was O +
detected O -
. O +

Yuki O +
et O +
al. O +
[ O -
11 O -
] O +
found O +
the O +
IgG B-Gene +
antibody I-Gene +
to O +
LM1 O +
in O +
8 O -
% O +
of O +
GBS O +
patients O -
, O +
3 O -
% O +
of O +
CIDP O +
patients O +
and O +
5 O -
% O +
of O +
MFS O +
patients O -
, O +
and O +
the O +
IgM B-Gene +
antibody I-Gene +
to O +
LM1 O +
in O +
13 O -
% O +
of O +
GBS O +
patients O -
, O +
7 O -
% O +
of O +
CIDP O +
patients O +
and O +
7 O -
% O +
of O +
MFS O +
patients O -
. O +

These O +
differences O +
in O +
results O +
could O +
have O +
been O +
caused O +
by O +
differences O +
in O +
the O +
cut O -
- O -
off O +
levels O +
of O +
the O +
methods O +
used O +
and O +
in O +
the O +
immunogenetic O +
background O -
. O +

We O +
then O +
investigated O +
the O +
clinical O +
and O +
electrophysiological O +
features O +
of O +
GBS O +
patients O +
with O +
the O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
IgG I-Gene +
antibody I-Gene -
, O +
which O +
have O +
never O +
been O +
reported O +
so O +
far O -
. O +

Considering O +
that O +
LM1 O +
is O +
the O +
predominant O +
ganglioside O +
in O +
the O +
peripheral O +
nerve O +
myelin O -
, O +
the O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
antibody I-Gene +
can O +
possibly O +
play O +
a O +
role O +
as O +
a O +
demyelinating O +
factor O +
in O +
the O +
pathogenesis O +
of O +
GBS O -
. O +

Of O +
the O +
seven O +
patients O +
with O +
the O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
IgG I-Gene +
antibody I-Gene +
in O +
this O +
study O -
, O +
demyelination O +
was O +
confirmed O +
in O +
five O -
, O +
and O +
two O +
patients O +
were O +
labeled O +
as O +
unclassifiable O -
. O +

Only O +
patient O +
7 O -
, O +
subsequent O +
to O +
C. O +
jejuni O +
infection O -
, O +
had O +
electrophysiological O +
findings O +
suggestive O +
of O +
axonal O +
damage O +
in O +
addition O +
to O +
demyelination O -
. O +

GBS O +
patients O +
subsequent O +
to O +
C. O +
jejuni O +
infection O +
have O +
been O +
reported O +
to O +
frequently O +
have O +
axonal O +
degeneration O +
[ O -
8 O -
] O +
. O +

In O +
patient O +
7 O -
, O +
some O +
other O +
factor O +
induced O +
by O +
the O +
preceding O +
C. O +
jejuni O +
infection O +
might O +
also O +
be O +
elevated O +
to O +
cause O +
axonal O +
damage O -
. O +

Except O +
for O +
patient O +
7 O -
, O +
all O +
patients O +
with O +
the O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
IgG I-Gene +
antibody I-Gene +
exhibited O +
good O +
recovery O -
, O +
being O +
classified O +
Grade O +
1 O +
within O +
one O +
month O +
of O +
the O +
onset O +
of O +
neuropathy O -
. O +

The O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
IgG I-Gene +
antibody I-Gene +
might O +
be O +
a O +
demyelinating O +
factor O -
, O +
not O +
being O +
associated O +
with O +
axonal O +
degeneration O -
. O +

Five O +
of O +
the O +
seven O +
GBS O +
patients O +
with O +
an O +
elevated O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
IgG I-Gene +
antibody I-Gene +
titer O +
also O +
had O +
anti B-Gene -
- I-Gene -
GQ1b I-Gene +
IgG I-Gene +
antibody I-Gene +
elevation O -
. O +

This O +
percentage O +
is O +
significantly O +
higher O +
than O +
that O +
in O +
the O +
GBS O +
patient O +
group O +
without O +
the O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
IgG I-Gene +
antibody I-Gene -
. O +

The O +
anti B-Gene -
- I-Gene -
GQ1b I-Gene +
IgG I-Gene +
antibody I-Gene +
is O +
specifically O +
and O +
very O +
frequently O +
found O +
in O +
patients O +
with O +
MFS O +
and O +
GBS O +
with O +
ophthalmoplegia O +
[ O -
12,13 O -
] O +
. O +

As O +
ganglioside O +
GQ1b O +
is O +
localized O +
in O +
the O +
paranodal O +
regions O +
of O +
the O +
human O +
cranial O +
nerves O +
innervating O +
the O +
extraocular O +
muscles O -
, O +
it O +
could O +
be O +
a O +
causative O +
factor O +
of O +
ophthalmoplegia O +
in O +
MFS O +
and O +
GBS O +
[ O -
13 O -
] O +
. O +

Because O +
the O +
carbohydrate O +
structure O +
of O +
LM1 O +
is O +
quite O +
different O +
from O +
that O +
of O +
GQ1b O +
( O -
Table O +
2 O +
) O -
, O +
coexistence O +
of O +
antibody B-Gene +
activities O +
against O +
LM1 O +
and O +
GQ1b O +
can O -
not O +
be O +
explained O +
by O +
cross O -
- O -
reactivity O -
. O +

Most O +
of O +
the O +
patients O +
with O +
elevated O +
titers O +
of O +
anti B-Gene -
- I-Gene -
GQ1b I-Gene +
IgG I-Gene +
antibody I-Gene +
have O +
the O +
antecedent O +
respiratory O +
tract O +
infections O +
( O -
Kusunoki O +
et O +
al. O -
, O +
unpublished O +
observation O -
) O -
. O +

The O +
data O +
in O +
this O +
study O +
show O +
that O +
all O +
five O +
patients O +
with O +
both O +
the O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
and O +
anti B-Gene -
- I-Gene -
GQ1b I-Gene +
IgG I-Gene +
antibodies I-Gene +
in O +
the O +
serum O +
had O +
a O +
respiratory O +
tract O +
infection O +
before O +
the O +
onset O +
of O +
neuropathy O -
. O +

This O +
is O +
in O +
striking O +
contrast O +
to O +
antibodies B-Gene +
to O +
GM1 O +
and O +
GalNAc O -
- O -
GD1a O -
, O +
which O +
are O +
elevated O +
mainly O +
subsequent O +
to O +
gastrointestinal O +
tract O +
infections O +
[ O -
2,14 O -
] O +
. O +

Elevated O +
titers O +
of O +
both O +
anti B-Gene -
- I-Gene -
GQ1b I-Gene +
and O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
antibodies I-Gene +
may O +
be O +
associated O +
with O +
some O +
unknown O +
infectious O +
agent O -
( O -
s O -
) O +
affecting O +
the O +
respiratory O +
tract O -
. O +

Direct O +
evidence O +
that O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
antibodies I-Gene +
cause O +
demyelination O +
has O +
not O +
yet O +
been O +
shown O -
. O +

Although O +
the O +
anti B-Gene -
- I-Gene -
LM1 I-Gene +
antibody I-Gene +
is O +
present O +
in O +
only O +
about O +
5 O -
% O +
of O +
GBS O +
patients O -
, O +
it O +
is O +
still O +
an O +
important O +
clue O +
to O +
understanding O +
the O +
pathogenetic O +
mechanisms O +
of O +
demyelination O +
in O +
a O +
subset O +
of O +
GBS O +
cases O -
. O +

Further O +
studies O +
are O +
needed O +
to O +
see O +
whether O +
it O +
is O +
actually O +
a O +
demyelinating O +
factor O +
or O +
not O -
. O +

Acknowledgments O +
This O +
work O +
was O +
supported O +
in O +
part O +
by O +
a O +
Grant O -
- O -
in O -
- O -
Aid O +
for O +
Scientific O +
Research O +
from O +
the O +
Ministry O +
of O +
Education O -
, O +
Science O +
and O +
Culture O +
of O +
Japan O +
( O -
10670576 O -
) O -
, O +
and O +
by O +
a O +
Research O +
Grant O +
for O +
Neuroimmunological O +
Diseases O +
from O +
the O +
Ministry O +
of O +
Health O +
and O +
Welfare O +
of O +
Japan O -
. O +

We O +
thank O +
Ms O +
R. O +
Mashiko O +
and O +
Ms O +
H. O +
Mashiko O +
for O +
their O +
technical O +
assistance O -
. O +

We O +
also O +
thank O +
Drs O +
K. O +
Ikeguchi O -
, O +
K. O +
Fujiwara O -
, O +
Y. O +
Yasukawa O -
, O +
K. O +
Ohta O -
, O +
N. O +
Shima O +
and O +
K. O +
Arimura O +
for O +
providing O +
us O +
with O +
the O +
clinical O +
information O +
of O +
the O +
patients O -
. O +

Chalcone B-Gene +
synthase I-Gene +
( O -
CHS B-Gene -
, O +
E.C. B-Gene +
2.3.1.74 I-Gene -
) O +
catalyzes O +
the O +
first O +
reaction O +
of O +
flavonoid O +
biosynthesis O +
and O +
stilbene B-Gene +
synthase I-Gene +
( O -
STS B-Gene -
, O +
E.C. B-Gene +
2.3.1.95 I-Gene -
) O +
catalyzes O +
biosynthesis O +
of O +
stilbene O +
backbone O +
of O +
stilbene O -
- O -
type O +
phytoalexins O -
. O +

CHS B-Gene +
and O +
STS B-Gene +
are O +
similar O +
both O +
in O +
mechanistic O +
and O +
structural O +
aspects O +
and O +
are O +
representative O +
members O +
of O +
the O +
CHS B-Gene +
superfamily O +
[ O -
1 O -
] O +
. O +

CHS B-Gene +
and O +
STS B-Gene +
are O +
homodimers O +
of O +
identical O +
subunits O +
of O +
43 O +
kDa O +
and O +
catalyze O +
repetitive O +
decarboxylative O +
condensation O +
of O +
a O +
p O +
-coumaroyl O +
residue O +
with O +
three O +
C2 O +
-units O +
from O +
malonyl O -
- O -
CoA. O +
Although O +
both O +
enzymes B-Gene +
share O +
common O +
starting O +
materials O +
with O +
identical O +
stoichiometry O +
and O +
apparently O +
use O +
the O +
same O +
condensation O +
mechanism O +
up O +
to O +
the O +
common O +
tetraketide O +
intermediate O -
, O +
CHS B-Gene +
and O +
STS B-Gene +
catalyze O +
different O +
ring O +
closure O +
reactions O +
involving O +
different O +
atoms O +
to O +
give O +
rise O +
to O +
different O +
products O -
, O +
naringenin O +
chalcone O +
and O +
resveratrol O -
, O +
respectively O +
( O -
Fig. O +
1 O +
) O -
. O +

The O +
amino O +
acid O +
homology O +
between O +
these O +
two O +
enzymes B-Gene +
is O +
more O +
than O +
65 O -
% O -
, O +
and O +
a O +
phylogenetic O +
analysis O +
showed O +
a O +
higher O +
homology O +
between O +
CHS B-Gene +
and O +
STS B-Gene +
from O +
related O +
plants O +
than O +
among O +
CHSs B-Gene +
and O +
STSs B-Gene -
, O +
suggesting O +
that O +
STSs B-Gene +
have O +
evolved O +
from O +
CHSs B-Gene +
several O +
times O +
independently O +
[ O -
2 O -
] O +
. O +

It O +
has O +
been O +
demonstrated O +
that O -
, O +
under O +
certain O +
in O +
vitro O +
conditions O -
, O +
CHS B-Gene +
produces O +
not O +
only O +
naringenin O +
chalcone O +
but O +
also O +
triacetic O +
acid O +
lactone O +
( O -
TAL O -
) O +
and O +
styrylpyrone O +
as O +
early O +
release O +
( O -
derailment O -
) O +
byproducts O +
[ O -
3,4 O -
] O +
. O +

TAL O +
was O +
also O +
detected O +
from O +
the O +
reaction O +
products O +
by O +
fatty B-Gene +
acid I-Gene +
synthase I-Gene +
[ O -
5 O -
] O +
and O +
certain O +
polyketide B-Gene +
synthases I-Gene +
[ O -
6,7 O -
] O +
. O +

On O +
the O +
other O +
hand O -
, O +
such O +
derailment O +
products O +
have O +
not O +
been O +
observed O +
in O +
the O +
reaction O +
catalyzed O +
by O +
STS B-Gene +
[ O -
8 O -
] O +
. O +

Using O +
purified O +
Pueraria O +
lobata O +
( O -
kudzu O -
) O +
CHS B-Gene +
and O +
Arachis O +
hypogaea O +
( O -
peanut O -
) O +
STS B-Gene +
that O +
was O +
overexpressed O +
in O +
Escherichia O +
coli O +
, O +
we O +
have O +
detected O +
bisnoryangonin O +
( O -
BNY O -
, O +
the O +
derailed O +
lactone O +
after O +
two O +
condensations O -
) O +
and O +
p O +
-coumaroyltriacetic O +
acid O +
lactone O +
( O -
CTAL O -
, O +
the O +
derailed O +
lactone O +
after O +
three O +
condensations O -
) O +
from O +
the O +
reaction O +
products O +
produced O +
by O +
either O +
CHS B-Gene +
or O +
STS B-Gene -
. O +

Furthermore O -
, O +
we O +
found O +
a O +
cross O -
- O -
reaction O +
between O +
CHS B-Gene +
and O +
STS B-Gene -
, O +
i.e. O +
resveratrol O +
production O +
by O +
CHS B-Gene +
and O +
naringenin O +
production O +
by O +
STS B-Gene +
in O +
small O +
but O +
detectable O +
amounts O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Cloning O +
Transcription O +
of O +
STS B-Gene +
was O +
induced O +
by O +
cutting O +
peanut O +
seedlings O +
( O -
Sakata O -
, O +
Japan O -
) O +
into O +
slices O +
( O -
1 O +
mm O +
thick O -
) O +
that O +
had O +
been O +
immersed O +
in O +
water O +
for O +
3 O +
days O +
[ O -
9 O -
] O +
. O +

The O +
slices O +
were O +
then O +
left O +
overnight O +
in O +
water O +
at O +
25 O -
° O -
C O +
in O +
darkness O -
. O +

Total O +
RNA O +
was O +
prepared O +
by O +
the O +
phenol O +
method O -
. O +

cDNA O +
was O +
synthesized O +
using O +
an O +
oligo O +
dT O -
- O -
Xba O +
I O +
primer O +
( O -
5′-GTC O +
GAC O +
TCT O +
AGA O +
( O -
T O -
) O -
15 O +
-3′ O -
) O +
and O +
PCR O -
- O -
amplified O +
with O +
primers O +
designed O +
from O +
the O +
published O +
A. O +
hypogaea O +
STS B-Gene +
sequence O +
[ O -
10 O -
] O +
; O +
the O +
forward O +
primer O +
( O -
5′-CAT O +
CCA O +
TG O +
G O +
TGT O +
CTG O +
TGA O +
GTG O +
AAT O +
TC-3′ O -
) O +
and O +
the O +
reverse O +
primer O +
( O -
5′-GTA O +
TTA O +
TAT O +
GGC O +
CAT O +
GCT O +
GCG O +
GAG-3′ O -
) O -
. O +

The O +
forward O +
primer O +
carries O +
an O +
Nco O +
I O +
site O +
suitable O +
for O +
cloning O +
into O +
the O +
expression O +
vector O -
, O +
pET-3d O -
. O +

The O +
resulting O +
PCR O +
product O +
was O +
first O +
blunt O -
- O -
ligated O +
into O +
the O +
Sma O +
I O +
site O +
of O +
pBluescriptIISK O -
( O -
+ O -
) O +
( O -
MBI O +
Fermentas O -
) O -
, O +
rescued O +
by O +
Nco O +
I O -
/ O -
Bam O +
HI O +
digestion O -
, O +
and O +
ligated O +
into O +
the O +
Nco O +
I O -
/ O -
Bam O +
HI O +
restricted O +
vector O +
pET-3d O +
to O +
give O +
pET-3d O -
/ O -
STS O -
. O +

The O +
Nco O +
I O +
digestion O +
was O +
carried O +
out O +
in O +
the O +
presence O +
of O +
EtBr O +
( O -
40 O +
μg O -
/ O -
ml O -
) O +
to O +
obtain O +
the O +
1.2-kb O +
full O -
- O -
length O +
cDNA O +
because O +
of O +
the O +
presence O +
of O +
another O +
Nco O +
I O +
site O +
in O +
the O +
coding O +
region O -
. O +

DNA O +
sequencing O +
was O +
carried O +
out O +
on O +
both O +
strands O +
with O +
several O +
forward O +
and O +
reverse O +
primers O +
using O +
the O +
Dye O +
Terminator O +
Cycle O +
Sequencing O +
kit O +
from O +
Applied O +
Biosystems O +
( O -
CA O -
, O +
USA O -
) O -
. O +

Construction O +
of O +
pET-3d O -
/ O -
CHS O +
using O +
similar O +
methods O +
has O +
been O +
described O +
[ O -
11 O -
] O +
. O +

2.2 O +
Protein B-Gene +
expression O +
and O +
purification O +
E. O +
coli O +
BL21 O -
( O -
DE3 O -
) O -
pLysE O +
cells O +
transformed O +
with O +
either O +
pET-3d O -
/ O -
CHS B-Gene +
or O +
pET-3d O -
/ O -
STS B-Gene +
were O +
grown O +
at O +
37 O -
° O -
C O +
in O +
LB O +
medium O +
containing O +
50 O +
μg O -
/ O -
ml O +
ampicillin O +
and O +
25 O +
μg O -
/ O -
ml O +
chloramphenicol O +
and O +
induced O +
with O +
0.4 O +
mM O +
IPTG O -
. O +

After O +
an O +
induction O +
period O +
of O +
4 O +
h O +
at O +
37 O -
° O -
C O -
, O +
the O +
cells O +
were O +
harvested O -
, O +
washed O +
and O +
suspended O +
in O +
buffer O +
A O +
( O -
10 O +
mM O +
potassium O +
phosphate O +
( O -
KPi O -
) O +
buffer O +
( O -
pH O +
7.5 O -
) O -
, O +
2 O +
mM O +
DTT O -
) O -
. O +

Following O +
sonication O +
( O -
10 O +
s O +
×10 O -
) O +
on O +
ice O +
and O +
centrifugation O +
( O -
12 O +
000 O -
× O -
g O +
, O +
4 O -
° O -
C O -
, O +
15 O +
min O -
) O -
, O +
soluble O +
fractions O +
were O +
obtained O -
. O +

After O +
( O -
NH4 O +
) O -
2 O +
SO4 O +
precipitation O +
( O -
30–80 O -
% O +
saturation O -
) O -
, O +
CHS B-Gene +
was O +
purified O +
to O +
apparent O +
homogeneity O +
by O +
successive O +
chromatography O +
procedures O -
: O +
( O -
1 O -
) O +
DEAE O -
- O -
Toyopearl O +
( O -
TOSOH O -
, O +
Tokyo O -
, O +
Japan O -
) O +
anion O +
exchange O +
chromatography O +
using O +
a O +
linear O +
gradient O +
of O +
NaCl O +
( O -
0–500 O +
mM O -
) O +
in O +
buffer O +
A O -
, O +
( O -
2 O -
) O +
Bio O -
- O -
Gel O +
hydroxyapatite O +
( O -
Bio O -
- O -
Rad O -
) O +
using O +
a O +
linear O +
gradient O +
of O +
10–300 O +
mM O +
KPi O +
( O -
pH O +
7.5 O -
) O +
containing O +
2 O +
mM O +
DTT O +
and O +
( O -
3 O -
) O +
chromatofocusing O +
on O +
polybuffer O +
exchanger O +
( O -
PBE94 O -
, O +
Pharmacia O -
) O +
pre O -
- O -
equilibrated O +
with O +
25 O +
mM O +
imidazole O -
- O -
HCl O +
( O -
pH O +
7.4 O -
) O -
, O +
2 O +
mM O +
DTT O +
and O +
eluted O +
with O +
Polybuffer74-HCl O +
( O -
pH O +
5.0 O -
) O -
, O +
2 O +
mM O +
DTT O -
. O +

STS B-Gene +
was O +
similarly O +
purified O +
after O +
successive O +
DEAE O +
ion O +
exchange O +
and O +
hydroapatite O +
chromatography O +
steps O -
. O +

Protein B-Gene +
contents O +
were O +
determined O +
with O +
Bradford O -
's O +
dye O +
method O +
( O -
Bio O -
- O -
Rad O -
) O +
[ O -
12 O -
] O +
, O +
using O +
bovine B-Gene +
serum I-Gene +
albumin I-Gene +
as O +
standard O -
. O +

Expression O +
and O +
purification O +
of O +
P. O +
lobata O +
CHS B-Gene +
and O +
A. O +
hypogaea O +
STS B-Gene +
as O +
thioredoxin B-Gene -
- B-Gene -
HisTag I-Gene +
fusion I-Gene +
proteins I-Gene +
( O -
Trx B-Gene -
- I-Gene -
CHS I-Gene +
and O +
Trx B-Gene -
- I-Gene -
STS I-Gene -
) O +
used O +
in O +
the O +
LC O -
- O -
MS O +
analysis O +
of O +
cross O -
- O -
reaction O +
will O +
be O +
described O +
elsewhere O -
. O +

2.3 O +
Enzyme B-Gene +
assay O +
For O +
both O +
CHS B-Gene +
and O +
STS B-Gene -
, O +
the O +
reaction O +
mixture O +
( O -
0.1 O +
ml O -
) O +
contained O +
appropriate O +
amounts O +
of O +
protein B-Gene +
( O -
2–5 O +
μg O +
of O +
purified O +
enzyme B-Gene -
) O -
, O +
0.1 O +
mM O +
p O +
-coumaroyl O -
- O -
CoA O +
and O +
16.8 O +
μM O +
[ O -
2 O -
- O -
14 O +
C O -
] O -
malonyl O -
- O -
CoA O +
( O -
2.2 O +
GBq O -
/ O -
mmol O -
, O +
NEN O -
) O +
in O +
0.1 O +
M O +
KPi O +
buffer O +
( O -
pH O +
7.5 O -
) O +
( O -
K2 O +
HPO4 O +
/KH2 O +
PO4 O +
) O +
containing O +
2 O +
mM O +
DTT O -
. O +

After O +
incubation O +
at O +
37 O -
° O -
C O +
for O +
30 O +
min O -
, O +
50 O +
μl O +
of O +
50 O -
% O +
acetic O +
acid O +
was O +
added O +
and O +
the O +
reaction O +
products O +
were O +
extracted O +
with O +
200 O +
μl O +
of O +
ethyl O +
acetate O -
. O +

A O +
portion O +
( O -
50 O +
μl O -
) O +
of O +
the O +
extract O +
was O +
analyzed O +
by O +
TLC O +
on O +
RP18 O +
plate O +
( O -
Merck O -
) O +
with O +
methanol O -
: O -
H2 O +
O O -
: O -
acetic O +
acid O +
( O -
60:40:1 O -
) O +
as O +
solvent O +
and O +
the O +
radioactive O +
products O +
were O +
quantified O +
with O +
an O +
Imaging O +
Plate O +
analyzer O +
( O -
BAS2000 O -
, O +
Fuji O -
) O -
. O +

Authentic O +
compounds O -
, O +
TAL O +
( O -
R O +
f O +
= O -
0.65 O -
, O +
Tokyo O +
Kasei O -
) O -
, O +
resveratrol O +
( O -
R O +
f O +
= O -
0.50 O -
, O +
Sigma O -
) O +
and O +
naringenin O +
( O -
R O +
f O +
= O -
0.32 O -
, O +
Nacalai O +
tesque O -
) O +
were O +
used O +
as O +
internal O +
standards O +
to O +
identify O +
the O +
products O -
. O +

The O +
specific O +
enzyme B-Gene +
activity O +
was O +
expressed O +
in O +
pmol O +
of O +
the O +
product O +
produced O -
/ O -
s O -
/ O -
mg O +
( O -
pkat O -
/ O -
mg O -
) O -
. O +

2.4 O +
Identification O +
of O +
bisnoryangonin O +
and O +
p O +
-coumaroyltriacetic O +
acid O +
lactone O +
For O +
identification O +
of O +
BNY O -
, O +
the O +
ethyl O +
acetate O -
- O -
extracted O +
products O +
produced O +
by O +
STS B-Gene +
and O +
CHS B-Gene +
were O +
first O +
separated O +
by O +
HPLC O -
. O +

The O +
column O +
( O -
5 O +
μm O -
, O +
4.6 O +
mm O +
I.D. O +
×150 O +
mm O -
, O +
ODS80Ts O -
, O +
TOSOH O -
) O +
was O +
washed O +
at O +
a O +
flow O +
rate O +
of O +
0.6 O +
ml O -
/ O -
min O +
at O +
40 O -
° O -
C O +
with O +
45 O -
% O +
methanol O +
in O +
H2 O +
O O +
containing O +
1 O -
% O +
acetic O +
acid O +
for O +
10 O +
min O +
and O +
then O +
the O +
concentration O +
of O +
methanol O +
was O +
increased O +
to O +
55 O -
% O +
during O +
the O +
next O +
30 O +
min O -
. O +

Detection O +
was O +
with O +
an O +
UV O +
monitor O +
at O +
254 O +
nm O -
. O +

The O +
peak O +
at O +
R O +
t O +
= O -
16.3 O +
min O +
was O +
collected O +
and O -
, O +
after O +
evaporation O +
of O +
the O +
solvent O -
, O +
the O +
residues O +
were O +
dissolved O +
in O +
methanol O +
and O +
reacted O +
with O +
trimethylsilyldiazomethane O +
in O +
the O +
dark O +
for O +
30 O +
min O +
at O +
22 O -
° O -
C O -
. O +

The O +
resulting O +
sample O +
was O +
subjected O +
to O +
GC O -
- O -
MS O +
( O -
Hewlett O +
Packard O +
5890 O +
coupled O +
with O +
JEOL O +
JMS O -
- O -
SX102A O -
) O +
analysis O +
using O +
a O +
DB5 O +
column O +
( O -
0.25 O +
mm O +
I.D. O +
×30 O +
m O -
, O +
film O +
thickness O +
0.25 O +
μm O -
, O +
J O +
and O +
W O -
) O +
at O +
200 O -
° O -
C O +
to O +
250 O -
° O -
C O +
( O -
10 O -
° O -
C O -
/ O -
min O -
) O -
. O +

The O +
retention O +
time O +
and O +
mass O +
spectrum O +
were O +
found O +
to O +
be O +
identical O +
to O +
those O +
of O +
authentic O +
yangonin O -
: O +
GC O -
, O +
R O +
t O +
= O -
22 O +
min O -
; O +
EIMS O +
( O -
70 O +
eV O -
, O +
m O +
/z O +
) O -
, O +
258 O +
( O -
M+ O +
) O -
, O +
230 O -
, O +
187 O -
. O +

Production O +
of O +
CTAL O +
by O +
CHS B-Gene +
and O +
STS B-Gene +
was O +
confirmed O +
by O +
LC O -
- O -
MS O +
( O -
see O +
below O -
) O -
. O +

CTAL O -
: O +
Multi O -
- O -
stage O +
LC O -
- O -
APCIMS O -
, O +
MS O +
m O +
/z O +
273.1 O +
[ O -
M+H O -
] O -
+ O +
, O +
271.1 O +
[ O -
M−H O -
] O -
− O +
, O +
MS O -
/ O -
MS O +
( O -
precursor O +
ion O +
of O +
m O +
/z O +
271.1 O -
) O +
227.2 O +
[ O -
M−H−CO2 O +
] O -
− O +
, O +
MS O -
/ O -
MS O -
/ O -
MS O +
( O -
transitions O +
m O +
/z O +
271.1>227.2 O -
) O +
185.2 O +
[ O -
M−H−CO2 O +
−CH2 O +
CO O -
] O -
− O +
. O +

2.5 O +
Cross O -
- O -
reaction O +
The O +
enzyme B-Gene +
reaction O +
was O +
carried O +
out O +
under O +
the O +
same O +
conditions O +
as O +
described O +
above O +
except O +
that O +
the O +
reaction O +
volume O +
was O +
1 O +
ml O +
and O +
about O +
50 O +
μg O +
of O +
enzyme B-Gene +
( O -
10–40 O +
pkat O -
/ O -
mg O -
) O +
was O +
used O -
. O +

Radioactive O +
products O +
thus O +
obtained O +
were O +
redissolved O +
in O +
500 O +
μl O +
of O +
50 O -
% O +
aqueous O +
methanol O +
containing O +
1 O -
% O +
acetic O +
acid O +
in O +
which O +
authentic O +
resveratrol O +
( O -
1.5 O +
μg O -
) O +
and O +
naringenin O +
( O -
2 O +
μg O -
) O +
were O +
added O -
. O +

Using O +
a O +
Hitachi O +
655 O +
HPLC O +
system O +
and O +
ODS-80Ts O +
column O +
( O -
TOSOH O -
) O -
, O +
the O +
radioactive O +
products O +
were O +
separated O +
with O +
isocratic O +
elution O +
with O +
50 O -
% O +
aqueous O +
methanol O +
containing O +
1 O -
% O +
acetic O +
acid O +
for O +
30 O +
min O -
. O +

Radioactivity O +
of O +
each O +
0.5 O +
ml O +
fraction O +
was O +
measured O +
with O +
a O +
β O -
- O -
scintillation O +
counter O +
and O +
the O +
fractions O +
corresponding O +
to O +
main O +
product O +
( O -
naringenin O +
for O +
CHS B-Gene +
and O +
resveratrol O +
for O +
STS B-Gene -
) O +
and O +
cross O -
- O -
reaction O +
product O +
( O -
resveratrol O +
for O +
CHS B-Gene +
and O +
naringenin O +
for O +
STS B-Gene -
) O +
were O +
collected O -
. O +

For O +
carrier O +
dilution O +
analysis O -
, O +
recrystallization O +
of O +
the O +
radioactive O +
products O +
with O +
carrier O +
compounds O +
was O +
performed O +
at O +
least O +
four O +
times O +
in O +
two O +
different O +
solvent O +
systems O +
( O -
methanol O +
and O +
ethyl O +
acetate O -
/ O -
hexane O -
) O +
and O +
specific O +
radioactivity O +
was O +
measured O +
after O +
each O +
recrystallization O +
step O -
. O +

The O +
identity O +
of O +
the O +
cross O -
- O -
reaction O +
products O +
was O +
further O +
confirmed O +
by O +
GC O -
- O -
MS O +
and O +
LC O -
- O -
MS O -
. O +

First O -
, O +
the O +
CHS B-Gene +
and O +
STS B-Gene +
reaction O +
products O +
were O +
methylated O +
with O +
trimethylsilyldiazomethane O +
and O +
analyzed O +
by O +
GC O -
- O -
MS O +
as O +
described O +
above O -
. O +

From O +
the O +
methylated O +
CHS B-Gene +
reaction O +
products O -
, O +
a O +
peak O +
of O +
m O +
/z O +
= O -
256 O +
( O -
R O +
t O +
= O -
12.99 O +
min O -
) O +
corresponding O +
to O +
dimethylresveratrol O +
was O +
detected O +
with O +
mono- O +
( O -
m O +
/z O +
286 O -
) O -
, O +
di- O +
( O -
m O +
/z O +
300 O -
) O +
and O +
trimethylnaringenin O +
( O -
m O +
/z O +
314 O -
) O -
. O +

Likewise O -
, O +
a O +
peak O +
of O +
m O +
/z O +
= O -
300 O +
( O -
R O +
t O +
= O -
15.35 O +
min O -
) O +
corresponding O +
to O +
dimethylnaringenin O +
was O +
detected O +
from O +
the O +
methylated O +
STS B-Gene +
reaction O +
mixture O +
together O +
with O +
di- O +
( O -
m O +
/z O +
256 O -
) O +
and O +
trimethylresveratrol O +
( O -
m O +
/z O +
270 O -
) O -
. O +

For O +
LC O -
- O -
MS O +
analysis O -
, O +
Trx B-Gene -
- I-Gene -
CHS I-Gene +
( O -
11 O +
mg O -
, O +
250 O +
pkat O -
) O +
or O +
Trx B-Gene -
- I-Gene -
STS I-Gene +
( O -
9.5 O +
mg O -
, O +
160 O +
pkat O -
) O +
was O +
incubated O +
with O +
0.1 O +
mM O +
p O +
-coumaroyl O -
- O -
CoA O +
and O +
0.3 O +
mM O +
malonyl O -
- O -
CoA O +
in O +
50 O +
ml O +
of O +
0.1 O +
M O +
KPi O +
buffer O +
( O -
pH O +
7.4 O -
) O +
containing O +
1 O +
mM O +
DTT O +
for O +
40 O +
min O +
at O +
37 O -
° O -
C O -
. O +

At O +
the O +
end O +
of O +
incubation O -
, O +
the O +
pH O +
was O +
raised O +
to O +
9 O +
with O +
1 O +
N O +
NaOH O -
, O +
and O +
the O +
reaction O +
mixture O +
was O +
further O +
incubated O +
at O +
37 O -
° O -
C O +
for O +
another O +
10 O +
min O +
to O +
complete O +
chemical O +
transformation O +
of O +
naringenin O +
chalcone O +
to O +
naringenin O +
[ O -
13 O -
] O +
. O +

The O +
ethyl O +
acetate O +
extract O +
was O +
dried O +
over O +
Na2 O +
SO4 O +
and O +
the O +
solvent O +
was O +
removed O +
under O +
vacuum O +
at O +
30 O -
° O -
C O -
. O +

The O +
remaining O +
products O +
were O +
analyzed O +
by O +
LC O -
- O -
MS O +
( O -
Thermoquest O +
LCQ O -
) O +
as O +
previously O +
described O +
[ O -
14 O -
] O +
. O +

Resveratrol O -
: O +
LC O -
- O -
APCIMS O +
( O -
positive O -
) O -
, O +
229.1 O +
[ O -
M+H O -
] O -
+ O +
, O +
MS O -
/ O -
MS O +
( O -
precursor O +
ion O +
at O +
229 O -
) O +
m O +
/z O +
( O -
rel O -
. O +

% O -
) O +
211 O +
( O -
65 O -
) O -
, O +
135 O +
( O -
100 O -
) O -
, O +
119 O +
( O -
12 O -
) O -
, O +
107 O +
( O -
11 O -
) O -
. O +

Naringenin O -
: O +
LC O -
- O -
APCIMS O +
( O -
positive O -
) O -
, O +
273.2 O +
[ O -
M+H O -
] O -
+ O +
, O +
MS O -
/ O -
MS O +
( O -
precursor O +
ion O +
at O +
273 O -
) O +
m O +
/z O +
( O -
rel O -
. O +

% O -
) O +
171 O +
( O -
18 O -
) O -
, O +
153 O +
( O -
80 O -
) O -
, O +
147 O +
( O -
100 O -
) O -
. O +

3 O +
Results O +
3.1 O +
Sequence O +
of O +
A. O +
hypogaea O +
STS B-Gene +
When O +
the O +
deduced O +
amino O +
acid O +
sequence O +
of O +
Japanese O +
peanut O +
STS B-Gene +
cloned O +
in O +
this O +
study O +
( O -
Accession O +
number O -
: O +
AB027606 O -
) O +
was O +
compared O +
to O +
the O +
published O +
peanut O +
STS B-Gene +
sequence O +
( O -
Swiss O -
- O -
Prot O +
P20178 O -
) O +
[ O -
10 O -
] O +
, O +
8 O +
out O +
of O +
389 O +
amino O +
acids O +
were O +
found O +
to O +
be O +
different O -
. O +

Those O +
are O +
Ser-46 O +
corresponding O +
to O +
Gly-46 O +
in O +
Ref O -
. O +

[ O -
10 O -
] O +
, O +
Ser-195 O +
to O +
Ala-195 O -
, O +
Ser-202 O +
to O +
Asn-202 O -
, O +
Leu-236 O +
to O +
Ile-236 O -
, O +
Asp-281 O +
to O +
Gly-281 O -
, O +
Pro-304 O +
to O +
Leu-304 O -
, O +
Glu-315 O +
to O +
Gln-315 O +
and O +
Ala-356 O +
to O +
Thr-356 O -
. O +

This O +
difference O +
in O +
amino O +
acid O +
sequence O +
probably O +
reflects O +
different O +
origins O +
of O +
the O +
plant O +
materials O +
used O -
. O +

3.2 O +
Purification O +
of O +
CHS B-Gene +
and O +
STS B-Gene +
Purification O +
of O +
CHS B-Gene +
and O +
STS B-Gene +
overexpressed O +
in O +
E. O +
coli O +
is O +
summarized O +
in O +
Table O +
1 O +
. O +

Typical O +
experiments O +
yielded O +
0.3–0.4 O +
mg O +
of O +
apparently O +
homogeneous O +
enzymes B-Gene +
from O +
300 O +
ml O +
bacteria O +
culture O +
( O -
Fig. O +
2A O +
) O -
. O +

Recovery O +
was O +
10–30 O -
% O +
with O +
about O +
10-fold O +
enrichment O -
. O +

3.3 O +
Identification O +
of O +
BNY O +
and O +
p O +
-coumaroyltriacetic O +
acid O +
lactone O +
Production O +
of O +
BNY O +
and O +
CTAL O +
by O +
STS B-Gene +
as O +
well O +
as O +
by O +
CHS B-Gene +
was O +
clearly O +
visualized O +
by O +
TLC O +
( O -
Fig. O +
2B O +
) O -
. O +

The O +
TLC O +
spots O +
were O +
identified O +
with O +
non O -
- O -
labeled O +
carrier O +
compounds O +
( O -
resveratrol O +
and O +
naringenin O -
) O +
and O +
with O +
parallel O +
experiment O +
using O +
p B-Gene +
-coumaroyltriacetic I-Gene +
acid I-Gene +
synthase I-Gene +
which O +
has O +
been O +
recently O +
cloned O +
from O +
Hydrangea O +
macrophylla O +
and O +
shown O +
to O +
produce O +
CTAL O +
and O +
BNY O +
as O +
the O +
main O +
product O +
and O +
a O +
major O +
byproduct O -
, O +
respectively O +
[ O -
14 O -
] O +
. O +

Further O -
, O +
the O +
identity O +
of O +
BNY O +
and O +
CTAL O +
was O +
unambiguously O +
determined O +
by O +
GC O -
- O -
MS O +
and O +
LC O -
- O -
MS O -
. O +

The O +
production O +
of O +
these O +
derailment O +
products O +
by O +
CHS B-Gene +
and O +
STS B-Gene +
were O +
dependent O +
on O +
the O +
presence O +
of O +
sulfhydryl O +
reagents O +
such O +
as O +
DTT O +
in O +
the O +
reaction O +
mixture O -
, O +
consistent O +
with O +
the O +
earlier O +
report O +
with O +
CHS B-Gene +
[ O -
3 O -
] O +
. O +

It O +
was O +
thought O +
that O +
sulfhydryl O +
reagent O +
would O +
act O +
as O +
an O +
acceptor O +
to O +
the O +
enzyme B-Gene -
- O -
bound O +
triketide O +
( O -
or O +
tetraketide O -
) O +
intermediate O +
in O +
a O +
non O -
- O -
enzymatic O +
trans O +
-esterification O +
to O +
form O +
unstable O +
thiol O +
adduct O -
, O +
which O +
should O +
be O +
immediately O +
converted O +
to O +
the O +
corresponding O +
pyrone O +
[ O -
3 O -
] O +
. O +

In O +
agreement O +
with O +
this O +
notion O -
, O +
DTT O +
showed O +
apparently O +
parallel O +
effects O +
on O +
formation O +
of O +
BNY O +
and O +
CTAL O -
. O +

However O -
, O +
the O +
requirement O +
of O +
the O +
sulfhydryl O +
reagent O +
was O +
not O +
absolute O -
, O +
as O +
these O +
byproducts O +
were O +
still O +
detectable O +
when O +
the O +
enzyme B-Gene +
reaction O +
was O +
carried O +
out O +
in O +
the O +
absence O +
of O +
DTT O +
( O -
data O +
not O +
shown O -
) O -
. O +

Acidification O +
of O +
the O +
reaction O +
mixture O +
to O +
pH<5 O +
greatly O +
enhanced O +
the O +
amounts O +
of O +
BNY O +
and O +
CTAL O +
detected O +
on O +
TLC O -
. O +

These O +
results O +
suggest O +
that O +
the O +
majority O +
of O +
these O +
compounds O -
, O +
both O +
being O +
pyrone O +
derivatives O -
, O +
are O +
present O +
in O +
the O +
reaction O +
mixture O +
as O +
free O +
acids O +
at O +
neutral O +
pH O -
, O +
thus O +
poorly O +
extractable O +
by O +
ethyl O +
acetate O -
, O +
and O +
that O +
lactonization O +
to O +
form O +
pyrone O +
ring O +
is O +
non O -
- O -
enzymatic O -
. O +

Similar O +
pH O -
- O -
dependence O +
of O +
extraction O +
of O +
pyrone O +
derivatives O +
was O +
also O +
reported O +
recently O +
by O +
others O +
[ O -
15 O -
] O +
. O +

Whereas O +
CTAL O +
was O +
a O +
major O +
byproduct O +
of O +
the O +
CHS B-Gene +
reaction O -
, O +
BNY O +
was O +
a O +
major O +
byproduct O +
of O +
the O +
STS B-Gene +
reaction O +
( O -
Fig. O +
2B O +
) O -
. O +

3.4 O +
Cross O -
- O -
reaction O +
When O +
the O +
reaction O +
products O +
produced O +
by O +
purified O +
recombinant B-Gene +
enzyme I-Gene +
were O +
analyzed O +
by O +
HPLC O -
, O +
a O +
small O +
radioactive O +
peak O +
corresponding O +
to O +
resveratrol O +
( O -
R O +
t O +
= O -
10 O +
min O -
) O +
was O +
detected O +
in O +
the O +
CHS B-Gene +
products O +
and O +
a O +
peak O +
corresponding O +
to O +
naringenin O +
( O -
R O +
t O +
= O -
20 O +
min O -
) O +
was O +
detected O +
in O +
the O +
STS B-Gene +
products O +
( O -
Fig. O +
3 O +
) O -
. O +

Cross O -
- O -
reaction O +
was O +
verified O +
by O +
carrier O +
dilution O +
analysis O -
. O +

Successive O +
rounds O +
of O +
recrystallization O +
of O +
radioactive O +
products O +
in O +
the O +
presence O +
of O +
non O -
- O -
labeled O +
compounds O +
gave O +
crystals O +
of O +
constant O +
specific O +
radioactivity O -
. O +

For O +
resveratrol O +
produced O +
by O +
CHS B-Gene -
, O +
the O +
specific O +
radioactivity O +
was O +
8200 O +
dpm O -
/ O -
mmol O +
( O -
methanol O -
) O -
, O +
7300 O +
( O -
methanol O -
) O -
, O +
7000 O +
( O -
ethyl O +
acetate O -
/ O -
hexane O -
) O +
and O +
6700 O +
( O -
ethyl O +
acetate O -
/ O -
hexane O -
) O -
, O +
and O +
for O +
naringenin O +
produced O +
by O +
STS B-Gene -
, O +
it O +
was O +
8900 O +
dpm O -
/ O -
mmol O +
( O -
methanol O -
) O -
, O +
7900 O +
( O -
methanol O -
) O -
, O +
7500 O +
( O -
ethyl O +
acetate O -
/ O -
hexane O -
) O +
and O +
8300 O +
( O -
ethyl O +
acetate O -
/ O -
hexane O -
) O -
. O +

The O +
cross O -
- O -
reaction O +
was O +
determined O +
to O +
be O +
2.7–4.2 O -
% O +
( O -
resveratrol O -
/ O -
naringenin O -
) O +
for O +
CHS B-Gene +
and O +
1.4–2.3 O -
% O +
( O -
naringenin O -
/ O -
resveratrol O -
) O +
for O +
STS B-Gene -
. O +

The O +
cross O -
- O -
reaction O +
was O +
further O +
confirmed O +
by O +
GC O -
- O -
MS O +
and O +
LC O -
- O -
MS O +
analyses O -
. O +

The O +
retention O +
time O -
, O +
molecular O +
mass O +
and O +
major O +
daughter O +
ions O +
in O +
MS O -
/ O -
MS O +
were O +
indistinguishable O +
to O +
those O +
of O +
authentic O +
compounds O +
and O +
those O +
found O +
in O +
the O +
literature O +
[ O -
16 O -
] O +
. O +

Trx B-Gene +
fusion I-Gene +
enzymes I-Gene +
were O +
indistinguishable O +
from O +
the O +
native B-Gene +
enzymes I-Gene +
with O +
regard O +
to O +
the O +
pattern O +
of O +
byproduct O +
production O +
and O +
kinetic O +
parameters O +
( O -
data O +
not O +
shown O -
) O -
. O +

4 O +
Discussion O +
CHS B-Gene +
purified O +
from O +
plants O +
was O +
shown O +
to O +
produce O +
styrylpyrones O +
and O +
other O +
minor O +
byproducts O +
in O +
certain O +
in O +
vitro O +
conditions O +
[ O -
3,4 O -
] O +
. O +

In O +
the O +
present O +
study O -
, O +
we O +
showed O +
that O -
, O +
like O +
CHS B-Gene -
, O +
purified O +
recombinant O +
peanut O +
STS B-Gene +
produced O +
not O +
only O +
BNY B-Gene -
, O +
a O +
styrylpyrone O -
, O +
but O +
also O +
CTAL O -
, O +
the O +
recently O +
found O +
derailment O +
product O +
at O +
the O +
stage O +
of O +
tetraketide O +
intermediate O +
[ O -
14 O -
] O +
. O +

This O +
was O +
not O +
unexpected O +
since O +
it O +
has O +
been O +
thought O +
that O +
CHS B-Gene +
and O +
STS B-Gene +
catalyze O +
identical O +
condensation O +
steps O +
leading O +
to O +
the O +
linear O +
tetraketide O +
intermediate O +
prior O +
to O +
different O +
cyclization O +
steps O +
[ O -
1 O -
] O +
. O +

Detection O +
of O +
BNY O +
and O +
CTAL O +
from O +
the O +
STS B-Gene +
reaction O +
products O +
provides O +
an O +
unequivocal O +
evidence O +
for O +
this O +
notion O -
. O +

Under O +
the O +
conditions O +
employed O -
, O +
CHS B-Gene +
produces O +
more O +
byproducts O +
than O +
STS B-Gene +
( O -
Figs. O +
2B O +
and O +
3 O +
) O -
. O +

This O +
may O +
reflect O +
the O +
more O +
loosely O +
structured O +
active O +
site O +
of O +
CHS B-Gene +
compared O +
with O +
that O +
of O +
STS B-Gene -
, O +
in O +
vitro O -
, O +
which O +
allows O +
to O +
a O +
greater O +
extent O +
premature O +
thioester O +
exchange O +
with O +
sulfhydryl O +
reagent O +
present O +
in O +
the O +
reaction O +
mixture O +
or O +
thioester O +
hydrolysis O +
by O +
water O +
to O +
give O +
derailment O +
products O -
. O +

CHS B-Gene +
is O +
believed O +
to O +
be O +
present O +
in O +
the O +
cell O +
as O +
a O +
part O +
of O +
multi O -
- O -
enzyme B-Gene +
complex O +
of O +
flavonoid O +
biosynthesis O +
including O +
polyketide B-Gene +
reductase I-Gene -
, O +
chalcone B-Gene +
isomerase I-Gene +
and O +
other O +
modifying O +
enzymes B-Gene +
to O +
achieve O +
' O -
metabolite O +
channeling O -
' O +
[ O -
1,17 O -
] O +
. O +

Cyclization O +
steps O +
in O +
CHS B-Gene +
and O +
STS B-Gene +
are O +
different O -
; O +
Dieckmann O +
condensation O +
leading O +
to O +
naringenin O +
chalcone O +
in O +
CHS B-Gene +
and O +
aldol O +
condensation O +
to O +
stilbene O +
in O +
STS B-Gene -
. O +

Nonetheless O -
, O +
CHS B-Gene +
and O +
STS B-Gene +
produce O +
counterpart O +
products O +
in O +
low O +
amounts O +
( O -
2–4 O -
% O +
of O +
main O +
products O -
) O +
which O +
could O +
not O +
be O +
detected O +
by O +
routine O +
assays O -
. O +

The O +
possibility O +
that O +
the O +
cross O -
- O -
reaction O +
products O +
were O +
formed O +
during O +
work O -
- O -
up O +
by O +
chemical O +
transformation O +
was O +
thought O +
to O +
be O +
unlikely O +
based O +
on O +
the O +
following O -
. O +

First O -
, O +
although O +
the O +
corresponding O +
chemical O +
transformations O +
are O +
known O -
, O +
they O +
are O +
normally O +
carried O +
out O +
under O +
harsh O +
conditions O +
unlike O +
the O +
work O -
- O -
up O +
procedures O +
used O +
in O +
this O +
study O -
. O +

For O +
example O -
, O +
the O +
Dieckmann O +
condensation O +
of O +
methyl O +
ester O +
of O +
7-phenyl-3,5,7-trioxoheptanoic O +
acid O +
to O +
corresponding O +
acylphloroglucinol O +
required O +
a O +
prolonged O +
incubation O +
under O +
strongly O +
basic O +
conditions O -
, O +
such O +
as O +
2 O +
M O +
KOH O +
[ O -
18 O -
] O +
. O +

Even O +
though O +
aldol O +
condensation O +
of O +
triketo O +
acids O +
can O +
proceed O +
in O +
weakly O +
acidic O +
( O -
pH O +
5 O -
) O +
aqueous O +
buffer O -
, O +
the O +
products O +
are O +
fairly O +
stable O +
β O -
- O -
resorcylic O +
acids O +
[ O -
18 O -
] O +
. O +

Decarboxylation O +
of O +
aromatic O +
carboxylic O +
acids O +
such O +
as O +
conversion O +
of O +
6-styryl O -
- O -
β O -
- O -
resorcylic O +
acid O +
to O +
pinosylvin O +
and O +
of O +
orsellinic O +
acid O +
to O +
orcinol O +
have O +
been O +
achieved O +
either O +
by O +
heat O +
( O -
180 O -
° O -
C O -
) O +
[ O -
18,19 O -
] O +
, O +
by O +
alcoholic O +
KOH O +
[ O -
20 O -
] O +
or O +
by O +
a O +
decarboxylase B-Gene +
[ O -
21 O -
] O +
. O +

It O +
should O +
be O +
noted O +
that O +
stilbene O +
carboxylic O +
acids O -
, O +
though O +
found O +
in O +
nature O +
[ O -
22 O -
] O +
, O +
have O +
not O +
been O +
detected O +
from O +
the O +
STS B-Gene +
reaction O +
mixture O -
. O +

Secondly O -
, O +
neither O +
naringenin O +
nor O +
resveratrol O +
was O +
detected O +
after O +
using O +
an O +
identical O +
work O -
- O -
up O +
procedure O +
in O +
the O +
reaction O +
mixture O +
produced O +
by O +
p B-Gene +
-coumaroyltriacetic I-Gene +
acid I-Gene +
synthase I-Gene +
( O -
CTAS B-Gene -
) O -
, O +
which O +
catalyzes O -
, O +
like O +
CHS B-Gene +
and O +
STS B-Gene -
, O +
three O +
condensation O +
reactions O +
between O +
p O +
-coumaroyl O -
- O -
CoA O +
and O +
malonyl O -
- O -
CoA O +
to O +
triketo O +
acid O +
but O +
does O +
not O +
catalyze O +
any O +
cyclization O +
reaction O +
[ O -
14 O -
] O +
. O +

This O +
suggested O +
that O +
lactonization O +
of O +
the O +
free O +
triketo O +
acid O +
predominates O +
during O +
work O -
- O -
up O +
to O +
give O +
CTAL O +
as O +
a O +
major O +
byproduct O +
( O -
Fig. O +
1 O +
) O +
and O -
, O +
therefore O -
, O +
we O +
concluded O +
that O +
the O +
cross O -
- O -
reaction O +
of O +
CHS B-Gene +
and O +
STS B-Gene +
was O +
most O +
likely O +
enzymatic O +
of O +
nature O -
. O +

One O +
reasonable O +
interpretation O +
for O +
this O +
seemingly O +
unnatural O +
cross O -
- O -
reaction O +
is O +
that O +
parts O +
of O +
heterologously O +
overexpressed O +
enzymes B-Gene +
are O +
in O +
unnatural O +
conformational O +
states O +
and O +
these O +
misfolded O -
, O +
yet O +
soluble O +
enzymes B-Gene +
are O +
responsible O +
for O +
the O +
observed O +
cross O -
- O -
reaction O -
. O +

Overexpression O +
in O +
E. O +
coli O +
often O +
leads O +
to O +
misfolding O +
especially O +
for O +
membrane O -
- O -
associated O +
eukaryotic O +
proteins B-Gene -
, O +
as O +
bacteria O +
lack O +
an O +
intracellular O +
membrane O +
environment O +
that O +
may O +
be O +
necessary O +
for O +
efficient O +
and O +
accurate O +
folding O +
[ O -
23 O -
] O +
. O +

Both O +
CHS B-Gene +
and O +
STS B-Gene +
are O +
shown O +
to O +
be O +
weakly O +
membrane O -
- O -
associated O +
in O +
the O +
plant O +
cells O +
[ O -
24,25 O -
] O +
and O +
CHS B-Gene +
is O +
associated O +
with O +
other O +
enzymes B-Gene +
involved O +
in O +
the O +
flavonoid O +
biosynthesis O +
pathway O +
[ O -
17 O -
] O +
. O +

However O -
, O +
an O +
attempt O +
to O +
resolve O +
conformational O +
heterogeneity O +
using O +
hydroxyapatite O +
chromatography O +
was O +
unsuccessful O -
, O +
as O +
cross O -
- O -
reaction O +
activities O +
were O +
co O -
- O -
purified O +
with O +
the O +
natural O +
activities O +
( O -
data O +
not O +
shown O -
) O -
. O +

Another O +
intriguing O +
and O +
probably O +
more O +
conceivable O +
possibility O +
is O +
that O +
CHS B-Gene +
and O +
STS B-Gene +
possess O +
intrinsic O +
potential O +
to O +
catalyze O +
cross O -
- O -
reaction O +
possibly O +
due O +
to O +
conformational O +
flexibility O +
of O +
their O +
active O +
sites O -
, O +
and O +
that O +
this O +
intrinsic O -
, O +
yet O +
' O -
cryptic O -
' O +
capability O +
of O +
these O +
enzymes B-Gene +
to O +
perform O +
the O +
cross O -
- O -
reaction O +
was O +
manifested O +
under O +
non O -
- O -
optimal O +
folding O +
conditions O +
during O +
bacterial O +
overexpression O -
. O +

Our O +
recent O +
finding O +
that O +
cross O -
- O -
reaction O +
of O +
CHS B-Gene +
and O +
STS B-Gene +
expressed O +
in O +
eukaryotic O +
systems O +
( O -
yeasts O +
and O +
insect O +
cells O -
) O +
apparently O +
decreased O +
as O +
compared O +
to O +
the O +
cross O -
- O -
reaction O +
found O +
in O +
this O +
study O +
with O +
bacterial O +
expression O +
system O +
seems O +
to O +
support O +
this O +
idea O +
( O -
Sankawa O -
, O +
unpublished O +
data O -
) O -
. O +

In O +
line O +
with O +
this O +
idea O -
, O +
it O +
should O +
be O +
noted O +
that O +
cyclization O +
steps O +
in O +
CHS B-Gene +
and O +
STS B-Gene +
are O +
proposed O +
to O +
be O +
under O +
pure O +
topological O +
control O +
[ O -
8 O -
] O +
. O +

Indeed O -
, O +
the O +
recently O +
solved O +
crystal O +
structure O +
of O +
alfalfa O +
( O -
Medicago O +
sativa O +
) O +
CHS B-Gene +
by O +
Ferrer O +
et O +
al. O +
did O +
not O +
reveal O +
apparent O +
functional O +
amino O +
acids O +
in O +
the O +
cyclization O +
pocket O +
that O +
might O +
participate O +
in O +
a O +
specific O +
CHS B-Gene -
- O -
type O +
cyclization O +
reaction O +
[ O -
26 O -
] O +
. O +

The O +
authors O -
, O +
therefore O -
, O +
proposed O +
that O +
alterations O +
in O +
the O +
surface O +
topology O +
of O +
the O +
cyclization O +
pockets O +
of O +
CHS B-Gene +
and O +
STS B-Gene +
may O +
affect O +
the O +
stereochemistry O +
of O +
the O +
cyclization O +
reactions O -
. O +

Based O +
on O +
phylogenetic O +
analysis O -
, O +
Schröder O +
et O +
al. O +
[ O -
2 O -
] O +
proposed O +
different O +
STSs B-Gene +
evolved O +
from O +
CHSs B-Gene +
independently O +
several O +
times O +
by O +
a O +
limited O +
number O +
of O +
amino O +
acid O +
exchanges O -
. O +

However O -
, O +
consensus O +
( O -
signature O -
) O +
amino O +
acid O +
sequences O +
characteristic O +
to O +
CHS B-Gene +
or O +
to O +
STS B-Gene +
have O +
yet O +
to O +
be O +
recognized O -
. O +

It O +
may O +
result O +
from O +
the O +
insufficient O +
number O +
of O +
STS B-Gene +
sequences O +
available O +
( O -
6 O +
entries O +
in O +
Swiss O -
- O -
Prot O -
) O -
. O +

On O +
the O +
other O +
hand O -
, O +
STS B-Gene +
conceivably O +
gained O +
its O +
new O +
activity O +
by O +
changing O +
active O +
site O +
geometry O +
rather O +
than O +
by O +
introducing O +
a O +
few O +
new O +
functional O +
amino O +
acids O +
in O +
the O +
active O +
site O +
of O +
STS B-Gene -
. O +

A O +
closely O +
related O +
case O +
can O +
be O +
found O +
in O +
chemical O +
diversity O +
of O +
higher O +
plant O +
fatty O +
acids O -
, O +
where O +
independent O -
, O +
multiple O +
evolution O +
of O +
oleate B-Gene +
12-hydroxylase I-Gene +
from O +
oleate B-Gene +
12-desaturase I-Gene +
was O +
proposed O -
. O +

Site O -
- O -
directed O +
mutagenesis O +
studies O +
involving O +
as O +
few O +
as O +
seven O +
amino O +
acids O +
suggested O +
that O +
catalytic O +
plasticity O +
in O +
these O +
two O +
enzymes B-Gene +
is O +
achieved O +
by O +
changing O +
active O +
site O +
geometry O +
leading O +
to O +
different O +
partitioning O +
of O +
a O +
common O +
intermediate O +
into O +
different O +
reaction O +
products O +
[ O -
27 O -
] O +
. O +

Clearly O -
, O +
further O +
studies O +
with O +
regard O +
to O +
the O +
origin O +
of O +
the O +
cross O -
- O -
reaction O +
of O +
CHS B-Gene +
and O +
STS B-Gene +
overexpressed O +
in O +
E. O +
coli O +
are O +
warranted O -
. O +

Acknowledgements O +
The O +
authors O +
are O +
grateful O +
to O +
the O +
Ministry O +
of O +
Education O -
, O +
Science O -
, O +
Sports O +
and O +
Culture O +
of O +
Japan O +
for O +
Grants O -
- O -
in O +
Aid O +
for O +
Scientific O +
Research O +
( O -
B O -
) O +
( O -
No. O +
09044212 O -
) O +
and O +
( O -
C O -
) O +
( O -
No. O +
10680564 O -
) O -
. O +

D O -
.- O -
Y. O +
Suh O +
thanks O +
the O +
Tokyo O +
Biochemistry O +
Research O +
Foundation O +
for O +
a O +
fellowship O +
( O -
TBRF-98 O -
- O -
10 O -
) O -
. O +

There O +
are O +
currently O +
several O +
potent O +
fungal O +
inhibitors O +
of O +
serine B-Gene +
palmitoyl- I-Gene +
transferase I-Gene +
( O -
3-ketosphinganine B-Gene +
synthase I-Gene -
) O +
[ B-Gene -
palmitoyl I-Gene -
- I-Gene -
CoA I-Gene -
: I-Gene +
L I-Gene -
- I-Gene -
serine I-Gene +
C I-Gene -
- I-Gene -
pal- I-Gene +
mitoyltransferase I-Gene +
( I-Gene -
decarboxylating I-Gene -
) I-Gene -
; O +
EC B-Gene +
2.31.50 I-Gene -
] O -
, O +
the O +
first O +
enzyme B-Gene +
in O +
the O +
de O +
novo O +
biosynthesis O +
of O +
ceramides O +
and O +
more O +
complex O +
sphingolipids O -
. O +

1'2 O +
In O +
t O +
A. O +
H. O +
Merrill O -
, O +
Jr. O +
and O +
E. O +
Wang O -
, O +
Methods O +
Enzymol O -
. O +
51 O -
, O +
427 O +
( O -
1992 O -
) O -
. O +

2 O +
R. O +
C. O +
Dickson O -
, O +
R. O +
L. O +
Lester O -
, O +
and O +
M. O +
Marek O -
, O +
Methods O +
Enzymol O -
. O +

311 O +
[ O -
1 O -
] O +
1999 O +
( O -
this O +
volume O -
) O -
. O +

Copyright O +
© O +
1999 O +
by O +
Academic O +
Press O +
All O +
rights O +
of O +
reproduction O +
in O +
any O +
form O +
reserved O -
. O +

0076 O -
- O -
6879 O -
/ O -
99 O +
$ O -
30.00 O +
METHODS O +
IN O +
ENZYMOLOGY O -
, O +
VOL O -
. O +

311 O +
is O +
measured O +
when O +
casamino O +
acids O +
are O +
omitted O +
from O +
the O +
sphingolipid O +
inhibition O +
assay O +
and O +
the O +
comparatively O +
poor O +
activity O +
that O +
australifungin O +
demonstrates O +
in O +
medium O +
that O +
contains O +
serum O +
or O +
peptone B-Gene -
. O +

In O +
addition O +
to O +
the O +
loss O +
in O +
potency O -
, O +
caution O +
is O +
also O +
advised O +
when O +
using O +
australifungin O +
in O +
assays O +
that O +
employ O +
trace O +
amounts O +
of O +
sphingoid O +
bases O -
; O +
high O +
concentrations O +
of O +
australifungin O +
can O +
result O +
in O +
nonspecific O +
inhibition O +
due O +
to O +
sequestration O +
of O +
the O +
sphingoid O +
base O -
. O +

Serine B-Gene +
Palmitolytransferase I-Gene +
Inhibitors O +
Viridiofungins O +
are O +
at O +
least O +
five O -
- O -
fold O +
less O +
potent O +
and O +
are O +
not O +
as O +
specific O +
for O +
serine B-Gene +
palmitoyltransferase I-Gene +
inhibition O +
as O +
the O +
sphingofungin O -
/ O -
myriocin O +
class O +
of O +
compounds O -
. O +

Viridiofungins O +
are O +
known O +
to O +
inhibit O +
squalene B-Gene +
synthase I-Gene -
, O +
geranyl B-Gene +
geranyltransferase I-Gene -
, O +
and O +
other O +
enzymes B-Gene +
that O +
are O +
sensitive O +
to O +
di- O +
and O +
tricarboxylic O +
acids O -
, O +
albeit O +
at O +
higher O +
concentrations O +
than O +
required O +
for O +
serine B-Gene +
palmitoyltransferase I-Gene +
inhibition O -
. O +

Because O +
of O +
this O +
difference O +
in O +
enzyme B-Gene +
sensi- O +
tivity O -
, O +
viridiofungin O +
A O +
showed O +
selective O +
inhibition O +
of O +
sphingolipid O +
synthesis O +
in O +
labeling O +
studies O +
in O +
C. O +
albicans O -
, O +
with O +
no O +
evidence O +
for O +
inhibition O +
of O +
sterol O +
synthesis O +
at O +
growth O +
inhibitory O +
concentrations O +
of O +
drug O -
. O +

7'22 O +
For O +
unknown O +
reasons O -
, O +
viridiofungins O +
lack O +
in O +
vitro O +
activity O +
against O +
Saccharomyces O +
serine B-Gene +
palmitoyltransferase I-Gene +
and O +
do O +
not O +
inhibit O +
sphingolipid O +
synthesis O +
in O +
this O +
yeast O -
, O +
although O +
they O +
do O +
inhibit O +
the O +
mammalian O +
enzyme B-Gene +
and O +
appear O +
to O +
be O +
selective O +
for O +
sphingolipid O +
inhibition O +
in O +
HepG2 O +
cells O -
. O +

2t~ O +
A. O +
H. O +
Merrill O -
, O +
Jr. O -
, O +
D. O +
C. O +
Liotta O -
, O +
and O +
R. O +
T. O +
Riley O -
, O +
Trends O +
Cell O +
Biol O -
. O +

6 O -
, O +
218 O +
( O -
1996 O -
) O -
. O +

3o O +
R. O +
T. O +
Riley O +
et O +
al. O -
, O +
J. O +
Food O +
Protect O -
. O +

57 O -
, O +
638 O +
( O -
1994 O -
) O -
. O +

INHIBITORS O +
OF O +
SPHINGOLIPID O +
BIOSYNTHESIS O +
348 O +
[ O -
36 O -
] O +
Inositol B-Gene +
Phosphoceramide I-Gene +
Synthase I-Gene +
Inhibitors O +
Unlike O +
inhibitors O +
to O +
earlier O +
steps O +
in O +
sphingolipid O +
synthesis O -
, O +
khafrefungin O +
and O +
rustmicin O +
do O +
not O +
have O +
any O +
detectable O +
effect O +
on O +
lipid O +
synthesis O +
in O +
mam- O +
malian O +
cells O +
( O -
unpublished O +
data O +
and O +
Ref O -
. O +
13 O -
) O -
, O +
and O +
rustmicin O +
and O +
aureobasidin O +
A O +
have O +
been O +
nontoxic O +
in O +
animal O +
studies O -
, O +
a4'31 O +
supporting O +
the O +
idea O +
that O +
inositol B-Gene +
phosphoceramide I-Gene +
synthase I-Gene +
is O +
a O +
fungal O +
selective O +
target O -
. O +

Khafrefungin O +
was O +
lytic O +
to O +
washed O +
red O +
blood O +
cells O +
at O +
12.5 O +
to O +
25 O -
/ O -
xg O -
/ O -
ml O -
. O +

However O -
, O +
this O +
toxicity O +
may O +
be O +
due O +
to O +
the O +
detergent O -
- O -
like O +
properties O +
of O +
the O +
compound O -
. O +

Although O +
all O +
three O +
inositol B-Gene +
phosphoceramide I-Gene +
synthase I-Gene +
inhibitors O +
are O +
very O +
potent O +
in O +
vitro O +
( O -
picomolar O +
to O +
low O +
nanomolar O -
) O -
, O +
substantially O +
higher O +
concentrations O +
are O +
required O +
to O +
kill O +
fungi O -
. O +

In O +
the O +
case O +
of O +
rustmicin O -
, O +
two O +
factors O +
that O +
limit O +
whole O +
cell O +
activity O +
were O +
identified O -
: O +
efflux O +
via O +
multidrug O +
transporters O +
and O +
chemical O +
instability O -
. O +

TM O +
Even O +
at O +
its O +
optimal O +
pH O +
of O +
5.5 O -
, O +
rustmicin O +
degrades O +
relatively O +
rapidly O +
in O +
aqueous O +
media O -
. O +

Despite O +
these O +
limitations O -
, O +
concentrations O +
of O +
rust- O +
micin O +
that O +
are O +
required O +
to O +
completely O +
inhibit O +
phosphosphingolipid O +
synthesis O +
and O +
accumulate O +
ceramide O +
in O +
fungi O +
are O +
achieved O +
easily O -
. O +

Acknowledgments O +

We O +
thank O +
M. O +
Zweerink O +
and O +
BS O -
: O -
MIE O +
00110948 O +
S0076 O -
- O -
6879 O -
( O -
00 O -
) O -
11094 O -
- O -
8 O +
10.1016 O -
/ O -
S0076 O -
- O -
6879 O -
( O -
00 O -
) O -
11094 O -
- O -
8 O +
Section O +
II O -
. O +

inhibitors O +
of O +
sphingolipid O +
biosynthesis O +
[ O -
35 O -
] O +
Isolation O +
and O +
characterization O +
of O +
novel O +
inhibitors O +
of O +
sphingolipid O +
synthesis O -
: O +
Australifungin O -
, O +
viridiofungins O -
, O +
rustmicin O -
, O +
and O +
khafrefungin O +
Suzanne O +
M. O +
Mandala O +
Guy O +
H. O +
Harris O +
Publisher O +
Summary O +
Sphingolipid O +
synthesis O +
is O +
an O +
essential O +
process O +
in O +
yeast O +
and O +
the O +
pathogenic O +
fungi O +
that O +
cause O +
life O -
- O -
threatening O +
human O +
infections O +
such O +
as O +
candidiasis O -
, O +
aspergillosis O -
, O +
and O +
cryptococcosis O -
. O +

Although O +
many O +
steps O +
in O +
the O +
human O +
and O +
fungal O +
sphingolipid O +
biosynthetic O +
pathway O +
are O +
similar O -
, O +
there O +
are O +
several O +
enzymes B-Gene +
found O +
uniquely O +
in O +
fungi O +
that O +
are O +
potential O +
targets O +
for O +
the O +
development O +
of O +
nontoxic O +
therapeutic O +
antifungals O -
. O +

In O +
the O +
screening O +
program O -
, O +
it O +
has O +
been O +
found O +
that O +
natural O +
products O +
are O +
a O +
rich O +
source O +
of O +
structurally O +
diverse O +
inhibitors O +
of O +
sphingolipid O +
synthesis O -
. O +

Natural O +
product O +
inhibitors O +
to O +
four O +
different O +
enzymes B-Gene +
that O +
affect O +
sphingolipid O +
synthesis O +
have O +
been O +
discovered O -
: O +
sphingofungins O -
, O +
lipoxamycin O -
, O +
myriocin O -
/ O -
ISP1 O -
, O +
and O +
viridiofungins O +
inhibit O +
serine B-Gene +
palmitoyltransferase I-Gene -
; O +
fumonisin O +
B1 O +
and O +
australifungin O -
, O +
inhibit O +
ceramide B-Gene +
synthase I-Gene -
; O +
aureobasidins O -
, O +
khafrefungin O -
, O +
and O +
rustmicin O +
inhibit O +
inositol B-Gene +
phosphoceramide I-Gene +
synthase I-Gene -
; O +
and O +
minimoidin O +
inhibits O +
the O +
fatty O +
acid O +
elongation O +
pathway O -
. O +

Most O +
of O +
these O +
compounds O +
have O +
fungicidal O +
activity O +
against O +
a O +
broad O +
spectrum O +
of O +
pathogenic O +
fungi O -
, O +
but O +
only O +
the O +
inhibitors O +
of O +
inositol O +
phosphoceramide O +
are O +
fungal O +
selective O -
; O +
compounds O +
that O +
inhibit O +
early O +
biosynthetic O +
steps O +
show O +
comparable O +
activity O +
against O +
orthologous O +
mammalian O +
enzymes B-Gene -
. O +

This O +
chapter O +
describes O +
a O +
method O +
to O +
identify O +
sphingolipid O +
inhibitors O +
and O +
detailed O +
protocol O +
for O +
the O +
isolation O +
of O +
australifungin O -
. O +

More O +
abbreviated O +
descriptions O +
of O +
the O +
isolation O +
of O +
viridiofungins O -
, O +
khafrefungin O -
, O +
and O +
rustmicin O +
are O +
also O +
included O -
. O +

The O +
protein B-Gene +
mediator O +
known O +
as O +
macrophage B-Gene +
migration I-Gene +
inhibitory I-Gene +
factor I-Gene +
( O -
MIF B-Gene -
) O +
has O +
emerged O +
to O +
play O +
a O +
central O +
role O +
in O +
the O +
control O +
of O +
the O +
host O +
inflammatory O +
and O +
immune O +
response O -
. O +

Described O +
originally O +
as O +
a O +
lymphocyte O +
" O -
activity O -
" O +
responsible O +
for O +
inhibiting O +
the O +
random O +
migration O +
of O +
macrophages O +
in O +
vitro O -
, O -
l'z O +
MIF B-Gene +
has O +
been O +
shown O +
to O +
be O +
released O +
from O +
the O +
anterior O +
pituitary O +
gland O +
during O +
stress O +
and O +
to O +
be O +
critically O +
involved O +
in O +
the O +
toxic O +
response O +
to O +
septic O +
shock.3 O +
Macrophages O -
, O +
T O +
cells O -
, O +
and O +
eosinophils O +
release O +
MIF B-Gene +
in O +
response O +
to O +
pro O -
- O -
inflammatory O +
stimuli O -
, O +
and O +
the O +
expression O +
of O +
MIF B-Gene +
is O +
required O +
for O +
T O -
- O -
cell O +
activation O +
and O +
antibody B-Gene +
production O +
by O +
B O +
cells.4'5 O +
More O +
recent O +
studies O +
have O +
shown O +
that O +
macrophages O +
and O +
T O +
cells O +
can O +
secrete O +
MIF B-Gene +
in O +
response O +
to O +
glucocorticoid O +
stimulation O -
, O +
and O +
that O +
once O +
released O -
, O +
MIF B-Gene +
can O +
" O -
override O -
" O +
the O +
immuno O -
- O -
suppressive O +
effects O +
of O +
steroids O +
on O +
cytokine B-Gene +
production O +
and O +
cellular O +
activation.4'5 O +
Studies O +
performed O +
in O +
models O +
of O +
the O +
inflammatory O +
and O +
immune O +
response O +
indicate O +
that O +
MIF B-Gene +
acts O +
extracellularly O +
by O +
stimulating O +
the O +
specific O +
response O +
of O +
target O +
cells O -
. O +

In O +
1996 O +
however O -
, O +
Rorsman O +
et O +
al. O +
reported O +
that O +
recombinant B-Gene +
MIF I-Gene +
( O -
rMIF B-Gene -
) O +
catalyzes O +
a O +
tautomerization O +
reaction O -
, O +
converting O +
the O +
non O -
- O -
naturally O +
occurring O +
D O -
- O -
isomer O +
of O +
dopachrome O +
( O -
2-carboxy-2,3-dihydroindole-5,6-quinone O -
) O +
to O +
dihydroxyindole O +
carboxylic O +
acid O +
( O -
DHICA O -
) O -
.6 O +
Intriguingly O -
, O +
subsequent O +
elucidation O +
of O +
the O +
three O -
- O -
dimensional O +
crystal O +
structure O +
of O +
MIF B-Gene +
revealed O +
it O +
to O +
exhibit O +
significant O +
three O -
- O -
dimensional O +
( O -
but O +
not O +
primary O +
sequence O -
) O +
homology O +
with O +
two O +
bacterial O +
isomerases B-Gene -
, O +
4- B-Gene +
oxalocrotonate I-Gene +
tautomerase I-Gene +
and O +
5-carboxymethyl-2-hydroxymuconate B-Gene +
isomerase.7 I-Gene -
- O -
9 O +
These O +
proteins B-Gene +
share O +
with O +
MIF B-Gene +
an O +
apparently O +
conserved O +
active O +
site O +
structure O +
that O +
consists O +
of O +
a O +
hydrophobic O +
cleft O +
bearing O +
an O +
active O +
site O +
proline O -
. O +

More O +
recently O -
, O +
Rorsman O +
and O +
colleagues O +
have O +
proposed O +
that O +
MIF B-Gene +
acts O +
physiologically O +
to O +
catalyze O +
the O +
keto O -
- O -
enol O +
tautomerization O +
of O +
p O -
- O -
hydroxyphenylpyruvate O +
and O +
phenylpyruvate.lFinally O -
, O +
the O +
presence O +
of O +
the O +
CXXC B-Gene +
* O -
Present O +
Address O -
: O +
Chemical O +
Development O -
, O +
New O +
Product O +
Research O -
, O +
R. O +
W. O +
Johnson O +
pharmaceutical O +
Research O +
Institute O -
, O +
Route O +
202 O -
, O +
Raritan O -
, O +
NJ O +
08869 O +
0960 O -
- O -
894X O -
/ O -
99 O -
/ O -
$ O +
- O +
see O +
front O +
matter O +
1999 O +
Elsevier O +
Science O +
Ltd. O +
All O +
rights O +
reserved O -
. O +

PII O -
: O +
S0960 O -
- O -
894X O -
( O -
99 O -
) O -
00561 O -
- O -
2 O +
3194 O +
X. O +
Zhang O -
, O +
R. O +
Bucala O -
/ O -
Bioorg O -
. O +

Med O -
. O +

Chem O -
. O +

Lett O -
. O +

9 O +
( O -
1999 O -
) O -
3193 O -
- O -
3198 O +
motif O +
in O +
MIF B-Gene +
has O +
prompted O +
yet O +
additional O +
studies O +
which O +
suggest O +
that O +
MIF B-Gene +
may O +
function O +
as O +
a O +
physiologically- O +
relevant O +
protein B-Gene -
- I-Gene -
thiol I-Gene +
oxidoreductase.~ I-Gene +
These O +
observations O +
notwithstanding O -
, O +
the O +
precise O +
relationship O +
between O +
MIF B-Gene -
's O +
enzymatic O +
and O +
immunological O +
activities O +
remain O +
unclear O -
. O +

In O +
two O +
separate O +
studies O -
, O +
the O +
creation O +
of O +
an O +
enzymatically O -
- O -
inactive O +
form O +
of O +
MIF B-Gene +
by O +
site O -
- O -
directed O +
mutagenesis O +
shows O +
the O +
protein B-Gene +
retains O +
full O +
glucocorticoid O -
- O -
regulatory O +
activity,12 O +
but O +
loses O +
neutrophil O +
priming O +
activity O -
) O -
3 O +
In O +
an O +
effort O +
to O +
further O +
explore O +
the O +
mechanism O +
of O +
action O +
of O +
MIF B-Gene +
in O +
biological O +
systems O -
, O +
we O +
have O +
endeavored O +
to O +
identify O +
potential O +
small O +
molecule O +
inhibitors O +
of O +
MIF O -
's O +
isomerization O +
activity O -
. O +

We O +
report O +
herein O +
a O +
study O +
of O +
MIF B-Gene +
substrate O +
analogs O +
which O +
inhibit O +
dopachrome O +
tautomerization O +
at O +
concentrations O +
tenfold O +
less O +
than O +
substrate O -
. O +

Such O +
inhibitors O +
may O +
prove O +
useful O +
in O +
the O +
study O +
of O +
MIF B-Gene +
structure O +
function O +
relationships O +
and O +
also O +
assist O +
in O +
the O +
development O +
of O +
small O +
molecules O +
that O +
can O +
be O +
specifically O +
targeted O +
to O +
MIF B-Gene +
for O +
pharmacological O +
purposes O -
. O +

Materials O +
and O +
Methods O +
Reagents O -
. O +

All O +
chemicals O +
were O +
from O +
Sigma O +
( O -
St. O +
Louis O -
, O +
MA O -
) O +
or O +
Aldrich O +
( O -
Milwaukee O -
, O +
WI O -
) O -
. O +

Pure O -
, O +
bioactive O +
recombinant B-Gene +
human O +
MIF B-Gene +
was O +
prepared O +
by O +
expression O +
in O +
E. O +
coli O +
following O +
methods O +
described O +
previously O -
) O -
4 O +
Preparation O +
of O +
MIF B-Gene +
Substrates O +
and O +
Analogs O -
. O +

The O +
MIF B-Gene -
- O -
substrates O +
lb-4b O +
( O -
Table O +
1 O -
) O +
and O +
the O +
test O +
inhibitors O +
5b O -
- O -
llb O +
were O +
prepared O +
by O +
oxidizing O +
their O +
precursors O +
la-4a O +
and O +
5a-10a O +
with O +
soCum O +
periodate,7'8 O +
as O +
shown O +
in O +
Scheme O +
1 O -
. O +

Compounds O +
7a O +
and O +
8a O +
were O +
prepared O +
from O +
5a O +
and O +
6a O +
by O +
an O +
esterification O +
procedure.8 O +

The O +
oxidation O +
was O +
performed O +
10 O +
min O +
prior O +
to O +
the O +
tautomerization O +
assay O +
and O +
the O +
dopachrome O +
compounds O +
were O +
tested O +
without O +
further O +
purification O -
. O +

The O +
test O +
compounds O +
11 O -
- O -
13 O +
( O -
Table O +
1 O -
) O +
were O +
obtained O +
from O +
Aldrich O -
. O +

Compd O +
D O -
/ O -
L O +
RI O +
R2 O +
R3 O +
R1 O +
, O -
. O +

O O -
~ O -
R2 O +
HO O -
~ O -
R2 O +
NalO4 O +
HO O +
I.,~ O -
/ O +
Iql~23 O +
HO O -
/ O -
~-~. O -
/ O -
-N O +
R3 O +
a O +
b O +
1 O +
2 O +
3 O +
4 O +
5 O +
6 O +
7 O +
8 O +
9 O +
l0 O +
D O +
L O +
L O +
DL O +
L O +
DL O +
L O +
DL O +
DL O +
DL O +
H O +
H O +
H O +
H O +
H O +
H O +
H O +
H O +
OH O +
OH O +
H O +
H O +
H O +
H O +
Me O +
Me O +
Me O +
Me O +
H O +
H O +
CO2H O +
CO2H O +
CO2Me O +
CO2Me O +
CO2H O +
CO2H O +
CO2Me O +
CO2Me O +
CO2H O +
CH3 O +
Scheme O +
1 O +
Dopachrome O +
Tautomerization O +
Assay O -
. O +

The O +
DOPA O -
- O -
related O +
precursors O +
( O -
la-10a O -
) O +
were O +
prepared O +
as O +
10 O +
mM O +
stock O +
solutions O +
in O +
MIF B-Gene +
assay O +
buffer O +
( O -
10 O +
mM O +
sodium O +
phosphate O -
, O +
pH O +
6.0 O -
) O -
. O +

Thirty O +
minutes O +
before O +
the O +
tautomerization O +
assay O -
, O +
1.0 O +
mL O +
of O +
each O +
stock O +
solution O +
was O +
diluted O +
with O +
7 O +
mL O +
of O +
assay O +
buffer O -
, O +
and O +
1.0 O +
mL O +
of O +
sodium O +
periodate O +
stock O +
solution O +
( O -
20 O +
mM O +
in O +
water O -
) O +
was O +
added O +
to O +
initiate O +
the O +
oxidation O +
of O +
the O +
precursors O -
, O +
thus O +
generating O +
each O +
respective O +
dopachrome O +
derivative O +
( O -
lb-10b O -
) O -
) O -
5 O +
After O +
10 O +
min O -
, O +
1 O +
mL O +
of O +
methionine O +
( O -
20 O +
mM O +
in O +
X O -
, O +
Zhang O -
, O +
R. O +
Bucala O -
/ O -
Bioorg O -
. O +

Med O -
. O +

Chem O -
. O +

Lett O -
. O +

9 O +
( O -
1999 O -
) O -
3193 O -
- O -
3198 O +
3195 O +
water O -
) O +
was O +
added O +
to O +
react O +
with O +
the O +
excess O +
periodate O -
. O +

The O +
dopachrome O +
compounds O +
were O +
generated O +
as O +
orange O +
solutions O +
at O +
a O +
final O +
concentration O +
of O +
1 O +
mM. O +
Test O +
inhibitors O +
11 O -
- O -
13 O +
were O +
prepared O +
as O +
10 O +
~M O +
stock O +
solution O +
and O +
diluted O +
to O +
1 O +
mM O +
solution O +
with O +
assay O +
buffer O +
before O +
the O +
assay O -
. O +

To O +
perform O +
the O +
tautomerization O +
assay O -
, O +
0.5 O +
mL O +
of O +
the O +
1 O +
mM O +
solution O +
of O +
the O +
MIF B-Gene -
- O -
substrate O +
( O -
lb O -
, O +
2b O -
, O +
3b O -
, O +
or O +
4b O -
) O +
was O +
mixed O +
with O +
0.5 O +
mL O +
of O +
assay O +
buffer O -
. O +

After O +
the O +
Table O +
1 O -
. O +

Inhibition O +
of O +
MIF B-Gene +
tautomerase I-Gene +
activity O +
by O +
test O +
compounds O +
No. O +
Structure O +
5b O +
L- O +
HO O +
~ O -
/ O -
~N O -
" O +
" O -
CO2H O +
6b O +
7b O +
8b O +
9b O +
10b O +
11 O +
12 O +
13 O +
DL- O +
DL- O +
HOAL'~' O -
/ O -
L O -
~ O -
N O -
" O +
" O -
CO2H O +
O O +

~e O +
L- O +
HO O +
~'~"~" O -
/ O -
~N~ O +
" O -
CO2Me O +
DL- O +
HO O +
~ O -
/ O -
t"~ O -
/ O -
X~'N O -
" O +
" O -
CO2Me O +
OH O +
OH O +
OH O +
OH3 O +
O O +
Conc O -
. O +

of O +
test O +
compounds O +
( O -
mM O -
) O +
0.5 O +
0.5 O +
0.5 O +
0.5 O +
0.5 O +
0.25 O +
0.125 O +
0.06 O +
0.5 O +
0.25 O +
0.125 O +
0.06 O +
0.5 O +
0.25 O +
0.125 O +
0.02 O +
0.5 O +
0.5 O +
% O +
inhibition O -
' O +
29 O +
35 O +
45 O +
34 O +
100 O +
98 O +
41 O +
9 O +
92 O +
88 O +
54 O +
22 O +
98 O +
79 O +
54 O +
21 O +
a0.5 O +
mM O +
of O +
3b O +
was O +
used O +
as O +
MIF B-Gene -
- O -
substrate O +
in O +
this O +
assay O -
. O +

3196 O +
X. O +
Zhang O -
, O +
R. O +
Bucala O -
/ O -
Bioorg O -
. O +

Med O -
. O +

Chem O -
. O +

Lett O -
. O +

9 O +
( O -
1999 O -
) O -
3193 O -
- O -
3198 O +
background O +
rate O +
was O +
monitored O -
, O +
10 O +
I.tL O +
of O +
recombinant B-Gene +
MIF I-Gene +
solution O +
from O +
a O +
20 O +
mg O -
/ O -
mL O +
stock O +
was O +
added O -
. O +

The O +
decrease O +
in O +
absorbance O +
( O -
~ O -
, O +
= O +
475 O +
nm O -
) O +
at O +
1 O +
min O +
following O +
addition O +
of O +
MIF B-Gene +
was O +
measured O +
as O +
an O +
index O +
of O +
tautomerase B-Gene +
activity O -
, O +
For O +
the O +
inhibitory O +
assay O -
, O +
0.5 O +
mL O +
of O +
the O +
1 O +
mM O +
solution O +
of O +
the O +
MIF B-Gene -
- O -
substrate O +
( O -
3b O -
) O +
was O +
mixed O +
with O +
0.5 O +
mL O +
of O +
the O +
1 O +
mM O +
solution O +
of O +
one O +
of O +
the O +
test O +
inhibitors O +
( O -
5b-10b O +
and O +
11 O -
- O -
13 O -
) O -
, O +
followed O +
by O +
addition O +
of O +
10 O +
mL O +
of O +
recombinant B-Gene +
MIF I-Gene +
stock O +
solution O +
( O -
20 O +
mg O -
/ O -
mL O -
) O -
. O +

Compounds O +
9b O -
, O +
10b O -
, O +
and O +
12 O +
were O +
tested O +
at O +
final O +
concentrations O +
of O +
0.25 O +
mM O -
, O +
0.125 O +
mM O -
, O +
and O +
0.06 O +
mM O +
in O +
addition O +
to O +
the O +
standard O +
0.5 O +
mM O +
assay O -
. O +

The O +
percent O +
inhibition O +
of O +
the O +
decrease O +
in O +
absorbance O +
( O -
~ O -
, O +
= O +
475 O +
nm O -
) O +
at O +
1 O +
min O +
in O +
the O +
presence O +
of O +
inhibitors O +
was O +
calculated O +
from O +
the O +
spectrophotometric O +
data O +
by O +
standard O +
methods.6 O +
Results O +
and O +
Discussion O +
Tautomerization O +
of O +
an O +
orange O +
colored O +
solution O +
of O +
D O -
- O -
dopachrome O +
( O -
lb O -
) O +
by O +
MIF B-Gene +
produces O +
the O +
non O -
- O -
colored O +
DHICA.6 O +
This O +
conversion O +
can O +
be O +
quantitated O +
spectrophotometrically O +
by O +
measuring O +
the O +
rate O +
of O +
decrease O +
of O +
the O +
iminochrome O +
absorbance O +
at O +
a O +
wavelength O +
of O +
475 O +
nm O -
. O +

The O +
methyl O +
ester O +
derivatives O +
of O +
D- O +
( O -
or O +
L- O -
) O +
dopachrome O +
were O +
found O +
to O +
be O +
better O +
substrates O +
for O +
this O +
reaction O +
than O +
dopachromes O +
( O -
lb O +
and O +
2b O -
) O -
. O +

In O +
our O +
study O +
L O -
- O -
dopachrome O +
methyl O +
ester O +
3b O +
was O +
used O +
as O +
a O +
test O +
substrate O +
for O +
the O +
identification O +
of O +
compounds O +
with O +
the O +
ability O +
to O +
inhibit O +
the O +
tautomerization O +
reaction O -
. O +

The O +
dopachrome O +
tautomerization O +
by O +
MIF B-Gene +
may O +
occur O +
by O +
two O +
different O +
pathways O +
as O +
shown O +
in O +
Scheme O +
2 O -
. O +

The O +
first O +
proceeds O +
via O +
the O +
initial O +
conversion O +
of O +
dopachrome O +
to O +
indolidine O +
14 O +
and O +
subsequent O +
rearrangement O +
to O +
an O +
indole O -
. O +

A O +
possible O +
alternative O +
pathway O +
involves O +
the O +
formation O +
of O +
quinone O +
methide O +
intermediate O +
15 O +
which O +
is O +
then O +
transformed O +
further O +
into O +
an O +
indole O -
. O +

H O +
H O +
O O +
H O +
H O +
H O +
O O +
H O +
H O +
H O +
. O +

HO~ O -
" O +
11 O +
... O -
L O +

/ O -
/ O -
'--CO2R O +
HO O -
/ O +
~ O +
~N O +
14 O +
HO O -
~ O -
H O +
f O +
O O -
/ O -
'~-.,J--~ O +
N~ O +
" O -
CO2R O +
H O +
15 O +
Scheme O +
2 O +
HO O -
~ O -
co2R O +
HO O -
/ O -
~ O +
~N O +
iH O +
Understanding O +
the O +
mechanism O +
of O +
MIF B-Gene +
catalyzed O +
substrate O +
tautomerization O +
is O +
helpful O +
in O +
the O +
design O +
and O +
search O +
of O +
MIF B-Gene +
inhibitors O -
. O +

Initial O +
molecular O +
modeling O +
studies O +
have O +
suggested O +
that O +
the O +
pathway O +
through O +
indolidine O +
14 O +
might O +
be O +
favored O -
, O +
while O +
comparison O +
to O +
structurally O +
related O +
tautomerases B-Gene +
and O +
more O +
recent O +
mechanistic O +
data O +
have O +
favored O +
the O +
quinone O +
methide O +
pathway O -
. O +

16,17 O +
It O +
is O +
known O +
that O +
s O -
- O -
methyl O +
quinone O +
methide O +
have O +
UV O +
and O +
visible O +
X. O +
Zhang O -
, O +
R. O +
Bucala O -
/ O -
Bioorg O -
. O +

Med O -
. O +

Chem O -
. O +

Lett O -
. O +

9 O +
( O -
1999 O -
) O +
3193 O -
- O -
3198 O +
3197 O +
spectra O +
which O +
are O +
easily O +
distinguished O +
from O +
the O +
corresponding O +
dopachrome O +
spectra.~ O +

When O +
5b-41b O +
were O +
exposed O +
to O +
MIF B-Gene -
, O +
no O +
change O +
of O +
their O +
spectra O +
was O +
observed O -
. O +

This O +
observation O +
supports O +
the O +
indolidine O +
pathway O +
described O +
above O +
and O +
suggests O +
that O +
R O -
- O -
proton O +
extraction O +
is O +
the O +
initial O +
step O +
in O +
dopachrome O +
tautomerization O +
by O +
MIF B-Gene -
. O +

L- O +
and O +
DL-~-methyl O +
dopachrome O +
( O -
Sb O +
and O +
6b O -
) O +
and O +
their O +
methyl O +
esters O +
( O -
7b O +
and O +
8b O -
) O -
, O +
when O +
present O +
at O +
the O +
same O +
concentration O +
( O -
0.5 O +
mM O -
) O +
as O +
the O +
MIF B-Gene -
- O -
substrate O +
3b O -
, O +
each O +
displayed O +
a O +
moderate O +
inhibitory O +
effect O +
on O +
MIF B-Gene +
tautomerase I-Gene +
activity O -
, O +
with O +
the O +
esters O +
showing O +
slightly O +
higher O +
activity O +
than O +
the O +
free O +
acids O +
as O +
shown O +
in O +
Table O +
1 O -
. O +

The O +
moderate O +
inhibitory O +
activity O +
of O +
or O -
- O -
substituted O +
dopachromes O +
may O +
result O +
from O +
the O +
competition O +
with O +
MIF B-Gene -
- O -
substrate O +
3b O +
for O +
the O +
active O +
site O +
of O +
MIF B-Gene +
protein I-Gene -
. O +

To O +
identify O +
inhibitors O +
with O +
higher O +
activity O -
, O +
we O +
needed O +
to O +
design O +
compounds O +
with O +
stronger O +
binding O +
affinity O +
or O +
even O +
ones O +
capable O +
of O +
binding O +
covalently O +
to O +
the O +
MIF B-Gene +
protein I-Gene +
thereby O +
blocking O +
the O +
active O +
site O +
and O +
possibly O +
changing O +
the O +
secondary O +
structure O +
of O +
MIF B-Gene -
. O +

As O +
proposed O +
in O +
Scheme O +
3 O -
, O +
dopachromes O +
with O +
a O +
leaving O +
group O +
at O +
~l O -
- O -
position O +
may O +
form O +
a O +
very O +
reactive O +
intermediate O +
16 O +
following O +
et O -
- O -
deprotonation O +
by O +
MIF B-Gene -
. O +

Compound O +
16 O +
may O +
react O +
with O +
nucleophilic O +
residues O +
of O +
the O +
MIF B-Gene +
protein I-Gene +
to O +
form O +
a O +
covalent O +
bond O +
with O +
the O +
protein B-Gene -
. O +

Our O +
data O +
have O +
indeed O +
shown O +
that O +
9b O -
, O +
10b O -
, O +
and O +
11 O +
all O +
displayed O +
strong O +
inhibition O +
on O +
MIF B-Gene +
tautomerase I-Gene +
activity O +
( O -
Table O +
1 O -
) O -
. O +

Particularly O -
, O +
compounds O +
9b O -
, O +
lOb O -
, O +
and O +
11 O +
all O +
showed O +
about O +
50 O -
% O +
inhibition O +
even O +
at O +
a O +
concentration O +
four O +
times O +
less O +
than O +
that O +
of O +
MIF B-Gene -
- O -
substrate O -
. O +

Further O -
, O +
10b O +
and O +
11 O +
showed O +
activity O +
at O +
a O +
concentration O +
ten O +
times O +
less O +
than O +
that O +
of O +
MIF B-Gene -
- O -
substrate O -
. O +

Studies O +
of O +
the O +
proposed O +
MIF B-Gene -
- B-Gene -
covalent I-Gene +
complexes I-Gene +
( O -
MIF-10b B-Gene +
or O +
11 B-Gene -
) O +
by O +
mass O +
spectrometry O +
were O -
, O +
however O -
, O +
inconclusive O -
. O +

Detailed O +
elucidation O +
of O +
the O +
nature O +
of O +
enhanced O +
binding O +
of O +
these O +
inhibitors O +
to O +
MIF B-Gene +
requires O +
further O +
study O -
. O +

H O +
H O +
MIF B-Gene +
O~~X- O +
HO~~N O +
H O +
R O +
HOI~ O +
-N O +
R O +
HOI~ O +
-N O +
HO O +
16 O +
Scheme O +
3 O +
Finally O -
, O +
we O +
examined O +
acyclic O +
compounds O +
containing O +
some O +
structural O +
features O +
similar O +
to O +
the O +
active O +
MIF B-Gene +
substrates O -
/ O -
inhibitors O -
. O +

Thus O -
, O +
compounds O +
12 O +
and O +
13 O +
were O +
tested O +
and O +
found O +
to O +
be O +
inactive O +
in O +
the O +
MIF B-Gene +
tautomerization O +
assay O -
. O +

We O +
have O +
identified O +
several O +
inhibitors O +
of O +
MIF B-Gene +
tautomerase I-Gene +
activity O -
. O +

This O +
discovery O +
should O +
lead O +
to O +
the O +
development O +
of O +
inhibitors O +
of O +
MIF B-Gene +
biological O +
activities O +
and O +
the O +
development O +
of O +
agents O +
for O +
the O +
treatment O +
of O +
MIF B-Gene +
related O +
diseases O -
. O +

Acknowledgments O -
: O +
These O +
studies O +
were O +
supported O +
by O +
NIH O +
grant O +
AI35931 O -
. O +

3198 O +
X. O +
Zhang O -
, O +
R. O +
Bucala O +
/ O +
Bioorg O -
. O +

Med O -
. O +

Chem O -
. O +

Lett O -
. O +

9 O +
( O -
1999 O -
) O -
3193 O -
- O -
3198 O +

Parasitic O +
diseases O +
caused O +
by O +
helminths O +
afflict O +
billions O +
of O +
people O +
worldwide O +
and O +
are O +
among O +
the O +
main O +
causes O +
of O +
morbidity O +
and O +
mortality O +
resulting O +
from O +
infectious O +
disease O -
. O +

Such O +
diseases O +
in O +
animals O +
also O +
have O +
major O +
economic O +
consequences O -
. O +

Recent O +
information O +
about O +
the O +
basic O +
biochemistry O +
and O +
the O +
immunological O +
responses O +
of O +
infected O +
hosts O +
to O +
parasitic O +
helminths O +
and O +
their O +
eggs O +
has O +
led O +
to O +
increased O +
interest O +
in O +
parasite O +
glycoconjugates O -
, O +
since O +
they O +
are O +
the O +
major O +
focus O +
of O +
the O +
immune O +
response O +
( O -
for O +
reviews O -
, O +
see O +
[ O -
1–4 O -
] O +
) O -
. O +

However O -
, O +
only O +
a O +
few O +
helminth O +
carbohydrate O +
structures O +
have O +
sofar O +
been O +
structurally O +
characterized O -
. O +

A O +
typical O +
feature O +
of O +
helminth O +
infections O +
is O +
the O +
induction O +
of O +
specific O +
IgE B-Gene +
[ O -
5,6 O -
] O +
and O +
this O +
is O +
the O +
result O +
of O +
a O +
T B-Gene -
- I-Gene -
helper-2 I-Gene +
( O -
Th2 B-Gene -
) O +
response O -
. O +

In O +
the O +
presence O +
of O +
antigen O +
this O +
IgE B-Gene +
triggers O +
the O +
activation O +
and O +
proliferation O +
of O +
mast O +
cells O +
and O +
eosinophils O +
( O -
i.e. O +
type O +
I O +
hypersensitivity O +
reactions O -
) O -
. O +

The O +
exact O +
implications O +
of O +
these O +
IgE B-Gene +
responses O -
, O +
however O -
, O +
are O +
still O +
unclear O -
. O +

Several O +
studies O +
have O +
shown O +
that O +
high O +
parasite O +
specific O +
IgE B-Gene +
levels O +
are O +
associated O +
with O +
resistance O +
to O +
reinfection O -
, O +
suggesting O +
a O +
protective O +
role O +
for O +
IgE B-Gene +
[ O -
6–9 O -
] O +
. O +

However O -
, O +
very O +
little O +
is O +
known O +
about O +
the O +
structures O +
of O +
the O +
parasite O +
antigens O +
that O +
induce O +
these O +
IgE B-Gene +
responses O -
. O +

N O -
- O -
glycans O +
carrying O +
a O +
' O -
core O +
α1→3-Fuc O -
' O +
( O -
R O -
- O -
GlcNAcβ1→4 O -
( O -
Fucα1→3 O -
) O -
GlcNAcβ1-Asn O -
) O +
or O +
a O +
' O -
core O +
β1→2-Xyl O -
' O +
( O -
Xylβ1→2Manβ1→4GlcNAcβ1-R O -
) O +
are O +
found O +
on O +
many O +
plant O -
, O +
insect O +
and O +
mollusc O -
, O +
but O +
not O +
mammalian O -
, O +
glycoproteins B-Gene +
[ O -
10–14 O -
] O +
, O +
and O +
can O +
contribute O +
to O +
the O +
allergenicity O +
and O +
IgE B-Gene +
cross O -
- O -
reactivity O +
between O +
extracts O +
of O +
these O +
organisms O +
[ O -
15–17 O -
] O +
. O +

Recently O +
it O +
has O +
been O +
reported O +
that O +
the O +
ruminant O +
nematode O +
Haemonchus O +
contortus O +
expresses O +
glycoproteins B-Gene +
carrying O +
core O +
α1→3-Fuc O +
residues O +
[ O -
18 O -
] O +
, O +
and O +
that O +
both O +
core O +
α1→3-Fuc O +
and O +
β1→2-Xyl O +
epitopes O +
have O +
been O +
observed O +
on O +
egg O +
glycoproteins O +
of O +
the O +
human O +
schistosomes O -
, O +
Schistosoma O +
mansoni O +
and O +
Schistosoma O +
japonicum O +
[ O -
19 O -
] O +
. O +

Thus O -
, O +
core O +
α1→3-Fuc O +
and O +
β1→2-Xyl O +
epitopes O +
might O +
contribute O +
to O +
the O +
IgE B-Gene +
response O +
observed O +
in O +
helminth O +
infections O -
. O +

To O +
identify O +
the O +
possible O +
presence O +
of O +
such O +
epitopes O +
in O +
other O +
helminths O -
, O +
we O +
have O +
analyzed O +
the O +
glycoproteins B-Gene +
of O +
different O +
parasitic O +
helminths O -
, O +
and O +
also O +
of O +
the O +
free O +
living O +
nematode O +
Caenorhabditis O +
elegans O +
in O +
Western O +
blots O +
using O +
immunopurified O +
core O +
α1→3-Fuc B-Gene +
specific I-Gene +
and O +
β1→2-Xyl B-Gene +
specific I-Gene +
antibodies I-Gene +
[ O -
20 O -
] O +
. O +

The O +
results O +
show O +
that O +
core O +
α1→3-fucosylation O +
and O +
β1→2-xylosylation O +
are O +
common O +
glycan O +
modifications O +
occurring O +
in O +
many O +
different O +
helminths O -
. O +

In O +
addition O -
, O +
we O +
report O +
that O +
glycans O +
carrying O +
core O +
α1→3-Fuc O +
are O +
recognized O +
by O +
IgE B-Gene +
antibodies I-Gene +
from O +
sheep O +
infected O +
with O +
H. O +
contortus O +
and O +
mice O +
infected O +
with O +
S. O +
mansoni O +
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Antigen O +
preparations O +
and O +
sera O +
Honeybee O +
venom O +
phospholipase B-Gene +
A2 I-Gene +
( O -
PLA2 B-Gene -
) O +
and O +
cucurbita O +
ascorbate B-Gene +
oxidase I-Gene +
were O +
purchased O +
from O +
Sigma O -
. O +

Adult O +
H. O +
contortus O +
were O +
obtained O +
post O +
mortem O +
from O +
the O +
abomasum O +
of O +
sheep O +
experimentally O +
infected O +
with O +
20 O +
000 O +
L3 O +
larvae O -
. O +

H. O +
contortus O +
excretory O +
secretory O +
( O -
ES O -
) O +
products O +
were O +
obtained O +
as O +
described O +
before O +
[ O -
21 O -
] O +
. O +

Sheep O +
antisera B-Gene +
were O +
collected O +
28 O +
days O +
after O +
infection O +
from O +
two O +
sheep O -
, O +
experimentally O +
infected O +
with O +
the O +
H. O +
contortus O +
larvae O -
. O +

The O +
preparation O +
of O +
extracts O +
of O +
adult O +
Dirofilaria O +
immitis O +
, O +
Hymenolepis O +
diminuta O +
, O +
Fasciola O +
hepatica O +
, O +
S. O +
mansoni O +
, O +
S. O +
japonicum O +
and O +
Schistosoma O +
haematobium O +
was O +
described O +
previously O +
[ O -
22 O -
] O +
. O +

Extracts O +
of O +
C. O +
elegans O +
were O +
generated O +
by O +
resuspending O +
the O +
worm O +
pellets O +
in O +
SDS O -
- O -
PAGE O +
buffer O -
, O +
followed O +
by O +
incubation O +
for O +
10 O +
min O +
at O +
100 O -
° O -
C O -
. O +

Insoluble O +
material O +
was O +
removed O +
by O +
centrifugation O -
. O +

Trichinella O +
spiralis O +
, O +
Toxocara O +
canis O +
and O +
cercariae O +
of O +
Trichobilharzia O +
ocellata O +
were O +
resuspended O +
in O +
100 O +
μl O +
PBS O +
including O +
the O +
protease B-Gene +
inhibitors O +
Pefabloc O +
( O -
1 O +
mg O -
/ O -
ml O -
) O -
, O +
EDTA O +
( O -
0,5 O +
mg O -
/ O -
ml O -
) O -
, O +
leupeptin O +
( O -
10 O +
μg O -
/ O -
ml O -
) O -
, O +
pepstatin O +
( O -
10 O +
μg O -
/ O -
ml O -
) O -
, O +
aprotinin B-Gene +
( O -
1 O +
μg O -
/ O -
ml O -
) O +
( O -
Boehringer O +
Mannheim O -
) O -
, O +
and O +
homogenized O +
with O +
a O +
polytron O -
. O +

Triton O +
X-100 O +
( O -
1 O -
% O -
) O +
was O +
added O -
, O +
and O +
the O +
mixture O +
incubated O +
on O +
ice O +
for O +
20 O +
min O -
. O +

After O +
addition O +
of O +
SDS O -
- O -
PAGE O +
buffer O +
and O +
incubation O +
for O +
10 O +
min O +
at O +
100 O -
° O -
C O -
, O +
insoluble O +
material O +
was O +
removed O +
by O +
centrifugation O -
. O +

2.2 O +
Preparation O +
of O +
antisera B-Gene +
The O +
core O +
α1→3-Fuc B-Gene +
and O +
β1→2-Xyl B-Gene +
specific I-Gene +
antisera I-Gene +
were O +
prepared O +
as O +
described O +
previously O +
[ O -
20 O -
] O +
. O +

Briefly O -
, O +
antiserum B-Gene +
raised O +
against O +
horseradish B-Gene +
peroxidase I-Gene +
was O +
fractionated O +
on O +
an O +
affinity O +
column O +
of O +
honeybee O +
PLA2 B-Gene -
, O +
resulting O +
in O +
serum O +
fractions O +
specific O +
for O +
core O +
α1→3-Fuc O +
and O +
β1→2-Xyl O -
, O +
respectively O -
. O +

Antisera B-Gene +
were O +
tested O +
for O +
their O +
specificity O +
as O +
described O -
. O +

2.3 O +
SDS O -
- O -
PAGE O +
and O +
Western O +
blotting O +
Helminth O +
extracts O +
( O -
approximately O +
20–40 O +
μg O +
of O +
protein B-Gene -
) O +
and O +
controls O +
were O +
separated O +
by O +
SDS O -
/ O -
PAGE O +
on O +
15 O -
% O +
gels O +
using O +
the O +
Mini O -
- O -
Protean O +
II O +
system O +
( O -
BioRad O -
) O -
. O +

Western O +
blotting O +
and O +
antibody B-Gene +
reactions O +
were O +
performed O +
essentially O +
as O +
described O +
previously O +
[ O -
23 O -
] O +
. O +

For O +
detection O +
of O +
core O +
α1→3-Fuc B-Gene +
and O +
β1→2-Xyl B-Gene +
containing I-Gene +
glycoproteins I-Gene -
, O +
rabbit O +
polyclonal O +
anti B-Gene -
- I-Gene -
core O +
α1→3-Fuc B-Gene +
or O +
anti B-Gene -
- I-Gene -
β1→2-Xyl I-Gene +
specific I-Gene +
antibodies I-Gene +
were O +
used O +
as O +
the O +
first O +
antibody B-Gene +
and O +
goat O +
anti O -
- O -
rabbit O +
( O -
IgG B-Gene -
/ O -
IgM B-Gene -
) O +
peroxidase B-Gene +
conjugate O +
( O -
TAGO O -
, O +
Inc. O +
Immunodiagnostic O +
reagents O -
) O +
as O +
the O +
second O +
antibody B-Gene -
. O +

For O +
detection O +
of O +
mouse O +
IgE B-Gene +
( O -
Fig. O +
4 O +
) O +
the O +
blots O +
were O +
incubated O +
overnight O +
with O +
1:2 O +
diluted O +
mouse O +
serum O +
followed O +
by O +
incubation O +
with O +
rabbit O +
anti O -
- O -
mouse O +
IgE B-Gene +
peroxidase B-Gene +
conjugate O +
( O -
Nordic O -
, O +
the O +
Netherlands O -
) O +
for O +
1 O +
h O +
at O +
room O +
temperature O -
. O +

Bound O +
antibodies B-Gene +
were O +
visualized O +
using O +
0.6 O +
mg O -
/ O -
ml O +
chloronaphtol O +
in O +
TBS O +
containing O +
0.03 O -
% O +
H2 O +
O2 O +
. O +

2.4 O +
ELISA O +
ELISA O +
was O +
performed O +
as O +
the O +
ES O +
specific O +
ELISA O +
described O +
previously O +
[ O -
24 O -
] O +
. O +

Plates O +
were O +
coated O +
with O +
H. O +
contortus O +
ES O -
, O +
PLA2 B-Gene -
, O +
Arabidopsis O +
thaliana O +
, O +
A. O +
thaliana O +
cgl O +
, O +
and O +
human O +
transferrin B-Gene -
. O +

Competitive O +
glycoproteins B-Gene +
were O +
added O +
to O +
the O +
sheep O +
serum O +
in O +
a O +
final O +
concentration O +
range O +
of O +
80 O +
to O +
0.026 O +
μg O -
/ O -
ml O -
. O +

Zero O +
% O +
inhibition O +
was O +
defined O +
as O +
the O +
OD O +
value O +
of O +
serum O +
without O +
competitive O +
glycoproteins B-Gene -
, O +
and O +
100 O -
% O +
inhibition O +
as O +
the O +
OD O +
value O +
measured O +
with O +
80 O +
μg O -
/ O -
ml O +
autologous O +
glycoproteins B-Gene -
. O +

The O +
monosaccharides O +
D O -
- O -
Glc O -
, O +
L O -
- O -
Fuc O -
, O +
D O -
- O -
Xyl O +
or O +
L O -
- O -
Xyl O +
were O +
added O +
to O +
the O +
sheep O +
serum O +
in O +
a O +
final O +
concentration O +
range O +
of O +
0.01 O +
to O +
1.4 O +
M. O +
3 O +
Results O +
3.1 O +
Specificity O +
of O +
the O +
core O +
α1→3-Fuc B-Gene +
and O +
β1→2-Xyl B-Gene +
specific I-Gene +
antisera I-Gene +
The O +
antisera B-Gene +
used O +
in O +
this O +
study O +
were O +
raised O +
against O +
the O +
plant O +
glycoprotein B-Gene +
horseradish B-Gene +
peroxidase I-Gene -
, O +
which O +
carries O +
glycans O +
shown O +
in O +
Fig. O +
1 O +
. O +

Fractionation O +
of O +
this O +
antiserum B-Gene +
on O +
an O +
affinity O +
column O +
of O +
honeybee O +
venom O +
phospholipase B-Gene +
A2 I-Gene +
( O -
PLA2 B-Gene -
) O +
resulted O +
in O +
serum O +
fractions O +
highly O +
specific O +
for O +
either O +
the O +
core O +
α1→3-Fuc O -
, O +
or O +
β1→2-Xyl O -
, O +
respectively O -
. O +

To O +
confirm O +
their O +
specificity O +
purified O +
antibodies B-Gene +
were O +
tested O +
with O +
many O +
different O +
plant O +
and O +
mammalian O +
glycoproteins B-Gene -
, O +
containing O +
either O +
a O +
core O +
α1→3-Fuc O +
or O +
a O +
β1→2-Xyl O -
, O +
or O +
no O +
core O +
modification O +
[ O -
20 O -
] O +
. O +

Furthermore O -
, O +
both O +
antisera B-Gene +
reacted O +
strongly O +
with O +
glycoproteins B-Gene +
isolated O +
from O +
the O +
leaves O +
of O +
A. O +
thaliana O +
( O -
Figs. O +
2 O -
, O +
4C O +
and O +
D O +
) O -
, O +
the O +
N O -
- O -
glycans O +
of O +
which O +
have O +
been O +
fully O +
identified O +
recently O +
and O +
shown O +
to O +
consist O +
of O +
high O +
mannose O -
- O -
type O +
N O -
- O -
glycans O +
and O +
complex O -
- O -
type O +
core O +
α1→3-fucosylated O +
and O +
β1→2-xylosylated O +
N O -
- O -
glycans O +
[ O -
25 O -
] O +
. O +

No O +
other O +
complex O -
- O -
type O +
modifications O +
have O +
been O +
demonstrated O +
in O +
A. O +
thaliana O +
[ O -
25 O -
] O +
. O +

The O +
antisera B-Gene +
did O +
not O +
bind O +
to O +
glycoproteins B-Gene +
of O +
the O +
cgl O +
mutant O +
of O +
A. O +
thaliana O +
, O +
lacking O +
N B-Gene +
-acetylglucosaminyltransferase I-Gene +
I I-Gene -
, O +
and O +
thus O +
lacking O +
the O +
expression O +
of O +
the O +
core O +
α3-fucosylated B-Gene +
and O +
β2-xylosylated O +
N B-Gene -
- I-Gene -
glycans I-Gene +
[ O -
26 O -
] O +
( O -
Figs. O +
2 O -
, O +
4C O +
and O +
D O +
) O -
. O +

Importantly O -
, O +
the O +
results O +
in O +
Fig. O +
2 O +
show O +
that O +
no O +
cross O -
- O -
reactivity O +
was O +
observed O +
of O +
the O +
core O +
α1→3-Fuc B-Gene +
antiserum I-Gene +
with O +
LPS O +
from O +
Helicobacter O +
pylori O +
strain O +
O3 O -
, O +
containing O +
Galβ1→4 O -
( O -
Fucα1→3 O -
) O -
GlcNAc O +
( O -
Lex O +
, O +
[ O -
27 O -
] O +
) O -
, O +
sialyl O -
- O -
Lex O +
containing O +
α1 B-Gene +
-acid I-Gene +
glycoprotein I-Gene +
( O -
AGP B-Gene -
) O +
derived O +
from O +
patients O +
suffering O +
from O +
rheumatoid O +
arthritis O +
[ O -
28 O -
] O +
, O +
core O +
α1→6-fucosylated B-Gene +
human I-Gene +
IgG I-Gene -
, O +
or O +
neoglycoprotein B-Gene +
containing I-Gene +
GalNAcβ1→4 I-Gene -
( I-Gene -
Fucα1→3 I-Gene -
) I-Gene -
GlcNAc I-Gene +
( O -
LDNF O -
) O +
units O -
, O +
indicating O +
that O +
the O +
core O +
α1→3-Fuc B-Gene +
specific I-Gene +
antiserum I-Gene +
does O +
not O +
recognize O +
other O +
Fucα1→3GlcNAc O +
moieties O +
found O +
in O +
the O +
core O +
or O +
outer O +
antennae O +
of O +
N- O +
or O +
O O -
- O -
linked O +
glycans O -
. O +

3.2 O +
Core O +
α1→3-Fuc O +
and O +
β1→2-Xyl O +
residues O +
on O +
protein B-Gene -
- O -
linked O +
glycans O +
of O +
different O +
helminths O +
The O +
presence O +
of O +
core O +
α1→3-Fuc O +
and O +
β1→2-Xyl O +
residues O +
on O +
protein B-Gene -
- O -
linked O +
glycans O +
of O +
different O +
helminths O +
was O +
determined O +
by O +
Western O +
blotting O -
, O +
using O +
the O +
affinity O +
purified O +
core O +
α1→3-Fuc B-Gene +
and O +
β1→2-Xyl B-Gene +
specific I-Gene +
antisera I-Gene +
[ O -
20 O -
] O +
. O +

The O +
extracts O +
were O +
derived O +
from O +
adult O +
helminths O -
, O +
except O +
the O +
extract O +
of O +
T. O +
ocellata O +
, O +
which O +
was O +
derived O +
from O +
cercariae O -
. O +

In O +
addition O +
to O +
the O +
adult O +
stages O -
, O +
soluble O +
antigens O +
were O +
tested O +
from O +
H. O +
contortus O +
( O -
i.e. O +
excretory O -
/ O -
secretory O +
( O -
ES O -
) O +
antigens O -
) O +
and O +
S. O +
mansoni O +
( O -
soluble O +
egg O +
antigens O +
( O -
SE O -
) O -
) O -
. O +

The O +
extracts O +
from O +
most O +
helminths O +
tested O +
contained O +
many O +
glycoproteins B-Gene +
that O +
reacted O +
moderate O +
to O +
strongly O +
with O +
the O +
core O +
α1→3-Fuc B-Gene +
specific I-Gene +
antibodies I-Gene -
, O +
whereas O +
reaction O +
of O +
H. O +
diminuta O +
, O +
F. O +
hepatica O +
and O +
T. O +
canis O +
glycoproteins B-Gene +
was O +
less O +
abundant O +
( O -
Fig. O +
3 O +
, O +
upper O +
panel O -
) O -
. O +

The O +
β1→2-Xyl B-Gene +
specific I-Gene +
antiserum I-Gene +
showed O +
binding O +
to O +
glycoproteins B-Gene +
of O +
some O +
of O +
the O +
extracts O -
, O +
i.e. O +
of O +
C. O +
elegans O +
, O +
S. O +
mansoni O +
, O +
S. O +
haematobium O +
, O +
S. O +
mansoni O +
SE O +
antigens O -
, O +
D. O +
immitis O +
, O +
T. O +
canis O +
, O +
and O +
of O +
cercariae O +
of O +
T. O +
ocellata O +
, O +
whereas O +
no O +
binding O +
was O +
observed O +
with O +
the O +
other O +
parasite O +
derived O +
samples O +
( O -
Fig. O +
3 O +
, O +
lower O +
panel O -
) O -
. O +

3.3 O +
IgE B-Gene +
in O +
sera O +
of O +
S. O +
mansoni O +
infected O +
mice O +
cross O -
- O -
reacts O +
with O +
A. O +
thaliana O +
glycoproteins B-Gene +
We O +
next O +
sought O +
to O +
determine O +
whether O +
infection O +
of O +
mice O +
with O +
S. O +
mansoni O +
results O +
in O +
IgE B-Gene +
to O +
core O +
α1→3-fucosylated O +
and/or O +
β1→2-xylosylated O +
N O -
- O -
glycans O -
. O +

Western O +
blots O +
containing O +
proteins B-Gene +
of O +
S. O +
mansoni O +
, O +
A. O +
thaliana O +
[ O -
25 O -
] O +
and O +
the O +
cgl O +
mutant O +
of O +
A. O +
thaliana O +
lacking O +
the O +
core O +
antigens O +
[ O -
26 O -
] O +
, O +
were O +
analyzed O +
using O +
different O +
antibodies B-Gene -
. O +

IgE B-Gene +
from O +
pooled O +
sera O +
of O +
mice O +
experimentally O +
infected O +
with O +
S. O +
mansoni O +
binds O +
to O +
several O +
S. O +
mansoni O +
proteins B-Gene -
, O +
in O +
contrast O +
to O +
IgE B-Gene +
from O +
normal O +
mouse O +
serum O +
that O +
showed O +
no O +
reactivity O -
. O +

IgE B-Gene +
from O +
the O +
infected O +
mice O +
serum O +
cross O -
- O -
reacted O +
with O +
many O +
proteins B-Gene +
of O +
A. O +
thaliana O +
, O +
but O +
not O +
with O +
the O +
cgl O +
mutant O -
, O +
indicating O +
that O +
the O +
antibodies B-Gene +
specifically O +
recognize O +
complex O -
- O -
type O +
glycans O +
carrying O +
a O +
core O +
α1→3-Fuc O +
or O +
β1→2-Xyl O +
residue O +
( O -
Fig. O +
4 O +
) O -
. O +

We O +
also O +
could O +
detect O +
a O +
weak O +
binding O +
of O +
the O +
IgE B-Gene +
antibodies B-Gene +
from O +
infected O +
mice O +
with O +
honeybee O +
PLA2 B-Gene +
( O -
data O +
not O +
shown O -
) O -
, O +
suggesting O +
that O +
the O +
core O -
- O -
linked O +
α1→3-Fuc O +
is O +
an O +
epitope O +
for O +
IgE O +
of O +
S. O +
mansoni O +
infected O +
mice O -
. O +

3.4 O +
IgE B-Gene +
in O +
sera O +
from O +
H. O +
contortus O +
infected O +
sheep O +
recognizes O +
core O +
α1→3-fucosylated O +
N O -
- O -
glycans O +
Sera O +
from O +
sheep O +
infected O +
with O +
H. O +
contortus O +
were O +
analyzed O +
by O +
ELISA O -
. O +

The O +
results O +
in O +
Fig. O +
5A O +
show O +
that O +
IgE B-Gene +
in O +
serum O +
of O +
infected O +
sheep O +
recognizes O +
H. O +
contortus O +
ES B-Gene +
glycoproteins I-Gene -
, O +
honeybee O +
PLA2 B-Gene +
and O +
A. O +
thaliana O +
glycoproteins B-Gene -
, O +
and O +
did O +
not O +
recognize O +
human O +
transferrin B-Gene +
or O +
glycoproteins B-Gene +
from O +
the O +
cgl O +
mutant O +
of O +
A. O +
thaliana O +
lacking O +
the O +
core O +
antigens O -
. O +

In O +
contrast O -
, O +
binding O +
of O +
IgG B-Gene +
antibodies B-Gene +
from O +
the O +
infected O +
sheep O +
sera O +
to O +
A. O +
thaliana O +
and O +
PLA2 B-Gene +
proteins B-Gene +
was O +
hardly O +
detectable O -
, O +
whereas O +
IgG B-Gene +
binding O +
was O +
observed O +
to O +
many O +
H. O +
contortus O +
ES B-Gene +
proteins I-Gene +
( O -
Fig. O +
5A O +
, O +
[ O -
29 O -
] O +
) O -
. O +

These O +
results O +
suggest O +
that O +
IgE B-Gene +
from O +
the O +
sera O +
of O +
H. O +
contortus O +
infected O +
sheep O +
recognizes O +
the O +
core O +
α1→3-Fuc O +
epitope O +
that O +
occurs O +
on O +
both O +
plant O +
glycoproteins B-Gene +
and O +
honeybee O +
PLA2 B-Gene -
. O +

To O +
further O +
validate O +
this O +
possibility O -
, O +
inhibition O +
experiments O +
were O +
performed O +
( O -
Fig. O +
5B O -
, O +
C O +
) O -
. O +

It O +
was O +
shown O +
that O +
PLA2 B-Gene +
could O +
block O +
the O +
binding O +
of O +
IgE B-Gene +
from O +
infected O +
sheep O +
to O +
ES B-Gene -
. O +

Similarly O -
, O +
ES B-Gene +
could O +
block O +
the O +
binding O +
of O +
this O +
IgE B-Gene +
to O +
PLA2 B-Gene -
, O +
whereas O +
human O +
transferrin B-Gene +
lacking O +
the O +
core O +
fucose O +
did O +
not O +
block O +
the O +
IgE B-Gene +
binding O -
. O +

Binding O +
of O +
sheep O +
IgE B-Gene +
to O +
H. O +
contortus O +
ES B-Gene +
was O +
inhibited O +
to O +
80 O -
% O +
by O +
L O -
- O -
Fuc O +
at O +
a O +
concentration O +
of O +
1 O +
M O -
, O +
whereas O +
the O +
same O +
concentrations O +
of O +
D O -
- O -
Xyl O -
, O +
L O -
- O -
Xyl O +
or O +
D O -
- O -
Glc O +
showed O +
only O +
25 O -
% O +
inhibition O +
in O +
the O +
same O +
experiment O +
( O -
data O +
not O +
shown O -
) O -
. O +

These O +
results O +
demonstrate O +
that O +
an O +
important O +
part O +
of O +
the O +
ES B-Gene +
specific O +
IgE B-Gene +
in O +
the O +
sera O +
of O +
H. O +
contortus O +
infected O +
sheep O +
recognizes O +
core O +
α1→3-fucosylated O +
N O -
- O -
glycans O -
. O +

4 O +
Discussion O +
We O +
report O +
in O +
this O +
study O +
that O +
IgE B-Gene +
from O +
serum O +
of O +
S. O +
mansoni O +
infected O +
mice O +
and O +
H. O +
contortus O +
infected O +
sheep O +
cross O -
- O -
reacts O +
with O +
A. O +
thaliana O +
glycoproteins B-Gene +
that O +
carry O +
core O +
α1→3-fucosylated O +
and O +
β1→2-xylosylated O +
N O -
- O -
glycans O -
. O +

In O +
contrast O -
, O +
IgE B-Gene +
from O +
these O +
sera O +
did O +
not O +
bind O +
to O +
glycoproteins B-Gene +
of O +
the O +
cgl O +
mutant O +
of O +
A. O +
thaliana O +
, O +
that O +
lack O +
the O +
core O +
antigens O +
and O +
other O +
complex O -
- O -
type O +
glycan O +
modifications O +
[ O -
14,25,26 O -
] O +
. O +

These O +
results O +
indicate O +
that O +
the O +
core O +
α1→3-Fuc O +
and/or O +
the O +
β1→2-Xyl O +
residues O +
are O +
epitopes O +
for O +
both O +
IgE B-Gene +
from O +
S. O +
mansoni O +
infected O +
mice O +
and O +
H. O +
contortus O +
infected O +
sheep O -
. O +

It O +
has O +
been O +
reported O +
that O +
the O +
human O +
schistosome O +
S. O +
mansoni O +
synthesizes O +
glycoproteins B-Gene +
carrying O +
both O +
core O +
α1→3-Fuc O +
and O +
β1→2-Xyl O +
residues O +
[ O -
19 O -
] O +
, O +
which O +
was O +
confirmed O +
by O +
our O +
studies O +
using O +
the O +
affinity O +
purified O +
α1→3-Fuc B-Gene +
and O +
β1→2-Xyl B-Gene +
specific I-Gene +
antibodies I-Gene -
. O +

Since O +
these O +
core O +
antigens O +
do O +
not O +
occur O +
in O +
mammals O +
they O +
may O +
induce O +
the O +
generation O +
of O +
anti B-Gene -
- I-Gene -
glycan I-Gene +
antibodies I-Gene +
during O +
schistosome O +
infection O -
. O +

We O +
can O -
not O +
deduce O +
from O +
our O +
data O +
whether O +
one O +
or O +
both O +
of O +
the O +
core O +
antigens O +
in O +
A. O +
thaliana O +
are O +
involved O +
in O +
binding O +
of O +
IgE B-Gene +
from O +
S. O +
mansoni O +
infected O +
mice O -
. O +

In O +
contrast O -
, O +
the O +
ruminant O +
nematode O +
H. O +
contortus O +
contains O +
glycoproteins B-Gene +
carrying O +
core O +
α1→3-fucosylated O +
N O -
- O -
glycans O +
but O +
no O +
evidence O +
was O +
presented O +
for O +
the O +
presence O +
of O +
a O +
β1→2-Xyl O +
( O -
[ O -
18 O -
] O +
, O +
this O +
study O -
) O -
. O +

This O +
suggests O +
that O +
the O +
core O +
α1→3-Fuc O +
is O +
likely O +
to O +
be O +
the O +
A. O +
thaliana O +
epitope O +
that O +
reacted O +
with O +
IgE B-Gene +
from O +
H. O +
contortus O +
infected O +
sheep O -
. O +

Evidence O +
is O +
presented O +
using O +
both O +
ELISA O +
and O +
competitive O +
ELISA O +
that O +
the O +
core O +
α1→3-Fuc O +
residue O +
indeed O +
is O +
a O +
major O +
epitope O +
recognized O +
by O +
parasite O +
specific O +
IgE O +
from O +
serum O +
of O +
H. O +
contortus O +
infected O +
sheep O -
. O +

Importantly O -
, O +
hardly O +
any O +
IgG B-Gene +
reactivity O +
to O +
this O +
core O +
antigen O +
was O +
demonstrable O +
in O +
these O +
sera O -
. O +

In O +
contrast O -
, O +
IgM B-Gene +
or O +
IgG B-Gene +
antibodies B-Gene +
have O +
been O +
demonstrated O +
in O +
sera O +
of O +
parasite O +
infected O +
hosts O +
to O +
other O +
parasite O +
derived O +
carbohydrate O +
components O +
( O -
[ O -
30 O -
] O +
; O +
Van O +
Remoortere O +
et O +
al. O -
, O +
manuscript O +
in O +
preparation O -
) O -
. O +

This O +
suggests O +
that O +
the O +
core O +
α1→3-Fuc O +
epitope O +
preferentially O +
triggers O +
a O +
Th2 B-Gene +
response O +
leading O +
to O +
the O +
production O +
of O +
IgE B-Gene -
, O +
although O +
we O +
can O -
not O +
rule O +
out O +
the O +
possibility O +
that O +
the O +
core O +
fucose O +
specific O +
IgE B-Gene +
is O +
a O +
product O +
rather O +
than O +
an O +
inducer O +
of O +
a O +
Th2 B-Gene +
response O -
. O +

Interestingly O -
, O +
several O +
T O +
cell O +
clones O +
have O +
been O +
identified O +
from O +
bee O +
venom B-Gene +
sensitized O +
subjects O +
which O +
proliferate O +
in O +
response O +
to O +
honeybee O +
PLA2 B-Gene +
but O +
not O +
to O +
its O +
non O -
- O -
glycosylated O +
variants O -
, O +
providing O +
evidence O +
for O +
the O +
involvement O +
of O +
an O +
N O -
- O -
glycan O +
in O +
T O +
cell O +
recognition O +
[ O -
31 O -
] O +
. O +

It O +
will O +
be O +
important O +
to O +
establish O +
whether O +
the O +
core O +
α-1→3-Fuc O +
antigen O +
is O +
involved O +
in O +
these O +
immunological O +
processes O -
. O +

Recently O +
it O +
has O +
been O +
demonstrated O +
that O +
vaccination O +
of O +
sheep O +
with O +
ES B-Gene +
antigens O +
of O +
H. O +
contortus O +
induces O +
protection O +
against O +
challenge O +
infection O +
and O +
that O +
this O +
protection O +
is O +
correlated O +
with O +
IgE B-Gene +
rather O +
than O +
with O +
IgG B-Gene +
[ O -
32 O -
] O +
. O +

It O +
thus O +
appears O +
that O +
the O +
core O +
α1→3-Fuc O +
antigen O +
may O +
be O +
an O +
important O +
protective O +
antigen O +
in O +
H. O +
contortus O +
infections O -
, O +
and O +
perhaps O +
other O +
helminth O +
infections O -
. O +

To O +
identify O +
the O +
possible O +
presence O +
of O +
core O -
- O -
fucosylated O +
and O +
core O -
- O -
xylosylated O +
epitopes O +
in O +
other O +
helminths O +
we O +
analyzed O +
different O +
species O -
. O +

Our O +
results O +
show O +
that O +
many O +
helminths O +
from O +
different O +
orders O +
of O +
the O +
phyla O +
Platyhelminthes O +
and O +
Nematodes O +
synthesize O +
glycoproteins B-Gene +
containing O +
core O +
α1→3-fucosylated O +
N O -
- O -
glycans O -
. O +

In O +
addition O +
several O +
of O +
these O +
organisms O +
also O +
synthesize O +
N O -
- O -
glycans O +
containing O +
β1→2-Xyl O -
. O +

Remarkably O -
, O +
only O +
small O +
amounts O +
of O +
β1→2-Xyl O +
were O +
found O +
on O +
glycoproteins B-Gene +
of O +
adult O +
S. O +
japonicum O +
, O +
whereas O +
the O +
related O +
S. O +
mansoni O +
and O +
S. O +
haematobium O +
showed O +
many O +
β1→2-xylosylated B-Gene +
glycoproteins I-Gene -
. O +

Recent O +
data O +
from O +
Khoo O +
et O +
al. O +
[ O -
19 O -
] O +
described O +
the O +
presence O +
of O +
β1→2-xylosylated O +
N O -
- O -
glycans O +
in O +
egg O +
glycoproteins B-Gene +
of O +
S. O +
japonicum O +
. O +

It O +
may O +
be O +
possible O +
that O +
in O +
S. O +
japonicum O +
β1→2-xylosylation O +
is O +
stage O +
specific O -
. O +

Alternatively O -
, O +
the O +
plant O +
specific O +
antiserum B-Gene +
may O +
be O +
unable O +
to O +
bind O +
some O +
core O +
β1→2-Xyl O +
residues O -
, O +
due O +
to O +
masking O +
of O +
the O +
epitope O -
, O +
e.g. O +
by O +
the O +
presence O +
of O +
multiple O +
core O +
fucose O +
residues O +
[ O -
19 O -
] O +
or O +
other O +
modifications O -
. O +

Cross O -
- O -
reactivity O +
has O +
been O +
observed O +
for O +
many O +
years O +
in O +
immunoassays O +
of O +
plant O -
, O +
arthropod O +
and O +
mollusc O +
extracts O +
[ O -
33–35 O -
] O +
. O +

Part O +
of O +
this O +
cross O -
- O -
reactivity O +
is O +
caused O +
by O +
conserved O +
proteins B-Gene -
, O +
as O +
profilins B-Gene +
in O +
plants O +
[ O -
36 O -
] O +
, O +
and O +
tropomyosins B-Gene +
in O +
crustacea O +
and O +
mollusca O +
[ O -
37 O -
] O +
. O +

In O +
addition O -
, O +
cross O -
- O -
reactivity O +
between O +
several O +
parasitic O +
helminths O -
, O +
and O +
between O +
helminths O +
and O +
molluscs O +
has O +
been O +
reported O +
[ O -
38–40 O -
] O +
. O +

The O +
highly O +
antigenic O +
core O +
α1→3-Fuc O +
and/or O +
β1→2-Xyl O +
in O +
N O -
- O -
glycans O -
, O +
that O +
are O +
conserved O +
among O +
many O +
invertebrates O +
and O +
plants O -
, O +
have O +
been O +
shown O +
to O +
contribute O +
to O +
such O +
cross O -
- O -
reactions O +
[ O -
35,41 O -
] O +
. O +

In O +
some O +
cases O +
it O +
has O +
been O +
established O +
that O +
IgE B-Gene +
antibodies B-Gene +
from O +
patients O +
allergic O +
for O +
honeybee O +
venom B-Gene +
or O +
plant O +
substances O +
such O +
as O +
cereal O +
flour O +
proteins B-Gene +
bind O +
to O +
core O +
α1→3-Fuc O +
and/or O +
β1→2-Xyl O +
containing O +
N O -
- O -
glycans O +
[ O -
15–17 O -
] O +
. O +

Our O +
results O +
indicate O +
that O +
the O +
core O +
α1→3-Fuc O +
structure O +
is O +
commonly O +
found O +
on O +
helminth O +
glycoproteins B-Gene +
and O +
that O +
IgE B-Gene +
antibodies B-Gene +
from O +
helminth O +
infected O +
hosts O +
bind O +
to O +
this O +
glycan O +
epitope O -
. O +

To O +
our O +
knowledge O -
, O +
this O +
is O +
the O +
first O +
description O +
of O +
an O +
antigen O +
that O +
may O +
be O +
important O +
in O +
the O +
induction O +
of O +
both O +
helminth O -
- O -
mediated O +
Th2-type B-Gene +
immunity O +
and O +
in O +
allergic O +
reactions O -
. O +

Recognition O +
of O +
putative O +
features O +
common O +
to O +
helminths O +
presumably O +
informs O +
the O +
host O +
immune O +
system O +
that O +
a O +
stereotypic O +
type O +
2 O +
cytokine B-Gene +
response O +
will O +
be O +
more O +
protective O +
than O +
a O +
type O +
1 O +
or O +
type O +
0 O -
. O +

It O +
has O +
been O +
hypothesized O +
previously O +
that O +
some O +
of O +
these O +
helminth O +
features O +
are O +
shared O +
with O +
allergens O +
and O +
may O +
be O +
responsible O +
for O +
the O +
obviously O +
maladaptive O +
responses O +
made O +
to O +
non O -
- O -
threatening O +
molecules O +
as O +
pollen O +
antigens O +
and O +
bee O +
venom B-Gene +
phospholipase B-Gene +
[ O -
42 O -
] O +
. O +

This O +
stresses O +
the O +
importance O +
of O +
the O +
conserved O +
core O +
α1→3-Fuc O +
epitope O +
as O +
a O +
potential O +
' O -
pan O +
allergen O -
' O +
[ O -
41 O -
] O +
. O +

Interestingly O -
, O +
several O +
studies O +
have O +
shown O +
an O +
inverse O +
relationship O +
between O +
exposure O +
to O +
helminth O +
infections O +
and O +
the O +
incidence O +
of O +
allergies O +
[ O -
43–45 O -
] O +
. O +

It O +
is O +
exciting O +
to O +
consider O +
the O +
possibility O +
that O +
detailed O +
knowledge O +
of O +
the O +
parasite O +
structures O +
involved O +
in O +
Th2 B-Gene +
activation O +
and O +
IgE B-Gene +
induction O +
and O +
a O +
better O +
understanding O +
of O +
the O +
mechanism O +
by O +
which O +
they O +
evoke O +
these O +
immune O +
responses O +
may O +
lead O +
to O +
novel O +
therapies O +
against O +
both O +
parasitic O +
diseases O +
and O +
atopic O +
disorders O -
. O +

Acknowledgments O +
We O +
gratefully O +
acknowledge O +
Ms. O +
A. O +
van O +
Tetering O +
for O +
technical O +
assistance O +
in O +
part O +
of O +
the O +
work O -
. O +

We O +
thank O +
Dr. O +
A.M. O +
Deelder O +
( O -
Dept O -
. O +

of O +
Parasitology O -
, O +
Leiden O -
, O +
The O +
Netherlands O -
) O +
for O +
serum O +
from O +
schistosome O +
infected O +
mice O -
, O +
Dr. O +
H. O +
Bakker O +
( O -
CPRO O -
- O -
DLO O -
, O +
Wageningen O -
, O +
The O +
Netherlands O -
) O +
for O +
extracts O +
of O +
A. O +
thaliana O +
, O +
Dr. O +
H. O +
van O +
Luenen O +
( O -
NKI O -
, O +
Amsterdam O -
, O +
The O +
Netherlands O -
) O +
for O +
C. O +
elegans O +
, O +
Drs O -
. O +

A.K. O +
Nyame O +
( O -
University O +
of O +
Oklahoma O -
, O +
USA O -
) O -
, O +
Y. O +
Rombouts O +
( O -
RIVM O -
, O +
Bilthoven O -
, O +
The O +
Netherlands O -
) O -
, O +
and O +
M. O +
de O +
Jong O -
- O -
Brink O +
( O -
Dept O -
. O +

of O +
Neurobiology O -
, O +
VU O -
, O +
Amsterdam O -
, O +
The O +
Netherlands O -
) O +
for O +
parasites O +
and O +
parasite O +
extracts O -
, O +
Drs O +
A. O +
van O +
Remoortere O +
( O -
Dept O -
. O +
of O +
Medical O +
Chemistry O -
, O +
VU O -
, O +
Amsterdam O -
, O +
The O +
Netherlands O -
) O +
for O +
gift O +
of O +
neoglycoprotein B-Gene -
, O +
Dr. O +
B. O +
Appelmelk O +
( O -
Dept O -
. O +
of O +
Medical O +
Microbiology O -
, O +
VU O -
, O +
Amsterdam O -
, O +
The O +
Netherlands O -
) O +
for O +
H. O +
pylori O +
LPS O -
, O +
and O +
Dr. O +
W. O +
van O +
Dijk O +
( O -
Dept O -
. O +
of O +
Medical O +
Chemistry O -
, O +
VU O -
, O +
Amsterdam O -
, O +
The O +
Netherlands O -
) O +
for O +
AGP O -
. O +

We O +
thank O +
Dr. O +
P. O +
Lerouge O +
( O -
CNRS O -
, O +
Rouen O -
, O +
France O -
) O +
for O +
stimulating O +
discussions O +
and O +
Dr. O +
A.W. O +
Cornelissen O +
( O -
Dept O -
. O +

of O +
Parasitology O -
, O +
Utrecht O -
, O +
The O +
Netherlands O -
) O +
for O +
critical O +
reading O +
of O +
the O +
manuscript O -
. O +

L.V. O +
was O +
supported O +
by O +
a O +
grant O +
from O +
The O +
Technology O +
Foundation O +
( O -
STW O -
, O +
The O +
Netherlands O -
; O +
project O -
: O +
UDG55.3762 O -
) O -
. O +

Collaboration O +
between O +
Drs O -
. O +

I. O +
van O +
Die O +
and O +
R. O +
Cummings O +
was O +
facilitated O +
by O +
a O +
NATO O +
Collaborative O +
Research O +
Grant O +
( O -
CRG972098 O -
) O -
. O +

It O +
is O +
now O +
well O +
established O +
that O +
there O +
are O +
two O +
isozymes B-Gene +
of O +
prostaglandin B-Gene +
( I-Gene -
PG I-Gene -
) I-Gene -
-forming I-Gene +
cyclooxygenase I-Gene -
; O +
constitutive O +
cyclooxygenase-1 B-Gene +
and O +
inducible O +
cyclooxygenase-2 B-Gene +
[ O -
1,2 O -
] O +
. O +

MC3T3-E1 O +
cell O +
cloned O +
from O +
newborn O +
mouse O +
calvaria O +
is O +
an O +
osteogenic O +
cell O +
line O +
which O +
differentiates O +
into O +
an O +
osteoblast O +
[ O -
3,4 O -
] O +
. O +

Much O +
earlier O +
our O +
extensive O +
studies O +
demonstrated O +
the O +
production O +
of O +
E2 O +
as O +
a O +
major O +
arachidonate O +
metabolite O +
in O +
this O +
cell O +
line O +
[ O -
5 O -
] O +
and O +
the O +
induction O +
of O +
cyclooxygenase B-Gene +
by O +
various O +
bioregulators O +
[ O -
5–9 O -
] O +
. O +

Later O +
the O +
induced O +
enzyme O +
in O +
MC3T3-E1 O +
cells O +
was O +
identified O +
as O +
cyclooxygenase-2 B-Gene +
[ O -
8–10 O -
] O +
. O +

Previously O +
humulon O +
( O -
( O -
R O +
) O -
-3,5,6-trihydroxy-4,6-bis O -
( O -
3-methyl-2-butenyl O -
) O -
-2- O -
( O -
3-methyl-1-oxobutyl O -
) O -
-2,4-cyclohexadien-1-one O -
) O +
( O -
Fig. O +
1 O +
) O +
isolated O +
from O +
hop O +
( O -
Humulus O +
lupulus O +
L. O -
) O +
extract O +
was O +
found O +
as O +
an O +
inhibitor O +
of O +
bone O +
resorption O +
( O -
IC50 O +
: O +
5.9 O +
nM O -
) O +
[ O -
11 O -
] O +
. O +

We O +
noted O +
this O +
activity O +
of O +
humulon O -
, O +
and O +
were O +
interested O +
in O +
a O +
possible O +
inhibitory O +
or O +
suppressive O +
effect O +
of O +
humulon O +
on O +
cyclooxygenase-2 B-Gene +
leading O +
to O +
a O +
decreased O +
production O +
of O +
PGE2 O +
as O +
a O +
bone O +
resorption O +
factor O +
[ O -
12 O -
] O +
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Materials O +
Humulon O +
was O +
purified O +
from O +
hop O +
paste O +
as O +
described O +
previously O +
[ O -
11 O -
] O +
, O +
and O +
the O +
purified O +
material O +
was O +
dissolved O +
in O +
dimethyl O +
sulfoxide O +
at O +
a O +
concentration O +
of O +
10 O +
mM. O +
MC3T3-E1 O +
cells O +
were O +
cultured O +
as O +
described O +
previously O +
[ O -
5 O -
] O +
. O +

Confluent O +
cultures O +
were O +
usually O +
obtained O +
on O +
the O +
4th O +
day O -
. O +

Then O -
, O +
the O +
medium O +
was O +
changed O +
to O +
α O -
- O -
MEM O +
( O -
Life O +
Technologies O -
, O +
Gaithersburg O -
, O +
MD O -
, O +
USA O -
) O +
supplemented O +
with O +
2 O -
% O +
newborn O +
bovine O +
serum O +
( O -
Irvine O +
Scientific O -
, O +
Santa O +
Ana O -
, O +
CA O -
, O +
USA O -
) O +
and O +
a O +
compound O +
to O +
be O +
tested O -
. O +

At O +
indicated O +
time O +
intervals O -
, O +
the O +
cells O +
were O +
scraped O +
from O +
dishes O +
and O +
subjected O +
to O +
various O +
assays O +
described O +
below O -
. O +

2.2 O +
Assays O +
of O +
cyclooxygenase-1 B-Gene +
and O +
-2 B-Gene +
activities O +
For O +
cyclooxygenase-1 B-Gene +
preparation O -
, O +
lyophilized O +
powder O +
of O +
sheep O +
seminal O +
vesicle O +
microsomes O +
( O -
Eldan O +
Technologies O -
, O +
Jerusalem O -
, O +
Israel O -
) O +
was O +
suspended O +
in O +
20 O +
mM O +
phosphate O +
buffer O +
( O -
pH O +
7.4 O -
) O +
containing O +
5 O +
mM O +
tryptophan O -
. O +

For O +
cyclooxygenase-2 B-Gene +
preparation O -
, O +
5 O -
× O -
107 O +
MC3T3-E1 O +
cells O +
were O +
incubated O +
with O +
100 O +
nM O +
phorbol O +
12-myristate O +
13-acetate O +
and O +
100 O +
nM O +
A23187 O +
for O +
9 O +
h. O +
The O +
cells O +
were O +
subjected O +
to O +
sonic O +
disruption O -
, O +
and O +
centrifuged O +
at O +
180 O +
000 O -
× O -
g O +
for O +
50 O +
min O -
. O +

The O +
resultant O +
pellet O +
was O +
collected O +
as O +
the O +
microsomal O +
fraction O -
, O +
and O +
suspended O +
in O +
1 O +
ml O +
of O +
20 O +
mM O +
Tris O -
– O -
HCl O +
( O -
pH O +
7.4 O -
) O +
containing O +
5 O +
mM O +
tryptophan O -
. O +

The O +
enzyme O +
assay O +
was O +
performed O +
as O +
described O +
previously O +
[ O -
9 O -
] O +
. O +

2.3 O +
Cyclooxygenase-2 B-Gene +
induction O +
MC3T3-E1 O +
cells O +
( O -
2.2 O -
× O -
106 O +
cells O -
) O +
were O +
incubated O +
with O +
tumor B-Gene +
necrosis I-Gene +
factor I-Gene +
α I-Gene +
( O -
TNFα B-Gene -
) O +
( O -
10–20 O +
ng O -
/ O -
ml O -
) O -
. O +

For O +
determination O +
of O +
PGE2 O +
synthesis O -
, O +
aliquots O +
were O +
removed O +
from O +
the O +
culture O +
medium O +
( O -
1 O +
ml O -
) O +
of O +
3 O -
× O -
105 O +
MC3T3-E1 O +
cells O -
, O +
and O +
subjected O +
to O +
radioimmunoassay O +
for O +
PGE2 O +
as O +
described O +
previously O +
[ O -
5 O -
] O +
. O +

For O +
catalytic O +
activity O +
assay O -
, O +
the O +
cells O +
were O +
scraped O +
from O +
the O +
dishes O -
, O +
suspended O +
in O +
200 O +
μl O +
of O +
20 O +
mM O +
Tris O -
– O -
HCl O +
( O -
pH O +
7.4 O -
) O +
containing O +
5 O +
mM O +
tryptophan O -
, O +
and O +
subjected O +
to O +
sonication O -
. O +

Aliquots O +
( O -
1–30 O +
μl O -
) O +
of O +
the O +
sonicate O +
were O +
incubated O +
with O +
10 O +
μM O +
[ O -
1 O -
- O -
14 O +
C O -
] O -
arachidonic O +
acid O +
( O -
2.1 O +
GBq O -
/ O -
mmol O -
, O +
Amersham O +
Pharmacia O +
Biotech O -
, O +
Bucks O -
, O +
UK O -
) O +
for O +
2 O +
min O +
at O +
24 O -
° O -
C O +
in O +
a O +
100-μl O +
mixture O +
containing O +
100 O +
mM O +
Tris O -
– O -
HCl O +
( O -
pH O +
8.0 O -
) O -
, O +
2 O +
μM O +
hematin O -
, O +
and O +
5 O +
mM O +
tryptophan O -
. O +

The O +
reaction O +
products O +
were O +
separated O +
by O +
thin O -
- O -
layer O +
chromatography O +
as O +
described O +
previously O +
[ O -
9 O -
] O +
. O +

Total O +
RNA O +
was O +
extracted O +
from O +
MC3T3-E1 O +
cells O +
using O +
ISOGEN O +
( O -
Nippon O +
Gene O -
, O +
Tokyo O -
, O +
Japan O -
) O +
and O +
subjected O +
to O +
Northern O +
blot O +
analysis O +
for O +
cyclooxygenase-2 B-Gene +
and O +
β B-Gene -
- I-Gene -
actin I-Gene +
mRNA O +
as O +
described O +
previously O +
[ O -
8 O -
] O +
. O +

2.4 O +
Reporter O +
gene O +
assay O +
A O +
DNA O +
fragment O +
( O -
nucleotides O +
−815 O +
to O +
+ O -
123 O -
) O +
was O +
prepared O +
from O +
the O +
5′-flanking O +
region O +
of O +
the O +
mouse O +
cyclooxygenase-2 B-Gene +
gene O +
as O +
described O +
previously O +
[ O -
9 O -
] O +
, O +
and O +
was O +
inserted O +
into O +
the O +
luciferase B-Gene +
plasmid O +
pGL3 O +
Basic O +
( O -
Promega O -
, O +
Madison O -
, O +
WI O -
, O +
USA O -
) O -
. O +

The O +
complementary O +
oligonucleotide O +
with O +
a O +
specific O +
sequence O +
of O +
glucocorticoid O +
response O +
element O +
( O -
5′-AGAGGATCTGTACA O +
GGATGTTCT O +
AGAT-3′ O -
; O +
consensus O +
sequence O +
of O +
the O +
glucocorticoid O +
response O +
element O +
is O +
underlined O -
) O +
was O +
synthesized O +
essentially O +
by O +
the O +
same O +
method O +
as O +
described O +
previously O +
[ O -
9 O -
] O +
. O +

The O +
oligonucleotide O +
of O +
the O +
glucocorticoid O +
response O +
element O -
, O +
NFκB B-Gene +
response O +
element O +
[ O -
9 O -
] O +
or O +
NF B-Gene -
- I-Gene -
IL6 I-Gene +
response O +
element O +
[ O -
9 O -
] O +
was O +
inserted O +
in O +
front O +
of O +
the O +
herpes O +
simplex O +
virus O +
thymidine B-Gene +
kinase I-Gene +
gene O +
[ O -
13 O -
] O +
of O +
the O +
tk O -
- O -
pGL3 O +
vector O +
[ O -
14 O -
] O +
. O +

For O +
the O +
transfection O +
of O +
luciferase B-Gene +
plasmid O -
, O +
7.8 O -
× O -
105 O +
confluent O +
cells O +
were O +
treated O +
with O +
pGL3 O +
plasmid O +
DNA O +
( O -
3 O +
μg O -
) O -
, O +
standard O +
β B-Gene -
- I-Gene -
galactosidase I-Gene +
DNA O +
( O -
1.5 O +
μg O -
) O -
, O +
and O +
13.5 O +
μl O +
of O +
Trans O +
IT O -
™ O -
-LT1 O +
( O -
Takara O -
, O +
Tokyo O -
, O +
Japan O -
) O +
in O +
2.3 O +
ml O +
of O +
serum O -
- O -
free O +
α O -
- O -
MEM O +
for O +
4 O +
h O +
at O +
37 O -
° O -
C O -
. O +

After O +
transfection O +
the O +
medium O +
was O +
changed O +
to O +
5 O +
ml O +
of O +
α O -
- O -
MEM O +
with O +
10 O -
% O +
fetal O +
bovine O +
serum O +
( O -
Life O +
Technologies O -
, O +
Gaithersburg O -
, O +
MD O -
, O +
USA O -
) O -
, O +
and O +
the O +
transfected O +
cells O +
were O +
further O +
incubated O +
for O +
3 O +
days O -
. O +

The O +
medium O +
was O +
changed O +
to O +
α O -
- O -
MEM O +
described O +
above O -
. O +

After O +
12 O +
h O +
the O +
cells O +
were O +
scraped O +
from O +
the O +
dishes O -
, O +
and O +
the O +
luciferase B-Gene +
assay O +
was O +
performed O +
as O +
described O +
previously O +
[ O -
9 O -
] O +
. O +

The O +
results O +
were O +
normalized O +
with O +
β B-Gene -
- I-Gene -
galactosidase I-Gene +
activity O -
. O +

3 O +
Results O +
We O +
investigated O +
the O +
possibility O +
that O +
humulon O +
suppressed O +
the O +
TNFα B-Gene -
- O -
mediated O +
induction O +
of O +
cyclooxygenase-2 B-Gene -
. O +

When O +
MC3T3-E1 O +
cells O +
were O +
incubated O +
with O +
10 O +
ng O -
/ O -
ml O +
TNFα B-Gene +
in O +
the O +
presence O +
of O +
humulon O +
for O +
12 O +
h O -
, O +
the O +
amount O +
of O +
released O +
PGE2 O +
decreased O +
depending O +
on O +
the O +
concentration O +
of O +
humulon O +
with O +
an O +
IC50 O +
of O +
about O +
30 O +
nM O +
( O -
Fig. O +
2A O +
) O -
. O +

As O +
shown O +
in O +
Fig. O +
2C O +
, O +
the O +
cyclooxygenase B-Gene +
activity O +
of O +
the O +
TNFα B-Gene -
- O -
treated O +
cells O +
was O +
reduced O +
by O +
humulon O +
dose O -
- O -
dependently O -
. O +

Furthermore O -
, O +
Northern O +
blot O +
analysis O +
showed O +
that O +
the O +
addition O +
of O +
humulon O +
suppressed O +
the O +
TNFα B-Gene -
- O -
induced O +
increase O +
of O +
cyclooxygenase-2 B-Gene +
mRNA O +
( O -
Fig. O +
2E O +
) O -
. O +

For O +
analysis O +
of O +
the O +
promoter O +
activity O -
, O +
a O +
luciferase B-Gene +
vector O +
of O +
cyclooxygenase-2 B-Gene +
gene O +
was O +
constructed O -
, O +
and O +
transfected O +
to O +
MC3T3-E1 O +
cells O +
by O +
the O +
lipofection O +
method O -
. O +

The O +
luciferase B-Gene +
activity O +
of O +
the O +
cell O +
lysate O +
was O +
measured O +
12 O +
h O +
after O +
the O +
addition O +
of O +
10 O +
ng O -
/ O -
ml O +
TNFα B-Gene +
in O +
the O +
presence O +
of O +
various O +
concentrations O +
of O +
humulon O +
( O -
Fig. O +
2 O -
G O +
) O -
. O +

Since O +
the O +
same O +
range O +
of O +
humulon O +
concentration O +
was O +
required O +
for O +
the O +
decrease O +
in O +
the O +
PGE2 O +
release O -
, O +
enzyme O +
activity O -
, O +
mRNA O +
level O +
and O +
promoter O +
activity O -
, O +
we O +
presumed O +
that O +
the O +
induction O +
of O +
cyclooxygenase-2 B-Gene +
by O +
TNFα B-Gene +
was O +
inhibited O +
at O +
the O +
step O +
of O +
transcription O -
. O +

Then O -
, O +
we O +
examined O +
whether O +
or O +
not O +
humulon O +
inhibited O +
the O +
catalytic O +
activities O +
of O +
cyclooxygenases-1 B-Gene +
and O +
-2 B-Gene -
. O +

As O +
shown O +
in O +
Fig. O +
3 O +
, O +
the O +
cyclooxygenase-1 B-Gene +
activity O +
was O +
hardly O +
affected O +
by O +
humulon O +
below O +
10 O +
μM O -
, O +
whereas O +
the O +
cyclooxygenase-2 B-Gene +
activity O +
was O +
inhibited O +
with O +
an O +
IC50 O +
value O +
of O +
about O +
1.6 O +
μM. O +
Thus O -
, O +
the O +
catalytic O +
activity O +
of O +
cyclooxygenase-2 B-Gene +
was O +
inhibited O +
by O +
humulon O -
, O +
but O +
its O +
IC50 O +
was O +
higher O +
by O +
about O +
two O +
orders O +
of O +
magnitude O +
than O +
the O +
IC50 O +
of O +
the O +
cyclooxygenase-2 B-Gene +
suppression O -
. O +

As O +
reported O +
preliminarily O +
earlier O +
[ O -
15 O -
] O +
, O +
the O +
TNFα B-Gene -
- O -
dependent O +
cyclooxygenase-2 B-Gene +
induction O +
in O +
MC3T3-E1 O +
cells O +
was O +
suppressed O +
by O +
dexamethasone O +
which O +
is O +
well O +
known O +
as O +
a O +
potent O +
anti O -
- O -
inflammatory O +
drug O +
and O +
a O +
suppressor O +
of O +
cyclooxygenase-2 B-Gene +
induction O +
in O +
most O +
cells O +
[ O -
1,2 O -
] O +
. O +

We O +
investigated O +
the O +
effect O +
of O +
dexamethasone O +
in O +
MC3T3-E1 O +
cells O -
. O +

When O +
the O +
cells O +
were O +
incubated O +
with O +
20 O +
ng O -
/ O -
ml O +
TNFα B-Gene +
for O +
12 O +
h O -
, O +
the O +
amount O +
of O +
released O +
PGE2 O +
( O -
Fig. O +
2B O +
) O +
and O +
the O +
cyclooxygenase-2 B-Gene +
activity O +
( O -
Fig. O +
2D O +
) O +
decreased O +
depending O +
on O +
the O +
concentration O +
of O +
added O +
dexamethasone O +
( O -
IC50 O +
: O +
1 O +
nM O -
) O -
. O +

As O +
shown O +
in O +
Fig. O +
2F O +
, O +
the O +
cyclooxygenase-2 B-Gene +
mRNA O +
level O +
was O +
also O +
decreased O +
in O +
the O +
presence O +
of O +
dexamethasone O -
. O +

The O +
TNFα B-Gene -
- O -
dependent O +
luciferase B-Gene +
activity O +
was O +
also O +
decreased O +
by O +
dexamethasone O +
with O +
an O +
IC50 O +
of O +
about O +
1 O +
nM O +
( O -
Fig. O +
2H O +
) O -
. O +

These O +
data O +
indicated O +
that O +
dexamethasone O +
suppressed O +
the O +
cyclooxygenase-2 B-Gene +
induction O +
by O +
reducing O +
its O +
mRNA O +
level O +
in O +
MC3T3-E1 O +
cells O -
. O +

Our O +
previous O +
work O +
with O +
MC3T3-E1 O +
cells O +
demonstrated O +
the O +
involvement O +
of O +
NFκB O +
and O +
NF B-Gene -
- I-Gene -
IL6 I-Gene +
as O +
transcription O +
factors O +
in O +
the O +
cyclooxygenase-2 B-Gene +
induction O +
by O +
TNFα B-Gene +
[ O -
9 O -
] O +
. O +

We O +
investigated O +
whether O +
or O +
not O +
humulon O +
and O +
dexamethasone O +
functioned O +
with O +
the O +
aid O +
of O +
NFκB B-Gene +
( O -
nucleotides O +
−401 O +
to O +
−393 O -
) O +
and O +
NF B-Gene -
- I-Gene -
IL6 I-Gene +
( O -
nucleotides O +
−138 O +
to O +
−130 O -
) O +
response O +
elements O -
. O +

As O +
shown O +
in O +
Fig. O +
4 O +
, O +
we O +
constructed O +
a O +
luciferase B-Gene +
vector O +
containing O +
thymidine B-Gene +
kinase I-Gene +
gene O +
and O +
NFκB B-Gene +
or O +
NF B-Gene -
- I-Gene -
IL6 I-Gene +
response O +
element O -
. O +

Each O +
vector O +
was O +
transfected O +
to O +
MC3T3-E1 O +
cells O -
, O +
and O +
the O +
luciferase B-Gene +
activity O +
was O +
measured O -
. O +

Both O +
humulon O +
and O +
dexamethasone O +
decreased O +
the O +
luciferase B-Gene +
activity O +
induced O +
by O +
TNFα B-Gene -
. O +

Thus O -
, O +
the O +
suppressive O +
effect O +
of O +
humulon O +
and O +
dexamethasone O +
on O +
the O +
cyclooxygenase-2 B-Gene +
induction O +
was O +
attributable O +
presumably O +
to O +
NFκB B-Gene +
or O +
NF B-Gene -
- I-Gene -
IL6 I-Gene +
or O +
both O -
. O +

To O +
investigate O +
whether O +
or O +
not O +
humulon O +
bound O +
to O +
glucocorticoid B-Gene +
receptor I-Gene -
, O +
we O +
used O +
RU486 O +
as O +
a O +
glucocorticoid B-Gene +
receptor I-Gene +
antagonist O +
[ O -
16 O -
] O +
. O +

The O +
TNFα B-Gene -
- O -
dependent O +
PGE2 O +
production O +
decreased O +
by O +
dexamethasone O +
was O +
reversed O +
by O +
RU486 O +
dose O -
- O -
dependently O +
( O -
Fig. O +
5A O +
) O -
. O +

However O -
, O +
the O +
decreased O +
PGE2 O +
production O +
by O +
humulon O +
was O +
not O +
affected O +
by O +
RU486 O +
( O -
Fig. O +
5A O +
) O -
. O +

Then O -
, O +
we O +
constructed O +
a O +
luciferase B-Gene +
vector O +
containing O +
thymidine B-Gene +
kinase I-Gene +
gene O +
and O +
glucocorticoid O +
response O +
element O +
( O -
Fig. O +
5B O +
) O -
. O +

The O +
vector O +
was O +
transfected O +
to O +
MC3T3-E1 O +
cells O -
, O +
and O +
the O +
luciferase B-Gene +
activity O +
of O +
the O +
cell O +
lysate O +
was O +
measured O +
12 O +
h O +
after O +
the O +
addition O +
of O +
TNFα B-Gene +
plus O +
dexamethasone O +
or O +
humulon O -
. O +

As O +
shown O +
in O +
Fig. O +
5B O +
, O +
the O +
addition O +
of O +
dexamethasone O +
increased O +
luciferase B-Gene +
activity O +
of O +
MC3T3-E1 O +
cells O +
by O +
16–18 O +
fold O -
. O +

Therefore O -
, O +
dexamethasone O +
bound O +
to O +
the O +
glucocorticoid B-Gene +
receptor I-Gene +
and O +
then O +
to O +
the O +
glucocorticoid O +
response O +
element O -
. O +

In O +
contrast O -
, O +
when O +
the O +
transfected O +
cells O +
were O +
incubated O +
with O +
humulon O -
, O +
the O +
luciferase B-Gene +
activity O +
was O +
not O +
increased O -
. O +

These O +
data O +
suggested O +
that O +
the O +
humulon O -
- O -
dependent O +
suppression O +
of O +
cyclooxygenase-2 B-Gene +
induction O +
was O +
not O +
mediated O +
by O +
glucocorticoid B-Gene +
receptor I-Gene -
. O +

4 O +
Discussion O +
As O +
for O +
the O +
inhibitors O +
of O +
cyclooxygenase B-Gene +
induction O +
other O +
than O +
glucocorticoid O -
, O +
a O +
recent O +
paper O +
reported O +
a O +
cyclooxygenase-2 B-Gene +
transcription O +
in O +
phorbol O +
ester O -
- O -
treated O +
human O +
epithelial O +
cells O +
inhibited O +
by O +
resveratrol O -
, O +
which O +
is O +
a O +
phytoalexin O +
found O +
in O +
grapes O +
and O +
other O +
foods O +
[ O -
17 O -
] O +
. O +

The O +
compound O +
reduced O +
both O +
the O +
enzyme B-Gene +
activity O +
and O +
the O +
gene O +
transcription O +
at O +
a O +
concentration O +
in O +
the O +
order O +
of O +
10 O +
μM. O +
Resveratrol O +
also O +
blocked O +
cyclooxygenase-2 B-Gene +
activation O +
by O +
protein B-Gene +
kinase I-Gene +
C I-Gene -
- I-Gene -
α I-Gene -
, O +
ERK1 B-Gene -
, O +
and O +
c B-Gene -
- I-Gene -
Jun I-Gene +
[ O -
17 O -
] O +
. O +

In O +
addition O -
, O +
sodium O +
salicylate O +
and O +
aspirin O +
at O +
pharmacological O +
concentrations O +
( O -
0.1–100 O +
μM O -
) O +
inhibited O +
cyclooxygenase-2 B-Gene +
transcription O +
induced O +
by O +
phorbol O +
ester O -
, O +
interleukin-1β B-Gene -
, O +
and O +
lipopolysaccharide O +
( O -
LPS O -
) O +
[ O -
18 O -
] O +
. O +

It O +
is O +
established O +
that O +
glucocorticoid O +
binds O +
to O +
its O +
intracellular O +
receptor B-Gene +
migrating O +
into O +
nucleus O +
and O +
the O +
steroid O -
- O -
receptor B-Gene +
complex O +
binds O +
to O +
a O +
glucocorticoid O +
response O +
element O +
of O +
the O +
promoter O +
region O +
of O +
target O +
gene O +
[ O -
19 O -
] O +
. O +

Inoue O +
and O +
others O +
reported O +
that O +
the O +
activation O +
of O +
the O +
cyclooxygenase-2 B-Gene +
gene O +
promoter O +
by O +
LPS O +
was O +
suppressed O +
by O +
glucocorticoid O -
, O +
and O +
the O +
suppression O +
was O +
enhanced O +
by O +
transfection O +
of O +
the O +
glucocorticoid B-Gene +
receptor I-Gene +
cDNA O +
to O +
vascular O +
endothelial O +
cells O +
[ O -
20 O -
] O +
. O +

However O -
, O +
there O +
is O +
no O +
typical O +
sequence O +
for O +
glucocorticoid O +
response O +
element O +
within O +
1.2 O +
kb O +
upstream O +
in O +
cyclooxygenase-2 B-Gene +
gene O +
promoter O +
[ O -
1,2 O -
] O +
. O +

One O +
of O +
the O +
two O +
NFκB B-Gene +
sites O +
( O -
nucleotides O +
–223 O +
to O +
–214 O -
) O +
was O +
involved O +
in O +
both O +
the O +
LPS O -
- O -
induced O +
human B-Gene +
cyclooxygenase-2 I-Gene +
gene O +
expression O +
in O +
U937 O +
cells O +
and O +
its O +
suppression O +
by O +
dexamethasone O +
and O +
herbimycin O +
A O +
[ O -
21 O -
] O +
. O +

In O +
conclusion O -
, O +
our O +
results O +
demonstrated O +
that O +
humulon O +
has O +
a O +
glucocorticoid O -
- O -
like O +
suppression O +
activity O +
in O +
TNFα B-Gene -
- O -
induced O +
cyclooxygenase-2 B-Gene +
transcription O +
and O +
its O +
signal O +
transduction O +
may O +
be O +
independent O +
from O +
glucocorticoid B-Gene +
receptor I-Gene -
. O +

However O -
, O +
these O +
results O +
required O +
further O +
investigations O +
of O +
a O +
detailed O +
molecular O +
mechanism O +
and O +
of O +
in O +
vivo O +
anti O -
- O -
inflammatory O +
action O +
of O +
humulon O -
. O +

Acknowledgements O +

We O +
thank O +
Dr. O +
H. O +
Kondoh O +
of O +
Osaka O +
University O +
for O +
providing O +
the O +
herpes O +
simplex O +
virus O +
thymidine B-Gene +
kinase I-Gene +
gene O -
; O +
Dr. O +
Y. O +
Taketani O +
of O +
the O +
University O +
of O +
Tokushima O +
for O +
providing O +
tk O -
- O -
pGL3 O +
vector O -
; O +
and O +
Mr. O +
H. O +
Kurobe O +
for O +
technical O +
assistance O -
. O +

This O +
work O +
was O +
supported O +
by O +
grants O -
- O -
in O -
- O -
aid O +
for O +
scientific O +
research O +
from O +
the O +
Ministry O +
of O +
Education O -
, O +
Science O -
, O +
Sports O +
and O +
Culture O +
of O +
Japan O -
, O +
the O +
Japanese O +
Foundation O +
of O +
Metabolism O +
and O +
Disease O -
, O +
and O +
the O +
Japan O +
Foundation O +
for O +
Applied O +
Enzymology O -
. O +

Butea O +
monosperma O +
( O -
Fabaceae O -
) O +
is O +
a O +
medium O +
sized O +
tree O +
native O +
of O +
the O +
mountainous O +
regions O +
of O +
India O +
and O +
Burma O +
and O +
now O +
grows O +
wild O +
throughout O +
India O +
( O -
Anonymous O -
, O +
1988 O +
) O -
. O +

The O +
bark O +
is O +
reported O +
to O +
possess O +
antitumour O +
and O +
antiulcer O +
properties O +
( O -
Anonymous O -
, O +
1988 O +
) O -
, O +
while O +
stem O +
bark O +
possess O +
antifungal O +
activity O +
( O -
Bandara O +
et O +
al. O -
, O +
1989 O -
; O +
1990 O +
) O -
. O +

The O +
root O +
bark O +
is O +
used O +
as O +
an O +
aphrodisiac O -
, O +
analgesic O +
and O +
anthelmintic O +
( O -
Anonymous O -
, O +
1988 O +
) O -
, O +
whereas O +
the O +
leaves O +
possess O +
antimicrobial O +
property O +
( O -
Zaffar O +
et O +
al. O -
, O +
1989 O +
) O -
. O +

The O +
flowers O +
are O +
used O +
for O +
the O +
treatment O +
of O +
liver O +
disorders O +
( O -
Wagner O +
et O +
al. O -
, O +
1986 O +
) O +
and O +
the O +
seeds O +
as O +
anthelmintic O +
( O -
Lal O +
et O +
al. O -
, O +
1978 O +
) O -
. O +

Flavonoids O +
from O +
flowers O +
( O -
Gupta O +
et O +
al. O -
, O +
1970 O +
) O -
, O +
stem O +
bark O +
( O -
Bandara O +
et O +
al. O -
, O +
1990 O +
) O +
and O +
nitrogenous O +
compounds O +
from O +
the O +
seeds O +
( O -
Guha O +
et O +
al. O -
, O +
1990 O -
; O +
Mehta O +
and O +
Bokadia O -
, O +
1981 O +
) O +
have O +
been O +
reported O +
earlier O -
. O +

During O +
the O +
course O +
of O +
investigation O +
on O +
the O +
yellow O +
dye O +
from O +
the O +
flowers O -
, O +
it O +
was O +
of O +
interest O +
to O +
work O +
on O +
the O +
stems O +
as O +
relatively O +
few O +
compounds O +
have O +
been O +
reported O +
from O +
it O -
. O +

This O +
report O +
describes O +
the O +
characterisation O +
of O +
a O +
new O +
euphane O +
and O +
a O +
new O +
lipid O +
derivative O -
. O +

2 O +
Results O +
and O +
discussion O +
Compounds O +
1–5 O +
were O +
isolated O +
from O +
the O +
stems O +
of O +
B. O +
monosperma O +
. O +

Compound O +
1 O +
was O +
obtained O +
as O +
colourless O +
needles O -
. O +

Its O +
IR O +
spectrum O +
bands O +
corresponded O +
to O +
OH O +
( O -
3480 O +
cm−1 O +
) O -
, O +
terminal O +
unsaturated O +
CH2 O +
( O -
1610 O -
, O +
880 O +
cm−1 O +
) O +
and O +
gem O +
dimethyl O +
( O -
1380 O -
, O +
1360 O +
cm−1 O +
) O +
functions O -
. O +

An O +
[ O -
M O -
] O -
+ O +
at O +
m O -
/ O -
z O +
428 O +
suggested O +
the O +
molecular O +
formula O +
as O +
C30 O +
H52 O +
O. O +
Its O +
1 O +
H O +
NMR O +
spectrum O +
exhibited O +
signals O +
due O +
to O +
five O +
quaternary O +
methyls O +
( O -
δ O +
0.79 O -
, O +
0.83 O -
, O +
0.94 O -
, O +
0.96 O -
, O +
1.04 O -
) O -
, O +
a O +
vinylic O +
methyl O +
( O -
δ O +
1.62 O -
) O -
, O +
and O +
a O +
secondary O +
methyl O +
( O -
δ O +
1.08 O -
) O +
indicative O +
of O +
a O +
tetracyclic O +
triterpene O +
skeleton O +
( O -
Hemmert O +
et O +
al. O -
, O +
1966 O +
) O -
. O +

Two O +
broad O +
singlets O +
at O +
δ O +
4.56 O +
and O +
4.68 O -
, O +
each O +
integrating O +
for O +
one O +
proton O -
, O +
corresponded O +
to O +
the O +
methine O +
protons O +
of O +
an O +
olefinic O +
methylene O +
group O +
( O -
Jagodzinska O +
et O +
al. O -
, O +
1985 O +
) O +
which O +
in O +
conjunction O +
with O +
a O +
broad O +
singlet O +
at O +
δ O +
1.62 O +
suggested O +
the O +
existence O +
of O +
a O +
isopropylidene O +
group O -
. O +

This O +
was O +
also O +
substantiated O +
by O +
the O +
appearance O +
of O +
signals O +
at O +
δ O +
151.0 O +
and O +
109.30 O +
in O +
the O +
13 O +
C O +
NMR O +
spectrum O +
for O +
> O -
CCH2 O +
grouping O +
( O -
Schneider O +
and O +
Agrawal O -
, O +
1984 O +
) O -
. O +

A O +
multiplet O +
at O +
δ O +
3.34 O +
( O -
W O +
1 O -
/ O -
2 O +
= O -
7 O +
Hz O -
) O +
was O +
assigned O +
to O +
a O +
methine O +
proton O +
with O +
an O +
axially O +
oriented O +
C-3 O +
OH O +
group O +
( O -
Jolad O +
et O +
al. O -
, O +
1981 O -
; O +
Nakanishi O +
et O +
al. O -
, O +
1986 O +
) O -
. O +

There O +
is O +
a O +
remarkable O +
similarity O +
in O +
the O +
13 O +
C O +
NMR O +
chemical O +
shifts O +
of O +
euphenol O +
and O +
lanosterol O +
except O +
for O +
those O +
of O +
C-12 O -
, O +
C-15 O -
, O +
C-16 O +
and O +
C-19 O +
( O -
Knight O -
, O +
1974 O +
) O -
. O +

This O +
excludes O +
1 O +
to O +
be O +
included O +
under O +
lanosterol O +
series O -
. O +

Such O +
difference O +
is O +
also O +
seen O +
in O +
euphane O +
and O +
tirucallane O +
triterpenoids O +
( O -
Jolad O +
et O +
al. O -
, O +
1981 O -
; O +
Bhakuni O +
et O +
al. O -
, O +
1987 O -
; O +
Singh O +
et O +
al. O -
, O +
1989 O +
) O -
. O +

The O +
chemical O +
shift O +
range O +
of O +
the O +
methyl O +
protons O +
except O +
for O +
vinylic O +
CH3 O +
suggested O +
a O +
euphane O +
or O +
tirucallane O +
skeleton O +
( O -
differing O +
C-20 O +
stereochemistry O -
) O +
in O +
1 O +
, O +
and O +
a O +
( O -
+ O -
) O +
optical O +
rotation O +
37.8 O -
° O +
of O +
1 O +
indicated O +
that O +
it O +
belonged O +
to O +
euphane O +
rather O +
than O +
tirucallane O +
series O +
( O -
Itoh O +
et O +
al. O -
, O +
1976 O +
) O -
. O +

In O +
the O +
MS O +
of O +
1 O +
, O +
the O +
loss O +
of O +
CH3 O +
and O +
H2 O +
O O +
from O +
[ O -
M O -
] O -
+ O +
was O +
seen O +
at O +
m O -
/ O -
z O +
413 O +
and O +
410 O -
. O +

The O +
formation O +
of O +
a O +
fragment O +
ion O +
at O +
m O -
/ O -
z O +
316 O +
[ O -
M O -
- O -
side O +
chain O +
( O -
C8 O +
H15 O +
) O -
–H O -
] O -
+ O +
suggested O +
the O +
presence O +
of O +
a O +
monounsaturated O +
side O +
chain O +
( O -
Wyllie O +
and O +
Djerassi O -
, O +
1968 O +
) O +
and O +
the O +
existence O +
of O +
OH O +
group O +
in O +
the O +
tetracyclic O +
system O -
. O +

Compound O +
1 O +
on O +
treatment O +
with O +
Ac2 O +
O O -
/ O -
pyridine O +
afforded O +
an O +
acetate O +
( O -
1a O +
) O -
, O +
C32 O +
H54 O +
O2 O +
, O +
whose O +
1 O +
H O +
NMR O +
spectrum O +
was O +
similar O +
to O +
1 O +
except O +
for O +
the O +
appearance O +
of O +
a O +
new O +
signal O +
at O +
δ O +
2.04 O +
and O +
downfield O +
shifted O +
C-3 O +
methine O +
by O +
1.11 O +
ppm O -
. O +

In O +
the O +
13 O +
C O +
NMR O +
spectrum O +
of O +
1 O +
, O +
the O +
appearance O +
of O +
C-18 O -
, O +
C-20 O +
and O +
C-21 O +
at O +
15.4 O -
, O +
35.6 O +
and O +
19.3 O +
also O +
established O +
the O +
euphane O +
skeleton O +
( O -
Wehrli O +
and O +
Nishida O -
, O +
1979 O -
; O +
Knight O -
, O +
1974 O +
) O -
. O +

The O +
13 O +
C O +
NMR O +
spectral O +
data O +
of O +
1 O +
( O -
Table O +
1 O +
) O +
were O +
analysed O +
by O +
analogy O +
with O +
the O +
reported O +
values O +
for O +
euphane O +
and O +
other O +
related O +
triterpenoids O +
( O -
Wehrli O +
et O +
al. O -
, O +
1979 O -
; O +
Knight O -
, O +
1974 O -
; O +
Singh O +
et O +
al. O -
, O +
1989 O +
) O -
. O +

These O +
data O +
led O +
to O +
characterise O +
1 O +
as O +
3α O -
- O -
hydroxyeuph-25-ene O -
. O +

Compound O +
4 O +
showed O +
IR O +
bands O +
at O +
3438 O +
( O -
OH O -
) O -
, O +
1730 O +
( O -
CO O -
) O -
, O +
1670 O +
( O -
tetrasubstituted O -
) O +
( O -
Nakanishi O +
and O +
Solomon O -
, O +
1977 O +
) O -
, O +
1386 O +
( O -
Me O -
) O +
and O +
720 O +
cm−1 O +
( O -
straight O +
chain O -
) O -
. O +

It O +
was O +
assigned O +
the O +
molecular O +
formula O +
C26 O +
H48 O +
O3 O +
( O +
[ O -
M O -
] O -
+ O +
= O +
408 O +
and O +
elemental O +
analysis O -
) O -
. O +

Successive O +
loss O +
of O +
two O +
H2 O +
O O +
molecules O +
was O +
seen O +
at O +
m O -
/ O -
z O +
390 O +
and O +
372 O -
, O +
whereas O +
the O +
location O +
of O +
these O +
OH O +
groups O +
was O +
assigned O +
at O +
C-2 O +
and O +
C-14 O +
since O +
significant O +
α O -
- O -
fission O +
ions O +
were O +
appeared O +
at O +
m O -
/ O -
z O +
311 O -
, O +
281 O -
, O +
127 O -
, O +
97 O +
and O +
351 O -
, O +
321 O -
, O +
87 O -
, O +
57 O -
, O +
respectively O -
. O +

The O +
other O +
diagnostic O +
α O -
- O -
fission O +
ions O +
at O +
m O -
/ O -
z O +
225 O -
, O +
211 O -
, O +
197 O -
, O +
183 O +
together O +
with O +
ß O -
- O -
fission O +
ions O +
involving O +
McLafferty O +
rearrangement O +
( O -
Budzikiewicz O +
et O +
al. O -
, O +
1964 O +
) O +
at O +
m O -
/ O -
z O +
226 O +
and O +
182 O +
located O +
the O +
keto O +
group O +
at O +
C-8 O -
. O +

The O +
abundant O +
ions O +
at O +
m O -
/ O -
z O +
83 O +
and O +
325 O +
indicated O +
the O +
presence O +
of O +
a O +
cyclohexyl O +
moiety O +
at O +
the O +
end O +
carbon O +
atom O +
( O -
Bhakuni O +
and O +
Shukla O -
, O +
1992 O +
) O -
. O +

The O +
tetrasubstituted O +
double O +
bond O +
along O +
with O +
the O +
two O +
methyl O +
groups O +
were O +
assigned O +
at O +
C-11,12 O +
since O +
significant O +
ions O +
were O +
seen O +
at O +
m O -
/ O -
z O +
307 O -
, O +
253 O -
, O +
155 O +
and O +
101 O -
. O +

These O +
data O +
suggested O +
the O +
structure O +
of O +
4 O +
as O +
2,14-dihydroxy-11,12-dimethyl-8-oxooctadec-11-enylcyclohexane O +
which O +
was O +
also O +
in O +
full O +
accord O +
with O +
its O +
1 O +
H O +
NMR O +
( O -
see O +
Section O +
3 O +
) O -
. O +

Compounds O +
2 O +
, O +
3 O +
and O +
5 O +
were O +
identified O +
as O +
nonacosanoic O +
acid O -
, O +
stigmasterol O +
and O +
stigmasterol O -
- O -
ßD O +
-glucopyranoside O -
, O +
respectively O -
, O +
by O +
comparison O +
with O +
authentic O +
samples O -
. O +

The O +
straight O +
chain O +
alcohols O +
having O +
a O +
cyclohexane O +
moiety O +
are O +
not O +
commonly O +
found O +
in O +
nature O -
. O +

3 O +
Experimental O +
3.1 O +
General O +
Mps O -
: O +
uncorrected O -
; O +
IR O -
: O +
KBr O -
; O +
1 O +
H O +
NMR O -
: O +
Bruker O +
( O -
200 O +
MHz O -
) O +
in O +
CDCl3 O +
, O +
chemical O +
shifts O +
in O +
δ O +
( O -
ppm O -
) O +
with O +
TMS O +
as O +
internal O +
standard O -
; O +
13 O +
C O +
NMR O -
: O +
75 O +
MHz O -
, O +
CDCl3 O +
; O +
EIMS O -
: O +
70 O +
ev O -
; O +
TLC O -
: O +
silica O +
gel O +
G O -
; O +
CC O -
: O +
silica O +
gel O +
( O -
Merk O -
, O +
60–120 O +
mesh O -
) O -
. O +

Spots O +
were O +
detected O +
by O +
exposure O +
to O +
I2 O +
vapour O -
. O +

The O +
homogeneity O +
of O +
the O +
isolates O +
was O +
checked O +
on O +
TLC O +
in O +
at O +
least O +
two O +
solvent O +
systems O -
. O +

3.2 O +
Plant O +
material O +
The O +
stems O +
of O +
B. O +
monosperma O +
were O +
collected O +
from O +
the O +
local O +
area O +
and O +
identified O +
in O +
our O +
Botany O +
Department O +
where O +
a O +
voucher O +
specimen O +
has O +
been O +
maintained O -
. O +

3.3 O +
Extraction O +
and O +
isolation O +
Dried O +
and O +
powdered O +
stems O +
( O -
2.8 O +
kg O -
) O +
were O +
extracted O +
with O +
MeOH O +
( O -
5 O -
× O -
11 O +
l O -
) O +
and O +
the O +
combined O +
extract O +
concentrated O +
to O +
500 O +
ml O -
. O +

After O +
the O +
addition O +
of O +
water O +
( O -
500 O +
ml O -
) O -
, O +
the O +
extract O +
was O +
fractionated O +
with O +
n O +
-hexane O +
( O -
5 O -
× O -
200 O +
ml O -
, O +
7.33 O +
g O -
) O -
, O +
EtOAc O +
( O -
5 O -
× O -
200 O +
ml O -
, O +
13.34 O +
g O -
) O +
and O +
n O +
-BuOH O +
( O -
5 O -
× O -
200 O +
ml O -
, O +
33.2 O +
g O -
) O -
. O +

A O +
portion O +
( O -
6.1 O +
g O -
) O +
of O +
the O +
hexane O +
fraction O +
was O +
chromatographed O +
over O +
silica O +
gel O +
( O -
300 O +
g O -
) O -
, O +
eluting O +
with O +
varying O +
proportions O +
of O +
hexane O -
, O +
EtOAc O +
and O +
MeOH O +
to O +
provide O +
compounds O +
1 O +
( O -
50 O +
mg O -
) O -
, O +
2 O +
( O -
61 O +
mg O -
) O -
, O +
3 O +
( O -
68 O +
mg O -
) O -
, O +
4 O +
( O -
25 O +
mg O -
) O +
and O +
5 O +
( O -
46 O +
mg O -
) O -
. O +

The O +
fractions O +
collected O +
were O +
100 O +
ml O +
each O +
and O +
monitored O +
by O +
TLC O -
. O +

3.4 O +
3α O -
- O -
Hydroxyeuph-25-ene O +
( O -
1 O +
) O +
Removal O +
of O +
solvent O +
from O +
the O +
fractions O +
65–68 O +
of O +
hexane O -
– O -
EtOAc O +
( O -
95:5 O -
) O +
gave O +
a O +
residue O -
, O +
mp O +
180–82 O -
° O -
C O -
, O +
α O +
D O +
+ O -
37.8 O -
° O +
( O -
CHCl3 O +
) O -
. O +

IR O -
: O +
γ O +
max O +
cm−1 O +
: O +
3480 O -
, O +
2930 O -
, O +
1610 O -
, O +
1450 O -
, O +
1360 O -
, O +
1244 O -
, O +
1110 O -
, O +
1014 O -
, O +
880 O -
; O +
1 O +
H O +
NMR O -
: O +
δ O +
0.79 O +
( O -
3H O -
, O +
s O +
, O +
19-H3 O +
) O -
, O +
0.83 O +
( O -
3H O -
, O +
s O +
, O +
18-H3 O +
) O -
, O +
0.94 O +
( O -
3H O -
, O +
s O +
, O +
29-H3 O +
) O -
, O +
0.96 O +
( O -
3H O -
, O +
s O +
, O +
28-H3 O +
) O -
, O +
1.04 O +
( O -
3H O -
, O +
s O +
, O +
30-H3 O +
) O -
, O +
1.08 O +
( O -
3H O -
, O +
d O +
, O +
J O +
= O -
6 O +
Hz O -
, O +
21-H3 O +
) O -
, O +
1.62 O -
( O -
3H O -
, O +
s O +
, O +
27-H3 O +
) O -
, O +
1.90 O +
( O -
1H O -
, O +
m O +
, O +
20-H O -
) O -
, O +
2.36 O +
( O -
2H O -
, O +
m O +
, O +
24-H2 O +
) O -
, O +
3.34 O +
( O -
1H O -
, O +
m O +
, O +
W O +
1 O -
/ O -
2 O +
= O -
7 O +
Hz O -
, O +
3ß O -
- O -
H O -
) O -
, O +
4.56 O -
, O +
4.68 O -
, O +
( O -
2H O -
, O +
each O +
br O +
s O +
, O +
26-H2 O +
) O -
; O +
MS O +
m O -
/ O -
z O +
( O -
rel O -
. O +

int O -
. O -
) O -
: O +
428 O +
[ O -
M O -
] O -
+ O +
( O -
C30 O +
H52 O +
O O -
, O +
67 O -
) O -
, O +
413 O +
[ O -
M O +
− O +
Me O -
] O -
+ O +
( O -
19 O -
) O -
, O +
410 O +
[ O -
M O +
− O +
H2 O +
O O -
] O -
+ O +
( O -
5 O -
) O -
, O +
395 O +
[ O -
M O +
− O +
Me O -
– O -
H2 O +
O O -
] O -
+ O +
( O -
5 O -
) O -
, O +
387 O +
[ O -
M O +
− O +
41 O -
] O -
+ O +
( O -
6 O -
) O -
, O +
317 O +
[ O -
M O +
− O +
sc O -
] O -
+ O +
( O -
15 O -
) O -
, O +
316 O +
[ O -
M O +
− O +
sc O -
– O -
H O -
] O -
+ O +
( O -
18 O -
) O -
, O +
301 O +
[ O -
316 O +
− O +
Me O -
] O -
+ O +
( O -
5 O -
) O -
, O +
298 O +
[ O -
316 O +
− O +
H2 O +
O O -
] O -
+ O +
( O -
5 O -
) O -
, O +
286 O +
[ O -
301 O +
− O +
Me O -
] O -
+ O +
( O -
5 O -
) O -
, O +
196 O +
( O -
5 O -
) O -
, O +
194 O +
( O -
8) O -
, O +
178 O +
[ O -
196 O +
− O +
H2 O +
O O -
] O -
+ O +
( O -
18 O -
) O -
, O +
179 O +
[ O -
194 O +
− O +
Me O -
] O -
+ O +
( O -
10 O -
) O -
, O +
161 O +
( O -
12 O -
) O -
, O +
128 O +
( O -
5 O -
) O -
, O +
111 O +
( O -
20 O -
) O -
, O +
110 O +
( O -
15 O -
) O -
, O +
95 O +
( O -
100 O -
) O -
, O +
81 O +
( O -
80 O -
) O -
, O +
69 O +
( O -
75 O -
) O -
. O +

3.5 O +
Monoacetate O +
( O -
1a O +
) O +
of O +
1 O +
Compound O +
1 O +
( O -
25 O +
mg O -
) O +
was O +
acetylated O +
with O +
C5 O +
H5 O +
N O -
– O -
Ac2 O +
O O +
( O -
1 O +
ml O +
each O -
) O -
, O +
overnight O +
at O +
room O +
temperature O -
. O +

The O +
usual O +
work O -
- O -
up O +
yielded O +
1a O +
, O +
mp O +
205 O -
° O -
C O -
, O +
20 O +
mg O -
. O +

IR O +
γ O +
max O +
cm−1 O +
: O +
2940 O -
, O +
2856 O -
, O +
1738 O -
, O +
1640 O -
, O +
1460 O -
, O +
1374 O -
, O +
1245 O -
, O +
1020 O -
, O +
978 O -
, O +
880 O -
; O +
1 O +
H O +
NMR O -
: O +
δ O +
0.79 O +
( O -
3H O -
, O +
s O +
, O +
19-H3 O +
) O -
, O +
0.84 O +
( O -
3H O -
, O +
s O +
, O +
18-H3 O +
) O -
, O +
0.94 O +
( O -
3H O -
, O +
s O +
, O +
29-H3 O +
) O -
, O +
0.97 O +
( O -
3H O -
, O +
s O +
, O +
28-H3 O +
) O -
, O +
1.03 O +
( O -
3H O -
, O +
s O +
, O +
30-H3 O +
) O -
, O +
1.08 O +
( O -
3H O -
, O +
d O +
, O +
J O +
= O -
6 O +
Hz O -
, O +
21-H3 O +
) O -
, O +
1.68 O +
( O -
3H O -
, O +
s O +
, O +
27-H3 O +
) O -
, O +
1.90 O +
( O -
1H O -
, O +
m O +
, O +
20-H O -
) O -
, O +
2.04 O +
( O -
3H O -
, O +
s O +
, O +
OAc O -
) O -
, O +
2.36 O +
( O -
2H O -
, O +
m O +
, O +
24-H2 O +
) O -
, O +
4.45 O +
( O -
1H O -
, O +
m O +
, O +
W O +
1 O -
/ O -
2 O +
= O -
7 O +
Hz O -
, O +
3ßH O -
) O -
, O +
4.56 O -
, O +
4.68 O +
( O -
2H O -
, O +
each O +
br O +
s O +
, O +
26-H2 O +
) O -
; O +
MS O +
m O -
/ O -
z O +
( O -
rel O -
. O +

int O -
. O -
) O -
: O +
470 O +
[ O -
M O -
] O -
+ O +
( O -
C32 O +
H54 O +
O2 O +
, O +
11 O -
) O -
, O +
455 O +
( O -
4 O -
) O -
, O +
429 O +
( O -
5 O -
) O -
, O +
410 O +
( O -
2 O -
) O -
, O +
359 O +
( O -
5 O -
) O -
, O +
257 O +
( O -
5 O -
) O -
, O +
238 O +
( O -
5 O -
) O -
, O +
236 O +
( O -
4 O -
) O -
, O +
188 O +
( O -
100 O -
) O -
, O +
176 O +
( O -
15 O -
) O -
, O +
161 O +
( O -
17 O -
) O -
, O +
160 O +
( O -
21 O -
) O -
, O +
111 O +
( O -
20 O -
) O -
, O +
110 O +
( O -
15 O -
) O -
, O +
95 O +
( O -
60 O -
) O -
, O +
81 O +
( O -
80 O -
) O -
, O +
69 O +
( O -
40 O -
) O -
, O +
55 O +
( O -
50 O -
) O -
, O +
43 O +
( O -
98 O -
) O -
. O +

3.6 O +
Nonacosanoic O +
acid O +
( O -
2 O +
) O +
Fractions O +
71–75 O +
of O +
hexane O -
– O -
EtOAc O +
( O -
95:5 O -
) O +
eluates O +
yielded O +
a O +
residue O -
, O +
mp O +
68–70 O -
° O -
C O -
, O +
identified O +
by O +
co O -
- O -
TLC O -
, O +
MS O -
, O +
1 O +
H O +
NMR O -
. O +

3.7 O +
Stigmasterol O +
( O -
3 O +
) O +
Fractions O +
90–95 O +
of O +
hexane O -
– O -
EtOAc O +
( O -
95:5 O -
) O +
eluates O +
when O +
freed O +
of O +
the O +
solvent O +
provided O +
3 O +
, O +
mp O +
160 O -
° O -
C O -
, O +
identified O +
by O +
co O -
- O -
TLC O -
, O +
MS O -
, O +
IR O -
, O +
1 O +
H O +
NMR O -
. O +

3.8 O +
2,14-Dihydroxy-11,12-dimethyl-8-oxooctadec-11-enylcyclohexane O +
( O -
4 O +
) O +
Elimination O +
of O +
solvent O +
from O +
the O +
fractions O +
221–226 O +
of O +
hexane O -
– O -
EtOAc O +
( O -
1:1 O -
) O +
eluates O +
furnished O +
4 O +
, O +
mp O +
83–84 O -
° O -
C O -
. O +

IR O +
γ O +
max O +
cm−1 O +
: O +
3438 O -
, O +
2920 O -
, O +
2850 O -
, O +
1730 O -
, O +
1670 O -
, O +
1450 O -
, O +
1386 O -
, O +
1180 O -
, O +
1110 O -
, O +
1052 O -
, O +
720 O -
; O +
1 O +
H O +
NMR O -
: O +
δ O +
0.88 O +
( O -
3H O -
, O +
t O +
, O +
J O +
= O -
6 O +
Hz O -
, O +
18-H3 O +
) O -
, O +
1.25 O +
( O -
10H O -
, O +
br O +
s O +
, O +
5 O +
× O +
CH2 O +
) O -
, O +
1.50 O +
( O -
10H O -
, O +
br O +
s O +
, O +
cyclohexyl O +
( O -
CH2 O +
) O -
5 O +
) O -
, O +
1.64 O +
( O -
1H O -
, O +
m O +
, O +
1′ O +
-H O -
) O -
, O +
1.60 O +
( O -
6H O -
, O +
s O +
, O +
11-H3 O +
, O +
12-H3 O -
) O -
, O +
1.90 O +
( O -
4H O -
, O +
m O +
, O +
3-H2 O +
, O +
15-H2 O +
) O -
, O +
2.02 O +
( O -
2H O -
, O +
m O +
, O +
1-H2 O +
) O -
, O +
2.35 O +
( O -
4H O -
, O +
t O +
, O +
J O +
= O -
6 O +
Hz O -
, O +
7-H2 O +
, O +
9-H2 O +
) O -
, O +
2.45 O +
( O -
2H O -
, O +
t O +
, O +
J O +
= O -
6 O +
Hz O -
, O +
10-H2 O +
) O -
, O +
2.48 O +
( O -
2H O -
, O +
d O +
, O +
J O +
= O -
5 O +
Hz O -
, O +
13-H2 O +
) O -
, O +
3.64 O +
( O -
1H O -
, O +
m O +
, O +
2-H O -
) O -
, O +
3.94 O +
( O -
1H O -
, O +
m O +
, O +
14-H O -
) O -
; O +
MS O +
m O -
/ O -
z O +
( O -
rel O -
. O +

int O -
. O -
) O -
: O +
408 O +
[ O -
M O -
] O -
+ O +
( O -
C26 O +
H48 O +
O3 O +
, O +
2 O -
) O -
, O +
390 O -
[ O -
M O +
− O +
H2 O +
O O -
] O -
+ O +
( O -
7 O -
) O -
, O +
372 O +
[ O -
M O +
− O +
2H2 O +
O O -
] O -
+ O +
( O -
7 O -
) O -
, O +
393 O +
[ O -
M O +
− O +
Me O -
] O -
+ O +
( O -
3 O -
) O -
, O +
378 O +
[ O -
M O +
−2 O +
× O +
Me O -
] O -
+ O +
( O -
3 O -
) O -
, O +
351 O +
( O -
4 O -
) O -
, O +
325 O +
( O -
5 O -
) O -
, O +
321 O +
( O -
3 O -
) O -
, O +
311 O +
( O -
4 O -
) O -
, O +
307 O +
( O -
5 O -
) O -
, O +
281 O +
( O -
4 O -
) O -
, O +
253 O +
( O -
5 O -
) O -
, O +
226 O +
( O -
6 O -
) O -
, O +
225 O +
( O -
5 O -
) O -
, O +
211 O +
( O -
7 O -
) O -
, O +
197 O +
( O -
6 O -
) O -
, O +
183 O +
( O -
10 O -
) O -
, O +
182 O +
( O -
7 O -
) O -
, O +
155 O +
( O -
4 O -
) O -
, O +
127 O +
( O -
19 O -
) O -
, O +
101 O +
( O -
6 O -
) O -
, O +
97 O +
( O -
90 O -
) O -
, O +
87 O +
( O -
12 O -
) O -
, O +
83 O +
( O -
65 O -
) O -
, O +
57 O +
( O -
100 O -
) O +
( O -
Found O -
: O +
C O -
, O +
76.40 O -
; O +
H O -
, O +
11.82 O -
. O +

C26 O +
H48 O +
O3 O +
requires O -
: O +
C O -
, O +
76.47 O -
; O +
H O -
, O +
11.76 O -
% O -
) O -
. O +

3.9 O +
Stigmasterol O -
- O -
ßD O +
-glucopyranoside O +
( O -
5 O +
) O +
Removal O +
of O +
solvent O +
from O +
290–301 O +
fractions O +
of O +
MeOH O -
– O -
EtOAc O +
( O -
2:98 O -
) O +
eluates O +
gave O +
5 O +
, O +
mp O +
263–65 O -
° O -
C O -
, O +
identified O +
by O +
MS O -
, O +
1 O +
H O +
NMR O +
and O +
hydrolysis O +
products O -
. O +

Acknowledgements O +
One O +
of O +
the O +
authors O +
( O -
M. O +
Mishra O -
) O +
is O +
grateful O +
to O +
the O +
Director O -
, O +
CIMAP O +
for O +
the O +
award O +
of O +
a O +
Junior O +
Research O +
Fellowship O -
. O +

Arachidonic O +
acid O +
( O -
AA O -
) O +
is O +
metabolized O +
to O +
form O +
four O +
different O +
epoxides O +
( O -
namely O +
5,6- O -
, O +
8,9- O -
, O +
11,12- O -
, O +
14,15-EET O -
) O +
via O +
the O +
cytochrome B-Gene +
P-450 I-Gene +
monooxygenase I-Gene +
( O -
epoxygenase B-Gene -
) O +
pathway O +
[ O -
1 O -
] O +
. O +

14,15-EET O +
is O +
found O +
in O +
the O +
urine O +
[ O -
2 O -
] O +
and O +
produced O +
by O +
platelets O +
and O +
endothelial O +
cells O +
[ O -
3,4 O -
] O +
. O +

The O +
occurrence O +
of O +
14,15-EET O +
and O +
other O +
EETs O +
in O +
tissues O +
and O +
various O +
cell O +
types O +
leads O +
to O +
the O +
hypothesis O +
that O +
these O +
substances O +
may O +
be O +
stored O +
in O +
cells O +
by O +
conjugative O +
protein B-Gene +
binding O +
or O +
by O +
incorporation O +
into O +
membrane O +
phospholipids O +
( O -
PL O -
) O +
[ O -
5 O -
] O +
. O +

The O +
stored O +
form O +
of O +
EETs O +
can O +
be O +
released O +
upon O +
activation O +
of O +
specific O +
phospholipase B-Gene -
, O +
for O +
example O -
, O +
phospholipase B-Gene +
A2 I-Gene +
( O -
PLA2 B-Gene +
) O +
or O +
phospholipase B-Gene +
C I-Gene +
( O -
PLC B-Gene -
) O -
, O +
by O +
neuronal O -
, O +
hormonal O +
or O +
chemical O +
stimulation O +
[ O -
6,7 O -
] O +
. O +

Of O +
the O +
various O +
systems O +
in O +
which O -
, O +
epoxygenase B-Gene +
and O +
its O +
epoxides O +
( O -
EETs O -
) O +
have O +
studied O -
, O +
the O +
kidney O +
seems O +
to O +
be O +
a O +
major O +
organ O +
for O +
production O +
and O +
action O +
of O +
the O +
EETs O -
. O +

The O +
main O +
forms O +
of O +
EETs O +
found O +
in O +
the O +
kidney O +
and O +
in O +
urine O +
are O +
8,9- O +
and O +
14,15-EET O +
[ O -
2 O -
] O +
. O +

The O +
levels O +
of O +
EETs O +
in O +
the O +
kidney O +
seemed O +
to O +
vary O +
as O +
a O +
function O +
of O +
renal O +
pathology O +
[ O -
8–10 O -
] O +
. O +

In O +
the O +
kidney O -
, O +
certain O +
EETs O +
and O +
their O +
dihydroxyeicosatrienoic O +
acid O +
metabolites O +
( O -
diols O +
or O +
DHETs O -
) O +
have O +
prominent O +
biological O +
functions O -
, O +
such O +
as O -
: O +
inhibition O +
of O +
Na+ B-Gene +
/K+ I-Gene +
ATPase I-Gene +
[ O -
11 O -
] O +
and O +
suppression O +
of O +
vasopressin O +
( O -
AVP O -
) O +
action O +
on O +
rabbit O +
kidney O +
cortical O +
collecting O +
duct O +
( O -
CCD O -
) O +
[ O -
9 O -
] O +
. O +

With O +
our O +
previous O +
reports O +
[ O -
12,13 O -
] O +
, O +
it O +
is O +
conceivable O +
that O +
14,15-EET O +
and O +
its O +
metabolite O +
( O -
14,15-DHET O -
) O +
may O +
play O +
an O +
important O +
role O +
in O +
maintaining O +
blood O +
pressure O -
, O +
modulating O +
renal O +
function O -
, O +
and O +
regulating O +
monocyte O +
adhesion O -
. O +

In O +
other O +
systems O -
, O +
Malcolm O +
and O +
Fitzpatrick O +
reported O +
that O +
14,15-EET O +
inhibited O +
Ca+2 O +
entry O +
into O +
cells O +
[ O -
14 O -
] O +
. O +

We O +
had O +
shown O +
that O +
14,15-EET O +
can O +
enhance O +
monocyte O +
attachment O +
to O +
endothelium O +
and O +
decrease O +
the O +
mean O +
arterial O +
blood O +
pressure O +
in O +
normal O +
and O +
spontaneously O +
hypertensive O +
rats O +
[ O -
12,13 O -
] O +
. O +

Catella O +
et O +
al. O +
[ O -
15 O -
] O +
reported O +
high O +
amounts O +
of O +
14,15-EET O +
in O +
the O +
urine O +
of O +
patients O +
with O +
pregnancy O -
- O -
induced O +
hypertension O -
, O +
suggesting O +
a O +
possible O +
role O +
of O +
14,15-EET O +
in O +
blood O +
pressure O +
regulation O -
. O +

These O +
wide O +
varieties O +
of O +
biological O +
function O +
suggest O +
that O +
14,15-EET O +
may O +
act O +
through O +
specific O +
receptors B-Gene +
and O +
signal O +
transduction O +
pathways O -
. O +

In O +
this O +
study O -
, O +
we O +
have O +
identified O +
a O +
population O +
of O +
specific O +
high O +
affinity O +
binding O +
sites O +
for O +
14,15-EET O +
in O +
GPM O +
cells O +
that O +
may O +
be O +
associated O +
with O +
receptors B-Gene -
. O +

This O +
population O +
of O +
14,15-EET O +
binding O +
sites O +
in O +
GPM O +
cells O +
was O +
down O +
regulated O +
by O +
cholera B-Gene +
toxin I-Gene +
or O +
dibutyryl O -
- O -
cAMP O +
that O +
suggested O +
a O +
postreceptor O +
mechanism O +
coupled O +
to O +
PKA B-Gene -
- O -
dependent O +
signal O +
transduction O +
pathway O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Materials O +
White O +
Hartley O +
guinea O +
pigs O +
weighing O +
250 O +
to O +
350 O +
g O +
were O +
obtained O +
from O +
Taconic O +
Farms O +
( O -
Germantown O -
, O +
NY O -
, O +
USA O -
) O -
. O +

Percoll O -
, O +
HEPES O -
, O +
deoxyribonuclease B-Gene -
, O +
cholera B-Gene +
toxin I-Gene -
, O +
pertussis B-Gene +
toxin I-Gene -
, O +
sodium O +
bicarbonate O +
( O -
a O +
cell O +
culture O +
grade O -
) O -
, O +
Tris O -
- O -
base O -
, O +
chymotrypsin B-Gene +
( O -
type B-Gene +
IS I-Gene +
and O +
type B-Gene +
II I-Gene -
) O -
, O +
papain B-Gene -
, O +
pronase B-Gene +
E I-Gene -
, O +
proteinase B-Gene +
K I-Gene -
, O +
and O +
dibutyryl O +
cAMP O +
were O +
purchased O +
from O +
Sigma O +
( O -
St. O +
Louis O -
, O +
MO O -
, O +
USA O -
) O -
. O +

The O +
gelatin B-Gene +
was O +
obtained O +
from O +
Fisher O +
Scientific O +
( O -
Fairlawn O -
, O +
NJ O -
, O +
USA O -
) O -
. O +

H-89 O +
and O +
K252a O +
were O +
from O +
LC O +
Laboratories O +
( O -
Woburn O -
, O +
MA O -
, O +
USA O -
) O -
. O +

Hank O -
's O +
Balanced O +
Salt O +
Solution O +
( O -
HBSS O -
) O +
and O +
horse O +
serums O +
were O +
obtained O +
from O +
GIBCO O +
( O -
Grand O +
Island O -
, O +
NY O -
, O +
USA O -
) O -
, O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
( O -
100 O +
Ci O -
/ O -
mmole O -
) O +
and O +
14,15-EET O +
was O +
synthesized O +
and O +
purified O +
by O +
RP O -
, O +
reversed O +
phase O -
- O -
HPLC O -
, O +
as O +
previously O +
described O +
[ O -
16 O -
] O +
. O +

2.2 O +
Harvest O +
and O +
purification O +
of O +
guinea O +
pig O +
monocytes O +
Female O +
white O +
Hartley O +
guinea O +
pigs O +
( O -
250–350 O +
g O -
) O +
were O +
injected O +
intraperitoneally O +
( O -
i.p O -
. O -
) O +
with O +
0.5 O +
ml O +
horse O +
serum O +
twice O +
a O +
week O +
for O +
2 O +
weeks O -
, O +
and O +
afterwards O -
, O +
once O +
weekly O -
. O +

After O +
a O +
minimum O +
of O +
48 O +
h O +
from O +
the O +
last O +
injection O -
, O +
the O +
cells O +
were O +
harvested O +
by O +
peritoneal O +
lavage O -
. O +

The O +
animals O +
were O +
anesthetized O +
with O +
metofane O +
and O +
a O +
20 O +
g O +
× O +
2″ O +
( O -
Surflo O -
) O +
Teflon O +
intercath O +
was O +
inserted O +
into O +
the O +
peritoneal O +
cavity O -
. O +

The O +
cavity O +
was O +
washed O +
with O +
20 O +
ml O +
of O +
Hank O -
's O +
buffered O +
saline O +
solution O +
without O +
calcium O +
or O +
magnesium O +
( O -
HBSS O -
) O -
, O +
containing O +
5 O +
mM O +
HEPES O -
, O +
pH O +
7.3 O +
and O +
10 O +
Units O -
/ O -
ml O +
of O +
heparin B-Gene -
. O +

The O +
collected O +
cells O +
were O +
centrifuged O +
at O +
275 O +
× O +
g O +
for O +
5 O +
min O -
, O +
washed O +
and O +
resuspended O +
in O +
4 O +
ml O +
of O +
HBSS O +
containing O +
10 O -
% O +
gelatin B-Gene +
and O +
5 O +
mg O +
deoxyribonuclease B-Gene +
( O -
HBSS O -
- O -
GD B-Gene -
) O -
. O +

Hypotonic O +
lysis O +
removed O +
contaminating O +
red O +
blood O +
cells O -
. O +

Four O +
milliliters O +
of O +
aliquots O +
of O +
the O +
cell O +
suspension O +
were O +
layered O +
on O +
top O +
of O +
a O +
Percoll O +
density O +
gradient O +
and O +
centrifuged O +
at O +
1600 O +
× O +
g O +
for O +
30 O +
min O -
. O +

The O +
discontinuous O +
density O +
gradient O +
was O +
prepared O +
by O +
overlaying O +
successive O +
layers O +
of O +
86 O -
% O -
, O +
76 O -
% O -
, O +
64 O -
% O -
, O +
and O +
45 O -
% O +
isotonic O +
Percoll O +
containing O +
0.03 O +
mg O -
/ O -
ml O +
deoxyribonuclease B-Gene +
to O +
give O +
the O +
following O +
densities O -
: O +
A O -
: O +
1.06 O -
, O +
B O -
: O +
1.08 O -
, O +
C O -
: O +
1.09 O -
, O +
D O -
: O +
1.10 O +
g O -
/ O -
ml O +
[ O -
17,18 O -
] O +
. O +

The O +
four O +
bands O +
of O +
cells O +
were O +
collected O +
at O +
the O +
interface O +
of O +
the O +
different O +
density O +
layers O -
, O +
and O +
to O +
remove O +
any O +
remaining O +
Percoll O -
, O +
each O +
was O +
diluted O +
1:4 O +
with O +
HBSS O -
- O -
GD B-Gene -
, O +
centrifuged O -
, O +
washed O +
once O -
, O +
and O +
resuspended O +
in O +
HBSS O -
- O -
GD B-Gene -
. O +

Differential O +
counts O +
were O +
obtained O +
using O +
slide O +
preparation O +
stained O +
with O +
Diff O +
Quick O +
( O -
American O +
Scientific O -
) O -
. O +

From O +
this O +
procedure O +
we O +
could O +
collect O +
the O +
lymphocytes O +
and O +
monocytes O -
, O +
A O +
and O +
B O +
bands O -
, O +
respectively O -
. O +

Eosinophils O +
were O +
collected O +
mainly O +
from O +
the O +
C O +
and O +
D O +
bands O +
[ O -
17,18 O -
] O +
. O +

Cell O +
viability O +
was O +
determined O +
by O +
trypan O +
blue O +
exclusion O +
and O +
found O +
to O +
be O +
> O -
99 O -
% O -
. O +

2.3 O +
Radioligand O +
binding O +
assays O +
All O +
assays O +
were O +
performed O +
in O +
duplicate O +
with O +
intact O +
GPM O +
cells O +
suspended O +
in O +
HBSS O +
buffer O -
, O +
pH O +
7.4 O +
containing O +
10 O +
mM O +
CaCl2 O +
and O +
10 O +
mM O +
MgCl2 O +
at O +
a O +
final O +
volume O +
of O +
250 O +
μl O -
. O +

In O +
the O +
saturation O +
binding O +
experiment O -
, O +
GPM O +
cells O +
( O -
106 O +
cells O -
) O +
were O +
added O +
to O +
polypropylene O +
tubes O +
( O -
12 O +
× O +
75 O +
mm O -
) O +
and O +
incubated O +
at O +
4 O -
° O -
C O +
for O +
4 O +
min O +
with O +
increasing O +
concentrations O +
of O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
( O -
0.4 O +
nM–30 O +
nM O -
) O +
in O +
the O +
presence O +
or O +
absence O +
of O +
20 O +
μM O +
unlabeled O +
14,15-EET O -
. O +

For O +
nonsaturation O +
experiments O -
, O +
1000-fold O +
excess O +
of O +
unlabeled O +
14,15-EET O +
was O +
used O -
. O +

Bound O +
and O +
free O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
were O +
separated O +
by O +
centrifugation O +
at O +
2000 O +
rev. O -
/ O -
min O -
, O +
4 O -
° O -
C O +
for O +
2 O +
min O -
. O +

Pellets O +
were O +
washed O +
with O +
250 O +
μl O +
of O +
HBSS O +
twice O +
and O +
centrifuged O +
at O +
2000 O +
rev. O -
/ O -
min O -
, O +
4 O -
° O -
C O +
for O +
2 O +
min O -
. O +

Pellets O +
were O +
taken O +
up O +
in O +
200 O +
μl O +
20 O -
% O +
NaOH O -
, O +
heated O +
on O +
40 O -
° O -
C O +
water O +
bath O +
with O +
constant O +
shaking O -
, O +
and O +
then O +
taken O +
up O +
in O +
4.8 O +
ml O +
of O +
scintillation O +
liquid O -
. O +

The O +
radioactivity O +
was O +
measured O +
by O +
a O +
Beckman O +
7500 O +
Scintillation O +
Counter O +
after O +
equilibration O +
for O +
13 O +
to O +
18 O +
h O +
in O +
5 O +
ml O +
of O +
scintillation O +
fluid O -
. O +

The O +
competition O +
studies O +
of O +
[ O -
3 O +
H O -
] O -
14,15-EET O +
specific O +
binding O +
to O +
guinea O +
pig O +
mononuclear O +
cells O +
was O +
conducted O +
by O +
incubating O +
GPM O +
cells O +
( O -
106 O +
cells O -
) O +
with O +
2 O +
nM O +
of O +
[ O -
3 O +
H O -
] O +
14,15-EET O +
in O +
the O +
presence O +
of O +
various O +
concentrations O +
( O -
10−11 O +
to O +
10−4 O +
M O -
) O +
of O +
stereo O +
isomers O +
and O +
analogs O +
of O +
14,15-EET O -
. O +

For O +
the O +
experiments O +
on O +
the O +
effects O +
of O +
proteases B-Gene +
( O -
chymotrypsin B-Gene -
, O +
papain B-Gene -
, O +
pronase B-Gene +
E I-Gene -
, O +
and O +
Proteinase B-Gene +
K I-Gene -
) O -
, O +
cholera B-Gene +
toxin I-Gene -
, O +
pertussis B-Gene +
toxin I-Gene -
, O +
dibutyryl O +
cAMP O -
, O +
and O +
H-89 O +
on O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
binding O +
to O +
GPM O +
cells O -
, O +
the O +
cells O +
were O +
pretreated O +
with O +
one O +
of O +
the O +
following O +
group O +
of O +
agents O -
: O +
1 O -
) O +
proteases B-Gene +
( O -
chymotrypsin B-Gene -
- I-Gene -
type B-Gene +
IS I-Gene +
and O +
type B-Gene +
II I-Gene -
, O +
papain B-Gene -
, O +
pronase B-Gene +
E I-Gene +
and O +
proteinase B-Gene +
K I-Gene -
, O +
100 O +
μg O -
/ O -
ml O -
) O +
at O +
37 O -
° O -
C O +
for O +
20 O +
min O -
; O +
2 O -
) O +
cholera B-Gene +
toxin I-Gene +
( O -
25–200 O +
μg O -
/ O -
ml O -
) O +
and O +
pertussis B-Gene +
toxin I-Gene +
( O -
20–200 O +
ng O -
/ O -
ml O -
) O +
at O +
37 O -
° O -
C O +
for O +
2 O +
h O -
; O +
3 O -
) O +
dibutyryl O +
cAMP O +
( O -
DBcAMP O -
) O +
( O -
10–100 O +
nM O -
) O +
at O +
37 O -
° O -
C O +
for O +
30 O +
min O -
; O +
4 O -
) O +
H-89 O +
( O -
0.01–1 O +
μm O -
) O +
at O +
37 O -
° O -
C O +
for O +
10 O +
min O -
, O +
then O +
in O +
the O +
presence O +
of O +
DBcAMP O +
( O -
100 O +
nM O -
) O +
at O +
37 O -
° O -
C O +
for O +
another O +
30 O +
min O -
, O +
separately O +
before O +
the O +
binding O +
assay O -
. O +

The O +
pretreated O +
GPM O +
cells O +
were O +
centrifuged O +
at O +
1000 O +
rev. O -
/ O -
min O -
, O +
at O +
4 O -
° O -
C O +
for O +
5 O +
min O -
, O +
washed O +
with O +
HBSS O +
buffer O -
, O +
centrifuged O -
, O +
and O +
resuspended O +
in O +
HBSS O +
before O +
the O +
binding O +
assay O -
. O +

2.4 O +
cAMP O +
and O +
cGMP O +
determination O +
GPM O +
cells O +
( O -
4 O +
× O +
106 O +
) O +
were O +
preincubated O +
with O +
or O +
without O +
400 O +
μM O +
of O +
IBMX O +
for O +
5 O +
min O +
before O +
the O +
addition O +
of O +
14,15-EET O +
( O -
0.1–100 O +
μM O -
) O -
. O +

The O +
assays O +
were O +
incubated O +
for O +
another O +
10 O +
min O +
at O +
37 O -
° O -
C O +
and O +
terminated O +
by O +
addition O +
of O +
ethanol O +
( O -
its O +
final O +
concentration O +
was O +
65 O -
% O -
) O -
. O +

The O +
cell O +
debris O +
was O +
removed O +
by O +
centrifugation O +
and O +
the O +
supernatant O +
was O +
dried O +
under O +
vacuum O +
and O +
redissolved O +
in O +
0.05 O +
M O +
acetate O +
buffer O +
for O +
further O +
determination O +
of O +
cAMP O +
and O +
cGMP O +
by O +
RIA O +
kit O +
( O -
Amersham O +
Corp. O -
, O +
Arlington O +
Heights O -
, O +
IL O -
, O +
USA O -
) O -
. O +

2.5 O +
Statistical O +
analysis O +
Experimental O +
results O +
were O +
summarized O +
as O +
mean O +
values O +
± O +
SEM O -
. O +

Data O +
were O +
analyzed O +
using O +
one O -
- O -
way O +
ANOVA O +
through O +
the O +
Sigma O +
stat O +
program O +
( O -
Jandel O +
Scientific O -
) O -
. O +

Difference O +
between O +
groups O +
was O +
then O +
determined O +
using O +
the O +
Bonferroni O -
's O +
t O +
-test O -
. O +

When O +
the O +
test O +
of O +
the O +
normality O +
failed O -
, O +
Dunn O -
's O +
test O +
of O +
ANOVA O +
by O +
ranks O +
was O +
used O -
. O +

Groups O +
were O +
deemed O +
to O +
be O +
significantly O +
different O +
from O +
one O +
another O +
when O +
P O +
< O +
0.05 O -
. O +

3 O +
Results O +
3.1 O +
Binding O +
of O +
[ O -
3 O +
H O -
] O -
- O +
14,15-EET O +
to O +
GPM O +
cells O +
The O +
binding O +
of O +
[ O -
3 O +
H O -
] O -
- O +
14,15-EET O +
to O +
GPM O +
cells O +
was O +
time O +
dependent O +
and O +
cell O +
concentration O +
dependent O +
( O -
Fig. O +
1A O +
and O +
B O -
) O +
. O +

Maximum O +
binding O +
at O +
4 O -
° O -
C O +
was O +
reached O +
at O +
4 O +
min O +
with O +
the O +
cell O +
density O +
of O +
2 O +
× O +
106 O +
cells O -
/ O -
ml O -
. O +

Cell O +
bound O +
[ O -
3 O +
H O -
] O -
- O +
14,15-EET O +
was O +
readily O +
dissociated O +
in O +
a O +
time O -
- O -
dependent O +
fashion O +
when O +
1000-fold O +
higher O +
concentration O +
of O +
unlabeled O +
of O +
14 O -
( O -
R O +
) O -
, O +
15 O -
( O -
S O +
) O -
-EET O -
, O +
or O +
14 O -
( O -
S O +
) O -
, O +
15 O -
( O -
R O +
) O -
-EET O +
was O +
added O +
to O +
the O +
reaction O +
mixture O +
with O +
14 O -
( O -
R O +
) O -
, O -
15 O -
( O -
S O +
) O -
-EET O +
more O +
effective O +
than O +
the O +
14 O -
( O -
S O +
) O -
, O -
15 O -
( O -
R O +
) O -
-EET O +
( O -
Fig. O +
2 O -
) O +
. O +

The O +
displacement O +
of O +
bound O +
radioligand O +
reached O +
maximum O +
( O -
66 O -
% O -
) O +
in O +
5 O +
min O +
after O +
the O +
addition O +
of O +
unlabeled O +
14 O -
( O -
R O -
) O -
, O +
15 O -
( O -
S O -
) O -
-EET O -
. O +

The O +
saturability O +
of O +
the O +
specific O +
[ O -
3 O +
H O -
] O -
- O +
14,15-EET O +
was O +
shown O +
by O +
incubating O +
the O +
GPM O +
cells O +
with O +
increasing O +
concentrations O +
of O +
radioligand O +
in O +
the O +
presence O +
or O +
absence O +
of O +
20 O +
μM O +
unlabeled O +
14,15-EET O -
. O +

As O +
shown O +
in O +
Fig. O +
3A O +
, O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
binding O +
to O +
GPM O +
cells O +
was O +
saturable O +
and O +
of O +
high O +
affinity O -
. O +

Nonspecific O +
binding O +
increased O +
linearly O +
with O +
increasing O +
concentration O +
of O +
ligand O -
. O +

Total O +
binding O +
also O +
increased O +
with O +
increasing O +
concentration O +
of O +
[ O -
3 O +
H O -
] O -
- O +
14,15-EET O -
. O +

This O +
showed O +
that O +
nonspecific O +
binding O +
was O +
of O +
high O +
capacity O -
, O +
nonsaturable O +
and O +
low O +
affinity O +
whereas O +
specific O +
binding O +
was O +
of O +
low O +
capacity O -
, O +
saturable O -
, O +
and O +
high O +
affinity O -
. O +

Scatchard O +
analysis O +
of O +
specific O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
binding O +
to O +
GPM O +
cells O +
( O -
Fig. O +
3B O -
) O +
shows O +
that O +
the O +
[ O -
3 O +
H O -
] O -
- O +
14,15-EET O +
binding O +
sites O +
in O +
GPM O +
cells O +
belong O +
to O +
a O +
high O +
affinity O +
population O -
. O +

The O +
dissociation O +
constant O +
( O -
K O +
d O +
) O +
is O +
35.06 O +
± O +
1.73 O +
nM O +
( O -
n O +
= O +
4 O -
) O -
, O +
and O +
the O +
maximum O +
number O +
of O +
binding O +
sites O +
( O -
B O +
max O +
) O +
was O +
estimated O +
to O +
be O +
2.36 O +
± O +
0.31 O +
pmol O -
/ O -
106 O +
cells O +
and O +
the O +
number O +
of O +
binding O +
sites O +
per O +
cell O +
calculated O +
to O +
be O +
1.42 O +
± O +
0.19 O +
× O +
106 O +
sites O -
/ O -
cell O +
( O -
n O +
= O +
4 O -
) O -
. O +

3.2 O +
Competition O +
studies O +
of O +
[ O -
3 O +
H O -
] O -
14,15-EET O +
specific O +
binding O +
to O +
guinea O +
pig O +
mononuclear O +
cells O +
by O +
14,15-EET O +
stereoisomers O +
and O +
other O +
EETs O +
To O +
examine O +
the O +
specificity O +
of O +
the O +
binding O +
sites O +
for O +
[ O -
3 O +
H O -
] O -
14,15-EET O -
, O +
we O +
conducted O +
competition O +
binding O +
studies O +
with O +
stereoisomers O +
and O +
analogs O +
of O +
14,15-EET O +
and O +
other O +
EETs O -
. O +

As O +
shown O +
in O +
Fig. O +
4 O +
, O +
14 O -
( O -
R O +
) O -
, O +
15 O -
( O -
S O +
) O -
-EET O +
was O +
an O +
effective O +
competing O +
ligand O +
with O +
a O +
K O +
i O +
of O +
226.3 O +
nM O +
followed O +
by O +
11 O -
( O -
R O +
) O -
, O -
12 O -
( O -
S O +
) O -
-EET O -
, O +
14 O -
( O -
S O +
) O -
, O -
15 O -
( O -
R O +
) O -
-EET O -
, O +
14,15 O +
thia O -
( O -
S O +
) O -
-ET O -
, O +
and O +
14,15-aza O -
( O -
N O +
) O -
-ET O +
with O +
K O +
i O +
of O +
595.1 O +
nM O -
, O +
612.5 O +
nM O -
, O +
3.54 O +
μM O -
, O +
and O +
5 O +
μM O -
, O +
respectively O -
. O +

3.3 O +
Effects O +
of O +
protease B-Gene +
enzymes O +
on O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
binding O +
on O +
GPM O +
cells O +
Preincubation O +
of O +
the O +
intact O +
GPM O +
cells O +
with O +
100 O +
μg O -
/ O -
ml O +
of O +
various O +
protease B-Gene +
enzymes I-Gene +
such O +
as O -
: O +
chymotrypsin B-Gene -
- I-Gene -
type B-Gene +
IS I-Gene +
and O +
type B-Gene +
II I-Gene -
, O +
papain B-Gene -
, O +
pronase B-Gene +
E I-Gene -
, O +
and O +
proteinase B-Gene +
K I-Gene +
at O +
37 O -
° O -
C O +
for O +
20 O +
min O +
led O +
to O +
significant O +
reduction O +
of O +
binding O +
( O -
n O +
= O +
3 O -
) O +
( O -
Fig. O +
5 O -
) O +
. O +

Papain B-Gene +
produced O +
the O +
most O +
reduction O +
( O -
51.60 O -
% O -
) O +
on O +
the O +
binding O +
of O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
to O +
its O +
receptor B-Gene +
followed O +
by O +
proteinase B-Gene +
K I-Gene +
( O -
47.14 O -
% O -
) O -
, O +
chymotrypsin B-Gene -
- I-Gene -
type I-Gene +
II I-Gene +
( O -
42.04 O -
% O -
) O -
, O +
chymotrypsin B-Gene -
- I-Gene -
type I-Gene +
IS I-Gene +
( O -
27.33 O -
% O -
) O -
, O +
and O +
pronase B-Gene +
E I-Gene +
( O -
15.98 O -
% O -
) O -
, O +
respectively O -
. O +

These O +
data O +
suggest O +
that O +
14,15-EET O +
binding O +
sites O +
of O +
the O +
intact O +
GPM O +
cells O +
are O +
protein B-Gene +
in O +
nature O -
. O +

3.4 O +
Effects O +
of O +
cholera B-Gene +
toxin I-Gene +
and O +
pertussis B-Gene +
toxin I-Gene +
on O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
binding O +
on O +
GPM O +
cells O +
The O +
effects O +
of O +
cholera B-Gene +
toxin I-Gene +
and O +
pertussis B-Gene +
toxin I-Gene -
, O +
agents O +
known O +
to O +
enhance O +
cAMP O +
levels O -
, O +
were O +
tested O +
on O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
in O +
GPM O +
cells O -
. O +

GPM O +
cells O +
were O +
pretreated O +
with O +
cholera B-Gene +
toxin I-Gene +
( O -
25–200 O +
μg O -
/ O -
ml O -
) O +
and O +
pertussis B-Gene +
toxin I-Gene +
( O -
20–200 O +
ng O -
/ O -
ml O -
) O +
separately O +
at O +
37 O -
° O -
C O +
for O +
2 O +
h O -
, O +
followed O +
by O +
radioligand O +
binding O +
assay O -
. O +

14,15-EET B-Gene +
receptor I-Gene +
binding O +
was O +
decreased O +
58.99 O +
± O +
6.37 O -
% O +
by O +
cholera B-Gene +
toxin I-Gene +
( O -
200 O +
μg O -
/ O -
ml O -
) O +
( O -
Fig. O +
6A O -
) O +
and O +
40.50 O +
± O +
3.78 O -
% O +
by O +
pertussis B-Gene +
toxin I-Gene +
( O -
200 O +
ng O -
/ O -
ml O -
) O +
( O -
data O +
not O +
shown O -
) O -
. O +

Thus O -
, O +
agents O +
that O +
increase O +
intracellular O +
cAMP O +
level O +
can O +
effectively O +
down O +
regulate O +
14,15-EET B-Gene +
receptor I-Gene +
binding O -
. O +

The O +
down O +
regulation O +
of O +
[ O -
3 O +
H O -
] O -
- O +
14,15-EET O +
binding O +
in O +
GPM O +
cells O +
by O +
cholera B-Gene +
toxin I-Gene +
( O -
200 O +
μg O -
/ O -
ml O -
) O +
is O +
shown O +
by O +
the O +
decrease O +
of O +
number O +
of O +
binding O +
sites O +
( O -
B O +
max O +
, O +
32.0 O -
% O +
decrease O -
) O +
on O +
the O +
cell O +
surface O +
without O +
changing O +
the O +
dissociation O +
constant O +
( O -
K O +
d O +
) O +
( O -
Fig. O +
6B O -
) O +
. O +

3.5 O +
Effects O +
of O +
dibutyryl O +
cAMP O +
on O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
binding O +
on O +
GPM O +
cells O +
We O +
pretreated O +
GPM O +
cells O +
with O +
various O +
concentrations O +
of O +
dibutyryl O +
cAMP O +
( O -
DBcAMP O -
) O +
at O +
37 O -
° O -
C O +
for O +
30 O +
min O +
followed O +
by O +
the O +
radioligand O +
binding O +
assays O +
as O +
described O -
. O +

Similar O +
to O +
the O +
effect O +
of O +
cholera B-Gene +
toxin I-Gene -
, O +
a O +
significant O +
reduction O +
of O +
specific O +
binding O +
( O -
> O -
35 O -
% O +
reduction O -
) O +
for O +
[ O -
3 O +
H O -
] O +
14,15-EET O +
was O +
observed O +
after O +
the O +
cells O +
were O +
treated O +
with O +
DBcAMP O -
. O +

The O +
reduction O +
of O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
binding O +
to O +
GPM O +
cells O +
was O +
dose O -
- O -
dependent O +
with O +
respect O +
to O +
DBcAMP O +
( O -
Fig. O +
7A O -
) O +
and O +
maximum O +
response O +
was O +
reached O +
at O +
100 O +
nM. O +
Scatchard O +
analysis O +
revealed O +
that O +
the O +
number O +
of O +
the O +
[ B-Gene -
3 I-Gene +
H I-Gene -
] I-Gene -
-14,15-EET I-Gene +
binding I-Gene +
sites I-Gene +
( O -
B O +
max O +
) O +
in O +
GPM O +
cell O +
surface O +
was O +
decreased O +
by O +
19.1 O -
% O +
after O +
incubation O +
with O +
100 O +
nM O +
of O +
DBcAMP O +
without O +
changing O +
the O +
K O +
d O +
( O -
Fig. O +
7B O -
) O +
in O +
the O +
same O +
fashion O +
as O +
the O +
treatment O +
with O +
cholera B-Gene +
toxin I-Gene -
. O +

3.6 O +
Effect O +
of O +
protein B-Gene +
kinase I-Gene +
inhibitors O +
on O +
the O +
reduction O +
of O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
binding O +
in O +
GPM O +
cells O +
by O +
DBcAMP O +
Because O +
pretreatment O +
of O +
GPM O +
cells O +
with O +
DBcAMP O +
or O +
cholera B-Gene +
toxin I-Gene +
resulted O +
in O +
the O +
down O +
regulation O +
of O +
14,15-EET B-Gene +
binding I-Gene +
site I-Gene +
density O -
, O +
we O +
further O +
examined O +
whether O +
this O +
effect O +
was O +
due O +
to O +
activation O +
of O +
PKA B-Gene -
. O +

GPM O +
cells O +
were O +
incubated O +
with O +
various O +
concentrations O +
of O +
PKA B-Gene +
inhibitor O -
, O +
H-89 O +
[ O -
19 O -
] O +
, O +
at O +
37 O -
° O -
C O +
for O +
10 O +
min O +
before O +
the O +
pretreatment O +
of O +
DBcAMP O +
( O -
100 O +
nM O -
) O +
at O +
37 O -
° O -
C O +
for O +
an O +
30 O +
min O -
. O +

The O +
cells O +
were O +
washed O +
with O +
HBSS O +
once O +
and O +
resuspended O +
in O +
HBSS O -
. O +

Low O +
doses O +
of O +
H-89 O +
( O -
0.01 O +
μM O -
) O +
alone O +
showed O +
a O +
slightly O +
decrease O +
in O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
binding O +
but O +
a O +
higher O +
dose O +
( O -
0.1–1.0 O +
μM O -
) O +
showed O +
significant O +
increases O +
as O +
compared O +
with O +
controls O +
( O -
untreated O +
GPM O +
cells O -
) O -
. O +

However O -
, O +
when O +
GPM O +
cells O +
were O +
pretreated O +
with O +
H-89 O +
from O +
0.1 O +
to O +
1.0 O +
μM O +
before O +
treatment O +
with O +
DBcAMP O -
, O +
H-89 O +
readily O +
reversed O +
the O +
down O +
regulatory O +
response O +
of O +
DBcAMP O +
on O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
binding O +
in O +
GPM O +
cells O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
( O -
Fig. O +
8) O +
. O +

Under O +
similar O +
conditions O -
, O +
K252a O +
( O -
a O +
protein B-Gene +
kinase I-Gene +
C I-Gene +
inhibitor O -
) O +
could O +
not O +
reverse O +
the O +
downward O +
regulatory O +
effect O +
of O +
DBcAMP O +
on O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
binding O +
in O +
GPM O +
cells O -
. O +

3.7 O +
Effects O +
of O +
14,15-EET O +
on O +
the O +
level O +
of O +
cAMP O +
and O +
cGMP O +
in O +
intact O +
GPM O +
cells O +
Because O +
cholera B-Gene +
toxin I-Gene +
and O +
cAMP O +
both O +
are O +
able O +
to O +
down O +
regulate O +
the O +
14,15-EET B-Gene +
receptor I-Gene +
binding O -
, O +
the O +
effects O +
of O +
14,15-EET O +
on O +
the O +
intracellular O +
levels O +
of O +
cAMP O +
or O +
cGMP O +
were O +
examined O -
. O +

GPM O +
cells O +
were O +
preincubated O +
with O +
or O +
without O +
400 O +
μM O +
of O +
IBMX O +
for O +
5 O +
min O +
at O +
37 O -
° O -
C O +
and O +
incubated O +
with O +
various O +
concentrations O +
of O +
14,15-EET O +
( O -
0.01–100 O +
μM O -
) O +
for O +
additional O +
10 O +
min O -
. O +

We O +
found O +
that O +
14,15-EET O +
can O +
indeed O +
induce O +
an O +
increase O +
of O +
intracellular O +
level O +
of O +
cAMP O +
in O +
GPM O +
cells O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
( O -
0.1 O +
to O +
100 O +
μM O -
) O +
( O -
Fig. O +
9 O -
) O +
. O +

Maximal O +
effect O +
on O +
the O +
increase O +
of O +
cAMP O +
in O +
GPM O +
cells O +
required O +
the O +
presence O +
of O +
IBMX O -
, O +
a O +
phospodiesterase B-Gene +
inhibitor O -
. O +

When O +
the O +
cells O +
were O +
pretreated O +
with O +
100 O +
μM O +
of O +
14,15-EET O -
, O +
there O +
was O +
a O +
nearly O +
12-fold O +
increase O +
in O +
intracellular O +
level O +
of O +
cAMP O -
, O +
from O +
2.67 O +
pmol O -
/ O -
106 O +
cells O +
( O -
without O +
14,15-EET O -
) O +
to O +
32.42 O +
pmol O -
/ O -
106 O +
cells O +
( O -
pretreated O +
with O +
100 O +
μM O +
of O +
14,15-EET O -
) O -
. O +

However O -
, O +
under O +
similar O +
conditions O -
, O +
14,15-EET O +
had O +
no O +
effect O +
on O +
the O +
levels O +
of O +
cGMP O +
in O +
GPM O +
cells O +
in O +
the O +
presence O +
of O +
IBMX O -
. O +

4 O +
Discussion O +
14,15-epoxyeicosatrienoic O +
acid O +
( O -
14,15-EET O -
) O +
was O +
originally O +
found O +
to O +
produce O +
by O +
platelets O +
and O +
subsequently O +
by O +
endothelial O +
cells O +
[ O -
3,4 O -
] O +
. O +

Our O +
earlier O +
data O +
showed O +
that O +
a O +
profound O +
increase O +
in O +
EET O +
( O -
especially O +
14,15-EET O -
) O +
generation O +
in O +
endothelial O +
cells O +
( O -
EC O -
) O +
after O +
exposure O +
to O +
240 O +
mg O -
/ O -
dl O +
low B-Gene -
- I-Gene -
density I-Gene +
lipoprotein I-Gene +
( O -
LDL B-Gene -
) O -
-cholesterol O -
. O +

Subsequent O +
data O +
showed O +
that O +
14,15-EET O +
induced O +
an O +
8-fold O +
increase O +
of O +
U-937 O +
cell O +
adhesion O +
to O +
cultured O +
human O +
umbilical O +
vein O +
endothelial O +
cells O +
( O -
HUVEC O -
) O +
as O +
compared O +
with O +
non O -
- O -
treated O +
control O +
[ O -
13 O -
] O +
. O +

These O +
results O +
support O +
the O +
notion O +
that O +
14,15-EET O +
may O +
mediate O +
the O +
atherogenic O +
LDL O +
induced O +
enhancement O +
of O +
U-937 O +
cells O -
' O +
adhesion O +
on O +
HUVEC O +
[ O -
20 O -
] O +
. O +

Because O +
endothelial O +
cells O +
derived O +
from O +
human O +
umbilical O +
veins O +
( O -
HUVE O -
) O +
do O +
not O +
possess O +
any O +
specific O +
binding O +
for O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
that O +
suggested O +
a O +
lack O +
of O +
14,15-EET B-Gene +
receptors I-Gene +
in O +
endothelium O +
[ O -
21,22 O -
] O +
, O +
the O +
enhancement O +
of O +
monocyte O +
adhesion O +
by O +
14,15-EET O +
may O +
act O +
through O +
a O +
receptor B-Gene +
and O +
the O +
activation O +
of O +
a O +
signal O +
transduction O +
mechanism O +
in O +
monocytes O -
. O +

In O +
this O +
report O -
, O +
we O +
have O +
identified O +
and O +
characterized O +
a O +
population O +
of O +
specific O +
high O +
affinity O +
binding O +
sites O +
for O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
in O +
GPM O +
cells O +
and O +
found O +
the O +
ligand O +
binding O +
is O +
high O +
affinity O +
with O +
a O +
K O +
d O +
of O +
35.06 O +
± O +
1.73 O +
nM O +
and O +
B O +
max O +
of O +
2.36 O +
± O +
0.32 O +
pmol O -
/ O -
106 O +
cells O -
. O +

The O +
calculated O +
number O +
of O +
binding O +
sites O +
per O +
cell O +
was O +
1.42 O +
± O +
0.19 O +
× O +
106 O +
sites O -
/ O -
cell O -
. O +

This O +
binding O +
site O +
is O +
stereospecific O +
for O +
14 O -
( O -
R O +
) O -
, O +
15 O -
( O -
S O +
) O -
-EET O +
and O +
has O +
less O +
affinity O +
toward O +
other O +
EETs O +
and O +
11 O -
( O -
R O +
) O -
, O +
12 O -
( O -
S O +
) O -
-EET O +
( O -
Fig. O +
4 O -
) O +
. O +

The O +
binding O +
of O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
to O +
GPM O +
cells O +
is O +
reversible O +
( O -
Fig. O +
2 O -
) O +
and O +
protease B-Gene +
sensitive O +
which O +
showed O +
that O +
this O +
binding O +
site O +
is O +
associated O +
with O +
a O +
protein B-Gene +
species O +
( O -
Fig. O +
5 O -
) O +
. O +

The O +
rapid O +
time O +
course O +
of O +
radioligand O +
binding O +
in O +
the O +
cold O +
temperature O +
and O +
the O +
reversibility O +
suggested O +
that O +
the O +
binding O +
be O +
not O +
likely O +
due O +
to O +
the O +
esterification O +
of O +
14,15-EET O +
into O +
the O +
membrane O +
phospholipids O -
. O +

14,15-EET O +
binding O +
in O +
GPM O +
cells O +
is O +
attenuated O +
by O +
cholera B-Gene +
toxin I-Gene +
or O +
pertussis B-Gene +
toxin I-Gene +
without O +
changing O +
the O +
dissociation O +
constant O +
( O -
K O +
d O +
) O -
. O +

Because O +
both O +
cholera B-Gene +
toxin I-Gene +
and O +
pertussis B-Gene +
toxin I-Gene +
activate O +
adenyl B-Gene +
cyclase I-Gene +
and O +
report O +
to O +
increase O +
intracellular O +
cAMP O +
[ O -
23 O -
] O +
, O +
we O +
found O +
that O +
addition O +
of O +
dibutyryl O +
cAMP O +
( O -
DBcAMP O -
) O +
can O +
reduce O +
the O +
binding O +
of O +
[ O -
3 O +
H O -
] O -
- O +
14,15-EET O +
on O +
GPM O +
cells O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
by O +
reducing O +
the O +
cell O +
surface O +
receptor O +
density O +
( O -
B O +
max O +
) O +
without O +
changing O +
the O +
dissociation O +
constant O +
( O -
K O +
d O +
) O +
( O -
Fig. O +
7A O +
and O +
B O -
) O +
. O +

However O +
pertussis B-Gene +
toxin I-Gene +
was O +
less O +
effective O +
as O +
compared O +
with O +
cholera B-Gene +
toxin I-Gene +
probably O +
due O +
to O +
the O +
fact O +
it O +
is O +
less O +
effective O +
in O +
increasing O +
intracellular O +
cAMP O +
level O +
in O +
GPM O +
cells O -
. O +

These O +
results O +
suggest O +
that O +
the O +
reagents O +
that O +
elevated O +
intracellular O +
cAMP O +
levels O +
in O +
GPM O +
cells O +
down O +
regulate O +
14,15-EET O +
binding O +
and O +
the O +
binding O +
sites O +
are O +
likely O +
associated O +
with O +
a O +
functional O +
receptor B-Gene -
. O +

The O +
fact O +
that O +
the O +
down O +
regulation O +
of O +
14,15-EET B-Gene +
receptor I-Gene +
binding O +
induced O +
by O +
cAMP O +
can O +
be O +
reversed O +
by O +
a O +
PKA B-Gene +
inhibitor O -
, O +
H-89 O -
, O +
further O +
suggest O +
these O +
processes O +
may O +
be O +
mediated O +
through O +
the O +
activation O +
of O +
PKA B-Gene +
linked O +
signal O +
transduction O +
pathway O -
. O +

The O +
high O +
concentration O +
( O -
μM O +
range O -
) O +
of O +
14,15-EET B-Gene +
required O +
to O +
increase O +
the O +
level O +
of O +
cAMP O +
possibly O +
due O +
to O +
phosphodiesterase B-Gene +
in O +
GPM O +
cells O +
being O +
active O +
that O +
cAMP O +
could O +
not O +
accumulate O +
even O +
in O +
the O +
presence O +
of O +
IBMX O -
. O +

Another O +
possibility O +
is O +
due O +
to O +
GPM O +
cells O +
that O +
might O +
have O +
different O +
types O +
of O +
phosphodiesterase B-Gene +
that O +
IBMX O +
can O -
not O +
effectively O +
inhibit O -
. O +

Although O +
it O +
seems O +
clear O +
that O +
14,15-EET O +
transduction O +
system O +
involves O +
cAMP O +
mediation O +
and O +
a O +
PKA B-Gene -
- O -
dependent O +
mechanism O -
, O +
the O +
precise O +
details O +
of O +
the O +
process O -
, O +
i.e. O +
whether O +
down O +
regulation O +
is O +
secondary O +
to O +
phosphorylation O +
of O +
receptor B-Gene +
protein I-Gene +
or O +
by O +
internalization O +
require O +
further O +
investigation O -
. O +

Salvia O +
is O +
an O +
important O +
genus O +
consisting O +
of O +
ca O +
900 O +
species O +
in O +
the O +
family O +
Lamiaceae O +
( O -
formerly O +
Labiatae O -
) O +
and O +
some O +
species O +
of O +
Salvia O +
have O +
been O +
cultivated O +
worldwide O +
for O +
use O +
in O +
folk O +
medicines O +
and O +
for O +
culinary O +
purposes O -
. O +

The O +
dried O +
root O +
of O +
Salvia O +
miltiorrhiza O +
( O -
Chinese O +
Danshen O -
) O -
, O +
for O +
example O -
, O +
has O +
been O +
used O +
extensively O +
for O +
the O +
treatment O +
of O +
coronary O +
heart O +
disease O -
, O +
cerebrovascular O +
disease O -
, O +
hepatitis O -
, O +
hepatocirrhosis O -
, O +
chronic O +
renal O +
failure O -
, O +
dysmenorrhea O +
and O +
neuroasthenic O +
insomnia O +
( O -
Li O -
, O +
1998 O +
) O -
. O +

Studies O +
on O +
the O +
chemical O +
constituents O +
of O +
Salvia O +
have O +
been O +
mainly O +
confined O +
to O +
the O +
diterpenoids O +
and O +
the O +
tanshinones O +
( O -
Chang O +
et O +
al. O -
, O +
1990 O -
; O +
Zhang O +
et O +
al. O -
, O +
1990 O +
) O +
and O +
several O +
reviews O +
on O +
these O +
components O +
have O +
now O +
been O +
published O +
( O -
Prokopenko O +
and O +
Litvinenko O -
, O +
1980 O -
; O +
Kong O -
, O +
1989 O -
; O +
Tang O +
and O +
Eisenbrand O -
, O +
1992 O -
; O +
Al O -
- O -
Hazimi O +
and O +
Miana O -
, O +
1994 O -
; O +
Rodriguez O -
- O -
Hahn O +
et O +
al. O -
, O +
1995 O -
; O +
Ulubelen O +
and O +
Topcu O -
, O +
1998 O +
) O -
. O +

However O -
, O +
in O +
recent O +
years O +
much O +
attention O +
has O +
been O +
directed O +
to O +
the O +
biologically O +
active O -
, O +
water O -
- O -
soluble O +
components O +
in O +
the O +
dried O +
root O +
decoction O +
used O +
in O +
traditional O +
medicine O +
( O -
Zhang O +
and O +
Liu O -
, O +
1996 O +
) O -
. O +

These O +
studies O -
, O +
particularly O +
in O +
China O -
, O +
have O +
led O +
to O +
the O +
isolation O +
and O +
identification O +
of O +
a O +
host O +
of O +
caffeic O +
acid O +
derived O +
metabolites O +
( O -
Li O -
, O +
1998 O +
) O -
, O +
many O +
of O +
which O +
possess O +
a O +
variety O +
of O +
biological O +
activities O +
including O +
antioxidant O -
, O +
antiplatelet O -
, O +
antitumor O +
and O +
antiviral O +
activity O +
( O -
see O +
Table O +
1 O +
) O -
. O +

This O +
review O +
is O +
written O +
to O +
take O +
into O +
account O +
of O +
the O +
rapid O +
development O +
in O +
the O +
phytochemistry O +
and O +
therapeutical O +
applications O +
of O +
species O +
of O +
Salvia O +
. O +

2 O +
Phenolic O +
acids O +
The O +
polar O +
phenolic O +
acids O +
constitute O +
the O +
major O +
part O +
of O +
the O +
water O -
- O -
soluble O +
components O +
of O +
the O +
Salvia O +
decoction O -
. O +

Most O +
of O +
the O +
phenolic O +
acids O +
identified O +
so O +
far O +
are O +
those O +
from O +
the O +
Chinese O +
Danshen O -
, O +
S. O +
miltiorrhiza O +
, O +
S. O +
chinensis O +
and O +
S. O +
yunnanensis O +
and O +
the O +
compounds O +
unique O +
to O +
Salvia O +
are O +
consequently O +
designated O +
salvianolic O +
acids O +
A O -
– O -
K O +
or O +
yunnaneic O +
acids O +
A O -
– O -
H O +
to O +
reflect O +
their O +
origin O +
( O -
see O +
Table O +
2 O +
) O -
. O +

Apart O +
from O +
a O +
few O +
simple O +
benzoic O +
acids O +
such O +
as O +
4-hydroxybenzoic O +
acid O +
( O -
Wang O +
et O +
al. O -
, O +
2000 O +
) O -
, O +
3,4-dihydroxybenzoic O +
acid O +
or O +
protocatechuic O +
acid O +
( O -
Wu O +
et O +
al. O -
, O +
1999a O +
) O -
, O +
3-methoxy-4-hydroxybenzoic O +
acid O +
or O +
vanillic O +
acid O +
( O -
Cuvelier O +
et O +
al. O -
, O +
1996 O +
) O +
and O +
2,4-dimethoxybenzoic O +
acid O +
( O -
Topcu O +
et O +
al. O -
, O +
1995 O +
) O -
, O +
an O +
ether O +
linked O +
dimer O +
of O +
hexyl O +
4-hydroxybenzoate O +
or O +
di O -
( O -
4-hexyloxycarbonylphenyl O -
) O -
ether O +
( O -
Ulubelen O +
et O +
al. O -
, O +
1995 O +
) O +
and O +
two O +
coumarins O +
6,7-dihydroxycoumarin O +
( O -
esculetin O -
) O +
( O -
Ulubelen O +
and O +
Tuzlaci O -
, O +
1990 O +
) O +
and O +
7-methoxycoumarin O +
( O -
herniarin O -
) O +
( O -
El O -
- O -
Missiry O +
et O +
al. O -
, O +
1994 O +
) O -
, O +
the O +
majority O +
of O +
the O +
phenolic O +
acids O +
in O +
Salvia O +
species O +
are O +
exclusively O +
those O +
of O +
caffeic O +
acid O +
( O -
1 O +
) O +
derivatives O -
, O +
which O +
are O +
unique O +
to O +
Salvia O +
except O +
for O +
rosmarinic O +
acid O +
( O -
2 O +
) O +
and O +
lithospermic O +
acid O +
( O -
9 O +
) O +
( O -
see O +
Fig. O +
1 O +
for O +
chemical O +
structures O -
) O -
. O +

2.1 O +
Caffeic O +
acid O +
metabolites O +
Caffeic O +
acid O +
plays O +
a O +
central O +
role O +
in O +
the O +
biochemistry O +
of O +
Lamiaceae O +
and O +
occurs O +
predominantly O +
in O +
the O +
dimer O +
form O +
as O +
rosmarinic O +
acid O +
( O -
Gerhardt O +
and O +
Schroeter O -
, O +
1983 O +
) O -
. O +

In O +
the O +
Salvia O +
species O +
the O +
caffeic O +
acid O +
is O +
the O +
building O +
block O +
of O +
a O +
variety O +
of O +
the O +
plant O +
metabolites O +
from O +
the O +
more O +
simple O +
monomers O +
to O +
multiple O +
condensation O +
products O +
to O +
give O +
rise O +
to O +
a O +
variety O +
of O +
oligomers O -
. O +

The O +
trimers O +
and O +
tetramers O +
are O +
more O +
interesting O +
from O +
the O +
therapeutic O +
point O +
of O +
view O +
as O +
they O +
have O +
been O +
shown O +
to O +
possess O +
significant O +
biological O +
activities O -
. O +

2.1.1 O +
Caffeic O +
acid O +
monomers O +
The O +
monomers O +
that O +
are O +
frequently O +
present O +
in O +
Salvia O +
are O +
represented O +
by O +
caffeic O +
acid O +
itself O +
and O +
3- O -
( O -
3,4-dihydroxyphenyl O -
) O -
lactic O +
acid O +
( O -
3 O +
) O +
( O -
Qian O +
and O +
Li O -
, O +
1992 O +
) O -
. O +

The O +
latter O +
compound O -
, O +
also O +
known O +
as O +
danshensu O +
( O -
Chinese O +
word O +
to O +
mean O +
literally O +
the O +
element O +
of O +
Danshen O -
) O +
was O +
first O +
isolated O +
from O +
S. O +
miltiorrhiza O +
( O -
Yang O +
and O +
Zhang O -
, O +
1981 O +
) O +
and O +
found O +
to O +
be O +
a O +
coronary O +
vasodilator O +
and O +
to O +
scavenge O +
the O +
free O +
oxygen O +
radicals O +
generated O +
during O +
ischemia O -
- O -
reperfusion O +
injury O +
in O +
the O +
myocardium O +
as O +
effectively O +
as O +
superoxide B-Gene +
dismutase I-Gene +
( O -
SOD B-Gene -
) O +
( O -
Zhao O +
et O +
al. O -
, O +
1996 O +
) O -
. O +

The O +
amide O +
of O +
3 O +
, O +
3- O -
( O -
3,4-dihydroxyphenyl O -
) O -
lactamide O +
( O -
4 O +
) O -
, O +
also O +
found O +
in O +
S. O +
miltiorrhiza O +
, O +
had O +
been O +
reported O +
to O +
possess O +
radical O +
scavenging O +
activity O +
greater O +
than O +
ascorbic O +
acid O +
( O -
Kang O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

Other O +
monomeric O +
derivatives O +
including O +
ferulic O +
acid O +
( O -
Cuvelier O +
et O +
al. O -
, O +
1996 O +
) O -
, O +
isoferulic O +
acid O +
( O -
Ai O +
and O +
Li O -
, O +
1992 O +
) O +
and O +
two O +
caffeic O +
acid O +
esters O +
mono O -
- O -
feruloyl O -
- O -
R O +
, O -
R O +
- O -
( O -
+ O -
) O -
-tartaric O +
acid O +
( O -
6 O +
) O +
( O -
Qian O +
et O +
al. O -
, O +
1993 O +
) O +
and O +
chlorogenic O +
acid O +
( O -
5-caffeoylquinic O +
acid O -
) O +
( O -
7 O +
) O +
( O -
Kokkalou O +
and O +
Kapetanidis O -
, O +
1988 O +
) O +
have O +
also O +
been O +
described O +
as O +
Salvia O +
constituents O -
. O +

The O +
identification O +
of O +
mono O -
- O -
feruloyl O -
- O -
R O +
, O -
R O +
- O -
( O -
+ O -
) O -
-tartaric O +
acid O +
has O +
been O +
corroborated O +
by O +
chemical O +
synthesis O -
, O +
along O +
with O +
its O +
two O +
S O +
, O -
S O +
- O -
( O -
- O -
) O -
- O +
and O +
R O +
, O -
S O +
- O -
( O -
meso O +
) O -
-isomers O -
. O +

Chlorogenic O +
acid O -
, O +
despite O +
being O +
common O +
and O +
widespread O +
in O +
fruits O -
, O +
is O +
surprisingly O +
uncommon O +
in O +
Lamiaceae O -
, O +
which O +
is O +
generally O +
dominated O +
by O +
rosmarinic O +
acid O +
( O -
Gerhardt O +
and O +
Schroeter O -
, O +
1983 O +
) O -
. O +

Caffeic O +
acids O +
esterified O +
with O +
sugars O +
are O +
quite O +
common O +
in O +
nature O +
and O +
those O +
identified O +
in O +
Salvia O +
are O +
discussed O +
under O +
Phenolic O +
Glycosides O +
( O -
see O +
below O -
) O -
. O +

2.1.2 O +
Caffeic O +
acid O +
dimers O +
Rosmarinic O +
acid O +
( O -
2 O +
) O +
is O +
the O +
most O +
abundant O +
caffeic O +
acid O +
dimer O +
in O +
Salvia O +
species O +
( O -
Ai O +
and O +
Li O -
, O +
1988 O -
; O +
Cuvelier O +
et O +
al. O -
, O +
1994 O -
; O +
Lu O +
and O +
Foo O -
, O +
1999 O +
) O +
and O +
has O +
been O +
reported O +
to O +
be O +
the O +
major O +
phenolic O +
compound O +
responsible O +
for O +
the O +
high O +
antioxidant O +
activity O +
of O +
Salvia O +
samples O +
( O -
Cuvelier O +
et O +
al. O -
, O +
1996 O +
) O -
. O +

There O +
have O +
been O +
many O +
publications O +
on O +
rosmarinic O +
acid O +
dealing O +
with O +
its O +
detection O +
and O +
quantitative O +
estimation O +
in O +
various O +
Salvia O +
preparations O +
( O -
Janicsak O +
and O +
Mathe O -
, O +
1997 O -
; O +
Yuan O +
et O +
al. O -
, O +
1998 O -
; O +
Areias O +
et O +
al. O -
, O +
2000 O +
) O -
, O +
its O +
biochemical O +
production O +
in O +
cell O +
cultures O +
( O -
Morimoto O +
et O +
al. O -
, O +
1994 O +
) O +
or O +
chemical O +
synthesis O +
( O -
Eicher O +
et O +
al. O -
, O +
1996 O +
) O +
and O +
its O +
metabolism O +
in O +
rats O +
( O -
Nakazawa O +
and O +
Ohsawa O -
, O +
1998 O +
) O -
. O +

Other O +
types O +
of O +
dimers O +
identified O +
in O +
Salvia O +
include O +
przewalskinic O +
acid O +
A O +
( O -
8 O +
) O +
from O +
the O +
Tibetan O +
sage O +
S. O +
przewalskii O +
( O -
Lu O +
et O +
al. O -
, O +
1991 O +
) O -
, O +
salvianolic O +
acid O +
G O +
( O -
11 O +
) O +
( O -
Ai O +
and O +
Li O -
, O +
1991 O +
) O +
and O +
the O +
stilbenoid O +
salvianolic O +
acid O +
F O +
or O +
2- O -
( O -
3,4-dihydroxystyryl O -
) O -
caffeic O +
acid O +
( O -
12 O +
) O +
( O -
Ai O +
and O +
Li O -
, O +
1996 O +
) O +
both O +
from O +
S. O +
miltiorrhiza O +
. O +

The O +
dihydrobenzofuran O +
compound O +
przewalskinic O +
acid O +
A O +
is O +
apparently O +
related O +
to O +
lithospermic O +
acid O +
( O -
9 O +
) O +
and O +
salvianolic O +
acid O +
B O +
or O +
lithospermic O +
acid O +
B O +
( O -
10 O +
) O -
, O +
whereas O +
salvianolic O +
acid O +
G O -
, O +
with O +
a O +
dibenzooxepin O +
skeleton O -
, O +
is O +
the O +
first O +
of O +
its O +
kind O +
found O +
in O +
Salvia O +
. O +

Salvianolic O +
acid O +
F O -
, O +
which O +
has O +
been O +
synthesised O +
by O +
Dalla O +
and O +
Cotelle O +
( O -
1999 O -
) O +
, O +
is O +
a O +
decarboxylated O +
caffeic O +
acid O +
dimer O -
. O +

In O +
addition O -
, O +
Ulubelen O +
and O +
co O -
- O -
workers O +
( O -
1996 O -
) O +
have O +
reported O +
the O +
existence O +
of O +
two O +
isomeric O +
caffeic O +
acid O +
ester O +
dimers O +
linked O +
by O +
ether O +
bond O -
, O +
namely O +
the O +
dioctyl O +
3-O O +
-3′-di O -
- O -
cis O +
- O +
and O +
di O -
- O -
trans O +
-isoferulate O +
( O -
14 O +
, O +
15 O +
) O +
in O +
S. O +
forskahlei O +
. O +

2.1.3 O +
Caffeic O +
acid O +
trimers O +
Trimers O +
derived O +
from O +
caffeic O +
acid O +
constitute O +
the O +
largest O +
group O +
of O +
metabolites O +
in O +
Salvia O -
. O +

They O +
include O +
compounds O +
such O +
as O +
lithospermic O +
acid O +
( O -
9 O +
) O +
( O -
Qian O +
and O +
Li O -
, O +
1992 O +
) O -
, O +
salvianolic O +
acids O +
H O +
( O -
16 O +
) O +
( O -
Zhang O +
and O +
Li O -
, O +
1993 O +
) O -
, O +
I O +
( O -
17 O +
) O +
( O -
Zhang O +
and O +
Li O -
, O +
1994 O +
) O -
, O +
J O +
( O -
18 O +
) O +
( O -
Ai O +
et O +
al. O -
, O +
1994 O +
) O +
and O +
K O +
( O -
19 O +
) O +
( O -
Tezuka O +
et O +
al. O -
, O +
1998 O -
; O +
Lu O +
and O +
Foo O -
, O +
1999 O +
) O -
, O +
sagecoumarin O +
( O -
20 O +
) O +
( O -
Lu O +
et O +
al. O -
, O +
1999 O +
) O -
, O +
three O +
decarboxylated O +
forms O +
of O +
salvianolic O +
acids O +
A O +
( O -
13 O +
) O +
( O -
Li O +
et O +
al. O -
, O +
1984 O +
) O -
, O +
C O +
( O -
21 O +
) O +
( O -
Ai O +
and O +
Li O -
, O +
1988 O +
) O +
and O +
isosalvianolic O +
acid O +
C O +
( O -
22 O +
) O +
( O -
Qian O +
and O +
Li O -
, O +
1992 O +
) O +
as O +
well O +
as O +
yunnaneic O +
acids O +
C O +
( O -
24 O +
) O -
, O +
D O +
( O -
25 O +
) O -
, O +
E O +
( O -
26 O +
) O +
and O +
F O +
( O -
27 O +
) O +
( O -
Tanaka O +
et O +
al. O -
, O +
1996 O -
; O +
1997 O +
) O -
. O +

These O +
last O +
mentioned O +
are O +
apparent O +
Diels O -
– O -
Alder O +
adducts O +
of O +
caffeic O +
acids O -
. O +

Lithospermic O +
acid O +
and O +
both O +
its O +
mono O -
- O -
and O +
dimethyl O +
esters O +
were O +
the O +
active O +
components O +
that O +
inhibited O +
adenylate B-Gene +
cyclase I-Gene +
( O -
Kohda O +
et O +
al. O -
, O +
1989 O +
) O -
. O +

In O +
addition O -
, O +
dimethyl O +
lithospermate O +
was O +
also O +
shown O +
to O +
be O +
a O +
stronger O +
radical O +
scavenger O +
than O +
ascorbic O +
acid O +
( O -
Kang O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

The O +
new O +
member O +
of O +
the O +
salvianolic O +
acid O +
series O +
is O +
salvianolic O +
acid O +
K O +
and O +
its O +
presence O +
has O +
been O +
detected O +
by O +
LC O -
– O -
MS O +
in O +
10 O +
Salvia O +
species O +
( O -
Kasimu O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

Salvianolic O +
acid O +
A O -
, O +
the O +
stilbenoid O +
caffeic O +
acid O +
trimer O +
has O +
been O +
shown O +
to O +
possess O +
a O +
strong O +
oxygen O +
free O +
radical O +
scavenging O +
activity O +
( O -
Huang O +
and O +
Zhang O -
, O +
1992 O -
; O +
Li O +
et O +
al. O -
, O +
1995 O +
) O +
which O +
may O +
be O +
the O +
basis O +
for O +
some O +
of O +
its O +
biological O +
activities O +
( O -
see O +
Table O +
1 O +
) O -
. O +

Salvianolic O +
acid O +
A O +
is O +
apparently O +
not O +
very O +
stable O +
and O +
its O +
reactivity O +
has O +
been O +
demonstrated O +
by O +
its O +
conversion O +
to O +
salvianolic O +
acid O +
C O +
on O +
a O +
TLC O +
plate O +
that O +
was O +
impregnated O +
with O +
2 O -
% O +
of O +
formic O +
acid O +
solution O -
. O +

This O +
suggested O +
that O +
salvianolic O +
acid O +
C O -
, O +
a O +
benzofuran O +
compound O -
, O +
was O +
likely O +
a O +
cyclization O +
product O +
of O +
salvianolic O +
acid O +
A O +
( O -
Ai O +
and O +
Li O -
, O +
1988 O +
) O -
. O +

Isosalvianolic O +
acid O +
C O -
, O +
a O +
second O +
depside O +
to O +
salvianolic O +
acid O +
G O +
with O +
a O +
dibenzooxepin O +
skeleton O -
, O +
has O +
been O +
identified O +
only O +
in O +
S. O +
chinensis O +
along O +
with O +
salvianolic O +
acid O +
D O +
( O -
23 O +
) O +
( O -
Qian O +
and O +
Li O -
, O +
1992 O +
) O -
, O +
the O +
latter O +
could O +
be O +
considered O +
as O +
an O +
abridged O +
caffeic O +
acid O +
trimer O +
that O +
was O +
first O +
found O +
in O +
S. O +
miltiorrhiza O +
( O -
Ai O +
and O +
Li O -
, O +
1992 O +
) O -
. O +

Yunnaneic O +
acids O +
C O +
and O +
D O +
both O +
of O +
which O +
contain O +
the O +
bicyclo O -
[ O -
2.2.2 O -
] O -
octane O +
core O +
structure O +
appear O +
to O +
be O +
the O +
Diels O -
– O -
Alder O +
adducts O +
involving O +
the O +
double O +
bond O +
of O +
the O +
caffeic O +
acid O +
and O +
the O +
phenol O +
ring O +
or O +
its O +
quinone O +
form O +
in O +
a O +
rosmarinic O +
acid O +
moiety O -
. O +

Further O +
oxidation O +
of O +
yunnaneic O +
acid O +
C O +
resulted O +
in O +
the O +
formation O +
of O +
yunnaneic O +
acid O +
E O +
while O +
the O +
addition O +
of O +
an O +
acetyl O +
group O +
to O +
the O +
bicyclo O -
[ O -
2.2.2 O -
] O -
octa-1,2-dione O +
skeleton O +
in O +
yunnaneic O +
acid O +
C O +
led O +
to O +
yunnaneic O +
acid O +
F. O +
2.1.4 O +
Caffeic O +
acid O +
tetramers O +
Caffeic O +
acid O +
tetramers O +
are O +
in O +
effect O +
dimerised O +
rosmarinic O +
acids O +
as O +
in O +
salvianolic O +
acids O +
B O +
( O -
10 O +
) O +
( O -
Ai O +
and O +
Li O -
, O +
1988 O +
) O -
, O +
E O +
( O -
28 O +
) O +
( O -
Ai O +
and O +
Li O -
, O +
1992 O +
) O +
and O +
L O +
( O -
32 O +
) O +
( O -
Lu O +
and O +
Foo O -
, O +
2001b O +
) O -
, O +
rabdosiin O +
( O -
29 O +
) O -
, O +
yunnaneic O +
acids O +
G O +
( O -
30 O +
) O +
and O +
H O +
( O -
31 O +
) O +
( O -
Tanaka O +
et O +
al. O -
, O +
1997 O +
) O -
, O +
and O +
sagerinic O +
acid O +
( O -
33 O +
) O +
( O -
Lu O +
and O +
Foo O -
, O +
1999 O +
) O -
. O +

Distribution O +
of O +
salvianolic O +
acid O +
E O +
is O +
more O +
restricted O +
and O +
has O +
been O +
reported O +
only O +
in O +
S. O +
miltiorrhiza O +
while O +
salvianolic O +
acid O +
B O -
, O +
which O +
is O +
also O +
known O +
as O +
lithospermic O +
acid O +
B O -
, O +
is O +
more O +
common O +
in O +
Salvia O +
species O +
and O +
occurs O +
mainly O +
as O +
potassium O -
, O +
ammonium O +
or O +
magnesium O +
salts O -
. O +

These O +
salts O +
constitute O +
largely O +
the O +
most O +
important O +
bioactive O +
Salvia O +
components O +
in O +
sage O +
( O -
see O +
Table O +
1 O +
) O -
. O +

Three O +
methyl O +
esters O +
of O +
lithospermic O +
acid O +
B O -
, O +
namely O +
the O +
9′- O +
and O +
9‴-monomethyl O +
lithospermate O +
B O +
and O +
dimethyl O +
lithospermate O +
B O -
, O +
have O +
been O +
found O +
recently O +
in O +
Tibetan O +
sage O +
together O +
with O +
other O +
known O +
polyphenolic O +
compounds O +
( O -
Wu O +
et O +
al. O -
, O +
1999b O +
) O -
. O +

In O +
addition O +
to O +
the O +
yunnaneic O +
acids O +
C O +
to O +
F O +
mentioned O +
above O -
, O +
Tanaka O +
et O +
al. O +
( O -
1997 O -
) O +
have O +
also O +
identified O +
three O +
oxidatively O +
cyclized O +
rosmarinic O +
acid O +
dimers O +
with O +
a O +
1,2-dihydronaphthalene O +
core O +
comprising O +
of O +
rabdosiin O -
, O +
yunnaneic O +
acids O +
G O +
and O +
H O +
in O +
S. O +
yunnanesis O -
. O +

Most O +
recently O -
, O +
salvianolic O +
acid O +
L O -
, O +
an O +
isomer O +
of O +
rabdosiin O +
or O +
yunnaneic O +
acid O +
G O -
, O +
has O +
been O +
found O +
in O +
S. O +
officinalis O +
. O +

In O +
addition O -
, O +
a O +
more O +
structurally O +
interesting O +
new O +
type O +
of O +
[ O -
2 O -
+ O -
2 O -
] O -
-rosmarinic O +
acid O +
dimer O +
is O +
sagerinic O +
acid O +
reported O +
in O +
S. O +
officinalis O +
, O +
which O +
contained O +
a O +
cyclobutane O +
ring O +
in O +
the O +
μ O -
- O -
truxinate O +
form O -
. O +

Sagerinic O +
acid O +
is O +
the O +
first O +
example O +
of O +
a O +
natural O +
[ O -
2 O -
+ O -
2 O -
] O -
-dimers O +
of O +
caffeic O +
acid O +
esters O -
. O +

2.1.5 O +
Higher O +
caffeic O +
acid O +
oligomers O +
Yunnaneic O +
acids O +
A O +
( O -
34 O +
) O +
and O +
B O +
( O -
35 O +
) O +
found O +
in O +
S. O +
yunnanesis O +
( O -
Tanaka O +
et O +
al. O -
, O +
1996 O +
) O +
are O +
the O +
only O +
known O +
hexamers O +
of O +
caffeic O +
acid O -
. O +

These O +
two O +
compounds O +
could O +
be O +
formed O +
by O +
spiroacetal O +
bonding O +
between O +
yunnaneic O +
acid O +
C O +
( O -
24 O +
) O +
and O +
yunnaneic O +
acid O +
D O +
( O -
25 O +
) O +
or O +
between O +
two O +
molecules O +
of O +
24 O +
. O +

The O +
presence O +
of O +
these O +
Diels O -
– O -
Alder O +
type O +
adducts O +
in O +
S. O +
yunnanesis O +
indicates O +
the O +
complexity O +
in O +
the O +
biochemistry O +
of O +
plant O +
metabolism O -
. O +

2.2 O +
Phenolic O +
glycosides O +
The O +
phenolic O +
glycosides O +
are O +
apparently O +
not O +
very O +
common O +
in O +
Salvia O +
and O +
rosmarinic O +
acid O +
3′-glucoside1 O +
1 O +
Unless O +
otherwise O +
mentioned O -
, O +
common O +
sugars O +
glucose O -
, O +
galactose O -
, O +
xylose O -
, O +
arabinose O -
, O +
rhamnose O -
, O +
fructose O +
and O +
apiose O +
denote O +
β O -
- O -
d O +
-glucopyranose O -
, O +
β O -
- O -
d O +
-galactopyranose O -
, O +
β O -
- O -
d O +
-xylopyranose O -
, O +
α O -
- O -
l O +
-arabiopyranose O -
, O +
α O -
- O -
l O +
-rhamnopyranose O -
, O +
β O -
- O -
d O +
-fructofuranose O +
and O +
β O -
- O -
d O +
-apiofuranose O -
, O +
respectively O -
. O +

( O -
salviaflaside O -
) O +
( O -
36 O +
) O +
and O +
its O +
methyl O +
ester O +
( O -
Zhao O +
et O +
al. O -
, O +
1996a O +
) O +
as O +
well O +
as O +
the O +
cis O +
and O +
trans O +
-p O +
-coumaric O +
acid O +
4-O O +
- O -
( O -
2-O O +
-apiosyl O -
) O -
glucosides O +
( O -
37 O +
, O +
38 O +
) O +
( O -
Lu O +
and O +
Foo O -
, O +
2000 O +
) O +
are O +
the O +
only O +
examples O +
of O +
the O +
glycosylated O +
phenolic O +
acids O -
. O +

In O +
contrast O +
the O +
phenolic O +
acids O +
esterified O +
with O +
sugars O -
, O +
in O +
which O +
the O +
phenolic O +
acids O +
serve O +
as O +
acylating O +
agents O +
to O +
give O +
rise O +
to O +
acylated O +
sugars O -
, O +
are O +
more O +
common O -
. O +

These O +
acylated O +
sugars O +
include O +
6-O O +
-feruloyl O -
- O -
α- O +
and O +
β O -
- O -
glucose O +
( O -
39 O +
, O +
40 O +
) O +
( O -
Wang O +
et O +
al. O -
, O +
1998 O +
) O -
, O +
1-O O +
- O -
( O -
2,3,4-trihydroxy-3-methyl O -
) O -
butyl-6-O O +
-feruloylglucoside O +
( O -
41 O +
) O +
( O -
Wang O +
et O +
al. O -
, O +
2000 O +
) O -
, O +
6-O O +
-caffeoyl-1-O O +
-fructosyl O -
- O -
α O -
- O -
glucoside O +
( O -
42 O +
) O -
, O +
1-O O +
-caffeoyl-6-O O +
-apiosylglucoside O +
( O -
43 O +
) O -
, O +
1-O O +
-p O +
-hydroxybenzoyl-6-O O +
-apiosylglucoside O +
( O -
44 O +
) O -
, O +
all O +
from O +
S. O +
officinalis O +
( O -
Wang O +
et O +
al. O -
, O +
1999 O +
) O -
, O +
and O +
prionitisides O +
A O +
( O -
45 O +
) O +
and O +
B O +
( O -
46 O +
) O +
from O +
S. O +
prionitis O +
. O +

The O +
structures O +
of O +
prionitisides O +
A O +
and O +
B O +
were O +
elucidated O +
as O +
2- O -
( O -
3,4-dihydroxyphenyl O -
) O -
-3-glucosyloxycarbonyl-4,6-dihydroxybenzofuran O +
and O +
2- O -
( O -
3,4-dihydroxyphenyl O -
) O -
-3-rutinosyloxy O +
carbonyl-4,6-dihydroxybenzofuran O -
, O +
respectively O +
( O -
Zhao O +
et O +
al. O -
, O +
1996b O +
) O -
. O +

Several O +
phenolic O +
acetophenone O +
glycosides O +
have O +
been O +
also O +
identified O +
in O +
S. O +
officinalis O +
and O +
these O +
include O +
4-hydroxyacetophenone O +
4-O O +
-glucoside O +
( O -
picein O -
) O +
( O -
47 O +
) O -
, O +
4-hydroxyacetophenone O +
4-O O +
- O -
( O -
6-O O +
-apiosyl O -
) O -
glucoside O +
( O -
48 O +
) O -
, O +
4-hydroxyacetophenone O +
4-O O +
- O -
( O -
2-O O +
- O -
( O -
5-O O +
-syringoylapiosyl O -
) O -
glucoside O -
) O +
( O -
49 O +
) O +
( O -
Wang O +
et O +
al. O -
, O +
2000 O +
) O -
. O +

Also O +
present O +
in O +
S. O +
officinalis O +
are O +
glycosides O +
of O +
neolignans O +
namely O +
1-hydroxypinoresinol O +
1-O O +
-glucoside O +
( O -
50 O +
) O -
, O +
isolariciresinol O +
3α O -
- O -
O O +
-glucoside O +
( O -
51 O +
) O +
and O +
2- O -
( O -
3-methoxy-4-glucosyloxyphenyl O -
) O -
-3-hydroxymethyl-5- O -
( O -
3-hydroxypropyl O -
) O -
-7-methoxy-2,3-dihydrobenzofuran O +
( O -
52 O -
) O +
( O -
Wang O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

In O +
addition O -
, O +
two O +
related O +
isolariciresinol O +
compounds O +
feruloyl O -
- O -
secoisolariciresinol O +
12-methylmyristate O +
( O -
53 O +
) O +
( O -
Powell O +
and O +
Plattner O -
, O +
1976 O +
) O +
and O +
secoisolariciresinol O +
di O -
( O -
12-methylmyristate O -
) O +
( O -
54 O +
) O +
( O -
Plattner O +
and O +
Powell O -
, O +
1978 O +
) O +
and O +
a O +
structurally O +
related O +
compound O +
to O +
52 O +
2- O -
( O -
3-methoxy-4-hydroxyphenyl O -
) O -
-5- O -
( O -
3-hydroxypropyl O -
) O -
-7-methoxybenzofuran-3-carbaldehyde O +
( O -
55 O +
) O +
( O -
Yang O +
et O +
al. O -
, O +
1991 O +
) O +
have O +
been O +
reported O +
in O +
the O +
seed O +
of O +
S. O +
plebeia O +
and O +
in O +
the O +
root O +
of O +
S. O +
miltiorrhiza O -
, O +
respectively O -
. O +

Compound O +
55 O +
has O +
also O +
been O +
produced O +
synthetically O +
( O -
Kuo O +
and O +
Wu O -
, O +
1996 O +
) O +
and O +
shown O +
to O +
be O +
a O +
novel O +
adenosine B-Gene +
A1 I-Gene +
receptor I-Gene +
ligand O -
. O +

3 O +
Flavonoids O +
Flavonoids O +
are O +
widely O +
distributed O +
in O +
species O +
of O +
Salvia O +
( O -
Sagdullaeva O +
and O +
Khazanovich O -
, O +
1972 O -
; O +
Smirnova O +
et O +
al. O -
, O +
1974b O -
; O +
Adzet O +
et O +
al. O -
, O +
1987 O -
; O +
Ulubelen O +
and O +
Tuzlaci O -
, O +
1990 O +
) O -
, O +
being O +
mostly O +
present O +
as O +
flavones O -
, O +
flavonols O +
and O +
their O +
glycosides O +
( O -
see O +
Tables O +
3 O +
and O +
4 O +
) O -
. O +

The O +
6-hydroxylated O +
flavones O +
have O +
been O +
reported O +
to O +
be O +
of O +
particularly O +
taxonomic O +
significance O +
to O +
this O +
genus O +
( O -
Tomas O -
- O -
Barberan O +
and O +
Wollenweber O -
, O +
1990 O +
) O -
. O +

3.1 O +
Flavone O +
and O +
flavonol O +
aglycones O +
The O +
majority O +
of O +
flavonoids O +
are O +
flavones O +
of O +
apigenin O +
( O -
5,7,4′-trihydroxyflavone O -
) O +
( O -
56 O +
) O +
and O +
luteolin O +
( O -
5,7,3′,4′-tetrahydroxyflavone O -
) O +
( O -
60 O +
) O +
and O +
their O +
corresponding O +
6-hydroxylated O +
derivatives O -
. O +

The O +
methyl O +
ethers O +
of O +
flavones O +
are O +
widely O +
distributed O +
in O +
the O +
leaves O +
of O +
Salvia O +
or O +
in O +
the O +
exudate O +
from O +
aerial O +
parts O +
( O -
Wollenweber O -
, O +
1974 O -
; O +
Wollenweber O +
et O +
al. O -
, O +
1992 O +
) O -
. O +

The O +
etherification O +
of O +
apigenin O +
seemed O +
to O +
occur O +
preferably O +
on O +
the O +
phenolic O +
7-OH O +
while O +
the O +
catechol O +
B O -
- O -
ring O +
of O +
luteolin O +
is O +
etherified O +
before O +
the O +
A O -
- O -
ring O -
. O +

Thus O +
apigenin O +
7-methyl O +
ether O +
( O -
genkwanin O -
) O +
( O -
57 O +
) O +
and O +
7,4′-dimethyl O +
ether O +
( O -
59 O +
) O +
are O +
common O +
( O -
Wollenweber O +
et O +
al. O -
, O +
1992 O +
) O +
while O +
the O +
4′-methyl O +
ether O +
( O -
acacetin O -
) O +
( O -
58 O +
) O +
has O +
been O +
found O +
only O +
in O +
S. O +
nicolsoniana O +
( O -
Pereda O -
- O -
Miranda O +
and O +
Delgado O -
, O +
1986 O +
) O +
and O +
S. O +
yosgadensis O +
( O -
Topcu O +
et O +
al. O -
, O +
1996 O +
) O -
. O +

Likewise O -
, O +
luteolin O +
3′-methyl O +
ether O +
( O -
chrysoeriol O -
) O +
( O -
62 O +
) O +
and O +
4′-methyl O +
ether O +
( O -
diosmetin O -
) O +
( O -
63 O +
) O +
are O +
more O +
frequently O +
encountered O +
( O -
Wollenweber O +
et O +
al. O -
, O +
1992 O -
; O +
Topcu O +
et O +
al. O -
, O +
1995 O +
) O -
, O +
followed O +
by O +
7-methyl O +
ether O +
( O -
61 O +
) O +
and O +
7,3′,4′-trimethyl O +
ether O +
( O -
66 O +
) O +
( O -
Ulubelen O +
and O +
Tuzlaci O -
, O +
1990 O +
) O -
. O +

Luteolin O +
7,4′-dimethyl O +
ether O +
( O -
64 O +
) O +
( O -
Miski O +
et O +
al. O -
, O +
1983 O +
) O +
and O +
3′,4′-dimethyl O +
ether O +
( O -
65 O +
) O +
( O -
Pereda O -
- O -
Miranda O +
and O +
Delgado O -
, O +
1986 O +
) O +
have O +
only O +
been O +
reported O +
once O +
before O +
in O +
S. O +
palaestina O +
and O +
S. O +
nicolsoniana O +
, O +
respectively O -
. O +

The O +
6-hydroxyflavones O +
are O +
the O +
flavonoids O +
that O +
characterise O +
species O +
of O +
Salvia O +
. O +

They O +
include O +
a O +
variety O +
of O +
6-hydroxylated O +
apigenin O +
and O +
luteolin O +
derivatives O -
, O +
with O +
6-hydroxyapigenin-6,7-dimethyl O +
ether O +
( O -
cirsimaritin O -
) O +
( O -
69 O +
) O -
, O +
6,7,4′-trimethyl O +
ether O +
( O -
salvigenin O -
) O +
( O -
72 O +
) O -
, O +
and O +
6-hydroxyluteolin O +
6-methyl O +
ether O +
( O -
nepetin O +
or O +
eupafolin O -
) O +
( O -
75 O +
) O -
, O +
6,7-dimethyl O +
ether O +
( O -
cirsiliol O -
) O +
( O -
77 O +
) O -
, O +
6,7,4′-trimethyl O +
ether O +
( O -
eupatorin O -
) O +
( O -
81 O +
) O +
and O +
6,7,3′,4′-tetramethyl O +
ether O +
( O -
83 O +
) O +
being O +
the O +
most O +
common O +
( O -
Tomas O -
- O -
Lorente O +
et O +
al. O -
, O +
1988 O -
; O +
Wollenweber O +
et O +
al. O -
, O +
1992 O +
) O -
. O +

6-Hydroxyapigenin O +
( O -
scutellarein O -
) O +
itself O +
( O -
67 O +
) O +
was O +
only O +
detected O +
in O +
sage O +
extracts O +
by O +
HPLC O +
( O -
Cuvelier O +
et O +
al. O -
, O +
1996 O +
) O +
and O +
other O +
6-hydroxyapigenin O +
methyl O +
ethers O +
including O +
6-methyl O +
ether O +
( O -
hispidulin O -
) O +
( O -
68 O +
) O -
, O +
6,4′-dimethyl O +
ether O +
( O -
pectolinarigenin O -
) O +
( O -
70 O +
) O -
, O +
7,4′-dimethyl O +
ether O +
( O -
71 O +
) O +
and O +
5,6,7,4′-tetramethyl O +
ether O +
( O -
5-methoxysalvigenin O -
) O +
( O -
73 O +
) O +
were O +
reported O +
only O +
occasionally O -
, O +
as O +
were O +
the O +
6-hydroxyluteolin O +
7-methyl O +
ether O +
( O -
pedalitin O -
) O +
( O -
76 O +
) O -
, O +
6,3′-dimethyl O +
ether O +
( O -
jaceosidin O -
) O +
( O -
78 O +
) O -
, O +
7,4′-dimethyl O +
ether O +
( O -
nuchensin O -
) O +
( O -
79 O +
) O -
, O +
6,7,3′-trimethyl O +
ether O +
( O -
cirsilineol O -
) O +
( O -
80 O +
) O +
and O +
6,3′,4′-trimethyl O +
ether O +
( O -
eupatilin O -
) O +
( O -
82 O +
) O -
. O +

Cirsimaritin O +
was O +
reported O +
to O +
have O +
a O +
high O +
anti O -
- O -
microbial O +
activity O +
against O +
several O +
bacteria O +
strains O +
( O -
Miski O +
et O +
al. O -
, O +
1983 O +
) O +
while O +
hispidulin O +
possessed O +
antihepatotoxic O +
activity O +
( O -
Oshima O +
et O +
al. O -
, O +
1984 O +
) O -
. O +

In O +
a O +
more O +
recent O +
report O +
( O -
Viola O +
et O +
al. O -
, O +
1998 O +
) O -
, O +
the O +
sedative O -
- O -
depressant O +
property O +
for O +
cirsiliol O +
was O +
described O -
. O +

An O +
unusual O +
flavone O +
which O +
lacks O +
the O +
5-OH O +
group O -
, O +
namely O +
6,7,3′,4′-tetramethoxyflavone O +
( O -
74 O +
) O -
, O +
was O +
described O +
by O +
Miski O +
et O +
al. O +
( O -
1983 O -
) O +
. O +

The O +
8-hydroxylated O +
flavones O +
are O +
rare O +
in O +
Salvia O +
, O +
with O +
8-hydroxyapigenin O +
7-methyl O +
ether O +
( O -
salvitin O -
) O +
( O -
85 O +
) O +
being O +
the O +
only O +
representative O +
found O +
in O +
S. O +
plebeia O +
( O -
Gupta O +
et O +
al. O -
, O +
1975 O +
) O +
while O +
8-hydroxyapigenin O +
( O -
isoscutellarein O -
) O +
( O -
84 O +
) O +
itself O +
was O +
detected O +
by O +
HPLC O +
in O +
sage O +
samples O +
( O -
Cuvelier O +
et O +
al. O -
, O +
1996 O +
) O -
. O +

The O +
four O +
dihydroflavones O +
that O +
have O +
been O +
described O +
to O +
date O +
in O +
Salvia O +
include O +
5-hydroxy-7-methoxyflavanone O +
( O -
86 O +
) O +
( O -
Gonzalez O +
et O +
al. O -
, O +
1989 O +
) O -
, O +
5,7-dihydroxy-4′-methoxyflavanone O +
( O -
isosakuranetin O +
or O +
narigenin-4′-methyl O +
ether O -
) O +
( O -
87 O +
) O +
( O -
Pereda O -
- O -
Miranda O +
and O +
Delgado O -
, O +
1986 O +
) O -
, O +
5,7,3′-trihydroxy-4′-methoxyflavanone O +
( O -
hesperetin O -
) O +
( O -
88 O +
) O +
( O -
Cuvelier O +
et O +
al. O -
, O +
1996 O +
) O +
and O +
5,3′-dihydroxy-7,4′-dimethoxyflavanone O +
( O -
89 O +
) O -
. O +

The O +
last O +
mentioned O +
compound O +
was O +
also O +
found O +
to O +
possess O +
coronary O +
dilator O +
activity O +
( O -
Chen O +
et O +
al. O -
, O +
1986 O +
) O -
. O +

Flavonols O +
are O +
mostly O +
those O +
of O +
kaempferol O +
( O -
5,7,4′-trihydroxyflavonol O -
) O +
and O +
quercetin O +
( O -
5,7,3′,4′-tetrahydroxyflavonol O -
) O +
methyl O +
ethers O -
. O +

Kaempferol O +
( O -
90 O +
) O +
itself O +
was O +
present O +
in O +
S. O +
farinacea O +
( O -
Kamel O +
et O +
al. O -
, O +
1992 O +
) O +
and O +
S. O +
folium O +
( O -
Tamas O +
et O +
al. O -
, O +
1986 O +
) O +
while O +
quercetin O +
was O +
only O +
reported O +
in O +
S. O +
dorrii O +
( O -
Wollenweber O +
et O +
al. O -
, O +
1992 O +
) O -
. O +

Kaempferol O +
3-methyl O +
ether O +
( O -
isokaempferide O -
) O +
( O -
91 O +
) O -
, O +
3,7-dimethyl O +
ether O +
( O -
kumatakenin O -
) O +
( O -
92 O +
) O +
and O +
quercetin O +
3-methyl O +
ether O +
( O -
94 O +
) O -
, O +
3′-methyl O +
ether O +
( O -
isorhamnetin O -
) O +
( O -
95 O +
) O -
, O +
3,3′-dimethyl O +
ether O +
( O -
96 O +
) O +
and O +
3,7,4′-trimethyl O +
ether O +
( O -
ayanin O -
) O +
( O -
97 O +
) O +
are O +
also O +
known O +
Salvia O +
constituents O +
( O -
Topcu O +
et O +
al. O -
, O +
1996 O -
; O +
Gökdil O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

Kaempferol-3-methyl O +
ether O -
, O +
together O +
with O +
seven O +
other O +
flavones O +
were O +
identified O +
in O +
S. O +
yosgadensis O +
( O -
Topcu O +
et O +
al. O -
, O +
1996 O +
) O -
. O +

Quercetin O +
3,7,3′,4′-tetramethyl O +
ether O -
, O +
or O +
retusin O +
( O -
98 O +
) O +
was O +
identified O +
by O +
TLC O +
in O +
S. O +
glutinosa O +
( O -
Wollenweber O -
, O +
1974 O +
) O -
. O +

6-Hydroxylated O +
flavonols O +
are O +
mostly O +
confined O +
to O +
6-hydroxykaempferol O +
derivatives O +
and O +
include O +
6-hydroxykaempferol O +
3,6-dimethyl O +
ether O +
( O -
99 O +
) O +
( O -
Gökdil O +
et O +
al. O -
, O +
1997 O +
) O -
, O +
3,6,4′-trimethyl O +
ether O +
( O -
santin O -
) O +
( O -
100 O +
) O +
( O -
Ulubelen O +
and O +
Tuzlaci O -
, O +
1990 O +
) O +
and O +
interestingly O +
the O +
5,6-dimethyl O +
ether O +
( O -
101 O +
) O +
( O -
Wollenweber O +
et O +
al. O -
, O +
1992 O +
) O -
. O +

Compound O +
101 O +
is O +
one O +
of O +
the O +
only O +
two O +
flavone O +
5-methyl O +
ethers O +
known O +
to O +
Salvia O +
species O -
, O +
the O +
other O +
being O +
6-hydroxygalangin O +
5,6-dimethyl O +
ether O +
( O -
102 O +
) O +
found O +
in O +
S. O +
columbariae O +
( O -
Wollenweber O +
et O +
al. O -
, O +
1992 O +
) O +
which O +
is O +
also O +
the O +
only O +
one O +
galangin O +
( O -
5,7-dihydroxyflavonol O -
) O +
compound O +
reported O +
in O +
Salvia O +
. O +

No O +
corresponding O +
6-hydroxyquercetin O +
derivatives O +
have O +
been O +
described O +
so O +
far O +
in O +
Salvia O +
. O +

3.2 O +
Flavone O +
and O +
flavonol O +
glycosides O +
Flavone O +
O O +
-glycosides O +
are O +
apparently O +
common O +
in O +
Salvia O +
and O +
most O +
of O +
them O +
are O +
flavone O +
7-glycosides O +
represented O +
by O +
apigenin O +
7-glucoside O +
( O -
cosmosiin O -
) O +
( O -
103 O +
) O -
, O +
luteolin O +
7-glucoside O +
( O -
cinaroside O -
) O +
( O -
110 O +
) O +
and O +
their O +
corresponding O +
7-glucuronides O +
( O -
104 O +
, O +
111 O +
) O -
. O +

There O +
are O +
several O +
apigenins O +
glycosylated O +
with O +
two O +
or O +
more O +
sugars O +
and O +
among O +
these O +
are O +
apigenin O +
7,4′-diglucoside O +
( O -
105 O +
) O +
( O -
Takeda O +
et O +
al. O -
, O +
1994 O +
) O -
, O +
apigenin O +
7-cellobioside O +
( O -
107 O +
) O +
( O -
Veitch O +
et O +
al. O -
, O +
1998 O +
) O -
, O +
apigenin O +
7-rutinoside O +
( O -
108 O +
) O +
( O -
Kokkalou O +
and O +
Kapetanidis O -
, O +
1988 O +
) O +
and O +
apigenin O +
7-cellobioside-4′-glucoside O +
( O -
109 O +
) O +
( O -
Veitch O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

The O +
latter O +
compound O +
is O +
the O +
only O +
trisaccharide O +
of O +
flavones O +
and O +
together O +
with O +
apigenin O +
7,4′-diglucoside O +
are O +
the O +
only O +
two O +
apigenin O +
derivatives O +
in O +
which O +
two O +
phenolic O +
hydroxyl O +
groups O +
are O +
glycosylated O -
. O +

Apigenin O +
7,4′-diglucoside O +
occurred O +
as O +
a O +
co O -
- O -
pigment O +
in O +
the O +
blue O +
flower O +
of O +
S. O +
patens O +
( O -
Takeda O +
et O +
al. O -
, O +
1994 O +
) O -
. O +

Other O +
flavone O +
disaccharides O +
like O +
apigenin O +
7-cellobioside O +
and O +
apigenin O +
7-cellobioside-4′-glucoside O +
present O +
in O +
Salvia O +
flowers O +
could O +
very O +
well O +
serve O +
as O +
co O -
- O -
pigments O +
( O -
Veitch O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

Compared O +
to O +
apigenin O -
, O +
luteolin O +
glycosides O +
appeared O +
to O +
be O +
more O +
common O -
. O +

Luteolin O +
3′-glucuronide O +
( O -
112 O +
) O +
was O +
present O +
in O +
S. O +
officinalis O +
( O -
Lu O +
and O +
Foo O -
, O +
2000 O +
) O +
while O +
luteolin O +
4′-glucuronide O +
( O -
113 O +
) O +
was O +
found O +
in O +
S. O +
lavandulifolia O +
along O +
with O +
other O +
flavonoids O +
( O -
Canigueral O +
et O +
al. O -
, O +
1989 O +
) O -
. O +

The O +
3′-OH O +
of O +
luteolin O +
is O +
often O +
methylated O +
and O +
thus O +
chrysoeriol O +
glycosides O +
such O +
as O +
7-glucoside O +
( O -
114 O +
) O -
, O +
7-glucuronide O +
( O -
115 O +
) O +
and O +
7-xyloside O +
( O -
116 O +
) O +
have O +
been O +
frequently O +
reported O +
in O +
Salvia O +
( O -
Smirnova O +
et O +
al. O -
, O +
1974b O -
; O +
Abdalla O +
et O +
al. O -
, O +
1983 O +
) O -
. O +

Several O +
luteolin O +
disaccharides O +
have O +
been O +
identified O +
in O +
Salvia O +
and O +
these O +
include O +
luteolin O +
3′-glucoside-7-glucuronide O +
( O -
117 O +
) O +
( O -
Abdalla O +
et O +
al. O -
, O +
1983 O +
) O -
, O +
7-rutinoside O +
( O -
118 O +
) O +
( O -
Kokkalou O +
and O +
Kapetanidis O -
, O +
1988 O -
; O +
Tomas O -
- O -
Lorente O +
et O +
al. O -
, O +
1988 O +
) O -
, O +
7-cellobioside O +
( O -
119 O +
) O +
( O -
Abdalla O -
, O +
1984 O +
) O +
and O +
5-rutinoside O +
( O -
127 O +
) O +
( O -
Zarzuelo O +
et O +
al. O -
, O +
1995 O +
) O -
. O +

The O +
6-hydroxyflavone O +
glycosides O -
, O +
like O +
their O +
aglycones O -
, O +
are O +
also O +
important O +
constituents O +
of O +
Salvia O -
. O +

While O +
6-hydroxyapigenin O +
glycosides O +
are O +
exclusively O +
those O +
of O +
6-methylated O +
derivatives O +
such O +
as O +
6-methoxyapigenin O +
7-glucoside O +
( O -
homoplantagenin O -
) O +
( O -
120 O +
) O +
and O +
7-glucuronide O +
( O -
121 O +
) O -
, O +
salvigenin O +
5-glucoside O +
( O -
122 O +
) O +
( O -
Abdalla O +
et O +
al. O -
, O +
1983 O -
; O +
Ulubelen O +
and O +
Topcu O -
, O +
1984 O +
) O -
, O +
the O +
corresponding O +
6-hydroxyluteolin O +
glycosides O +
are O +
evenly O +
distributed O +
between O +
those O +
that O +
are O +
methylated O +
and O +
unmethylated O -
, O +
thus O +
6-hydroxyluteolin O +
7-glucoside O +
( O -
123 O +
) O +
and O +
7-glucuronide O +
( O -
124 O +
) O +
( O -
Lu O +
and O +
Foo O -
, O +
2000 O +
) O -
, O +
6-methoxyluteolin O +
7-glucoside O +
( O -
nepitrin O -
) O +
( O -
125 O +
) O -
, O +
7-glucuronide O +
( O -
126 O +
) O +
( O -
Abdalla O +
et O +
al. O -
, O +
1983 O +
) O -
, O +
6-hydroxyluteolin O +
5-glucoside O +
( O -
128 O +
) O +
( O -
Ulubelen O +
et O +
al. O -
, O +
1981 O +
) O +
and O +
6-methoxyluteolin O +
7-methyl O +
ether-5-glucoside O +
( O -
129 O +
) O +
( O -
Saleh O +
and O +
Sabri O -
, O +
1980 O +
) O +
have O +
all O +
been O +
found O +
in O +
Salvia O +
. O +

Another O +
compound O -
, O +
identified O +
as O +
acetylpectolinarin O +
by O +
Smirnova O +
et O +
al. O +
( O -
1974a O -
) O +
, O +
could O +
likely O +
be O +
6-methoxyapigenin O +
4′-methyl O +
ether-7-rutinoside O -
, O +
as O +
its O +
acidic O +
hydrolysis O +
gave O +
pectolinarigenin O +
( O -
6-hydroxyapigenin O +
6,4′-dimethyl O +
ether O -
) O +
together O +
with O +
glucose O +
and O +
rhamnose O -
. O +

Flavone O +
C O +
-glycosides O +
are O +
widespread O +
in O +
nature O +
and O +
those O +
present O +
in O +
Salvia O +
are O +
mostly O +
those O +
of O +
apigenin O +
including O +
apigenin O +
8-C O +
-glucoside O +
( O -
vitexin O -
) O +
( O -
130 O +
) O +
and O +
apigenin O +
8-C O +
-arabinoside O +
( O -
schaftoside O -
) O +
( O -
131 O +
) O +
from O +
S. O +
blepharophylla O +
( O -
Bisio O +
et O +
al. O -
, O +
1997 O +
) O +
and O +
the O +
more O +
common O +
apigenin O +
6,8-di O -
- O -
C O +
-glucoside O +
( O -
vicenin-2 O -
) O +
( O -
132 O +
) O +
( O -
Abdalla O -
, O +
1984 O -
; O +
Lu O +
and O +
Foo O -
, O +
2000 O +
) O -
. O +

Luteolin O +
6,8-di O -
- O -
C O +
-glucoside O +
( O -
133 O +
) O +
from O +
S. O +
aegypteacae O +
( O -
Abdalla O -
, O +
1984 O +
) O +
is O +
the O +
only O +
example O +
of O +
luteolin O +
C O +
-glycosides O +
reported O -
. O +

The O +
flavonol O +
glycosides O +
found O +
in O +
Salvia O +
are O +
exclusively O +
those O +
of O +
the O +
3-glycosides O -
. O +

There O +
are O +
three O +
kaempferol O +
glycosides O +
known O +
but O +
they O +
cover O +
a O +
range O +
of O +
compounds O +
from O +
mono- O +
to O +
triglycoside O +
which O +
are O +
exemplified O +
by O +
kaempferol O +
3-glucoside O +
( O -
astragalin O -
) O +
( O -
134 O +
) O +
in O +
S. O +
cavaleriei O +
( O -
Zhao O +
et O +
al. O -
, O +
1997 O +
) O -
, O +
3-robinoside O +
( O -
141 O +
) O +
and O +
3- O -
( O -
2,6-dirhamnosylglucoside O -
) O +
or O +
3- O -
( O -
2 O -
G O +
-rhamnosylrutinoside O -
) O +
( O -
135 O +
) O +
in O +
S. O +
farnacea O +
( O -
Kamel O +
et O +
al. O -
, O +
1992 O +
) O -
. O +

The O +
quercetin O +
glycosides O +
also O +
include O +
their O +
methyl O +
ethers O -
, O +
thus O +
in O +
addition O +
to O +
the O +
more O +
common O +
3-glucoside O +
( O -
isoquercitrin O -
) O +
( O -
137 O +
) O -
, O +
3-glucuronide O +
( O -
miquelianin O -
) O +
( O -
138 O +
) O +
and O +
3-robinoside O +
( O -
142 O +
) O -
, O +
all O +
of O +
which O +
occur O +
in O +
S. O +
blepharophylla O +
( O -
Bisio O +
et O +
al. O -
, O +
1997 O +
) O -
, O +
rhamnetin O +
( O -
quercetin O +
7-methyl O +
ether O -
) O +
3-glucoside O +
( O -
139 O +
) O +
from O +
S. O +
blepharophylla O +
( O -
Bisio O +
et O +
al. O -
, O +
1997 O +
) O -
, O +
isorhamnetin O +
( O -
quercetin O +
3′-methyl O +
ether O -
) O +
3-galactoside O +
( O -
140 O +
) O +
and O +
3- O -
( O -
2 O -
G O +
-rhamnosylrutinoside O -
) O +
( O -
136 O +
) O +
both O +
from O +
S. O +
farinacea O +
( O -
Kamel O +
et O +
al. O -
, O +
1992 O +
) O +
have O +
also O +
been O +
reported O -
. O +

3.3 O +
Anthocyanins O +
The O +
anthocyanins O +
are O +
particularly O +
abundant O +
in O +
the O +
red O +
or O +
purple O +
flowers O +
of O +
Salvia O +
( O -
Asen O -
, O +
1961 O -
; O +
Shibata O +
et O +
al. O -
, O +
1966 O -
; O +
Cornu O +
and O +
Paynot O -
, O +
1969 O -
; O +
Albulescu O +
and O +
Gavrila O -
- O -
Dinu O -
, O +
1981 O -
; O +
Zhang O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

Salvia O +
anthocyanins O +
( O -
see O +
Table O +
5 O +
) O +
were O +
first O +
studied O +
by O +
Willstätter O +
and O +
Bolton O +
( O -
1916 O -
) O +
and O +
the O +
pigment O +
known O +
as O +
salvianin O +
was O +
identified O +
as O +
pelargonidin O +
diglucoside O +
with O +
caffeic O +
acid O +
and O +
malonic O +
acid O +
substituents O -
. O +

Subsequent O +
investigations O +
led O +
to O +
the O +
first O +
structural O +
assignment O +
of O +
salvianin O +
as O +
pelargonidin O +
3- O -
( O -
6-caffeoylglucoside O -
) O -
-5-glucoside O +
( O -
145 O +
) O +
( O -
Birkofer O +
et O +
al. O -
, O +
1965 O +
) O -
, O +
but O +
this O +
structure O +
was O +
later O +
revised O +
to O +
pelargonidin O +
3- O -
( O -
6-caffeoylglucoside O -
) O -
-5- O -
( O -
4,6-dimalonylglucoside O -
) O +
( O -
143 O +
) O +
( O -
Kondo O +
et O +
al. O -
, O +
1989 O +
) O -
. O +

The O +
earlier O +
structure O +
was O +
revised O +
because O +
plant O +
pigments O +
were O +
extracted O +
with O +
alcohols O +
which O +
were O +
acidified O +
with O +
mineral O +
acids O +
causing O +
hydrolysis O +
of O +
the O +
labile O +
malonyl O +
moiety O +
( O -
Tomas O -
- O -
Barberan O +
et O +
al. O -
, O +
1987 O +
) O -
. O +

The O +
mono- O +
and O +
bis O -
- O -
demalonyl O +
derivatives O +
of O +
salvianin O +
( O -
144 O +
, O +
145 O +
) O +
have O +
also O +
been O +
identified O +
( O -
Tomas O -
- O -
Barberan O +
et O +
al. O -
, O +
1987 O -
; O +
Kondo O +
et O +
al. O -
, O +
1989 O +
) O -
. O +

Furthermore O -
, O +
the O +
caffeoyl O +
group O +
in O +
salvianin O +
can O +
be O +
replaced O +
by O +
a O +
p O +
-coumaroyl O +
group O -
, O +
leading O +
to O +
the O +
corresponding O +
pelargonidin O +
3- O -
( O -
6-p O +
-coumaroylglucoside O -
) O -
-5- O -
( O -
4,6-dimalonylglucoside O -
) O +
or O +
monardaein O +
( O -
146 O +
) O +
and O +
its O +
demalonated O +
derivatives O +
( O -
147 O +
, O +
148 O +
) O +
( O -
Tomas O -
- O -
Barberan O +
et O +
al. O -
, O +
1987 O +
) O -
. O +

Likewise O -
, O +
the O +
pelargonidin O +
aglycone O +
can O +
be O +
replaced O +
by O +
cyanidin O -
, O +
delphinidin O +
and O +
even O +
malvidin O -
, O +
so O +
the O +
respective O +
cyanidin O +
and O +
delphinidin O +
3- O -
( O -
caffeoylglucoside O -
) O -
-5- O -
( O -
dimalonylglucosides O -
) O +
( O -
149 O +
, O +
155 O +
) O +
or O +
3- O -
( O -
p O +
-coumaroylglucoside O -
) O -
-5- O -
( O -
dimalonylglucosides O -
) O +
( O -
152 O +
, O +
158 O +
) O +
and O +
their O +
demalonated O +
derivatives O +
( O -
150 O +
, O +
151 O +
, O +
153 O +
, O +
154 O +
, O +
156 O +
, O +
157 O +
, O +
159 O +
, O +
160 O +
) O +
have O +
all O +
been O +
identified O +
in O +
scarlet O -
, O +
purple O +
and O +
blue O +
flowers O +
of O +
Salvia O +
( O -
Takeda O +
et O +
al. O -
, O +
1986 O -
; O +
Tomas O -
- O -
Barberan O +
et O +
al. O -
, O +
1987 O -
; O +
Kondo O +
et O +
al. O -
, O +
1989 O +
) O -
. O +

Malvidin O +
3- O -
( O -
6-p O +
-coumaroylglucoside O -
) O -
-5- O -
( O -
6-malonylglucoside O -
) O +
( O -
salviamalvin O -
) O +
( O -
162 O +
) O -
, O +
along O +
with O +
malonylawobanin O +
( O -
159 O +
) O -
, O +
have O +
been O +
isolated O +
from O +
the O +
blue O +
flowers O +
of O +
S. O +
farinacea O +
( O -
Kondo O +
et O +
al. O -
, O +
1989 O +
) O -
. O +

Studies O +
on O +
the O +
distribution O +
pattern O +
of O +
anthocyanins O +
in O +
10 O +
species O +
of O +
Salvia O +
showed O +
that O +
the O +
red O -
, O +
scarlet O +
and O +
pink O -
- O -
coloured O +
flower O +
varieties O +
contained O +
pelargonidin O -
, O +
the O +
blue O +
ones O +
the O +
delphinidin O +
and O +
the O +
amethyst- O +
and O +
grape O -
- O -
violet O -
- O -
colored O +
ones O +
were O +
the O +
cyanidin O +
derivatives O +
( O -
Haque O +
et O +
al. O -
, O +
1981 O +
) O -
. O +

An O +
acetylated O +
anthocyanin O -
, O +
delphinidin O +
3- O -
( O -
6-p O +
-coumaroylglucoside O -
) O -
-5- O -
( O -
4-acetyl-6-malonylglucoside O -
) O +
( O -
161 O +
) O +
together O +
with O +
its O +
parent O +
compound O +
have O +
been O +
reported O +
in O +
the O +
blue O +
petals O +
of O +
S. O +
uliginosa O +
( O -
Ishikawa O +
et O +
al. O -
, O +
1999 O +
) O -
. O +

An O +
example O +
of O +
a O +
stable O +
complex O +
of O +
anthocyanins O +
with O +
flavonoids O +
as O +
co O -
- O -
pigments O +
is O +
a O +
blue O +
pigment O +
found O +
in O +
the O +
blue O +
flowers O +
of O +
S. O +
patens O +
. O +

The O +
pigment O +
is O +
composed O +
of O +
delphinidin O +
3- O -
( O -
6-p O +
-coumaroylglucoside O -
) O -
-5- O -
( O -
6-malonylglucoside O -
) O +
( O -
malonylawobanin O -
) O +
( O -
159 O +
) O -
, O +
apigenin O +
7,4′-diglucoside O +
( O -
105 O +
) O +
and O +
magnesium O +
cation O +
( O -
Takeda O +
et O +
al. O -
, O +
1994 O +
) O -
. O +

3.4 O +
Proanthocyanidins O +
Proanthocyanidins O -
, O +
or O +
condensed O +
tannins O -
, O +
have O +
been O +
reported O +
in O +
Salvia O +
species O +
( O -
Brieskorn O -
, O +
1949 O -
; O +
Savin O +
and O +
Ivanic O -
, O +
1973 O -
; O +
Murko O +
and O +
Baldasar O -
, O +
1977 O +
) O -
. O +

The O +
so O -
- O -
called O +
salviatannin O +
( O -
164 O +
) O +
has O +
only O +
been O +
investigated O +
with O +
UV O +
and O +
IR O +
and O +
deduced O +
to O +
be O +
based O +
on O +
catechin O +
( O -
163 O +
) O +
which O +
gave O +
catechol O +
and O +
catechuic O +
acid O +
after O +
alkali O +
pyrolysis O +
( O -
Murko O +
et O +
al. O -
, O +
1974 O +
) O -
. O +

Later O -
, O +
salviatannin O +
was O +
also O +
detected O +
by O +
paper O +
chromatography O +
followed O +
by O +
spraying O +
color O +
reagent O +
( O -
Hu O -
, O +
1982 O +
) O +
or O +
analysed O +
by O +
absorption O +
onto O +
hide O +
powder O +
followed O +
by O +
gravimetry O +
( O -
Karuza O -
- O -
Stojakovic O +
et O +
al. O -
, O +
1989 O +
) O -
. O +

The O +
tannins O +
present O +
in O +
Salvia O +
intravenous O +
preparations O +
could O +
be O +
removed O +
by O +
passing O +
through O +
a O +
polyamide O +
column O +
( O -
Hu O -
, O +
1982 O +
) O +
or O +
by O +
precipitation O +
with O +
5 O -
% O +
gelatin B-Gene +
solutions O +
followed O +
by O +
filtration O +
( O -
Ren O +
et O +
al. O -
, O +
1986 O +
) O -
. O +

4 O +
Conclusion O +
Salvia O +
species O +
commonly O +
called O +
sages O +
are O +
widely O +
used O +
in O +
traditional O +
medicine O +
and O +
are O +
a O +
rich O +
source O +
of O +
polyphenolic O +
flavonoids O +
and O +
phenolic O +
acids O -
. O +

Flavones O -
, O +
flavonols O +
and O +
their O +
glycosides O +
constitute O +
the O +
majority O +
of O +
flavonoids O +
present O -
. O +

Malonylated O +
anthocyanins O +
are O +
abundant O +
in O +
red O +
to O +
blue O +
Salvia O +
flowers O +
while O +
the O +
presence O +
of O +
proanthocyanidins O +
( O -
condensed O +
tannins O -
) O +
in O +
Salvia O +
have O +
not O +
been O +
demonstrated O +
conclusively O -
. O +

The O +
phenolic O +
acids O +
are O +
exclusively O +
those O +
based O +
on O +
caffeic O +
acid O +
building O +
block O +
with O +
compounds O +
formed O +
from O +
two O +
to O +
four O +
or O +
more O +
caffeic O +
acid O +
units O -
. O +

The O +
depsides O +
formed O +
from O +
these O +
are O +
believed O +
to O +
be O +
responsible O +
for O +
the O +
many O +
biological O +
activities O +
in O +
the O +
sage O +
decoction O +
used O +
in O +
traditional O +
medicine O -
. O +

In O +
addition O +
to O +
the O +
dried O +
root O -
, O +
the O +
aerial O +
part O +
of O +
sage O +
has O +
been O +
shown O +
to O +
also O +
contain O +
a O +
rich O +
source O +
of O +
polar O +
polyphenols O +
including O +
flavonoids O +
and O +
phenolic O +
acids O +
which O +
could O +
potentially O +
be O +
used O +
also O +
as O +
herbal O +
materials O -
. O +

Daphnia O +
are O +
an O +
important O +
and O +
widely O +
studied O +
model O +
species O +
in O +
ecological O +
and O +
toxicological O +
studies O +
throughout O +
the O +
world O +
and O +
an O +
official O +
( O -
OECD O -
) O +
recommended O +
test O +
organism O -
. O +

Their O +
small O +
size O -
, O +
wide O +
distribution O +
and O +
easy O +
growth O +
conditions O +
make O +
this O +
organism O +
ideal O +
for O +
functional O +
genomics O +
based O +
studies O -
, O +
including O +
metabolic O +
profiling O +
and O +
transcriptomics O -
. O +

In O +
this O +
study O +
we O +
used O +
an O +
integrated O +
systems O +
approach O +
in O +
which O +
transcriptomic O -
, O +
metabolomic O +
and O +
energetic O +
responses O +
of O +
juvenile O +
( O -
4days O +
old O -
) O +
daphnids O +
were O +
evaluated O +
in O +
response O +
to O +
exposure O +
to O +
two O +
poly O +
aromatic O +
hydrocarbons O +
( O -
pyrene O +
and O +
fluoranthene O -
) O +
and O +
binary O +
mixtures O +
thereof O -
. O +

In O +
addition O -
, O +
these O +
responses O +
were O +
linked O +
to O +
responses O +
measured O +
during O +
chronic O +
experiments O +
( O -
21days O -
) O +
assessing O +
survival O -
, O +
growth O +
and O +
reproductive O +
traits O -
. O +

Custom O +
Daphnia O +
magna O +
microarrays O +
were O +
used O +
to O +
assess O +
transcriptomic O +
changes O -
. O +

Hierarchical O +
cluster O +
analysis O +
did O +
not O +
result O +
in O +
a O +
clear O +
distinction O +
between O +
the O +
single O +
compounds O +
suggesting O +
similar O +
molecular O +
modes O +
of O +
action O -
. O +

Cluster O +
analysis O +
with O +
both O +
the O +
single O +
compounds O +
and O +
the O +
binary O +
mixture O +
treatments O +
resulted O +
in O +
a O +
separation O +
of O +
treatments O +
based O +
on O +
differences O +
in O +
toxic O +
ratios O +
rather O +
than O +
component O +
differences O -
. O +

Changes O +
in O +
the O +
metabolic O +
profiles O +
of O +
the O +
organisms O +
were O +
investigated O +
using O +
Nuclear O +
Magnetic O +
Resonance O +
Spectroscopy O +
and O +
Gas O +
and O +
Liquid O +
Chromatography O +
Mass O +
Spectrometry O -
. O +

These O +
multivariate O +
metabolomic O +
datasets O +
were O +
analyzed O +
with O +
Principal O +
Components O +
Analysis O +
and O +
Partial O +
Least O +
Squares O +
Discriminant O +
Analysis O -
. O +

The O +
major O +
metabolite O +
changes O +
responsible O +
for O +
the O +
differences O +
observed O +
indicated O +
a O +
disturbance O +
in O +
aminosugar O +
metabolism O +
in O +
all O +
cases O -
. O +

The O +
study O +
demonstrates O +
the O +
potential O +
of O +
' O -
omics O -
' O +
to O +
provide O +
screening O +
tools O +
for O +
monitoring O +
of O +
the O +
freshwater O +
environment O -
-- O -
in O +
invertebrate O +
species O -
-- O -
which O +
is O +
reasonably O +
rapid O -
, O +
cost O -
- O -
effective O +
and O +
has O +
the O +
potential O +
to O +
greatly O +
increase O +
the O +
amount O +
of O +
information O +
obtained O +
from O +
aquatic O +
toxicology O +
testing O -
. O +

